data_6szc_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6szc _Structure_validation_residue.Date_analyzed 2020-04-03 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.153 0.502 . . . . 2.42 111.384 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.23 -40.18 4.86 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.002 2.468 . . . . 1.98 112.46 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2058 ' ' LEU . . . . . 0.445 ' N ' HD12 ' A' 2058 ' ' LEU . 0.0 OUTLIER -81.97 -2.08 50.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 2.8 111.607 -177.591 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.5 t -136.92 84.42 25.75 Favored Pre-proline 0 C--N 1.326 -0.426 0 N-CA-C 109.159 -0.682 . . . . 1.56 109.159 178.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2060 ' ' PRO . . . . . 0.514 ' O ' ' HG3' ' A' 2114 ' ' LYS . 41.6 Cg_exo -55.73 130.64 41.48 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.532 2.155 . . . . 1.35 111.804 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2061 ' ' ILE . . . . . 0.416 ' HA ' ' HA ' ' A' 2113 ' ' ASP . 41.6 mm -64.49 141.74 17.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.561 . . . . 1.33 109.709 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.519 ' O ' HG23 ' A' 2065 ' ' VAL . 10.3 t70 -80.05 128.11 33.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.361 -0.381 . . . . 1.42 110.289 -175.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -91.34 1.96 56.74 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.404 -0.362 . . . . 1.55 111.958 -172.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 74.4 p -110.73 -5.04 15.06 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.009 0.433 . . . . 1.29 111.171 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.64 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.9 m -91.67 -174.01 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.453 . . . . 1.47 109.857 178.187 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -89.64 111.26 44.94 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.154 0.502 . . . . 0.78 111.162 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.64 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.2 Cg_endo -100.71 109.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 123.608 2.872 . . . . 0.52 110.792 166.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 9.0 p -148.31 -176.52 5.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.146 0.498 . . . . 1.07 110.963 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.59 ' CD2' HG13 ' A' 2109 ' ' VAL . 3.5 m-30 -101.6 156.39 17.51 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 107.165 -1.42 . . . . 1.99 107.165 166.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -53.8 -34.95 60.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 118.261 0.482 . . . . 2.09 111.951 -169.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -74.81 -4.92 40.62 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.886 0.374 . . . . 2.15 111.312 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.91 14.49 57.82 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 121.246 -0.502 . . . . 0.63 111.854 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2073 ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' 2069 ' ' PHE . 0.3 OUTLIER -85.78 161.78 18.99 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.666 0.27 . . . . 1.14 111.277 -174.769 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -115.52 -23.82 8.61 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.431 -0.35 . . . . 1.68 111.912 -174.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' 2084 ' ' TYR . 1.6 tm-20 -151.87 137.31 17.67 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.254 0.55 . . . . 2.08 110.167 173.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.435 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.0 OUTLIER -131.64 99.7 4.88 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.472 -0.786 . . . . 2.03 109.99 175.44 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 7.7 m -103.06 111.78 24.3 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.945 -0.57 . . . . 1.28 110.598 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.507 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 44.4 mm -114.39 123.05 33.05 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 108.004 -1.11 . . . . 2.24 108.004 173.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.27 108.69 0.17 Allowed 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.043 2.495 . . . . 1.09 113.039 -176.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 100.99 -18.55 54.57 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.644 -0.707 . . . . 0.94 112.886 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.507 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -90.59 -30.19 17.35 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.257 0.551 . . . . 2.02 110.827 -173.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.56 -174.58 15.31 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.587 -0.733 . . . . 0.58 111.58 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 15.5 m -133.88 134.41 42.67 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.583 0.706 . . . . 1.21 110.523 176.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.547 ' O ' ' HA ' ' A' 2075 ' ' GLU . 1.5 m-85 -109.47 120.18 41.7 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.986 -1.487 . . . . 2.34 106.986 172.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -127.89 121.59 30.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 112.447 0.536 . . . . 1.26 112.447 -171.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.443 ' CG1' HG23 ' A' 2092 ' ' VAL . 0.0 OUTLIER -115.54 134.91 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.089 -0.505 . . . . 1.76 110.198 173.703 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 33.6 m -118.2 150.37 47.47 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 109.413 -0.588 . . . . 1.35 109.413 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.99 -4.08 0.85 Allowed 'Trans proline' 0 N--CA 1.481 0.768 0 C-N-CA 123.959 3.106 . . . . 1.32 114.637 -172.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.73 -7.8 52.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.902 0.382 . . . . 2.29 110.506 176.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 91.18 16.98 52.54 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.91 -0.662 . . . . 0.83 112.063 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.2 t -118.61 138.54 52.51 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.854 0.359 . . . . 1.8 110.433 -179.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.443 HG23 ' CG1' ' A' 2086 ' ' ILE . 7.4 t -131.21 140.58 48.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.126 -0.488 . . . . 1.67 110.512 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -101.99 108.92 20.52 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 116.299 -0.41 . . . . 1.94 110.49 174.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -86.69 96.32 10.1 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.162 -1.051 . . . . 2.13 108.162 173.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 25.1 m -119.04 88.25 36.21 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 121.121 0.486 . . . . 1.21 110.554 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.29 2.66 . . . . 1.23 111.877 176.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.2 t70 -132.14 99.43 4.71 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.883 0.373 . . . . 2.72 110.083 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.23 13.9 2.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.275 -0.42 . . . . 5.15 111.101 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 -109.52 5.57 23.32 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.256 0.551 . . . . 5.07 109.716 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 52.5 t80 -89.3 92.55 9.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 3.08 110.992 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 92.0 t -83.76 107.78 15.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.586 -0.524 . . . . 3.01 109.586 174.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.14 -133.55 2.85 Favored Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.673 -0.694 . . . . 3.84 111.456 -178.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 61.6 tttm -127.67 99.07 27.06 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.769 0.284 . . . . 7.31 110.94 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.92 155.03 48.37 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.318 2.012 . . . . 2.77 111.73 174.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.3 t70 -83.42 127.02 70.09 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.066 -0.515 . . . . 2.33 109.968 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.612 ' HA ' ' O ' ' A' 2123 ' ' TYR . 43.1 Cg_exo -56.34 102.68 0.1 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.026 2.484 . . . . 1.29 112.881 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.2 p -147.42 138.93 18.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.095 -0.502 . . . . 1.23 110.38 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 56.6 m -112.96 124.16 51.99 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.001 -0.545 . . . . 1.11 110.149 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.7 t -91.63 131.17 39.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.835 -0.802 . . . . 1.35 108.835 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.471 ' HZ1' ' HB3' ' A' 2110 ' ' LYS . 5.4 ttpm? -143.6 108.94 5.04 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 112.989 0.737 . . . . 2.25 112.989 -173.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.407 ' HD2' HG21 ' A' 2061 ' ' ILE . 28.1 ptt180 -129.65 140.62 51.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.741 -0.837 . . . . 3.95 108.741 171.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.9 m -99.58 142.01 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 120.358 -0.537 . . . . 1.09 110.997 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.661 ' OD1' ' HB ' ' A' 2117 ' ' THR . 4.3 p30 -85.24 -170.72 3.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.949 -0.569 . . . . 1.46 111.615 -178.034 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2114 ' ' LYS . . . . . 0.514 ' HG3' ' O ' ' A' 2060 ' ' PRO . 91.5 mttt -57.55 -37.17 72.67 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.851 0.315 . . . . 2.25 111.851 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -80.09 -29.7 39.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.313 0.578 . . . . 1.84 109.901 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 112.6 21.62 6.04 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.321 -0.854 . . . . 0.46 112.418 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.661 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 92.4 m -86.91 120.97 71.88 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 110.214 -0.291 . . . . 1.22 110.214 177.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -73.16 101.88 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.453 2.102 . . . . 0.72 112.433 178.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.7 m -75.07 113.0 13.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.527 -0.916 . . . . 1.37 108.527 171.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.622 ' HA ' ' O ' ' A' 2109 ' ' VAL . 37.8 p -119.66 154.82 33.46 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 115.483 -0.781 . . . . 1.23 112.617 -169.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -130.29 127.54 39.71 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.892 -1.151 . . . . 1.33 107.892 167.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.2 m -115.87 103.87 11.06 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.072 0.463 . . . . 2.66 110.527 -174.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.612 ' O ' ' HA ' ' A' 2106 ' ' PRO . 3.1 m-85 -98.33 132.29 43.92 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-O 121.198 0.523 . . . . 3.23 111.19 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 44.3 m -157.14 165.37 18.95 Favored Pre-proline 0 C--N 1.321 -0.635 0 N-CA-C 108.433 -0.951 . . . . 2.37 108.433 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo . . . . . 0 C--N 1.353 0.783 0 C-N-CA 123.199 2.599 . . . . 2.51 114.064 -176.686 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 CA--C 1.519 -0.233 0 CA-C-O 120.582 0.23 . . . . 2.42 110.621 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.87 -21.91 18.1 Favored 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.404 2.07 . . . . 1.98 111.933 -178.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.74 -18.48 59.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.673 -0.694 . . . . 2.8 110.465 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2059 ' ' VAL . . . . . 0.555 HG12 ' OD2' ' A' 2113 ' ' ASP . 5.0 t -133.63 98.38 14.99 Favored Pre-proline 0 N--CA 1.452 -0.341 0 CA-C-N 116.062 -0.517 . . . . 1.56 109.811 177.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2060 ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' 2059 ' ' VAL . 11.3 Cg_endo -55.76 118.86 5.69 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.039 1.826 . . . . 1.35 111.827 178.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.8 mm -53.6 136.84 14.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.251 -0.886 . . . . 1.33 111.346 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.509 ' O ' HG22 ' A' 2065 ' ' VAL . 14.8 t70 -71.57 131.56 43.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 1.42 110.144 178.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -86.76 -5.2 59.19 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.238 -0.437 . . . . 1.55 112.131 -172.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.7 p -111.37 3.82 18.53 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.091 0.404 . . . . 1.29 112.091 -177.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' 2062 ' ' ASP . 27.1 m -90.19 -177.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.728 -0.471 . . . . 1.47 109.728 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -94.06 116.73 66.79 Favored Pre-proline 0 C--O 1.241 0.625 0 CA-C-O 121.382 0.61 . . . . 0.78 111.6 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.491 ' HB2' HG13 ' A' 2086 ' ' ILE . 28.4 Cg_endo -100.39 108.55 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 123.59 2.86 . . . . 0.52 111.416 167.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2068 ' ' THR . . . . . 0.452 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.4 p -143.37 145.25 32.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.887 0.375 . . . . 1.07 110.549 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.676 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-30 -70.78 156.13 39.91 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 107.936 -1.135 . . . . 1.99 107.936 177.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -51.73 -39.13 57.92 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 123.404 0.44 . . . . 2.09 111.819 -170.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -91.12 19.18 6.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 2.15 111.358 -177.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 75.44 29.44 59.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.047 -0.597 . . . . 0.63 112.66 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2073 ' ' SER . . . . . 0.415 ' HB2' ' CD1' ' A' 2069 ' ' PHE . 7.4 m -95.34 162.32 13.72 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 122.743 -0.269 . . . . 1.14 110.904 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.7 mmtp -121.57 -24.9 5.23 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.268 -0.424 . . . . 1.68 111.673 -177.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' A' 2084 ' ' TYR . 2.0 tt0 -158.62 124.64 4.54 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.368 0.604 . . . . 2.08 110.583 175.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -123.55 102.19 7.73 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.375 -0.829 . . . . 2.03 109.931 175.211 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.7 m -95.92 113.22 24.82 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.204 0.526 . . . . 1.28 110.576 175.157 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.518 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 27.3 mm -116.07 108.86 45.48 Favored Pre-proline 0 C--N 1.31 -1.133 0 N-CA-C 107.627 -1.249 . . . . 2.24 107.627 170.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.08 115.43 1.7 Allowed 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 123.183 2.589 . . . . 1.09 113.41 -173.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2080 ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' 2100 ' ' PHE . . . 89.58 -8.41 79.88 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.775 -0.648 . . . . 0.94 112.513 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.518 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.0 OUTLIER -107.49 -31.05 8.3 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.219 0.533 . . . . 2.02 109.903 -176.679 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 136.45 172.0 12.45 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.519 -0.848 . . . . 0.58 112.94 173.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 77.7 m -138.23 127.93 25.12 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.304 0.573 . . . . 1.21 109.696 172.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.676 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.1 OUTLIER -108.16 125.99 52.26 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 107.698 -1.223 . . . . 2.34 107.698 175.52 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 1.3 p -127.86 129.31 46.71 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 112.074 0.398 . . . . 1.26 112.074 -174.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.491 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.47 132.09 71.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.854 -0.612 . . . . 1.76 110.52 174.601 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -125.79 142.56 42.52 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.788 -0.642 . . . . 1.35 109.3 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.57 -0.05 1.71 Allowed 'Trans proline' 0 N--CA 1.476 0.491 0 C-N-CA 123.827 3.018 . . . . 1.32 114.177 -170.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 36.8 t70 -72.77 -11.8 60.75 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.41 0.624 . . . . 2.29 109.836 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 106.26 6.24 36.6 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.629 -0.714 . . . . 0.83 112.381 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 2.2 t -110.8 128.06 55.62 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.257 0.551 . . . . 1.8 110.274 -179.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 18.8 t -137.17 137.25 46.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.527 -0.76 . . . . 1.67 109.624 -175.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 24.0 m -119.8 109.77 15.99 Favored 'General case' 0 N--CA 1.439 -0.997 0 CA-C-O 120.816 0.341 . . . . 1.94 111.3 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -89.65 98.88 12.02 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.26 -0.645 . . . . 2.13 109.26 174.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 23.0 m -114.01 89.42 16.72 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 120.683 0.278 . . . . 1.21 111.662 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -92.52 119.34 0.44 Allowed 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.971 2.447 . . . . 1.23 112.702 175.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -89.87 84.68 6.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.34 0.59 . . . . 2.72 109.563 173.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.69 -1.91 27.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.566 -0.743 . . . . 5.15 112.374 -171.596 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -84.9 -2.02 57.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.168 0.509 . . . . 5.07 110.523 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2100 ' ' PHE . . . . . 0.472 ' HB2' ' O ' ' A' 2080 ' ' GLY . 69.0 t80 -83.49 85.47 7.24 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 3.08 110.377 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.8 t -92.35 99.63 10.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.147 -0.478 . . . . 3.01 110.196 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -169.53 -101.93 0.15 Allowed Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.415 -0.674 . . . . 3.84 111.415 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 53.3 mtmt -131.6 73.25 79.59 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-O 120.611 0.244 . . . . 7.31 110.615 174.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2104 ' ' PRO . . . . . 0.407 ' HD2' ' O ' ' A' 2125 ' ' PRO . 18.9 Cg_exo -66.06 127.93 18.63 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.383 2.055 . . . . 2.77 111.312 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.3 t70 -60.79 122.88 71.85 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.001 -0.545 . . . . 2.33 110.665 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.482 ' HA ' ' O ' ' A' 2123 ' ' TYR . 31.8 Cg_exo -58.93 120.37 8.19 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 123.101 2.534 . . . . 1.29 112.174 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.7 p -156.72 161.51 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.93 -0.577 . . . . 1.23 109.731 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.465 ' HA ' ' O ' ' A' 2121 ' ' ALA . 67.0 m -140.88 119.74 12.62 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.933 0.397 . . . . 1.11 110.08 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.4 t -92.5 145.18 7.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.029 -0.73 . . . . 1.35 109.029 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.452 ' HB3' ' O ' ' A' 2068 ' ' THR . 0.0 OUTLIER -147.47 143.21 27.72 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.224 0.465 . . . . 2.25 111.341 -174.787 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.41 ' N ' ' HD2' ' A' 2110 ' ' LYS . 27.2 ptt180 -166.95 146.07 5.28 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.676 -0.861 . . . . 3.95 108.676 166.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' 2065 ' ' VAL . 30.5 m -99.01 149.19 5.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 C-N-CA 120.44 -0.504 . . . . 1.09 111.289 -175.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.555 ' OD2' HG12 ' A' 2059 ' ' VAL . 2.8 p-10 -90.51 -169.39 2.38 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.951 -0.568 . . . . 1.46 109.976 178.433 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.9 mttt -59.97 -38.56 82.88 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.542 0.21 . . . . 2.25 111.008 178.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2115 ' ' ASN . . . . . 0.407 HD21 HG12 ' A' 2059 ' ' VAL . 40.2 m-80 -71.66 -30.28 65.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.844 0.354 . . . . 1.84 110.857 177.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 110.55 12.93 15.65 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.851 -0.69 . . . . 0.46 112.214 179.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 5.7 m -79.72 121.58 82.57 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 110.128 -0.323 . . . . 1.22 110.128 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.6 Cg_exo -73.95 103.92 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 122.301 2.001 . . . . 0.72 112.234 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.5 m -75.32 117.62 19.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.381 -0.97 . . . . 1.37 108.381 171.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.561 ' HA ' ' O ' ' A' 2109 ' ' VAL . 47.2 p -129.75 163.35 26.38 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.539 -0.755 . . . . 1.23 111.751 -170.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -130.98 126.84 37.07 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.528 -0.915 . . . . 1.33 108.528 169.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 20.3 m -100.12 100.45 11.3 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.041 0.448 . . . . 2.66 110.335 -176.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.482 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -96.99 114.39 26.0 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.143 -0.48 . . . . 3.23 110.899 -177.407 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 17.8 m -127.39 158.57 69.15 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.537 -0.756 . . . . 2.37 109.651 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' 2104 ' ' PRO . 95.2 Cg_exo . . . . . 0 C--N 1.346 0.402 0 C-N-CA 123.069 2.513 . . . . 2.51 113.828 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.3 t70 . . . . . 0 CA--C 1.522 -0.129 0 CA-C-O 120.698 0.285 . . . . 2.42 111.744 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -76.45 -22.47 12.34 Favored 'Trans proline' 0 N--CA 1.46 -0.471 0 C-N-CA 122.414 2.076 . . . . 1.98 112.477 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.52 -9.57 20.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.821 0.343 . . . . 2.8 110.656 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 21.4 t -127.48 84.48 63.27 Favored Pre-proline 0 CA--C 1.511 -0.534 0 N-CA-C 108.034 -1.099 . . . . 1.56 108.034 175.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -40.48 117.77 0.52 Allowed 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.922 2.415 . . . . 1.35 112.228 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 33.3 mm -54.46 114.96 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.263 -0.88 . . . . 1.33 110.911 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2062 ' ' ASP . . . . . . . . . . . . . 15.7 t70 -72.86 125.71 28.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.47 -0.787 . . . . 1.42 111.308 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2063 ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' 2089 ' ' ASP . 44.0 mt-10 -86.89 -2.88 58.94 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.127 -0.488 . . . . 1.55 111.805 -173.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 43.9 p -106.06 -5.53 19.39 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.741 -0.384 . . . . 1.29 111.863 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.492 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.2 m -96.26 163.66 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.863 -0.421 . . . . 1.47 109.863 176.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -73.15 114.09 27.93 Favored Pre-proline 0 C--O 1.24 0.591 0 CA-C-O 121.271 0.557 . . . . 0.78 112.22 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.492 ' HD3' ' O ' ' A' 2065 ' ' VAL . 68.0 Cg_endo -102.29 108.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.423 0 C-N-CA 123.682 2.921 . . . . 0.52 112.097 169.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 20.9 p -138.61 -178.64 5.4 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.403 0.62 . . . . 1.07 111.273 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.494 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.7 OUTLIER -102.01 152.23 21.2 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.862 -1.162 . . . . 1.99 107.862 168.72 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -52.39 -39.21 60.56 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.066 0.394 . . . . 2.09 111.741 -170.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.36 -2.94 43.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.91 -0.586 . . . . 2.15 111.335 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.78 29.36 13.47 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.849 -0.691 . . . . 0.63 112.159 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 9.1 m -98.06 169.15 9.82 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.894 -0.18 . . . . 1.14 110.697 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2074 ' ' LYS . . . . . 0.403 ' O ' HG21 ' A' 2086 ' ' ILE . 34.6 mmtp -128.06 -16.64 4.52 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.964 0.412 . . . . 1.68 111.343 -179.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -156.24 121.09 4.64 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.719 -0.475 . . . . 2.08 109.719 172.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' A' 2076 ' ' LYS . 4.5 mmmm -115.45 121.86 44.02 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.967 -0.561 . . . . 2.03 109.534 171.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 55.2 m -129.53 121.48 27.28 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.729 -0.669 . . . . 1.28 110.85 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 48.4 mm -119.69 124.49 27.96 Favored Pre-proline 0 C--N 1.314 -0.965 0 N-CA-C 107.584 -1.265 . . . . 2.24 107.584 171.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.73 107.86 0.21 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.332 2.021 . . . . 1.09 112.304 -176.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.19 -23.37 27.31 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.811 -0.631 . . . . 0.94 112.534 -178.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.4 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 15.7 tt0 -90.73 -31.14 16.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.003 0.43 . . . . 2.02 110.261 -176.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.62 -173.32 14.72 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.714 -0.755 . . . . 0.58 112.86 176.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 46.4 m -129.99 132.65 46.35 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.556 0.693 . . . . 1.21 110.127 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.469 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 0.5 OUTLIER -111.31 112.47 24.26 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 106.735 -1.58 . . . . 2.34 106.735 172.397 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.89 131.69 55.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.429 0.529 . . . . 1.26 112.429 -170.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.496 ' CG1' HG23 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.93 137.7 54.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.392 -0.822 . . . . 1.76 109.561 174.54 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 31.7 m -118.67 153.3 52.19 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 109.889 -0.411 . . . . 1.35 109.889 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -60.3 -4.81 3.43 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.773 2.982 . . . . 1.32 114.264 -170.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2089 ' ' ASP . . . . . 0.414 ' O ' ' HB3' ' A' 2063 ' ' GLU . 27.7 m-20 -72.93 -13.08 61.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.907 0.384 . . . . 2.29 110.215 177.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.72 16.06 32.37 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.967 -0.635 . . . . 0.83 112.263 177.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.7 t -115.61 141.25 48.32 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.806 0.336 . . . . 1.8 110.44 -178.111 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.496 HG23 ' CG1' ' A' 2086 ' ' ILE . 12.5 t -133.32 150.78 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.977 -0.556 . . . . 1.67 109.96 -178.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -125.86 122.0 34.82 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.94 110.05 173.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -90.47 98.82 12.0 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.265 -0.642 . . . . 2.13 109.265 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 8.9 m -113.25 87.49 11.12 Favored Pre-proline 0 N--CA 1.454 -0.242 0 CA-C-O 120.964 0.411 . . . . 1.21 110.431 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -92.55 -179.88 1.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 123.292 2.661 . . . . 1.23 112.399 178.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.4 t70 -131.7 139.65 49.09 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.222 -0.659 . . . . 2.72 109.222 170.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2098 ' ' LYS . . . . . 0.51 ' HZ3' ' HB2' ' A' 2098 ' ' LYS . 3.8 ttmp? -90.23 -26.1 20.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.87 -0.605 . . . . 5.15 111.833 -172.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -120.32 36.83 4.43 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.788 0.292 . . . . 5.07 111.788 -171.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 19.4 t80 -82.41 87.01 6.64 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.37 0.605 . . . . 3.08 110.737 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.2 t -92.14 109.84 21.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.793 -0.64 . . . . 3.01 109.745 176.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2102 ' ' GLY . . . . . 0.418 ' C ' ' HD3' ' A' 2104 ' ' PRO . . . 170.75 -113.29 0.49 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.492 -0.643 . . . . 3.84 111.492 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -120.01 76.87 22.95 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 121.115 0.483 . . . . 7.31 111.533 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2104 ' ' PRO . . . . . 0.418 ' HD3' ' C ' ' A' 2102 ' ' GLY . 8.1 Cg_exo -74.68 157.68 43.93 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.198 2.599 . . . . 2.77 111.684 178.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.0 t70 -120.09 117.48 32.06 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.477 -0.328 . . . . 2.33 110.435 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' 2123 ' ' TYR . 52.6 Cg_exo -54.94 128.41 30.42 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.864 2.376 . . . . 1.29 111.828 177.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.1 p -157.51 161.29 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.312 -0.404 . . . . 1.23 110.257 -176.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.5 m -140.15 119.05 12.54 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.149 0.5 . . . . 1.11 110.269 176.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.6 t -91.35 138.06 20.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 108.131 -1.063 . . . . 1.35 108.131 176.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.451 ' HA ' HG23 ' A' 2120 ' ' THR . 2.2 tmmm? -145.14 108.32 4.57 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.275 0.559 . . . . 2.25 111.476 -172.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.467 ' NH1' ' HB3' ' A' 2067 ' ' PRO . 1.4 ptm180 -139.72 142.95 36.82 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 109.207 -0.664 . . . . 3.95 109.207 174.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' 2117 ' ' THR . 24.0 m -99.6 161.06 3.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.426 -0.51 . . . . 1.09 111.49 -175.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.506 ' OD2' ' HB ' ' A' 2117 ' ' THR . 3.9 p30 -110.01 -169.13 1.41 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.571 -0.74 . . . . 1.46 111.004 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 65.2 mttm -63.49 -25.12 68.12 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 111.938 0.347 . . . . 2.25 111.938 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.67 -9.98 56.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.949 0.404 . . . . 1.84 110.251 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 86.27 15.99 63.41 Favored Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.333 -0.707 . . . . 0.46 111.333 -176.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.506 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 0.2 OUTLIER -84.99 131.23 49.45 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 109.954 -0.388 . . . . 1.22 109.954 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' 2117 ' ' THR . 12.3 Cg_endo -87.78 103.9 0.52 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 122.208 1.938 . . . . 0.72 112.428 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 14.8 m -75.42 109.29 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 108.692 -0.855 . . . . 1.37 108.692 171.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' 2109 ' ' VAL . 35.5 p -124.55 169.27 12.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.094 -0.957 . . . . 1.23 111.55 -170.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -135.49 127.73 30.08 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.52 -0.764 . . . . 1.33 109.6 173.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 13.4 p -94.71 99.67 11.73 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.254 -0.43 . . . . 2.66 109.892 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.52 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -103.77 123.93 47.97 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.34 0.59 . . . . 3.23 111.788 -174.859 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 25.2 m -154.19 153.07 27.75 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.141 -0.936 . . . . 2.37 108.484 175.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.402 ' HA ' ' HG2' ' A' 2104 ' ' PRO . 88.7 Cg_exo . . . . . 0 CA--C 1.535 0.55 0 C-N-CA 122.837 2.358 . . . . 2.51 113.891 -178.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 7.1 t70 . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.678 0.275 . . . . 2.42 110.359 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.7 -21.78 33.28 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.387 2.058 . . . . 1.98 112.55 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.9 mm? -93.2 -26.83 17.21 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.887 0.375 . . . . 2.8 110.043 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2059 ' ' VAL . . . . . 0.468 HG11 ' OD2' ' A' 2113 ' ' ASP . 1.8 t -126.88 90.7 48.9 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.239 -0.437 . . . . 1.56 110.429 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -57.32 121.57 10.28 Favored 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 122.188 1.925 . . . . 1.35 111.586 176.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 48.9 mm -53.04 132.31 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.572 -0.74 . . . . 1.33 110.828 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.559 ' O ' HG21 ' A' 2065 ' ' VAL . 24.4 t70 -66.78 135.39 53.89 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 1.42 110.493 -177.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -92.91 -2.58 55.7 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.195 -0.457 . . . . 1.55 111.889 -171.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 31.0 p -106.7 2.21 25.61 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.763 -0.375 . . . . 1.29 111.832 178.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.559 HG21 ' O ' ' A' 2062 ' ' ASP . 35.4 m -92.68 -174.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 110.326 -0.249 . . . . 1.47 110.326 176.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -91.25 114.13 60.65 Favored Pre-proline 0 C--O 1.24 0.597 0 CA-C-O 121.02 0.438 . . . . 0.78 111.389 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.504 ' HD3' ' O ' ' A' 2065 ' ' VAL . 53.8 Cg_endo -101.06 108.06 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 123.362 2.708 . . . . 0.52 111.296 166.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 23.2 p -149.25 -177.2 5.7 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.93 0.395 . . . . 1.07 110.665 -177.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.611 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 9.3 m-30 -101.56 142.85 32.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.832 -1.173 . . . . 1.99 107.832 166.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -64.18 -15.78 60.57 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.421 0.451 . . . . 2.09 111.248 -172.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -84.4 2.02 42.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.039 -0.528 . . . . 2.15 110.902 176.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 85.58 23.47 46.73 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.111 -0.566 . . . . 0.63 112.706 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.7 p -110.64 164.38 12.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.974 0.416 . . . . 1.14 111.37 -177.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2074 ' ' LYS . . . . . 0.592 ' O ' HG23 ' A' 2086 ' ' ILE . 47.9 mmtm -113.32 -44.78 3.2 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.684 -0.689 . . . . 1.68 110.696 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.582 ' HG3' HG21 ' A' 2085 ' ' THR . 4.6 mp0 -119.97 138.11 53.67 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.772 -0.455 . . . . 2.08 109.772 173.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.5 OUTLIER -127.71 99.25 5.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.15 -0.477 . . . . 2.03 109.736 178.258 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 48.7 m -110.69 121.77 46.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.11 0.481 . . . . 1.28 110.476 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 88.0 mt -126.84 126.17 24.39 Favored Pre-proline 0 C--N 1.315 -0.91 0 N-CA-C 108.521 -0.918 . . . . 2.24 108.521 174.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -47.14 109.67 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.295 2.664 . . . . 1.09 113.257 -175.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2080 ' ' GLY . . . . . 0.49 ' O ' ' HD2' ' A' 2100 ' ' PHE . . . 93.9 -12.95 68.44 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.706 -0.679 . . . . 0.94 113.009 177.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.491 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -94.7 -32.47 13.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 117.122 0.461 . . . . 2.02 110.661 -175.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.7 -155.24 16.28 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.811 -0.709 . . . . 0.58 111.9 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.557 ' HA ' ' O ' ' A' 2076 ' ' LYS . 55.8 m -155.28 138.92 16.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.698 0.761 . . . . 1.21 111.011 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.611 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.2 m-85 -109.01 121.69 45.68 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.774 -1.565 . . . . 2.34 106.774 170.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2085 ' ' THR . . . . . 0.582 HG21 ' HG3' ' A' 2075 ' ' GLU . 16.8 p -118.84 133.56 55.75 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.721 0.296 . . . . 1.26 111.584 -175.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.592 HG23 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -113.02 136.9 47.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.278 -0.419 . . . . 1.76 110.186 176.16 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 18.6 m -122.71 144.82 43.55 Favored Pre-proline 0 C--N 1.319 -0.732 0 N-CA-C 109.975 -0.38 . . . . 1.35 109.975 173.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -62.18 0.01 1.52 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.542 2.828 . . . . 1.32 114.014 -172.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 37.2 t70 -68.04 -21.29 65.02 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.411 -0.589 . . . . 2.29 109.411 173.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.33 5.18 28.5 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.374 -0.83 . . . . 0.83 111.715 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2091 ' ' THR . . . . . 0.494 ' HA ' ' NH2' ' A' 2111 ' ' ARG . 4.9 t -114.23 143.34 45.0 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.185 0.517 . . . . 1.8 110.945 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 27.6 t -139.32 137.52 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.529 -0.759 . . . . 1.67 109.309 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 7.2 t -107.1 121.23 44.08 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.206 0.527 . . . . 1.94 110.166 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -87.53 97.86 11.08 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.087 -1.079 . . . . 2.13 108.087 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2095 ' ' THR . . . . . 0.452 ' HB ' ' O ' ' A' 2083 ' ' THR . 43.9 m -117.63 99.09 52.27 Favored Pre-proline 0 N--CA 1.453 -0.31 0 N-CA-C 112.501 0.556 . . . . 1.21 112.501 -174.063 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -86.17 143.17 7.75 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.567 2.178 . . . . 1.23 110.231 166.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 17.1 t70 -61.34 135.01 57.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.955 0.407 . . . . 2.72 110.499 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 58.9 mttp -72.24 -14.22 61.72 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.618 -0.719 . . . . 5.15 111.913 -172.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -120.16 23.41 10.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.998 -0.371 . . . . 5.07 109.998 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2100 ' ' PHE . . . . . 0.49 ' HD2' ' O ' ' A' 2080 ' ' GLY . 64.1 t80 -72.64 124.88 26.18 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-O 121.152 0.501 . . . . 3.08 110.311 179.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.3 p -74.89 99.91 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.226 -0.897 . . . . 3.01 110.478 177.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 102.56 -147.96 17.29 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.803 -0.635 . . . . 3.84 112.039 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 48.7 mttp -111.02 134.4 21.03 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 120.613 0.245 . . . . 7.31 110.876 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -43.72 149.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 124.409 3.406 . . . . 2.77 114.035 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2105 ' ' ASP . . . . . 0.419 ' H ' ' HG3' ' A' 2081 ' ' GLN . 1.4 m-20 -56.68 153.94 19.74 Favored Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 114.962 -1.017 . . . . 2.33 111.898 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -53.22 113.16 1.15 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 124.235 3.29 . . . . 1.29 114.598 -174.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.2 p -160.66 119.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.092 -0.958 . . . . 1.23 109.776 172.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' 2121 ' ' ALA . 62.3 m -95.87 118.29 32.24 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.453 0.644 . . . . 1.11 110.17 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' 2120 ' ' THR . 6.1 t -91.65 136.36 24.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.259 -0.882 . . . . 1.35 108.989 -178.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.588 ' HD2' ' C ' ' A' 2110 ' ' LYS . 0.0 OUTLIER -139.97 108.86 5.99 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.156 0.503 . . . . 2.25 112.188 -173.089 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.494 ' NH2' ' HA ' ' A' 2091 ' ' THR . 4.2 ptm180 -142.4 132.76 24.95 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.719 -0.845 . . . . 3.95 108.719 170.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.51 ' O ' HG22 ' A' 2065 ' ' VAL . 33.0 m -99.12 152.82 4.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.587 -0.445 . . . . 1.09 111.695 -174.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.468 ' OD2' HG11 ' A' 2059 ' ' VAL . 1.2 p-10 -92.48 -170.68 2.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.969 -0.56 . . . . 1.46 110.15 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -64.72 -34.05 77.4 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.585 0.231 . . . . 2.25 111.255 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -69.66 -30.13 67.74 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 1.84 110.568 175.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 109.97 7.43 27.14 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.964 -0.636 . . . . 0.46 111.978 -178.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.415 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 87.9 m -81.97 118.73 73.15 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 110.142 -0.318 . . . . 1.22 110.142 178.678 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' 2112 ' ' VAL . 3.3 Cg_exo -78.88 116.63 3.77 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 122.21 1.94 . . . . 0.72 112.307 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 6.8 m -74.85 108.88 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.423 0 N-CA-C 107.89 -1.152 . . . . 1.37 107.89 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' 2109 ' ' VAL . 68.5 p -123.3 168.48 12.43 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.662 -1.154 . . . . 1.23 111.006 -170.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.04 126.36 39.31 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.083 -1.08 . . . . 1.33 108.083 168.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 37.6 m -94.66 98.71 10.99 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.147 -0.686 . . . . 2.66 109.147 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -120.57 123.95 44.11 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.574 0.702 . . . . 3.23 111.796 -176.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A 2124 ' ' SER . . . . . 0.591 ' OG ' ' HD2' ' A' 2125 ' ' PRO . 6.6 t -132.87 162.16 59.18 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 114.459 -1.246 . . . . 2.37 108.391 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.591 ' HD2' ' OG ' ' A' 2124 ' ' SER . 49.2 Cg_endo . . . . . 0 C--N 1.353 0.776 0 C-N-CA 122.584 2.189 . . . . 2.51 112.838 176.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.458 -0.042 0 CA-C-O 120.816 0.341 . . . . 2.42 111.343 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -76.88 -21.44 12.45 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.341 2.028 . . . . 1.98 111.915 176.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.6 mp -85.14 -22.4 28.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.874 -0.603 . . . . 2.8 110.048 177.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.8 t -126.17 83.32 63.82 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 108.711 -0.848 . . . . 1.56 108.711 178.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2060 ' ' PRO . . . . . 0.491 ' O ' ' HG3' ' A' 2114 ' ' LYS . 33.3 Cg_exo -58.53 141.59 97.46 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.625 2.217 . . . . 1.35 112.196 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.1 mm -63.12 135.79 26.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.693 -0.685 . . . . 1.33 110.112 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.443 ' O ' HG23 ' A' 2065 ' ' VAL . 11.7 t70 -70.51 128.69 37.02 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.28 -0.418 . . . . 1.42 110.064 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -89.38 0.19 57.01 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.112 -0.494 . . . . 1.55 112.005 -171.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -105.11 -12.76 15.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.955 0.407 . . . . 1.29 110.972 178.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.533 ' O ' ' HD3' ' A' 2067 ' ' PRO . 33.3 m -91.72 -174.59 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.744 -0.465 . . . . 1.47 109.744 175.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -92.8 113.53 59.94 Favored Pre-proline 0 C--O 1.245 0.829 0 CA-C-O 121.268 0.556 . . . . 0.78 111.354 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' A' 2065 ' ' VAL . 51.0 Cg_endo -100.71 106.93 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.658 0 C-N-CA 123.096 2.531 . . . . 0.52 111.45 167.13 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 16.7 p -138.88 178.88 6.83 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.072 0.463 . . . . 1.07 111.176 -178.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.538 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 97.2 m-85 -103.0 159.45 15.5 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.71 -0.848 . . . . 1.99 108.71 168.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -51.13 -44.13 61.32 Favored 'General case' 0 N--CA 1.468 0.474 0 O-C-N 123.755 0.66 . . . . 2.09 112.203 -168.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 36.9 t70 -81.19 6.04 15.15 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.393 0.616 . . . . 2.15 111.109 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 89.87 11.76 63.12 Favored Glycine 0 N--CA 1.45 -0.381 0 N-CA-C 111.675 -0.57 . . . . 0.63 111.675 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2073 ' ' SER . . . . . 0.452 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 4.2 m -74.57 161.58 29.59 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.797 0.332 . . . . 1.14 110.875 -173.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -120.37 -21.2 6.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 1.68 110.883 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.416 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.0 tt0 -156.43 129.91 8.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.983 0.42 . . . . 2.08 110.108 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.1 OUTLIER -126.78 100.59 6.25 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.972 -0.558 . . . . 2.03 110.816 178.029 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 32.2 m -96.34 123.7 40.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.077 -0.511 . . . . 1.28 110.287 174.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.535 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 2.7 mp -126.36 122.55 23.97 Favored Pre-proline 0 C--N 1.314 -0.936 0 N-CA-C 109.206 -0.664 . . . . 2.24 109.206 177.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 68.9 Cg_exo -51.36 109.99 0.37 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.329 2.686 . . . . 1.09 113.274 -175.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 94.46 -6.65 71.35 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.94 112.757 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.535 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.6 tt0 -109.1 -33.39 6.9 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.123 0.487 . . . . 2.02 110.584 -175.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.77 -155.18 16.29 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.628 -0.796 . . . . 0.58 112.552 176.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.439 ' HA ' ' O ' ' A' 2076 ' ' LYS . 32.1 m -150.72 137.4 18.92 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.32 0.581 . . . . 1.21 110.533 178.136 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.538 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.3 OUTLIER -111.51 121.88 46.36 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.481 -1.303 . . . . 2.34 107.481 170.784 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 2.6 p -118.88 158.15 26.23 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 112.828 0.677 . . . . 1.26 112.828 -171.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.521 ' HB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -159.33 124.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 115.009 -0.996 . . . . 1.76 109.57 172.223 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A 2087 ' ' VAL . . . . . 0.589 HG23 ' OG1' ' A' 2091 ' ' THR . 9.9 m -107.58 157.52 35.59 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.871 -0.788 . . . . 1.35 108.871 173.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.99 0.52 1.2 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 123.392 2.728 . . . . 1.32 114.299 -171.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -82.45 -12.81 57.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 2.29 110.099 174.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 97.08 32.57 6.38 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.948 -0.644 . . . . 0.83 112.338 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2091 ' ' THR . . . . . 0.589 ' OG1' HG23 ' A' 2087 ' ' VAL . 63.7 p -87.86 136.06 33.12 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.261 -0.274 . . . . 1.8 110.261 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 48.9 t -136.78 126.38 38.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 120.891 0.376 . . . . 1.67 111.55 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.7 t -146.92 109.72 4.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.529 0.681 . . . . 1.94 110.382 171.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2094 ' ' PHE . . . . . 0.662 ' CE2' HG13 ' A' 2109 ' ' VAL . 13.6 m-30 -84.91 101.99 12.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.373 -0.973 . . . . 2.13 108.373 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 2.1 m -110.13 88.62 7.28 Favored Pre-proline 0 N--CA 1.452 -0.356 0 CA-C-O 120.9 0.381 . . . . 1.21 110.812 -177.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2096 ' ' PRO . . . . . 0.541 ' HD3' ' O ' ' A' 2094 ' ' PHE . 93.3 Cg_endo -92.27 166.97 2.95 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 123.436 2.758 . . . . 1.23 112.547 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 13.0 t70 -131.8 110.17 10.65 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.401 -0.592 . . . . 2.72 109.401 171.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.59 18.77 4.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.816 0.341 . . . . 5.15 111.381 -176.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -119.86 7.13 10.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.076 0.465 . . . . 5.07 110.158 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 53.3 t80 -83.57 113.14 20.61 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.635 -0.711 . . . . 3.08 111.047 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.5 t -113.46 98.78 7.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.947 -0.57 . . . . 3.01 109.664 175.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 172.17 43.3 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.711 -0.677 . . . . 3.84 111.512 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 37.1 ttpt 60.45 83.49 0.21 Allowed Pre-proline 0 CA--C 1.531 0.226 0 C-N-CA 123.425 0.69 . . . . 7.31 111.441 -178.327 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2104 ' ' PRO . . . . . 0.414 ' HG2' ' O ' ' A' 2124 ' ' SER . 14.1 Cg_endo -58.9 134.24 58.86 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.186 1.924 . . . . 2.77 111.042 173.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.4 t70 -60.85 124.99 82.19 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.092 -0.504 . . . . 2.33 110.889 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' 2123 ' ' TYR . 27.2 Cg_endo -64.1 95.85 0.21 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.728 2.286 . . . . 1.29 112.048 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.9 p -128.58 160.83 38.51 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.386 -0.824 . . . . 1.23 109.499 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 93.8 m -140.75 131.19 25.27 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.356 -0.609 . . . . 1.11 109.356 174.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.662 HG13 ' CE2' ' A' 2094 ' ' PHE . 6.0 t -92.04 137.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.773 -0.825 . . . . 1.35 108.773 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -144.92 108.22 4.59 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.974 -0.38 . . . . 2.25 109.974 -178.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.53 ' CB ' ' HA ' ' A' 2067 ' ' PRO . 15.0 ptp180 -159.6 156.55 28.17 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.162 -0.472 . . . . 3.95 109.751 175.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 34.7 m -109.41 140.65 27.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 C-N-CA 120.202 -0.599 . . . . 1.09 111.577 -176.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.591 ' OD2' ' HB ' ' A' 2117 ' ' THR . 2.5 p30 -90.04 -169.04 2.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.62 -0.718 . . . . 1.46 111.121 178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2114 ' ' LYS . . . . . 0.491 ' HG3' ' O ' ' A' 2060 ' ' PRO . 99.4 mttt -59.47 -29.78 68.06 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.184 0.439 . . . . 2.25 112.184 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -86.05 -11.32 53.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 1.84 110.738 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.14 13.03 59.39 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.906 -0.664 . . . . 0.46 112.048 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.591 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 73.5 m -78.81 128.3 77.29 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-O 120.569 0.223 . . . . 1.22 110.549 178.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' 2117 ' ' THR . 2.7 Cg_exo -75.61 99.0 1.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.322 2.014 . . . . 0.72 111.814 177.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 17.2 m -75.39 109.41 8.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.535 0.683 . . . . 1.37 109.466 175.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.533 ' HA ' ' O ' ' A' 2109 ' ' VAL . 80.3 p -120.33 167.26 12.49 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 115.319 -0.855 . . . . 1.23 110.898 -175.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -140.56 128.58 22.07 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.875 -0.787 . . . . 1.33 108.875 173.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 10.9 p -92.1 98.87 11.81 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.236 0.541 . . . . 2.66 110.664 -177.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.425 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.0 OUTLIER -115.5 123.41 48.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.784 -0.644 . . . . 3.23 110.959 -178.43 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A 2124 ' ' SER . . . . . 0.414 ' O ' ' HG2' ' A' 2104 ' ' PRO . 68.8 m -157.35 163.73 23.93 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.515 -0.766 . . . . 2.37 109.04 178.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 93.0 Cg_exo . . . . . 0 C--N 1.346 0.427 0 C-N-CA 122.659 2.239 . . . . 2.51 112.523 177.965 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 CA--C 1.519 -0.247 0 N-CA-C 110.184 -0.302 . . . . 2.42 110.184 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -68.43 -9.41 25.91 Favored 'Trans proline' 0 CA--C 1.528 0.218 0 C-N-CA 122.192 1.928 . . . . 1.98 111.862 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.5 mp -84.78 -18.85 33.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.923 -0.58 . . . . 2.8 110.11 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2059 ' ' VAL . . . . . 0.487 HG11 ' OD2' ' A' 2113 ' ' ASP . 4.6 t -138.84 89.86 12.74 Favored Pre-proline 0 CA--C 1.514 -0.41 0 N-CA-C 109.322 -0.621 . . . . 1.56 109.322 -177.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -53.25 120.68 8.13 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.315 2.01 . . . . 1.35 111.619 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.4 mm -49.77 134.82 8.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.152 -0.931 . . . . 1.33 111.679 -176.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.543 ' O ' HG22 ' A' 2065 ' ' VAL . 14.6 t70 -76.65 130.26 37.54 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.437 -0.802 . . . . 1.42 110.691 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -87.43 -8.29 56.69 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.238 0.458 . . . . 1.55 112.238 -174.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 29.7 p -101.75 0.79 36.47 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 120.5 -0.48 . . . . 1.29 111.883 -178.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.592 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.6 m -92.87 -174.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.663 -0.244 . . . . 1.47 110.507 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -97.35 107.89 41.36 Favored Pre-proline 0 C--O 1.24 0.598 0 CA-C-O 121.364 0.602 . . . . 0.78 111.468 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.592 ' HD3' ' O ' ' A' 2065 ' ' VAL . 5.8 Cg_endo -93.71 108.75 0.17 Allowed 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.518 2.812 . . . . 0.52 110.88 167.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2068 ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.3 p -148.84 146.1 27.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.912 0.387 . . . . 1.07 110.64 -177.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.486 ' N ' ' CD2' ' A' 2069 ' ' PHE . 2.4 m-30 -71.64 148.32 46.66 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.44 -1.319 . . . . 1.99 107.44 176.071 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -61.08 -19.53 61.55 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.406 0.521 . . . . 2.09 112.406 -165.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -92.03 1.33 57.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.621 0.248 . . . . 2.15 111.131 178.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 87.59 25.21 33.5 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.86 -0.686 . . . . 0.63 112.018 -176.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 19.5 m -95.22 152.33 18.46 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 1.14 110.511 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -111.62 -22.47 11.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.084 -0.507 . . . . 1.68 110.58 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.518 ' HA ' ' O ' ' A' 2084 ' ' TYR . 3.0 tt0 -144.35 144.43 31.44 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.113 0.482 . . . . 2.08 110.243 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.4 OUTLIER -139.59 108.14 5.88 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.401 -0.818 . . . . 2.03 109.505 179.854 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 19.2 m -118.64 133.23 56.01 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.189 0.518 . . . . 1.28 111.493 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.502 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 4.2 mp -136.39 123.03 14.01 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 108.106 -1.072 . . . . 2.24 108.106 172.276 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -52.29 109.48 0.34 Allowed 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.669 2.246 . . . . 1.09 112.458 -178.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.65 -22.23 28.73 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.736 -0.665 . . . . 0.94 112.383 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.502 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 52.7 tt0 -96.06 -31.52 12.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.085 0.469 . . . . 2.02 110.463 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.49 -153.64 17.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.837 -0.697 . . . . 0.58 112.141 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' 2076 ' ' LYS . 43.0 m -150.0 144.96 26.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.65 0.738 . . . . 1.21 110.824 178.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.518 ' O ' ' HA ' ' A' 2075 ' ' GLU . 7.6 m-85 -120.15 125.01 47.17 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 107.236 -1.394 . . . . 2.34 107.236 172.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2085 ' ' THR . . . . . 0.41 ' O ' ' HA ' ' A' 2092 ' ' VAL . 17.3 p -129.07 134.75 48.23 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.544 0.572 . . . . 1.26 112.544 -174.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' 2067 ' ' PRO . 0.7 OUTLIER -130.82 123.94 55.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.562 -0.744 . . . . 1.76 110.142 170.155 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 19.2 m -112.15 151.58 43.75 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.003 -0.74 . . . . 1.35 109.003 172.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.76 -6.27 1.06 Allowed 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.057 3.171 . . . . 1.32 114.922 -168.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 27.1 t70 -66.85 -24.07 66.1 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.126 0.489 . . . . 2.29 110.179 175.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 104.11 20.07 10.94 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.738 -0.665 . . . . 0.83 112.223 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.8 t -110.42 126.38 54.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.962 0.41 . . . . 1.8 110.64 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.499 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 7.6 t -133.08 137.42 53.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.016 -0.538 . . . . 1.67 110.384 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.3 t -119.36 118.29 30.79 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.042 0.448 . . . . 1.94 110.19 173.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 9.4 m-30 -85.24 97.21 9.8 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.663 -0.866 . . . . 2.13 108.663 173.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 13.3 m -116.49 87.05 19.44 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.994 0.426 . . . . 1.21 110.76 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2096 ' ' PRO . . . . . 0.446 ' HB2' ' HH ' ' A' 2123 ' ' TYR . 91.6 Cg_endo -92.44 169.69 2.64 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.327 2.685 . . . . 1.23 112.42 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.9 t70 -118.35 106.51 12.83 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.872 -0.788 . . . . 2.72 108.872 171.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 93.2 mttt -69.77 -10.1 57.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.961 -0.563 . . . . 5.15 112.194 -171.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -110.46 8.88 23.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.703 0.287 . . . . 5.07 111.111 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 44.9 t80 -89.63 76.98 7.25 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.2 0.524 . . . . 3.08 110.904 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 4.2 p -103.96 124.98 58.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.216 0.531 . . . . 3.01 110.083 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 164.63 -81.9 0.11 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.047 -0.821 . . . . 3.84 111.047 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 22.7 tptm -140.42 76.72 24.99 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 120.935 0.398 . . . . 7.31 110.707 175.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -80.53 169.57 16.85 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.16 2.573 . . . . 2.77 111.445 173.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.3 t70 -103.06 125.3 35.64 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 116.544 -0.298 . . . . 2.33 110.198 178.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' 2123 ' ' TYR . 24.7 Cg_endo -62.96 103.5 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.734 2.29 . . . . 1.29 111.928 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2107 ' ' VAL . . . . . 0.403 HG12 ' HG2' ' A' 2076 ' ' LYS . 7.7 p -141.37 133.78 29.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.137 -0.483 . . . . 1.23 111.049 -177.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.3 m -102.5 108.71 20.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.652 -0.704 . . . . 1.11 109.906 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.63 ' O ' ' HA ' ' A' 2120 ' ' THR . 8.5 t -91.09 123.09 43.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.772 -0.825 . . . . 1.35 108.772 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.516 ' HB3' ' O ' ' A' 2068 ' ' THR . 1.7 tmmt? -129.59 149.6 51.28 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.402 0.62 . . . . 2.25 112.203 -169.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.499 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.3 ptt180 -166.91 138.2 3.28 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.97 -1.014 . . . . 3.95 108.292 165.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.519 ' O ' HG23 ' A' 2065 ' ' VAL . 27.1 m -98.61 148.88 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 C-N-CA 120.357 -0.537 . . . . 1.09 110.871 -175.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.487 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.7 p-10 -94.12 -168.7 1.91 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.933 -0.576 . . . . 1.46 110.448 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.5 mttm -62.88 -32.34 73.57 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.702 0.287 . . . . 2.25 111.393 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -77.54 -14.96 59.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.955 0.407 . . . . 1.84 110.599 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.87 12.47 59.13 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.906 -0.664 . . . . 0.46 112.333 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 27.8 m -85.83 121.26 73.15 Favored Pre-proline 0 C--N 1.324 -0.533 0 N-CA-C 110.106 -0.331 . . . . 1.22 110.106 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' 2117 ' ' THR . 3.1 Cg_exo -74.74 107.86 2.57 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.261 1.974 . . . . 0.72 112.653 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2119 ' ' VAL . . . . . 0.402 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 15.6 m -74.78 112.03 11.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 107.737 -1.208 . . . . 1.37 107.737 169.141 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.63 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.7 p -127.41 159.32 34.83 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.636 -0.711 . . . . 1.23 112.192 -169.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.46 127.63 42.86 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.8 -1.185 . . . . 1.33 107.8 169.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 12.5 p -115.67 99.53 7.39 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.23 0.538 . . . . 2.66 111.171 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.497 ' O ' ' HA ' ' A' 2106 ' ' PRO . 4.4 m-85 -90.08 151.98 21.36 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.677 -0.692 . . . . 3.23 111.099 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2124 ' ' SER . . . . . 0.404 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 33.3 p -148.2 168.01 12.04 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 115.957 -0.565 . . . . 2.37 110.551 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' 2124 ' ' SER . 71.3 Cg_exo . . . . . 0 C--N 1.351 0.669 0 C-N-CA 122.574 2.183 . . . . 2.51 112.975 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2056 ' ' ASP . . . . . 0.512 ' HB2' ' O ' ' A' 2059 ' ' VAL . 4.1 p-10 . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 121.262 0.553 . . . . 2.42 110.812 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -69.0 -53.11 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.375 2.05 . . . . 1.98 112.618 -170.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.8 mm? -121.32 19.4 11.4 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.999 -0.371 . . . . 2.8 109.999 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2059 ' ' VAL . . . . . 0.512 ' O ' ' HB2' ' A' 2056 ' ' ASP . 0.0 OUTLIER -131.85 77.52 72.01 Favored Pre-proline 0 N--CA 1.449 -0.523 0 C-N-CA 120.332 -0.547 . . . . 1.56 110.026 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.82 120.99 8.77 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.511 2.141 . . . . 1.35 111.95 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2061 ' ' ILE . . . . . 0.626 HG13 ' NE ' ' A' 2111 ' ' ARG . 47.1 mm -49.94 128.55 6.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.354 -0.839 . . . . 1.33 111.846 -178.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.492 ' O ' HG23 ' A' 2065 ' ' VAL . 11.1 t70 -66.81 136.8 55.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.746 -0.661 . . . . 1.42 110.171 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -88.71 1.19 55.57 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 112.567 0.58 . . . . 1.55 112.567 -171.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 70.1 p -120.29 -0.39 10.44 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.885 0.328 . . . . 1.29 111.885 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.663 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.8 m -86.35 -173.13 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.162 -0.31 . . . . 1.47 110.162 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -95.65 105.47 20.97 Favored Pre-proline 0 C--O 1.238 0.474 0 CA-C-O 120.966 0.412 . . . . 0.78 111.513 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.663 ' HD3' ' O ' ' A' 2065 ' ' VAL . 33.4 Cg_endo -100.31 106.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 122.898 2.399 . . . . 0.52 110.872 167.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2068 ' ' THR . . . . . 0.501 ' O ' ' HB3' ' A' 2110 ' ' LYS . 18.7 p -141.1 148.27 39.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.223 0.535 . . . . 1.07 110.585 -176.118 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.532 ' N ' ' HD1' ' A' 2069 ' ' PHE . 1.3 m-30 -74.58 149.36 40.16 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.416 -0.957 . . . . 1.99 108.416 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2070 ' ' GLU . . . . . 0.461 ' CB ' ' HB ' ' A' 2108 ' ' THR . 5.2 tm-20 -50.78 -42.12 57.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.955 0.407 . . . . 2.09 110.459 -173.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -71.89 0.79 8.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 115.638 -0.71 . . . . 2.15 112.563 -178.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 82.92 29.94 33.21 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.572 -0.823 . . . . 0.63 112.001 -176.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 15.7 m -106.75 159.15 16.44 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.849 0.357 . . . . 1.14 111.043 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -109.84 -18.8 13.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 1.68 110.638 176.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.4 ' HB2' HG23 ' A' 2085 ' ' THR . 6.0 tt0 -148.68 136.69 20.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.146 0.498 . . . . 2.08 109.853 173.045 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 32.9 tptt -128.29 113.65 15.9 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.541 -0.754 . . . . 2.03 109.183 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 46.3 m -117.91 124.9 49.4 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 121.482 0.658 . . . . 1.28 110.895 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.555 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 12.3 mt -120.2 120.74 29.89 Favored Pre-proline 0 C--N 1.313 -1.013 0 N-CA-C 107.774 -1.195 . . . . 2.24 107.774 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -41.91 108.66 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 123.551 2.834 . . . . 1.09 113.806 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.19 -30.48 6.71 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.486 -0.779 . . . . 0.94 113.037 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.555 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -74.83 -30.29 61.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.246 0.546 . . . . 2.02 110.172 -174.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 125.82 -171.34 17.67 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.471 -0.871 . . . . 0.58 112.571 175.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 38.3 m -140.25 132.29 27.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.534 0.683 . . . . 1.21 110.695 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.479 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.6 OUTLIER -106.49 129.82 54.38 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.882 -1.525 . . . . 2.34 106.882 169.521 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A 2085 ' ' THR . . . . . 0.4 HG23 ' HB2' ' A' 2075 ' ' GLU . 0.8 OUTLIER -133.06 140.59 47.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.258 0.551 . . . . 1.26 112.438 -175.939 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.462 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -130.27 131.64 65.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.152 -0.931 . . . . 1.76 109.672 173.289 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 27.7 m -115.33 149.42 42.75 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.727 -0.472 . . . . 1.35 109.727 174.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.04 -6.42 3.62 Favored 'Trans proline' 0 C--N 1.349 0.595 0 C-N-CA 123.808 3.005 . . . . 1.32 114.147 -170.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -70.23 -13.89 62.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.002 0.43 . . . . 2.29 110.206 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 96.9 17.71 31.81 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.929 -0.653 . . . . 0.83 112.182 178.521 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 4.8 t -115.52 133.46 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.049 0.452 . . . . 1.8 109.824 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.496 ' HB ' HH11 ' A' 2111 ' ' ARG . 11.6 t -135.12 149.79 29.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.581 . . . . 1.67 110.237 -173.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.0 t -136.23 123.74 22.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.287 0.565 . . . . 1.94 110.871 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.6 m-30 -99.13 98.72 9.7 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.193 -0.669 . . . . 2.13 109.193 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 12.0 m -113.96 96.79 42.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.873 0.368 . . . . 1.21 111.026 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -89.17 176.35 3.17 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 123.246 2.631 . . . . 1.23 112.787 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2097 ' ' ASP . . . . . 0.425 ' HB3' ' HA ' ' A' 2081 ' ' GLN . 6.4 p-10 -71.7 102.02 2.7 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.319 -0.855 . . . . 2.72 112.139 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2098 ' ' LYS . . . . . 0.579 ' H ' ' HD2' ' A' 2098 ' ' LYS . 0.0 OUTLIER -92.05 -9.76 41.6 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.087 -0.506 . . . . 5.15 110.263 173.694 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -120.64 -52.55 2.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.073 -0.512 . . . . 5.07 110.299 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.13 145.31 42.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.426 -0.806 . . . . 3.08 111.454 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 8.9 p -160.32 143.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 115.655 -0.702 . . . . 3.01 109.382 175.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 152.57 -94.07 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.578 -0.82 . . . . 3.84 112.453 -178.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 63.7 tttp -120.73 89.17 44.75 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-O 120.857 0.36 . . . . 7.31 110.507 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.74 139.44 25.03 Favored 'Trans proline' 0 N--CA 1.459 -0.531 0 C-N-CA 122.712 2.275 . . . . 2.77 111.097 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2105 ' ' ASP . . . . . 0.465 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 32.0 t70 -85.17 130.69 50.97 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 109.555 -0.535 . . . . 2.33 109.555 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.567 ' HA ' ' O ' ' A' 2123 ' ' TYR . 18.0 Cg_endo -60.41 119.55 6.8 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.117 2.544 . . . . 1.29 112.93 -177.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.5 p -159.36 133.64 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.746 -0.661 . . . . 1.23 110.372 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.534 ' HA ' ' O ' ' A' 2121 ' ' ALA . 34.1 m -105.51 119.31 38.79 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.188 0.518 . . . . 1.11 109.718 173.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -95.29 139.04 19.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.863 -0.792 . . . . 1.35 108.863 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.501 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.9 tmmm? -140.68 147.65 39.59 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 118.366 0.53 . . . . 2.25 111.438 -171.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.626 ' NE ' HG13 ' A' 2061 ' ' ILE . 29.1 ptt180 -168.98 135.28 1.73 Allowed 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.838 -0.801 . . . . 3.95 108.838 171.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 23.2 m -99.8 149.99 5.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 C-N-CA 120.393 -0.523 . . . . 1.09 111.207 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.423 ' HA ' ' HA ' ' A' 2061 ' ' ILE . 4.7 p-10 -93.93 -168.92 1.97 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.923 -0.581 . . . . 1.46 110.736 178.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.31 -41.78 85.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.19 -0.459 . . . . 2.25 111.929 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -18.74 46.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.869 0.366 . . . . 1.84 110.45 -177.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 106.14 16.76 14.11 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.543 -0.837 . . . . 0.46 113.641 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.411 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.8 m -83.83 119.26 73.28 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 117.187 0.494 . . . . 1.22 110.376 175.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -77.92 102.15 1.55 Allowed 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.369 2.046 . . . . 0.72 111.988 177.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.7 m -74.88 117.59 19.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 108.545 -0.909 . . . . 1.37 108.545 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' 2109 ' ' VAL . 61.2 p -126.25 161.14 28.43 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.524 -0.762 . . . . 1.23 111.78 -170.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.09 127.44 41.48 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 107.981 -1.118 . . . . 1.33 107.981 169.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 21.9 m -116.15 103.93 11.03 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 120.974 0.416 . . . . 2.66 110.54 -174.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' 2106 ' ' PRO . 2.3 m-85 -100.72 131.01 46.83 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.244 0.545 . . . . 3.23 112.048 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 16.1 m -131.77 146.81 63.42 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.135 -0.939 . . . . 2.37 109.391 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 CA--C 1.53 0.305 0 C-N-CA 122.815 2.343 . . . . 2.51 112.957 -178.278 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 121.114 0.483 . . . . 2.42 110.269 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -69.32 -52.82 0.33 Allowed 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.87 2.38 . . . . 1.98 111.862 177.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2058 ' ' LEU . . . . . 0.491 HD11 ' N ' ' A' 2058 ' ' LEU . 0.2 OUTLIER -68.33 -9.38 47.45 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.423 -0.808 . . . . 2.8 112.854 176.677 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A 2059 ' ' VAL . . . . . 0.417 HG22 HD13 ' A' 2058 ' ' LEU . 5.7 t -137.72 86.69 18.16 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 109.666 -0.494 . . . . 1.56 109.666 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.41 131.05 43.91 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.378 2.052 . . . . 1.35 111.847 -177.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 43.1 mm -62.86 122.66 14.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.904 -0.589 . . . . 1.33 109.935 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.541 ' O ' HG21 ' A' 2065 ' ' VAL . 21.1 t70 -70.46 134.52 47.84 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.236 0.541 . . . . 1.42 110.496 -176.431 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -89.3 -2.09 58.32 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.844 -0.616 . . . . 1.55 111.914 -171.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -113.99 -2.67 13.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.829 -0.348 . . . . 1.29 111.848 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.577 ' O ' ' HD3' ' A' 2067 ' ' PRO . 26.8 m -81.59 -174.59 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.973 -0.291 . . . . 1.47 110.284 177.391 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.11 109.27 51.11 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.211 0.529 . . . . 0.78 111.202 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.577 ' HD3' ' O ' ' A' 2065 ' ' VAL . 50.5 Cg_endo -99.57 111.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.518 0 C-N-CA 123.305 2.67 . . . . 0.52 110.875 165.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 8.4 p -145.13 -178.98 6.33 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.211 0.529 . . . . 1.07 110.758 -176.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.542 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 39.0 m-85 -102.73 148.25 25.84 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.735 -0.839 . . . . 1.99 108.735 168.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -59.98 -24.23 64.27 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.962 0.789 . . . . 2.09 111.593 -172.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -86.05 -3.45 58.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.309 -0.405 . . . . 2.15 110.858 178.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.57 29.88 12.97 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.147 -0.549 . . . . 0.63 113.066 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 26.3 p -110.61 179.15 4.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.032 0.416 . . . . 1.14 111.276 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2074 ' ' LYS . . . . . 0.425 ' O ' HG22 ' A' 2086 ' ' ILE . 34.6 mmtp -124.78 -4.8 7.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-O 120.957 0.408 . . . . 1.68 111.159 -178.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -159.56 132.32 6.76 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.457 -0.571 . . . . 2.08 109.457 169.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.445 ' HD2' ' HA ' ' A' 2076 ' ' LYS . 3.7 mmmm -120.01 100.89 7.48 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.968 -0.56 . . . . 2.03 110.306 174.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 89.5 m -97.51 111.57 23.78 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.876 -0.602 . . . . 1.28 110.242 173.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.457 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 96.6 mt -110.8 117.26 50.83 Favored Pre-proline 0 C--N 1.31 -1.113 0 N-CA-C 108.74 -0.837 . . . . 2.24 108.74 175.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -46.37 112.52 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.501 2.801 . . . . 1.09 113.574 -174.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 87.74 -11.09 67.55 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.783 -0.644 . . . . 0.94 112.795 177.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.457 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -101.19 -31.88 10.8 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.22 0.533 . . . . 2.02 110.296 -174.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 131.63 -170.42 21.58 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.45 -0.881 . . . . 0.58 113.095 173.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.536 ' O ' ' HB ' ' A' 2095 ' ' THR . 86.6 m -144.38 136.58 26.37 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.476 -0.564 . . . . 1.21 109.476 177.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.542 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -117.77 126.86 53.23 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.493 -1.299 . . . . 2.34 107.493 174.189 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 11.9 p -120.38 127.43 52.28 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.822 -0.351 . . . . 1.26 111.709 -175.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.458 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -108.08 135.44 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.955 -0.566 . . . . 1.76 109.864 175.58 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 26.7 m -122.22 150.69 57.48 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 109.41 -0.589 . . . . 1.35 109.41 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 34.6 Cg_exo -60.0 -1.28 1.17 Allowed 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.737 2.958 . . . . 1.32 113.792 -174.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 16.8 t70 -66.4 -20.17 65.99 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.267 0.556 . . . . 2.29 109.865 173.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 99.49 14.79 34.1 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.245 -0.742 . . . . 0.83 111.245 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.8 t -120.31 146.61 45.95 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.312 -0.444 . . . . 1.8 110.376 -177.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 21.5 t -132.82 138.56 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.353 -0.61 . . . . 1.67 109.353 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 51.6 m -97.76 109.98 22.63 Favored 'General case' 0 N--CA 1.439 -0.98 0 CA-C-O 120.789 0.328 . . . . 1.94 110.251 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 7.8 m-30 -86.81 98.41 11.17 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.64 -0.504 . . . . 2.13 109.64 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2095 ' ' THR . . . . . 0.536 ' HB ' ' O ' ' A' 2083 ' ' THR . 58.4 m -109.4 99.11 35.37 Favored Pre-proline 0 C--O 1.234 0.241 0 CA-C-O 120.942 0.401 . . . . 1.21 110.524 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -88.27 162.15 6.96 Favored 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 123.346 2.697 . . . . 1.23 113.966 -174.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2097 ' ' ASP . . . . . 0.456 ' HB2' ' CB ' ' A' 2100 ' ' PHE . 10.4 p-10 -72.46 48.31 0.19 Allowed 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.091 -0.959 . . . . 2.72 111.776 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -70.63 -10.01 58.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.079 0.466 . . . . 5.15 111.167 -175.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -116.65 24.44 11.29 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.117 -0.492 . . . . 5.07 110.753 178.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2100 ' ' PHE . . . . . 0.456 ' CB ' ' HB2' ' A' 2097 ' ' ASP . 63.7 t80 -113.8 142.2 46.36 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.156 0.503 . . . . 3.08 111.762 -173.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 74.3 t -132.26 105.01 8.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.633 -0.712 . . . . 3.01 110.19 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.29 -99.46 0.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 N-CA-C 111.279 -0.729 . . . . 3.84 111.279 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.18 120.51 0.89 Allowed Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 109.715 -0.476 . . . . 7.31 109.715 170.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.52 147.66 22.63 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.73 2.287 . . . . 2.77 112.162 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2105 ' ' ASP . . . . . 0.409 ' HB2' HD13 ' A' 2078 ' ' ILE . 18.8 m-20 -80.46 147.02 62.78 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.029 -0.532 . . . . 2.33 109.94 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.466 ' HA ' ' O ' ' A' 2123 ' ' TYR . 45.9 Cg_endo -68.04 128.95 18.51 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.147 2.565 . . . . 1.29 113.908 -171.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 5.5 p -158.08 160.0 2.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.38 -0.827 . . . . 1.23 109.169 177.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 26.5 m -141.25 122.35 14.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.115 0.483 . . . . 1.11 110.415 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 5.2 t -92.22 133.47 33.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 108.922 -0.77 . . . . 1.35 108.922 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -125.84 109.63 12.74 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 120.683 0.278 . . . . 2.25 111.387 -169.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.474 ' HG3' HG23 ' A' 2119 ' ' VAL . 30.8 ptt180 -147.3 135.4 21.46 Favored 'General case' 0 C--N 1.317 -0.818 0 O-C-N 121.797 -0.565 . . . . 3.95 110.133 168.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.489 ' O ' HG22 ' A' 2065 ' ' VAL . 34.2 m -99.09 154.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 120.998 0.428 . . . . 1.09 110.758 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.538 ' OD2' ' HB ' ' A' 2117 ' ' THR . 10.1 p30 -94.38 -169.59 2.08 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.81 -0.632 . . . . 1.46 110.778 178.139 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.7 mttm -65.06 -22.85 67.03 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.15 0.426 . . . . 2.25 112.15 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -90.5 -19.01 24.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.054 0.455 . . . . 1.84 110.235 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 102.94 15.13 24.93 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.662 -0.699 . . . . 0.46 111.962 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.538 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 24.1 m -91.62 119.63 68.44 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 120.805 0.336 . . . . 1.22 110.221 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' 2117 ' ' THR . 8.2 Cg_exo -72.68 107.34 2.3 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.46 2.106 . . . . 0.72 113.241 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2119 ' ' VAL . . . . . 0.474 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.95 109.25 9.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 108.088 -1.078 . . . . 1.37 108.088 165.008 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A 2120 ' ' THR . . . . . . . . . . . . . 75.0 p -125.14 179.5 5.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.105 -0.952 . . . . 1.23 110.553 -171.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.61 127.2 41.8 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.606 -0.887 . . . . 1.33 108.606 170.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 30.9 p -93.39 101.67 13.9 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.877 -0.601 . . . . 2.66 109.898 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' 2106 ' ' PRO . 5.4 m-85 -120.25 122.96 42.04 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.633 0.73 . . . . 3.23 112.17 -175.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 46.9 p -152.42 158.18 33.5 Favored Pre-proline 0 C--N 1.321 -0.642 0 CA-C-N 114.478 -1.237 . . . . 2.37 108.859 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo . . . . . 0 C--N 1.346 0.41 0 C-N-CA 122.474 2.116 . . . . 2.51 112.794 -179.428 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 6.9 t70 . . . . . 0 N--CA 1.452 -0.364 0 N-CA-C 110.106 -0.331 . . . . 2.42 110.106 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.34 -20.31 42.68 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.585 2.19 . . . . 1.98 112.596 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.8 mp -100.29 -26.78 13.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.795 0.331 . . . . 2.8 110.301 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 4.6 t -116.52 82.43 12.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.186 -0.461 . . . . 1.56 109.818 178.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.44 120.1 7.25 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.374 2.049 . . . . 1.35 111.559 179.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.7 mm -49.9 131.21 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.522 -0.763 . . . . 1.33 110.908 179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' 2065 ' ' VAL . 10.6 t70 -69.25 135.1 50.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.458 -0.792 . . . . 1.42 110.588 -176.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -97.49 2.96 50.83 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.987 0.366 . . . . 1.55 111.987 -173.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.2 p -109.74 3.32 20.75 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.08 0.943 . . . . 1.29 108.97 173.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.709 ' O ' ' HD3' ' A' 2067 ' ' PRO . 1.0 OUTLIER -91.29 165.22 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 CA-C-N 114.041 -1.436 . . . . 1.47 110.108 -178.807 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.37 108.98 9.85 Favored Pre-proline 0 C--O 1.24 0.553 0 CA-C-O 120.697 0.284 . . . . 0.78 111.368 177.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' 2065 ' ' VAL . 60.7 Cg_endo -102.34 108.6 0.04 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.57 0 C-N-CA 123.454 2.769 . . . . 0.52 111.328 166.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 21.3 p -134.5 174.45 10.53 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.529 0.68 . . . . 1.07 111.335 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.532 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.7 OUTLIER -101.13 151.4 21.87 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.64 -1.245 . . . . 1.99 107.64 170.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -45.71 -41.72 10.91 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 123.719 0.637 . . . . 2.09 112.391 -171.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -90.17 16.58 8.27 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 111.944 0.35 . . . . 2.15 111.944 -175.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 30.0 58.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.663 -0.78 . . . . 0.63 112.668 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.3 p -102.92 167.96 9.52 Favored 'General case' 0 C--N 1.323 -0.564 0 O-C-N 122.859 -0.201 . . . . 1.14 110.496 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2074 ' ' LYS . . . . . 0.419 ' O ' HG22 ' A' 2086 ' ' ILE . 42.1 mmtm -123.39 -10.45 7.97 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.246 0.462 . . . . 1.68 112.246 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -158.77 128.1 5.59 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.928 0.394 . . . . 2.08 110.156 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.35 100.47 6.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.185 -0.672 . . . . 2.03 109.185 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 62.8 m -109.78 127.21 54.49 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.282 -0.417 . . . . 1.28 111.112 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.564 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 35.4 mm -131.32 132.01 23.37 Favored Pre-proline 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.917 . . . . 2.24 108.523 171.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.76 108.9 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.478 2.119 . . . . 1.09 112.197 178.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2080 ' ' GLY . . . . . 0.413 ' HA3' ' O ' ' A' 2101 ' ' VAL . . . 99.83 -4.09 57.6 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.018 -0.61 . . . . 0.94 112.319 -179.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.564 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.1 tt0 -107.33 -29.79 9.08 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.125 0.488 . . . . 2.02 110.222 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 103.89 -162.35 15.49 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.565 -0.743 . . . . 0.58 111.641 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.51 ' O ' ' HB ' ' A' 2095 ' ' THR . 47.1 m -139.76 135.43 33.08 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.568 0.699 . . . . 1.21 110.729 178.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.486 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.6 m-85 -104.58 110.74 23.15 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.069 -1.456 . . . . 2.34 107.069 171.368 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 13.3 p -108.24 123.67 49.12 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.323 0.49 . . . . 1.26 112.323 -171.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.473 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.93 130.8 72.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.112 -0.494 . . . . 1.76 109.84 170.349 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.5 m -122.33 150.59 57.59 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.01 -0.541 . . . . 1.35 109.748 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.94 -3.9 1.78 Allowed 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 123.949 3.099 . . . . 1.32 114.276 -172.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.3 -13.95 62.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.223 0.535 . . . . 2.29 110.057 176.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.57 8.16 54.92 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.531 -0.759 . . . . 0.83 111.552 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -111.44 129.01 56.16 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.381 0.61 . . . . 1.8 110.501 -177.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.59 HG13 ' NH1' ' A' 2111 ' ' ARG . 1.1 p -150.08 139.29 15.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.529 -0.76 . . . . 1.67 110.538 -176.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -127.57 130.92 49.93 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.098 0.475 . . . . 1.94 110.747 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2094 ' ' PHE . . . . . 0.445 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.5 m-30 -84.36 99.02 10.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.463 -0.94 . . . . 2.13 108.463 175.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2095 ' ' THR . . . . . 0.51 ' HB ' ' O ' ' A' 2083 ' ' THR . 19.6 m -116.54 89.35 27.25 Favored Pre-proline 0 N--CA 1.454 -0.259 0 CA-C-O 121.215 0.531 . . . . 1.21 111.815 -175.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2096 ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' 2094 ' ' PHE . 5.3 Cg_endo -87.41 142.2 6.02 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 123.207 2.605 . . . . 1.23 110.877 172.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.49 137.23 58.19 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.184 -0.462 . . . . 2.72 110.712 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2098 ' ' LYS . . . . . 0.473 ' HZ2' ' HB3' ' A' 2098 ' ' LYS . 0.3 OUTLIER -62.15 -20.21 63.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.378 -0.828 . . . . 5.15 112.184 -175.636 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -103.49 -44.73 5.05 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.711 -0.477 . . . . 5.07 109.711 177.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2100 ' ' PHE . . . . . 0.447 ' CE1' ' HB3' ' A' 2104 ' ' PRO . 43.1 t80 65.1 72.2 0.44 Allowed 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.654 0.74 . . . . 3.08 110.804 177.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2101 ' ' VAL . . . . . 0.413 ' O ' ' HA3' ' A' 2080 ' ' GLY . 77.1 t -145.03 117.81 2.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.125 -0.943 . . . . 3.01 109.832 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 154.58 48.7 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.038 -1.077 . . . . 3.84 113.13 178.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.4 ttpp 55.87 72.56 0.99 Allowed Pre-proline 0 CA--C 1.535 0.367 0 C-N-CA 122.616 0.366 . . . . 7.31 111.213 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2104 ' ' PRO . . . . . 0.447 ' HB3' ' CE1' ' A' 2100 ' ' PHE . 19.2 Cg_endo -58.87 135.6 68.0 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.906 2.404 . . . . 2.77 113.299 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.0 t70 -92.88 130.92 34.83 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.616 -0.72 . . . . 2.33 109.723 178.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.473 ' HA ' ' O ' ' A' 2123 ' ' TYR . 30.8 Cg_endo -64.71 106.61 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.634 2.223 . . . . 1.29 112.235 -176.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.1 p -142.94 135.54 25.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.264 0.554 . . . . 1.23 111.34 -178.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' 2121 ' ' ALA . 88.5 m -111.21 122.85 48.93 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.564 -0.744 . . . . 1.11 109.412 171.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.583 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.3 t -95.54 136.73 25.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.929 -0.767 . . . . 1.35 108.929 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -141.95 113.58 7.82 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.09 0.774 . . . . 2.25 113.09 -171.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.59 ' NH1' HG13 ' A' 2092 ' ' VAL . 23.9 ptt180 -140.69 143.44 35.07 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.26 -0.644 . . . . 3.95 109.26 171.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.554 ' O ' HG11 ' A' 2065 ' ' VAL . 34.8 m -98.41 149.95 5.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.238 -0.585 . . . . 1.09 111.179 -176.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 25.1 p30 -88.01 -168.93 2.38 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.708 -0.678 . . . . 1.46 110.783 179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.3 mttt -65.69 -23.59 66.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.716 0.293 . . . . 2.25 111.553 -178.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -82.57 -27.26 31.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.104 0.478 . . . . 1.84 110.56 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 108.29 11.53 23.58 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.358 -0.697 . . . . 0.46 111.358 -177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.413 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 61.6 m -90.59 118.96 69.08 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 120.595 0.236 . . . . 1.22 110.481 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' 2117 ' ' THR . 10.5 Cg_exo -71.38 119.72 6.46 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.719 2.279 . . . . 0.72 113.014 -179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.6 m -84.79 109.39 17.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.326 -0.991 . . . . 1.37 108.326 169.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.583 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.6 p -119.58 149.87 41.22 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.125 -0.943 . . . . 1.23 111.747 -170.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.602 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.57 126.15 39.71 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.125 -1.065 . . . . 1.33 108.125 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 46.5 m -113.57 101.7 9.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.644 -0.502 . . . . 2.66 109.644 -177.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.8 m-85 -97.68 124.95 42.19 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.967 -0.561 . . . . 3.23 112.045 -174.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 26.0 m -91.02 150.55 41.98 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 115.105 -0.952 . . . . 2.37 110.98 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.448 ' HB3' ' HD3' ' A' 2106 ' ' PRO . 73.5 Cg_endo . . . . . 0 N--CA 1.46 -0.468 0 C-N-CA 122.769 2.313 . . . . 2.51 111.863 177.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 16.5 t70 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.532 -0.544 . . . . 2.42 109.532 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.0 -18.57 46.25 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.895 2.397 . . . . 1.98 112.706 -176.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.4 mp -87.48 -33.3 19.06 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.377 -0.374 . . . . 2.8 110.403 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 2.6 t -135.41 87.38 27.49 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.418 -0.355 . . . . 1.56 110.048 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -38.66 119.71 0.43 Allowed 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 123.411 2.741 . . . . 1.35 112.661 173.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 42.4 mm -56.18 123.66 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.828 -0.623 . . . . 1.33 111.477 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.511 ' O ' HG23 ' A' 2065 ' ' VAL . 30.8 t70 -68.01 135.98 53.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.788 -0.642 . . . . 1.42 110.502 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -86.62 -6.62 58.81 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.082 -0.508 . . . . 1.55 111.782 -172.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.5 p -111.18 4.01 18.92 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.166 0.432 . . . . 1.29 112.166 -177.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.677 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.7 m -86.99 -174.07 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.904 -0.406 . . . . 1.47 109.904 174.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -93.57 105.77 17.79 Favored Pre-proline 0 C--O 1.238 0.494 0 CA-C-O 120.974 0.416 . . . . 0.78 111.293 176.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.677 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.4 Cg_endo -100.74 108.64 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.548 0 C-N-CA 123.308 2.672 . . . . 0.52 110.62 166.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2068 ' ' THR . . . . . 0.487 HG22 ' HE2' ' A' 2074 ' ' LYS . 18.5 p -138.75 177.07 8.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.646 0.736 . . . . 1.07 111.101 -175.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.464 ' CE1' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-85 -101.55 142.18 33.3 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 107.147 -1.427 . . . . 1.99 107.147 165.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -58.78 -19.08 37.59 Favored 'General case' 0 C--N 1.328 -0.329 0 O-C-N 123.849 0.718 . . . . 2.09 111.975 -168.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2071 ' ' ASP . . . . . 0.454 ' CG ' ' HG ' ' A' 2073 ' ' SER . 12.7 p-10 -98.58 8.04 45.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.82 0.343 . . . . 2.15 111.038 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.07 17.72 52.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.089 -0.577 . . . . 0.63 113.195 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2073 ' ' SER . . . . . 0.454 ' HG ' ' CG ' ' A' 2071 ' ' ASP . 32.3 m -93.89 167.55 11.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.916 0.358 . . . . 1.14 110.999 -178.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2074 ' ' LYS . . . . . 0.514 ' O ' HG21 ' A' 2086 ' ' ILE . 34.5 mmtp -127.67 -16.86 4.67 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 116.161 -0.472 . . . . 1.68 111.12 178.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.626 ' HG2' HG22 ' A' 2085 ' ' THR . 0.9 OUTLIER -149.72 98.51 2.75 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.761 -0.459 . . . . 2.08 109.761 174.239 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 26.1 tptt -92.19 108.35 19.88 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.281 -0.418 . . . . 2.03 110.073 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 86.9 m -107.84 118.13 35.93 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-O 121.408 0.623 . . . . 1.28 110.478 174.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.556 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 72.1 mt -114.02 115.07 45.94 Favored Pre-proline 0 N--CA 1.438 -1.034 0 CA-C-N 114.911 -1.04 . . . . 2.24 108.471 175.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -47.84 109.52 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 123.332 2.688 . . . . 1.09 113.567 -174.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 90.68 -8.64 79.5 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.923 -0.58 . . . . 0.94 112.694 176.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.556 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.6 tm0? -100.82 -31.11 11.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.096 0.474 . . . . 2.02 109.829 -176.19 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 129.13 -167.57 21.13 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.818 -0.706 . . . . 0.58 112.492 177.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 55.0 m -149.57 129.89 13.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.507 0.67 . . . . 1.21 110.341 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.464 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 2.7 m-85 -101.85 130.42 48.31 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 106.789 -1.559 . . . . 2.34 106.789 171.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2085 ' ' THR . . . . . 0.626 HG22 ' HG2' ' A' 2075 ' ' GLU . 77.5 p -125.67 137.63 53.87 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.176 -0.61 . . . . 1.26 111.932 -172.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.514 HG21 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -130.9 133.36 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-N 115.573 -0.739 . . . . 1.76 109.878 173.962 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 24.5 m -116.61 149.17 43.38 Favored Pre-proline 0 C--N 1.32 -0.684 0 N-CA-C 109.143 -0.688 . . . . 1.35 109.143 172.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -61.99 -0.75 1.81 Allowed 'Trans proline' 0 N--CA 1.477 0.533 0 C-N-CA 123.633 2.889 . . . . 1.32 113.95 -170.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.08 -14.71 62.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.08 0.467 . . . . 2.29 110.064 177.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.14 21.11 18.72 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.868 -0.605 . . . . 0.83 112.082 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -120.63 135.97 54.96 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.916 0.389 . . . . 1.8 110.349 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.621 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 5.2 t -136.35 149.44 27.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.922 -0.581 . . . . 1.67 110.002 -176.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.9 t -134.96 130.03 35.15 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.273 0.558 . . . . 1.94 110.409 172.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.4 m-30 -93.82 98.78 11.31 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.032 -0.729 . . . . 2.13 109.032 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 21.3 m -117.56 88.7 30.13 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-O 120.919 0.39 . . . . 1.21 111.891 -177.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -91.78 161.26 3.42 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 123.213 2.609 . . . . 1.23 111.822 171.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2097 ' ' ASP . . . . . 0.454 ' HB3' ' HB2' ' A' 2100 ' ' PHE . 11.6 t70 -75.41 114.17 13.65 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.613 -0.514 . . . . 2.72 109.613 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 2.7 tpmt? -43.56 -53.31 5.7 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 124.059 0.849 . . . . 5.15 113.262 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -121.27 37.4 4.34 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 111.88 0.326 . . . . 5.07 111.88 -171.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2100 ' ' PHE . . . . . 0.454 ' HB2' ' HB3' ' A' 2097 ' ' ASP . 56.5 t80 -78.59 84.59 4.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.486 0.66 . . . . 3.08 110.287 177.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.2 t -93.9 113.22 28.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.627 -0.715 . . . . 3.01 110.16 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 179.52 -110.13 0.28 Allowed Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.521 -0.632 . . . . 3.84 111.521 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.9 ptpt -135.03 72.97 66.75 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-O 121.207 0.527 . . . . 7.31 110.987 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.94 144.86 84.25 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.889 2.392 . . . . 2.77 111.592 177.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -76.6 142.95 71.16 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.424 -0.353 . . . . 2.33 110.481 177.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.635 ' HA ' ' O ' ' A' 2123 ' ' TYR . 71.7 Cg_endo -80.32 132.58 9.25 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 123.086 2.524 . . . . 1.29 113.441 -176.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 9.0 p -161.5 144.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.734 -0.666 . . . . 1.23 110.059 177.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.548 ' HA ' ' O ' ' A' 2121 ' ' ALA . 80.9 m -115.03 126.75 55.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.334 0.588 . . . . 1.11 110.523 175.165 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 1.9 t -98.55 137.7 25.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.535 -0.757 . . . . 1.35 109.118 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.55 ' HA ' HG23 ' A' 2120 ' ' THR . 0.6 OUTLIER -133.0 109.57 9.64 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 112.301 0.482 . . . . 2.25 112.301 -168.004 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.621 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -143.96 137.27 27.64 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 121.874 -0.517 . . . . 3.95 110.473 172.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.411 ' O ' HG21 ' A' 2065 ' ' VAL . 34.1 m -102.03 157.72 4.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.439 -0.346 . . . . 1.09 110.884 179.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.678 ' OD2' ' HB ' ' A' 2117 ' ' THR . 40.1 p30 -97.89 -167.97 1.6 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.028 -0.533 . . . . 1.46 110.541 177.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.4 mttt -55.08 -41.5 71.65 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.319 0.489 . . . . 2.25 112.319 -177.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.3 p30 -86.73 -25.42 24.74 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.766 -0.373 . . . . 1.84 110.684 -176.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 119.49 15.31 5.48 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.657 -0.783 . . . . 0.46 112.368 178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.678 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 47.1 m -77.39 115.64 51.06 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-O 120.763 0.316 . . . . 1.22 110.237 174.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.466 ' HA ' ' O ' ' A' 2111 ' ' ARG . 3.0 Cg_endo -82.36 103.93 1.31 Allowed 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.434 2.09 . . . . 0.72 112.624 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2119 ' ' VAL . . . . . 0.478 HG22 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.33 108.32 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 N-CA-C 107.839 -1.171 . . . . 1.37 107.839 167.856 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.55 HG23 ' HA ' ' A' 2110 ' ' LYS . 69.1 p -126.47 156.53 40.53 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.142 -0.935 . . . . 1.23 110.492 -171.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.548 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.94 127.1 41.06 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.732 -0.84 . . . . 1.33 108.732 172.155 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 57.7 m -115.89 99.75 7.5 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.278 -0.638 . . . . 2.66 109.278 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.635 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.7 m-85 -98.67 145.67 26.64 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.422 -0.808 . . . . 3.23 111.268 -175.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2124 ' ' SER . . . . . 0.479 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 26.5 m -152.97 169.53 9.55 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.67 -0.696 . . . . 2.37 109.447 -177.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.479 ' HD2' ' HB3' ' A' 2124 ' ' SER . 82.7 Cg_exo . . . . . 0 C--N 1.354 0.857 0 C-N-CA 122.706 2.271 . . . . 2.51 112.912 177.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.455 -0.221 0 CA-C-O 121.17 0.51 . . . . 2.42 112.191 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2057 ' ' PRO . . . . . 0.415 ' HG2' ' HG ' ' A' 2058 ' ' LEU . 36.8 Cg_endo -71.95 -44.43 0.93 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 121.958 1.772 . . . . 1.98 111.471 176.097 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2058 ' ' LEU . . . . . 0.492 ' N ' HD12 ' A' 2058 ' ' LEU . 0.2 OUTLIER -83.91 -12.95 54.68 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 114.289 1.218 . . . . 2.8 114.289 -176.081 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A 2059 ' ' VAL . . . . . 0.473 HG11 ' OD2' ' A' 2113 ' ' ASP . 0.3 OUTLIER -140.21 82.76 16.44 Favored Pre-proline 0 CA--C 1.508 -0.645 0 C-N-CA 119.739 -0.785 . . . . 1.56 110.929 -176.784 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -52.96 119.09 5.51 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.87 1.713 . . . . 1.35 111.547 179.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2061 ' ' ILE . . . . . 0.543 HG13 ' NE ' ' A' 2111 ' ' ARG . 39.3 mm -45.51 135.92 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.236 -0.893 . . . . 1.33 112.241 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.548 ' O ' HG22 ' A' 2065 ' ' VAL . 13.0 t70 -71.91 141.51 49.49 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.442 -0.799 . . . . 1.42 109.953 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -87.01 -7.79 57.79 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.131 0.419 . . . . 1.55 112.131 -172.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 67.2 p -106.81 6.37 29.42 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.702 -0.399 . . . . 1.29 111.792 -178.155 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.626 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.4 m -97.84 -174.42 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 1.47 109.997 177.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -97.08 105.07 21.73 Favored Pre-proline 0 C--O 1.239 0.504 0 CA-C-O 120.808 0.337 . . . . 0.78 110.998 178.545 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.626 ' HD3' ' O ' ' A' 2065 ' ' VAL . 56.5 Cg_endo -100.34 109.59 0.06 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 123.175 2.584 . . . . 0.52 111.154 167.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.1 p -137.39 178.08 7.37 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.321 0.581 . . . . 1.07 111.086 -175.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.507 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -100.81 149.41 23.86 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.02 -1.104 . . . . 1.99 108.02 169.157 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -48.31 -44.52 34.0 Favored 'General case' 0 C--N 1.329 -0.283 0 O-C-N 123.509 0.505 . . . . 2.09 111.618 -172.403 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -84.16 13.76 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 2.15 111.796 -175.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 81.6 26.15 51.55 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 121.017 -0.611 . . . . 0.63 112.706 177.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.32 166.93 11.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.541 0.21 . . . . 1.14 110.978 -179.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.4 mmtp -123.21 -26.48 4.31 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.812 0.339 . . . . 1.68 111.461 -178.012 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -147.54 135.2 20.98 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 2.08 109.497 172.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.499 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.1 OUTLIER -127.97 99.6 5.57 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.475 -0.565 . . . . 2.03 109.475 177.349 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.0 m -110.23 114.17 27.44 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 121.139 0.495 . . . . 1.28 110.753 177.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2078 ' ' ILE . . . . . . . . . . . . . 75.2 mt -121.76 120.07 28.78 Favored Pre-proline 0 C--N 1.315 -0.908 0 N-CA-C 108.343 -0.984 . . . . 2.24 108.343 173.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.53 111.47 0.37 Allowed 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 123.251 2.634 . . . . 1.09 112.9 -176.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.78 -15.88 37.23 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.616 -0.72 . . . . 0.94 112.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.584 ' CD ' ' HA ' ' A' 2104 ' ' PRO . 24.0 mt-30 -97.8 -37.24 9.93 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.981 0.419 . . . . 2.02 110.837 -178.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 118.69 -166.73 12.98 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 111.083 -0.807 . . . . 0.58 111.083 -177.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 62.1 m -129.03 119.31 24.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.856 0.836 . . . . 1.21 110.738 174.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.412 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 1.9 m-85 -94.82 122.88 37.9 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 105.854 -1.906 . . . . 2.34 105.854 168.004 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.33 143.06 41.86 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.801 0.667 . . . . 1.26 112.801 -168.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.482 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -138.88 132.59 40.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.404 -0.816 . . . . 1.76 109.559 170.732 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 30.4 m -119.94 150.42 50.79 Favored Pre-proline 0 C--N 1.325 -0.499 0 N-CA-C 109.657 -0.497 . . . . 1.35 109.657 173.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -62.38 0.69 1.25 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 123.686 2.924 . . . . 1.32 114.215 -170.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -68.33 -18.9 64.61 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.007 0.432 . . . . 2.29 109.876 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 101.92 11.81 36.28 Favored Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.506 -0.77 . . . . 0.83 111.767 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.6 t -109.5 136.14 49.38 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.131 0.491 . . . . 1.8 110.419 -178.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.407 HG11 ' HB ' ' A' 2086 ' ' ILE . 3.6 t -133.41 149.23 31.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.753 -0.658 . . . . 1.67 109.796 -176.554 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -137.76 119.75 15.43 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.147 0.498 . . . . 1.94 111.098 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 16.3 m-30 -94.04 97.27 10.21 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.319 -0.993 . . . . 2.13 108.319 174.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 18.8 m -120.27 87.99 41.01 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 120.772 -0.371 . . . . 1.21 111.654 -176.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -91.77 157.51 3.45 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.27 2.646 . . . . 1.23 112.582 174.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.1 136.56 56.86 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.066 -0.515 . . . . 2.72 110.271 169.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 23.1 tptm -91.86 -30.89 15.93 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.937 -0.574 . . . . 5.15 111.875 -177.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -107.8 -47.1 3.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.852 1.056 . . . . 5.07 113.852 -165.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.5 122.98 13.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.732 0.777 . . . . 3.08 112.279 -169.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.1 t -80.98 143.47 12.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.287 -0.869 . . . . 3.01 110.362 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 117.63 -52.49 0.69 Allowed Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 108.823 -1.711 . . . . 3.84 108.823 -169.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2103 ' ' LYS . . . . . 0.463 ' HD3' ' HA ' ' A' 2103 ' ' LYS . 70.1 mmtt 68.69 159.33 0.15 Allowed Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 113.89 1.07 . . . . 7.31 113.89 167.425 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2104 ' ' PRO . . . . . 0.584 ' HA ' ' CD ' ' A' 2081 ' ' GLN . 62.4 Cg_exo -44.86 144.25 3.74 Favored 'Trans proline' 0 C--N 1.348 0.548 0 C-N-CA 124.371 3.381 . . . . 2.77 116.156 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 25.9 t70 -65.77 132.06 94.78 Favored Pre-proline 0 N--CA 1.451 -0.42 0 CA-C-N 114.312 -1.313 . . . . 2.33 107.999 164.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' 2123 ' ' TYR . 6.5 Cg_endo -47.12 112.86 0.57 Allowed 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 124.196 3.264 . . . . 1.29 114.595 -170.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 6.0 p -150.15 123.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.34 -0.845 . . . . 1.23 110.087 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.6 m -100.62 133.99 44.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.131 -0.486 . . . . 1.11 110.609 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.9 t -110.14 147.77 14.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.465 -0.568 . . . . 1.35 109.465 177.407 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.416 ' HE2' ' HB3' ' A' 2110 ' ' LYS . 18.5 ttpt -143.78 109.48 5.2 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.135 0.421 . . . . 2.25 112.135 -174.01 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.543 ' NE ' HG13 ' A' 2061 ' ' ILE . 18.2 ptt180 -131.52 136.3 47.76 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.119 -0.697 . . . . 3.95 109.119 174.028 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.45 ' O ' HG23 ' A' 2065 ' ' VAL . 34.4 m -98.94 145.13 10.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.431 -0.508 . . . . 1.09 111.014 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.473 ' OD2' HG11 ' A' 2059 ' ' VAL . 3.3 p-10 -91.94 -168.86 2.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.073 -0.512 . . . . 1.46 110.723 -178.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 68.4 mttm -65.77 -28.81 69.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 2.25 111.557 -178.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -74.26 -20.75 60.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.176 0.512 . . . . 1.84 110.081 174.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 94.43 9.8 58.7 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.682 -0.69 . . . . 0.46 111.851 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2117 ' ' THR . . . . . . . . . . . . . 30.5 m -82.04 120.06 76.52 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 110.012 -0.366 . . . . 1.22 110.012 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -72.93 106.29 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.441 2.094 . . . . 0.72 112.528 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 35.3 m -77.48 108.73 11.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.008 -1.108 . . . . 1.37 108.008 171.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.4 p -119.98 145.01 47.19 Favored 'General case' 0 N--CA 1.438 -1.031 0 CA-C-N 114.537 -1.21 . . . . 1.23 110.573 -172.318 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.542 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.48 126.41 40.42 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.581 -0.736 . . . . 1.33 109.265 175.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 35.0 p -100.33 97.76 8.48 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.874 -0.788 . . . . 2.66 108.874 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.552 ' O ' ' HA ' ' A' 2106 ' ' PRO . 24.3 m-85 -89.69 99.75 12.69 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-O 121.493 0.663 . . . . 3.23 111.666 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 7.9 p -148.86 170.12 8.13 Favored Pre-proline 0 N--CA 1.435 -1.192 0 CA-C-N 114.456 -1.247 . . . . 2.37 109.441 178.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.455 ' HA ' ' HB2' ' A' 2103 ' ' LYS . 51.0 Cg_exo . . . . . 0 C--N 1.349 0.565 0 C-N-CA 122.447 2.098 . . . . 2.51 111.811 175.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 120.94 0.4 . . . . 2.42 110.647 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -47.19 11.55 Favored 'Trans proline' 0 N--CA 1.473 0.304 0 C-N-CA 123.317 2.678 . . . . 1.98 112.559 -179.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2058 ' ' LEU . . . . . 0.575 ' N ' HD12 ' A' 2058 ' ' LEU . 0.1 OUTLIER -61.41 -20.33 62.93 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 115.358 -0.837 . . . . 2.8 113.24 177.281 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 6.1 t -130.11 86.72 53.44 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.124 -0.324 . . . . 1.56 110.124 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.01 126.37 20.87 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.396 2.064 . . . . 1.35 111.955 -177.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 37.9 mm -59.54 132.97 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.819 -0.628 . . . . 1.33 110.374 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' 2065 ' ' VAL . 13.8 t70 -78.17 138.15 38.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.145 -0.48 . . . . 1.42 110.635 -176.098 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -93.66 -0.43 56.09 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.184 -0.462 . . . . 1.55 111.877 -172.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.5 p -108.29 -1.83 19.76 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.78 -0.368 . . . . 1.29 111.164 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' 2062 ' ' ASP . 32.8 m -89.87 -176.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.441 -0.345 . . . . 1.47 110.172 178.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -93.47 111.65 53.16 Favored Pre-proline 0 C--O 1.238 0.485 0 CA-C-O 121.08 0.467 . . . . 0.78 111.451 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.555 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -100.88 107.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.523 0 C-N-CA 123.025 2.483 . . . . 0.52 111.327 167.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2068 ' ' THR . . . . . 0.493 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.2 p -145.68 146.51 31.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.853 0.358 . . . . 1.07 110.522 -177.703 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.522 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.9 OUTLIER -71.61 148.23 46.78 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.942 -1.133 . . . . 1.99 107.942 177.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -52.93 -37.42 60.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 118.412 0.551 . . . . 2.09 111.297 -171.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 29.1 t70 -67.73 -11.66 58.86 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.679 -0.691 . . . . 2.15 111.928 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 91.06 29.85 12.04 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.848 -0.691 . . . . 0.63 112.012 -176.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.6 p -110.08 161.68 15.3 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.887 0.375 . . . . 1.14 111.22 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.4 mmtp -110.94 -21.07 12.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.898 -0.592 . . . . 1.68 110.985 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.603 ' CG ' HG23 ' A' 2085 ' ' THR . 3.9 mt-10 -147.57 142.21 26.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.268 -0.424 . . . . 2.08 110.141 176.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.431 ' C ' ' HD3' ' A' 2076 ' ' LYS . 1.7 tmtp? -141.24 119.72 12.34 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.09 -0.707 . . . . 2.03 109.09 177.385 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.5 m -123.45 125.09 44.31 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.425 0.631 . . . . 1.28 111.356 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 93.8 mt -125.46 120.98 24.8 Favored Pre-proline 0 C--N 1.316 -0.863 0 N-CA-C 108.536 -0.913 . . . . 2.24 108.536 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -47.51 110.65 0.32 Allowed 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 123.203 2.602 . . . . 1.09 112.956 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 101.25 -21.45 43.06 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.74 -0.664 . . . . 0.94 112.63 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.463 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.2 tt0 -93.3 -31.74 14.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.105 0.478 . . . . 2.02 110.678 -175.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.98 -178.42 16.88 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.797 -0.716 . . . . 0.58 112.24 177.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 45.7 m -128.07 141.95 51.35 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.483 0.659 . . . . 1.21 110.103 176.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.459 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.9 m-85 -113.87 122.56 47.39 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.343 -1.354 . . . . 2.34 107.343 173.25 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2085 ' ' THR . . . . . 0.603 HG23 ' CG ' ' A' 2075 ' ' GLU . 30.5 p -122.93 129.79 52.03 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.19 0.441 . . . . 1.26 112.19 -173.501 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.522 ' CG1' HG21 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.5 129.71 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.817 -0.629 . . . . 1.76 109.923 170.74 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.7 m -110.1 148.73 38.91 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 115.644 -0.707 . . . . 1.35 109.501 175.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -61.67 0.17 1.24 Allowed 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.679 2.919 . . . . 1.32 113.755 -173.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -70.25 -13.64 62.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.124 0.488 . . . . 2.29 109.859 174.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 95.5 14.06 48.9 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.71 -0.677 . . . . 0.83 111.744 179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 10.2 t -119.83 139.24 52.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.06 0.457 . . . . 1.8 110.279 -177.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.522 HG21 ' CG1' ' A' 2086 ' ' ILE . 9.6 t -134.83 153.44 34.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.899 -0.592 . . . . 1.67 109.968 -175.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.9 t -131.92 122.31 25.43 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.261 0.553 . . . . 1.94 110.044 171.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2094 ' ' PHE . . . . . 0.409 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.1 m-30 -90.15 98.45 11.78 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.343 -0.984 . . . . 2.13 108.343 175.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 28.5 m -113.93 89.64 17.05 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.123 0.487 . . . . 1.21 111.467 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2096 ' ' PRO . . . . . 0.409 ' HD3' ' O ' ' A' 2094 ' ' PHE . 85.2 Cg_endo -90.56 149.04 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.008 2.472 . . . . 1.23 111.55 174.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.61 126.02 30.17 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.922 0.391 . . . . 2.72 110.012 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -84.01 -10.63 57.74 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.153 -0.476 . . . . 5.15 112.067 -174.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -115.27 13.21 16.63 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.572 -0.451 . . . . 5.07 111.247 -175.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 42.5 t80 -77.65 110.89 12.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.004 0.431 . . . . 3.08 111.039 -178.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 47.0 t -111.99 98.59 7.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.327 -0.62 . . . . 3.01 109.327 174.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -178.2 -142.32 4.64 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.972 -0.632 . . . . 3.84 111.65 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2103 ' ' LYS . . . . . 0.411 ' HG3' ' O ' ' A' 2103 ' ' LYS . 24.2 pttm -113.91 101.94 54.36 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-O 121.203 0.525 . . . . 7.31 111.287 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 10.5 Cg_exo -71.86 147.18 49.44 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.62 2.213 . . . . 2.77 111.159 174.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2105 ' ' ASP . . . . . 0.423 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.9 t70 -95.77 132.29 27.55 Favored Pre-proline 0 C--N 1.322 -0.61 0 N-CA-C 109.802 -0.444 . . . . 2.33 109.802 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.573 ' HA ' ' O ' ' A' 2123 ' ' TYR . 15.7 Cg_endo -57.17 113.31 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 123.515 2.81 . . . . 1.29 114.128 -173.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.7 p -147.19 141.81 20.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.362 -0.836 . . . . 1.23 109.525 174.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 18.0 m -115.92 113.71 23.67 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.139 0.495 . . . . 1.11 110.276 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.557 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.2 t -92.24 132.23 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.058 -0.719 . . . . 1.35 109.058 -179.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.493 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.0 tmmm? -133.45 145.88 50.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.227 0.537 . . . . 2.25 111.664 -170.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.468 ' N ' ' HD2' ' A' 2110 ' ' LYS . 32.2 ptt180 -164.57 137.86 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.543 -0.91 . . . . 3.95 108.543 169.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.412 ' O ' HG21 ' A' 2065 ' ' VAL . 33.8 m -98.82 148.98 5.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.213 -0.595 . . . . 1.09 111.52 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.594 ' OD1' ' HB ' ' A' 2117 ' ' THR . 8.5 p30 -88.91 -168.53 2.21 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.403 -0.817 . . . . 1.46 111.341 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.0 mttm -64.88 -34.25 77.95 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.561 0.578 . . . . 2.25 112.561 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.6 p30 -84.55 -22.92 29.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 119.685 -0.806 . . . . 1.84 110.515 177.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 116.67 12.09 8.92 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.809 -0.71 . . . . 0.46 112.958 173.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.594 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 86.5 m -83.27 125.64 73.89 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 117.221 0.511 . . . . 1.22 110.005 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.482 ' HD3' ' HA ' ' A' 2117 ' ' THR . 1.8 Cg_endo -81.36 111.46 2.37 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.451 2.101 . . . . 0.72 112.987 -178.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 11.6 m -75.94 127.0 37.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.357 -0.979 . . . . 1.37 108.357 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.557 ' HA ' ' O ' ' A' 2109 ' ' VAL . 39.9 p -130.89 166.42 20.95 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 115.699 -0.682 . . . . 1.23 111.332 -170.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -127.56 126.75 42.7 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 107.677 -1.231 . . . . 1.33 107.677 169.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 3.5 m -110.08 99.42 8.51 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.324 -0.398 . . . . 2.66 110.582 -172.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.573 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.2 m-85 -104.74 151.69 23.44 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 121.252 0.549 . . . . 3.23 111.577 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 6.6 p -168.62 170.97 3.86 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 114.778 -1.101 . . . . 2.37 108.33 -173.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo . . . . . 0 C--N 1.351 0.68 0 C-N-CA 122.712 2.275 . . . . 2.51 112.185 177.098 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 C--O 1.226 -0.167 0 CA-C-O 120.831 0.348 . . . . 2.42 110.733 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -64.95 -56.01 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.887 2.391 . . . . 1.98 112.064 177.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2058 ' ' LEU . . . . . 0.46 HD11 ' N ' ' A' 2058 ' ' LEU . 0.2 OUTLIER -63.81 -12.46 35.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.43 -0.804 . . . . 2.8 113.167 177.498 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 86.06 22.72 Favored Pre-proline 0 C--N 1.322 -0.615 0 N-CA-C 109.814 -0.439 . . . . 1.56 109.814 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.63 137.82 83.1 Favored 'Trans proline' 0 C--O 1.235 0.363 0 C-N-CA 122.629 2.219 . . . . 1.35 112.3 -176.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.9 mm -65.27 136.46 26.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.672 -0.694 . . . . 1.33 110.313 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2062 ' ' ASP . . . . . . . . . . . . . 35.5 t70 -82.77 134.42 35.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.301 0.572 . . . . 1.42 111.038 -175.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -87.32 -8.47 56.66 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.661 -0.7 . . . . 1.55 111.588 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 76.5 p -104.49 7.88 35.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.971 0.415 . . . . 1.29 111.557 -178.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.555 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.1 m -110.23 -177.83 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.447 -0.575 . . . . 1.47 109.447 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -94.88 110.9 52.3 Favored Pre-proline 0 C--O 1.243 0.729 0 CA-C-O 121.092 0.472 . . . . 0.78 110.984 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.555 ' HD3' ' O ' ' A' 2065 ' ' VAL . 43.4 Cg_endo -100.98 106.8 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.62 0 C-N-CA 123.077 2.518 . . . . 0.52 111.688 169.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.0 p -142.87 -177.93 5.57 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.177 0.513 . . . . 1.07 110.907 -176.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.538 ' CE2' ' HB2' ' A' 2084 ' ' TYR . 93.9 m-85 -101.51 164.97 11.49 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 108.731 -0.84 . . . . 1.99 108.731 170.054 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -53.76 -33.23 55.13 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-N 118.004 0.365 . . . . 2.09 111.687 -172.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -86.61 12.65 10.09 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 111.872 0.323 . . . . 2.15 111.872 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 17.91 79.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 121.053 -0.594 . . . . 0.63 111.944 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2073 ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 2.2 m -78.6 164.23 24.84 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.743 0.306 . . . . 1.14 111.097 -173.334 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -115.5 -18.34 10.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.219 0.533 . . . . 1.68 110.425 178.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -147.32 140.64 25.34 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.316 -0.624 . . . . 2.08 109.316 173.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.472 ' O ' ' HA ' ' A' 2083 ' ' THR . 27.1 tptt -127.97 116.17 19.65 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.939 -0.393 . . . . 2.03 109.939 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 59.3 m -113.6 132.99 55.54 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.294 0.569 . . . . 1.28 110.957 176.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.551 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 36.0 mt -134.63 121.2 14.91 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.102 -0.954 . . . . 2.24 108.859 178.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -51.04 108.97 0.26 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.231 2.621 . . . . 1.09 113.186 -175.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 95.2 -11.15 69.42 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.908 -0.663 . . . . 0.94 112.75 176.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.551 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.5 tt0 -103.57 -26.51 12.79 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.262 0.554 . . . . 2.02 109.957 -176.246 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.29 -156.08 15.89 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.405 -0.816 . . . . 0.58 112.538 175.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.472 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -144.69 137.3 26.48 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.714 0.769 . . . . 1.21 110.729 177.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.538 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 5.7 m-85 -108.38 126.27 52.68 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.114 -1.439 . . . . 2.34 107.114 171.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -128.15 147.12 50.54 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 112.826 0.676 . . . . 1.26 112.826 -172.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.517 ' CB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -141.8 127.1 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 115.248 -0.887 . . . . 1.76 109.807 172.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -102.62 148.28 35.27 Favored Pre-proline 0 C--N 1.321 -0.643 0 N-CA-C 109.144 -0.687 . . . . 1.35 109.144 173.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -61.18 0.24 1.02 Allowed 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.712 2.942 . . . . 1.32 114.32 -171.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -71.74 -20.42 61.9 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.758 -0.46 . . . . 2.29 109.758 175.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 105.34 17.44 13.76 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.997 -0.62 . . . . 0.83 112.289 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.2 t -112.71 135.76 53.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.13 0.49 . . . . 1.8 110.481 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 6.7 t -129.46 152.35 37.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.958 -0.565 . . . . 1.67 111.033 -172.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 8.9 t -141.76 123.55 15.23 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.416 0.627 . . . . 1.94 110.267 172.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2094 ' ' PHE . . . . . 0.547 ' CE2' HG13 ' A' 2109 ' ' VAL . 19.3 m-30 -98.55 98.91 10.03 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.522 -0.918 . . . . 2.13 108.522 177.1 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 10.1 m -116.43 87.99 22.29 Favored Pre-proline 0 N--CA 1.454 -0.264 0 C-N-CA 120.238 -0.585 . . . . 1.21 111.341 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2096 ' ' PRO . . . . . 0.406 ' HD3' ' O ' ' A' 2094 ' ' PHE . 18.2 Cg_endo -92.55 143.55 2.44 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.516 2.811 . . . . 1.23 112.166 173.453 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 52.7 t0 -88.63 92.52 9.23 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.264 -0.643 . . . . 2.72 109.264 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -75.59 -1.48 24.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.031 -0.531 . . . . 5.15 111.247 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.3 mt-30 -81.95 -16.38 50.64 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.125 -0.694 . . . . 5.07 109.125 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 78.2 t80 -99.99 110.51 22.84 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.072 -0.967 . . . . 3.08 109.673 177.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.6 p -144.24 100.75 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.944 0.878 . . . . 3.01 111.452 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -151.73 -77.64 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 110.437 -1.065 . . . . 3.84 110.437 175.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 57.8 pttt -129.31 71.73 82.02 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-O 120.982 0.42 . . . . 7.31 110.896 173.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.88 148.84 91.14 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.407 2.071 . . . . 2.77 111.027 175.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2105 ' ' ASP . . . . . 0.483 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.4 t70 -75.65 132.99 74.11 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 109.582 -0.525 . . . . 2.33 109.582 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.555 ' HA ' ' O ' ' A' 2123 ' ' TYR . 33.5 Cg_endo -65.24 106.06 0.78 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.024 2.482 . . . . 1.29 112.645 -176.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2107 ' ' VAL . . . . . 0.429 HG21 ' HG2' ' A' 2076 ' ' LYS . 9.5 p -147.42 134.31 13.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.645 -0.707 . . . . 1.23 110.501 177.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.4 m -109.75 128.23 55.15 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 115.88 -0.6 . . . . 1.11 110.065 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.64 ' O ' ' HA ' ' A' 2120 ' ' THR . 13.0 t -91.42 117.99 35.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 108.697 -0.853 . . . . 1.35 108.697 176.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -125.47 108.49 11.69 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.633 -0.427 . . . . 2.25 110.918 -172.532 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.517 HH12 ' CB ' ' A' 2086 ' ' ILE . 12.7 ptp180 -155.18 157.46 37.41 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.776 -0.453 . . . . 3.95 109.776 175.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.3 m -112.04 149.39 14.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.377 -0.529 . . . . 1.09 111.69 -177.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.609 ' OD2' ' HB ' ' A' 2117 ' ' THR . 5.0 p30 -91.73 -169.33 2.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.632 -0.713 . . . . 1.46 110.756 177.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.8 mttm -62.99 -31.95 73.19 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.014 0.376 . . . . 2.25 112.014 -178.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -78.43 -18.62 54.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.083 0.468 . . . . 1.84 110.122 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 99.61 10.57 46.82 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.563 -0.744 . . . . 0.46 111.304 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.609 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 62.2 m -81.9 125.89 76.53 Favored Pre-proline 0 N--CA 1.448 -0.542 0 CA-C-O 120.515 0.197 . . . . 1.22 110.487 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' A' 2111 ' ' ARG . 11.9 Cg_exo -70.35 101.43 0.99 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.468 2.112 . . . . 0.72 112.589 177.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2119 ' ' VAL . . . . . 0.425 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 23.7 m -75.37 108.63 7.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.374 -0.973 . . . . 1.37 108.374 169.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.64 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.6 p -126.63 154.4 44.04 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.189 -0.914 . . . . 1.23 111.196 -171.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.59 127.77 42.92 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.282 -1.007 . . . . 1.33 108.282 170.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 29.6 p -105.12 99.63 9.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.095 0.474 . . . . 2.66 110.172 -177.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.555 ' O ' ' HA ' ' A' 2106 ' ' PRO . 10.6 m-85 -113.38 134.42 54.65 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.966 -0.561 . . . . 3.23 111.225 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2124 ' ' SER . . . . . 0.413 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 26.3 p -160.08 161.19 26.38 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 115.602 -0.726 . . . . 2.37 109.935 -175.113 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' 2124 ' ' SER . 57.3 Cg_endo . . . . . 0 C--N 1.351 0.661 0 C-N-CA 122.956 2.438 . . . . 2.51 113.011 -177.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2056 ' ' ASP . . . . . 0.451 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 1.8 t70 . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.211 -0.663 . . . . 2.42 109.211 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -44.25 -55.08 3.4 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 123.296 2.664 . . . . 1.98 113.231 -175.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2058 ' ' LEU . . . . . 0.501 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -101.16 2.07 39.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.014 0.435 . . . . 2.8 112.085 -177.909 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A 2059 ' ' VAL . . . . . 0.501 HG23 HD13 ' A' 2058 ' ' LEU . 2.1 t -131.65 78.42 70.88 Favored Pre-proline 0 C--N 1.327 -0.386 0 N-CA-C 110.091 -0.337 . . . . 1.56 110.091 178.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.42 140.03 92.35 Favored 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.182 1.921 . . . . 1.35 111.349 176.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.3 mm -61.06 130.97 25.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.856 -0.611 . . . . 1.33 111.404 -178.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.595 ' O ' HG21 ' A' 2065 ' ' VAL . 12.5 t70 -73.67 140.36 46.03 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.393 -0.821 . . . . 1.42 109.867 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -86.83 -10.47 53.39 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 111.914 0.338 . . . . 1.55 111.914 -171.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 39.7 p -109.24 10.12 25.8 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.755 0.312 . . . . 1.29 111.817 -177.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.605 ' O ' ' HD3' ' A' 2067 ' ' PRO . 35.8 m -91.66 -174.94 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 110.059 -0.348 . . . . 1.47 110.059 175.215 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -97.0 105.05 21.24 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.551 -0.295 . . . . 0.78 110.775 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.605 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -99.91 106.48 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.603 0 C-N-CA 122.562 2.175 . . . . 0.52 110.92 168.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2068 ' ' THR . . . . . 0.511 ' O ' ' HB3' ' A' 2110 ' ' LYS . 40.7 p -145.35 147.66 32.54 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.104 -0.498 . . . . 1.07 110.09 -176.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.541 ' HD2' ' N ' ' A' 2069 ' ' PHE . 1.2 m-30 -72.62 153.75 41.09 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.5 -0.926 . . . . 1.99 108.5 178.235 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -50.55 -43.51 56.22 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.958 0.409 . . . . 2.09 111.139 -173.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 38.1 t70 -77.43 2.58 15.64 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 115.671 -0.695 . . . . 2.15 111.587 -177.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 86.28 29.98 23.57 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.162 -0.542 . . . . 0.63 112.558 179.367 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 12.5 m -101.24 162.47 12.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.788 0.328 . . . . 1.14 110.941 -176.565 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -115.83 -19.62 10.37 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.092 -0.504 . . . . 1.68 110.87 178.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2075 ' ' GLU . . . . . 0.431 ' HA ' ' O ' ' A' 2084 ' ' TYR . 7.2 tt0 -156.0 125.88 6.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.999 -0.546 . . . . 2.08 109.737 172.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.404 ' O ' ' HA ' ' A' 2083 ' ' THR . 32.1 tptt -117.33 118.89 33.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.655 -0.702 . . . . 2.03 109.411 178.353 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.4 m -111.85 113.73 26.24 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.482 0.658 . . . . 1.28 110.882 176.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.52 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 67.0 mt -110.18 113.9 56.23 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.302 -0.999 . . . . 2.24 108.302 174.364 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -47.41 109.4 0.22 Allowed 'Trans proline' 0 N--CA 1.474 0.324 0 C-N-CA 123.49 2.793 . . . . 1.09 113.879 -171.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 89.42 -11.56 69.49 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.814 -0.63 . . . . 0.94 112.73 176.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.52 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.5 tm0? -98.22 -28.45 13.7 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.059 0.456 . . . . 2.02 110.008 -175.098 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 130.37 -173.8 19.88 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.712 -0.756 . . . . 0.58 112.765 173.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -147.79 138.96 23.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.71 0.767 . . . . 1.21 110.436 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.521 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.2 OUTLIER -114.14 131.4 56.44 Favored 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 107.261 -1.385 . . . . 2.34 107.261 175.382 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 23.7 p -127.84 128.72 45.72 Favored 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 120.527 -0.469 . . . . 1.26 112.173 -174.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.513 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -116.96 129.66 73.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.579 -0.737 . . . . 1.76 109.753 170.727 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 27.5 m -118.45 145.37 37.18 Favored Pre-proline 0 C--N 1.319 -0.734 0 CA-C-N 115.968 -0.56 . . . . 1.35 109.534 173.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -59.76 -5.33 3.43 Favored 'Trans proline' 0 N--CA 1.477 0.548 0 C-N-CA 123.85 3.033 . . . . 1.32 114.682 -168.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 28.5 t70 -68.82 -21.35 64.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.276 0.56 . . . . 2.29 109.81 176.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.24 7.86 26.08 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.899 -0.667 . . . . 0.83 112.077 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.6 t -107.21 124.44 49.74 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.34 0.591 . . . . 1.8 110.559 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.622 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 10.1 t -129.49 138.48 54.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.351 -0.841 . . . . 1.67 109.716 -178.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.8 t -123.05 115.29 21.6 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.456 0.646 . . . . 1.94 110.571 175.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2094 ' ' PHE . . . . . 0.458 ' O ' ' HD3' ' A' 2096 ' ' PRO . 14.2 m-30 -85.8 98.47 10.76 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.648 -0.871 . . . . 2.13 108.648 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 7.5 m -113.28 88.08 12.14 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.968 0.414 . . . . 1.21 111.302 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2096 ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' 2094 ' ' PHE . 96.8 Cg_endo -92.63 145.44 2.59 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.294 2.663 . . . . 1.23 112.683 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.46 102.69 11.28 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.19 -0.67 . . . . 2.72 109.19 170.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2098 ' ' LYS . . . . . 0.579 ' H ' ' HD3' ' A' 2098 ' ' LYS . 0.0 OUTLIER -87.08 10.89 15.19 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.763 -0.653 . . . . 5.15 111.371 -175.036 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 -106.44 8.85 31.74 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.193 0.521 . . . . 5.07 109.83 177.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 64.9 t80 -79.58 80.59 5.95 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.52 -0.764 . . . . 3.08 109.666 174.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 16.6 t -85.13 98.24 6.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.079 -0.51 . . . . 3.01 109.78 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.3 48.98 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.639 -0.71 . . . . 3.84 111.436 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 1.2 mptm? 59.27 73.76 0.65 Allowed Pre-proline 0 CA--C 1.532 0.26 0 C-N-CA 122.895 0.478 . . . . 7.31 111.418 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.04 131.89 41.69 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.456 2.104 . . . . 2.77 111.115 175.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2105 ' ' ASP . . . . . 0.427 ' HB3' HD11 ' A' 2078 ' ' ILE . 35.6 t70 -68.99 131.23 90.96 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-N 116.098 -0.501 . . . . 2.33 110.373 -178.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.54 131.98 18.27 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 123.083 2.522 . . . . 1.29 113.616 -177.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 14.7 p -161.26 144.03 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.372 -0.831 . . . . 1.23 109.644 174.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2108 ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' 2121 ' ' ALA . 42.9 m -109.79 125.5 52.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.433 0.635 . . . . 1.11 110.744 177.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -102.56 138.91 25.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.46 -0.791 . . . . 1.35 108.946 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2110 ' ' LYS . . . . . 0.529 ' HG2' ' N ' ' A' 2111 ' ' ARG . 23.5 ttpt -139.68 153.43 47.27 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.296 0.498 . . . . 2.25 112.297 -172.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.622 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 31.7 ptt180 -175.38 142.76 0.61 Allowed 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 108.447 -0.945 . . . . 3.95 108.447 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2112 ' ' VAL . . . . . 0.48 ' O ' HG22 ' A' 2065 ' ' VAL . 33.7 m -99.22 150.21 5.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.393 -0.523 . . . . 1.09 111.297 -178.088 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.672 ' OD1' ' HB ' ' A' 2117 ' ' THR . 7.1 p30 -91.32 -169.31 2.29 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.72 -0.673 . . . . 1.46 111.22 179.535 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 97.5 mttt -58.93 -38.04 78.08 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.354 -0.385 . . . . 2.25 111.64 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -78.72 -30.27 45.82 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.256 0.551 . . . . 1.84 109.79 -177.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 115.74 17.85 6.29 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.268 -0.878 . . . . 0.46 112.055 178.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.672 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.3 m -88.15 119.21 70.28 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 110.167 -0.309 . . . . 1.22 110.167 178.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2118 ' ' PRO . . . . . 0.448 ' HA ' ' O ' ' A' 2111 ' ' ARG . 8.7 Cg_exo -71.89 104.12 1.58 Allowed 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.365 2.044 . . . . 0.72 112.173 177.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 15.4 m -75.08 113.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 108.254 -1.017 . . . . 1.37 108.254 170.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2120 ' ' THR . . . . . 0.488 ' HA ' ' O ' ' A' 2109 ' ' VAL . 60.6 p -120.93 161.23 21.94 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.467 -0.788 . . . . 1.23 111.391 -172.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2121 ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.36 127.04 41.89 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 107.601 -1.259 . . . . 1.33 107.601 168.334 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.5 m -115.78 100.65 8.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.285 0.564 . . . . 2.66 110.696 -172.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -89.83 131.7 35.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.827 -0.624 . . . . 3.23 110.306 176.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 13.4 m -124.01 166.26 20.04 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.716 -0.675 . . . . 2.37 109.486 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 70.1 Cg_exo . . . . . 0 C--O 1.236 0.414 0 C-N-CA 122.466 2.111 . . . . 2.51 112.251 177.109 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.519 -0.221 0 CA-C-O 120.636 0.255 . . . . 2.42 111.087 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -73.56 -14.83 24.8 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.176 1.918 . . . . 1.98 111.313 176.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.47 -41.13 61.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.629 -0.714 . . . . 2.8 110.04 177.314 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 1.8 t -126.4 98.77 31.6 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.711 -0.477 . . . . 1.56 109.711 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.69 131.62 41.05 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.171 1.914 . . . . 1.35 111.842 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 49.8 mm -55.67 129.68 17.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 CA-C-N 115.68 -0.691 . . . . 1.33 110.622 -178.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2062 ' ' ASP . . . . . 0.592 ' O ' HG22 ' A' 2065 ' ' VAL . 11.3 t70 -75.62 139.62 42.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.983 0.42 . . . . 1.42 110.232 -177.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -89.71 -4.75 57.57 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.149 0.425 . . . . 1.55 112.149 -171.492 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 81.8 p -99.33 -13.61 19.55 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.527 -0.469 . . . . 1.29 111.238 178.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2065 ' ' VAL . . . . . 0.634 ' O ' ' HD3' ' A' 2067 ' ' PRO . 31.4 m -79.92 -174.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.891 -0.411 . . . . 1.47 109.891 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -95.33 109.55 45.73 Favored Pre-proline 0 C--O 1.238 0.447 0 CA-C-O 121.078 0.466 . . . . 0.78 111.63 -179.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2067 ' ' PRO . . . . . 0.634 ' HD3' ' O ' ' A' 2065 ' ' VAL . 65.4 Cg_endo -100.77 123.23 0.11 Allowed 'Trans proline' 0 N--CA 1.441 -1.605 0 C-N-CA 123.46 2.774 . . . . 0.52 110.851 165.384 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 3.6 p -153.28 -179.23 7.54 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 1.07 110.601 -178.479 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2069 ' ' PHE . . . . . 0.597 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 8.5 m-30 -102.43 154.63 18.9 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 107.405 -1.332 . . . . 1.99 107.405 163.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -54.45 -35.84 63.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 118.65 0.659 . . . . 2.09 111.748 -171.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -78.35 4.9 11.73 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.235 0.457 . . . . 2.15 112.235 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 80.48 24.95 57.91 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.127 -0.558 . . . . 0.63 111.903 -177.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 14.7 m -94.07 156.46 16.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.629 0.252 . . . . 1.14 110.797 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.79 5.18 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.25 0.548 . . . . 1.68 110.913 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.58 140.75 4.98 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.123 -0.695 . . . . 2.08 109.123 170.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2076 ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' 2083 ' ' THR . 16.5 tptt -138.88 104.0 4.95 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.273 -0.421 . . . . 2.03 110.065 174.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 49.0 m -101.51 118.03 36.13 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.123 0.487 . . . . 1.28 110.273 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2078 ' ' ILE . . . . . 0.537 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 75.5 mt -117.16 119.89 34.29 Favored Pre-proline 0 C--N 1.315 -0.925 0 N-CA-C 108.407 -0.96 . . . . 2.24 108.407 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -47.11 109.87 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.486 2.791 . . . . 1.09 113.496 -174.102 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.42 -12.76 68.95 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.81 -0.632 . . . . 0.94 112.677 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2081 ' ' GLN . . . . . 0.537 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.9 tt0 -101.13 -26.28 13.73 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.164 0.507 . . . . 2.02 110.183 -177.354 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 112.85 -163.95 12.1 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.539 -0.838 . . . . 0.58 112.782 173.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2083 ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' 2076 ' ' LYS . 28.1 m -137.14 145.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 121.808 0.814 . . . . 1.21 110.553 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2084 ' ' TYR . . . . . 0.597 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 12.8 m-85 -107.13 112.48 25.41 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 106.892 -1.522 . . . . 2.34 106.892 166.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 25.3 p -104.99 134.76 47.55 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.745 -0.382 . . . . 1.26 111.563 -173.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2086 ' ' ILE . . . . . 0.598 ' HA ' ' O ' ' A' 2091 ' ' THR . 1.6 tt -151.19 130.55 3.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.799 -0.637 . . . . 1.76 111.422 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2087 ' ' VAL . . . . . 0.58 HG22 ' OG1' ' A' 2091 ' ' THR . 18.6 m -115.1 157.75 42.74 Favored Pre-proline 0 C--N 1.328 -0.343 0 N-CA-C 109.565 -0.531 . . . . 1.35 109.565 175.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.17 -0.54 2.28 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 123.69 2.926 . . . . 1.32 114.137 -172.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 19.1 t70 -78.03 -23.18 48.29 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.293 0.568 . . . . 2.29 109.927 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 112.74 17.17 8.13 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.581 -0.736 . . . . 0.83 112.133 -178.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2091 ' ' THR . . . . . 0.598 ' O ' ' HA ' ' A' 2086 ' ' ILE . 3.2 p -90.51 116.2 28.24 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.355 -0.609 . . . . 1.8 109.355 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2092 ' ' VAL . . . . . 0.462 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 3.8 t -136.2 132.38 49.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.781 -0.368 . . . . 1.67 110.285 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.2 t -137.33 122.8 19.58 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.401 0.62 . . . . 1.94 110.239 176.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -86.33 98.41 10.96 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.976 -0.75 . . . . 2.13 108.976 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 16.4 m -121.38 84.59 41.61 Favored Pre-proline 0 N--CA 1.453 -0.284 0 C-N-CA 119.676 -0.81 . . . . 1.21 111.585 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -93.47 147.71 2.29 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 123.248 2.632 . . . . 1.23 111.884 170.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.27 86.35 5.04 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.225 -0.658 . . . . 2.72 109.225 171.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 43.8 mtmt -63.26 -24.03 67.69 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.488 -0.778 . . . . 5.15 110.92 -175.282 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -96.44 12.98 29.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.789 -0.641 . . . . 5.07 111.052 -176.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.72 104.09 13.55 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.732 -0.667 . . . . 3.08 110.414 176.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 86.3 t -90.7 98.7 8.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.399 0.619 . . . . 3.01 109.529 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -162.78 -152.86 6.95 Favored Glycine 0 N--CA 1.445 -0.756 0 N-CA-C 110.704 -0.958 . . . . 3.84 110.704 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2103 ' ' LYS . . . . . 0.48 ' NZ ' ' HB3' ' A' 2103 ' ' LYS . 0.0 OUTLIER -109.76 94.86 18.05 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 121.3 0.571 . . . . 7.31 110.235 177.123 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -76.81 161.43 33.44 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.868 2.379 . . . . 2.77 112.391 -177.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.01 141.04 21.74 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.027 -0.533 . . . . 2.33 110.508 179.63 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2106 ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' 2123 ' ' TYR . 55.5 Cg_endo -68.99 121.25 8.1 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 123.181 2.587 . . . . 1.29 113.467 -176.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.6 p -157.51 143.85 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.414 -0.812 . . . . 1.23 109.707 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 15.6 m -121.48 130.68 53.71 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 1.11 110.574 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2109 ' ' VAL . . . . . 0.411 HG11 ' CD2' ' A' 2069 ' ' PHE . 2.7 t -92.99 144.68 8.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.101 -0.703 . . . . 1.35 109.101 177.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -143.36 108.35 4.95 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 118.157 0.435 . . . . 2.25 111.635 -173.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2111 ' ' ARG . . . . . 0.462 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -147.25 139.09 24.24 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 121.722 -0.611 . . . . 3.95 109.88 171.324 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.5 m -103.5 154.69 5.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 120.926 0.393 . . . . 1.09 110.907 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2113 ' ' ASP . . . . . 0.418 ' OD1' ' HB ' ' A' 2117 ' ' THR . 2.3 p-10 -96.29 -167.74 1.63 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.029 -0.532 . . . . 1.46 110.102 178.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.4 mttt -53.64 -44.47 69.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.954 -0.566 . . . . 2.25 112.175 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 5.9 p30 -85.28 -14.92 45.11 Favored 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 120.487 -0.485 . . . . 1.84 111.157 -176.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 104.29 15.23 22.04 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.272 -0.966 . . . . 0.46 112.937 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2117 ' ' THR . . . . . 0.418 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 98.1 m -75.85 114.65 38.94 Favored Pre-proline 0 C--N 1.324 -0.538 0 N-CA-C 109.887 -0.412 . . . . 1.22 109.887 174.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -77.49 100.79 1.42 Allowed 'Trans proline' 0 N--CA 1.454 -0.817 0 C-N-CA 122.407 2.072 . . . . 0.72 112.318 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 7.0 m -74.94 109.36 7.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.433 -0.951 . . . . 1.37 108.433 169.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2120 ' ' THR . . . . . . . . . . . . . 69.3 p -118.86 -174.31 2.67 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.88 -1.054 . . . . 1.23 109.977 -174.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -149.88 127.21 11.41 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.743 -0.836 . . . . 1.33 108.743 170.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 34.5 p -100.44 97.87 8.55 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.568 -0.53 . . . . 2.66 109.568 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A 2123 ' ' TYR . . . . . 0.545 ' O ' ' HA ' ' A' 2106 ' ' PRO . 12.1 m-85 -118.44 124.35 47.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.244 0.545 . . . . 3.23 111.568 -177.231 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2124 ' ' SER . . . . . 0.465 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 49.5 m -157.77 171.82 6.94 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.689 -1.141 . . . . 2.37 108.75 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A 2125 ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' 2124 ' ' SER . 90.4 Cg_exo . . . . . 0 C--N 1.348 0.516 0 C-N-CA 122.318 2.012 . . . . 2.51 112.45 173.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 3.3 pt20 . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 110.113 -0.328 . . . . 7.47 110.113 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 72.39 -77.06 0.75 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.094 -0.574 . . . . 3.62 112.47 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -158.61 84.0 0.13 Allowed Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 111.192 -0.763 . . . . 2.08 111.192 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -63.68 121.44 70.64 Favored Pre-proline 0 C--N 1.327 -0.413 0 CA-C-O 121.153 0.502 . . . . 2.42 111.384 -177.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.23 -40.18 4.86 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.002 2.468 . . . . 1.98 112.46 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2058 ' ' LEU . . . . . 0.445 ' N ' HD12 ' A' 2058 ' ' LEU . 0.0 OUTLIER -81.97 -2.08 50.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 2.8 111.607 -177.591 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.5 t -136.92 84.42 25.75 Favored Pre-proline 0 C--N 1.326 -0.426 0 N-CA-C 109.159 -0.682 . . . . 1.56 109.159 178.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2060 ' ' PRO . . . . . 0.514 ' O ' ' HG3' ' A' 2114 ' ' LYS . 41.6 Cg_exo -55.73 130.64 41.48 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.532 2.155 . . . . 1.35 111.804 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2061 ' ' ILE . . . . . 0.416 ' HA ' ' HA ' ' A' 2113 ' ' ASP . 41.6 mm -64.49 141.74 17.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.561 . . . . 1.33 109.709 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.519 ' O ' HG23 ' A' 2065 ' ' VAL . 10.3 t70 -80.05 128.11 33.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.361 -0.381 . . . . 1.42 110.289 -175.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -91.34 1.96 56.74 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.404 -0.362 . . . . 1.55 111.958 -172.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 74.4 p -110.73 -5.04 15.06 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.009 0.433 . . . . 1.29 111.171 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.64 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.9 m -91.67 -174.01 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.453 . . . . 1.47 109.857 178.187 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -89.64 111.26 44.94 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.154 0.502 . . . . 0.78 111.162 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.64 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.2 Cg_endo -100.71 109.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 123.608 2.872 . . . . 0.52 110.792 166.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 9.0 p -148.31 -176.52 5.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.146 0.498 . . . . 1.07 110.963 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.59 ' CD2' HG13 ' A' 2109 ' ' VAL . 3.5 m-30 -101.6 156.39 17.51 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 107.165 -1.42 . . . . 1.99 107.165 166.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -53.8 -34.95 60.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 118.261 0.482 . . . . 2.09 111.951 -169.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -74.81 -4.92 40.62 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.886 0.374 . . . . 2.15 111.312 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.91 14.49 57.82 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 121.246 -0.502 . . . . 0.63 111.854 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2073 ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' 2069 ' ' PHE . 0.3 OUTLIER -85.78 161.78 18.99 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.666 0.27 . . . . 1.14 111.277 -174.769 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -115.52 -23.82 8.61 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.431 -0.35 . . . . 1.68 111.912 -174.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' 2084 ' ' TYR . 1.6 tm-20 -151.87 137.31 17.67 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.254 0.55 . . . . 2.08 110.167 173.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.435 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.0 OUTLIER -131.64 99.7 4.88 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.472 -0.786 . . . . 2.03 109.99 175.44 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 7.7 m -103.06 111.78 24.3 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.945 -0.57 . . . . 1.28 110.598 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.507 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 44.4 mm -114.39 123.05 33.05 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 108.004 -1.11 . . . . 2.24 108.004 173.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.27 108.69 0.17 Allowed 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.043 2.495 . . . . 1.09 113.039 -176.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 100.99 -18.55 54.57 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.644 -0.707 . . . . 0.94 112.886 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.507 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -90.59 -30.19 17.35 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.257 0.551 . . . . 2.02 110.827 -173.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.56 -174.58 15.31 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.587 -0.733 . . . . 0.58 111.58 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 15.5 m -133.88 134.41 42.67 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.583 0.706 . . . . 1.21 110.523 176.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.547 ' O ' ' HA ' ' A' 2075 ' ' GLU . 1.5 m-85 -109.47 120.18 41.7 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.986 -1.487 . . . . 2.34 106.986 172.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -127.89 121.59 30.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 112.447 0.536 . . . . 1.26 112.447 -171.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.443 ' CG1' HG23 ' A' 2092 ' ' VAL . 0.0 OUTLIER -115.54 134.91 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.089 -0.505 . . . . 1.76 110.198 173.703 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 33.6 m -118.2 150.37 47.47 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 109.413 -0.588 . . . . 1.35 109.413 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.99 -4.08 0.85 Allowed 'Trans proline' 0 N--CA 1.481 0.768 0 C-N-CA 123.959 3.106 . . . . 1.32 114.637 -172.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.73 -7.8 52.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.902 0.382 . . . . 2.29 110.506 176.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 91.18 16.98 52.54 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.91 -0.662 . . . . 0.83 112.063 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.2 t -118.61 138.54 52.51 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.854 0.359 . . . . 1.8 110.433 -179.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.443 HG23 ' CG1' ' A' 2086 ' ' ILE . 7.4 t -131.21 140.58 48.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.126 -0.488 . . . . 1.67 110.512 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -101.99 108.92 20.52 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 116.299 -0.41 . . . . 1.94 110.49 174.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -86.69 96.32 10.1 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.162 -1.051 . . . . 2.13 108.162 173.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 25.1 m -119.04 88.25 36.21 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 121.121 0.486 . . . . 1.21 110.554 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.29 2.66 . . . . 1.23 111.877 176.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.2 t70 -132.14 99.43 4.71 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.883 0.373 . . . . 2.72 110.083 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.23 13.9 2.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.275 -0.42 . . . . 5.15 111.101 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 -109.52 5.57 23.32 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.256 0.551 . . . . 5.07 109.716 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 52.5 t80 -89.3 92.55 9.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 3.08 110.992 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 92.0 t -83.76 107.78 15.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.586 -0.524 . . . . 3.01 109.586 174.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.14 -133.55 2.85 Favored Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.673 -0.694 . . . . 3.84 111.456 -178.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 61.6 tttm -127.67 99.07 27.06 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.769 0.284 . . . . 7.31 110.94 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.92 155.03 48.37 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.318 2.012 . . . . 2.77 111.73 174.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.3 t70 -83.42 127.02 70.09 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.066 -0.515 . . . . 2.33 109.968 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.612 ' HA ' ' O ' ' A' 2123 ' ' TYR . 43.1 Cg_exo -56.34 102.68 0.1 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.026 2.484 . . . . 1.29 112.881 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.2 p -147.42 138.93 18.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.095 -0.502 . . . . 1.23 110.38 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 56.6 m -112.96 124.16 51.99 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.001 -0.545 . . . . 1.11 110.149 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.7 t -91.63 131.17 39.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.835 -0.802 . . . . 1.35 108.835 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.471 ' HZ1' ' HB3' ' A' 2110 ' ' LYS . 5.4 ttpm? -143.6 108.94 5.04 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 112.989 0.737 . . . . 2.25 112.989 -173.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.407 ' HD2' HG21 ' A' 2061 ' ' ILE . 28.1 ptt180 -129.65 140.62 51.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.741 -0.837 . . . . 3.95 108.741 171.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.9 m -99.58 142.01 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 120.358 -0.537 . . . . 1.09 110.997 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.661 ' OD1' ' HB ' ' A' 2117 ' ' THR . 4.3 p30 -85.24 -170.72 3.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.949 -0.569 . . . . 1.46 111.615 -178.034 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2114 ' ' LYS . . . . . 0.514 ' HG3' ' O ' ' A' 2060 ' ' PRO . 91.5 mttt -57.55 -37.17 72.67 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.851 0.315 . . . . 2.25 111.851 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -80.09 -29.7 39.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.313 0.578 . . . . 1.84 109.901 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 112.6 21.62 6.04 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.321 -0.854 . . . . 0.46 112.418 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.661 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 92.4 m -86.91 120.97 71.88 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 110.214 -0.291 . . . . 1.22 110.214 177.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -73.16 101.88 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.453 2.102 . . . . 0.72 112.433 178.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.7 m -75.07 113.0 13.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.527 -0.916 . . . . 1.37 108.527 171.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.622 ' HA ' ' O ' ' A' 2109 ' ' VAL . 37.8 p -119.66 154.82 33.46 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 115.483 -0.781 . . . . 1.23 112.617 -169.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -130.29 127.54 39.71 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.892 -1.151 . . . . 1.33 107.892 167.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.2 m -115.87 103.87 11.06 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.072 0.463 . . . . 2.66 110.527 -174.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.612 ' O ' ' HA ' ' A' 2106 ' ' PRO . 3.1 m-85 -98.33 132.29 43.92 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-O 121.198 0.523 . . . . 3.23 111.19 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 44.3 m -157.14 165.37 18.95 Favored Pre-proline 0 C--N 1.321 -0.635 0 N-CA-C 108.433 -0.951 . . . . 2.37 108.433 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -58.5 -6.09 2.89 Favored 'Trans proline' 0 C--N 1.353 0.783 0 C-N-CA 123.199 2.599 . . . . 2.51 114.064 -176.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -81.45 -36.23 29.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.357 0.598 . . . . 4.33 109.468 175.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -86.12 68.55 10.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.544 -0.753 . . . . 4.51 110.703 -175.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -117.82 -81.11 0.62 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.038 -0.528 . . . . 5.72 111.05 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 17.3 ptpt -87.99 52.04 2.36 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.654 0.74 . . . . 5.6 110.578 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 29.4 t . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.197 -0.91 . . . . 6.27 110.223 -177.214 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 26.4 mp0 . . . . . 0 N--CA 1.483 1.193 0 CA-C-O 120.785 0.326 . . . . 7.47 110.337 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 63.67 39.04 97.11 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.762 -0.732 . . . . 3.62 111.376 -175.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 127.5 123.38 2.61 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.171 -0.772 . . . . 2.08 111.171 -175.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -88.42 117.02 67.91 Favored Pre-proline 0 C--N 1.322 -0.588 0 CA-C-O 120.582 0.23 . . . . 2.42 110.621 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.87 -21.91 18.1 Favored 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.404 2.07 . . . . 1.98 111.933 -178.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.74 -18.48 59.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.673 -0.694 . . . . 2.8 110.465 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2059 ' ' VAL . . . . . 0.555 HG12 ' OD2' ' A' 2113 ' ' ASP . 5.0 t -133.63 98.38 14.99 Favored Pre-proline 0 N--CA 1.452 -0.341 0 CA-C-N 116.062 -0.517 . . . . 1.56 109.811 177.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2060 ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' 2059 ' ' VAL . 11.3 Cg_endo -55.76 118.86 5.69 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.039 1.826 . . . . 1.35 111.827 178.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.8 mm -53.6 136.84 14.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.251 -0.886 . . . . 1.33 111.346 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.509 ' O ' HG22 ' A' 2065 ' ' VAL . 14.8 t70 -71.57 131.56 43.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 1.42 110.144 178.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -86.76 -5.2 59.19 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.238 -0.437 . . . . 1.55 112.131 -172.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.7 p -111.37 3.82 18.53 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.091 0.404 . . . . 1.29 112.091 -177.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' 2062 ' ' ASP . 27.1 m -90.19 -177.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.728 -0.471 . . . . 1.47 109.728 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -94.06 116.73 66.79 Favored Pre-proline 0 C--O 1.241 0.625 0 CA-C-O 121.382 0.61 . . . . 0.78 111.6 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.491 ' HB2' HG13 ' A' 2086 ' ' ILE . 28.4 Cg_endo -100.39 108.55 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 123.59 2.86 . . . . 0.52 111.416 167.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2068 ' ' THR . . . . . 0.452 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.4 p -143.37 145.25 32.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.887 0.375 . . . . 1.07 110.549 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.676 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-30 -70.78 156.13 39.91 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 107.936 -1.135 . . . . 1.99 107.936 177.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -51.73 -39.13 57.92 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 123.404 0.44 . . . . 2.09 111.819 -170.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -91.12 19.18 6.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 2.15 111.358 -177.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 75.44 29.44 59.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.047 -0.597 . . . . 0.63 112.66 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2073 ' ' SER . . . . . 0.415 ' HB2' ' CD1' ' A' 2069 ' ' PHE . 7.4 m -95.34 162.32 13.72 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 122.743 -0.269 . . . . 1.14 110.904 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.7 mmtp -121.57 -24.9 5.23 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.268 -0.424 . . . . 1.68 111.673 -177.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' A' 2084 ' ' TYR . 2.0 tt0 -158.62 124.64 4.54 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.368 0.604 . . . . 2.08 110.583 175.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -123.55 102.19 7.73 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.375 -0.829 . . . . 2.03 109.931 175.211 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.7 m -95.92 113.22 24.82 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.204 0.526 . . . . 1.28 110.576 175.157 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.518 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 27.3 mm -116.07 108.86 45.48 Favored Pre-proline 0 C--N 1.31 -1.133 0 N-CA-C 107.627 -1.249 . . . . 2.24 107.627 170.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.08 115.43 1.7 Allowed 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 123.183 2.589 . . . . 1.09 113.41 -173.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2080 ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' 2100 ' ' PHE . . . 89.58 -8.41 79.88 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.775 -0.648 . . . . 0.94 112.513 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.518 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.0 OUTLIER -107.49 -31.05 8.3 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.219 0.533 . . . . 2.02 109.903 -176.679 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 136.45 172.0 12.45 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.519 -0.848 . . . . 0.58 112.94 173.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 77.7 m -138.23 127.93 25.12 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.304 0.573 . . . . 1.21 109.696 172.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.676 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.1 OUTLIER -108.16 125.99 52.26 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 107.698 -1.223 . . . . 2.34 107.698 175.52 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 1.3 p -127.86 129.31 46.71 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 112.074 0.398 . . . . 1.26 112.074 -174.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.491 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.47 132.09 71.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.854 -0.612 . . . . 1.76 110.52 174.601 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -125.79 142.56 42.52 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.788 -0.642 . . . . 1.35 109.3 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.57 -0.05 1.71 Allowed 'Trans proline' 0 N--CA 1.476 0.491 0 C-N-CA 123.827 3.018 . . . . 1.32 114.177 -170.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 36.8 t70 -72.77 -11.8 60.75 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.41 0.624 . . . . 2.29 109.836 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 106.26 6.24 36.6 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.629 -0.714 . . . . 0.83 112.381 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 2.2 t -110.8 128.06 55.62 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.257 0.551 . . . . 1.8 110.274 -179.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 18.8 t -137.17 137.25 46.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.527 -0.76 . . . . 1.67 109.624 -175.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 24.0 m -119.8 109.77 15.99 Favored 'General case' 0 N--CA 1.439 -0.997 0 CA-C-O 120.816 0.341 . . . . 1.94 111.3 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -89.65 98.88 12.02 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.26 -0.645 . . . . 2.13 109.26 174.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 23.0 m -114.01 89.42 16.72 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 120.683 0.278 . . . . 1.21 111.662 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -92.52 119.34 0.44 Allowed 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.971 2.447 . . . . 1.23 112.702 175.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -89.87 84.68 6.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.34 0.59 . . . . 2.72 109.563 173.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2098 ' ' LYS . . . . . 0.497 ' HA ' ' CG2' ' A' 2128 ' ' THR . 0.0 OUTLIER -75.69 -1.91 27.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.566 -0.743 . . . . 5.15 112.374 -171.596 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -84.9 -2.02 57.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.168 0.509 . . . . 5.07 110.523 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2100 ' ' PHE . . . . . 0.472 ' HB2' ' O ' ' A' 2080 ' ' GLY . 69.0 t80 -83.49 85.47 7.24 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 3.08 110.377 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.8 t -92.35 99.63 10.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.147 -0.478 . . . . 3.01 110.196 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -169.53 -101.93 0.15 Allowed Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.415 -0.674 . . . . 3.84 111.415 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 53.3 mtmt -131.6 73.25 79.59 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-O 120.611 0.244 . . . . 7.31 110.615 174.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2104 ' ' PRO . . . . . 0.407 ' HD2' ' O ' ' A' 2125 ' ' PRO . 18.9 Cg_exo -66.06 127.93 18.63 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.383 2.055 . . . . 2.77 111.312 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.3 t70 -60.79 122.88 71.85 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.001 -0.545 . . . . 2.33 110.665 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.482 ' HA ' ' O ' ' A' 2123 ' ' TYR . 31.8 Cg_exo -58.93 120.37 8.19 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 123.101 2.534 . . . . 1.29 112.174 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.7 p -156.72 161.51 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.93 -0.577 . . . . 1.23 109.731 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.465 ' HA ' ' O ' ' A' 2121 ' ' ALA . 67.0 m -140.88 119.74 12.62 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.933 0.397 . . . . 1.11 110.08 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.4 t -92.5 145.18 7.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.029 -0.73 . . . . 1.35 109.029 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.452 ' HB3' ' O ' ' A' 2068 ' ' THR . 0.0 OUTLIER -147.47 143.21 27.72 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.224 0.465 . . . . 2.25 111.341 -174.787 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.41 ' N ' ' HD2' ' A' 2110 ' ' LYS . 27.2 ptt180 -166.95 146.07 5.28 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.676 -0.861 . . . . 3.95 108.676 166.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' 2065 ' ' VAL . 30.5 m -99.01 149.19 5.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 C-N-CA 120.44 -0.504 . . . . 1.09 111.289 -175.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.555 ' OD2' HG12 ' A' 2059 ' ' VAL . 2.8 p-10 -90.51 -169.39 2.38 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.951 -0.568 . . . . 1.46 109.976 178.433 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.9 mttt -59.97 -38.56 82.88 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.542 0.21 . . . . 2.25 111.008 178.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2115 ' ' ASN . . . . . 0.407 HD21 HG12 ' A' 2059 ' ' VAL . 40.2 m-80 -71.66 -30.28 65.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.844 0.354 . . . . 1.84 110.857 177.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 110.55 12.93 15.65 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.851 -0.69 . . . . 0.46 112.214 179.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 5.7 m -79.72 121.58 82.57 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 110.128 -0.323 . . . . 1.22 110.128 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.6 Cg_exo -73.95 103.92 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 122.301 2.001 . . . . 0.72 112.234 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.5 m -75.32 117.62 19.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.381 -0.97 . . . . 1.37 108.381 171.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.561 ' HA ' ' O ' ' A' 2109 ' ' VAL . 47.2 p -129.75 163.35 26.38 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.539 -0.755 . . . . 1.23 111.751 -170.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -130.98 126.84 37.07 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.528 -0.915 . . . . 1.33 108.528 169.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 20.3 m -100.12 100.45 11.3 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.041 0.448 . . . . 2.66 110.335 -176.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.482 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -96.99 114.39 26.0 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.143 -0.48 . . . . 3.23 110.899 -177.407 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 17.8 m -127.39 158.57 69.15 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.537 -0.756 . . . . 2.37 109.651 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' 2104 ' ' PRO . 95.2 Cg_exo -45.31 -45.32 15.35 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.069 2.513 . . . . 2.51 113.828 -177.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -108.29 28.15 8.61 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 122.213 -0.304 . . . . 4.33 111.516 -176.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 79.9 t80 -79.38 -47.09 16.37 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.086 0.47 . . . . 4.51 110.8 -179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2128 ' ' THR . . . . . 0.497 ' CG2' ' HA ' ' A' 2098 ' ' LYS . 22.2 p -88.77 109.13 19.91 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.951 -0.568 . . . . 5.72 111.934 -173.307 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 9.7 ptmm? -178.24 40.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.85 -1.068 . . . . 5.6 109.864 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.248 1.004 0 CA-C-N 115.073 -0.967 . . . . 6.27 111.264 -176.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 35.5 tt0 . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.833 0.349 . . . . 7.47 110.535 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 101.45 -14.13 58.06 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.611 -0.804 . . . . 3.62 112.434 178.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 159.67 -107.93 0.34 Allowed Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.402 -0.904 . . . . 2.08 113.12 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.3 t70 -83.88 127.2 68.27 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 120.698 0.285 . . . . 2.42 111.744 -171.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -76.45 -22.47 12.34 Favored 'Trans proline' 0 N--CA 1.46 -0.471 0 C-N-CA 122.414 2.076 . . . . 1.98 112.477 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.52 -9.57 20.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.821 0.343 . . . . 2.8 110.656 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 21.4 t -127.48 84.48 63.27 Favored Pre-proline 0 CA--C 1.511 -0.534 0 N-CA-C 108.034 -1.099 . . . . 1.56 108.034 175.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -40.48 117.77 0.52 Allowed 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.922 2.415 . . . . 1.35 112.228 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 33.3 mm -54.46 114.96 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.263 -0.88 . . . . 1.33 110.911 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2062 ' ' ASP . . . . . . . . . . . . . 15.7 t70 -72.86 125.71 28.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.47 -0.787 . . . . 1.42 111.308 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2063 ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' 2089 ' ' ASP . 44.0 mt-10 -86.89 -2.88 58.94 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.127 -0.488 . . . . 1.55 111.805 -173.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 43.9 p -106.06 -5.53 19.39 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.741 -0.384 . . . . 1.29 111.863 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.492 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.2 m -96.26 163.66 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.863 -0.421 . . . . 1.47 109.863 176.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -73.15 114.09 27.93 Favored Pre-proline 0 C--O 1.24 0.591 0 CA-C-O 121.271 0.557 . . . . 0.78 112.22 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.492 ' HD3' ' O ' ' A' 2065 ' ' VAL . 68.0 Cg_endo -102.29 108.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.423 0 C-N-CA 123.682 2.921 . . . . 0.52 112.097 169.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 20.9 p -138.61 -178.64 5.4 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.403 0.62 . . . . 1.07 111.273 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.494 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.7 OUTLIER -102.01 152.23 21.2 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.862 -1.162 . . . . 1.99 107.862 168.72 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -52.39 -39.21 60.56 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.066 0.394 . . . . 2.09 111.741 -170.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.36 -2.94 43.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.91 -0.586 . . . . 2.15 111.335 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.78 29.36 13.47 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.849 -0.691 . . . . 0.63 112.159 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 9.1 m -98.06 169.15 9.82 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.894 -0.18 . . . . 1.14 110.697 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2074 ' ' LYS . . . . . 0.403 ' O ' HG21 ' A' 2086 ' ' ILE . 34.6 mmtp -128.06 -16.64 4.52 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.964 0.412 . . . . 1.68 111.343 -179.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -156.24 121.09 4.64 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.719 -0.475 . . . . 2.08 109.719 172.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' A' 2076 ' ' LYS . 4.5 mmmm -115.45 121.86 44.02 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.967 -0.561 . . . . 2.03 109.534 171.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 55.2 m -129.53 121.48 27.28 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.729 -0.669 . . . . 1.28 110.85 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 48.4 mm -119.69 124.49 27.96 Favored Pre-proline 0 C--N 1.314 -0.965 0 N-CA-C 107.584 -1.265 . . . . 2.24 107.584 171.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.73 107.86 0.21 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.332 2.021 . . . . 1.09 112.304 -176.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.19 -23.37 27.31 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.811 -0.631 . . . . 0.94 112.534 -178.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.4 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 15.7 tt0 -90.73 -31.14 16.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.003 0.43 . . . . 2.02 110.261 -176.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.62 -173.32 14.72 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.714 -0.755 . . . . 0.58 112.86 176.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 46.4 m -129.99 132.65 46.35 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.556 0.693 . . . . 1.21 110.127 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.469 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 0.5 OUTLIER -111.31 112.47 24.26 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 106.735 -1.58 . . . . 2.34 106.735 172.397 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.89 131.69 55.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.429 0.529 . . . . 1.26 112.429 -170.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.496 ' CG1' HG23 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.93 137.7 54.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.392 -0.822 . . . . 1.76 109.561 174.54 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 31.7 m -118.67 153.3 52.19 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 109.889 -0.411 . . . . 1.35 109.889 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -60.3 -4.81 3.43 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.773 2.982 . . . . 1.32 114.264 -170.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2089 ' ' ASP . . . . . 0.414 ' O ' ' HB3' ' A' 2063 ' ' GLU . 27.7 m-20 -72.93 -13.08 61.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.907 0.384 . . . . 2.29 110.215 177.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.72 16.06 32.37 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.967 -0.635 . . . . 0.83 112.263 177.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.7 t -115.61 141.25 48.32 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.806 0.336 . . . . 1.8 110.44 -178.111 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.496 HG23 ' CG1' ' A' 2086 ' ' ILE . 12.5 t -133.32 150.78 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.977 -0.556 . . . . 1.67 109.96 -178.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -125.86 122.0 34.82 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.94 110.05 173.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -90.47 98.82 12.0 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.265 -0.642 . . . . 2.13 109.265 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 8.9 m -113.25 87.49 11.12 Favored Pre-proline 0 N--CA 1.454 -0.242 0 CA-C-O 120.964 0.411 . . . . 1.21 110.431 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -92.55 -179.88 1.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 123.292 2.661 . . . . 1.23 112.399 178.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.4 t70 -131.7 139.65 49.09 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.222 -0.659 . . . . 2.72 109.222 170.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2098 ' ' LYS . . . . . 0.51 ' HZ3' ' HB2' ' A' 2098 ' ' LYS . 3.8 ttmp? -90.23 -26.1 20.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.87 -0.605 . . . . 5.15 111.833 -172.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -120.32 36.83 4.43 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.788 0.292 . . . . 5.07 111.788 -171.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 19.4 t80 -82.41 87.01 6.64 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.37 0.605 . . . . 3.08 110.737 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2101 ' ' VAL . . . . . 0.418 ' HA ' ' HB3' ' A' 2129 ' ' LYS . 46.2 t -92.14 109.84 21.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.793 -0.64 . . . . 3.01 109.745 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2102 ' ' GLY . . . . . 0.418 ' C ' ' HD3' ' A' 2104 ' ' PRO . . . 170.75 -113.29 0.49 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.492 -0.643 . . . . 3.84 111.492 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -120.01 76.87 22.95 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 121.115 0.483 . . . . 7.31 111.533 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2104 ' ' PRO . . . . . 0.418 ' HD3' ' C ' ' A' 2102 ' ' GLY . 8.1 Cg_exo -74.68 157.68 43.93 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.198 2.599 . . . . 2.77 111.684 178.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.0 t70 -120.09 117.48 32.06 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.477 -0.328 . . . . 2.33 110.435 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' 2123 ' ' TYR . 52.6 Cg_exo -54.94 128.41 30.42 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.864 2.376 . . . . 1.29 111.828 177.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.1 p -157.51 161.29 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.312 -0.404 . . . . 1.23 110.257 -176.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.5 m -140.15 119.05 12.54 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.149 0.5 . . . . 1.11 110.269 176.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.6 t -91.35 138.06 20.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 108.131 -1.063 . . . . 1.35 108.131 176.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.451 ' HA ' HG23 ' A' 2120 ' ' THR . 2.2 tmmm? -145.14 108.32 4.57 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.275 0.559 . . . . 2.25 111.476 -172.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.467 ' NH1' ' HB3' ' A' 2067 ' ' PRO . 1.4 ptm180 -139.72 142.95 36.82 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 109.207 -0.664 . . . . 3.95 109.207 174.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' 2117 ' ' THR . 24.0 m -99.6 161.06 3.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.426 -0.51 . . . . 1.09 111.49 -175.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.506 ' OD2' ' HB ' ' A' 2117 ' ' THR . 3.9 p30 -110.01 -169.13 1.41 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.571 -0.74 . . . . 1.46 111.004 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 65.2 mttm -63.49 -25.12 68.12 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 111.938 0.347 . . . . 2.25 111.938 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.67 -9.98 56.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.949 0.404 . . . . 1.84 110.251 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 86.27 15.99 63.41 Favored Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.333 -0.707 . . . . 0.46 111.333 -176.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.506 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 0.2 OUTLIER -84.99 131.23 49.45 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 109.954 -0.388 . . . . 1.22 109.954 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' 2117 ' ' THR . 12.3 Cg_endo -87.78 103.9 0.52 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 122.208 1.938 . . . . 0.72 112.428 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 14.8 m -75.42 109.29 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 108.692 -0.855 . . . . 1.37 108.692 171.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' 2109 ' ' VAL . 35.5 p -124.55 169.27 12.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.094 -0.957 . . . . 1.23 111.55 -170.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -135.49 127.73 30.08 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.52 -0.764 . . . . 1.33 109.6 173.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 13.4 p -94.71 99.67 11.73 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.254 -0.43 . . . . 2.66 109.892 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.52 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -103.77 123.93 47.97 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.34 0.59 . . . . 3.23 111.788 -174.859 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 25.2 m -154.19 153.07 27.75 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.141 -0.936 . . . . 2.37 108.484 175.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.402 ' HA ' ' HG2' ' A' 2104 ' ' PRO . 88.7 Cg_exo -43.45 -38.91 8.98 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 122.837 2.358 . . . . 2.51 113.891 -178.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -64.66 -11.79 39.29 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 112.76 0.652 . . . . 4.33 112.76 -177.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.54 -5.36 46.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.715 0.293 . . . . 4.51 111.416 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 33.0 p -123.25 -39.98 2.42 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.149 0.499 . . . . 5.72 110.938 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A 2129 ' ' LYS . . . . . 0.44 ' HG3' HG23 ' A' 2130 ' ' VAL . 51.6 pttt -126.64 -165.27 1.43 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.764 -0.653 . . . . 5.6 110.23 177.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A 2130 ' ' VAL . . . . . 0.44 HG23 ' HG3' ' A' 2129 ' ' LYS . 42.6 t . . . . . 0 C--O 1.248 1.026 0 CA-C-O 117.929 -1.034 . . . . 6.27 110.185 -178.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 22.0 mp0 . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.821 0.343 . . . . 7.47 110.519 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 97.58 79.46 1.46 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.734 -0.746 . . . . 3.62 112.188 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 144.58 122.6 1.59 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.712 -0.756 . . . . 2.08 112.016 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 7.1 t70 -79.92 129.36 70.79 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-O 120.678 0.275 . . . . 2.42 110.359 -176.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.7 -21.78 33.28 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.387 2.058 . . . . 1.98 112.55 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.9 mm? -93.2 -26.83 17.21 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.887 0.375 . . . . 2.8 110.043 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2059 ' ' VAL . . . . . 0.468 HG11 ' OD2' ' A' 2113 ' ' ASP . 1.8 t -126.88 90.7 48.9 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.239 -0.437 . . . . 1.56 110.429 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -57.32 121.57 10.28 Favored 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 122.188 1.925 . . . . 1.35 111.586 176.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 48.9 mm -53.04 132.31 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.572 -0.74 . . . . 1.33 110.828 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.559 ' O ' HG21 ' A' 2065 ' ' VAL . 24.4 t70 -66.78 135.39 53.89 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 1.42 110.493 -177.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -92.91 -2.58 55.7 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.195 -0.457 . . . . 1.55 111.889 -171.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 31.0 p -106.7 2.21 25.61 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.763 -0.375 . . . . 1.29 111.832 178.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.559 HG21 ' O ' ' A' 2062 ' ' ASP . 35.4 m -92.68 -174.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 110.326 -0.249 . . . . 1.47 110.326 176.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -91.25 114.13 60.65 Favored Pre-proline 0 C--O 1.24 0.597 0 CA-C-O 121.02 0.438 . . . . 0.78 111.389 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.504 ' HD3' ' O ' ' A' 2065 ' ' VAL . 53.8 Cg_endo -101.06 108.06 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 123.362 2.708 . . . . 0.52 111.296 166.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 23.2 p -149.25 -177.2 5.7 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.93 0.395 . . . . 1.07 110.665 -177.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.611 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 9.3 m-30 -101.56 142.85 32.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.832 -1.173 . . . . 1.99 107.832 166.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -64.18 -15.78 60.57 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.421 0.451 . . . . 2.09 111.248 -172.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -84.4 2.02 42.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.039 -0.528 . . . . 2.15 110.902 176.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 85.58 23.47 46.73 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.111 -0.566 . . . . 0.63 112.706 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.7 p -110.64 164.38 12.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.974 0.416 . . . . 1.14 111.37 -177.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2074 ' ' LYS . . . . . 0.592 ' O ' HG23 ' A' 2086 ' ' ILE . 47.9 mmtm -113.32 -44.78 3.2 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.684 -0.689 . . . . 1.68 110.696 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.582 ' HG3' HG21 ' A' 2085 ' ' THR . 4.6 mp0 -119.97 138.11 53.67 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.772 -0.455 . . . . 2.08 109.772 173.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.5 OUTLIER -127.71 99.25 5.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.15 -0.477 . . . . 2.03 109.736 178.258 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 48.7 m -110.69 121.77 46.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.11 0.481 . . . . 1.28 110.476 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 88.0 mt -126.84 126.17 24.39 Favored Pre-proline 0 C--N 1.315 -0.91 0 N-CA-C 108.521 -0.918 . . . . 2.24 108.521 174.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -47.14 109.67 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.295 2.664 . . . . 1.09 113.257 -175.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2080 ' ' GLY . . . . . 0.49 ' O ' ' HD2' ' A' 2100 ' ' PHE . . . 93.9 -12.95 68.44 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.706 -0.679 . . . . 0.94 113.009 177.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.491 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -94.7 -32.47 13.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 117.122 0.461 . . . . 2.02 110.661 -175.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.7 -155.24 16.28 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.811 -0.709 . . . . 0.58 111.9 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.557 ' HA ' ' O ' ' A' 2076 ' ' LYS . 55.8 m -155.28 138.92 16.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.698 0.761 . . . . 1.21 111.011 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.611 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.2 m-85 -109.01 121.69 45.68 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.774 -1.565 . . . . 2.34 106.774 170.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2085 ' ' THR . . . . . 0.582 HG21 ' HG3' ' A' 2075 ' ' GLU . 16.8 p -118.84 133.56 55.75 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.721 0.296 . . . . 1.26 111.584 -175.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.592 HG23 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -113.02 136.9 47.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.278 -0.419 . . . . 1.76 110.186 176.16 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 18.6 m -122.71 144.82 43.55 Favored Pre-proline 0 C--N 1.319 -0.732 0 N-CA-C 109.975 -0.38 . . . . 1.35 109.975 173.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -62.18 0.01 1.52 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.542 2.828 . . . . 1.32 114.014 -172.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 37.2 t70 -68.04 -21.29 65.02 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.411 -0.589 . . . . 2.29 109.411 173.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.33 5.18 28.5 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.374 -0.83 . . . . 0.83 111.715 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2091 ' ' THR . . . . . 0.494 ' HA ' ' NH2' ' A' 2111 ' ' ARG . 4.9 t -114.23 143.34 45.0 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.185 0.517 . . . . 1.8 110.945 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 27.6 t -139.32 137.52 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.529 -0.759 . . . . 1.67 109.309 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 7.2 t -107.1 121.23 44.08 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.206 0.527 . . . . 1.94 110.166 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -87.53 97.86 11.08 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.087 -1.079 . . . . 2.13 108.087 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2095 ' ' THR . . . . . 0.452 ' HB ' ' O ' ' A' 2083 ' ' THR . 43.9 m -117.63 99.09 52.27 Favored Pre-proline 0 N--CA 1.453 -0.31 0 N-CA-C 112.501 0.556 . . . . 1.21 112.501 -174.063 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -86.17 143.17 7.75 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.567 2.178 . . . . 1.23 110.231 166.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 17.1 t70 -61.34 135.01 57.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.955 0.407 . . . . 2.72 110.499 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 58.9 mttp -72.24 -14.22 61.72 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.618 -0.719 . . . . 5.15 111.913 -172.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -120.16 23.41 10.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.998 -0.371 . . . . 5.07 109.998 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2100 ' ' PHE . . . . . 0.49 ' HD2' ' O ' ' A' 2080 ' ' GLY . 64.1 t80 -72.64 124.88 26.18 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-O 121.152 0.501 . . . . 3.08 110.311 179.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2101 ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' 2129 ' ' LYS . 2.3 p -74.89 99.91 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.226 -0.897 . . . . 3.01 110.478 177.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 102.56 -147.96 17.29 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.803 -0.635 . . . . 3.84 112.039 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 48.7 mttp -111.02 134.4 21.03 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 120.613 0.245 . . . . 7.31 110.876 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -43.72 149.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 124.409 3.406 . . . . 2.77 114.035 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2105 ' ' ASP . . . . . 0.419 ' H ' ' HG3' ' A' 2081 ' ' GLN . 1.4 m-20 -56.68 153.94 19.74 Favored Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 114.962 -1.017 . . . . 2.33 111.898 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -53.22 113.16 1.15 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 124.235 3.29 . . . . 1.29 114.598 -174.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.2 p -160.66 119.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.092 -0.958 . . . . 1.23 109.776 172.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' 2121 ' ' ALA . 62.3 m -95.87 118.29 32.24 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.453 0.644 . . . . 1.11 110.17 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' 2120 ' ' THR . 6.1 t -91.65 136.36 24.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.259 -0.882 . . . . 1.35 108.989 -178.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.588 ' HD2' ' C ' ' A' 2110 ' ' LYS . 0.0 OUTLIER -139.97 108.86 5.99 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.156 0.503 . . . . 2.25 112.188 -173.089 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.494 ' NH2' ' HA ' ' A' 2091 ' ' THR . 4.2 ptm180 -142.4 132.76 24.95 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.719 -0.845 . . . . 3.95 108.719 170.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.51 ' O ' HG22 ' A' 2065 ' ' VAL . 33.0 m -99.12 152.82 4.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.587 -0.445 . . . . 1.09 111.695 -174.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.468 ' OD2' HG11 ' A' 2059 ' ' VAL . 1.2 p-10 -92.48 -170.68 2.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.969 -0.56 . . . . 1.46 110.15 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -64.72 -34.05 77.4 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.585 0.231 . . . . 2.25 111.255 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -69.66 -30.13 67.74 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 1.84 110.568 175.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 109.97 7.43 27.14 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.964 -0.636 . . . . 0.46 111.978 -178.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.415 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 87.9 m -81.97 118.73 73.15 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 110.142 -0.318 . . . . 1.22 110.142 178.678 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' 2112 ' ' VAL . 3.3 Cg_exo -78.88 116.63 3.77 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 122.21 1.94 . . . . 0.72 112.307 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 6.8 m -74.85 108.88 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.423 0 N-CA-C 107.89 -1.152 . . . . 1.37 107.89 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' 2109 ' ' VAL . 68.5 p -123.3 168.48 12.43 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.662 -1.154 . . . . 1.23 111.006 -170.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.04 126.36 39.31 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.083 -1.08 . . . . 1.33 108.083 168.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 37.6 m -94.66 98.71 10.99 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.147 -0.686 . . . . 2.66 109.147 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -120.57 123.95 44.11 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.574 0.702 . . . . 3.23 111.796 -176.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2124 ' ' SER . . . . . 0.591 ' OG ' ' HD2' ' A' 2125 ' ' PRO . 6.6 t -132.87 162.16 59.18 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 114.459 -1.246 . . . . 2.37 108.391 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.591 ' HD2' ' OG ' ' A' 2124 ' ' SER . 49.2 Cg_endo -69.17 52.11 0.77 Allowed 'Trans proline' 0 C--N 1.353 0.776 0 C-N-CA 122.584 2.189 . . . . 2.51 112.838 176.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -133.08 151.09 52.05 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.965 -1.124 . . . . 4.33 107.965 175.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 61.1 m-85 63.87 47.19 3.6 Favored 'General case' 0 C--N 1.331 -0.237 0 O-C-N 123.533 0.52 . . . . 4.51 109.969 -173.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 8.4 p -75.57 -168.57 0.86 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.765 -0.652 . . . . 5.72 111.241 -178.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A 2129 ' ' LYS . . . . . 0.445 ' HA ' ' O ' ' A' 2101 ' ' VAL . 0.0 OUTLIER -63.97 170.9 3.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.241 0.543 . . . . 5.6 111.155 179.575 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 10.1 p . . . . . 0 C--O 1.248 1.006 0 N-CA-C 108.432 -0.951 . . . . 6.27 108.432 171.902 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A 2053 ' ' GLN . . . . . 0.458 ' HG2' ' H ' ' A' 2054 ' ' GLY . 21.9 tt0 . . . . . 0 N--CA 1.481 1.077 0 N-CA-C 109.37 -0.604 . . . . 7.47 109.37 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2054 ' ' GLY . . . . . 0.458 ' H ' ' HG2' ' A' 2053 ' ' GLN . . . -156.3 167.78 33.49 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.682 -0.77 . . . . 3.62 112.17 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 84.39 45.38 6.19 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.016 -0.611 . . . . 2.08 112.097 178.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.21 120.88 58.74 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.816 0.341 . . . . 2.42 111.343 -179.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -76.88 -21.44 12.45 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.341 2.028 . . . . 1.98 111.915 176.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.6 mp -85.14 -22.4 28.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.874 -0.603 . . . . 2.8 110.048 177.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.8 t -126.17 83.32 63.82 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 108.711 -0.848 . . . . 1.56 108.711 178.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2060 ' ' PRO . . . . . 0.491 ' O ' ' HG3' ' A' 2114 ' ' LYS . 33.3 Cg_exo -58.53 141.59 97.46 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.625 2.217 . . . . 1.35 112.196 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.1 mm -63.12 135.79 26.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.693 -0.685 . . . . 1.33 110.112 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.443 ' O ' HG23 ' A' 2065 ' ' VAL . 11.7 t70 -70.51 128.69 37.02 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.28 -0.418 . . . . 1.42 110.064 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -89.38 0.19 57.01 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.112 -0.494 . . . . 1.55 112.005 -171.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -105.11 -12.76 15.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.955 0.407 . . . . 1.29 110.972 178.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.533 ' O ' ' HD3' ' A' 2067 ' ' PRO . 33.3 m -91.72 -174.59 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.744 -0.465 . . . . 1.47 109.744 175.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -92.8 113.53 59.94 Favored Pre-proline 0 C--O 1.245 0.829 0 CA-C-O 121.268 0.556 . . . . 0.78 111.354 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' A' 2065 ' ' VAL . 51.0 Cg_endo -100.71 106.93 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.658 0 C-N-CA 123.096 2.531 . . . . 0.52 111.45 167.13 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 16.7 p -138.88 178.88 6.83 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.072 0.463 . . . . 1.07 111.176 -178.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.538 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 97.2 m-85 -103.0 159.45 15.5 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.71 -0.848 . . . . 1.99 108.71 168.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -51.13 -44.13 61.32 Favored 'General case' 0 N--CA 1.468 0.474 0 O-C-N 123.755 0.66 . . . . 2.09 112.203 -168.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 36.9 t70 -81.19 6.04 15.15 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.393 0.616 . . . . 2.15 111.109 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 89.87 11.76 63.12 Favored Glycine 0 N--CA 1.45 -0.381 0 N-CA-C 111.675 -0.57 . . . . 0.63 111.675 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2073 ' ' SER . . . . . 0.452 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 4.2 m -74.57 161.58 29.59 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.797 0.332 . . . . 1.14 110.875 -173.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -120.37 -21.2 6.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 1.68 110.883 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.416 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.0 tt0 -156.43 129.91 8.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.983 0.42 . . . . 2.08 110.108 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.1 OUTLIER -126.78 100.59 6.25 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.972 -0.558 . . . . 2.03 110.816 178.029 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 32.2 m -96.34 123.7 40.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.077 -0.511 . . . . 1.28 110.287 174.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.535 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 2.7 mp -126.36 122.55 23.97 Favored Pre-proline 0 C--N 1.314 -0.936 0 N-CA-C 109.206 -0.664 . . . . 2.24 109.206 177.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 68.9 Cg_exo -51.36 109.99 0.37 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.329 2.686 . . . . 1.09 113.274 -175.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 94.46 -6.65 71.35 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.94 112.757 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.535 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.6 tt0 -109.1 -33.39 6.9 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.123 0.487 . . . . 2.02 110.584 -175.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.77 -155.18 16.29 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.628 -0.796 . . . . 0.58 112.552 176.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.439 ' HA ' ' O ' ' A' 2076 ' ' LYS . 32.1 m -150.72 137.4 18.92 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.32 0.581 . . . . 1.21 110.533 178.136 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.538 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.3 OUTLIER -111.51 121.88 46.36 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.481 -1.303 . . . . 2.34 107.481 170.784 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 2.6 p -118.88 158.15 26.23 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 112.828 0.677 . . . . 1.26 112.828 -171.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.521 ' HB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -159.33 124.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 115.009 -0.996 . . . . 1.76 109.57 172.223 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A 2087 ' ' VAL . . . . . 0.589 HG23 ' OG1' ' A' 2091 ' ' THR . 9.9 m -107.58 157.52 35.59 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.871 -0.788 . . . . 1.35 108.871 173.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.99 0.52 1.2 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 123.392 2.728 . . . . 1.32 114.299 -171.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -82.45 -12.81 57.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 2.29 110.099 174.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 97.08 32.57 6.38 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.948 -0.644 . . . . 0.83 112.338 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2091 ' ' THR . . . . . 0.589 ' OG1' HG23 ' A' 2087 ' ' VAL . 63.7 p -87.86 136.06 33.12 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.261 -0.274 . . . . 1.8 110.261 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 48.9 t -136.78 126.38 38.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 120.891 0.376 . . . . 1.67 111.55 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.7 t -146.92 109.72 4.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.529 0.681 . . . . 1.94 110.382 171.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2094 ' ' PHE . . . . . 0.662 ' CE2' HG13 ' A' 2109 ' ' VAL . 13.6 m-30 -84.91 101.99 12.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.373 -0.973 . . . . 2.13 108.373 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 2.1 m -110.13 88.62 7.28 Favored Pre-proline 0 N--CA 1.452 -0.356 0 CA-C-O 120.9 0.381 . . . . 1.21 110.812 -177.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2096 ' ' PRO . . . . . 0.541 ' HD3' ' O ' ' A' 2094 ' ' PHE . 93.3 Cg_endo -92.27 166.97 2.95 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 123.436 2.758 . . . . 1.23 112.547 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 13.0 t70 -131.8 110.17 10.65 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.401 -0.592 . . . . 2.72 109.401 171.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.59 18.77 4.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.816 0.341 . . . . 5.15 111.381 -176.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -119.86 7.13 10.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.076 0.465 . . . . 5.07 110.158 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 53.3 t80 -83.57 113.14 20.61 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.635 -0.711 . . . . 3.08 111.047 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.5 t -113.46 98.78 7.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.947 -0.57 . . . . 3.01 109.664 175.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 172.17 43.3 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.711 -0.677 . . . . 3.84 111.512 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 37.1 ttpt 60.45 83.49 0.21 Allowed Pre-proline 0 CA--C 1.531 0.226 0 C-N-CA 123.425 0.69 . . . . 7.31 111.441 -178.327 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2104 ' ' PRO . . . . . 0.414 ' HG2' ' O ' ' A' 2124 ' ' SER . 14.1 Cg_endo -58.9 134.24 58.86 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.186 1.924 . . . . 2.77 111.042 173.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.4 t70 -60.85 124.99 82.19 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.092 -0.504 . . . . 2.33 110.889 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' 2123 ' ' TYR . 27.2 Cg_endo -64.1 95.85 0.21 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.728 2.286 . . . . 1.29 112.048 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.9 p -128.58 160.83 38.51 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.386 -0.824 . . . . 1.23 109.499 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 93.8 m -140.75 131.19 25.27 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.356 -0.609 . . . . 1.11 109.356 174.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.662 HG13 ' CE2' ' A' 2094 ' ' PHE . 6.0 t -92.04 137.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.773 -0.825 . . . . 1.35 108.773 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -144.92 108.22 4.59 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.974 -0.38 . . . . 2.25 109.974 -178.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.53 ' CB ' ' HA ' ' A' 2067 ' ' PRO . 15.0 ptp180 -159.6 156.55 28.17 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.162 -0.472 . . . . 3.95 109.751 175.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 34.7 m -109.41 140.65 27.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 C-N-CA 120.202 -0.599 . . . . 1.09 111.577 -176.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.591 ' OD2' ' HB ' ' A' 2117 ' ' THR . 2.5 p30 -90.04 -169.04 2.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.62 -0.718 . . . . 1.46 111.121 178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2114 ' ' LYS . . . . . 0.491 ' HG3' ' O ' ' A' 2060 ' ' PRO . 99.4 mttt -59.47 -29.78 68.06 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.184 0.439 . . . . 2.25 112.184 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -86.05 -11.32 53.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 1.84 110.738 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.14 13.03 59.39 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.906 -0.664 . . . . 0.46 112.048 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.591 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 73.5 m -78.81 128.3 77.29 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-O 120.569 0.223 . . . . 1.22 110.549 178.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' 2117 ' ' THR . 2.7 Cg_exo -75.61 99.0 1.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.322 2.014 . . . . 0.72 111.814 177.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2119 ' ' VAL . . . . . 0.428 ' HB ' ' CA ' ' A' 2054 ' ' GLY . 17.2 m -75.39 109.41 8.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.535 0.683 . . . . 1.37 109.466 175.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.533 ' HA ' ' O ' ' A' 2109 ' ' VAL . 80.3 p -120.33 167.26 12.49 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 115.319 -0.855 . . . . 1.23 110.898 -175.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -140.56 128.58 22.07 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.875 -0.787 . . . . 1.33 108.875 173.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 10.9 p -92.1 98.87 11.81 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.236 0.541 . . . . 2.66 110.664 -177.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.425 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.0 OUTLIER -115.5 123.41 48.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.784 -0.644 . . . . 3.23 110.959 -178.43 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A 2124 ' ' SER . . . . . 0.414 ' O ' ' HG2' ' A' 2104 ' ' PRO . 68.8 m -157.35 163.73 23.93 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.515 -0.766 . . . . 2.37 109.04 178.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 93.0 Cg_exo -44.94 -49.23 9.98 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.659 2.239 . . . . 2.51 112.523 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -81.99 59.16 4.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.56 0.695 . . . . 4.33 110.707 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2127 ' ' PHE . . . . . 0.435 ' C ' ' HG1' ' A' 2128 ' ' THR . 90.3 t80 -126.84 124.7 40.24 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.412 -0.813 . . . . 4.51 109.207 174.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2128 ' ' THR . . . . . 0.435 ' HG1' ' C ' ' A' 2127 ' ' PHE . 71.9 p 50.29 -149.82 0.25 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 123.401 0.68 . . . . 5.72 111.724 -178.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 21.2 mtmm 74.13 -172.94 0.13 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.647 0.779 . . . . 5.6 111.514 178.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 C--O 1.247 0.972 0 CA-C-N 115.162 -0.926 . . . . 6.27 110.257 177.232 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 62.0 tt0 . . . . . 0 N--CA 1.481 1.12 0 CA-C-O 120.702 0.287 . . . . 7.47 110.628 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 83.99 -65.51 4.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.682 -0.771 . . . . 3.62 112.65 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 163.9 -68.3 0.22 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.97 -0.852 . . . . 2.08 110.97 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -120.42 102.21 45.66 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 110.184 -0.302 . . . . 2.42 110.184 173.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -68.43 -9.41 25.91 Favored 'Trans proline' 0 CA--C 1.528 0.218 0 C-N-CA 122.192 1.928 . . . . 1.98 111.862 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.5 mp -84.78 -18.85 33.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.923 -0.58 . . . . 2.8 110.11 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2059 ' ' VAL . . . . . 0.487 HG11 ' OD2' ' A' 2113 ' ' ASP . 4.6 t -138.84 89.86 12.74 Favored Pre-proline 0 CA--C 1.514 -0.41 0 N-CA-C 109.322 -0.621 . . . . 1.56 109.322 -177.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -53.25 120.68 8.13 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.315 2.01 . . . . 1.35 111.619 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.4 mm -49.77 134.82 8.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.152 -0.931 . . . . 1.33 111.679 -176.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.543 ' O ' HG22 ' A' 2065 ' ' VAL . 14.6 t70 -76.65 130.26 37.54 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.437 -0.802 . . . . 1.42 110.691 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -87.43 -8.29 56.69 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.238 0.458 . . . . 1.55 112.238 -174.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 29.7 p -101.75 0.79 36.47 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 120.5 -0.48 . . . . 1.29 111.883 -178.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.592 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.6 m -92.87 -174.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.663 -0.244 . . . . 1.47 110.507 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -97.35 107.89 41.36 Favored Pre-proline 0 C--O 1.24 0.598 0 CA-C-O 121.364 0.602 . . . . 0.78 111.468 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.592 ' HD3' ' O ' ' A' 2065 ' ' VAL . 5.8 Cg_endo -93.71 108.75 0.17 Allowed 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.518 2.812 . . . . 0.52 110.88 167.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2068 ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.3 p -148.84 146.1 27.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.912 0.387 . . . . 1.07 110.64 -177.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.486 ' N ' ' CD2' ' A' 2069 ' ' PHE . 2.4 m-30 -71.64 148.32 46.66 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.44 -1.319 . . . . 1.99 107.44 176.071 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -61.08 -19.53 61.55 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.406 0.521 . . . . 2.09 112.406 -165.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -92.03 1.33 57.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.621 0.248 . . . . 2.15 111.131 178.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 87.59 25.21 33.5 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.86 -0.686 . . . . 0.63 112.018 -176.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 19.5 m -95.22 152.33 18.46 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 1.14 110.511 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -111.62 -22.47 11.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.084 -0.507 . . . . 1.68 110.58 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.518 ' HA ' ' O ' ' A' 2084 ' ' TYR . 3.0 tt0 -144.35 144.43 31.44 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.113 0.482 . . . . 2.08 110.243 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.4 OUTLIER -139.59 108.14 5.88 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.401 -0.818 . . . . 2.03 109.505 179.854 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 19.2 m -118.64 133.23 56.01 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.189 0.518 . . . . 1.28 111.493 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.502 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 4.2 mp -136.39 123.03 14.01 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 108.106 -1.072 . . . . 2.24 108.106 172.276 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -52.29 109.48 0.34 Allowed 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.669 2.246 . . . . 1.09 112.458 -178.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.65 -22.23 28.73 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.736 -0.665 . . . . 0.94 112.383 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.502 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 52.7 tt0 -96.06 -31.52 12.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.085 0.469 . . . . 2.02 110.463 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.49 -153.64 17.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.837 -0.697 . . . . 0.58 112.141 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' 2076 ' ' LYS . 43.0 m -150.0 144.96 26.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.65 0.738 . . . . 1.21 110.824 178.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.518 ' O ' ' HA ' ' A' 2075 ' ' GLU . 7.6 m-85 -120.15 125.01 47.17 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 107.236 -1.394 . . . . 2.34 107.236 172.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2085 ' ' THR . . . . . 0.41 ' O ' ' HA ' ' A' 2092 ' ' VAL . 17.3 p -129.07 134.75 48.23 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.544 0.572 . . . . 1.26 112.544 -174.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' 2067 ' ' PRO . 0.7 OUTLIER -130.82 123.94 55.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.562 -0.744 . . . . 1.76 110.142 170.155 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 19.2 m -112.15 151.58 43.75 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.003 -0.74 . . . . 1.35 109.003 172.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.76 -6.27 1.06 Allowed 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.057 3.171 . . . . 1.32 114.922 -168.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 27.1 t70 -66.85 -24.07 66.1 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.126 0.489 . . . . 2.29 110.179 175.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 104.11 20.07 10.94 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.738 -0.665 . . . . 0.83 112.223 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.8 t -110.42 126.38 54.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.962 0.41 . . . . 1.8 110.64 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.499 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 7.6 t -133.08 137.42 53.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.016 -0.538 . . . . 1.67 110.384 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.3 t -119.36 118.29 30.79 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.042 0.448 . . . . 1.94 110.19 173.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 9.4 m-30 -85.24 97.21 9.8 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.663 -0.866 . . . . 2.13 108.663 173.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 13.3 m -116.49 87.05 19.44 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.994 0.426 . . . . 1.21 110.76 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2096 ' ' PRO . . . . . 0.446 ' HB2' ' HH ' ' A' 2123 ' ' TYR . 91.6 Cg_endo -92.44 169.69 2.64 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.327 2.685 . . . . 1.23 112.42 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.9 t70 -118.35 106.51 12.83 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.872 -0.788 . . . . 2.72 108.872 171.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 93.2 mttt -69.77 -10.1 57.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.961 -0.563 . . . . 5.15 112.194 -171.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -110.46 8.88 23.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.703 0.287 . . . . 5.07 111.111 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 44.9 t80 -89.63 76.98 7.25 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.2 0.524 . . . . 3.08 110.904 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2101 ' ' VAL . . . . . 0.417 ' HB ' ' O ' ' A' 2128 ' ' THR . 4.2 p -103.96 124.98 58.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.216 0.531 . . . . 3.01 110.083 174.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 164.63 -81.9 0.11 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.047 -0.821 . . . . 3.84 111.047 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 22.7 tptm -140.42 76.72 24.99 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 120.935 0.398 . . . . 7.31 110.707 175.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -80.53 169.57 16.85 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.16 2.573 . . . . 2.77 111.445 173.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.3 t70 -103.06 125.3 35.64 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 116.544 -0.298 . . . . 2.33 110.198 178.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' 2123 ' ' TYR . 24.7 Cg_endo -62.96 103.5 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.734 2.29 . . . . 1.29 111.928 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2107 ' ' VAL . . . . . 0.403 HG12 ' HG2' ' A' 2076 ' ' LYS . 7.7 p -141.37 133.78 29.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.137 -0.483 . . . . 1.23 111.049 -177.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.3 m -102.5 108.71 20.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.652 -0.704 . . . . 1.11 109.906 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.63 ' O ' ' HA ' ' A' 2120 ' ' THR . 8.5 t -91.09 123.09 43.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.772 -0.825 . . . . 1.35 108.772 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.516 ' HB3' ' O ' ' A' 2068 ' ' THR . 1.7 tmmt? -129.59 149.6 51.28 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.402 0.62 . . . . 2.25 112.203 -169.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.499 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.3 ptt180 -166.91 138.2 3.28 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.97 -1.014 . . . . 3.95 108.292 165.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.519 ' O ' HG23 ' A' 2065 ' ' VAL . 27.1 m -98.61 148.88 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 C-N-CA 120.357 -0.537 . . . . 1.09 110.871 -175.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.487 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.7 p-10 -94.12 -168.7 1.91 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.933 -0.576 . . . . 1.46 110.448 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.5 mttm -62.88 -32.34 73.57 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.702 0.287 . . . . 2.25 111.393 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -77.54 -14.96 59.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.955 0.407 . . . . 1.84 110.599 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.87 12.47 59.13 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.906 -0.664 . . . . 0.46 112.333 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 27.8 m -85.83 121.26 73.15 Favored Pre-proline 0 C--N 1.324 -0.533 0 N-CA-C 110.106 -0.331 . . . . 1.22 110.106 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' 2117 ' ' THR . 3.1 Cg_exo -74.74 107.86 2.57 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.261 1.974 . . . . 0.72 112.653 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2119 ' ' VAL . . . . . 0.402 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 15.6 m -74.78 112.03 11.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 107.737 -1.208 . . . . 1.37 107.737 169.141 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.63 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.7 p -127.41 159.32 34.83 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.636 -0.711 . . . . 1.23 112.192 -169.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.46 127.63 42.86 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.8 -1.185 . . . . 1.33 107.8 169.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 12.5 p -115.67 99.53 7.39 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.23 0.538 . . . . 2.66 111.171 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.497 ' O ' ' HA ' ' A' 2106 ' ' PRO . 4.4 m-85 -90.08 151.98 21.36 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.677 -0.692 . . . . 3.23 111.099 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2124 ' ' SER . . . . . 0.404 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 33.3 p -148.2 168.01 12.04 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 115.957 -0.565 . . . . 2.37 110.551 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' 2124 ' ' SER . 71.3 Cg_exo -51.23 -40.68 60.5 Favored 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.574 2.183 . . . . 2.51 112.975 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 19.6 mm-40 -91.35 -54.77 3.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.874 0.369 . . . . 4.33 110.528 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 63.7 t80 63.51 -94.62 0.04 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.332 -0.849 . . . . 4.51 111.821 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2128 ' ' THR . . . . . 0.417 ' O ' ' HB ' ' A' 2101 ' ' VAL . 13.1 m -162.42 158.19 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.231 -0.655 . . . . 5.72 109.231 -176.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -125.82 179.15 5.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.806 0.336 . . . . 5.6 110.292 175.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.728 -0.653 . . . . 6.27 110.382 -176.099 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 8.2 mp0 . . . . . 0 N--CA 1.482 1.131 0 CA-C-O 121.081 0.467 . . . . 7.47 110.604 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -170.08 -86.18 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.885 -0.674 . . . . 3.62 111.96 -179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2055 ' ' GLY . . . . . 0.471 ' O ' ' HD3' ' A' 2057 ' ' PRO . . . 137.3 -9.41 3.8 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.452 -0.88 . . . . 2.08 112.903 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2056 ' ' ASP . . . . . 0.512 ' HB2' ' O ' ' A' 2059 ' ' VAL . 4.1 p-10 -92.82 95.99 1.24 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-O 121.262 0.553 . . . . 2.42 110.812 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2057 ' ' PRO . . . . . 0.471 ' HD3' ' O ' ' A' 2055 ' ' GLY . 57.6 Cg_endo -69.0 -53.11 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.375 2.05 . . . . 1.98 112.618 -170.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.8 mm? -121.32 19.4 11.4 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.999 -0.371 . . . . 2.8 109.999 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2059 ' ' VAL . . . . . 0.512 ' O ' ' HB2' ' A' 2056 ' ' ASP . 0.0 OUTLIER -131.85 77.52 72.01 Favored Pre-proline 0 N--CA 1.449 -0.523 0 C-N-CA 120.332 -0.547 . . . . 1.56 110.026 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.82 120.99 8.77 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.511 2.141 . . . . 1.35 111.95 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2061 ' ' ILE . . . . . 0.626 HG13 ' NE ' ' A' 2111 ' ' ARG . 47.1 mm -49.94 128.55 6.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.354 -0.839 . . . . 1.33 111.846 -178.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.492 ' O ' HG23 ' A' 2065 ' ' VAL . 11.1 t70 -66.81 136.8 55.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.746 -0.661 . . . . 1.42 110.171 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -88.71 1.19 55.57 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 112.567 0.58 . . . . 1.55 112.567 -171.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 70.1 p -120.29 -0.39 10.44 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.885 0.328 . . . . 1.29 111.885 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.663 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.8 m -86.35 -173.13 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.162 -0.31 . . . . 1.47 110.162 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -95.65 105.47 20.97 Favored Pre-proline 0 C--O 1.238 0.474 0 CA-C-O 120.966 0.412 . . . . 0.78 111.513 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.663 ' HD3' ' O ' ' A' 2065 ' ' VAL . 33.4 Cg_endo -100.31 106.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 122.898 2.399 . . . . 0.52 110.872 167.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2068 ' ' THR . . . . . 0.501 ' O ' ' HB3' ' A' 2110 ' ' LYS . 18.7 p -141.1 148.27 39.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.223 0.535 . . . . 1.07 110.585 -176.118 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.532 ' N ' ' HD1' ' A' 2069 ' ' PHE . 1.3 m-30 -74.58 149.36 40.16 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.416 -0.957 . . . . 1.99 108.416 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2070 ' ' GLU . . . . . 0.461 ' CB ' ' HB ' ' A' 2108 ' ' THR . 5.2 tm-20 -50.78 -42.12 57.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.955 0.407 . . . . 2.09 110.459 -173.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -71.89 0.79 8.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 115.638 -0.71 . . . . 2.15 112.563 -178.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 82.92 29.94 33.21 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.572 -0.823 . . . . 0.63 112.001 -176.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 15.7 m -106.75 159.15 16.44 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.849 0.357 . . . . 1.14 111.043 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -109.84 -18.8 13.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 1.68 110.638 176.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.4 ' HB2' HG23 ' A' 2085 ' ' THR . 6.0 tt0 -148.68 136.69 20.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.146 0.498 . . . . 2.08 109.853 173.045 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 32.9 tptt -128.29 113.65 15.9 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.541 -0.754 . . . . 2.03 109.183 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 46.3 m -117.91 124.9 49.4 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 121.482 0.658 . . . . 1.28 110.895 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.555 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 12.3 mt -120.2 120.74 29.89 Favored Pre-proline 0 C--N 1.313 -1.013 0 N-CA-C 107.774 -1.195 . . . . 2.24 107.774 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -41.91 108.66 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 123.551 2.834 . . . . 1.09 113.806 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.19 -30.48 6.71 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.486 -0.779 . . . . 0.94 113.037 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.555 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -74.83 -30.29 61.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.246 0.546 . . . . 2.02 110.172 -174.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 125.82 -171.34 17.67 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.471 -0.871 . . . . 0.58 112.571 175.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 38.3 m -140.25 132.29 27.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.534 0.683 . . . . 1.21 110.695 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.479 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.6 OUTLIER -106.49 129.82 54.38 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.882 -1.525 . . . . 2.34 106.882 169.521 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A 2085 ' ' THR . . . . . 0.4 HG23 ' HB2' ' A' 2075 ' ' GLU . 0.8 OUTLIER -133.06 140.59 47.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.258 0.551 . . . . 1.26 112.438 -175.939 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.462 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -130.27 131.64 65.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.152 -0.931 . . . . 1.76 109.672 173.289 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 27.7 m -115.33 149.42 42.75 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.727 -0.472 . . . . 1.35 109.727 174.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.04 -6.42 3.62 Favored 'Trans proline' 0 C--N 1.349 0.595 0 C-N-CA 123.808 3.005 . . . . 1.32 114.147 -170.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -70.23 -13.89 62.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.002 0.43 . . . . 2.29 110.206 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 96.9 17.71 31.81 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.929 -0.653 . . . . 0.83 112.182 178.521 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 4.8 t -115.52 133.46 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.049 0.452 . . . . 1.8 109.824 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.496 ' HB ' HH11 ' A' 2111 ' ' ARG . 11.6 t -135.12 149.79 29.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.581 . . . . 1.67 110.237 -173.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.0 t -136.23 123.74 22.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.287 0.565 . . . . 1.94 110.871 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.6 m-30 -99.13 98.72 9.7 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.193 -0.669 . . . . 2.13 109.193 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 12.0 m -113.96 96.79 42.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.873 0.368 . . . . 1.21 111.026 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -89.17 176.35 3.17 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 123.246 2.631 . . . . 1.23 112.787 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2097 ' ' ASP . . . . . 0.425 ' HB3' ' HA ' ' A' 2081 ' ' GLN . 6.4 p-10 -71.7 102.02 2.7 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.319 -0.855 . . . . 2.72 112.139 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2098 ' ' LYS . . . . . 0.579 ' H ' ' HD2' ' A' 2098 ' ' LYS . 0.0 OUTLIER -92.05 -9.76 41.6 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.087 -0.506 . . . . 5.15 110.263 173.694 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -120.64 -52.55 2.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.073 -0.512 . . . . 5.07 110.299 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.13 145.31 42.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.426 -0.806 . . . . 3.08 111.454 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2101 ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' 2128 ' ' THR . 8.9 p -160.32 143.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 115.655 -0.702 . . . . 3.01 109.382 175.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 152.57 -94.07 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.578 -0.82 . . . . 3.84 112.453 -178.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 63.7 tttp -120.73 89.17 44.75 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-O 120.857 0.36 . . . . 7.31 110.507 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.74 139.44 25.03 Favored 'Trans proline' 0 N--CA 1.459 -0.531 0 C-N-CA 122.712 2.275 . . . . 2.77 111.097 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2105 ' ' ASP . . . . . 0.465 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 32.0 t70 -85.17 130.69 50.97 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 109.555 -0.535 . . . . 2.33 109.555 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.567 ' HA ' ' O ' ' A' 2123 ' ' TYR . 18.0 Cg_endo -60.41 119.55 6.8 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.117 2.544 . . . . 1.29 112.93 -177.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.5 p -159.36 133.64 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.746 -0.661 . . . . 1.23 110.372 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.534 ' HA ' ' O ' ' A' 2121 ' ' ALA . 34.1 m -105.51 119.31 38.79 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.188 0.518 . . . . 1.11 109.718 173.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -95.29 139.04 19.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.863 -0.792 . . . . 1.35 108.863 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.501 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.9 tmmm? -140.68 147.65 39.59 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 118.366 0.53 . . . . 2.25 111.438 -171.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.626 ' NE ' HG13 ' A' 2061 ' ' ILE . 29.1 ptt180 -168.98 135.28 1.73 Allowed 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.838 -0.801 . . . . 3.95 108.838 171.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 23.2 m -99.8 149.99 5.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 C-N-CA 120.393 -0.523 . . . . 1.09 111.207 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.423 ' HA ' ' HA ' ' A' 2061 ' ' ILE . 4.7 p-10 -93.93 -168.92 1.97 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.923 -0.581 . . . . 1.46 110.736 178.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.31 -41.78 85.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.19 -0.459 . . . . 2.25 111.929 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -18.74 46.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.869 0.366 . . . . 1.84 110.45 -177.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 106.14 16.76 14.11 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.543 -0.837 . . . . 0.46 113.641 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.411 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.8 m -83.83 119.26 73.28 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 117.187 0.494 . . . . 1.22 110.376 175.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -77.92 102.15 1.55 Allowed 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.369 2.046 . . . . 0.72 111.988 177.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.7 m -74.88 117.59 19.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 108.545 -0.909 . . . . 1.37 108.545 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' 2109 ' ' VAL . 61.2 p -126.25 161.14 28.43 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.524 -0.762 . . . . 1.23 111.78 -170.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.09 127.44 41.48 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 107.981 -1.118 . . . . 1.33 107.981 169.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 21.9 m -116.15 103.93 11.03 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 120.974 0.416 . . . . 2.66 110.54 -174.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' 2106 ' ' PRO . 2.3 m-85 -100.72 131.01 46.83 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.244 0.545 . . . . 3.23 112.048 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 16.1 m -131.77 146.81 63.42 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.135 -0.939 . . . . 2.37 109.391 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.13 21.13 0.45 Allowed 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.815 2.343 . . . . 2.51 112.957 -178.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -81.73 -31.19 32.17 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.029 0.442 . . . . 4.33 110.75 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 36.2 t80 -86.12 124.86 33.01 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.681 -0.489 . . . . 4.51 109.681 178.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2128 ' ' THR . . . . . 0.469 ' O ' HG23 ' A' 2101 ' ' VAL . 6.0 m -103.59 -81.08 0.52 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.362 -0.381 . . . . 5.72 110.592 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 18.8 ptpt 178.16 -176.4 0.2 Allowed 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.303 -0.629 . . . . 5.6 109.303 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.441 -0.79 . . . . 6.27 110.112 178.218 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 80.6 mt-30 . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.569 0.223 . . . . 7.47 110.87 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 59.8 38.22 93.64 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-N 116.0 -0.546 . . . . 3.62 113.339 176.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -136.7 -131.85 3.02 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.483 -0.865 . . . . 2.08 111.904 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.31 124.44 29.04 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-O 121.114 0.483 . . . . 2.42 110.269 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -69.32 -52.82 0.33 Allowed 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.87 2.38 . . . . 1.98 111.862 177.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2058 ' ' LEU . . . . . 0.491 HD11 ' N ' ' A' 2058 ' ' LEU . 0.2 OUTLIER -68.33 -9.38 47.45 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.423 -0.808 . . . . 2.8 112.854 176.677 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A 2059 ' ' VAL . . . . . 0.417 HG22 HD13 ' A' 2058 ' ' LEU . 5.7 t -137.72 86.69 18.16 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 109.666 -0.494 . . . . 1.56 109.666 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.41 131.05 43.91 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.378 2.052 . . . . 1.35 111.847 -177.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 43.1 mm -62.86 122.66 14.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.904 -0.589 . . . . 1.33 109.935 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.541 ' O ' HG21 ' A' 2065 ' ' VAL . 21.1 t70 -70.46 134.52 47.84 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.236 0.541 . . . . 1.42 110.496 -176.431 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -89.3 -2.09 58.32 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.844 -0.616 . . . . 1.55 111.914 -171.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -113.99 -2.67 13.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.829 -0.348 . . . . 1.29 111.848 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.577 ' O ' ' HD3' ' A' 2067 ' ' PRO . 26.8 m -81.59 -174.59 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.973 -0.291 . . . . 1.47 110.284 177.391 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.11 109.27 51.11 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.211 0.529 . . . . 0.78 111.202 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.577 ' HD3' ' O ' ' A' 2065 ' ' VAL . 50.5 Cg_endo -99.57 111.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.518 0 C-N-CA 123.305 2.67 . . . . 0.52 110.875 165.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 8.4 p -145.13 -178.98 6.33 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.211 0.529 . . . . 1.07 110.758 -176.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.542 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 39.0 m-85 -102.73 148.25 25.84 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.735 -0.839 . . . . 1.99 108.735 168.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -59.98 -24.23 64.27 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.962 0.789 . . . . 2.09 111.593 -172.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -86.05 -3.45 58.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.309 -0.405 . . . . 2.15 110.858 178.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.57 29.88 12.97 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.147 -0.549 . . . . 0.63 113.066 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 26.3 p -110.61 179.15 4.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.032 0.416 . . . . 1.14 111.276 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2074 ' ' LYS . . . . . 0.425 ' O ' HG22 ' A' 2086 ' ' ILE . 34.6 mmtp -124.78 -4.8 7.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-O 120.957 0.408 . . . . 1.68 111.159 -178.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -159.56 132.32 6.76 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.457 -0.571 . . . . 2.08 109.457 169.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.445 ' HD2' ' HA ' ' A' 2076 ' ' LYS . 3.7 mmmm -120.01 100.89 7.48 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.968 -0.56 . . . . 2.03 110.306 174.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 89.5 m -97.51 111.57 23.78 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.876 -0.602 . . . . 1.28 110.242 173.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.457 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 96.6 mt -110.8 117.26 50.83 Favored Pre-proline 0 C--N 1.31 -1.113 0 N-CA-C 108.74 -0.837 . . . . 2.24 108.74 175.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -46.37 112.52 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.501 2.801 . . . . 1.09 113.574 -174.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 87.74 -11.09 67.55 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.783 -0.644 . . . . 0.94 112.795 177.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.457 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -101.19 -31.88 10.8 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.22 0.533 . . . . 2.02 110.296 -174.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 131.63 -170.42 21.58 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.45 -0.881 . . . . 0.58 113.095 173.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.536 ' O ' ' HB ' ' A' 2095 ' ' THR . 86.6 m -144.38 136.58 26.37 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.476 -0.564 . . . . 1.21 109.476 177.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.542 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -117.77 126.86 53.23 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.493 -1.299 . . . . 2.34 107.493 174.189 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 11.9 p -120.38 127.43 52.28 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.822 -0.351 . . . . 1.26 111.709 -175.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.458 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -108.08 135.44 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.955 -0.566 . . . . 1.76 109.864 175.58 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 26.7 m -122.22 150.69 57.48 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 109.41 -0.589 . . . . 1.35 109.41 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 34.6 Cg_exo -60.0 -1.28 1.17 Allowed 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.737 2.958 . . . . 1.32 113.792 -174.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 16.8 t70 -66.4 -20.17 65.99 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.267 0.556 . . . . 2.29 109.865 173.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 99.49 14.79 34.1 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.245 -0.742 . . . . 0.83 111.245 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.8 t -120.31 146.61 45.95 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.312 -0.444 . . . . 1.8 110.376 -177.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 21.5 t -132.82 138.56 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.353 -0.61 . . . . 1.67 109.353 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 51.6 m -97.76 109.98 22.63 Favored 'General case' 0 N--CA 1.439 -0.98 0 CA-C-O 120.789 0.328 . . . . 1.94 110.251 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 7.8 m-30 -86.81 98.41 11.17 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.64 -0.504 . . . . 2.13 109.64 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2095 ' ' THR . . . . . 0.536 ' HB ' ' O ' ' A' 2083 ' ' THR . 58.4 m -109.4 99.11 35.37 Favored Pre-proline 0 C--O 1.234 0.241 0 CA-C-O 120.942 0.401 . . . . 1.21 110.524 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -88.27 162.15 6.96 Favored 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 123.346 2.697 . . . . 1.23 113.966 -174.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2097 ' ' ASP . . . . . 0.456 ' HB2' ' CB ' ' A' 2100 ' ' PHE . 10.4 p-10 -72.46 48.31 0.19 Allowed 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.091 -0.959 . . . . 2.72 111.776 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -70.63 -10.01 58.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.079 0.466 . . . . 5.15 111.167 -175.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -116.65 24.44 11.29 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.117 -0.492 . . . . 5.07 110.753 178.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2100 ' ' PHE . . . . . 0.456 ' CB ' ' HB2' ' A' 2097 ' ' ASP . 63.7 t80 -113.8 142.2 46.36 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.156 0.503 . . . . 3.08 111.762 -173.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2101 ' ' VAL . . . . . 0.465 HG11 ' HB3' ' A' 2129 ' ' LYS . 74.3 t -132.26 105.01 8.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.633 -0.712 . . . . 3.01 110.19 176.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.29 -99.46 0.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 N-CA-C 111.279 -0.729 . . . . 3.84 111.279 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.18 120.51 0.89 Allowed Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 109.715 -0.476 . . . . 7.31 109.715 170.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.52 147.66 22.63 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.73 2.287 . . . . 2.77 112.162 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2105 ' ' ASP . . . . . 0.409 ' HB2' HD13 ' A' 2078 ' ' ILE . 18.8 m-20 -80.46 147.02 62.78 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.029 -0.532 . . . . 2.33 109.94 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.466 ' HA ' ' O ' ' A' 2123 ' ' TYR . 45.9 Cg_endo -68.04 128.95 18.51 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.147 2.565 . . . . 1.29 113.908 -171.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 5.5 p -158.08 160.0 2.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.38 -0.827 . . . . 1.23 109.169 177.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 26.5 m -141.25 122.35 14.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.115 0.483 . . . . 1.11 110.415 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 5.2 t -92.22 133.47 33.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 108.922 -0.77 . . . . 1.35 108.922 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -125.84 109.63 12.74 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 120.683 0.278 . . . . 2.25 111.387 -169.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.474 ' HG3' HG23 ' A' 2119 ' ' VAL . 30.8 ptt180 -147.3 135.4 21.46 Favored 'General case' 0 C--N 1.317 -0.818 0 O-C-N 121.797 -0.565 . . . . 3.95 110.133 168.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.489 ' O ' HG22 ' A' 2065 ' ' VAL . 34.2 m -99.09 154.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 120.998 0.428 . . . . 1.09 110.758 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.538 ' OD2' ' HB ' ' A' 2117 ' ' THR . 10.1 p30 -94.38 -169.59 2.08 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.81 -0.632 . . . . 1.46 110.778 178.139 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.7 mttm -65.06 -22.85 67.03 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.15 0.426 . . . . 2.25 112.15 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -90.5 -19.01 24.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.054 0.455 . . . . 1.84 110.235 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 102.94 15.13 24.93 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.662 -0.699 . . . . 0.46 111.962 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.538 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 24.1 m -91.62 119.63 68.44 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 120.805 0.336 . . . . 1.22 110.221 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' 2117 ' ' THR . 8.2 Cg_exo -72.68 107.34 2.3 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.46 2.106 . . . . 0.72 113.241 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2119 ' ' VAL . . . . . 0.474 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.95 109.25 9.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 108.088 -1.078 . . . . 1.37 108.088 165.008 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A 2120 ' ' THR . . . . . . . . . . . . . 75.0 p -125.14 179.5 5.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.105 -0.952 . . . . 1.23 110.553 -171.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.61 127.2 41.8 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.606 -0.887 . . . . 1.33 108.606 170.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 30.9 p -93.39 101.67 13.9 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.877 -0.601 . . . . 2.66 109.898 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' 2106 ' ' PRO . 5.4 m-85 -120.25 122.96 42.04 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.633 0.73 . . . . 3.23 112.17 -175.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 46.9 p -152.42 158.18 33.5 Favored Pre-proline 0 C--N 1.321 -0.642 0 CA-C-N 114.478 -1.237 . . . . 2.37 108.859 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -72.57 10.75 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.474 2.116 . . . . 2.51 112.794 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -79.06 -26.29 43.08 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.201 0.524 . . . . 4.33 109.679 176.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -77.22 154.43 33.06 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.606 -0.725 . . . . 4.51 109.266 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 14.6 p -135.22 -73.71 0.46 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.152 0.501 . . . . 5.72 110.832 -177.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A 2129 ' ' LYS . . . . . 0.465 ' HB3' HG11 ' A' 2101 ' ' VAL . 0.1 OUTLIER -120.48 166.38 13.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.72 -0.673 . . . . 5.6 110.066 179.897 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 38.2 t . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.419 -0.801 . . . . 6.27 110.007 179.931 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 . . . . . 0 N--CA 1.479 1.005 0 N-CA-C 110.204 -0.295 . . . . 7.47 110.204 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 73.66 43.32 36.53 Favored Glycine 0 N--CA 1.453 -0.175 0 C-N-CA 120.692 -0.766 . . . . 3.62 111.842 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -172.46 -100.12 0.13 Allowed Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 111.031 -0.827 . . . . 2.08 111.031 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 6.9 t70 -125.74 123.43 24.76 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 110.106 -0.331 . . . . 2.42 110.106 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.34 -20.31 42.68 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.585 2.19 . . . . 1.98 112.596 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.8 mp -100.29 -26.78 13.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.795 0.331 . . . . 2.8 110.301 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 4.6 t -116.52 82.43 12.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.186 -0.461 . . . . 1.56 109.818 178.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.44 120.1 7.25 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.374 2.049 . . . . 1.35 111.559 179.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.7 mm -49.9 131.21 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.522 -0.763 . . . . 1.33 110.908 179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' 2065 ' ' VAL . 10.6 t70 -69.25 135.1 50.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.458 -0.792 . . . . 1.42 110.588 -176.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -97.49 2.96 50.83 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.987 0.366 . . . . 1.55 111.987 -173.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.2 p -109.74 3.32 20.75 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.08 0.943 . . . . 1.29 108.97 173.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.709 ' O ' ' HD3' ' A' 2067 ' ' PRO . 1.0 OUTLIER -91.29 165.22 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 CA-C-N 114.041 -1.436 . . . . 1.47 110.108 -178.807 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.37 108.98 9.85 Favored Pre-proline 0 C--O 1.24 0.553 0 CA-C-O 120.697 0.284 . . . . 0.78 111.368 177.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' 2065 ' ' VAL . 60.7 Cg_endo -102.34 108.6 0.04 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.57 0 C-N-CA 123.454 2.769 . . . . 0.52 111.328 166.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 21.3 p -134.5 174.45 10.53 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.529 0.68 . . . . 1.07 111.335 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.532 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.7 OUTLIER -101.13 151.4 21.87 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.64 -1.245 . . . . 1.99 107.64 170.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -45.71 -41.72 10.91 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 123.719 0.637 . . . . 2.09 112.391 -171.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -90.17 16.58 8.27 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 111.944 0.35 . . . . 2.15 111.944 -175.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 30.0 58.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.663 -0.78 . . . . 0.63 112.668 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.3 p -102.92 167.96 9.52 Favored 'General case' 0 C--N 1.323 -0.564 0 O-C-N 122.859 -0.201 . . . . 1.14 110.496 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2074 ' ' LYS . . . . . 0.419 ' O ' HG22 ' A' 2086 ' ' ILE . 42.1 mmtm -123.39 -10.45 7.97 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.246 0.462 . . . . 1.68 112.246 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -158.77 128.1 5.59 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.928 0.394 . . . . 2.08 110.156 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.35 100.47 6.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.185 -0.672 . . . . 2.03 109.185 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 62.8 m -109.78 127.21 54.49 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.282 -0.417 . . . . 1.28 111.112 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.564 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 35.4 mm -131.32 132.01 23.37 Favored Pre-proline 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.917 . . . . 2.24 108.523 171.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.76 108.9 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.478 2.119 . . . . 1.09 112.197 178.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2080 ' ' GLY . . . . . 0.413 ' HA3' ' O ' ' A' 2101 ' ' VAL . . . 99.83 -4.09 57.6 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.018 -0.61 . . . . 0.94 112.319 -179.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.564 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.1 tt0 -107.33 -29.79 9.08 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.125 0.488 . . . . 2.02 110.222 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 103.89 -162.35 15.49 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.565 -0.743 . . . . 0.58 111.641 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.51 ' O ' ' HB ' ' A' 2095 ' ' THR . 47.1 m -139.76 135.43 33.08 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.568 0.699 . . . . 1.21 110.729 178.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.486 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.6 m-85 -104.58 110.74 23.15 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.069 -1.456 . . . . 2.34 107.069 171.368 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 13.3 p -108.24 123.67 49.12 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.323 0.49 . . . . 1.26 112.323 -171.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.473 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.93 130.8 72.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.112 -0.494 . . . . 1.76 109.84 170.349 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.5 m -122.33 150.59 57.59 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.01 -0.541 . . . . 1.35 109.748 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.94 -3.9 1.78 Allowed 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 123.949 3.099 . . . . 1.32 114.276 -172.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.3 -13.95 62.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.223 0.535 . . . . 2.29 110.057 176.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.57 8.16 54.92 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.531 -0.759 . . . . 0.83 111.552 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -111.44 129.01 56.16 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.381 0.61 . . . . 1.8 110.501 -177.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.59 HG13 ' NH1' ' A' 2111 ' ' ARG . 1.1 p -150.08 139.29 15.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.529 -0.76 . . . . 1.67 110.538 -176.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -127.57 130.92 49.93 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.098 0.475 . . . . 1.94 110.747 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2094 ' ' PHE . . . . . 0.445 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.5 m-30 -84.36 99.02 10.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.463 -0.94 . . . . 2.13 108.463 175.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2095 ' ' THR . . . . . 0.51 ' HB ' ' O ' ' A' 2083 ' ' THR . 19.6 m -116.54 89.35 27.25 Favored Pre-proline 0 N--CA 1.454 -0.259 0 CA-C-O 121.215 0.531 . . . . 1.21 111.815 -175.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2096 ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' 2094 ' ' PHE . 5.3 Cg_endo -87.41 142.2 6.02 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 123.207 2.605 . . . . 1.23 110.877 172.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.49 137.23 58.19 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.184 -0.462 . . . . 2.72 110.712 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2098 ' ' LYS . . . . . 0.473 ' HZ2' ' HB3' ' A' 2098 ' ' LYS . 0.3 OUTLIER -62.15 -20.21 63.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.378 -0.828 . . . . 5.15 112.184 -175.636 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -103.49 -44.73 5.05 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.711 -0.477 . . . . 5.07 109.711 177.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2100 ' ' PHE . . . . . 0.447 ' CE1' ' HB3' ' A' 2104 ' ' PRO . 43.1 t80 65.1 72.2 0.44 Allowed 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.654 0.74 . . . . 3.08 110.804 177.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2101 ' ' VAL . . . . . 0.413 ' O ' ' HA3' ' A' 2080 ' ' GLY . 77.1 t -145.03 117.81 2.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.125 -0.943 . . . . 3.01 109.832 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 154.58 48.7 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.038 -1.077 . . . . 3.84 113.13 178.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.4 ttpp 55.87 72.56 0.99 Allowed Pre-proline 0 CA--C 1.535 0.367 0 C-N-CA 122.616 0.366 . . . . 7.31 111.213 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2104 ' ' PRO . . . . . 0.447 ' HB3' ' CE1' ' A' 2100 ' ' PHE . 19.2 Cg_endo -58.87 135.6 68.0 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.906 2.404 . . . . 2.77 113.299 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.0 t70 -92.88 130.92 34.83 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.616 -0.72 . . . . 2.33 109.723 178.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.473 ' HA ' ' O ' ' A' 2123 ' ' TYR . 30.8 Cg_endo -64.71 106.61 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.634 2.223 . . . . 1.29 112.235 -176.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.1 p -142.94 135.54 25.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.264 0.554 . . . . 1.23 111.34 -178.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' 2121 ' ' ALA . 88.5 m -111.21 122.85 48.93 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.564 -0.744 . . . . 1.11 109.412 171.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.583 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.3 t -95.54 136.73 25.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.929 -0.767 . . . . 1.35 108.929 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -141.95 113.58 7.82 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.09 0.774 . . . . 2.25 113.09 -171.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.59 ' NH1' HG13 ' A' 2092 ' ' VAL . 23.9 ptt180 -140.69 143.44 35.07 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.26 -0.644 . . . . 3.95 109.26 171.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.554 ' O ' HG11 ' A' 2065 ' ' VAL . 34.8 m -98.41 149.95 5.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.238 -0.585 . . . . 1.09 111.179 -176.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 25.1 p30 -88.01 -168.93 2.38 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.708 -0.678 . . . . 1.46 110.783 179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.3 mttt -65.69 -23.59 66.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.716 0.293 . . . . 2.25 111.553 -178.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -82.57 -27.26 31.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.104 0.478 . . . . 1.84 110.56 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 108.29 11.53 23.58 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.358 -0.697 . . . . 0.46 111.358 -177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.413 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 61.6 m -90.59 118.96 69.08 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 120.595 0.236 . . . . 1.22 110.481 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' 2117 ' ' THR . 10.5 Cg_exo -71.38 119.72 6.46 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.719 2.279 . . . . 0.72 113.014 -179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.6 m -84.79 109.39 17.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.326 -0.991 . . . . 1.37 108.326 169.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.583 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.6 p -119.58 149.87 41.22 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.125 -0.943 . . . . 1.23 111.747 -170.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.602 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.57 126.15 39.71 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.125 -1.065 . . . . 1.33 108.125 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 46.5 m -113.57 101.7 9.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.644 -0.502 . . . . 2.66 109.644 -177.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.8 m-85 -97.68 124.95 42.19 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.967 -0.561 . . . . 3.23 112.045 -174.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 26.0 m -91.02 150.55 41.98 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 115.105 -0.952 . . . . 2.37 110.98 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.448 ' HB3' ' HD3' ' A' 2106 ' ' PRO . 73.5 Cg_endo -78.9 157.91 27.4 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.769 2.313 . . . . 2.51 111.863 177.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 39.6 tt0 58.7 87.53 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 O-C-N 123.697 0.623 . . . . 4.33 111.516 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 28.1 t80 -129.97 111.85 12.93 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.469 -0.937 . . . . 4.51 108.469 175.173 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 4.7 t -60.4 160.64 8.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.965 0.888 . . . . 5.72 112.266 -174.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A 2129 ' ' LYS . . . . . 0.446 ' O ' ' HD3' ' A' 2129 ' ' LYS . 0.0 OUTLIER -84.67 47.55 1.39 Allowed 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.356 -1.293 . . . . 5.6 111.635 -176.717 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 67.6 t . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.119 -0.943 . . . . 6.27 110.559 -177.853 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 1.2 mp0 . . . . . 0 N--CA 1.484 1.225 0 CA-C-O 120.758 0.313 . . . . 7.47 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -74.79 -25.22 70.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.045 -0.597 . . . . 3.62 112.274 179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 164.31 -112.33 0.5 Allowed Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.522 -0.631 . . . . 2.08 111.522 177.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 16.5 t70 -138.46 121.14 10.8 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.532 -0.544 . . . . 2.42 109.532 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.0 -18.57 46.25 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.895 2.397 . . . . 1.98 112.706 -176.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.4 mp -87.48 -33.3 19.06 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.377 -0.374 . . . . 2.8 110.403 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 2.6 t -135.41 87.38 27.49 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.418 -0.355 . . . . 1.56 110.048 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -38.66 119.71 0.43 Allowed 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 123.411 2.741 . . . . 1.35 112.661 173.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 42.4 mm -56.18 123.66 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.828 -0.623 . . . . 1.33 111.477 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.511 ' O ' HG23 ' A' 2065 ' ' VAL . 30.8 t70 -68.01 135.98 53.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.788 -0.642 . . . . 1.42 110.502 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -86.62 -6.62 58.81 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.082 -0.508 . . . . 1.55 111.782 -172.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.5 p -111.18 4.01 18.92 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.166 0.432 . . . . 1.29 112.166 -177.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.677 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.7 m -86.99 -174.07 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.904 -0.406 . . . . 1.47 109.904 174.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -93.57 105.77 17.79 Favored Pre-proline 0 C--O 1.238 0.494 0 CA-C-O 120.974 0.416 . . . . 0.78 111.293 176.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.677 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.4 Cg_endo -100.74 108.64 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.548 0 C-N-CA 123.308 2.672 . . . . 0.52 110.62 166.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2068 ' ' THR . . . . . 0.487 HG22 ' HE2' ' A' 2074 ' ' LYS . 18.5 p -138.75 177.07 8.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.646 0.736 . . . . 1.07 111.101 -175.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.464 ' CE1' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-85 -101.55 142.18 33.3 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 107.147 -1.427 . . . . 1.99 107.147 165.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -58.78 -19.08 37.59 Favored 'General case' 0 C--N 1.328 -0.329 0 O-C-N 123.849 0.718 . . . . 2.09 111.975 -168.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2071 ' ' ASP . . . . . 0.454 ' CG ' ' HG ' ' A' 2073 ' ' SER . 12.7 p-10 -98.58 8.04 45.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.82 0.343 . . . . 2.15 111.038 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.07 17.72 52.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.089 -0.577 . . . . 0.63 113.195 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2073 ' ' SER . . . . . 0.454 ' HG ' ' CG ' ' A' 2071 ' ' ASP . 32.3 m -93.89 167.55 11.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.916 0.358 . . . . 1.14 110.999 -178.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2074 ' ' LYS . . . . . 0.514 ' O ' HG21 ' A' 2086 ' ' ILE . 34.5 mmtp -127.67 -16.86 4.67 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 116.161 -0.472 . . . . 1.68 111.12 178.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.626 ' HG2' HG22 ' A' 2085 ' ' THR . 0.9 OUTLIER -149.72 98.51 2.75 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.761 -0.459 . . . . 2.08 109.761 174.239 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 26.1 tptt -92.19 108.35 19.88 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.281 -0.418 . . . . 2.03 110.073 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 86.9 m -107.84 118.13 35.93 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-O 121.408 0.623 . . . . 1.28 110.478 174.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.556 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 72.1 mt -114.02 115.07 45.94 Favored Pre-proline 0 N--CA 1.438 -1.034 0 CA-C-N 114.911 -1.04 . . . . 2.24 108.471 175.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -47.84 109.52 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 123.332 2.688 . . . . 1.09 113.567 -174.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 90.68 -8.64 79.5 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.923 -0.58 . . . . 0.94 112.694 176.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.556 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.6 tm0? -100.82 -31.11 11.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.096 0.474 . . . . 2.02 109.829 -176.19 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 129.13 -167.57 21.13 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.818 -0.706 . . . . 0.58 112.492 177.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 55.0 m -149.57 129.89 13.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.507 0.67 . . . . 1.21 110.341 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.464 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 2.7 m-85 -101.85 130.42 48.31 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 106.789 -1.559 . . . . 2.34 106.789 171.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2085 ' ' THR . . . . . 0.626 HG22 ' HG2' ' A' 2075 ' ' GLU . 77.5 p -125.67 137.63 53.87 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.176 -0.61 . . . . 1.26 111.932 -172.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.514 HG21 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -130.9 133.36 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-N 115.573 -0.739 . . . . 1.76 109.878 173.962 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 24.5 m -116.61 149.17 43.38 Favored Pre-proline 0 C--N 1.32 -0.684 0 N-CA-C 109.143 -0.688 . . . . 1.35 109.143 172.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -61.99 -0.75 1.81 Allowed 'Trans proline' 0 N--CA 1.477 0.533 0 C-N-CA 123.633 2.889 . . . . 1.32 113.95 -170.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.08 -14.71 62.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.08 0.467 . . . . 2.29 110.064 177.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.14 21.11 18.72 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.868 -0.605 . . . . 0.83 112.082 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -120.63 135.97 54.96 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.916 0.389 . . . . 1.8 110.349 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.621 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 5.2 t -136.35 149.44 27.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.922 -0.581 . . . . 1.67 110.002 -176.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.9 t -134.96 130.03 35.15 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.273 0.558 . . . . 1.94 110.409 172.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.4 m-30 -93.82 98.78 11.31 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.032 -0.729 . . . . 2.13 109.032 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 21.3 m -117.56 88.7 30.13 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-O 120.919 0.39 . . . . 1.21 111.891 -177.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -91.78 161.26 3.42 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 123.213 2.609 . . . . 1.23 111.822 171.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2097 ' ' ASP . . . . . 0.454 ' HB3' ' HB2' ' A' 2100 ' ' PHE . 11.6 t70 -75.41 114.17 13.65 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.613 -0.514 . . . . 2.72 109.613 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 2.7 tpmt? -43.56 -53.31 5.7 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 124.059 0.849 . . . . 5.15 113.262 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -121.27 37.4 4.34 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 111.88 0.326 . . . . 5.07 111.88 -171.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2100 ' ' PHE . . . . . 0.454 ' HB2' ' HB3' ' A' 2097 ' ' ASP . 56.5 t80 -78.59 84.59 4.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.486 0.66 . . . . 3.08 110.287 177.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.2 t -93.9 113.22 28.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.627 -0.715 . . . . 3.01 110.16 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 179.52 -110.13 0.28 Allowed Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.521 -0.632 . . . . 3.84 111.521 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.9 ptpt -135.03 72.97 66.75 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-O 121.207 0.527 . . . . 7.31 110.987 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.94 144.86 84.25 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.889 2.392 . . . . 2.77 111.592 177.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -76.6 142.95 71.16 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.424 -0.353 . . . . 2.33 110.481 177.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.635 ' HA ' ' O ' ' A' 2123 ' ' TYR . 71.7 Cg_endo -80.32 132.58 9.25 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 123.086 2.524 . . . . 1.29 113.441 -176.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 9.0 p -161.5 144.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.734 -0.666 . . . . 1.23 110.059 177.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.548 ' HA ' ' O ' ' A' 2121 ' ' ALA . 80.9 m -115.03 126.75 55.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.334 0.588 . . . . 1.11 110.523 175.165 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 1.9 t -98.55 137.7 25.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.535 -0.757 . . . . 1.35 109.118 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.55 ' HA ' HG23 ' A' 2120 ' ' THR . 0.6 OUTLIER -133.0 109.57 9.64 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 112.301 0.482 . . . . 2.25 112.301 -168.004 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.621 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -143.96 137.27 27.64 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 121.874 -0.517 . . . . 3.95 110.473 172.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.411 ' O ' HG21 ' A' 2065 ' ' VAL . 34.1 m -102.03 157.72 4.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.439 -0.346 . . . . 1.09 110.884 179.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.678 ' OD2' ' HB ' ' A' 2117 ' ' THR . 40.1 p30 -97.89 -167.97 1.6 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.028 -0.533 . . . . 1.46 110.541 177.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.4 mttt -55.08 -41.5 71.65 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.319 0.489 . . . . 2.25 112.319 -177.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.3 p30 -86.73 -25.42 24.74 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.766 -0.373 . . . . 1.84 110.684 -176.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 119.49 15.31 5.48 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.657 -0.783 . . . . 0.46 112.368 178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.678 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 47.1 m -77.39 115.64 51.06 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-O 120.763 0.316 . . . . 1.22 110.237 174.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.466 ' HA ' ' O ' ' A' 2111 ' ' ARG . 3.0 Cg_endo -82.36 103.93 1.31 Allowed 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.434 2.09 . . . . 0.72 112.624 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2119 ' ' VAL . . . . . 0.478 HG22 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.33 108.32 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 N-CA-C 107.839 -1.171 . . . . 1.37 107.839 167.856 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.55 HG23 ' HA ' ' A' 2110 ' ' LYS . 69.1 p -126.47 156.53 40.53 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.142 -0.935 . . . . 1.23 110.492 -171.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.548 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.94 127.1 41.06 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.732 -0.84 . . . . 1.33 108.732 172.155 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 57.7 m -115.89 99.75 7.5 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.278 -0.638 . . . . 2.66 109.278 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.635 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.7 m-85 -98.67 145.67 26.64 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.422 -0.808 . . . . 3.23 111.268 -175.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2124 ' ' SER . . . . . 0.479 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 26.5 m -152.97 169.53 9.55 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.67 -0.696 . . . . 2.37 109.447 -177.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.479 ' HD2' ' HB3' ' A' 2124 ' ' SER . 82.7 Cg_exo -46.84 -51.64 8.86 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.706 2.271 . . . . 2.51 112.912 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -105.74 113.98 27.87 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.153 0.502 . . . . 4.33 110.604 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 14.6 p90 -129.81 11.28 5.63 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.623 -0.717 . . . . 4.51 109.907 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 1.5 m 70.55 144.46 0.06 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.297 -0.865 . . . . 5.72 110.577 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 55.7 pttt -105.74 128.45 53.7 Favored 'General case' 0 C--N 1.323 -0.572 0 O-C-N 122.187 -0.32 . . . . 5.6 111.317 -176.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A 2130 ' ' VAL . . . . . 0.43 ' OXT' HG12 ' A' 2130 ' ' VAL . 9.3 p . . . . . 0 C--O 1.249 1.052 0 CA-C-O 117.609 -1.186 . . . . 6.27 112.52 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 11.2 pt20 . . . . . 0 N--CA 1.483 1.208 0 CA-C-O 120.583 0.23 . . . . 7.47 111.288 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 85.25 27.59 32.98 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.766 -0.73 . . . . 3.62 111.909 -176.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -112.96 -139.16 7.36 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.712 -0.756 . . . . 2.08 112.306 -176.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -149.01 94.05 4.08 Favored Pre-proline 0 C--N 1.32 -0.679 0 CA-C-O 121.17 0.51 . . . . 2.42 112.191 -172.292 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2057 ' ' PRO . . . . . 0.415 ' HG2' ' HG ' ' A' 2058 ' ' LEU . 36.8 Cg_endo -71.95 -44.43 0.93 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 121.958 1.772 . . . . 1.98 111.471 176.097 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2058 ' ' LEU . . . . . 0.492 ' N ' HD12 ' A' 2058 ' ' LEU . 0.2 OUTLIER -83.91 -12.95 54.68 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 114.289 1.218 . . . . 2.8 114.289 -176.081 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A 2059 ' ' VAL . . . . . 0.473 HG11 ' OD2' ' A' 2113 ' ' ASP . 0.3 OUTLIER -140.21 82.76 16.44 Favored Pre-proline 0 CA--C 1.508 -0.645 0 C-N-CA 119.739 -0.785 . . . . 1.56 110.929 -176.784 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -52.96 119.09 5.51 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.87 1.713 . . . . 1.35 111.547 179.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2061 ' ' ILE . . . . . 0.543 HG13 ' NE ' ' A' 2111 ' ' ARG . 39.3 mm -45.51 135.92 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.236 -0.893 . . . . 1.33 112.241 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.548 ' O ' HG22 ' A' 2065 ' ' VAL . 13.0 t70 -71.91 141.51 49.49 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.442 -0.799 . . . . 1.42 109.953 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -87.01 -7.79 57.79 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.131 0.419 . . . . 1.55 112.131 -172.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 67.2 p -106.81 6.37 29.42 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.702 -0.399 . . . . 1.29 111.792 -178.155 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.626 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.4 m -97.84 -174.42 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 1.47 109.997 177.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -97.08 105.07 21.73 Favored Pre-proline 0 C--O 1.239 0.504 0 CA-C-O 120.808 0.337 . . . . 0.78 110.998 178.545 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.626 ' HD3' ' O ' ' A' 2065 ' ' VAL . 56.5 Cg_endo -100.34 109.59 0.06 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 123.175 2.584 . . . . 0.52 111.154 167.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.1 p -137.39 178.08 7.37 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.321 0.581 . . . . 1.07 111.086 -175.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.507 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -100.81 149.41 23.86 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.02 -1.104 . . . . 1.99 108.02 169.157 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -48.31 -44.52 34.0 Favored 'General case' 0 C--N 1.329 -0.283 0 O-C-N 123.509 0.505 . . . . 2.09 111.618 -172.403 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -84.16 13.76 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 2.15 111.796 -175.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 81.6 26.15 51.55 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 121.017 -0.611 . . . . 0.63 112.706 177.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.32 166.93 11.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.541 0.21 . . . . 1.14 110.978 -179.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.4 mmtp -123.21 -26.48 4.31 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.812 0.339 . . . . 1.68 111.461 -178.012 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -147.54 135.2 20.98 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 2.08 109.497 172.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.499 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.1 OUTLIER -127.97 99.6 5.57 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.475 -0.565 . . . . 2.03 109.475 177.349 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.0 m -110.23 114.17 27.44 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 121.139 0.495 . . . . 1.28 110.753 177.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2078 ' ' ILE . . . . . . . . . . . . . 75.2 mt -121.76 120.07 28.78 Favored Pre-proline 0 C--N 1.315 -0.908 0 N-CA-C 108.343 -0.984 . . . . 2.24 108.343 173.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.53 111.47 0.37 Allowed 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 123.251 2.634 . . . . 1.09 112.9 -176.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.78 -15.88 37.23 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.616 -0.72 . . . . 0.94 112.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.584 ' CD ' ' HA ' ' A' 2104 ' ' PRO . 24.0 mt-30 -97.8 -37.24 9.93 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.981 0.419 . . . . 2.02 110.837 -178.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 118.69 -166.73 12.98 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 111.083 -0.807 . . . . 0.58 111.083 -177.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 62.1 m -129.03 119.31 24.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.856 0.836 . . . . 1.21 110.738 174.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.412 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 1.9 m-85 -94.82 122.88 37.9 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 105.854 -1.906 . . . . 2.34 105.854 168.004 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.33 143.06 41.86 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.801 0.667 . . . . 1.26 112.801 -168.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.482 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -138.88 132.59 40.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.404 -0.816 . . . . 1.76 109.559 170.732 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 30.4 m -119.94 150.42 50.79 Favored Pre-proline 0 C--N 1.325 -0.499 0 N-CA-C 109.657 -0.497 . . . . 1.35 109.657 173.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -62.38 0.69 1.25 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 123.686 2.924 . . . . 1.32 114.215 -170.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -68.33 -18.9 64.61 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.007 0.432 . . . . 2.29 109.876 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 101.92 11.81 36.28 Favored Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.506 -0.77 . . . . 0.83 111.767 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.6 t -109.5 136.14 49.38 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.131 0.491 . . . . 1.8 110.419 -178.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.407 HG11 ' HB ' ' A' 2086 ' ' ILE . 3.6 t -133.41 149.23 31.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.753 -0.658 . . . . 1.67 109.796 -176.554 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -137.76 119.75 15.43 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.147 0.498 . . . . 1.94 111.098 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 16.3 m-30 -94.04 97.27 10.21 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.319 -0.993 . . . . 2.13 108.319 174.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 18.8 m -120.27 87.99 41.01 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 120.772 -0.371 . . . . 1.21 111.654 -176.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -91.77 157.51 3.45 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.27 2.646 . . . . 1.23 112.582 174.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.1 136.56 56.86 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.066 -0.515 . . . . 2.72 110.271 169.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 23.1 tptm -91.86 -30.89 15.93 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.937 -0.574 . . . . 5.15 111.875 -177.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -107.8 -47.1 3.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.852 1.056 . . . . 5.07 113.852 -165.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.5 122.98 13.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.732 0.777 . . . . 3.08 112.279 -169.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.1 t -80.98 143.47 12.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.287 -0.869 . . . . 3.01 110.362 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 117.63 -52.49 0.69 Allowed Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 108.823 -1.711 . . . . 3.84 108.823 -169.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2103 ' ' LYS . . . . . 0.463 ' HD3' ' HA ' ' A' 2103 ' ' LYS . 70.1 mmtt 68.69 159.33 0.15 Allowed Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 113.89 1.07 . . . . 7.31 113.89 167.425 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2104 ' ' PRO . . . . . 0.584 ' HA ' ' CD ' ' A' 2081 ' ' GLN . 62.4 Cg_exo -44.86 144.25 3.74 Favored 'Trans proline' 0 C--N 1.348 0.548 0 C-N-CA 124.371 3.381 . . . . 2.77 116.156 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 25.9 t70 -65.77 132.06 94.78 Favored Pre-proline 0 N--CA 1.451 -0.42 0 CA-C-N 114.312 -1.313 . . . . 2.33 107.999 164.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' 2123 ' ' TYR . 6.5 Cg_endo -47.12 112.86 0.57 Allowed 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 124.196 3.264 . . . . 1.29 114.595 -170.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 6.0 p -150.15 123.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.34 -0.845 . . . . 1.23 110.087 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.6 m -100.62 133.99 44.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.131 -0.486 . . . . 1.11 110.609 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.9 t -110.14 147.77 14.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.465 -0.568 . . . . 1.35 109.465 177.407 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.416 ' HE2' ' HB3' ' A' 2110 ' ' LYS . 18.5 ttpt -143.78 109.48 5.2 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.135 0.421 . . . . 2.25 112.135 -174.01 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.543 ' NE ' HG13 ' A' 2061 ' ' ILE . 18.2 ptt180 -131.52 136.3 47.76 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.119 -0.697 . . . . 3.95 109.119 174.028 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.45 ' O ' HG23 ' A' 2065 ' ' VAL . 34.4 m -98.94 145.13 10.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.431 -0.508 . . . . 1.09 111.014 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.473 ' OD2' HG11 ' A' 2059 ' ' VAL . 3.3 p-10 -91.94 -168.86 2.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.073 -0.512 . . . . 1.46 110.723 -178.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 68.4 mttm -65.77 -28.81 69.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 2.25 111.557 -178.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -74.26 -20.75 60.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.176 0.512 . . . . 1.84 110.081 174.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 94.43 9.8 58.7 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.682 -0.69 . . . . 0.46 111.851 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2117 ' ' THR . . . . . . . . . . . . . 30.5 m -82.04 120.06 76.52 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 110.012 -0.366 . . . . 1.22 110.012 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -72.93 106.29 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.441 2.094 . . . . 0.72 112.528 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 35.3 m -77.48 108.73 11.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.008 -1.108 . . . . 1.37 108.008 171.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.4 p -119.98 145.01 47.19 Favored 'General case' 0 N--CA 1.438 -1.031 0 CA-C-N 114.537 -1.21 . . . . 1.23 110.573 -172.318 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.542 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.48 126.41 40.42 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.581 -0.736 . . . . 1.33 109.265 175.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 35.0 p -100.33 97.76 8.48 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.874 -0.788 . . . . 2.66 108.874 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.552 ' O ' ' HA ' ' A' 2106 ' ' PRO . 24.3 m-85 -89.69 99.75 12.69 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-O 121.493 0.663 . . . . 3.23 111.666 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 7.9 p -148.86 170.12 8.13 Favored Pre-proline 0 N--CA 1.435 -1.192 0 CA-C-N 114.456 -1.247 . . . . 2.37 109.441 178.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.455 ' HA ' ' HB2' ' A' 2103 ' ' LYS . 51.0 Cg_exo -55.86 97.93 0.06 OUTLIER 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.447 2.098 . . . . 2.51 111.811 175.296 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -161.59 -56.03 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.613 -0.721 . . . . 4.33 109.981 -177.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -68.7 137.53 54.19 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.427 -0.806 . . . . 4.51 111.8 -175.196 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 38.4 m 74.53 -56.74 0.63 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.5 0.72 . . . . 5.72 112.914 172.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 8.0 ptmm? -73.7 149.58 41.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.866 0.365 . . . . 5.6 111.124 -176.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 20.5 t . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.481 -0.771 . . . . 6.27 109.718 176.46 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A 2053 ' ' GLN . . . . . 0.45 ' HG3' ' O ' ' A' 2120 ' ' THR . 4.1 pt20 . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.379 0.133 . . . . 7.47 111.115 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -101.16 -6.11 51.94 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.736 -0.745 . . . . 3.62 113.353 -173.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -166.88 115.99 0.66 Allowed Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.695 -0.765 . . . . 2.08 111.708 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -101.38 113.97 65.76 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 120.94 0.4 . . . . 2.42 110.647 178.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -47.19 11.55 Favored 'Trans proline' 0 N--CA 1.473 0.304 0 C-N-CA 123.317 2.678 . . . . 1.98 112.559 -179.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2058 ' ' LEU . . . . . 0.575 ' N ' HD12 ' A' 2058 ' ' LEU . 0.1 OUTLIER -61.41 -20.33 62.93 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 115.358 -0.837 . . . . 2.8 113.24 177.281 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 6.1 t -130.11 86.72 53.44 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.124 -0.324 . . . . 1.56 110.124 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.01 126.37 20.87 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.396 2.064 . . . . 1.35 111.955 -177.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 37.9 mm -59.54 132.97 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.819 -0.628 . . . . 1.33 110.374 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' 2065 ' ' VAL . 13.8 t70 -78.17 138.15 38.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.145 -0.48 . . . . 1.42 110.635 -176.098 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -93.66 -0.43 56.09 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.184 -0.462 . . . . 1.55 111.877 -172.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.5 p -108.29 -1.83 19.76 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.78 -0.368 . . . . 1.29 111.164 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' 2062 ' ' ASP . 32.8 m -89.87 -176.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.441 -0.345 . . . . 1.47 110.172 178.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -93.47 111.65 53.16 Favored Pre-proline 0 C--O 1.238 0.485 0 CA-C-O 121.08 0.467 . . . . 0.78 111.451 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.555 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -100.88 107.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.523 0 C-N-CA 123.025 2.483 . . . . 0.52 111.327 167.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2068 ' ' THR . . . . . 0.493 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.2 p -145.68 146.51 31.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.853 0.358 . . . . 1.07 110.522 -177.703 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.522 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.9 OUTLIER -71.61 148.23 46.78 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.942 -1.133 . . . . 1.99 107.942 177.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -52.93 -37.42 60.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 118.412 0.551 . . . . 2.09 111.297 -171.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 29.1 t70 -67.73 -11.66 58.86 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.679 -0.691 . . . . 2.15 111.928 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 91.06 29.85 12.04 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.848 -0.691 . . . . 0.63 112.012 -176.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.6 p -110.08 161.68 15.3 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.887 0.375 . . . . 1.14 111.22 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.4 mmtp -110.94 -21.07 12.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.898 -0.592 . . . . 1.68 110.985 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.603 ' CG ' HG23 ' A' 2085 ' ' THR . 3.9 mt-10 -147.57 142.21 26.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.268 -0.424 . . . . 2.08 110.141 176.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.431 ' C ' ' HD3' ' A' 2076 ' ' LYS . 1.7 tmtp? -141.24 119.72 12.34 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.09 -0.707 . . . . 2.03 109.09 177.385 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.5 m -123.45 125.09 44.31 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.425 0.631 . . . . 1.28 111.356 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 93.8 mt -125.46 120.98 24.8 Favored Pre-proline 0 C--N 1.316 -0.863 0 N-CA-C 108.536 -0.913 . . . . 2.24 108.536 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -47.51 110.65 0.32 Allowed 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 123.203 2.602 . . . . 1.09 112.956 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 101.25 -21.45 43.06 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.74 -0.664 . . . . 0.94 112.63 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.463 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.2 tt0 -93.3 -31.74 14.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.105 0.478 . . . . 2.02 110.678 -175.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.98 -178.42 16.88 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.797 -0.716 . . . . 0.58 112.24 177.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 45.7 m -128.07 141.95 51.35 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.483 0.659 . . . . 1.21 110.103 176.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.459 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.9 m-85 -113.87 122.56 47.39 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.343 -1.354 . . . . 2.34 107.343 173.25 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2085 ' ' THR . . . . . 0.603 HG23 ' CG ' ' A' 2075 ' ' GLU . 30.5 p -122.93 129.79 52.03 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.19 0.441 . . . . 1.26 112.19 -173.501 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.522 ' CG1' HG21 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.5 129.71 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.817 -0.629 . . . . 1.76 109.923 170.74 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.7 m -110.1 148.73 38.91 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 115.644 -0.707 . . . . 1.35 109.501 175.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -61.67 0.17 1.24 Allowed 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.679 2.919 . . . . 1.32 113.755 -173.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -70.25 -13.64 62.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.124 0.488 . . . . 2.29 109.859 174.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 95.5 14.06 48.9 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.71 -0.677 . . . . 0.83 111.744 179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 10.2 t -119.83 139.24 52.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.06 0.457 . . . . 1.8 110.279 -177.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.522 HG21 ' CG1' ' A' 2086 ' ' ILE . 9.6 t -134.83 153.44 34.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.899 -0.592 . . . . 1.67 109.968 -175.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.9 t -131.92 122.31 25.43 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.261 0.553 . . . . 1.94 110.044 171.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2094 ' ' PHE . . . . . 0.409 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.1 m-30 -90.15 98.45 11.78 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.343 -0.984 . . . . 2.13 108.343 175.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 28.5 m -113.93 89.64 17.05 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.123 0.487 . . . . 1.21 111.467 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2096 ' ' PRO . . . . . 0.409 ' HD3' ' O ' ' A' 2094 ' ' PHE . 85.2 Cg_endo -90.56 149.04 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.008 2.472 . . . . 1.23 111.55 174.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.61 126.02 30.17 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.922 0.391 . . . . 2.72 110.012 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2098 ' ' LYS . . . . . 0.467 ' O ' ' HB ' ' A' 2130 ' ' VAL . 67.9 mttm -84.01 -10.63 57.74 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.153 -0.476 . . . . 5.15 112.067 -174.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -115.27 13.21 16.63 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.572 -0.451 . . . . 5.07 111.247 -175.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 42.5 t80 -77.65 110.89 12.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.004 0.431 . . . . 3.08 111.039 -178.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 47.0 t -111.99 98.59 7.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.327 -0.62 . . . . 3.01 109.327 174.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -178.2 -142.32 4.64 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.972 -0.632 . . . . 3.84 111.65 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2103 ' ' LYS . . . . . 0.411 ' HG3' ' O ' ' A' 2103 ' ' LYS . 24.2 pttm -113.91 101.94 54.36 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-O 121.203 0.525 . . . . 7.31 111.287 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 10.5 Cg_exo -71.86 147.18 49.44 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.62 2.213 . . . . 2.77 111.159 174.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2105 ' ' ASP . . . . . 0.423 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.9 t70 -95.77 132.29 27.55 Favored Pre-proline 0 C--N 1.322 -0.61 0 N-CA-C 109.802 -0.444 . . . . 2.33 109.802 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.573 ' HA ' ' O ' ' A' 2123 ' ' TYR . 15.7 Cg_endo -57.17 113.31 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 123.515 2.81 . . . . 1.29 114.128 -173.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.7 p -147.19 141.81 20.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.362 -0.836 . . . . 1.23 109.525 174.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 18.0 m -115.92 113.71 23.67 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.139 0.495 . . . . 1.11 110.276 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.557 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.2 t -92.24 132.23 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.058 -0.719 . . . . 1.35 109.058 -179.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.493 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.0 tmmm? -133.45 145.88 50.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.227 0.537 . . . . 2.25 111.664 -170.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.468 ' N ' ' HD2' ' A' 2110 ' ' LYS . 32.2 ptt180 -164.57 137.86 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.543 -0.91 . . . . 3.95 108.543 169.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.412 ' O ' HG21 ' A' 2065 ' ' VAL . 33.8 m -98.82 148.98 5.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.213 -0.595 . . . . 1.09 111.52 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.594 ' OD1' ' HB ' ' A' 2117 ' ' THR . 8.5 p30 -88.91 -168.53 2.21 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.403 -0.817 . . . . 1.46 111.341 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.0 mttm -64.88 -34.25 77.95 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.561 0.578 . . . . 2.25 112.561 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.6 p30 -84.55 -22.92 29.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 119.685 -0.806 . . . . 1.84 110.515 177.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 116.67 12.09 8.92 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.809 -0.71 . . . . 0.46 112.958 173.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.594 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 86.5 m -83.27 125.64 73.89 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 117.221 0.511 . . . . 1.22 110.005 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.482 ' HD3' ' HA ' ' A' 2117 ' ' THR . 1.8 Cg_endo -81.36 111.46 2.37 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.451 2.101 . . . . 0.72 112.987 -178.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 11.6 m -75.94 127.0 37.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.357 -0.979 . . . . 1.37 108.357 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.557 ' HA ' ' O ' ' A' 2109 ' ' VAL . 39.9 p -130.89 166.42 20.95 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 115.699 -0.682 . . . . 1.23 111.332 -170.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -127.56 126.75 42.7 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 107.677 -1.231 . . . . 1.33 107.677 169.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 3.5 m -110.08 99.42 8.51 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.324 -0.398 . . . . 2.66 110.582 -172.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.573 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.2 m-85 -104.74 151.69 23.44 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 121.252 0.549 . . . . 3.23 111.577 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 6.6 p -168.62 170.97 3.86 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 114.778 -1.101 . . . . 2.37 108.33 -173.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -70.6 53.16 1.35 Allowed 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.712 2.275 . . . . 2.51 112.185 177.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -124.63 -145.92 0.34 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.309 -0.859 . . . . 4.33 108.778 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 93.6 m-85 59.52 83.36 0.13 Allowed 'General case' 0 C--O 1.235 0.302 0 O-C-N 123.601 0.563 . . . . 4.51 111.444 174.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 16.1 p -56.52 -53.89 52.18 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.005 -0.543 . . . . 5.72 110.128 177.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -170.74 152.62 3.78 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.289 -0.869 . . . . 5.6 109.214 174.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A 2130 ' ' VAL . . . . . 0.467 ' HB ' ' O ' ' A' 2098 ' ' LYS . 45.5 t . . . . . 0 C--O 1.246 0.892 0 CA-C-O 118.499 -0.762 . . . . 6.27 110.191 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2053 ' ' GLN . . . . . 0.425 ' OE1' ' HB3' ' A' 2057 ' ' PRO . 23.5 mt-30 . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.352 -0.24 . . . . 7.47 110.352 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -137.36 48.42 0.9 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.072 -0.585 . . . . 3.62 112.076 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2055 ' ' GLY . . . . . 0.44 ' HA3' HD13 ' A' 2061 ' ' ILE . . . 161.86 -102.1 0.2 Allowed Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 121.039 -0.601 . . . . 2.08 112.013 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -136.31 131.66 18.66 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-O 120.831 0.348 . . . . 2.42 110.733 -179.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2057 ' ' PRO . . . . . 0.425 ' HB3' ' OE1' ' A' 2053 ' ' GLN . 31.1 Cg_endo -64.95 -56.01 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.887 2.391 . . . . 1.98 112.064 177.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2058 ' ' LEU . . . . . 0.46 HD11 ' N ' ' A' 2058 ' ' LEU . 0.2 OUTLIER -63.81 -12.46 35.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.43 -0.804 . . . . 2.8 113.167 177.498 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 86.06 22.72 Favored Pre-proline 0 C--N 1.322 -0.615 0 N-CA-C 109.814 -0.439 . . . . 1.56 109.814 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.63 137.82 83.1 Favored 'Trans proline' 0 C--O 1.235 0.363 0 C-N-CA 122.629 2.219 . . . . 1.35 112.3 -176.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2061 ' ' ILE . . . . . 0.44 HD13 ' HA3' ' A' 2055 ' ' GLY . 45.9 mm -65.27 136.46 26.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.672 -0.694 . . . . 1.33 110.313 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2062 ' ' ASP . . . . . . . . . . . . . 35.5 t70 -82.77 134.42 35.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.301 0.572 . . . . 1.42 111.038 -175.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -87.32 -8.47 56.66 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.661 -0.7 . . . . 1.55 111.588 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 76.5 p -104.49 7.88 35.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.971 0.415 . . . . 1.29 111.557 -178.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.555 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.1 m -110.23 -177.83 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.447 -0.575 . . . . 1.47 109.447 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -94.88 110.9 52.3 Favored Pre-proline 0 C--O 1.243 0.729 0 CA-C-O 121.092 0.472 . . . . 0.78 110.984 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.555 ' HD3' ' O ' ' A' 2065 ' ' VAL . 43.4 Cg_endo -100.98 106.8 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.62 0 C-N-CA 123.077 2.518 . . . . 0.52 111.688 169.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.0 p -142.87 -177.93 5.57 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.177 0.513 . . . . 1.07 110.907 -176.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.538 ' CE2' ' HB2' ' A' 2084 ' ' TYR . 93.9 m-85 -101.51 164.97 11.49 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 108.731 -0.84 . . . . 1.99 108.731 170.054 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -53.76 -33.23 55.13 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-N 118.004 0.365 . . . . 2.09 111.687 -172.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -86.61 12.65 10.09 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 111.872 0.323 . . . . 2.15 111.872 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 17.91 79.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 121.053 -0.594 . . . . 0.63 111.944 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2073 ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 2.2 m -78.6 164.23 24.84 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.743 0.306 . . . . 1.14 111.097 -173.334 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -115.5 -18.34 10.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.219 0.533 . . . . 1.68 110.425 178.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -147.32 140.64 25.34 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.316 -0.624 . . . . 2.08 109.316 173.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.472 ' O ' ' HA ' ' A' 2083 ' ' THR . 27.1 tptt -127.97 116.17 19.65 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.939 -0.393 . . . . 2.03 109.939 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 59.3 m -113.6 132.99 55.54 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.294 0.569 . . . . 1.28 110.957 176.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.551 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 36.0 mt -134.63 121.2 14.91 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.102 -0.954 . . . . 2.24 108.859 178.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -51.04 108.97 0.26 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.231 2.621 . . . . 1.09 113.186 -175.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 95.2 -11.15 69.42 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.908 -0.663 . . . . 0.94 112.75 176.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.551 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.5 tt0 -103.57 -26.51 12.79 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.262 0.554 . . . . 2.02 109.957 -176.246 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.29 -156.08 15.89 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.405 -0.816 . . . . 0.58 112.538 175.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.472 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -144.69 137.3 26.48 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.714 0.769 . . . . 1.21 110.729 177.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.538 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 5.7 m-85 -108.38 126.27 52.68 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.114 -1.439 . . . . 2.34 107.114 171.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -128.15 147.12 50.54 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 112.826 0.676 . . . . 1.26 112.826 -172.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.517 ' CB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -141.8 127.1 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 115.248 -0.887 . . . . 1.76 109.807 172.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -102.62 148.28 35.27 Favored Pre-proline 0 C--N 1.321 -0.643 0 N-CA-C 109.144 -0.687 . . . . 1.35 109.144 173.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -61.18 0.24 1.02 Allowed 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.712 2.942 . . . . 1.32 114.32 -171.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -71.74 -20.42 61.9 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.758 -0.46 . . . . 2.29 109.758 175.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 105.34 17.44 13.76 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.997 -0.62 . . . . 0.83 112.289 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.2 t -112.71 135.76 53.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.13 0.49 . . . . 1.8 110.481 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 6.7 t -129.46 152.35 37.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.958 -0.565 . . . . 1.67 111.033 -172.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 8.9 t -141.76 123.55 15.23 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.416 0.627 . . . . 1.94 110.267 172.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2094 ' ' PHE . . . . . 0.547 ' CE2' HG13 ' A' 2109 ' ' VAL . 19.3 m-30 -98.55 98.91 10.03 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.522 -0.918 . . . . 2.13 108.522 177.1 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 10.1 m -116.43 87.99 22.29 Favored Pre-proline 0 N--CA 1.454 -0.264 0 C-N-CA 120.238 -0.585 . . . . 1.21 111.341 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2096 ' ' PRO . . . . . 0.406 ' HD3' ' O ' ' A' 2094 ' ' PHE . 18.2 Cg_endo -92.55 143.55 2.44 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.516 2.811 . . . . 1.23 112.166 173.453 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 52.7 t0 -88.63 92.52 9.23 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.264 -0.643 . . . . 2.72 109.264 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -75.59 -1.48 24.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.031 -0.531 . . . . 5.15 111.247 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.3 mt-30 -81.95 -16.38 50.64 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.125 -0.694 . . . . 5.07 109.125 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 78.2 t80 -99.99 110.51 22.84 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.072 -0.967 . . . . 3.08 109.673 177.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.6 p -144.24 100.75 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.944 0.878 . . . . 3.01 111.452 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -151.73 -77.64 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 110.437 -1.065 . . . . 3.84 110.437 175.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 57.8 pttt -129.31 71.73 82.02 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-O 120.982 0.42 . . . . 7.31 110.896 173.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.88 148.84 91.14 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.407 2.071 . . . . 2.77 111.027 175.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2105 ' ' ASP . . . . . 0.483 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.4 t70 -75.65 132.99 74.11 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 109.582 -0.525 . . . . 2.33 109.582 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.555 ' HA ' ' O ' ' A' 2123 ' ' TYR . 33.5 Cg_endo -65.24 106.06 0.78 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.024 2.482 . . . . 1.29 112.645 -176.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2107 ' ' VAL . . . . . 0.429 HG21 ' HG2' ' A' 2076 ' ' LYS . 9.5 p -147.42 134.31 13.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.645 -0.707 . . . . 1.23 110.501 177.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.4 m -109.75 128.23 55.15 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 115.88 -0.6 . . . . 1.11 110.065 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.64 ' O ' ' HA ' ' A' 2120 ' ' THR . 13.0 t -91.42 117.99 35.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 108.697 -0.853 . . . . 1.35 108.697 176.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -125.47 108.49 11.69 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.633 -0.427 . . . . 2.25 110.918 -172.532 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.517 HH12 ' CB ' ' A' 2086 ' ' ILE . 12.7 ptp180 -155.18 157.46 37.41 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.776 -0.453 . . . . 3.95 109.776 175.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.3 m -112.04 149.39 14.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.377 -0.529 . . . . 1.09 111.69 -177.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.609 ' OD2' ' HB ' ' A' 2117 ' ' THR . 5.0 p30 -91.73 -169.33 2.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.632 -0.713 . . . . 1.46 110.756 177.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.8 mttm -62.99 -31.95 73.19 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.014 0.376 . . . . 2.25 112.014 -178.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -78.43 -18.62 54.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.083 0.468 . . . . 1.84 110.122 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 99.61 10.57 46.82 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.563 -0.744 . . . . 0.46 111.304 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.609 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 62.2 m -81.9 125.89 76.53 Favored Pre-proline 0 N--CA 1.448 -0.542 0 CA-C-O 120.515 0.197 . . . . 1.22 110.487 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' A' 2111 ' ' ARG . 11.9 Cg_exo -70.35 101.43 0.99 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.468 2.112 . . . . 0.72 112.589 177.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2119 ' ' VAL . . . . . 0.425 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 23.7 m -75.37 108.63 7.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.374 -0.973 . . . . 1.37 108.374 169.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.64 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.6 p -126.63 154.4 44.04 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.189 -0.914 . . . . 1.23 111.196 -171.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.59 127.77 42.92 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.282 -1.007 . . . . 1.33 108.282 170.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 29.6 p -105.12 99.63 9.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.095 0.474 . . . . 2.66 110.172 -177.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.555 ' O ' ' HA ' ' A' 2106 ' ' PRO . 10.6 m-85 -113.38 134.42 54.65 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.966 -0.561 . . . . 3.23 111.225 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2124 ' ' SER . . . . . 0.413 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 26.3 p -160.08 161.19 26.38 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 115.602 -0.726 . . . . 2.37 109.935 -175.113 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' 2124 ' ' SER . 57.3 Cg_endo -71.18 3.32 3.55 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 122.956 2.438 . . . . 2.51 113.011 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -105.0 6.98 33.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.062 0.458 . . . . 4.33 109.933 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 29.3 t80 -60.47 122.86 15.67 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.419 -0.81 . . . . 4.51 110.28 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 17.7 p -89.73 153.03 21.02 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.216 -0.447 . . . . 5.72 111.474 -177.13 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -97.18 145.64 25.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 5.6 110.609 -178.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 6.3 p . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.191 -0.909 . . . . 6.27 110.454 179.875 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 . . . . . 0 N--CA 1.478 0.956 0 N-CA-C 110.303 -0.258 . . . . 7.47 110.303 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -62.21 -41.0 99.71 Favored Glycine 0 C--N 1.33 0.223 0 C-N-CA 121.04 -0.6 . . . . 3.62 112.945 -177.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 162.75 -96.76 0.14 Allowed Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 111.212 -0.755 . . . . 2.08 111.212 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2056 ' ' ASP . . . . . 0.451 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 1.8 t70 -124.38 134.12 25.26 Favored Pre-proline 0 C--N 1.32 -0.676 0 N-CA-C 109.211 -0.663 . . . . 2.42 109.211 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -44.25 -55.08 3.4 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 123.296 2.664 . . . . 1.98 113.231 -175.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2058 ' ' LEU . . . . . 0.501 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -101.16 2.07 39.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.014 0.435 . . . . 2.8 112.085 -177.909 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A 2059 ' ' VAL . . . . . 0.501 HG23 HD13 ' A' 2058 ' ' LEU . 2.1 t -131.65 78.42 70.88 Favored Pre-proline 0 C--N 1.327 -0.386 0 N-CA-C 110.091 -0.337 . . . . 1.56 110.091 178.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.42 140.03 92.35 Favored 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.182 1.921 . . . . 1.35 111.349 176.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.3 mm -61.06 130.97 25.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.856 -0.611 . . . . 1.33 111.404 -178.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.595 ' O ' HG21 ' A' 2065 ' ' VAL . 12.5 t70 -73.67 140.36 46.03 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.393 -0.821 . . . . 1.42 109.867 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -86.83 -10.47 53.39 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 111.914 0.338 . . . . 1.55 111.914 -171.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 39.7 p -109.24 10.12 25.8 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.755 0.312 . . . . 1.29 111.817 -177.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.605 ' O ' ' HD3' ' A' 2067 ' ' PRO . 35.8 m -91.66 -174.94 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 110.059 -0.348 . . . . 1.47 110.059 175.215 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -97.0 105.05 21.24 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.551 -0.295 . . . . 0.78 110.775 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.605 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -99.91 106.48 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.603 0 C-N-CA 122.562 2.175 . . . . 0.52 110.92 168.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2068 ' ' THR . . . . . 0.511 ' O ' ' HB3' ' A' 2110 ' ' LYS . 40.7 p -145.35 147.66 32.54 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.104 -0.498 . . . . 1.07 110.09 -176.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.541 ' HD2' ' N ' ' A' 2069 ' ' PHE . 1.2 m-30 -72.62 153.75 41.09 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.5 -0.926 . . . . 1.99 108.5 178.235 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -50.55 -43.51 56.22 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.958 0.409 . . . . 2.09 111.139 -173.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 38.1 t70 -77.43 2.58 15.64 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 115.671 -0.695 . . . . 2.15 111.587 -177.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 86.28 29.98 23.57 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.162 -0.542 . . . . 0.63 112.558 179.367 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 12.5 m -101.24 162.47 12.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.788 0.328 . . . . 1.14 110.941 -176.565 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -115.83 -19.62 10.37 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.092 -0.504 . . . . 1.68 110.87 178.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2075 ' ' GLU . . . . . 0.431 ' HA ' ' O ' ' A' 2084 ' ' TYR . 7.2 tt0 -156.0 125.88 6.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.999 -0.546 . . . . 2.08 109.737 172.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.404 ' O ' ' HA ' ' A' 2083 ' ' THR . 32.1 tptt -117.33 118.89 33.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.655 -0.702 . . . . 2.03 109.411 178.353 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.4 m -111.85 113.73 26.24 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.482 0.658 . . . . 1.28 110.882 176.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.52 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 67.0 mt -110.18 113.9 56.23 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.302 -0.999 . . . . 2.24 108.302 174.364 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -47.41 109.4 0.22 Allowed 'Trans proline' 0 N--CA 1.474 0.324 0 C-N-CA 123.49 2.793 . . . . 1.09 113.879 -171.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 89.42 -11.56 69.49 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.814 -0.63 . . . . 0.94 112.73 176.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.52 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.5 tm0? -98.22 -28.45 13.7 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.059 0.456 . . . . 2.02 110.008 -175.098 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 130.37 -173.8 19.88 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.712 -0.756 . . . . 0.58 112.765 173.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -147.79 138.96 23.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.71 0.767 . . . . 1.21 110.436 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.521 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.2 OUTLIER -114.14 131.4 56.44 Favored 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 107.261 -1.385 . . . . 2.34 107.261 175.382 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 23.7 p -127.84 128.72 45.72 Favored 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 120.527 -0.469 . . . . 1.26 112.173 -174.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.513 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -116.96 129.66 73.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.579 -0.737 . . . . 1.76 109.753 170.727 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 27.5 m -118.45 145.37 37.18 Favored Pre-proline 0 C--N 1.319 -0.734 0 CA-C-N 115.968 -0.56 . . . . 1.35 109.534 173.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -59.76 -5.33 3.43 Favored 'Trans proline' 0 N--CA 1.477 0.548 0 C-N-CA 123.85 3.033 . . . . 1.32 114.682 -168.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 28.5 t70 -68.82 -21.35 64.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.276 0.56 . . . . 2.29 109.81 176.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.24 7.86 26.08 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.899 -0.667 . . . . 0.83 112.077 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.6 t -107.21 124.44 49.74 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.34 0.591 . . . . 1.8 110.559 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.622 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 10.1 t -129.49 138.48 54.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.351 -0.841 . . . . 1.67 109.716 -178.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.8 t -123.05 115.29 21.6 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.456 0.646 . . . . 1.94 110.571 175.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2094 ' ' PHE . . . . . 0.458 ' O ' ' HD3' ' A' 2096 ' ' PRO . 14.2 m-30 -85.8 98.47 10.76 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.648 -0.871 . . . . 2.13 108.648 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 7.5 m -113.28 88.08 12.14 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.968 0.414 . . . . 1.21 111.302 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2096 ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' 2094 ' ' PHE . 96.8 Cg_endo -92.63 145.44 2.59 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.294 2.663 . . . . 1.23 112.683 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.46 102.69 11.28 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.19 -0.67 . . . . 2.72 109.19 170.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2098 ' ' LYS . . . . . 0.579 ' H ' ' HD3' ' A' 2098 ' ' LYS . 0.0 OUTLIER -87.08 10.89 15.19 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.763 -0.653 . . . . 5.15 111.371 -175.036 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 -106.44 8.85 31.74 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.193 0.521 . . . . 5.07 109.83 177.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 64.9 t80 -79.58 80.59 5.95 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.52 -0.764 . . . . 3.08 109.666 174.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 16.6 t -85.13 98.24 6.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.079 -0.51 . . . . 3.01 109.78 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.3 48.98 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.639 -0.71 . . . . 3.84 111.436 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 1.2 mptm? 59.27 73.76 0.65 Allowed Pre-proline 0 CA--C 1.532 0.26 0 C-N-CA 122.895 0.478 . . . . 7.31 111.418 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2104 ' ' PRO . . . . . 0.467 ' HD2' ' HA ' ' A' 2126 ' ' GLU . 31.4 Cg_exo -60.04 131.89 41.69 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.456 2.104 . . . . 2.77 111.115 175.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2105 ' ' ASP . . . . . 0.427 ' HB3' HD11 ' A' 2078 ' ' ILE . 35.6 t70 -68.99 131.23 90.96 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-N 116.098 -0.501 . . . . 2.33 110.373 -178.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.54 131.98 18.27 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 123.083 2.522 . . . . 1.29 113.616 -177.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 14.7 p -161.26 144.03 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.372 -0.831 . . . . 1.23 109.644 174.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2108 ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' 2121 ' ' ALA . 42.9 m -109.79 125.5 52.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.433 0.635 . . . . 1.11 110.744 177.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -102.56 138.91 25.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.46 -0.791 . . . . 1.35 108.946 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2110 ' ' LYS . . . . . 0.529 ' HG2' ' N ' ' A' 2111 ' ' ARG . 23.5 ttpt -139.68 153.43 47.27 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.296 0.498 . . . . 2.25 112.297 -172.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.622 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 31.7 ptt180 -175.38 142.76 0.61 Allowed 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 108.447 -0.945 . . . . 3.95 108.447 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2112 ' ' VAL . . . . . 0.48 ' O ' HG22 ' A' 2065 ' ' VAL . 33.7 m -99.22 150.21 5.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.393 -0.523 . . . . 1.09 111.297 -178.088 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.672 ' OD1' ' HB ' ' A' 2117 ' ' THR . 7.1 p30 -91.32 -169.31 2.29 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.72 -0.673 . . . . 1.46 111.22 179.535 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 97.5 mttt -58.93 -38.04 78.08 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.354 -0.385 . . . . 2.25 111.64 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -78.72 -30.27 45.82 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.256 0.551 . . . . 1.84 109.79 -177.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 115.74 17.85 6.29 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.268 -0.878 . . . . 0.46 112.055 178.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.672 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.3 m -88.15 119.21 70.28 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 110.167 -0.309 . . . . 1.22 110.167 178.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2118 ' ' PRO . . . . . 0.448 ' HA ' ' O ' ' A' 2111 ' ' ARG . 8.7 Cg_exo -71.89 104.12 1.58 Allowed 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.365 2.044 . . . . 0.72 112.173 177.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 15.4 m -75.08 113.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 108.254 -1.017 . . . . 1.37 108.254 170.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.488 ' HA ' ' O ' ' A' 2109 ' ' VAL . 60.6 p -120.93 161.23 21.94 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.467 -0.788 . . . . 1.23 111.391 -172.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2121 ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.36 127.04 41.89 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 107.601 -1.259 . . . . 1.33 107.601 168.334 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.5 m -115.78 100.65 8.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.285 0.564 . . . . 2.66 110.696 -172.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -89.83 131.7 35.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.827 -0.624 . . . . 3.23 110.306 176.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 13.4 m -124.01 166.26 20.04 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.716 -0.675 . . . . 2.37 109.486 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 70.1 Cg_exo -53.48 115.93 2.64 Favored 'Trans proline' 0 C--O 1.236 0.414 0 C-N-CA 122.466 2.111 . . . . 2.51 112.251 177.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2126 ' ' GLU . . . . . 0.467 ' HA ' ' HD2' ' A' 2104 ' ' PRO . 43.7 mt-10 64.65 30.66 12.51 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.814 -0.63 . . . . 4.33 111.82 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 68.7 t80 -87.72 134.28 33.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.584 -0.28 . . . . 4.51 110.331 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 25.2 p 55.53 105.24 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.336 0 O-C-N 124.387 1.054 . . . . 5.72 113.104 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 16.0 ptmt -135.4 101.8 4.94 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.481 -1.236 . . . . 5.6 109.797 -178.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A 2130 ' ' VAL . . . . . 0.415 ' OXT' HG13 ' A' 2130 ' ' VAL . 12.2 p . . . . . 0 C--O 1.252 1.235 0 CA-C-O 117.491 -1.242 . . . . 6.27 112.19 -177.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2053 ' ' GLN . . . . . 0.482 ' HB3' ' O ' ' A' 2120 ' ' THR . 72.6 mm-40 . . . . . 0 N--CA 1.48 1.067 0 N-CA-C 109.667 -0.494 . . . . 7.47 109.667 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2054 ' ' GLY . . . . . 0.542 ' HA2' ' CD1' ' A' 2094 ' ' PHE . . . 100.64 -84.73 0.57 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.595 -0.812 . . . . 3.62 112.3 -178.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -171.33 112.74 0.46 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 121.023 -0.608 . . . . 2.08 111.779 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.55 117.7 46.86 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-O 120.636 0.255 . . . . 2.42 111.087 179.032 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -73.56 -14.83 24.8 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.176 1.918 . . . . 1.98 111.313 176.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.47 -41.13 61.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.629 -0.714 . . . . 2.8 110.04 177.314 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 1.8 t -126.4 98.77 31.6 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.711 -0.477 . . . . 1.56 109.711 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.69 131.62 41.05 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.171 1.914 . . . . 1.35 111.842 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 49.8 mm -55.67 129.68 17.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 CA-C-N 115.68 -0.691 . . . . 1.33 110.622 -178.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2062 ' ' ASP . . . . . 0.592 ' O ' HG22 ' A' 2065 ' ' VAL . 11.3 t70 -75.62 139.62 42.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.983 0.42 . . . . 1.42 110.232 -177.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -89.71 -4.75 57.57 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.149 0.425 . . . . 1.55 112.149 -171.492 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 81.8 p -99.33 -13.61 19.55 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.527 -0.469 . . . . 1.29 111.238 178.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2065 ' ' VAL . . . . . 0.634 ' O ' ' HD3' ' A' 2067 ' ' PRO . 31.4 m -79.92 -174.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.891 -0.411 . . . . 1.47 109.891 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -95.33 109.55 45.73 Favored Pre-proline 0 C--O 1.238 0.447 0 CA-C-O 121.078 0.466 . . . . 0.78 111.63 -179.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2067 ' ' PRO . . . . . 0.634 ' HD3' ' O ' ' A' 2065 ' ' VAL . 65.4 Cg_endo -100.77 123.23 0.11 Allowed 'Trans proline' 0 N--CA 1.441 -1.605 0 C-N-CA 123.46 2.774 . . . . 0.52 110.851 165.384 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 3.6 p -153.28 -179.23 7.54 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 1.07 110.601 -178.479 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2069 ' ' PHE . . . . . 0.597 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 8.5 m-30 -102.43 154.63 18.9 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 107.405 -1.332 . . . . 1.99 107.405 163.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -54.45 -35.84 63.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 118.65 0.659 . . . . 2.09 111.748 -171.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -78.35 4.9 11.73 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.235 0.457 . . . . 2.15 112.235 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 80.48 24.95 57.91 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.127 -0.558 . . . . 0.63 111.903 -177.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 14.7 m -94.07 156.46 16.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.629 0.252 . . . . 1.14 110.797 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.79 5.18 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.25 0.548 . . . . 1.68 110.913 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.58 140.75 4.98 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.123 -0.695 . . . . 2.08 109.123 170.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2076 ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' 2083 ' ' THR . 16.5 tptt -138.88 104.0 4.95 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.273 -0.421 . . . . 2.03 110.065 174.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 49.0 m -101.51 118.03 36.13 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.123 0.487 . . . . 1.28 110.273 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2078 ' ' ILE . . . . . 0.537 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 75.5 mt -117.16 119.89 34.29 Favored Pre-proline 0 C--N 1.315 -0.925 0 N-CA-C 108.407 -0.96 . . . . 2.24 108.407 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -47.11 109.87 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.486 2.791 . . . . 1.09 113.496 -174.102 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.42 -12.76 68.95 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.81 -0.632 . . . . 0.94 112.677 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2081 ' ' GLN . . . . . 0.537 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.9 tt0 -101.13 -26.28 13.73 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.164 0.507 . . . . 2.02 110.183 -177.354 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 112.85 -163.95 12.1 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.539 -0.838 . . . . 0.58 112.782 173.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2083 ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' 2076 ' ' LYS . 28.1 m -137.14 145.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 121.808 0.814 . . . . 1.21 110.553 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2084 ' ' TYR . . . . . 0.597 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 12.8 m-85 -107.13 112.48 25.41 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 106.892 -1.522 . . . . 2.34 106.892 166.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 25.3 p -104.99 134.76 47.55 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.745 -0.382 . . . . 1.26 111.563 -173.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2086 ' ' ILE . . . . . 0.598 ' HA ' ' O ' ' A' 2091 ' ' THR . 1.6 tt -151.19 130.55 3.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.799 -0.637 . . . . 1.76 111.422 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2087 ' ' VAL . . . . . 0.58 HG22 ' OG1' ' A' 2091 ' ' THR . 18.6 m -115.1 157.75 42.74 Favored Pre-proline 0 C--N 1.328 -0.343 0 N-CA-C 109.565 -0.531 . . . . 1.35 109.565 175.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.17 -0.54 2.28 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 123.69 2.926 . . . . 1.32 114.137 -172.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 19.1 t70 -78.03 -23.18 48.29 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.293 0.568 . . . . 2.29 109.927 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 112.74 17.17 8.13 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.581 -0.736 . . . . 0.83 112.133 -178.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2091 ' ' THR . . . . . 0.598 ' O ' ' HA ' ' A' 2086 ' ' ILE . 3.2 p -90.51 116.2 28.24 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.355 -0.609 . . . . 1.8 109.355 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2092 ' ' VAL . . . . . 0.462 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 3.8 t -136.2 132.38 49.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.781 -0.368 . . . . 1.67 110.285 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.2 t -137.33 122.8 19.58 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.401 0.62 . . . . 1.94 110.239 176.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2094 ' ' PHE . . . . . 0.542 ' CD1' ' HA2' ' A' 2054 ' ' GLY . 3.2 m-30 -86.33 98.41 10.96 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.976 -0.75 . . . . 2.13 108.976 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 16.4 m -121.38 84.59 41.61 Favored Pre-proline 0 N--CA 1.453 -0.284 0 C-N-CA 119.676 -0.81 . . . . 1.21 111.585 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -93.47 147.71 2.29 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 123.248 2.632 . . . . 1.23 111.884 170.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.27 86.35 5.04 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.225 -0.658 . . . . 2.72 109.225 171.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 43.8 mtmt -63.26 -24.03 67.69 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.488 -0.778 . . . . 5.15 110.92 -175.282 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -96.44 12.98 29.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.789 -0.641 . . . . 5.07 111.052 -176.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.72 104.09 13.55 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.732 -0.667 . . . . 3.08 110.414 176.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 86.3 t -90.7 98.7 8.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.399 0.619 . . . . 3.01 109.529 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -162.78 -152.86 6.95 Favored Glycine 0 N--CA 1.445 -0.756 0 N-CA-C 110.704 -0.958 . . . . 3.84 110.704 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2103 ' ' LYS . . . . . 0.48 ' NZ ' ' HB3' ' A' 2103 ' ' LYS . 0.0 OUTLIER -109.76 94.86 18.05 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 121.3 0.571 . . . . 7.31 110.235 177.123 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -76.81 161.43 33.44 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.868 2.379 . . . . 2.77 112.391 -177.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.01 141.04 21.74 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.027 -0.533 . . . . 2.33 110.508 179.63 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2106 ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' 2123 ' ' TYR . 55.5 Cg_endo -68.99 121.25 8.1 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 123.181 2.587 . . . . 1.29 113.467 -176.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.6 p -157.51 143.85 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.414 -0.812 . . . . 1.23 109.707 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 15.6 m -121.48 130.68 53.71 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 1.11 110.574 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2109 ' ' VAL . . . . . 0.411 HG11 ' CD2' ' A' 2069 ' ' PHE . 2.7 t -92.99 144.68 8.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.101 -0.703 . . . . 1.35 109.101 177.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -143.36 108.35 4.95 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 118.157 0.435 . . . . 2.25 111.635 -173.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2111 ' ' ARG . . . . . 0.462 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -147.25 139.09 24.24 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 121.722 -0.611 . . . . 3.95 109.88 171.324 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.5 m -103.5 154.69 5.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 120.926 0.393 . . . . 1.09 110.907 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2113 ' ' ASP . . . . . 0.418 ' OD1' ' HB ' ' A' 2117 ' ' THR . 2.3 p-10 -96.29 -167.74 1.63 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.029 -0.532 . . . . 1.46 110.102 178.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.4 mttt -53.64 -44.47 69.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.954 -0.566 . . . . 2.25 112.175 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 5.9 p30 -85.28 -14.92 45.11 Favored 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 120.487 -0.485 . . . . 1.84 111.157 -176.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 104.29 15.23 22.04 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.272 -0.966 . . . . 0.46 112.937 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2117 ' ' THR . . . . . 0.418 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 98.1 m -75.85 114.65 38.94 Favored Pre-proline 0 C--N 1.324 -0.538 0 N-CA-C 109.887 -0.412 . . . . 1.22 109.887 174.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -77.49 100.79 1.42 Allowed 'Trans proline' 0 N--CA 1.454 -0.817 0 C-N-CA 122.407 2.072 . . . . 0.72 112.318 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 7.0 m -74.94 109.36 7.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.433 -0.951 . . . . 1.37 108.433 169.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2120 ' ' THR . . . . . 0.482 ' O ' ' HB3' ' A' 2053 ' ' GLN . 69.3 p -118.86 -174.31 2.67 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.88 -1.054 . . . . 1.23 109.977 -174.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -149.88 127.21 11.41 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.743 -0.836 . . . . 1.33 108.743 170.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 34.5 p -100.44 97.87 8.55 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.568 -0.53 . . . . 2.66 109.568 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2123 ' ' TYR . . . . . 0.545 ' O ' ' HA ' ' A' 2106 ' ' PRO . 12.1 m-85 -118.44 124.35 47.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.244 0.545 . . . . 3.23 111.568 -177.231 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2124 ' ' SER . . . . . 0.465 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 49.5 m -157.77 171.82 6.94 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.689 -1.141 . . . . 2.37 108.75 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2125 ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' 2124 ' ' SER . 90.4 Cg_exo -47.54 140.82 15.81 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.318 2.012 . . . . 2.51 112.45 173.568 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A 2126 ' ' GLU . . . . . 0.432 ' HA ' ' CD ' ' A' 2129 ' ' LYS . 0.9 OUTLIER 66.39 23.0 10.69 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.75 -0.659 . . . . 4.33 112.673 179.332 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 62.1 t80 -107.99 -49.6 3.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.549 -0.461 . . . . 4.51 110.56 173.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 2.9 m -63.14 -36.33 83.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.029 -0.532 . . . . 5.72 112.393 -174.445 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A 2129 ' ' LYS . . . . . 0.432 ' CD ' ' HA ' ' A' 2126 ' ' GLU . 0.0 OUTLIER -92.64 173.87 7.55 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.367 -0.533 . . . . 5.6 110.214 179.154 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.249 1.043 0 CA-C-N 115.812 -0.631 . . . . 6.27 111.206 -176.972 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.153 0.502 . . . . 2.4199999999999999 111.384 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.23 -40.18 4.86 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.002 2.468 . . . . 1.72 112.46 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2058 ' ' LEU . . . . . 0.596 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -81.97 -2.08 50.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 2.3399999999999999 111.607 -177.591 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.596 HG23 HD13 ' A' 2058 ' ' LEU . 13.5 t -136.92 84.42 25.75 Favored Pre-proline 0 C--N 1.326 -0.426 0 N-CA-C 109.159 -0.682 . . . . 0.87 109.159 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2060 ' ' PRO . . . . . 0.508 ' O ' ' HG3' ' A' 2114 ' ' LYS . 41.6 Cg_exo -55.73 130.64 41.48 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.532 2.155 . . . . 1.04 111.804 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2061 ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' 2113 ' ' ASP . 41.6 mm -64.49 141.74 17.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.561 . . . . 0.77000000000000002 109.709 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.512 ' O ' HG22 ' A' 2065 ' ' VAL . 10.3 t70 -80.05 128.11 33.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.361 -0.381 . . . . 1.4199999999999999 110.289 -175.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -91.34 1.96 56.74 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.404 -0.362 . . . . 1.55 111.958 -172.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 74.4 p -110.73 -5.04 15.06 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.009 0.433 . . . . 0.68999999999999995 111.171 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.637 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.9 m -91.67 -174.01 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.453 . . . . 0.81999999999999995 109.857 178.187 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -89.64 111.26 44.94 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.154 0.502 . . . . 0.78000000000000003 111.162 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.637 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.2 Cg_endo -100.71 109.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 123.608 2.872 . . . . 0.45000000000000001 110.792 166.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 9.0 p -148.31 -176.52 5.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.146 0.498 . . . . 0.69999999999999996 110.963 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.606 ' CD2' HG13 ' A' 2109 ' ' VAL . 3.5 m-30 -101.6 156.39 17.51 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 107.165 -1.42 . . . . 1.1599999999999999 107.165 166.15 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -53.8 -34.95 60.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 118.261 0.482 . . . . 2.0899999999999999 111.951 -169.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -74.81 -4.92 40.62 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.886 0.374 . . . . 2.1499999999999999 111.312 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.91 14.49 57.82 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 121.246 -0.502 . . . . 0.63 111.854 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2073 ' ' SER . . . . . 0.473 ' OG ' ' HB2' ' A' 2069 ' ' PHE . 0.3 OUTLIER -85.78 161.78 18.99 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.666 0.27 . . . . 0.89000000000000001 111.277 -174.769 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -115.52 -23.82 8.61 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.431 -0.35 . . . . 1.1299999999999999 111.912 -174.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' 2084 ' ' TYR . 1.6 tm-20 -151.87 137.31 17.67 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.254 0.55 . . . . 2.0800000000000001 110.167 173.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.0 OUTLIER -131.64 99.7 4.88 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.472 -0.786 . . . . 1.48 109.99 175.44 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 7.7 m -103.06 111.78 24.3 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.945 -0.57 . . . . 0.63 110.598 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.548 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 44.4 mm -114.39 123.05 33.05 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 108.004 -1.11 . . . . 1.6200000000000001 108.004 173.046 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.27 108.69 0.17 Allowed 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.043 2.495 . . . . 0.97999999999999998 113.039 -176.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 100.99 -18.55 54.57 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.644 -0.707 . . . . 0.93999999999999995 112.886 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.548 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -90.59 -30.19 17.35 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.257 0.551 . . . . 2.02 110.827 -173.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.56 -174.58 15.31 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.587 -0.733 . . . . 0.5 111.58 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.45 HG22 HG23 ' A' 2085 ' ' THR . 15.5 m -133.88 134.41 42.67 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.583 0.706 . . . . 0.48999999999999999 110.523 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' 2075 ' ' GLU . 1.5 m-85 -109.47 120.18 41.7 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.986 -1.487 . . . . 1.4399999999999999 106.986 172.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.45 HG23 HG22 ' A' 2083 ' ' THR . 0.7 OUTLIER -127.89 121.59 30.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 112.447 0.536 . . . . 0.63 112.447 -171.789 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.458 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -115.54 134.91 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.089 -0.505 . . . . 1.1799999999999999 110.198 173.703 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 33.6 m -118.2 150.37 47.47 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 109.413 -0.588 . . . . 0.80000000000000004 109.413 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.99 -4.08 0.85 Allowed 'Trans proline' 0 N--CA 1.481 0.768 0 C-N-CA 123.959 3.106 . . . . 0.96999999999999997 114.637 -172.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.73 -7.8 52.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.902 0.382 . . . . 2.29 110.506 176.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 91.18 16.98 52.54 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.91 -0.662 . . . . 0.82999999999999996 112.063 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.2 t -118.61 138.54 52.51 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.854 0.359 . . . . 1.51 110.433 -179.213 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.461 ' CG2' ' HB2' ' A' 2067 ' ' PRO . 7.4 t -131.21 140.58 48.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.126 -0.488 . . . . 1.1799999999999999 110.512 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -101.99 108.92 20.52 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 116.299 -0.41 . . . . 1.46 110.49 174.124 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -86.69 96.32 10.1 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.162 -1.051 . . . . 1.27 108.162 173.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 25.1 m -119.04 88.25 36.21 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 121.121 0.486 . . . . 0.57999999999999996 110.554 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.29 2.66 . . . . 0.97999999999999998 111.877 176.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.2 t70 -132.14 99.43 4.71 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.883 0.373 . . . . 2.7200000000000002 110.083 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.23 13.9 2.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.275 -0.42 . . . . 4.8099999999999996 111.101 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 69.1 mt-30 -109.52 5.57 23.32 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.256 0.551 . . . . 4.4199999999999999 109.716 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 52.5 t80 -89.3 92.55 9.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 2.3599999999999999 110.992 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 92.0 t -83.76 107.78 15.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.586 -0.524 . . . . 2.6800000000000002 109.586 174.377 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.14 -133.55 2.85 Favored Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.673 -0.694 . . . . 3.8399999999999999 111.456 -178.062 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 61.6 tttm -127.67 99.07 27.06 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.769 0.284 . . . . 6.7800000000000002 110.94 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.92 155.03 48.37 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.318 2.012 . . . . 2.4300000000000002 111.73 174.476 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.3 t70 -83.42 127.02 70.09 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.066 -0.515 . . . . 2.3300000000000001 109.968 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.654 ' HA ' ' O ' ' A' 2123 ' ' TYR . 43.1 Cg_exo -56.34 102.68 0.1 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.026 2.484 . . . . 1.03 112.881 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.2 p -147.42 138.93 18.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.095 -0.502 . . . . 0.59999999999999998 110.38 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 56.6 m -112.96 124.16 51.99 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.001 -0.545 . . . . 0.37 110.149 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.606 HG13 ' CD2' ' A' 2069 ' ' PHE . 4.7 t -91.63 131.17 39.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.835 -0.802 . . . . 0.76000000000000001 108.835 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -143.6 108.94 5.04 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 112.989 0.737 . . . . 1.6299999999999999 112.989 -173.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.42 ' HD2' HG21 ' A' 2061 ' ' ILE . 28.1 ptt180 -129.65 140.62 51.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.741 -0.837 . . . . 3.4700000000000002 108.741 171.486 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.457 HG23 HG21 ' A' 2065 ' ' VAL . 35.9 m -99.58 142.01 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 120.358 -0.537 . . . . 0.40000000000000002 110.997 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.669 ' OD1' ' HB ' ' A' 2117 ' ' THR . 4.3 p30 -85.24 -170.72 3.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.949 -0.569 . . . . 1.46 111.615 -178.034 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2114 ' ' LYS . . . . . 0.508 ' HG3' ' O ' ' A' 2060 ' ' PRO . 91.5 mttt -57.55 -37.17 72.67 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.851 0.315 . . . . 1.72 111.851 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -80.09 -29.7 39.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.313 0.578 . . . . 1.8400000000000001 109.901 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 112.6 21.62 6.04 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.321 -0.854 . . . . 0.44 112.418 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.669 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 92.4 m -86.91 120.97 71.88 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 110.214 -0.291 . . . . 0.56999999999999995 110.214 177.67 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' 2117 ' ' THR . 7.5 Cg_exo -73.16 101.88 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.453 2.102 . . . . 0.60999999999999999 112.433 178.384 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.7 m -75.07 113.0 13.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.527 -0.916 . . . . 0.59999999999999998 108.527 171.582 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' 2109 ' ' VAL . 37.8 p -119.66 154.82 33.46 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 115.483 -0.781 . . . . 0.67000000000000004 112.617 -169.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -130.29 127.54 39.71 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.892 -1.151 . . . . 0.72999999999999998 107.892 167.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.2 m -115.87 103.87 11.06 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.072 0.463 . . . . 2.1899999999999999 110.527 -174.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.654 ' O ' ' HA ' ' A' 2106 ' ' PRO . 3.1 m-85 -98.33 132.29 43.92 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-O 121.198 0.523 . . . . 2.8100000000000001 111.19 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 44.3 m -157.14 165.37 18.95 Favored Pre-proline 0 C--N 1.321 -0.635 0 N-CA-C 108.433 -0.951 . . . . 2.0600000000000001 108.433 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo . . . . . 0 C--N 1.353 0.783 0 C-N-CA 123.199 2.599 . . . . 2.1600000000000001 114.064 -176.686 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 CA--C 1.519 -0.233 0 CA-C-O 120.582 0.23 . . . . 2.4199999999999999 110.621 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.87 -21.91 18.1 Favored 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.404 2.07 . . . . 1.72 111.933 -178.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.74 -18.48 59.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.673 -0.694 . . . . 2.3399999999999999 110.465 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.456 HG11 ' OD2' ' A' 2113 ' ' ASP . 5.0 t -133.63 98.38 14.99 Favored Pre-proline 0 N--CA 1.452 -0.341 0 CA-C-N 116.062 -0.517 . . . . 0.87 109.811 177.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2060 ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' 2059 ' ' VAL . 11.3 Cg_endo -55.76 118.86 5.69 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.039 1.826 . . . . 1.04 111.827 178.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.8 mm -53.6 136.84 14.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.251 -0.886 . . . . 0.77000000000000002 111.346 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.517 ' O ' HG22 ' A' 2065 ' ' VAL . 14.8 t70 -71.57 131.56 43.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 1.4199999999999999 110.144 178.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -86.76 -5.2 59.19 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.238 -0.437 . . . . 1.55 112.131 -172.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.7 p -111.37 3.82 18.53 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.091 0.404 . . . . 0.68999999999999995 112.091 -177.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' 2062 ' ' ASP . 27.1 m -90.19 -177.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.728 -0.471 . . . . 0.81999999999999995 109.728 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -94.06 116.73 66.79 Favored Pre-proline 0 C--O 1.241 0.625 0 CA-C-O 121.382 0.61 . . . . 0.78000000000000003 111.6 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.515 ' HB2' HG13 ' A' 2086 ' ' ILE . 28.4 Cg_endo -100.39 108.55 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 123.59 2.86 . . . . 0.45000000000000001 111.416 167.155 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.459 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.4 p -143.37 145.25 32.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.887 0.375 . . . . 0.69999999999999996 110.549 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.692 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-30 -70.78 156.13 39.91 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 107.936 -1.135 . . . . 1.1599999999999999 107.936 177.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -51.73 -39.13 57.92 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 123.404 0.44 . . . . 2.0899999999999999 111.819 -170.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -91.12 19.18 6.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 2.1499999999999999 111.358 -177.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 75.44 29.44 59.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.047 -0.597 . . . . 0.63 112.66 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2073 ' ' SER . . . . . 0.436 ' HB2' ' CD1' ' A' 2069 ' ' PHE . 7.4 m -95.34 162.32 13.72 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 122.743 -0.269 . . . . 0.89000000000000001 110.904 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.7 mmtp -121.57 -24.9 5.23 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.268 -0.424 . . . . 1.1299999999999999 111.673 -177.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.628 ' HA ' ' O ' ' A' 2084 ' ' TYR . 2.0 tt0 -158.62 124.64 4.54 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.368 0.604 . . . . 2.0800000000000001 110.583 175.771 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -123.55 102.19 7.73 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.375 -0.829 . . . . 1.48 109.931 175.211 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.7 m -95.92 113.22 24.82 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.204 0.526 . . . . 0.63 110.576 175.157 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 27.3 mm -116.07 108.86 45.48 Favored Pre-proline 0 C--N 1.31 -1.133 0 N-CA-C 107.627 -1.249 . . . . 1.6200000000000001 107.627 170.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.08 115.43 1.7 Allowed 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 123.183 2.589 . . . . 0.97999999999999998 113.41 -173.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2080 ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' 2100 ' ' PHE . . . 89.58 -8.41 79.88 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.775 -0.648 . . . . 0.93999999999999995 112.513 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.529 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.0 OUTLIER -107.49 -31.05 8.3 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.219 0.533 . . . . 2.02 109.903 -176.679 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 136.45 172.0 12.45 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.519 -0.848 . . . . 0.5 112.94 173.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.4 ' O ' ' HB ' ' A' 2095 ' ' THR . 77.7 m -138.23 127.93 25.12 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.304 0.573 . . . . 0.48999999999999999 109.696 172.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.692 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.1 OUTLIER -108.16 125.99 52.26 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 107.698 -1.223 . . . . 1.4399999999999999 107.698 175.52 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 1.3 p -127.86 129.31 46.71 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 112.074 0.398 . . . . 0.63 112.074 -174.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.515 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.47 132.09 71.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.854 -0.612 . . . . 1.1799999999999999 110.52 174.601 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -125.79 142.56 42.52 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.788 -0.642 . . . . 0.80000000000000004 109.3 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.57 -0.05 1.71 Allowed 'Trans proline' 0 N--CA 1.476 0.491 0 C-N-CA 123.827 3.018 . . . . 0.96999999999999997 114.177 -170.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 36.8 t70 -72.77 -11.8 60.75 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.41 0.624 . . . . 2.29 109.836 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 106.26 6.24 36.6 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.629 -0.714 . . . . 0.82999999999999996 112.381 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 2.2 t -110.8 128.06 55.62 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.257 0.551 . . . . 1.51 110.274 -179.118 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.471 HG13 ' HB ' ' A' 2086 ' ' ILE . 18.8 t -137.17 137.25 46.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.527 -0.76 . . . . 1.1799999999999999 109.624 -175.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 24.0 m -119.8 109.77 15.99 Favored 'General case' 0 N--CA 1.439 -0.997 0 CA-C-O 120.816 0.341 . . . . 1.46 111.3 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2094 ' ' PHE . . . . . 0.414 ' O ' ' HD3' ' A' 2096 ' ' PRO . 5.8 m-30 -89.65 98.88 12.02 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.26 -0.645 . . . . 1.27 109.26 174.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2095 ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' 2083 ' ' THR . 23.0 m -114.01 89.42 16.72 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 120.683 0.278 . . . . 0.57999999999999996 111.662 -178.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2096 ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' 2094 ' ' PHE . 73.0 Cg_endo -92.52 119.34 0.44 Allowed 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.971 2.447 . . . . 0.97999999999999998 112.702 175.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -89.87 84.68 6.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.34 0.59 . . . . 2.7200000000000002 109.563 173.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.69 -1.91 27.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.566 -0.743 . . . . 4.8099999999999996 112.374 -171.596 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -84.9 -2.02 57.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.168 0.509 . . . . 4.4199999999999999 110.523 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2100 ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' 2080 ' ' GLY . 69.0 t80 -83.49 85.47 7.24 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 2.3599999999999999 110.377 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.8 t -92.35 99.63 10.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.147 -0.478 . . . . 2.6800000000000002 110.196 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -169.53 -101.93 0.15 Allowed Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.415 -0.674 . . . . 3.8399999999999999 111.415 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 53.3 mtmt -131.6 73.25 79.59 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-O 120.611 0.244 . . . . 6.7800000000000002 110.615 174.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2104 ' ' PRO . . . . . 0.426 ' HD2' ' O ' ' A' 2125 ' ' PRO . 18.9 Cg_exo -66.06 127.93 18.63 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.383 2.055 . . . . 2.4300000000000002 111.312 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.3 t70 -60.79 122.88 71.85 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.001 -0.545 . . . . 2.3300000000000001 110.665 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' 2123 ' ' TYR . 31.8 Cg_exo -58.93 120.37 8.19 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 123.101 2.534 . . . . 1.03 112.174 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.7 p -156.72 161.51 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.93 -0.577 . . . . 0.59999999999999998 109.731 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' 2121 ' ' ALA . 67.0 m -140.88 119.74 12.62 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.933 0.397 . . . . 0.37 110.08 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.4 t -92.5 145.18 7.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.029 -0.73 . . . . 0.76000000000000001 109.029 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.459 ' HB3' ' O ' ' A' 2068 ' ' THR . 0.0 OUTLIER -147.47 143.21 27.72 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.224 0.465 . . . . 1.6299999999999999 111.341 -174.787 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.425 ' N ' ' HD2' ' A' 2110 ' ' LYS . 27.2 ptt180 -166.95 146.07 5.28 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.676 -0.861 . . . . 3.4700000000000002 108.676 166.238 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.444 ' O ' HG21 ' A' 2065 ' ' VAL . 30.5 m -99.01 149.19 5.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 C-N-CA 120.44 -0.504 . . . . 0.40000000000000002 111.289 -175.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.456 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.8 p-10 -90.51 -169.39 2.38 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.951 -0.568 . . . . 1.46 109.976 178.433 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2114 ' ' LYS . . . . . 0.402 ' HG2' ' HB2' ' A' 2062 ' ' ASP . 96.9 mttt -59.97 -38.56 82.88 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.542 0.21 . . . . 1.72 111.008 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 18.2 m120 -71.66 -30.28 65.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.844 0.354 . . . . 1.8400000000000001 110.857 177.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 110.55 12.93 15.65 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.851 -0.69 . . . . 0.44 112.214 179.022 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 5.7 m -79.72 121.58 82.57 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 110.128 -0.323 . . . . 0.56999999999999995 110.128 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.6 Cg_exo -73.95 103.92 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 122.301 2.001 . . . . 0.60999999999999999 112.234 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.5 m -75.32 117.62 19.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.381 -0.97 . . . . 0.59999999999999998 108.381 171.579 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.545 ' HA ' ' O ' ' A' 2109 ' ' VAL . 47.2 p -129.75 163.35 26.38 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.539 -0.755 . . . . 0.67000000000000004 111.751 -170.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -130.98 126.84 37.07 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.528 -0.915 . . . . 0.72999999999999998 108.528 169.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 20.3 m -100.12 100.45 11.3 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.041 0.448 . . . . 2.1899999999999999 110.335 -176.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.494 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -96.99 114.39 26.0 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.143 -0.48 . . . . 2.8100000000000001 110.899 -177.407 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 17.8 m -127.39 158.57 69.15 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.537 -0.756 . . . . 2.0600000000000001 109.651 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.426 ' O ' ' HD2' ' A' 2104 ' ' PRO . 95.2 Cg_exo . . . . . 0 C--N 1.346 0.402 0 C-N-CA 123.069 2.513 . . . . 2.1600000000000001 113.828 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2056 ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 2.3 t70 . . . . . 0 CA--C 1.522 -0.129 0 CA-C-O 120.698 0.285 . . . . 2.4199999999999999 111.744 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -76.45 -22.47 12.34 Favored 'Trans proline' 0 N--CA 1.46 -0.471 0 C-N-CA 122.414 2.076 . . . . 1.72 112.477 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.52 -9.57 20.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.821 0.343 . . . . 2.3399999999999999 110.656 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' 2056 ' ' ASP . 21.4 t -127.48 84.48 63.27 Favored Pre-proline 0 CA--C 1.511 -0.534 0 N-CA-C 108.034 -1.099 . . . . 0.87 108.034 175.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -40.48 117.77 0.52 Allowed 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.922 2.415 . . . . 1.04 112.228 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 33.3 mm -54.46 114.96 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.263 -0.88 . . . . 0.77000000000000002 110.911 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 15.7 t70 -72.86 125.71 28.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.47 -0.787 . . . . 1.4199999999999999 111.308 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2063 ' ' GLU . . . . . 0.423 ' HB3' ' O ' ' A' 2089 ' ' ASP . 44.0 mt-10 -86.89 -2.88 58.94 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.127 -0.488 . . . . 1.55 111.805 -173.622 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 43.9 p -106.06 -5.53 19.39 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.741 -0.384 . . . . 0.68999999999999995 111.863 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.2 m -96.26 163.66 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.863 -0.421 . . . . 0.81999999999999995 109.863 176.088 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -73.15 114.09 27.93 Favored Pre-proline 0 C--O 1.24 0.591 0 CA-C-O 121.271 0.557 . . . . 0.78000000000000003 112.22 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.492 ' HB3' ' NH1' ' A' 2111 ' ' ARG . 68.0 Cg_endo -102.29 108.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.423 0 C-N-CA 123.682 2.921 . . . . 0.45000000000000001 112.097 169.105 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 20.9 p -138.61 -178.64 5.4 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.403 0.62 . . . . 0.69999999999999996 111.273 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.489 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.7 OUTLIER -102.01 152.23 21.2 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.862 -1.162 . . . . 1.1599999999999999 107.862 168.72 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -52.39 -39.21 60.56 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.066 0.394 . . . . 2.0899999999999999 111.741 -170.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.36 -2.94 43.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.91 -0.586 . . . . 2.1499999999999999 111.335 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.78 29.36 13.47 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.849 -0.691 . . . . 0.63 112.159 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 9.1 m -98.06 169.15 9.82 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.894 -0.18 . . . . 0.89000000000000001 110.697 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -128.06 -16.64 4.52 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.964 0.412 . . . . 1.1299999999999999 111.343 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.402 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.8 tt0 -156.24 121.09 4.64 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.719 -0.475 . . . . 2.0800000000000001 109.719 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD2' ' HA ' ' A' 2076 ' ' LYS . 4.5 mmmm -115.45 121.86 44.02 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.967 -0.561 . . . . 1.48 109.534 171.584 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 55.2 m -129.53 121.48 27.28 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.729 -0.669 . . . . 0.63 110.85 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.436 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 48.4 mm -119.69 124.49 27.96 Favored Pre-proline 0 C--N 1.314 -0.965 0 N-CA-C 107.584 -1.265 . . . . 1.6200000000000001 107.584 171.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.73 107.86 0.21 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.332 2.021 . . . . 0.97999999999999998 112.304 -176.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.19 -23.37 27.31 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.811 -0.631 . . . . 0.93999999999999995 112.534 -178.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.436 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 15.7 tt0 -90.73 -31.14 16.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.003 0.43 . . . . 2.02 110.261 -176.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.62 -173.32 14.72 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.714 -0.755 . . . . 0.5 112.86 176.353 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 46.4 m -129.99 132.65 46.35 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.556 0.693 . . . . 0.48999999999999999 110.127 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.478 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 0.5 OUTLIER -111.31 112.47 24.26 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 106.735 -1.58 . . . . 1.4399999999999999 106.735 172.397 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.89 131.69 55.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.429 0.529 . . . . 0.63 112.429 -170.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.504 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.93 137.7 54.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.392 -0.822 . . . . 1.1799999999999999 109.561 174.54 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 31.7 m -118.67 153.3 52.19 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 109.889 -0.411 . . . . 0.80000000000000004 109.889 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -60.3 -4.81 3.43 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.773 2.982 . . . . 0.96999999999999997 114.264 -170.315 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2089 ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' 2063 ' ' GLU . 27.7 m-20 -72.93 -13.08 61.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.907 0.384 . . . . 2.29 110.215 177.223 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.72 16.06 32.37 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.967 -0.635 . . . . 0.82999999999999996 112.263 177.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.7 t -115.61 141.25 48.32 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.806 0.336 . . . . 1.51 110.44 -178.111 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.504 HG22 ' CG1' ' A' 2086 ' ' ILE . 12.5 t -133.32 150.78 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.977 -0.556 . . . . 1.1799999999999999 109.96 -178.491 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -125.86 122.0 34.82 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.46 110.05 173.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -90.47 98.82 12.0 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.265 -0.642 . . . . 1.27 109.265 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 8.9 m -113.25 87.49 11.12 Favored Pre-proline 0 N--CA 1.454 -0.242 0 CA-C-O 120.964 0.411 . . . . 0.57999999999999996 110.431 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -92.55 -179.88 1.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 123.292 2.661 . . . . 0.97999999999999998 112.399 178.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.4 t70 -131.7 139.65 49.09 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.222 -0.659 . . . . 2.7200000000000002 109.222 170.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -90.23 -26.1 20.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.87 -0.605 . . . . 4.8099999999999996 111.833 -172.314 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 86.4 mm-40 -120.32 36.83 4.43 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.788 0.292 . . . . 4.4199999999999999 111.788 -171.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 19.4 t80 -82.41 87.01 6.64 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.37 0.605 . . . . 2.3599999999999999 110.737 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.2 t -92.14 109.84 21.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.793 -0.64 . . . . 2.6800000000000002 109.745 176.056 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2102 ' ' GLY . . . . . 0.425 ' C ' ' HD3' ' A' 2104 ' ' PRO . . . 170.75 -113.29 0.49 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.492 -0.643 . . . . 3.8399999999999999 111.492 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -120.01 76.87 22.95 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 121.115 0.483 . . . . 6.7800000000000002 111.533 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2104 ' ' PRO . . . . . 0.425 ' HD3' ' C ' ' A' 2102 ' ' GLY . 8.1 Cg_exo -74.68 157.68 43.93 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.198 2.599 . . . . 2.4300000000000002 111.684 178.184 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.0 t70 -120.09 117.48 32.06 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.477 -0.328 . . . . 2.3300000000000001 110.435 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.532 ' HA ' ' O ' ' A' 2123 ' ' TYR . 52.6 Cg_exo -54.94 128.41 30.42 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.864 2.376 . . . . 1.03 111.828 177.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.1 p -157.51 161.29 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.312 -0.404 . . . . 0.59999999999999998 110.257 -176.125 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.43 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.5 m -140.15 119.05 12.54 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.149 0.5 . . . . 0.37 110.269 176.664 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.6 t -91.35 138.06 20.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 108.131 -1.063 . . . . 0.76000000000000001 108.131 176.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.495 ' HA ' HG22 ' A' 2120 ' ' THR . 2.2 tmmm? -145.14 108.32 4.57 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.275 0.559 . . . . 1.6299999999999999 111.476 -172.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.492 ' NH1' ' HB3' ' A' 2067 ' ' PRO . 1.4 ptm180 -139.72 142.95 36.82 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 109.207 -0.664 . . . . 3.4700000000000002 109.207 174.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' 2117 ' ' THR . 24.0 m -99.6 161.06 3.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.426 -0.51 . . . . 0.40000000000000002 111.49 -175.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.507 ' OD2' ' HB ' ' A' 2117 ' ' THR . 3.9 p30 -110.01 -169.13 1.41 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.571 -0.74 . . . . 1.46 111.004 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 65.2 mttm -63.49 -25.12 68.12 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 111.938 0.347 . . . . 1.72 111.938 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -85.67 -9.98 56.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.949 0.404 . . . . 1.8400000000000001 110.251 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 86.27 15.99 63.41 Favored Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.333 -0.707 . . . . 0.44 111.333 -176.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.507 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 0.2 OUTLIER -84.99 131.23 49.45 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 109.954 -0.388 . . . . 0.56999999999999995 109.954 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 12.3 Cg_endo -87.78 103.9 0.52 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 122.208 1.938 . . . . 0.60999999999999999 112.428 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 14.8 m -75.42 109.29 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 108.692 -0.855 . . . . 0.59999999999999998 108.692 171.735 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.495 HG22 ' HA ' ' A' 2110 ' ' LYS . 35.5 p -124.55 169.27 12.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.094 -0.957 . . . . 0.67000000000000004 111.55 -170.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -135.49 127.73 30.08 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.52 -0.764 . . . . 0.72999999999999998 109.6 173.812 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 13.4 p -94.71 99.67 11.73 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.254 -0.43 . . . . 2.1899999999999999 109.892 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.532 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -103.77 123.93 47.97 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.34 0.59 . . . . 2.8100000000000001 111.788 -174.859 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 25.2 m -154.19 153.07 27.75 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.141 -0.936 . . . . 2.0600000000000001 108.484 175.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.535 0.55 0 C-N-CA 122.837 2.358 . . . . 2.1600000000000001 113.891 -178.733 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 7.1 t70 . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.678 0.275 . . . . 2.4199999999999999 110.359 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.7 -21.78 33.28 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.387 2.058 . . . . 1.72 112.55 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.9 mm? -93.2 -26.83 17.21 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.887 0.375 . . . . 2.3399999999999999 110.043 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.433 HG11 HD22 ' A' 2115 ' ' ASN . 1.8 t -126.88 90.7 48.9 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.239 -0.437 . . . . 0.87 110.429 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -57.32 121.57 10.28 Favored 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 122.188 1.925 . . . . 1.04 111.586 176.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 48.9 mm -53.04 132.31 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.572 -0.74 . . . . 0.77000000000000002 110.828 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.568 ' O ' HG22 ' A' 2065 ' ' VAL . 24.4 t70 -66.78 135.39 53.89 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 1.4199999999999999 110.493 -177.482 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -92.91 -2.58 55.7 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.195 -0.457 . . . . 1.55 111.889 -171.29 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 31.0 p -106.7 2.21 25.61 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.763 -0.375 . . . . 0.68999999999999995 111.832 178.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' 2062 ' ' ASP . 35.4 m -92.68 -174.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 110.326 -0.249 . . . . 0.81999999999999995 110.326 176.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -91.25 114.13 60.65 Favored Pre-proline 0 C--O 1.24 0.597 0 CA-C-O 121.02 0.438 . . . . 0.78000000000000003 111.389 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' 2065 ' ' VAL . 53.8 Cg_endo -101.06 108.06 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 123.362 2.708 . . . . 0.45000000000000001 111.296 166.46 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 23.2 p -149.25 -177.2 5.7 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.93 0.395 . . . . 0.69999999999999996 110.665 -177.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.632 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 9.3 m-30 -101.56 142.85 32.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.832 -1.173 . . . . 1.1599999999999999 107.832 166.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -64.18 -15.78 60.57 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.421 0.451 . . . . 2.0899999999999999 111.248 -172.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -84.4 2.02 42.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.039 -0.528 . . . . 2.1499999999999999 110.902 176.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 85.58 23.47 46.73 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.111 -0.566 . . . . 0.63 112.706 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.7 p -110.64 164.38 12.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.974 0.416 . . . . 0.89000000000000001 111.37 -177.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2074 ' ' LYS . . . . . 0.602 ' O ' HG22 ' A' 2086 ' ' ILE . 47.9 mmtm -113.32 -44.78 3.2 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.684 -0.689 . . . . 1.1299999999999999 110.696 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.763 ' HG3' HG22 ' A' 2085 ' ' THR . 4.6 mp0 -119.97 138.11 53.67 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.772 -0.455 . . . . 2.0800000000000001 109.772 173.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.5 OUTLIER -127.71 99.25 5.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.15 -0.477 . . . . 1.48 109.736 178.258 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 48.7 m -110.69 121.77 46.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.11 0.481 . . . . 0.63 110.476 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 88.0 mt -126.84 126.17 24.39 Favored Pre-proline 0 C--N 1.315 -0.91 0 N-CA-C 108.521 -0.918 . . . . 1.6200000000000001 108.521 174.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -47.14 109.67 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.295 2.664 . . . . 0.97999999999999998 113.257 -175.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2080 ' ' GLY . . . . . 0.488 ' O ' ' HD2' ' A' 2100 ' ' PHE . . . 93.9 -12.95 68.44 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.706 -0.679 . . . . 0.93999999999999995 113.009 177.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.516 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 0.0 OUTLIER -94.7 -32.47 13.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 117.122 0.461 . . . . 2.02 110.661 -175.96 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.7 -155.24 16.28 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.811 -0.709 . . . . 0.5 111.9 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.555 ' HA ' ' O ' ' A' 2076 ' ' LYS . 55.8 m -155.28 138.92 16.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.698 0.761 . . . . 0.48999999999999999 111.011 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.632 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.2 m-85 -109.01 121.69 45.68 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.774 -1.565 . . . . 1.4399999999999999 106.774 170.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.763 HG22 ' HG3' ' A' 2075 ' ' GLU . 16.8 p -118.84 133.56 55.75 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.721 0.296 . . . . 0.63 111.584 -175.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.602 HG22 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -113.02 136.9 47.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.278 -0.419 . . . . 1.1799999999999999 110.186 176.16 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 18.6 m -122.71 144.82 43.55 Favored Pre-proline 0 C--N 1.319 -0.732 0 N-CA-C 109.975 -0.38 . . . . 0.80000000000000004 109.975 173.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -62.18 0.01 1.52 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.542 2.828 . . . . 0.96999999999999997 114.014 -172.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 37.2 t70 -68.04 -21.29 65.02 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.411 -0.589 . . . . 2.29 109.411 173.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.33 5.18 28.5 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.374 -0.83 . . . . 0.82999999999999996 111.715 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2091 ' ' THR . . . . . 0.505 ' HA ' ' NH2' ' A' 2111 ' ' ARG . 4.9 t -114.23 143.34 45.0 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.185 0.517 . . . . 1.51 110.945 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.407 HG22 ' CG1' ' A' 2086 ' ' ILE . 27.6 t -139.32 137.52 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.529 -0.759 . . . . 1.1799999999999999 109.309 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 7.2 t -107.1 121.23 44.08 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.206 0.527 . . . . 1.46 110.166 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -87.53 97.86 11.08 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.087 -1.079 . . . . 1.27 108.087 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2095 ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' 2083 ' ' THR . 43.9 m -117.63 99.09 52.27 Favored Pre-proline 0 N--CA 1.453 -0.31 0 N-CA-C 112.501 0.556 . . . . 0.57999999999999996 112.501 -174.063 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -86.17 143.17 7.75 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.567 2.178 . . . . 0.97999999999999998 110.231 166.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 17.1 t70 -61.34 135.01 57.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.955 0.407 . . . . 2.7200000000000002 110.499 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 58.9 mttp -72.24 -14.22 61.72 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.618 -0.719 . . . . 4.8099999999999996 111.913 -172.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -120.16 23.41 10.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.998 -0.371 . . . . 4.4199999999999999 109.998 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2100 ' ' PHE . . . . . 0.488 ' HD2' ' O ' ' A' 2080 ' ' GLY . 64.1 t80 -72.64 124.88 26.18 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-O 121.152 0.501 . . . . 2.3599999999999999 110.311 179.499 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.3 p -74.89 99.91 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.226 -0.897 . . . . 2.6800000000000002 110.478 177.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 102.56 -147.96 17.29 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.803 -0.635 . . . . 3.8399999999999999 112.039 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 48.7 mttp -111.02 134.4 21.03 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 120.613 0.245 . . . . 6.7800000000000002 110.876 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -43.72 149.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 124.409 3.406 . . . . 2.4300000000000002 114.035 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.444 ' H ' ' HG3' ' A' 2081 ' ' GLN . 1.4 m-20 -56.68 153.94 19.74 Favored Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 114.962 -1.017 . . . . 2.3300000000000001 111.898 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -53.22 113.16 1.15 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 124.235 3.29 . . . . 1.03 114.598 -174.596 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2107 ' ' VAL . . . . . 0.497 HG21 ' HG3' ' A' 2076 ' ' LYS . 4.2 p -160.66 119.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.092 -0.958 . . . . 0.59999999999999998 109.776 172.05 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.486 ' HA ' ' O ' ' A' 2121 ' ' ALA . 62.3 m -95.87 118.29 32.24 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.453 0.644 . . . . 0.37 110.17 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' 2120 ' ' THR . 6.1 t -91.65 136.36 24.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.259 -0.882 . . . . 0.76000000000000001 108.989 -178.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.583 ' HD2' ' C ' ' A' 2110 ' ' LYS . 0.0 OUTLIER -139.97 108.86 5.99 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.156 0.503 . . . . 1.6299999999999999 112.188 -173.089 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.505 ' NH2' ' HA ' ' A' 2091 ' ' THR . 4.2 ptm180 -142.4 132.76 24.95 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.719 -0.845 . . . . 3.4700000000000002 108.719 170.347 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.521 ' O ' HG21 ' A' 2065 ' ' VAL . 33.0 m -99.12 152.82 4.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.587 -0.445 . . . . 0.40000000000000002 111.695 -174.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -92.48 -170.68 2.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.969 -0.56 . . . . 1.46 110.15 178.113 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -64.72 -34.05 77.4 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.585 0.231 . . . . 1.72 111.255 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2115 ' ' ASN . . . . . 0.433 HD22 HG11 ' A' 2059 ' ' VAL . 37.0 m-80 -69.66 -30.13 67.74 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 1.8400000000000001 110.568 175.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 109.97 7.43 27.14 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.964 -0.636 . . . . 0.44 111.978 -178.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.434 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 87.9 m -81.97 118.73 73.15 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 110.142 -0.318 . . . . 0.56999999999999995 110.142 178.678 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' 2112 ' ' VAL . 3.3 Cg_exo -78.88 116.63 3.77 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 122.21 1.94 . . . . 0.60999999999999999 112.307 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 6.8 m -74.85 108.88 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.423 0 N-CA-C 107.89 -1.152 . . . . 0.59999999999999998 107.89 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' 2109 ' ' VAL . 68.5 p -123.3 168.48 12.43 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.662 -1.154 . . . . 0.67000000000000004 111.006 -170.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.04 126.36 39.31 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.083 -1.08 . . . . 0.72999999999999998 108.083 168.328 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 37.6 m -94.66 98.71 10.99 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.147 -0.686 . . . . 2.1899999999999999 109.147 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -120.57 123.95 44.11 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.574 0.702 . . . . 2.8100000000000001 111.796 -176.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A 2124 ' ' SER . . . . . 0.598 ' OG ' ' HD2' ' A' 2125 ' ' PRO . 6.6 t -132.87 162.16 59.18 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 114.459 -1.246 . . . . 2.0600000000000001 108.391 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.598 ' HD2' ' OG ' ' A' 2124 ' ' SER . 49.2 Cg_endo . . . . . 0 C--N 1.353 0.776 0 C-N-CA 122.584 2.189 . . . . 2.1600000000000001 112.838 176.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.458 -0.042 0 CA-C-O 120.816 0.341 . . . . 2.4199999999999999 111.343 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -76.88 -21.44 12.45 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.341 2.028 . . . . 1.72 111.915 176.03 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.6 mp -85.14 -22.4 28.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.874 -0.603 . . . . 2.3399999999999999 110.048 177.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.8 t -126.17 83.32 63.82 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 108.711 -0.848 . . . . 0.87 108.711 178.162 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2060 ' ' PRO . . . . . 0.495 ' O ' ' HG3' ' A' 2114 ' ' LYS . 33.3 Cg_exo -58.53 141.59 97.46 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.625 2.217 . . . . 1.04 112.196 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.1 mm -63.12 135.79 26.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.693 -0.685 . . . . 0.77000000000000002 110.112 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.421 ' HB3' HG22 ' A' 2065 ' ' VAL . 11.7 t70 -70.51 128.69 37.02 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.28 -0.418 . . . . 1.4199999999999999 110.064 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -89.38 0.19 57.01 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.112 -0.494 . . . . 1.55 112.005 -171.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -105.11 -12.76 15.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.955 0.407 . . . . 0.68999999999999995 110.972 178.329 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' A' 2067 ' ' PRO . 33.3 m -91.72 -174.59 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.744 -0.465 . . . . 0.81999999999999995 109.744 175.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -92.8 113.53 59.94 Favored Pre-proline 0 C--O 1.245 0.829 0 CA-C-O 121.268 0.556 . . . . 0.78000000000000003 111.354 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.548 ' HA ' ' CB ' ' A' 2111 ' ' ARG . 51.0 Cg_endo -100.71 106.93 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.658 0 C-N-CA 123.096 2.531 . . . . 0.45000000000000001 111.45 167.13 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 16.7 p -138.88 178.88 6.83 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.072 0.463 . . . . 0.69999999999999996 111.176 -178.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 97.2 m-85 -103.0 159.45 15.5 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.71 -0.848 . . . . 1.1599999999999999 108.71 168.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2070 ' ' GLU . . . . . 0.414 ' HB2' ' O ' ' A' 2108 ' ' THR . 1.8 tm-20 -51.13 -44.13 61.32 Favored 'General case' 0 N--CA 1.468 0.474 0 O-C-N 123.755 0.66 . . . . 2.0899999999999999 112.203 -168.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 36.9 t70 -81.19 6.04 15.15 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.393 0.616 . . . . 2.1499999999999999 111.109 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 89.87 11.76 63.12 Favored Glycine 0 N--CA 1.45 -0.381 0 N-CA-C 111.675 -0.57 . . . . 0.63 111.675 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2073 ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 4.2 m -74.57 161.58 29.59 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.797 0.332 . . . . 0.89000000000000001 110.875 -173.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -120.37 -21.2 6.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 1.1299999999999999 110.883 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.0 tt0 -156.43 129.91 8.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.983 0.42 . . . . 2.0800000000000001 110.108 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.44 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.1 OUTLIER -126.78 100.59 6.25 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.972 -0.558 . . . . 1.48 110.816 178.029 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 32.2 m -96.34 123.7 40.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.077 -0.511 . . . . 0.63 110.287 174.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.564 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 2.7 mp -126.36 122.55 23.97 Favored Pre-proline 0 C--N 1.314 -0.936 0 N-CA-C 109.206 -0.664 . . . . 1.6200000000000001 109.206 177.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2079 ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' 2078 ' ' ILE . 68.9 Cg_exo -51.36 109.99 0.37 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.329 2.686 . . . . 0.97999999999999998 113.274 -175.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 94.46 -6.65 71.35 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.93999999999999995 112.757 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.564 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.6 tt0 -109.1 -33.39 6.9 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.123 0.487 . . . . 2.02 110.584 -175.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.77 -155.18 16.29 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.628 -0.796 . . . . 0.5 112.552 176.248 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.454 HG22 HG23 ' A' 2085 ' ' THR . 32.1 m -150.72 137.4 18.92 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.32 0.581 . . . . 0.48999999999999999 110.533 178.136 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.3 OUTLIER -111.51 121.88 46.36 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.481 -1.303 . . . . 1.4399999999999999 107.481 170.784 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.454 HG23 HG22 ' A' 2083 ' ' THR . 2.6 p -118.88 158.15 26.23 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 112.828 0.677 . . . . 0.63 112.828 -171.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.558 ' HB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -159.33 124.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 115.009 -0.996 . . . . 1.1799999999999999 109.57 172.223 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A 2087 ' ' VAL . . . . . 0.599 HG22 ' OG1' ' A' 2091 ' ' THR . 9.9 m -107.58 157.52 35.59 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.871 -0.788 . . . . 0.80000000000000004 108.871 173.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.99 0.52 1.2 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 123.392 2.728 . . . . 0.96999999999999997 114.299 -171.258 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2089 ' ' ASP . . . . . 0.44 ' H ' HG23 ' A' 2087 ' ' VAL . 12.9 m-20 -82.45 -12.81 57.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 2.29 110.099 174.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 97.08 32.57 6.38 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.948 -0.644 . . . . 0.82999999999999996 112.338 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2091 ' ' THR . . . . . 0.599 ' OG1' HG22 ' A' 2087 ' ' VAL . 63.7 p -87.86 136.06 33.12 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.261 -0.274 . . . . 1.51 110.261 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.481 HG13 HH11 ' A' 2111 ' ' ARG . 48.9 t -136.78 126.38 38.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 120.891 0.376 . . . . 1.1799999999999999 111.55 -177.536 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.7 t -146.92 109.72 4.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.529 0.681 . . . . 1.46 110.382 171.287 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2094 ' ' PHE . . . . . 0.67 ' CE2' HG11 ' A' 2109 ' ' VAL . 13.6 m-30 -84.91 101.99 12.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.373 -0.973 . . . . 1.27 108.373 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 2.1 m -110.13 88.62 7.28 Favored Pre-proline 0 N--CA 1.452 -0.356 0 CA-C-O 120.9 0.381 . . . . 0.57999999999999996 110.812 -177.503 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2096 ' ' PRO . . . . . 0.562 ' HD3' ' O ' ' A' 2094 ' ' PHE . 93.3 Cg_endo -92.27 166.97 2.95 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 123.436 2.758 . . . . 0.97999999999999998 112.547 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 13.0 t70 -131.8 110.17 10.65 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.401 -0.592 . . . . 2.7200000000000002 109.401 171.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2098 ' ' LYS . . . . . 0.48 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.2 OUTLIER -88.59 18.77 4.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.816 0.341 . . . . 4.8099999999999996 111.381 -176.403 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -119.86 7.13 10.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.076 0.465 . . . . 4.4199999999999999 110.158 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 53.3 t80 -83.57 113.14 20.61 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.635 -0.711 . . . . 2.3599999999999999 111.047 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.5 t -113.46 98.78 7.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.947 -0.57 . . . . 2.6800000000000002 109.664 175.503 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 172.17 43.3 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.711 -0.677 . . . . 3.8399999999999999 111.512 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 37.1 ttpt 60.45 83.49 0.21 Allowed Pre-proline 0 CA--C 1.531 0.226 0 C-N-CA 123.425 0.69 . . . . 6.7800000000000002 111.441 -178.327 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2104 ' ' PRO . . . . . 0.432 ' HG2' ' O ' ' A' 2124 ' ' SER . 14.1 Cg_endo -58.9 134.24 58.86 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.186 1.924 . . . . 2.4300000000000002 111.042 173.695 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.4 t70 -60.85 124.99 82.19 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.092 -0.504 . . . . 2.3300000000000001 110.889 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.462 ' HA ' ' O ' ' A' 2123 ' ' TYR . 27.2 Cg_endo -64.1 95.85 0.21 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.728 2.286 . . . . 1.03 112.048 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.9 p -128.58 160.83 38.51 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.386 -0.824 . . . . 0.59999999999999998 109.499 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' 2070 ' ' GLU . 93.8 m -140.75 131.19 25.27 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.356 -0.609 . . . . 0.37 109.356 174.32 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.67 HG11 ' CE2' ' A' 2094 ' ' PHE . 6.0 t -92.04 137.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.773 -0.825 . . . . 0.76000000000000001 108.773 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -144.92 108.22 4.59 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.974 -0.38 . . . . 1.6299999999999999 109.974 -178.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.558 HH12 ' HB ' ' A' 2086 ' ' ILE . 15.0 ptp180 -159.6 156.55 28.17 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.162 -0.472 . . . . 3.4700000000000002 109.751 175.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.455 HG23 HG21 ' A' 2065 ' ' VAL . 34.7 m -109.41 140.65 27.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 C-N-CA 120.202 -0.599 . . . . 0.40000000000000002 111.577 -176.007 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.601 ' OD2' ' HB ' ' A' 2117 ' ' THR . 2.5 p30 -90.04 -169.04 2.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.62 -0.718 . . . . 1.46 111.121 178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2114 ' ' LYS . . . . . 0.495 ' HG3' ' O ' ' A' 2060 ' ' PRO . 99.4 mttt -59.47 -29.78 68.06 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.184 0.439 . . . . 1.72 112.184 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -86.05 -11.32 53.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 1.8400000000000001 110.738 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.14 13.03 59.39 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.048 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.601 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 73.5 m -78.81 128.3 77.29 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-O 120.569 0.223 . . . . 0.56999999999999995 110.549 178.208 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 2.7 Cg_exo -75.61 99.0 1.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.322 2.014 . . . . 0.60999999999999999 111.814 177.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 17.2 m -75.39 109.41 8.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.535 0.683 . . . . 0.59999999999999998 109.466 175.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' 2109 ' ' VAL . 80.3 p -120.33 167.26 12.49 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 115.319 -0.855 . . . . 0.67000000000000004 110.898 -175.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.461 ' HB3' HG23 ' A' 2109 ' ' VAL . . . -140.56 128.58 22.07 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.875 -0.787 . . . . 0.72999999999999998 108.875 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 10.9 p -92.1 98.87 11.81 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.236 0.541 . . . . 2.1899999999999999 110.664 -177.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.0 OUTLIER -115.5 123.41 48.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.784 -0.644 . . . . 2.8100000000000001 110.959 -178.43 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A 2124 ' ' SER . . . . . 0.432 ' O ' ' HG2' ' A' 2104 ' ' PRO . 68.8 m -157.35 163.73 23.93 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.515 -0.766 . . . . 2.0600000000000001 109.04 178.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 93.0 Cg_exo . . . . . 0 C--N 1.346 0.427 0 C-N-CA 122.659 2.239 . . . . 2.1600000000000001 112.523 177.965 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 CA--C 1.519 -0.247 0 N-CA-C 110.184 -0.302 . . . . 2.4199999999999999 110.184 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -68.43 -9.41 25.91 Favored 'Trans proline' 0 CA--C 1.528 0.218 0 C-N-CA 122.192 1.928 . . . . 1.72 111.862 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.5 mp -84.78 -18.85 33.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.923 -0.58 . . . . 2.3399999999999999 110.11 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.471 HG11 HD22 ' A' 2115 ' ' ASN . 4.6 t -138.84 89.86 12.74 Favored Pre-proline 0 CA--C 1.514 -0.41 0 N-CA-C 109.322 -0.621 . . . . 0.87 109.322 -177.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -53.25 120.68 8.13 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.315 2.01 . . . . 1.04 111.619 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.4 mm -49.77 134.82 8.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.152 -0.931 . . . . 0.77000000000000002 111.679 -176.15 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.552 ' O ' HG22 ' A' 2065 ' ' VAL . 14.6 t70 -76.65 130.26 37.54 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.437 -0.802 . . . . 1.4199999999999999 110.691 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -87.43 -8.29 56.69 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.238 0.458 . . . . 1.55 112.238 -174.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 29.7 p -101.75 0.79 36.47 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 120.5 -0.48 . . . . 0.68999999999999995 111.883 -178.291 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.595 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.6 m -92.87 -174.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.663 -0.244 . . . . 0.81999999999999995 110.507 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -97.35 107.89 41.36 Favored Pre-proline 0 C--O 1.24 0.598 0 CA-C-O 121.364 0.602 . . . . 0.78000000000000003 111.468 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.595 ' HD3' ' O ' ' A' 2065 ' ' VAL . 5.8 Cg_endo -93.71 108.75 0.17 Allowed 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.518 2.812 . . . . 0.45000000000000001 110.88 167.611 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.512 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.3 p -148.84 146.1 27.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.912 0.387 . . . . 0.69999999999999996 110.64 -177.187 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.486 ' CD2' ' N ' ' A' 2069 ' ' PHE . 2.4 m-30 -71.64 148.32 46.66 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.44 -1.319 . . . . 1.1599999999999999 107.44 176.071 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -61.08 -19.53 61.55 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.406 0.521 . . . . 2.0899999999999999 112.406 -165.193 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -92.03 1.33 57.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.621 0.248 . . . . 2.1499999999999999 111.131 178.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 87.59 25.21 33.5 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.86 -0.686 . . . . 0.63 112.018 -176.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 19.5 m -95.22 152.33 18.46 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.89000000000000001 110.511 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -111.62 -22.47 11.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.084 -0.507 . . . . 1.1299999999999999 110.58 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' 2084 ' ' TYR . 3.0 tt0 -144.35 144.43 31.44 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.113 0.482 . . . . 2.0800000000000001 110.243 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.425 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.4 OUTLIER -139.59 108.14 5.88 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.401 -0.818 . . . . 1.48 109.505 179.854 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 19.2 m -118.64 133.23 56.01 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.189 0.518 . . . . 0.63 111.493 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.549 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 4.2 mp -136.39 123.03 14.01 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 108.106 -1.072 . . . . 1.6200000000000001 108.106 172.276 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -52.29 109.48 0.34 Allowed 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.669 2.246 . . . . 0.97999999999999998 112.458 -178.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.65 -22.23 28.73 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.736 -0.665 . . . . 0.93999999999999995 112.383 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.549 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 52.7 tt0 -96.06 -31.52 12.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.085 0.469 . . . . 2.02 110.463 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.49 -153.64 17.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.837 -0.697 . . . . 0.5 112.141 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.49 HG22 HG23 ' A' 2085 ' ' THR . 43.0 m -150.0 144.96 26.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.65 0.738 . . . . 0.48999999999999999 110.824 178.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.528 ' O ' ' HA ' ' A' 2075 ' ' GLU . 7.6 m-85 -120.15 125.01 47.17 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 107.236 -1.394 . . . . 1.4399999999999999 107.236 172.625 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.49 HG23 HG22 ' A' 2083 ' ' THR . 17.3 p -129.07 134.75 48.23 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.544 0.572 . . . . 0.63 112.544 -174.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.563 HD13 HG22 ' A' 2092 ' ' VAL . 0.7 OUTLIER -130.82 123.94 55.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.562 -0.744 . . . . 1.1799999999999999 110.142 170.155 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 19.2 m -112.15 151.58 43.75 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.003 -0.74 . . . . 0.80000000000000004 109.003 172.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.76 -6.27 1.06 Allowed 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.057 3.171 . . . . 0.96999999999999997 114.922 -168.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 27.1 t70 -66.85 -24.07 66.1 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.126 0.489 . . . . 2.29 110.179 175.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 104.11 20.07 10.94 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.738 -0.665 . . . . 0.82999999999999996 112.223 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.8 t -110.42 126.38 54.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.962 0.41 . . . . 1.51 110.64 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.563 HG22 HD13 ' A' 2086 ' ' ILE . 7.6 t -133.08 137.42 53.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.016 -0.538 . . . . 1.1799999999999999 110.384 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.3 t -119.36 118.29 30.79 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.042 0.448 . . . . 1.46 110.19 173.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 9.4 m-30 -85.24 97.21 9.8 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.663 -0.866 . . . . 1.27 108.663 173.442 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 13.3 m -116.49 87.05 19.44 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.994 0.426 . . . . 0.57999999999999996 110.76 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -92.44 169.69 2.64 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.327 2.685 . . . . 0.97999999999999998 112.42 176.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.9 t70 -118.35 106.51 12.83 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.872 -0.788 . . . . 2.7200000000000002 108.872 171.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 93.2 mttt -69.77 -10.1 57.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.961 -0.563 . . . . 4.8099999999999996 112.194 -171.523 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -110.46 8.88 23.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.703 0.287 . . . . 4.4199999999999999 111.111 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 44.9 t80 -89.63 76.98 7.25 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.2 0.524 . . . . 2.3599999999999999 110.904 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 4.2 p -103.96 124.98 58.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.216 0.531 . . . . 2.6800000000000002 110.083 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 164.63 -81.9 0.11 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.047 -0.821 . . . . 3.8399999999999999 111.047 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 22.7 tptm -140.42 76.72 24.99 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 120.935 0.398 . . . . 6.7800000000000002 110.707 175.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -80.53 169.57 16.85 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.16 2.573 . . . . 2.4300000000000002 111.445 173.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.3 t70 -103.06 125.3 35.64 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 116.544 -0.298 . . . . 2.3300000000000001 110.198 178.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' 2123 ' ' TYR . 24.7 Cg_endo -62.96 103.5 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.734 2.29 . . . . 1.03 111.928 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2107 ' ' VAL . . . . . 0.425 HG11 ' HG2' ' A' 2076 ' ' LYS . 7.7 p -141.37 133.78 29.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.137 -0.483 . . . . 0.59999999999999998 111.049 -177.107 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.3 m -102.5 108.71 20.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.652 -0.704 . . . . 0.37 109.906 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' 2120 ' ' THR . 8.5 t -91.09 123.09 43.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.772 -0.825 . . . . 0.76000000000000001 108.772 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.512 ' HB3' ' O ' ' A' 2068 ' ' THR . 1.7 tmmt? -129.59 149.6 51.28 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.402 0.62 . . . . 1.6299999999999999 112.203 -169.432 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.51 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.3 ptt180 -166.91 138.2 3.28 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.97 -1.014 . . . . 3.4700000000000002 108.292 165.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.526 ' O ' HG21 ' A' 2065 ' ' VAL . 27.1 m -98.61 148.88 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 C-N-CA 120.357 -0.537 . . . . 0.40000000000000002 110.871 -175.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.433 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.7 p-10 -94.12 -168.7 1.91 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.933 -0.576 . . . . 1.46 110.448 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.5 mttm -62.88 -32.34 73.57 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.702 0.287 . . . . 1.72 111.393 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2115 ' ' ASN . . . . . 0.471 HD22 HG11 ' A' 2059 ' ' VAL . 41.1 m-80 -77.54 -14.96 59.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.955 0.407 . . . . 1.8400000000000001 110.599 176.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.87 12.47 59.13 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.333 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 27.8 m -85.83 121.26 73.15 Favored Pre-proline 0 C--N 1.324 -0.533 0 N-CA-C 110.106 -0.331 . . . . 0.56999999999999995 110.106 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 3.1 Cg_exo -74.74 107.86 2.57 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.261 1.974 . . . . 0.60999999999999999 112.653 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2119 ' ' VAL . . . . . 0.424 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 15.6 m -74.78 112.03 11.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 107.737 -1.208 . . . . 0.59999999999999998 107.737 169.141 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.616 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.7 p -127.41 159.32 34.83 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.636 -0.711 . . . . 0.67000000000000004 112.192 -169.627 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.46 127.63 42.86 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.8 -1.185 . . . . 0.72999999999999998 107.8 169.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 12.5 p -115.67 99.53 7.39 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.23 0.538 . . . . 2.1899999999999999 111.171 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.508 ' O ' ' HA ' ' A' 2106 ' ' PRO . 4.4 m-85 -90.08 151.98 21.36 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.677 -0.692 . . . . 2.8100000000000001 111.099 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2124 ' ' SER . . . . . 0.435 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 33.3 p -148.2 168.01 12.04 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 115.957 -0.565 . . . . 2.0600000000000001 110.551 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' 2124 ' ' SER . 71.3 Cg_exo . . . . . 0 C--N 1.351 0.669 0 C-N-CA 122.574 2.183 . . . . 2.1600000000000001 112.975 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2056 ' ' ASP . . . . . 0.526 ' HB2' ' O ' ' A' 2059 ' ' VAL . 4.1 p-10 . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 121.262 0.553 . . . . 2.4199999999999999 110.812 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2057 ' ' PRO . . . . . 0.408 ' HB2' HD22 ' A' 2058 ' ' LEU . 57.6 Cg_endo -69.0 -53.11 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.375 2.05 . . . . 1.72 112.618 -170.126 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2058 ' ' LEU . . . . . 0.408 HD22 ' HB2' ' A' 2057 ' ' PRO . 3.8 mm? -121.32 19.4 11.4 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.999 -0.371 . . . . 2.3399999999999999 109.999 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.526 ' O ' ' HB2' ' A' 2056 ' ' ASP . 0.0 OUTLIER -131.85 77.52 72.01 Favored Pre-proline 0 N--CA 1.449 -0.523 0 C-N-CA 120.332 -0.547 . . . . 0.87 110.026 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.82 120.99 8.77 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.511 2.141 . . . . 1.04 111.95 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2061 ' ' ILE . . . . . 0.633 HG13 ' NE ' ' A' 2111 ' ' ARG . 47.1 mm -49.94 128.55 6.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.354 -0.839 . . . . 0.77000000000000002 111.846 -178.176 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.489 ' O ' HG22 ' A' 2065 ' ' VAL . 11.1 t70 -66.81 136.8 55.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.746 -0.661 . . . . 1.4199999999999999 110.171 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -88.71 1.19 55.57 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 112.567 0.58 . . . . 1.55 112.567 -171.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 70.1 p -120.29 -0.39 10.44 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.885 0.328 . . . . 0.68999999999999995 111.885 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.676 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.8 m -86.35 -173.13 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.162 -0.31 . . . . 0.81999999999999995 110.162 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -95.65 105.47 20.97 Favored Pre-proline 0 C--O 1.238 0.474 0 CA-C-O 120.966 0.412 . . . . 0.78000000000000003 111.513 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' 2065 ' ' VAL . 33.4 Cg_endo -100.31 106.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 122.898 2.399 . . . . 0.45000000000000001 110.872 167.031 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.51 ' O ' ' HB3' ' A' 2110 ' ' LYS . 18.7 p -141.1 148.27 39.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.223 0.535 . . . . 0.69999999999999996 110.585 -176.118 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.53 ' N ' ' HD1' ' A' 2069 ' ' PHE . 1.3 m-30 -74.58 149.36 40.16 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.416 -0.957 . . . . 1.1599999999999999 108.416 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2070 ' ' GLU . . . . . 0.475 ' CB ' ' HB ' ' A' 2108 ' ' THR . 5.2 tm-20 -50.78 -42.12 57.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.955 0.407 . . . . 2.0899999999999999 110.459 -173.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -71.89 0.79 8.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 115.638 -0.71 . . . . 2.1499999999999999 112.563 -178.152 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 82.92 29.94 33.21 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.572 -0.823 . . . . 0.63 112.001 -176.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 15.7 m -106.75 159.15 16.44 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.849 0.357 . . . . 0.89000000000000001 111.043 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -109.84 -18.8 13.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 1.1299999999999999 110.638 176.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.477 ' HB2' HG22 ' A' 2085 ' ' THR . 6.0 tt0 -148.68 136.69 20.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.146 0.498 . . . . 2.0800000000000001 109.853 173.045 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.408 ' HE2' HD11 ' A' 2078 ' ' ILE . 32.9 tptt -128.29 113.65 15.9 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.541 -0.754 . . . . 1.48 109.183 175.206 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 46.3 m -117.91 124.9 49.4 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 121.482 0.658 . . . . 0.63 110.895 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.595 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 12.3 mt -120.2 120.74 29.89 Favored Pre-proline 0 C--N 1.313 -1.013 0 N-CA-C 107.774 -1.195 . . . . 1.6200000000000001 107.774 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -41.91 108.66 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 123.551 2.834 . . . . 0.97999999999999998 113.806 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.19 -30.48 6.71 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.486 -0.779 . . . . 0.93999999999999995 113.037 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.595 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -74.83 -30.29 61.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.246 0.546 . . . . 2.02 110.172 -174.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 125.82 -171.34 17.67 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.471 -0.871 . . . . 0.5 112.571 175.098 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 38.3 m -140.25 132.29 27.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.534 0.683 . . . . 0.48999999999999999 110.695 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.498 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.6 OUTLIER -106.49 129.82 54.38 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.882 -1.525 . . . . 1.4399999999999999 106.882 169.521 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.477 HG22 ' HB2' ' A' 2075 ' ' GLU . 0.8 OUTLIER -133.06 140.59 47.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.258 0.551 . . . . 0.63 112.438 -175.939 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.538 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -130.27 131.64 65.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.152 -0.931 . . . . 1.1799999999999999 109.672 173.289 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A 2087 ' ' VAL . . . . . 0.401 ' HA ' ' HD3' ' A' 2088 ' ' PRO . 27.7 m -115.33 149.42 42.75 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.727 -0.472 . . . . 0.80000000000000004 109.727 174.527 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2088 ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' 2087 ' ' VAL . 32.2 Cg_exo -59.04 -6.42 3.62 Favored 'Trans proline' 0 C--N 1.349 0.595 0 C-N-CA 123.808 3.005 . . . . 0.96999999999999997 114.147 -170.282 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -70.23 -13.89 62.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.002 0.43 . . . . 2.29 110.206 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 96.9 17.71 31.81 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.929 -0.653 . . . . 0.82999999999999996 112.182 178.521 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 4.8 t -115.52 133.46 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.049 0.452 . . . . 1.51 109.824 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.538 HG13 ' HB ' ' A' 2086 ' ' ILE . 11.6 t -135.12 149.79 29.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.581 . . . . 1.1799999999999999 110.237 -173.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.0 t -136.23 123.74 22.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.287 0.565 . . . . 1.46 110.871 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.6 m-30 -99.13 98.72 9.7 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.193 -0.669 . . . . 1.27 109.193 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 12.0 m -113.96 96.79 42.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.873 0.368 . . . . 0.57999999999999996 111.026 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -89.17 176.35 3.17 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 123.246 2.631 . . . . 0.97999999999999998 112.787 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2097 ' ' ASP . . . . . 0.465 ' HB3' ' HA ' ' A' 2081 ' ' GLN . 6.4 p-10 -71.7 102.02 2.7 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.319 -0.855 . . . . 2.7200000000000002 112.139 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2098 ' ' LYS . . . . . 0.66 ' HD2' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -92.05 -9.76 41.6 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.087 -0.506 . . . . 4.8099999999999996 110.263 173.694 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A 2099 ' ' GLN . . . . . 0.402 ' HG3' ' HG2' ' A' 2098 ' ' LYS . 94.3 mt-30 -120.64 -52.55 2.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.073 -0.512 . . . . 4.4199999999999999 110.299 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.13 145.31 42.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.426 -0.806 . . . . 2.3599999999999999 111.454 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 8.9 p -160.32 143.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 115.655 -0.702 . . . . 2.6800000000000002 109.382 175.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 152.57 -94.07 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.578 -0.82 . . . . 3.8399999999999999 112.453 -178.207 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 63.7 tttp -120.73 89.17 44.75 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-O 120.857 0.36 . . . . 6.7800000000000002 110.507 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.74 139.44 25.03 Favored 'Trans proline' 0 N--CA 1.459 -0.531 0 C-N-CA 122.712 2.275 . . . . 2.4300000000000002 111.097 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.51 ' HB3' HD13 ' A' 2078 ' ' ILE . 32.0 t70 -85.17 130.69 50.97 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 109.555 -0.535 . . . . 2.3300000000000001 109.555 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' 2123 ' ' TYR . 18.0 Cg_endo -60.41 119.55 6.8 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.117 2.544 . . . . 1.03 112.93 -177.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.5 p -159.36 133.64 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.746 -0.661 . . . . 0.59999999999999998 110.372 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' 2121 ' ' ALA . 34.1 m -105.51 119.31 38.79 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.188 0.518 . . . . 0.37 109.718 173.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -95.29 139.04 19.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.863 -0.792 . . . . 0.76000000000000001 108.863 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.51 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.9 tmmm? -140.68 147.65 39.59 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 118.366 0.53 . . . . 1.6299999999999999 111.438 -171.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.633 ' NE ' HG13 ' A' 2061 ' ' ILE . 29.1 ptt180 -168.98 135.28 1.73 Allowed 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.838 -0.801 . . . . 3.4700000000000002 108.838 171.481 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 23.2 m -99.8 149.99 5.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.207 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.436 ' HB3' HD13 ' A' 2061 ' ' ILE . 4.7 p-10 -93.93 -168.92 1.97 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.923 -0.581 . . . . 1.46 110.736 178.732 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.31 -41.78 85.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.19 -0.459 . . . . 1.72 111.929 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -18.74 46.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.869 0.366 . . . . 1.8400000000000001 110.45 -177.335 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 106.14 16.76 14.11 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.543 -0.837 . . . . 0.44 113.641 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.419 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.8 m -83.83 119.26 73.28 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 117.187 0.494 . . . . 0.56999999999999995 110.376 175.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -77.92 102.15 1.55 Allowed 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.369 2.046 . . . . 0.60999999999999999 111.988 177.278 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.7 m -74.88 117.59 19.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 108.545 -0.909 . . . . 0.59999999999999998 108.545 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' 2109 ' ' VAL . 61.2 p -126.25 161.14 28.43 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.524 -0.762 . . . . 0.67000000000000004 111.78 -170.077 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.537 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.09 127.44 41.48 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 107.981 -1.118 . . . . 0.72999999999999998 107.981 169.04 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 21.9 m -116.15 103.93 11.03 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 120.974 0.416 . . . . 2.1899999999999999 110.54 -174.366 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.572 ' O ' ' HA ' ' A' 2106 ' ' PRO . 2.3 m-85 -100.72 131.01 46.83 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 112.048 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 16.1 m -131.77 146.81 63.42 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.135 -0.939 . . . . 2.0600000000000001 109.391 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 CA--C 1.53 0.305 0 C-N-CA 122.815 2.343 . . . . 2.1600000000000001 112.957 -178.278 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 121.114 0.483 . . . . 2.4199999999999999 110.269 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -69.32 -52.82 0.33 Allowed 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.87 2.38 . . . . 1.72 111.862 177.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2058 ' ' LEU . . . . . 0.828 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -68.33 -9.38 47.45 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.423 -0.808 . . . . 2.3399999999999999 112.854 176.677 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.828 HG23 HD13 ' A' 2058 ' ' LEU . 5.7 t -137.72 86.69 18.16 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 109.666 -0.494 . . . . 0.87 109.666 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.41 131.05 43.91 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.378 2.052 . . . . 1.04 111.847 -177.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 43.1 mm -62.86 122.66 14.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.904 -0.589 . . . . 0.77000000000000002 109.935 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' 2065 ' ' VAL . 21.1 t70 -70.46 134.52 47.84 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.236 0.541 . . . . 1.4199999999999999 110.496 -176.431 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -89.3 -2.09 58.32 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.844 -0.616 . . . . 1.55 111.914 -171.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -113.99 -2.67 13.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.829 -0.348 . . . . 0.68999999999999995 111.848 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.59 ' O ' ' HD3' ' A' 2067 ' ' PRO . 26.8 m -81.59 -174.59 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.973 -0.291 . . . . 0.81999999999999995 110.284 177.391 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.11 109.27 51.11 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.211 0.529 . . . . 0.78000000000000003 111.202 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.59 ' HD3' ' O ' ' A' 2065 ' ' VAL . 50.5 Cg_endo -99.57 111.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.518 0 C-N-CA 123.305 2.67 . . . . 0.45000000000000001 110.875 165.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 8.4 p -145.13 -178.98 6.33 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.211 0.529 . . . . 0.69999999999999996 110.758 -176.488 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 39.0 m-85 -102.73 148.25 25.84 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.735 -0.839 . . . . 1.1599999999999999 108.735 168.304 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -59.98 -24.23 64.27 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.962 0.789 . . . . 2.0899999999999999 111.593 -172.165 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -86.05 -3.45 58.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.309 -0.405 . . . . 2.1499999999999999 110.858 178.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.57 29.88 12.97 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.147 -0.549 . . . . 0.63 113.066 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 26.3 p -110.61 179.15 4.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.032 0.416 . . . . 0.89000000000000001 111.276 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2074 ' ' LYS . . . . . 0.411 ' O ' HG22 ' A' 2086 ' ' ILE . 34.6 mmtp -124.78 -4.8 7.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-O 120.957 0.408 . . . . 1.1299999999999999 111.159 -178.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -159.56 132.32 6.76 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.457 -0.571 . . . . 2.0800000000000001 109.457 169.556 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.457 ' HA ' ' HD2' ' A' 2076 ' ' LYS . 3.7 mmmm -120.01 100.89 7.48 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.968 -0.56 . . . . 1.48 110.306 174.072 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 89.5 m -97.51 111.57 23.78 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.876 -0.602 . . . . 0.63 110.242 173.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.469 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 96.6 mt -110.8 117.26 50.83 Favored Pre-proline 0 C--N 1.31 -1.113 0 N-CA-C 108.74 -0.837 . . . . 1.6200000000000001 108.74 175.483 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -46.37 112.52 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.501 2.801 . . . . 0.97999999999999998 113.574 -174.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 87.74 -11.09 67.55 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.783 -0.644 . . . . 0.93999999999999995 112.795 177.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.469 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -101.19 -31.88 10.8 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.22 0.533 . . . . 2.02 110.296 -174.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 131.63 -170.42 21.58 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.45 -0.881 . . . . 0.5 113.095 173.208 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.536 ' O ' ' HB ' ' A' 2095 ' ' THR . 86.6 m -144.38 136.58 26.37 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.476 -0.564 . . . . 0.48999999999999999 109.476 177.586 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -117.77 126.86 53.23 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.493 -1.299 . . . . 1.4399999999999999 107.493 174.189 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 11.9 p -120.38 127.43 52.28 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.822 -0.351 . . . . 0.63 111.709 -175.258 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.481 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -108.08 135.44 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.955 -0.566 . . . . 1.1799999999999999 109.864 175.58 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 26.7 m -122.22 150.69 57.48 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 109.41 -0.589 . . . . 0.80000000000000004 109.41 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 34.6 Cg_exo -60.0 -1.28 1.17 Allowed 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.737 2.958 . . . . 0.96999999999999997 113.792 -174.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2089 ' ' ASP . . . . . 0.423 ' HB3' HG22 ' A' 2091 ' ' THR . 16.8 t70 -66.4 -20.17 65.99 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.267 0.556 . . . . 2.29 109.865 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 99.49 14.79 34.1 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.245 -0.742 . . . . 0.82999999999999996 111.245 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2091 ' ' THR . . . . . 0.423 HG22 ' HB3' ' A' 2089 ' ' ASP . 8.8 t -120.31 146.61 45.95 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.312 -0.444 . . . . 1.51 110.376 -177.19 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 21.5 t -132.82 138.56 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.353 -0.61 . . . . 1.1799999999999999 109.353 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 51.6 m -97.76 109.98 22.63 Favored 'General case' 0 N--CA 1.439 -0.98 0 CA-C-O 120.789 0.328 . . . . 1.46 110.251 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 7.8 m-30 -86.81 98.41 11.17 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.64 -0.504 . . . . 1.27 109.64 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2095 ' ' THR . . . . . 0.536 ' HB ' ' O ' ' A' 2083 ' ' THR . 58.4 m -109.4 99.11 35.37 Favored Pre-proline 0 C--O 1.234 0.241 0 CA-C-O 120.942 0.401 . . . . 0.57999999999999996 110.524 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -88.27 162.15 6.96 Favored 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 123.346 2.697 . . . . 0.97999999999999998 113.966 -174.2 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2097 ' ' ASP . . . . . 0.462 ' HB2' ' CB ' ' A' 2100 ' ' PHE . 10.4 p-10 -72.46 48.31 0.19 Allowed 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.091 -0.959 . . . . 2.7200000000000002 111.776 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -70.63 -10.01 58.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.079 0.466 . . . . 4.8099999999999996 111.167 -175.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -116.65 24.44 11.29 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.117 -0.492 . . . . 4.4199999999999999 110.753 178.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2100 ' ' PHE . . . . . 0.462 ' CB ' ' HB2' ' A' 2097 ' ' ASP . 63.7 t80 -113.8 142.2 46.36 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.156 0.503 . . . . 2.3599999999999999 111.762 -173.4 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 74.3 t -132.26 105.01 8.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.633 -0.712 . . . . 2.6800000000000002 110.19 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.29 -99.46 0.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 N-CA-C 111.279 -0.729 . . . . 3.8399999999999999 111.279 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.18 120.51 0.89 Allowed Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 109.715 -0.476 . . . . 6.7800000000000002 109.715 170.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.52 147.66 22.63 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.73 2.287 . . . . 2.4300000000000002 112.162 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 18.8 m-20 -80.46 147.02 62.78 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.029 -0.532 . . . . 2.3300000000000001 109.94 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.467 ' HA ' ' O ' ' A' 2123 ' ' TYR . 45.9 Cg_endo -68.04 128.95 18.51 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.147 2.565 . . . . 1.03 113.908 -171.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 5.5 p -158.08 160.0 2.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.38 -0.827 . . . . 0.59999999999999998 109.169 177.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 26.5 m -141.25 122.35 14.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.115 0.483 . . . . 0.37 110.415 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 5.2 t -92.22 133.47 33.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 108.922 -0.77 . . . . 0.76000000000000001 108.922 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -125.84 109.63 12.74 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 120.683 0.278 . . . . 1.6299999999999999 111.387 -169.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' 2119 ' ' VAL . 30.8 ptt180 -147.3 135.4 21.46 Favored 'General case' 0 C--N 1.317 -0.818 0 O-C-N 121.797 -0.565 . . . . 3.4700000000000002 110.133 168.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.498 ' O ' HG21 ' A' 2065 ' ' VAL . 34.2 m -99.09 154.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 120.998 0.428 . . . . 0.40000000000000002 110.758 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.546 ' OD2' ' HB ' ' A' 2117 ' ' THR . 10.1 p30 -94.38 -169.59 2.08 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.81 -0.632 . . . . 1.46 110.778 178.139 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.7 mttm -65.06 -22.85 67.03 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.15 0.426 . . . . 1.72 112.15 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -90.5 -19.01 24.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.054 0.455 . . . . 1.8400000000000001 110.235 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 102.94 15.13 24.93 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.662 -0.699 . . . . 0.44 111.962 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.546 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 24.1 m -91.62 119.63 68.44 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 120.805 0.336 . . . . 0.56999999999999995 110.221 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' 2117 ' ' THR . 8.2 Cg_exo -72.68 107.34 2.3 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.46 2.106 . . . . 0.60999999999999999 113.241 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2119 ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.95 109.25 9.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 108.088 -1.078 . . . . 0.59999999999999998 108.088 165.008 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A 2120 ' ' THR . . . . . . . . . . . . . 75.0 p -125.14 179.5 5.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.105 -0.952 . . . . 0.67000000000000004 110.553 -171.034 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.61 127.2 41.8 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.606 -0.887 . . . . 0.72999999999999998 108.606 170.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 30.9 p -93.39 101.67 13.9 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.877 -0.601 . . . . 2.1899999999999999 109.898 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' 2106 ' ' PRO . 5.4 m-85 -120.25 122.96 42.04 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.633 0.73 . . . . 2.8100000000000001 112.17 -175.26 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 46.9 p -152.42 158.18 33.5 Favored Pre-proline 0 C--N 1.321 -0.642 0 CA-C-N 114.478 -1.237 . . . . 2.0600000000000001 108.859 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo . . . . . 0 C--N 1.346 0.41 0 C-N-CA 122.474 2.116 . . . . 2.1600000000000001 112.794 -179.428 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 6.9 t70 . . . . . 0 N--CA 1.452 -0.364 0 N-CA-C 110.106 -0.331 . . . . 2.4199999999999999 110.106 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.34 -20.31 42.68 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.585 2.19 . . . . 1.72 112.596 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.8 mp -100.29 -26.78 13.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.795 0.331 . . . . 2.3399999999999999 110.301 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 4.6 t -116.52 82.43 12.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.186 -0.461 . . . . 0.87 109.818 178.425 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.44 120.1 7.25 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.374 2.049 . . . . 1.04 111.559 179.089 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.7 mm -49.9 131.21 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.522 -0.763 . . . . 0.77000000000000002 110.908 179.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' 2065 ' ' VAL . 10.6 t70 -69.25 135.1 50.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.458 -0.792 . . . . 1.4199999999999999 110.588 -176.017 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -97.49 2.96 50.83 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.987 0.366 . . . . 1.55 111.987 -173.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.2 p -109.74 3.32 20.75 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.08 0.943 . . . . 0.68999999999999995 108.97 173.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.709 ' O ' ' HD3' ' A' 2067 ' ' PRO . 1.0 OUTLIER -91.29 165.22 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 CA-C-N 114.041 -1.436 . . . . 0.81999999999999995 110.108 -178.807 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.37 108.98 9.85 Favored Pre-proline 0 C--O 1.24 0.553 0 CA-C-O 120.697 0.284 . . . . 0.78000000000000003 111.368 177.265 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' 2065 ' ' VAL . 60.7 Cg_endo -102.34 108.6 0.04 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.57 0 C-N-CA 123.454 2.769 . . . . 0.45000000000000001 111.328 166.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 21.3 p -134.5 174.45 10.53 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.529 0.68 . . . . 0.69999999999999996 111.335 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.528 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.7 OUTLIER -101.13 151.4 21.87 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.64 -1.245 . . . . 1.1599999999999999 107.64 170.214 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -45.71 -41.72 10.91 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 123.719 0.637 . . . . 2.0899999999999999 112.391 -171.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -90.17 16.58 8.27 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 111.944 0.35 . . . . 2.1499999999999999 111.944 -175.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 30.0 58.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.663 -0.78 . . . . 0.63 112.668 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.3 p -102.92 167.96 9.52 Favored 'General case' 0 C--N 1.323 -0.564 0 O-C-N 122.859 -0.201 . . . . 0.89000000000000001 110.496 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2074 ' ' LYS . . . . . 0.425 ' O ' HG22 ' A' 2086 ' ' ILE . 42.1 mmtm -123.39 -10.45 7.97 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.246 0.462 . . . . 1.1299999999999999 112.246 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -158.77 128.1 5.59 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.928 0.394 . . . . 2.0800000000000001 110.156 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.35 100.47 6.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.185 -0.672 . . . . 1.48 109.185 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 62.8 m -109.78 127.21 54.49 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.282 -0.417 . . . . 0.63 111.112 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.614 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 35.4 mm -131.32 132.01 23.37 Favored Pre-proline 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.917 . . . . 1.6200000000000001 108.523 171.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.76 108.9 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.478 2.119 . . . . 0.97999999999999998 112.197 178.313 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2080 ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' 2101 ' ' VAL . . . 99.83 -4.09 57.6 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.018 -0.61 . . . . 0.93999999999999995 112.319 -179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.614 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.1 tt0 -107.33 -29.79 9.08 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.125 0.488 . . . . 2.02 110.222 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 103.89 -162.35 15.49 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.565 -0.743 . . . . 0.5 111.641 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.518 ' O ' ' HB ' ' A' 2095 ' ' THR . 47.1 m -139.76 135.43 33.08 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.568 0.699 . . . . 0.48999999999999999 110.729 178.036 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.508 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.6 m-85 -104.58 110.74 23.15 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.069 -1.456 . . . . 1.4399999999999999 107.069 171.368 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.491 HG23 HG22 ' A' 2083 ' ' THR . 13.3 p -108.24 123.67 49.12 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.323 0.49 . . . . 0.63 112.323 -171.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.5 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.93 130.8 72.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.112 -0.494 . . . . 1.1799999999999999 109.84 170.349 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.5 m -122.33 150.59 57.59 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.01 -0.541 . . . . 0.80000000000000004 109.748 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.94 -3.9 1.78 Allowed 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 123.949 3.099 . . . . 0.96999999999999997 114.276 -172.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2089 ' ' ASP . . . . . 0.401 ' HB2' HG22 ' A' 2091 ' ' THR . 5.3 m-20 -69.3 -13.95 62.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.223 0.535 . . . . 2.29 110.057 176.15 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.57 8.16 54.92 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.531 -0.759 . . . . 0.82999999999999996 111.552 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2091 ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' 2089 ' ' ASP . 6.8 t -111.44 129.01 56.16 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.381 0.61 . . . . 1.51 110.501 -177.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.6 HG13 ' NH1' ' A' 2111 ' ' ARG . 1.1 p -150.08 139.29 15.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.529 -0.76 . . . . 1.1799999999999999 110.538 -176.707 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -127.57 130.92 49.93 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.098 0.475 . . . . 1.46 110.747 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2094 ' ' PHE . . . . . 0.466 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.5 m-30 -84.36 99.02 10.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.463 -0.94 . . . . 1.27 108.463 175.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2095 ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' 2083 ' ' THR . 19.6 m -116.54 89.35 27.25 Favored Pre-proline 0 N--CA 1.454 -0.259 0 CA-C-O 121.215 0.531 . . . . 0.57999999999999996 111.815 -175.281 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2096 ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' 2094 ' ' PHE . 5.3 Cg_endo -87.41 142.2 6.02 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 123.207 2.605 . . . . 0.97999999999999998 110.877 172.339 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.49 137.23 58.19 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.184 -0.462 . . . . 2.7200000000000002 110.712 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.15 -20.21 63.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.378 -0.828 . . . . 4.8099999999999996 112.184 -175.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -103.49 -44.73 5.05 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.711 -0.477 . . . . 4.4199999999999999 109.711 177.105 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2100 ' ' PHE . . . . . 0.465 ' CE1' ' HB3' ' A' 2104 ' ' PRO . 43.1 t80 65.1 72.2 0.44 Allowed 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.654 0.74 . . . . 2.3599999999999999 110.804 177.253 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2101 ' ' VAL . . . . . 0.424 ' O ' ' HA3' ' A' 2080 ' ' GLY . 77.1 t -145.03 117.81 2.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.125 -0.943 . . . . 2.6800000000000002 109.832 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 154.58 48.7 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.038 -1.077 . . . . 3.8399999999999999 113.13 178.096 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.4 ttpp 55.87 72.56 0.99 Allowed Pre-proline 0 CA--C 1.535 0.367 0 C-N-CA 122.616 0.366 . . . . 6.7800000000000002 111.213 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2104 ' ' PRO . . . . . 0.465 ' HB3' ' CE1' ' A' 2100 ' ' PHE . 19.2 Cg_endo -58.87 135.6 68.0 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.906 2.404 . . . . 2.4300000000000002 113.299 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.0 t70 -92.88 130.92 34.83 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.616 -0.72 . . . . 2.3300000000000001 109.723 178.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' 2123 ' ' TYR . 30.8 Cg_endo -64.71 106.61 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.634 2.223 . . . . 1.03 112.235 -176.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.1 p -142.94 135.54 25.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.264 0.554 . . . . 0.59999999999999998 111.34 -178.088 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.607 ' HA ' ' O ' ' A' 2121 ' ' ALA . 88.5 m -111.21 122.85 48.93 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.564 -0.744 . . . . 0.37 109.412 171.553 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.3 t -95.54 136.73 25.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.929 -0.767 . . . . 0.76000000000000001 108.929 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -141.95 113.58 7.82 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.09 0.774 . . . . 1.6299999999999999 113.09 -171.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.6 ' NH1' HG13 ' A' 2092 ' ' VAL . 23.9 ptt180 -140.69 143.44 35.07 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.26 -0.644 . . . . 3.4700000000000002 109.26 171.375 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.569 ' O ' HG11 ' A' 2065 ' ' VAL . 34.8 m -98.41 149.95 5.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.238 -0.585 . . . . 0.40000000000000002 111.179 -176.138 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 25.1 p30 -88.01 -168.93 2.38 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.708 -0.678 . . . . 1.46 110.783 179.503 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.3 mttt -65.69 -23.59 66.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.716 0.293 . . . . 1.72 111.553 -178.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -82.57 -27.26 31.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.104 0.478 . . . . 1.8400000000000001 110.56 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 108.29 11.53 23.58 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.358 -0.697 . . . . 0.44 111.358 -177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.438 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 61.6 m -90.59 118.96 69.08 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 120.595 0.236 . . . . 0.56999999999999995 110.481 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' 2117 ' ' THR . 10.5 Cg_exo -71.38 119.72 6.46 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.719 2.279 . . . . 0.60999999999999999 113.014 -179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.6 m -84.79 109.39 17.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.326 -0.991 . . . . 0.59999999999999998 108.326 169.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.573 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.6 p -119.58 149.87 41.22 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.125 -0.943 . . . . 0.67000000000000004 111.747 -170.026 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.607 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.57 126.15 39.71 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.125 -1.065 . . . . 0.72999999999999998 108.125 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 46.5 m -113.57 101.7 9.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.644 -0.502 . . . . 2.1899999999999999 109.644 -177.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.496 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.8 m-85 -97.68 124.95 42.19 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.967 -0.561 . . . . 2.8100000000000001 112.045 -174.738 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 26.0 m -91.02 150.55 41.98 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 115.105 -0.952 . . . . 2.0600000000000001 110.98 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.46 ' HB3' ' HD3' ' A' 2106 ' ' PRO . 73.5 Cg_endo . . . . . 0 N--CA 1.46 -0.468 0 C-N-CA 122.769 2.313 . . . . 2.1600000000000001 111.863 177.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 16.5 t70 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.532 -0.544 . . . . 2.4199999999999999 109.532 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.0 -18.57 46.25 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.895 2.397 . . . . 1.72 112.706 -176.15 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.4 mp -87.48 -33.3 19.06 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.377 -0.374 . . . . 2.3399999999999999 110.403 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 2.6 t -135.41 87.38 27.49 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.418 -0.355 . . . . 0.87 110.048 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -38.66 119.71 0.43 Allowed 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 123.411 2.741 . . . . 1.04 112.661 173.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2061 ' ' ILE . . . . . 0.428 HD11 HG21 ' A' 2119 ' ' VAL . 42.4 mm -56.18 123.66 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.828 -0.623 . . . . 0.77000000000000002 111.477 -176.048 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.518 ' O ' HG22 ' A' 2065 ' ' VAL . 30.8 t70 -68.01 135.98 53.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.788 -0.642 . . . . 1.4199999999999999 110.502 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -86.62 -6.62 58.81 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.082 -0.508 . . . . 1.55 111.782 -172.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.5 p -111.18 4.01 18.92 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.166 0.432 . . . . 0.68999999999999995 112.166 -177.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.688 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.7 m -86.99 -174.07 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.904 -0.406 . . . . 0.81999999999999995 109.904 174.484 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -93.57 105.77 17.79 Favored Pre-proline 0 C--O 1.238 0.494 0 CA-C-O 120.974 0.416 . . . . 0.78000000000000003 111.293 176.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.688 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.4 Cg_endo -100.74 108.64 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.548 0 C-N-CA 123.308 2.672 . . . . 0.45000000000000001 110.62 166.344 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.601 HG22 ' HE2' ' A' 2074 ' ' LYS . 18.5 p -138.75 177.07 8.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.646 0.736 . . . . 0.69999999999999996 111.101 -175.01 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.472 ' CE1' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-85 -101.55 142.18 33.3 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 107.147 -1.427 . . . . 1.1599999999999999 107.147 165.632 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -58.78 -19.08 37.59 Favored 'General case' 0 C--N 1.328 -0.329 0 O-C-N 123.849 0.718 . . . . 2.0899999999999999 111.975 -168.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -98.58 8.04 45.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.82 0.343 . . . . 2.1499999999999999 111.038 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.07 17.72 52.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.089 -0.577 . . . . 0.63 113.195 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 32.3 m -93.89 167.55 11.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.916 0.358 . . . . 0.89000000000000001 110.999 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2074 ' ' LYS . . . . . 0.601 ' HE2' HG22 ' A' 2068 ' ' THR . 34.5 mmtp -127.67 -16.86 4.67 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 116.161 -0.472 . . . . 1.1299999999999999 111.12 178.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.813 ' HG2' HG22 ' A' 2085 ' ' THR . 0.9 OUTLIER -149.72 98.51 2.75 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.761 -0.459 . . . . 2.0800000000000001 109.761 174.239 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 26.1 tptt -92.19 108.35 19.88 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.281 -0.418 . . . . 1.48 110.073 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 86.9 m -107.84 118.13 35.93 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-O 121.408 0.623 . . . . 0.63 110.478 174.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.579 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 72.1 mt -114.02 115.07 45.94 Favored Pre-proline 0 N--CA 1.438 -1.034 0 CA-C-N 114.911 -1.04 . . . . 1.6200000000000001 108.471 175.099 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -47.84 109.52 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 123.332 2.688 . . . . 0.97999999999999998 113.567 -174.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 90.68 -8.64 79.5 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.923 -0.58 . . . . 0.93999999999999995 112.694 176.258 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.579 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.6 tm0? -100.82 -31.11 11.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.096 0.474 . . . . 2.02 109.829 -176.19 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 129.13 -167.57 21.13 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.818 -0.706 . . . . 0.5 112.492 177.142 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 55.0 m -149.57 129.89 13.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.507 0.67 . . . . 0.48999999999999999 110.341 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.472 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 2.7 m-85 -101.85 130.42 48.31 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 106.789 -1.559 . . . . 1.4399999999999999 106.789 171.478 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.813 HG22 ' HG2' ' A' 2075 ' ' GLU . 77.5 p -125.67 137.63 53.87 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.176 -0.61 . . . . 0.63 111.932 -172.639 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.507 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -130.9 133.36 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-N 115.573 -0.739 . . . . 1.1799999999999999 109.878 173.962 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 24.5 m -116.61 149.17 43.38 Favored Pre-proline 0 C--N 1.32 -0.684 0 N-CA-C 109.143 -0.688 . . . . 0.80000000000000004 109.143 172.175 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -61.99 -0.75 1.81 Allowed 'Trans proline' 0 N--CA 1.477 0.533 0 C-N-CA 123.633 2.889 . . . . 0.96999999999999997 113.95 -170.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.08 -14.71 62.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.08 0.467 . . . . 2.29 110.064 177.27 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.14 21.11 18.72 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.868 -0.605 . . . . 0.82999999999999996 112.082 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -120.63 135.97 54.96 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.916 0.389 . . . . 1.51 110.349 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.63 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 5.2 t -136.35 149.44 27.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.922 -0.581 . . . . 1.1799999999999999 110.002 -176.639 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.9 t -134.96 130.03 35.15 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.273 0.558 . . . . 1.46 110.409 172.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.4 m-30 -93.82 98.78 11.31 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.032 -0.729 . . . . 1.27 109.032 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 21.3 m -117.56 88.7 30.13 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-O 120.919 0.39 . . . . 0.57999999999999996 111.891 -177.273 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -91.78 161.26 3.42 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 123.213 2.609 . . . . 0.97999999999999998 111.822 171.802 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2097 ' ' ASP . . . . . 0.481 ' HB3' ' HB2' ' A' 2100 ' ' PHE . 11.6 t70 -75.41 114.17 13.65 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.613 -0.514 . . . . 2.7200000000000002 109.613 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 2.7 tpmt? -43.56 -53.31 5.7 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 124.059 0.849 . . . . 4.8099999999999996 113.262 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -121.27 37.4 4.34 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 111.88 0.326 . . . . 4.4199999999999999 111.88 -171.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2100 ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' A' 2097 ' ' ASP . 56.5 t80 -78.59 84.59 4.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.486 0.66 . . . . 2.3599999999999999 110.287 177.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.2 t -93.9 113.22 28.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.627 -0.715 . . . . 2.6800000000000002 110.16 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 179.52 -110.13 0.28 Allowed Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.521 -0.632 . . . . 3.8399999999999999 111.521 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.9 ptpt -135.03 72.97 66.75 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-O 121.207 0.527 . . . . 6.7800000000000002 110.987 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2104 ' ' PRO . . . . . 0.427 ' HB3' ' HG3' ' A' 2081 ' ' GLN . 23.5 Cg_exo -64.94 144.86 84.25 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.889 2.392 . . . . 2.4300000000000002 111.592 177.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 3.7 m-20 -76.6 142.95 71.16 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.424 -0.353 . . . . 2.3300000000000001 110.481 177.341 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.632 ' HA ' ' O ' ' A' 2123 ' ' TYR . 71.7 Cg_endo -80.32 132.58 9.25 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 123.086 2.524 . . . . 1.03 113.441 -176.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 9.0 p -161.5 144.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.734 -0.666 . . . . 0.59999999999999998 110.059 177.295 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' 2121 ' ' ALA . 80.9 m -115.03 126.75 55.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.334 0.588 . . . . 0.37 110.523 175.165 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 1.9 t -98.55 137.7 25.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.535 -0.757 . . . . 0.76000000000000001 109.118 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.588 ' HA ' HG22 ' A' 2120 ' ' THR . 0.6 OUTLIER -133.0 109.57 9.64 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 112.301 0.482 . . . . 1.6299999999999999 112.301 -168.004 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.63 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -143.96 137.27 27.64 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 121.874 -0.517 . . . . 3.4700000000000002 110.473 172.585 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.422 ' O ' HG21 ' A' 2065 ' ' VAL . 34.1 m -102.03 157.72 4.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.439 -0.346 . . . . 0.40000000000000002 110.884 179.309 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.686 ' OD2' ' HB ' ' A' 2117 ' ' THR . 40.1 p30 -97.89 -167.97 1.6 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.028 -0.533 . . . . 1.46 110.541 177.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.4 mttt -55.08 -41.5 71.65 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.319 0.489 . . . . 1.72 112.319 -177.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -86.73 -25.42 24.74 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.766 -0.373 . . . . 1.8400000000000001 110.684 -176.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 119.49 15.31 5.48 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.657 -0.783 . . . . 0.44 112.368 178.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.686 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 47.1 m -77.39 115.64 51.06 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-O 120.763 0.316 . . . . 0.56999999999999995 110.237 174.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' 2111 ' ' ARG . 3.0 Cg_endo -82.36 103.93 1.31 Allowed 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.434 2.09 . . . . 0.60999999999999999 112.624 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2119 ' ' VAL . . . . . 0.558 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.33 108.32 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 N-CA-C 107.839 -1.171 . . . . 0.59999999999999998 107.839 167.856 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.588 HG22 ' HA ' ' A' 2110 ' ' LYS . 69.1 p -126.47 156.53 40.53 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.142 -0.935 . . . . 0.67000000000000004 110.492 -171.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.94 127.1 41.06 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.732 -0.84 . . . . 0.72999999999999998 108.732 172.155 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 57.7 m -115.89 99.75 7.5 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.278 -0.638 . . . . 2.1899999999999999 109.278 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.632 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.7 m-85 -98.67 145.67 26.64 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.422 -0.808 . . . . 2.8100000000000001 111.268 -175.711 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2124 ' ' SER . . . . . 0.512 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 26.5 m -152.97 169.53 9.55 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.67 -0.696 . . . . 2.0600000000000001 109.447 -177.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.512 ' HD2' ' HB3' ' A' 2124 ' ' SER . 82.7 Cg_exo . . . . . 0 C--N 1.354 0.857 0 C-N-CA 122.706 2.271 . . . . 2.1600000000000001 112.912 177.79 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.455 -0.221 0 CA-C-O 121.17 0.51 . . . . 2.4199999999999999 112.191 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2057 ' ' PRO . . . . . 0.431 ' HG2' ' HG ' ' A' 2058 ' ' LEU . 36.8 Cg_endo -71.95 -44.43 0.93 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 121.958 1.772 . . . . 1.72 111.471 176.097 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2058 ' ' LEU . . . . . 0.681 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -83.91 -12.95 54.68 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 114.289 1.218 . . . . 2.3399999999999999 114.289 -176.081 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.681 HG23 HD13 ' A' 2058 ' ' LEU . 0.3 OUTLIER -140.21 82.76 16.44 Favored Pre-proline 0 CA--C 1.508 -0.645 0 C-N-CA 119.739 -0.785 . . . . 0.87 110.929 -176.784 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -52.96 119.09 5.51 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.87 1.713 . . . . 1.04 111.547 179.426 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2061 ' ' ILE . . . . . 0.555 HG13 ' NE ' ' A' 2111 ' ' ARG . 39.3 mm -45.51 135.92 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.236 -0.893 . . . . 0.77000000000000002 112.241 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.557 ' O ' HG22 ' A' 2065 ' ' VAL . 13.0 t70 -71.91 141.51 49.49 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.442 -0.799 . . . . 1.4199999999999999 109.953 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -87.01 -7.79 57.79 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.131 0.419 . . . . 1.55 112.131 -172.32 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 67.2 p -106.81 6.37 29.42 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.702 -0.399 . . . . 0.68999999999999995 111.792 -178.155 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.644 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.4 m -97.84 -174.42 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.81999999999999995 109.997 177.458 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -97.08 105.07 21.73 Favored Pre-proline 0 C--O 1.239 0.504 0 CA-C-O 120.808 0.337 . . . . 0.78000000000000003 110.998 178.545 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.644 ' HD3' ' O ' ' A' 2065 ' ' VAL . 56.5 Cg_endo -100.34 109.59 0.06 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 123.175 2.584 . . . . 0.45000000000000001 111.154 167.631 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.428 HG22 ' HE2' ' A' 2074 ' ' LYS . 12.1 p -137.39 178.08 7.37 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.321 0.581 . . . . 0.69999999999999996 111.086 -175.615 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.503 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -100.81 149.41 23.86 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.02 -1.104 . . . . 1.1599999999999999 108.02 169.157 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -48.31 -44.52 34.0 Favored 'General case' 0 C--N 1.329 -0.283 0 O-C-N 123.509 0.505 . . . . 2.0899999999999999 111.618 -172.403 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -84.16 13.76 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 2.1499999999999999 111.796 -175.096 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 81.6 26.15 51.55 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 121.017 -0.611 . . . . 0.63 112.706 177.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.32 166.93 11.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.541 0.21 . . . . 0.89000000000000001 110.978 -179.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2074 ' ' LYS . . . . . 0.428 ' HE2' HG22 ' A' 2068 ' ' THR . 35.4 mmtp -123.21 -26.48 4.31 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.812 0.339 . . . . 1.1299999999999999 111.461 -178.012 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -147.54 135.2 20.98 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 2.0800000000000001 109.497 172.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.1 OUTLIER -127.97 99.6 5.57 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.475 -0.565 . . . . 1.48 109.475 177.349 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.0 m -110.23 114.17 27.44 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 121.139 0.495 . . . . 0.63 110.753 177.066 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2078 ' ' ILE . . . . . . . . . . . . . 75.2 mt -121.76 120.07 28.78 Favored Pre-proline 0 C--N 1.315 -0.908 0 N-CA-C 108.343 -0.984 . . . . 1.6200000000000001 108.343 173.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.53 111.47 0.37 Allowed 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 123.251 2.634 . . . . 0.97999999999999998 112.9 -176.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.78 -15.88 37.23 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.616 -0.72 . . . . 0.93999999999999995 112.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.565 ' CD ' ' HA ' ' A' 2104 ' ' PRO . 24.0 mt-30 -97.8 -37.24 9.93 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.981 0.419 . . . . 2.02 110.837 -178.589 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 118.69 -166.73 12.98 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 111.083 -0.807 . . . . 0.5 111.083 -177.087 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 62.1 m -129.03 119.31 24.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.856 0.836 . . . . 0.48999999999999999 110.738 174.432 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.43 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 1.9 m-85 -94.82 122.88 37.9 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 105.854 -1.906 . . . . 1.4399999999999999 105.854 168.004 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.33 143.06 41.86 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.801 0.667 . . . . 0.63 112.801 -168.518 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -138.88 132.59 40.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.404 -0.816 . . . . 1.1799999999999999 109.559 170.732 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 30.4 m -119.94 150.42 50.79 Favored Pre-proline 0 C--N 1.325 -0.499 0 N-CA-C 109.657 -0.497 . . . . 0.80000000000000004 109.657 173.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -62.38 0.69 1.25 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 123.686 2.924 . . . . 0.96999999999999997 114.215 -170.377 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -68.33 -18.9 64.61 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.007 0.432 . . . . 2.29 109.876 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 101.92 11.81 36.28 Favored Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.506 -0.77 . . . . 0.82999999999999996 111.767 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.6 t -109.5 136.14 49.38 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.131 0.491 . . . . 1.51 110.419 -178.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' 2086 ' ' ILE . 3.6 t -133.41 149.23 31.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.753 -0.658 . . . . 1.1799999999999999 109.796 -176.554 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -137.76 119.75 15.43 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.147 0.498 . . . . 1.46 111.098 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 16.3 m-30 -94.04 97.27 10.21 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.319 -0.993 . . . . 1.27 108.319 174.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 18.8 m -120.27 87.99 41.01 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 120.772 -0.371 . . . . 0.57999999999999996 111.654 -176.63 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -91.77 157.51 3.45 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.27 2.646 . . . . 0.97999999999999998 112.582 174.689 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.1 136.56 56.86 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.066 -0.515 . . . . 2.7200000000000002 110.271 169.744 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 23.1 tptm -91.86 -30.89 15.93 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.937 -0.574 . . . . 4.8099999999999996 111.875 -177.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -107.8 -47.1 3.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.852 1.056 . . . . 4.4199999999999999 113.852 -165.164 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.5 122.98 13.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.732 0.777 . . . . 2.3599999999999999 112.279 -169.017 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.1 t -80.98 143.47 12.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.287 -0.869 . . . . 2.6800000000000002 110.362 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 117.63 -52.49 0.69 Allowed Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 108.823 -1.711 . . . . 3.8399999999999999 108.823 -169.178 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2103 ' ' LYS . . . . . 0.467 ' HB2' ' HA ' ' A' 2125 ' ' PRO . 70.1 mmtt 68.69 159.33 0.15 Allowed Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 113.89 1.07 . . . . 6.7800000000000002 113.89 167.425 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2104 ' ' PRO . . . . . 0.565 ' HA ' ' CD ' ' A' 2081 ' ' GLN . 62.4 Cg_exo -44.86 144.25 3.74 Favored 'Trans proline' 0 C--N 1.348 0.548 0 C-N-CA 124.371 3.381 . . . . 2.4300000000000002 116.156 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 25.9 t70 -65.77 132.06 94.78 Favored Pre-proline 0 N--CA 1.451 -0.42 0 CA-C-N 114.312 -1.313 . . . . 2.3300000000000001 107.999 164.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.619 ' HA ' ' O ' ' A' 2123 ' ' TYR . 6.5 Cg_endo -47.12 112.86 0.57 Allowed 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 124.196 3.264 . . . . 1.03 114.595 -170.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 6.0 p -150.15 123.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.34 -0.845 . . . . 0.59999999999999998 110.087 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.6 m -100.62 133.99 44.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.131 -0.486 . . . . 0.37 110.609 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.9 t -110.14 147.77 14.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.465 -0.568 . . . . 0.76000000000000001 109.465 177.407 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' 2110 ' ' LYS . 18.5 ttpt -143.78 109.48 5.2 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.135 0.421 . . . . 1.6299999999999999 112.135 -174.01 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.555 ' NE ' HG13 ' A' 2061 ' ' ILE . 18.2 ptt180 -131.52 136.3 47.76 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.119 -0.697 . . . . 3.4700000000000002 109.119 174.028 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' 2065 ' ' VAL . 34.4 m -98.94 145.13 10.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.431 -0.508 . . . . 0.40000000000000002 111.014 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -91.94 -168.86 2.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.073 -0.512 . . . . 1.46 110.723 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 68.4 mttm -65.77 -28.81 69.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 1.72 111.557 -178.583 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2115 ' ' ASN . . . . . 0.443 HD22 HG11 ' A' 2059 ' ' VAL . 42.4 m-80 -74.26 -20.75 60.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.176 0.512 . . . . 1.8400000000000001 110.081 174.103 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 94.43 9.8 58.7 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.682 -0.69 . . . . 0.44 111.851 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2117 ' ' THR . . . . . . . . . . . . . 30.5 m -82.04 120.06 76.52 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 110.012 -0.366 . . . . 0.56999999999999995 110.012 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -72.93 106.29 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.441 2.094 . . . . 0.60999999999999999 112.528 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 35.3 m -77.48 108.73 11.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.008 -1.108 . . . . 0.59999999999999998 108.008 171.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.4 p -119.98 145.01 47.19 Favored 'General case' 0 N--CA 1.438 -1.031 0 CA-C-N 114.537 -1.21 . . . . 0.67000000000000004 110.573 -172.318 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.48 126.41 40.42 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.581 -0.736 . . . . 0.72999999999999998 109.265 175.493 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 35.0 p -100.33 97.76 8.48 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.874 -0.788 . . . . 2.1899999999999999 108.874 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.619 ' O ' ' HA ' ' A' 2106 ' ' PRO . 24.3 m-85 -89.69 99.75 12.69 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-O 121.493 0.663 . . . . 2.8100000000000001 111.666 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 7.9 p -148.86 170.12 8.13 Favored Pre-proline 0 N--CA 1.435 -1.192 0 CA-C-N 114.456 -1.247 . . . . 2.0600000000000001 109.441 178.624 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.467 ' HA ' ' HB2' ' A' 2103 ' ' LYS . 51.0 Cg_exo . . . . . 0 C--N 1.349 0.565 0 C-N-CA 122.447 2.098 . . . . 2.1600000000000001 111.811 175.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 120.94 0.4 . . . . 2.4199999999999999 110.647 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -47.19 11.55 Favored 'Trans proline' 0 N--CA 1.473 0.304 0 C-N-CA 123.317 2.678 . . . . 1.72 112.559 -179.332 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2058 ' ' LEU . . . . . 0.608 HD13 HG23 ' A' 2059 ' ' VAL . 0.1 OUTLIER -61.41 -20.33 62.93 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 115.358 -0.837 . . . . 2.3399999999999999 113.24 177.281 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.608 HG23 HD13 ' A' 2058 ' ' LEU . 6.1 t -130.11 86.72 53.44 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.124 -0.324 . . . . 0.87 110.124 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.01 126.37 20.87 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.396 2.064 . . . . 1.04 111.955 -177.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 37.9 mm -59.54 132.97 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.819 -0.628 . . . . 0.77000000000000002 110.374 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.581 ' O ' HG22 ' A' 2065 ' ' VAL . 13.8 t70 -78.17 138.15 38.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.145 -0.48 . . . . 1.4199999999999999 110.635 -176.098 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2063 ' ' GLU . . . . . 0.405 ' O ' ' HA3' ' A' 2090 ' ' GLY . 41.8 mt-10 -93.66 -0.43 56.09 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.184 -0.462 . . . . 1.55 111.877 -172.284 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.5 p -108.29 -1.83 19.76 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.78 -0.368 . . . . 0.68999999999999995 111.164 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' 2062 ' ' ASP . 32.8 m -89.87 -176.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.441 -0.345 . . . . 0.81999999999999995 110.172 178.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -93.47 111.65 53.16 Favored Pre-proline 0 C--O 1.238 0.485 0 CA-C-O 121.08 0.467 . . . . 0.78000000000000003 111.451 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.556 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -100.88 107.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.523 0 C-N-CA 123.025 2.483 . . . . 0.45000000000000001 111.327 167.44 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.503 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.2 p -145.68 146.51 31.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.853 0.358 . . . . 0.69999999999999996 110.522 -177.703 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.52 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.9 OUTLIER -71.61 148.23 46.78 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.942 -1.133 . . . . 1.1599999999999999 107.942 177.908 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -52.93 -37.42 60.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 118.412 0.551 . . . . 2.0899999999999999 111.297 -171.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 29.1 t70 -67.73 -11.66 58.86 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.679 -0.691 . . . . 2.1499999999999999 111.928 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 91.06 29.85 12.04 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.848 -0.691 . . . . 0.63 112.012 -176.179 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.6 p -110.08 161.68 15.3 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.887 0.375 . . . . 0.89000000000000001 111.22 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2074 ' ' LYS . . . . . 0.4 ' O ' HG22 ' A' 2086 ' ' ILE . 35.4 mmtp -110.94 -21.07 12.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.898 -0.592 . . . . 1.1299999999999999 110.985 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.709 ' HG2' HG22 ' A' 2085 ' ' THR . 3.9 mt-10 -147.57 142.21 26.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.268 -0.424 . . . . 2.0800000000000001 110.141 176.201 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD3' ' C ' ' A' 2076 ' ' LYS . 1.7 tmtp? -141.24 119.72 12.34 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.09 -0.707 . . . . 1.48 109.09 177.385 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2077 ' ' THR . . . . . 0.402 ' N ' ' HD3' ' A' 2076 ' ' LYS . 34.5 m -123.45 125.09 44.31 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.425 0.631 . . . . 0.63 111.356 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.494 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 93.8 mt -125.46 120.98 24.8 Favored Pre-proline 0 C--N 1.316 -0.863 0 N-CA-C 108.536 -0.913 . . . . 1.6200000000000001 108.536 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -47.51 110.65 0.32 Allowed 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 123.203 2.602 . . . . 0.97999999999999998 112.956 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 101.25 -21.45 43.06 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.74 -0.664 . . . . 0.93999999999999995 112.63 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.494 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.2 tt0 -93.3 -31.74 14.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.105 0.478 . . . . 2.02 110.678 -175.322 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.98 -178.42 16.88 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.797 -0.716 . . . . 0.5 112.24 177.669 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.409 HG22 HG23 ' A' 2085 ' ' THR . 45.7 m -128.07 141.95 51.35 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.483 0.659 . . . . 0.48999999999999999 110.103 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.481 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.9 m-85 -113.87 122.56 47.39 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.343 -1.354 . . . . 1.4399999999999999 107.343 173.25 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.709 HG22 ' HG2' ' A' 2075 ' ' GLU . 30.5 p -122.93 129.79 52.03 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.19 0.441 . . . . 0.63 112.19 -173.501 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.514 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.5 129.71 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.817 -0.629 . . . . 1.1799999999999999 109.923 170.74 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.7 m -110.1 148.73 38.91 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 115.644 -0.707 . . . . 0.80000000000000004 109.501 175.341 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -61.67 0.17 1.24 Allowed 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.679 2.919 . . . . 0.96999999999999997 113.755 -173.222 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2089 ' ' ASP . . . . . 0.43 ' HB2' HG22 ' A' 2091 ' ' THR . 5.1 m-20 -70.25 -13.64 62.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.124 0.488 . . . . 2.29 109.859 174.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2090 ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' 2063 ' ' GLU . . . 95.5 14.06 48.9 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.71 -0.677 . . . . 0.82999999999999996 111.744 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2091 ' ' THR . . . . . 0.43 HG22 ' HB2' ' A' 2089 ' ' ASP . 10.2 t -119.83 139.24 52.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.06 0.457 . . . . 1.51 110.279 -177.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.514 HG22 ' CG1' ' A' 2086 ' ' ILE . 9.6 t -134.83 153.44 34.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.899 -0.592 . . . . 1.1799999999999999 109.968 -175.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.9 t -131.92 122.31 25.43 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.261 0.553 . . . . 1.46 110.044 171.139 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2094 ' ' PHE . . . . . 0.434 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.1 m-30 -90.15 98.45 11.78 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.343 -0.984 . . . . 1.27 108.343 175.307 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 28.5 m -113.93 89.64 17.05 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.123 0.487 . . . . 0.57999999999999996 111.467 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2096 ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' 2094 ' ' PHE . 85.2 Cg_endo -90.56 149.04 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.008 2.472 . . . . 0.97999999999999998 111.55 174.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.61 126.02 30.17 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.922 0.391 . . . . 2.7200000000000002 110.012 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -84.01 -10.63 57.74 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.153 -0.476 . . . . 4.8099999999999996 112.067 -174.353 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -115.27 13.21 16.63 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.572 -0.451 . . . . 4.4199999999999999 111.247 -175.364 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 42.5 t80 -77.65 110.89 12.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.004 0.431 . . . . 2.3599999999999999 111.039 -178.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 47.0 t -111.99 98.59 7.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.327 -0.62 . . . . 2.6800000000000002 109.327 174.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -178.2 -142.32 4.64 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.972 -0.632 . . . . 3.8399999999999999 111.65 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2103 ' ' LYS . . . . . 0.41 ' HG3' ' O ' ' A' 2103 ' ' LYS . 24.2 pttm -113.91 101.94 54.36 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-O 121.203 0.525 . . . . 6.7800000000000002 111.287 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 10.5 Cg_exo -71.86 147.18 49.44 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.62 2.213 . . . . 2.4300000000000002 111.159 174.705 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.447 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.9 t70 -95.77 132.29 27.55 Favored Pre-proline 0 C--N 1.322 -0.61 0 N-CA-C 109.802 -0.444 . . . . 2.3300000000000001 109.802 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.571 ' HA ' ' O ' ' A' 2123 ' ' TYR . 15.7 Cg_endo -57.17 113.31 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 123.515 2.81 . . . . 1.03 114.128 -173.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.7 p -147.19 141.81 20.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.362 -0.836 . . . . 0.59999999999999998 109.525 174.59 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 18.0 m -115.92 113.71 23.67 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.139 0.495 . . . . 0.37 110.276 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.2 t -92.24 132.23 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.058 -0.719 . . . . 0.76000000000000001 109.058 -179.438 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.503 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.0 tmmm? -133.45 145.88 50.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.227 0.537 . . . . 1.6299999999999999 111.664 -170.607 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.475 ' N ' ' HD2' ' A' 2110 ' ' LYS . 32.2 ptt180 -164.57 137.86 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.543 -0.91 . . . . 3.4700000000000002 108.543 169.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.428 ' O ' HG21 ' A' 2065 ' ' VAL . 33.8 m -98.82 148.98 5.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.213 -0.595 . . . . 0.40000000000000002 111.52 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.603 ' OD1' ' HB ' ' A' 2117 ' ' THR . 8.5 p30 -88.91 -168.53 2.21 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.403 -0.817 . . . . 1.46 111.341 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.0 mttm -64.88 -34.25 77.95 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.561 0.578 . . . . 1.72 112.561 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.6 p30 -84.55 -22.92 29.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 119.685 -0.806 . . . . 1.8400000000000001 110.515 177.369 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 116.67 12.09 8.92 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.809 -0.71 . . . . 0.44 112.958 173.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.603 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 86.5 m -83.27 125.64 73.89 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 117.221 0.511 . . . . 0.56999999999999995 110.005 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' 2117 ' ' THR . 1.8 Cg_endo -81.36 111.46 2.37 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.451 2.101 . . . . 0.60999999999999999 112.987 -178.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 11.6 m -75.94 127.0 37.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.357 -0.979 . . . . 0.59999999999999998 108.357 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' 2109 ' ' VAL . 39.9 p -130.89 166.42 20.95 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 115.699 -0.682 . . . . 0.67000000000000004 111.332 -170.711 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -127.56 126.75 42.7 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 107.677 -1.231 . . . . 0.72999999999999998 107.677 169.257 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 3.5 m -110.08 99.42 8.51 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.324 -0.398 . . . . 2.1899999999999999 110.582 -172.293 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.571 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.2 m-85 -104.74 151.69 23.44 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 121.252 0.549 . . . . 2.8100000000000001 111.577 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 6.6 p -168.62 170.97 3.86 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 114.778 -1.101 . . . . 2.0600000000000001 108.33 -173.676 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo . . . . . 0 C--N 1.351 0.68 0 C-N-CA 122.712 2.275 . . . . 2.1600000000000001 112.185 177.098 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 C--O 1.226 -0.167 0 CA-C-O 120.831 0.348 . . . . 2.4199999999999999 110.733 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -64.95 -56.01 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.887 2.391 . . . . 1.72 112.064 177.69 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2058 ' ' LEU . . . . . 0.697 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -63.81 -12.46 35.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.43 -0.804 . . . . 2.3399999999999999 113.167 177.498 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.697 HG23 HD13 ' A' 2058 ' ' LEU . 21.5 t -136.77 86.06 22.72 Favored Pre-proline 0 C--N 1.322 -0.615 0 N-CA-C 109.814 -0.439 . . . . 0.87 109.814 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.63 137.82 83.1 Favored 'Trans proline' 0 C--O 1.235 0.363 0 C-N-CA 122.629 2.219 . . . . 1.04 112.3 -176.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.9 mm -65.27 136.46 26.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.672 -0.694 . . . . 0.77000000000000002 110.313 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 35.5 t70 -82.77 134.42 35.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.301 0.572 . . . . 1.4199999999999999 111.038 -175.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -87.32 -8.47 56.66 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.661 -0.7 . . . . 1.55 111.588 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 76.5 p -104.49 7.88 35.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.971 0.415 . . . . 0.68999999999999995 111.557 -178.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.554 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.1 m -110.23 -177.83 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.447 -0.575 . . . . 0.81999999999999995 109.447 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -94.88 110.9 52.3 Favored Pre-proline 0 C--O 1.243 0.729 0 CA-C-O 121.092 0.472 . . . . 0.78000000000000003 110.984 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' 2065 ' ' VAL . 43.4 Cg_endo -100.98 106.8 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.62 0 C-N-CA 123.077 2.518 . . . . 0.45000000000000001 111.688 169.04 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.0 p -142.87 -177.93 5.57 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.177 0.513 . . . . 0.69999999999999996 110.907 -176.783 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.562 ' CE2' ' HB2' ' A' 2084 ' ' TYR . 93.9 m-85 -101.51 164.97 11.49 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 108.731 -0.84 . . . . 1.1599999999999999 108.731 170.054 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -53.76 -33.23 55.13 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-N 118.004 0.365 . . . . 2.0899999999999999 111.687 -172.491 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -86.61 12.65 10.09 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 111.872 0.323 . . . . 2.1499999999999999 111.872 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 17.91 79.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 121.053 -0.594 . . . . 0.63 111.944 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.2 m -78.6 164.23 24.84 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.743 0.306 . . . . 0.89000000000000001 111.097 -173.334 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -115.5 -18.34 10.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.219 0.533 . . . . 1.1299999999999999 110.425 178.334 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -147.32 140.64 25.34 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.316 -0.624 . . . . 2.0800000000000001 109.316 173.057 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' 2083 ' ' THR . 27.1 tptt -127.97 116.17 19.65 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.939 -0.393 . . . . 1.48 109.939 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 59.3 m -113.6 132.99 55.54 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.294 0.569 . . . . 0.63 110.957 176.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.573 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 36.0 mt -134.63 121.2 14.91 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.102 -0.954 . . . . 1.6200000000000001 108.859 178.078 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -51.04 108.97 0.26 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.231 2.621 . . . . 0.97999999999999998 113.186 -175.744 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 95.2 -11.15 69.42 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.908 -0.663 . . . . 0.93999999999999995 112.75 176.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.573 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.5 tt0 -103.57 -26.51 12.79 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.262 0.554 . . . . 2.02 109.957 -176.246 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.29 -156.08 15.89 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.405 -0.816 . . . . 0.5 112.538 175.271 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.469 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -144.69 137.3 26.48 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.714 0.769 . . . . 0.48999999999999999 110.729 177.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 5.7 m-85 -108.38 126.27 52.68 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.114 -1.439 . . . . 1.4399999999999999 107.114 171.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2085 ' ' THR . . . . . 0.467 HG23 HG22 ' A' 2083 ' ' THR . 0.9 OUTLIER -128.15 147.12 50.54 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 112.826 0.676 . . . . 0.63 112.826 -172.221 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.541 ' CB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -141.8 127.1 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 115.248 -0.887 . . . . 1.1799999999999999 109.807 172.7 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -102.62 148.28 35.27 Favored Pre-proline 0 C--N 1.321 -0.643 0 N-CA-C 109.144 -0.687 . . . . 0.80000000000000004 109.144 173.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -61.18 0.24 1.02 Allowed 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.712 2.942 . . . . 0.96999999999999997 114.32 -171.309 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -71.74 -20.42 61.9 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.758 -0.46 . . . . 2.29 109.758 175.141 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 105.34 17.44 13.76 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.997 -0.62 . . . . 0.82999999999999996 112.289 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.2 t -112.71 135.76 53.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.13 0.49 . . . . 1.51 110.481 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 6.7 t -129.46 152.35 37.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.958 -0.565 . . . . 1.1799999999999999 111.033 -172.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 8.9 t -141.76 123.55 15.23 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.416 0.627 . . . . 1.46 110.267 172.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2094 ' ' PHE . . . . . 0.559 ' CE2' HG11 ' A' 2109 ' ' VAL . 19.3 m-30 -98.55 98.91 10.03 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.522 -0.918 . . . . 1.27 108.522 177.1 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 10.1 m -116.43 87.99 22.29 Favored Pre-proline 0 N--CA 1.454 -0.264 0 C-N-CA 120.238 -0.585 . . . . 0.57999999999999996 111.341 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2096 ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' 2094 ' ' PHE . 18.2 Cg_endo -92.55 143.55 2.44 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.516 2.811 . . . . 0.97999999999999998 112.166 173.453 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 52.7 t0 -88.63 92.52 9.23 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.264 -0.643 . . . . 2.7200000000000002 109.264 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -75.59 -1.48 24.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.031 -0.531 . . . . 4.8099999999999996 111.247 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -81.95 -16.38 50.64 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.125 -0.694 . . . . 4.4199999999999999 109.125 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 78.2 t80 -99.99 110.51 22.84 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.072 -0.967 . . . . 2.3599999999999999 109.673 177.324 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.6 p -144.24 100.75 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.944 0.878 . . . . 2.6800000000000002 111.452 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -151.73 -77.64 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 110.437 -1.065 . . . . 3.8399999999999999 110.437 175.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 57.8 pttt -129.31 71.73 82.02 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-O 120.982 0.42 . . . . 6.7800000000000002 110.896 173.201 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.88 148.84 91.14 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.407 2.071 . . . . 2.4300000000000002 111.027 175.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.538 ' HB3' HD13 ' A' 2078 ' ' ILE . 16.4 t70 -75.65 132.99 74.11 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 109.582 -0.525 . . . . 2.3300000000000001 109.582 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.603 ' HA ' ' O ' ' A' 2123 ' ' TYR . 33.5 Cg_endo -65.24 106.06 0.78 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.024 2.482 . . . . 1.03 112.645 -176.83 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2107 ' ' VAL . . . . . 0.44 HG21 ' HG2' ' A' 2076 ' ' LYS . 9.5 p -147.42 134.31 13.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.645 -0.707 . . . . 0.59999999999999998 110.501 177.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.4 m -109.75 128.23 55.15 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 115.88 -0.6 . . . . 0.37 110.065 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' 2120 ' ' THR . 13.0 t -91.42 117.99 35.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 108.697 -0.853 . . . . 0.76000000000000001 108.697 176.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.418 ' HA ' HG22 ' A' 2120 ' ' THR . 0.2 OUTLIER -125.47 108.49 11.69 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.633 -0.427 . . . . 1.6299999999999999 110.918 -172.532 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.541 HH12 ' CB ' ' A' 2086 ' ' ILE . 12.7 ptp180 -155.18 157.46 37.41 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.776 -0.453 . . . . 3.4700000000000002 109.776 175.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.3 m -112.04 149.39 14.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.377 -0.529 . . . . 0.40000000000000002 111.69 -177.133 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.615 ' OD2' ' HB ' ' A' 2117 ' ' THR . 5.0 p30 -91.73 -169.33 2.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.632 -0.713 . . . . 1.46 110.756 177.04 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.8 mttm -62.99 -31.95 73.19 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.014 0.376 . . . . 1.72 112.014 -178.187 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -78.43 -18.62 54.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.083 0.468 . . . . 1.8400000000000001 110.122 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 99.61 10.57 46.82 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.563 -0.744 . . . . 0.44 111.304 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.615 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 62.2 m -81.9 125.89 76.53 Favored Pre-proline 0 N--CA 1.448 -0.542 0 CA-C-O 120.515 0.197 . . . . 0.56999999999999995 110.487 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' 2111 ' ' ARG . 11.9 Cg_exo -70.35 101.43 0.99 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.468 2.112 . . . . 0.60999999999999999 112.589 177.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2119 ' ' VAL . . . . . 0.449 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 23.7 m -75.37 108.63 7.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.374 -0.973 . . . . 0.59999999999999998 108.374 169.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.635 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.6 p -126.63 154.4 44.04 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.189 -0.914 . . . . 0.67000000000000004 111.196 -171.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.59 127.77 42.92 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.282 -1.007 . . . . 0.72999999999999998 108.282 170.5 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 29.6 p -105.12 99.63 9.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.095 0.474 . . . . 2.1899999999999999 110.172 -177.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.603 ' O ' ' HA ' ' A' 2106 ' ' PRO . 10.6 m-85 -113.38 134.42 54.65 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.966 -0.561 . . . . 2.8100000000000001 111.225 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2124 ' ' SER . . . . . 0.43 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 26.3 p -160.08 161.19 26.38 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 115.602 -0.726 . . . . 2.0600000000000001 109.935 -175.113 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' 2124 ' ' SER . 57.3 Cg_endo . . . . . 0 C--N 1.351 0.661 0 C-N-CA 122.956 2.438 . . . . 2.1600000000000001 113.011 -177.696 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2056 ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 1.8 t70 . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.211 -0.663 . . . . 2.4199999999999999 109.211 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -44.25 -55.08 3.4 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 123.296 2.664 . . . . 1.72 113.231 -175.075 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2058 ' ' LEU . . . . . 0.641 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -101.16 2.07 39.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.014 0.435 . . . . 2.3399999999999999 112.085 -177.909 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A 2059 ' ' VAL . . . . . 0.641 HG23 HD13 ' A' 2058 ' ' LEU . 2.1 t -131.65 78.42 70.88 Favored Pre-proline 0 C--N 1.327 -0.386 0 N-CA-C 110.091 -0.337 . . . . 0.87 110.091 178.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.42 140.03 92.35 Favored 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.182 1.921 . . . . 1.04 111.349 176.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.3 mm -61.06 130.97 25.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.856 -0.611 . . . . 0.77000000000000002 111.404 -178.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.603 ' O ' HG22 ' A' 2065 ' ' VAL . 12.5 t70 -73.67 140.36 46.03 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.393 -0.821 . . . . 1.4199999999999999 109.867 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -86.83 -10.47 53.39 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 111.914 0.338 . . . . 1.55 111.914 -171.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 39.7 p -109.24 10.12 25.8 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.755 0.312 . . . . 0.68999999999999995 111.817 -177.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.617 ' O ' ' HD3' ' A' 2067 ' ' PRO . 35.8 m -91.66 -174.94 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 110.059 -0.348 . . . . 0.81999999999999995 110.059 175.215 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -97.0 105.05 21.24 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.551 -0.295 . . . . 0.78000000000000003 110.775 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -99.91 106.48 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.603 0 C-N-CA 122.562 2.175 . . . . 0.45000000000000001 110.92 168.411 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.517 ' O ' ' HB3' ' A' 2110 ' ' LYS . 40.7 p -145.35 147.66 32.54 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.104 -0.498 . . . . 0.69999999999999996 110.09 -176.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.538 ' HD2' ' N ' ' A' 2069 ' ' PHE . 1.2 m-30 -72.62 153.75 41.09 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.5 -0.926 . . . . 1.1599999999999999 108.5 178.235 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -50.55 -43.51 56.22 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.958 0.409 . . . . 2.0899999999999999 111.139 -173.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 38.1 t70 -77.43 2.58 15.64 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 115.671 -0.695 . . . . 2.1499999999999999 111.587 -177.731 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 86.28 29.98 23.57 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.162 -0.542 . . . . 0.63 112.558 179.367 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 12.5 m -101.24 162.47 12.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.788 0.328 . . . . 0.89000000000000001 110.941 -176.565 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -115.83 -19.62 10.37 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.092 -0.504 . . . . 1.1299999999999999 110.87 178.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2075 ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' 2084 ' ' TYR . 7.2 tt0 -156.0 125.88 6.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.999 -0.546 . . . . 2.0800000000000001 109.737 172.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' 2083 ' ' THR . 32.1 tptt -117.33 118.89 33.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.655 -0.702 . . . . 1.48 109.411 178.353 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.4 m -111.85 113.73 26.24 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.482 0.658 . . . . 0.63 110.882 176.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 67.0 mt -110.18 113.9 56.23 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.302 -0.999 . . . . 1.6200000000000001 108.302 174.364 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -47.41 109.4 0.22 Allowed 'Trans proline' 0 N--CA 1.474 0.324 0 C-N-CA 123.49 2.793 . . . . 0.97999999999999998 113.879 -171.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 89.42 -11.56 69.49 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.814 -0.63 . . . . 0.93999999999999995 112.73 176.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.54 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.5 tm0? -98.22 -28.45 13.7 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.059 0.456 . . . . 2.02 110.008 -175.098 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 130.37 -173.8 19.88 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.712 -0.756 . . . . 0.5 112.765 173.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -147.79 138.96 23.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.71 0.767 . . . . 0.48999999999999999 110.436 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.536 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.2 OUTLIER -114.14 131.4 56.44 Favored 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 107.261 -1.385 . . . . 1.4399999999999999 107.261 175.382 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 23.7 p -127.84 128.72 45.72 Favored 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 120.527 -0.469 . . . . 0.63 112.173 -174.665 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.539 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -116.96 129.66 73.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.579 -0.737 . . . . 1.1799999999999999 109.753 170.727 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A 2087 ' ' VAL . . . . . 0.426 ' CG2' HG23 ' A' 2091 ' ' THR . 27.5 m -118.45 145.37 37.18 Favored Pre-proline 0 C--N 1.319 -0.734 0 CA-C-N 115.968 -0.56 . . . . 0.80000000000000004 109.534 173.785 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -59.76 -5.33 3.43 Favored 'Trans proline' 0 N--CA 1.477 0.548 0 C-N-CA 123.85 3.033 . . . . 0.96999999999999997 114.682 -168.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 28.5 t70 -68.82 -21.35 64.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.276 0.56 . . . . 2.29 109.81 176.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.24 7.86 26.08 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.899 -0.667 . . . . 0.82999999999999996 112.077 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2091 ' ' THR . . . . . 0.426 HG23 ' CG2' ' A' 2087 ' ' VAL . 1.6 t -107.21 124.44 49.74 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.34 0.591 . . . . 1.51 110.559 -179.139 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.634 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 10.1 t -129.49 138.48 54.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.351 -0.841 . . . . 1.1799999999999999 109.716 -178.727 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.8 t -123.05 115.29 21.6 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.456 0.646 . . . . 1.46 110.571 175.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2094 ' ' PHE . . . . . 0.485 ' O ' ' HD3' ' A' 2096 ' ' PRO . 14.2 m-30 -85.8 98.47 10.76 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.648 -0.871 . . . . 1.27 108.648 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 7.5 m -113.28 88.08 12.14 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.968 0.414 . . . . 0.57999999999999996 111.302 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2096 ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' 2094 ' ' PHE . 96.8 Cg_endo -92.63 145.44 2.59 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.294 2.663 . . . . 0.97999999999999998 112.683 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.46 102.69 11.28 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.19 -0.67 . . . . 2.7200000000000002 109.19 170.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2098 ' ' LYS . . . . . 0.682 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -87.08 10.89 15.19 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.763 -0.653 . . . . 4.8099999999999996 111.371 -175.036 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -106.44 8.85 31.74 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.193 0.521 . . . . 4.4199999999999999 109.83 177.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 64.9 t80 -79.58 80.59 5.95 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.52 -0.764 . . . . 2.3599999999999999 109.666 174.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 16.6 t -85.13 98.24 6.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.079 -0.51 . . . . 2.6800000000000002 109.78 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.3 48.98 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.639 -0.71 . . . . 3.8399999999999999 111.436 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 1.2 mptm? 59.27 73.76 0.65 Allowed Pre-proline 0 CA--C 1.532 0.26 0 C-N-CA 122.895 0.478 . . . . 6.7800000000000002 111.418 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.04 131.89 41.69 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.456 2.104 . . . . 2.4300000000000002 111.115 175.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.482 ' HB3' HD13 ' A' 2078 ' ' ILE . 35.6 t70 -68.99 131.23 90.96 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-N 116.098 -0.501 . . . . 2.3300000000000001 110.373 -178.053 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.54 131.98 18.27 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 123.083 2.522 . . . . 1.03 113.616 -177.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 14.7 p -161.26 144.03 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.372 -0.831 . . . . 0.59999999999999998 109.644 174.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2108 ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' 2121 ' ' ALA . 42.9 m -109.79 125.5 52.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.433 0.635 . . . . 0.37 110.744 177.206 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -102.56 138.91 25.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.46 -0.791 . . . . 0.76000000000000001 108.946 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2110 ' ' LYS . . . . . 0.536 ' HG2' ' N ' ' A' 2111 ' ' ARG . 23.5 ttpt -139.68 153.43 47.27 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.296 0.498 . . . . 1.6299999999999999 112.297 -172.768 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.634 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 31.7 ptt180 -175.38 142.76 0.61 Allowed 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 108.447 -0.945 . . . . 3.4700000000000002 108.447 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2112 ' ' VAL . . . . . 0.485 ' O ' HG21 ' A' 2065 ' ' VAL . 33.7 m -99.22 150.21 5.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.297 -178.088 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.677 ' OD1' ' HB ' ' A' 2117 ' ' THR . 7.1 p30 -91.32 -169.31 2.29 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.72 -0.673 . . . . 1.46 111.22 179.535 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 97.5 mttt -58.93 -38.04 78.08 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.354 -0.385 . . . . 1.72 111.64 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -78.72 -30.27 45.82 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.256 0.551 . . . . 1.8400000000000001 109.79 -177.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 115.74 17.85 6.29 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.268 -0.878 . . . . 0.44 112.055 178.271 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.677 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.3 m -88.15 119.21 70.28 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 110.167 -0.309 . . . . 0.56999999999999995 110.167 178.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' 2111 ' ' ARG . 8.7 Cg_exo -71.89 104.12 1.58 Allowed 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.365 2.044 . . . . 0.60999999999999999 112.173 177.453 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 15.4 m -75.08 113.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 108.254 -1.017 . . . . 0.59999999999999998 108.254 170.345 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2120 ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' 2109 ' ' VAL . 60.6 p -120.93 161.23 21.94 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.467 -0.788 . . . . 0.67000000000000004 111.391 -172.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2121 ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.36 127.04 41.89 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 107.601 -1.259 . . . . 0.72999999999999998 107.601 168.334 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.5 m -115.78 100.65 8.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.285 0.564 . . . . 2.1899999999999999 110.696 -172.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -89.83 131.7 35.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.827 -0.624 . . . . 2.8100000000000001 110.306 176.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 13.4 m -124.01 166.26 20.04 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.716 -0.675 . . . . 2.0600000000000001 109.486 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 70.1 Cg_exo . . . . . 0 C--O 1.236 0.414 0 C-N-CA 122.466 2.111 . . . . 2.1600000000000001 112.251 177.109 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.519 -0.221 0 CA-C-O 120.636 0.255 . . . . 2.4199999999999999 111.087 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -73.56 -14.83 24.8 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.176 1.918 . . . . 1.72 111.313 176.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.47 -41.13 61.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.629 -0.714 . . . . 2.3399999999999999 110.04 177.314 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 1.8 t -126.4 98.77 31.6 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.711 -0.477 . . . . 0.87 109.711 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.69 131.62 41.05 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.171 1.914 . . . . 1.04 111.842 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 49.8 mm -55.67 129.68 17.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 CA-C-N 115.68 -0.691 . . . . 0.77000000000000002 110.622 -178.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2062 ' ' ASP . . . . . 0.602 ' O ' HG22 ' A' 2065 ' ' VAL . 11.3 t70 -75.62 139.62 42.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.983 0.42 . . . . 1.4199999999999999 110.232 -177.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -89.71 -4.75 57.57 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.149 0.425 . . . . 1.55 112.149 -171.492 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 81.8 p -99.33 -13.61 19.55 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.527 -0.469 . . . . 0.68999999999999995 111.238 178.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2065 ' ' VAL . . . . . 0.643 ' O ' ' HD3' ' A' 2067 ' ' PRO . 31.4 m -79.92 -174.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.891 -0.411 . . . . 0.81999999999999995 109.891 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -95.33 109.55 45.73 Favored Pre-proline 0 C--O 1.238 0.447 0 CA-C-O 121.078 0.466 . . . . 0.78000000000000003 111.63 -179.605 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2067 ' ' PRO . . . . . 0.643 ' HD3' ' O ' ' A' 2065 ' ' VAL . 65.4 Cg_endo -100.77 123.23 0.11 Allowed 'Trans proline' 0 N--CA 1.441 -1.605 0 C-N-CA 123.46 2.774 . . . . 0.45000000000000001 110.851 165.384 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2068 ' ' THR . . . . . 0.492 HG22 ' HE3' ' A' 2074 ' ' LYS . 3.6 p -153.28 -179.23 7.54 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.69999999999999996 110.601 -178.479 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2069 ' ' PHE . . . . . 0.625 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 8.5 m-30 -102.43 154.63 18.9 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 107.405 -1.332 . . . . 1.1599999999999999 107.405 163.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -54.45 -35.84 63.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 118.65 0.659 . . . . 2.0899999999999999 111.748 -171.188 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -78.35 4.9 11.73 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.235 0.457 . . . . 2.1499999999999999 112.235 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 80.48 24.95 57.91 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.127 -0.558 . . . . 0.63 111.903 -177.686 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 14.7 m -94.07 156.46 16.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.629 0.252 . . . . 0.89000000000000001 110.797 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2074 ' ' LYS . . . . . 0.492 ' HE3' HG22 ' A' 2068 ' ' THR . 0.1 OUTLIER -120.79 5.18 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.25 0.548 . . . . 1.1299999999999999 110.913 179.768 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.58 140.75 4.98 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.123 -0.695 . . . . 2.0800000000000001 109.123 170.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2076 ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' 2083 ' ' THR . 16.5 tptt -138.88 104.0 4.95 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.273 -0.421 . . . . 1.48 110.065 174.329 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 49.0 m -101.51 118.03 36.13 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.123 0.487 . . . . 0.63 110.273 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2078 ' ' ILE . . . . . 0.563 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 75.5 mt -117.16 119.89 34.29 Favored Pre-proline 0 C--N 1.315 -0.925 0 N-CA-C 108.407 -0.96 . . . . 1.6200000000000001 108.407 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -47.11 109.87 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.486 2.791 . . . . 0.97999999999999998 113.496 -174.102 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.42 -12.76 68.95 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.81 -0.632 . . . . 0.93999999999999995 112.677 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2081 ' ' GLN . . . . . 0.563 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.9 tt0 -101.13 -26.28 13.73 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.164 0.507 . . . . 2.02 110.183 -177.354 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 112.85 -163.95 12.1 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.539 -0.838 . . . . 0.5 112.782 173.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2083 ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' 2076 ' ' LYS . 28.1 m -137.14 145.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 121.808 0.814 . . . . 0.48999999999999999 110.553 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2084 ' ' TYR . . . . . 0.625 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 12.8 m-85 -107.13 112.48 25.41 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 106.892 -1.522 . . . . 1.4399999999999999 106.892 166.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 25.3 p -104.99 134.76 47.55 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.745 -0.382 . . . . 0.63 111.563 -173.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2086 ' ' ILE . . . . . 0.599 ' HA ' ' O ' ' A' 2091 ' ' THR . 1.6 tt -151.19 130.55 3.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.799 -0.637 . . . . 1.1799999999999999 111.422 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2087 ' ' VAL . . . . . 0.59 HG22 ' OG1' ' A' 2091 ' ' THR . 18.6 m -115.1 157.75 42.74 Favored Pre-proline 0 C--N 1.328 -0.343 0 N-CA-C 109.565 -0.531 . . . . 0.80000000000000004 109.565 175.43 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.17 -0.54 2.28 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 123.69 2.926 . . . . 0.96999999999999997 114.137 -172.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 19.1 t70 -78.03 -23.18 48.29 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.293 0.568 . . . . 2.29 109.927 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 112.74 17.17 8.13 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.581 -0.736 . . . . 0.82999999999999996 112.133 -178.26 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2091 ' ' THR . . . . . 0.599 ' O ' ' HA ' ' A' 2086 ' ' ILE . 3.2 p -90.51 116.2 28.24 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.355 -0.609 . . . . 1.51 109.355 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2092 ' ' VAL . . . . . 0.473 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 3.8 t -136.2 132.38 49.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.781 -0.368 . . . . 1.1799999999999999 110.285 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.2 t -137.33 122.8 19.58 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.401 0.62 . . . . 1.46 110.239 176.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -86.33 98.41 10.96 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.976 -0.75 . . . . 1.27 108.976 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 16.4 m -121.38 84.59 41.61 Favored Pre-proline 0 N--CA 1.453 -0.284 0 C-N-CA 119.676 -0.81 . . . . 0.57999999999999996 111.585 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -93.47 147.71 2.29 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 123.248 2.632 . . . . 0.97999999999999998 111.884 170.341 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.27 86.35 5.04 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.225 -0.658 . . . . 2.7200000000000002 109.225 171.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 43.8 mtmt -63.26 -24.03 67.69 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.488 -0.778 . . . . 4.8099999999999996 110.92 -175.282 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 83.1 mm-40 -96.44 12.98 29.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.789 -0.641 . . . . 4.4199999999999999 111.052 -176.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.72 104.09 13.55 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.732 -0.667 . . . . 2.3599999999999999 110.414 176.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 86.3 t -90.7 98.7 8.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.399 0.619 . . . . 2.6800000000000002 109.529 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -162.78 -152.86 6.95 Favored Glycine 0 N--CA 1.445 -0.756 0 N-CA-C 110.704 -0.958 . . . . 3.8399999999999999 110.704 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2103 ' ' LYS . . . . . 0.479 ' HB3' ' NZ ' ' A' 2103 ' ' LYS . 0.0 OUTLIER -109.76 94.86 18.05 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 121.3 0.571 . . . . 6.7800000000000002 110.235 177.123 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -76.81 161.43 33.44 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.868 2.379 . . . . 2.4300000000000002 112.391 -177.482 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2105 ' ' ASP . . . . . 0.47 ' HB2' HD13 ' A' 2078 ' ' ILE . 0.6 OUTLIER -102.01 141.04 21.74 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.027 -0.533 . . . . 2.3300000000000001 110.508 179.63 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A 2106 ' ' PRO . . . . . 0.587 ' HA ' ' O ' ' A' 2123 ' ' TYR . 55.5 Cg_endo -68.99 121.25 8.1 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 123.181 2.587 . . . . 1.03 113.467 -176.669 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.6 p -157.51 143.85 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.414 -0.812 . . . . 0.59999999999999998 109.707 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 15.6 m -121.48 130.68 53.71 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.37 110.574 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2109 ' ' VAL . . . . . 0.435 HG13 ' CD2' ' A' 2069 ' ' PHE . 2.7 t -92.99 144.68 8.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.101 -0.703 . . . . 0.76000000000000001 109.101 177.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -143.36 108.35 4.95 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 118.157 0.435 . . . . 1.6299999999999999 111.635 -173.084 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2111 ' ' ARG . . . . . 0.473 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -147.25 139.09 24.24 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 121.722 -0.611 . . . . 3.4700000000000002 109.88 171.324 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.5 m -103.5 154.69 5.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 120.926 0.393 . . . . 0.40000000000000002 110.907 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2113 ' ' ASP . . . . . 0.421 ' OD1' ' HB ' ' A' 2117 ' ' THR . 2.3 p-10 -96.29 -167.74 1.63 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.029 -0.532 . . . . 1.46 110.102 178.232 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.4 mttt -53.64 -44.47 69.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.954 -0.566 . . . . 1.72 112.175 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.28 -14.92 45.11 Favored 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 120.487 -0.485 . . . . 1.8400000000000001 111.157 -176.165 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 104.29 15.23 22.04 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.272 -0.966 . . . . 0.44 112.937 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2117 ' ' THR . . . . . 0.45 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 98.1 m -75.85 114.65 38.94 Favored Pre-proline 0 C--N 1.324 -0.538 0 N-CA-C 109.887 -0.412 . . . . 0.56999999999999995 109.887 174.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2118 ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.2 Cg_exo -77.49 100.79 1.42 Allowed 'Trans proline' 0 N--CA 1.454 -0.817 0 C-N-CA 122.407 2.072 . . . . 0.60999999999999999 112.318 179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 7.0 m -74.94 109.36 7.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.433 -0.951 . . . . 0.59999999999999998 108.433 169.524 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2120 ' ' THR . . . . . . . . . . . . . 69.3 p -118.86 -174.31 2.67 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.88 -1.054 . . . . 0.67000000000000004 109.977 -174.514 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -149.88 127.21 11.41 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.743 -0.836 . . . . 0.72999999999999998 108.743 170.153 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 34.5 p -100.44 97.87 8.55 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.568 -0.53 . . . . 2.1899999999999999 109.568 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A 2123 ' ' TYR . . . . . 0.587 ' O ' ' HA ' ' A' 2106 ' ' PRO . 12.1 m-85 -118.44 124.35 47.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 111.568 -177.231 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2124 ' ' SER . . . . . 0.5 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 49.5 m -157.77 171.82 6.94 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.689 -1.141 . . . . 2.0600000000000001 108.75 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A 2125 ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' 2124 ' ' SER . 90.4 Cg_exo . . . . . 0 C--N 1.348 0.516 0 C-N-CA 122.318 2.012 . . . . 2.1600000000000001 112.45 173.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 28.2 pt20 . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 110.113 -0.328 . . . . 6.8499999999999996 110.113 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 72.39 -77.06 0.75 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.094 -0.574 . . . . 3.4100000000000001 112.47 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -158.61 84.0 0.13 Allowed Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 111.192 -0.763 . . . . 1.77 111.192 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -63.68 121.44 70.64 Favored Pre-proline 0 C--N 1.327 -0.413 0 CA-C-O 121.153 0.502 . . . . 2.4199999999999999 111.384 -177.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.23 -40.18 4.86 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.002 2.468 . . . . 1.72 112.46 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2058 ' ' LEU . . . . . 0.596 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -81.97 -2.08 50.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 2.3399999999999999 111.607 -177.591 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.596 HG23 HD13 ' A' 2058 ' ' LEU . 13.5 t -136.92 84.42 25.75 Favored Pre-proline 0 C--N 1.326 -0.426 0 N-CA-C 109.159 -0.682 . . . . 0.87 109.159 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2060 ' ' PRO . . . . . 0.508 ' O ' ' HG3' ' A' 2114 ' ' LYS . 41.6 Cg_exo -55.73 130.64 41.48 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.532 2.155 . . . . 1.04 111.804 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2061 ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' 2113 ' ' ASP . 41.6 mm -64.49 141.74 17.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.561 . . . . 0.77000000000000002 109.709 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.512 ' O ' HG22 ' A' 2065 ' ' VAL . 10.3 t70 -80.05 128.11 33.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.361 -0.381 . . . . 1.4199999999999999 110.289 -175.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -91.34 1.96 56.74 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.404 -0.362 . . . . 1.55 111.958 -172.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 74.4 p -110.73 -5.04 15.06 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.009 0.433 . . . . 0.68999999999999995 111.171 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.637 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.9 m -91.67 -174.01 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.453 . . . . 0.81999999999999995 109.857 178.187 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -89.64 111.26 44.94 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.154 0.502 . . . . 0.78000000000000003 111.162 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.637 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.2 Cg_endo -100.71 109.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 123.608 2.872 . . . . 0.45000000000000001 110.792 166.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 9.0 p -148.31 -176.52 5.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.146 0.498 . . . . 0.69999999999999996 110.963 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.606 ' CD2' HG13 ' A' 2109 ' ' VAL . 3.5 m-30 -101.6 156.39 17.51 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 107.165 -1.42 . . . . 1.1599999999999999 107.165 166.15 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -53.8 -34.95 60.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 118.261 0.482 . . . . 2.0899999999999999 111.951 -169.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -74.81 -4.92 40.62 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.886 0.374 . . . . 2.1499999999999999 111.312 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.91 14.49 57.82 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 121.246 -0.502 . . . . 0.63 111.854 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2073 ' ' SER . . . . . 0.473 ' OG ' ' HB2' ' A' 2069 ' ' PHE . 0.3 OUTLIER -85.78 161.78 18.99 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.666 0.27 . . . . 0.89000000000000001 111.277 -174.769 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -115.52 -23.82 8.61 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.431 -0.35 . . . . 1.1299999999999999 111.912 -174.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' 2084 ' ' TYR . 1.6 tm-20 -151.87 137.31 17.67 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.254 0.55 . . . . 2.0800000000000001 110.167 173.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.0 OUTLIER -131.64 99.7 4.88 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.472 -0.786 . . . . 1.48 109.99 175.44 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 7.7 m -103.06 111.78 24.3 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.945 -0.57 . . . . 0.63 110.598 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.548 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 44.4 mm -114.39 123.05 33.05 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 108.004 -1.11 . . . . 1.6200000000000001 108.004 173.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.27 108.69 0.17 Allowed 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.043 2.495 . . . . 0.97999999999999998 113.039 -176.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 100.99 -18.55 54.57 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.644 -0.707 . . . . 0.93999999999999995 112.886 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.548 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -90.59 -30.19 17.35 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.257 0.551 . . . . 2.02 110.827 -173.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.56 -174.58 15.31 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.587 -0.733 . . . . 0.5 111.58 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.45 HG22 HG23 ' A' 2085 ' ' THR . 15.5 m -133.88 134.41 42.67 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.583 0.706 . . . . 0.48999999999999999 110.523 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' 2075 ' ' GLU . 1.5 m-85 -109.47 120.18 41.7 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.986 -1.487 . . . . 1.4399999999999999 106.986 172.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.45 HG23 HG22 ' A' 2083 ' ' THR . 0.7 OUTLIER -127.89 121.59 30.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 112.447 0.536 . . . . 0.63 112.447 -171.789 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.458 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -115.54 134.91 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.089 -0.505 . . . . 1.1799999999999999 110.198 173.703 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 33.6 m -118.2 150.37 47.47 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 109.413 -0.588 . . . . 0.80000000000000004 109.413 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.99 -4.08 0.85 Allowed 'Trans proline' 0 N--CA 1.481 0.768 0 C-N-CA 123.959 3.106 . . . . 0.96999999999999997 114.637 -172.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.73 -7.8 52.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.902 0.382 . . . . 2.29 110.506 176.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 91.18 16.98 52.54 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.91 -0.662 . . . . 0.82999999999999996 112.063 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.2 t -118.61 138.54 52.51 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.854 0.359 . . . . 1.51 110.433 -179.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.461 ' CG2' ' HB2' ' A' 2067 ' ' PRO . 7.4 t -131.21 140.58 48.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.126 -0.488 . . . . 1.1799999999999999 110.512 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -101.99 108.92 20.52 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 116.299 -0.41 . . . . 1.46 110.49 174.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -86.69 96.32 10.1 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.162 -1.051 . . . . 1.27 108.162 173.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 25.1 m -119.04 88.25 36.21 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 121.121 0.486 . . . . 0.57999999999999996 110.554 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.29 2.66 . . . . 0.97999999999999998 111.877 176.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.2 t70 -132.14 99.43 4.71 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.883 0.373 . . . . 2.7200000000000002 110.083 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.23 13.9 2.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.275 -0.42 . . . . 4.8099999999999996 111.101 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 69.1 mt-30 -109.52 5.57 23.32 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.256 0.551 . . . . 4.4199999999999999 109.716 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 52.5 t80 -89.3 92.55 9.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 2.3599999999999999 110.992 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 92.0 t -83.76 107.78 15.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.586 -0.524 . . . . 2.6800000000000002 109.586 174.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.14 -133.55 2.85 Favored Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.673 -0.694 . . . . 3.8399999999999999 111.456 -178.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 61.6 tttm -127.67 99.07 27.06 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.769 0.284 . . . . 6.7800000000000002 110.94 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.92 155.03 48.37 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.318 2.012 . . . . 2.4300000000000002 111.73 174.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.3 t70 -83.42 127.02 70.09 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.066 -0.515 . . . . 2.3300000000000001 109.968 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.654 ' HA ' ' O ' ' A' 2123 ' ' TYR . 43.1 Cg_exo -56.34 102.68 0.1 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.026 2.484 . . . . 1.03 112.881 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.2 p -147.42 138.93 18.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.095 -0.502 . . . . 0.59999999999999998 110.38 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 56.6 m -112.96 124.16 51.99 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.001 -0.545 . . . . 0.37 110.149 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.606 HG13 ' CD2' ' A' 2069 ' ' PHE . 4.7 t -91.63 131.17 39.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.835 -0.802 . . . . 0.76000000000000001 108.835 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -143.6 108.94 5.04 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 112.989 0.737 . . . . 1.6299999999999999 112.989 -173.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.42 ' HD2' HG21 ' A' 2061 ' ' ILE . 28.1 ptt180 -129.65 140.62 51.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.741 -0.837 . . . . 3.4700000000000002 108.741 171.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.457 HG23 HG21 ' A' 2065 ' ' VAL . 35.9 m -99.58 142.01 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 120.358 -0.537 . . . . 0.40000000000000002 110.997 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.669 ' OD1' ' HB ' ' A' 2117 ' ' THR . 4.3 p30 -85.24 -170.72 3.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.949 -0.569 . . . . 1.46 111.615 -178.034 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2114 ' ' LYS . . . . . 0.508 ' HG3' ' O ' ' A' 2060 ' ' PRO . 91.5 mttt -57.55 -37.17 72.67 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.851 0.315 . . . . 1.72 111.851 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -80.09 -29.7 39.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.313 0.578 . . . . 1.8400000000000001 109.901 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 112.6 21.62 6.04 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.321 -0.854 . . . . 0.44 112.418 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.669 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 92.4 m -86.91 120.97 71.88 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 110.214 -0.291 . . . . 0.56999999999999995 110.214 177.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' 2117 ' ' THR . 7.5 Cg_exo -73.16 101.88 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.453 2.102 . . . . 0.60999999999999999 112.433 178.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.7 m -75.07 113.0 13.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.527 -0.916 . . . . 0.59999999999999998 108.527 171.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' 2109 ' ' VAL . 37.8 p -119.66 154.82 33.46 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 115.483 -0.781 . . . . 0.67000000000000004 112.617 -169.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -130.29 127.54 39.71 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.892 -1.151 . . . . 0.72999999999999998 107.892 167.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.2 m -115.87 103.87 11.06 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.072 0.463 . . . . 2.1899999999999999 110.527 -174.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.654 ' O ' ' HA ' ' A' 2106 ' ' PRO . 3.1 m-85 -98.33 132.29 43.92 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-O 121.198 0.523 . . . . 2.8100000000000001 111.19 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 44.3 m -157.14 165.37 18.95 Favored Pre-proline 0 C--N 1.321 -0.635 0 N-CA-C 108.433 -0.951 . . . . 2.0600000000000001 108.433 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -58.5 -6.09 2.89 Favored 'Trans proline' 0 C--N 1.353 0.783 0 C-N-CA 123.199 2.599 . . . . 2.1600000000000001 114.064 -176.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -81.45 -36.23 29.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.357 0.598 . . . . 4.3300000000000001 109.468 175.08 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -86.12 68.55 10.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.544 -0.753 . . . . 3.8300000000000001 110.703 -175.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -117.82 -81.11 0.62 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.038 -0.528 . . . . 5.1100000000000003 111.05 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 17.3 ptpt -87.99 52.04 2.36 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.654 0.74 . . . . 5.2199999999999998 110.578 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 29.4 t . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.197 -0.91 . . . . 5.8799999999999999 110.223 -177.214 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 26.4 mp0 . . . . . 0 N--CA 1.483 1.193 0 CA-C-O 120.785 0.326 . . . . 6.8499999999999996 110.337 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 63.67 39.04 97.11 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.762 -0.732 . . . . 3.4100000000000001 111.376 -175.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 127.5 123.38 2.61 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.171 -0.772 . . . . 1.77 111.171 -175.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -88.42 117.02 67.91 Favored Pre-proline 0 C--N 1.322 -0.588 0 CA-C-O 120.582 0.23 . . . . 2.4199999999999999 110.621 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.87 -21.91 18.1 Favored 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.404 2.07 . . . . 1.72 111.933 -178.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.74 -18.48 59.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.673 -0.694 . . . . 2.3399999999999999 110.465 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.456 HG11 ' OD2' ' A' 2113 ' ' ASP . 5.0 t -133.63 98.38 14.99 Favored Pre-proline 0 N--CA 1.452 -0.341 0 CA-C-N 116.062 -0.517 . . . . 0.87 109.811 177.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2060 ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' 2059 ' ' VAL . 11.3 Cg_endo -55.76 118.86 5.69 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.039 1.826 . . . . 1.04 111.827 178.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.8 mm -53.6 136.84 14.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.251 -0.886 . . . . 0.77000000000000002 111.346 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.517 ' O ' HG22 ' A' 2065 ' ' VAL . 14.8 t70 -71.57 131.56 43.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 1.4199999999999999 110.144 178.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -86.76 -5.2 59.19 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.238 -0.437 . . . . 1.55 112.131 -172.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.7 p -111.37 3.82 18.53 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.091 0.404 . . . . 0.68999999999999995 112.091 -177.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' 2062 ' ' ASP . 27.1 m -90.19 -177.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.728 -0.471 . . . . 0.81999999999999995 109.728 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -94.06 116.73 66.79 Favored Pre-proline 0 C--O 1.241 0.625 0 CA-C-O 121.382 0.61 . . . . 0.78000000000000003 111.6 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.515 ' HB2' HG13 ' A' 2086 ' ' ILE . 28.4 Cg_endo -100.39 108.55 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 123.59 2.86 . . . . 0.45000000000000001 111.416 167.155 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.459 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.4 p -143.37 145.25 32.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.887 0.375 . . . . 0.69999999999999996 110.549 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.692 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-30 -70.78 156.13 39.91 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 107.936 -1.135 . . . . 1.1599999999999999 107.936 177.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -51.73 -39.13 57.92 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 123.404 0.44 . . . . 2.0899999999999999 111.819 -170.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -91.12 19.18 6.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 2.1499999999999999 111.358 -177.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 75.44 29.44 59.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.047 -0.597 . . . . 0.63 112.66 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2073 ' ' SER . . . . . 0.436 ' HB2' ' CD1' ' A' 2069 ' ' PHE . 7.4 m -95.34 162.32 13.72 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 122.743 -0.269 . . . . 0.89000000000000001 110.904 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.7 mmtp -121.57 -24.9 5.23 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.268 -0.424 . . . . 1.1299999999999999 111.673 -177.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.628 ' HA ' ' O ' ' A' 2084 ' ' TYR . 2.0 tt0 -158.62 124.64 4.54 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.368 0.604 . . . . 2.0800000000000001 110.583 175.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -123.55 102.19 7.73 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.375 -0.829 . . . . 1.48 109.931 175.211 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.7 m -95.92 113.22 24.82 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.204 0.526 . . . . 0.63 110.576 175.157 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 27.3 mm -116.07 108.86 45.48 Favored Pre-proline 0 C--N 1.31 -1.133 0 N-CA-C 107.627 -1.249 . . . . 1.6200000000000001 107.627 170.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.08 115.43 1.7 Allowed 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 123.183 2.589 . . . . 0.97999999999999998 113.41 -173.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2080 ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' 2100 ' ' PHE . . . 89.58 -8.41 79.88 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.775 -0.648 . . . . 0.93999999999999995 112.513 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.529 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.0 OUTLIER -107.49 -31.05 8.3 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.219 0.533 . . . . 2.02 109.903 -176.679 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 136.45 172.0 12.45 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.519 -0.848 . . . . 0.5 112.94 173.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.4 ' O ' ' HB ' ' A' 2095 ' ' THR . 77.7 m -138.23 127.93 25.12 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.304 0.573 . . . . 0.48999999999999999 109.696 172.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.692 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.1 OUTLIER -108.16 125.99 52.26 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 107.698 -1.223 . . . . 1.4399999999999999 107.698 175.52 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 1.3 p -127.86 129.31 46.71 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 112.074 0.398 . . . . 0.63 112.074 -174.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.515 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.47 132.09 71.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.854 -0.612 . . . . 1.1799999999999999 110.52 174.601 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -125.79 142.56 42.52 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.788 -0.642 . . . . 0.80000000000000004 109.3 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.57 -0.05 1.71 Allowed 'Trans proline' 0 N--CA 1.476 0.491 0 C-N-CA 123.827 3.018 . . . . 0.96999999999999997 114.177 -170.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 36.8 t70 -72.77 -11.8 60.75 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.41 0.624 . . . . 2.29 109.836 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 106.26 6.24 36.6 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.629 -0.714 . . . . 0.82999999999999996 112.381 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 2.2 t -110.8 128.06 55.62 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.257 0.551 . . . . 1.51 110.274 -179.118 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.471 HG13 ' HB ' ' A' 2086 ' ' ILE . 18.8 t -137.17 137.25 46.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.527 -0.76 . . . . 1.1799999999999999 109.624 -175.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 24.0 m -119.8 109.77 15.99 Favored 'General case' 0 N--CA 1.439 -0.997 0 CA-C-O 120.816 0.341 . . . . 1.46 111.3 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2094 ' ' PHE . . . . . 0.414 ' O ' ' HD3' ' A' 2096 ' ' PRO . 5.8 m-30 -89.65 98.88 12.02 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.26 -0.645 . . . . 1.27 109.26 174.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2095 ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' 2083 ' ' THR . 23.0 m -114.01 89.42 16.72 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 120.683 0.278 . . . . 0.57999999999999996 111.662 -178.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2096 ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' 2094 ' ' PHE . 73.0 Cg_endo -92.52 119.34 0.44 Allowed 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.971 2.447 . . . . 0.97999999999999998 112.702 175.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -89.87 84.68 6.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.34 0.59 . . . . 2.7200000000000002 109.563 173.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2098 ' ' LYS . . . . . 0.511 ' HA ' ' CG2' ' A' 2128 ' ' THR . 0.0 OUTLIER -75.69 -1.91 27.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.566 -0.743 . . . . 4.8099999999999996 112.374 -171.596 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -84.9 -2.02 57.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.168 0.509 . . . . 4.4199999999999999 110.523 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2100 ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' 2080 ' ' GLY . 69.0 t80 -83.49 85.47 7.24 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 2.3599999999999999 110.377 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.8 t -92.35 99.63 10.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.147 -0.478 . . . . 2.6800000000000002 110.196 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -169.53 -101.93 0.15 Allowed Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.415 -0.674 . . . . 3.8399999999999999 111.415 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 53.3 mtmt -131.6 73.25 79.59 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-O 120.611 0.244 . . . . 6.7800000000000002 110.615 174.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2104 ' ' PRO . . . . . 0.426 ' HD2' ' O ' ' A' 2125 ' ' PRO . 18.9 Cg_exo -66.06 127.93 18.63 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.383 2.055 . . . . 2.4300000000000002 111.312 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.3 t70 -60.79 122.88 71.85 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.001 -0.545 . . . . 2.3300000000000001 110.665 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' 2123 ' ' TYR . 31.8 Cg_exo -58.93 120.37 8.19 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 123.101 2.534 . . . . 1.03 112.174 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.7 p -156.72 161.51 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.93 -0.577 . . . . 0.59999999999999998 109.731 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' 2121 ' ' ALA . 67.0 m -140.88 119.74 12.62 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.933 0.397 . . . . 0.37 110.08 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.4 t -92.5 145.18 7.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.029 -0.73 . . . . 0.76000000000000001 109.029 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.459 ' HB3' ' O ' ' A' 2068 ' ' THR . 0.0 OUTLIER -147.47 143.21 27.72 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.224 0.465 . . . . 1.6299999999999999 111.341 -174.787 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.425 ' N ' ' HD2' ' A' 2110 ' ' LYS . 27.2 ptt180 -166.95 146.07 5.28 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.676 -0.861 . . . . 3.4700000000000002 108.676 166.238 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.444 ' O ' HG21 ' A' 2065 ' ' VAL . 30.5 m -99.01 149.19 5.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 C-N-CA 120.44 -0.504 . . . . 0.40000000000000002 111.289 -175.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.456 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.8 p-10 -90.51 -169.39 2.38 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.951 -0.568 . . . . 1.46 109.976 178.433 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2114 ' ' LYS . . . . . 0.402 ' HG2' ' HB2' ' A' 2062 ' ' ASP . 96.9 mttt -59.97 -38.56 82.88 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.542 0.21 . . . . 1.72 111.008 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 18.2 m120 -71.66 -30.28 65.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.844 0.354 . . . . 1.8400000000000001 110.857 177.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 110.55 12.93 15.65 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.851 -0.69 . . . . 0.44 112.214 179.022 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 5.7 m -79.72 121.58 82.57 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 110.128 -0.323 . . . . 0.56999999999999995 110.128 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.6 Cg_exo -73.95 103.92 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 122.301 2.001 . . . . 0.60999999999999999 112.234 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.5 m -75.32 117.62 19.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.381 -0.97 . . . . 0.59999999999999998 108.381 171.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.545 ' HA ' ' O ' ' A' 2109 ' ' VAL . 47.2 p -129.75 163.35 26.38 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.539 -0.755 . . . . 0.67000000000000004 111.751 -170.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -130.98 126.84 37.07 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.528 -0.915 . . . . 0.72999999999999998 108.528 169.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 20.3 m -100.12 100.45 11.3 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.041 0.448 . . . . 2.1899999999999999 110.335 -176.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.494 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -96.99 114.39 26.0 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.143 -0.48 . . . . 2.8100000000000001 110.899 -177.407 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 17.8 m -127.39 158.57 69.15 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.537 -0.756 . . . . 2.0600000000000001 109.651 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.426 ' O ' ' HD2' ' A' 2104 ' ' PRO . 95.2 Cg_exo -45.31 -45.32 15.35 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.069 2.513 . . . . 2.1600000000000001 113.828 -177.301 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -108.29 28.15 8.61 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 122.213 -0.304 . . . . 4.3300000000000001 111.516 -176.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 79.9 t80 -79.38 -47.09 16.37 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.086 0.47 . . . . 3.8300000000000001 110.8 -179.008 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2128 ' ' THR . . . . . 0.511 ' CG2' ' HA ' ' A' 2098 ' ' LYS . 22.2 p -88.77 109.13 19.91 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.951 -0.568 . . . . 5.1100000000000003 111.934 -173.307 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 9.7 ptmm? -178.24 40.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.85 -1.068 . . . . 5.2199999999999998 109.864 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.248 1.004 0 CA-C-N 115.073 -0.967 . . . . 5.8799999999999999 111.264 -176.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 35.5 tt0 . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.833 0.349 . . . . 6.8499999999999996 110.535 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 101.45 -14.13 58.06 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.611 -0.804 . . . . 3.4100000000000001 112.434 178.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 159.67 -107.93 0.34 Allowed Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.402 -0.904 . . . . 1.77 113.12 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2056 ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 2.3 t70 -83.88 127.2 68.27 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 120.698 0.285 . . . . 2.4199999999999999 111.744 -171.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -76.45 -22.47 12.34 Favored 'Trans proline' 0 N--CA 1.46 -0.471 0 C-N-CA 122.414 2.076 . . . . 1.72 112.477 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.52 -9.57 20.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.821 0.343 . . . . 2.3399999999999999 110.656 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' 2056 ' ' ASP . 21.4 t -127.48 84.48 63.27 Favored Pre-proline 0 CA--C 1.511 -0.534 0 N-CA-C 108.034 -1.099 . . . . 0.87 108.034 175.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -40.48 117.77 0.52 Allowed 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.922 2.415 . . . . 1.04 112.228 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 33.3 mm -54.46 114.96 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.263 -0.88 . . . . 0.77000000000000002 110.911 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 15.7 t70 -72.86 125.71 28.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.47 -0.787 . . . . 1.4199999999999999 111.308 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2063 ' ' GLU . . . . . 0.423 ' HB3' ' O ' ' A' 2089 ' ' ASP . 44.0 mt-10 -86.89 -2.88 58.94 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.127 -0.488 . . . . 1.55 111.805 -173.622 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 43.9 p -106.06 -5.53 19.39 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.741 -0.384 . . . . 0.68999999999999995 111.863 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.2 m -96.26 163.66 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.863 -0.421 . . . . 0.81999999999999995 109.863 176.088 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -73.15 114.09 27.93 Favored Pre-proline 0 C--O 1.24 0.591 0 CA-C-O 121.271 0.557 . . . . 0.78000000000000003 112.22 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.492 ' HB3' ' NH1' ' A' 2111 ' ' ARG . 68.0 Cg_endo -102.29 108.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.423 0 C-N-CA 123.682 2.921 . . . . 0.45000000000000001 112.097 169.105 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 20.9 p -138.61 -178.64 5.4 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.403 0.62 . . . . 0.69999999999999996 111.273 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.489 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.7 OUTLIER -102.01 152.23 21.2 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.862 -1.162 . . . . 1.1599999999999999 107.862 168.72 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -52.39 -39.21 60.56 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.066 0.394 . . . . 2.0899999999999999 111.741 -170.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.36 -2.94 43.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.91 -0.586 . . . . 2.1499999999999999 111.335 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.78 29.36 13.47 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.849 -0.691 . . . . 0.63 112.159 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 9.1 m -98.06 169.15 9.82 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.894 -0.18 . . . . 0.89000000000000001 110.697 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -128.06 -16.64 4.52 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.964 0.412 . . . . 1.1299999999999999 111.343 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.402 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.8 tt0 -156.24 121.09 4.64 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.719 -0.475 . . . . 2.0800000000000001 109.719 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD2' ' HA ' ' A' 2076 ' ' LYS . 4.5 mmmm -115.45 121.86 44.02 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.967 -0.561 . . . . 1.48 109.534 171.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 55.2 m -129.53 121.48 27.28 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.729 -0.669 . . . . 0.63 110.85 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.436 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 48.4 mm -119.69 124.49 27.96 Favored Pre-proline 0 C--N 1.314 -0.965 0 N-CA-C 107.584 -1.265 . . . . 1.6200000000000001 107.584 171.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.73 107.86 0.21 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.332 2.021 . . . . 0.97999999999999998 112.304 -176.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.19 -23.37 27.31 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.811 -0.631 . . . . 0.93999999999999995 112.534 -178.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.436 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 15.7 tt0 -90.73 -31.14 16.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.003 0.43 . . . . 2.02 110.261 -176.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.62 -173.32 14.72 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.714 -0.755 . . . . 0.5 112.86 176.353 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 46.4 m -129.99 132.65 46.35 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.556 0.693 . . . . 0.48999999999999999 110.127 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.478 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 0.5 OUTLIER -111.31 112.47 24.26 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 106.735 -1.58 . . . . 1.4399999999999999 106.735 172.397 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.89 131.69 55.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.429 0.529 . . . . 0.63 112.429 -170.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.504 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.93 137.7 54.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.392 -0.822 . . . . 1.1799999999999999 109.561 174.54 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 31.7 m -118.67 153.3 52.19 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 109.889 -0.411 . . . . 0.80000000000000004 109.889 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -60.3 -4.81 3.43 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.773 2.982 . . . . 0.96999999999999997 114.264 -170.315 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2089 ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' 2063 ' ' GLU . 27.7 m-20 -72.93 -13.08 61.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.907 0.384 . . . . 2.29 110.215 177.223 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.72 16.06 32.37 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.967 -0.635 . . . . 0.82999999999999996 112.263 177.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.7 t -115.61 141.25 48.32 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.806 0.336 . . . . 1.51 110.44 -178.111 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.504 HG22 ' CG1' ' A' 2086 ' ' ILE . 12.5 t -133.32 150.78 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.977 -0.556 . . . . 1.1799999999999999 109.96 -178.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -125.86 122.0 34.82 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.46 110.05 173.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -90.47 98.82 12.0 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.265 -0.642 . . . . 1.27 109.265 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 8.9 m -113.25 87.49 11.12 Favored Pre-proline 0 N--CA 1.454 -0.242 0 CA-C-O 120.964 0.411 . . . . 0.57999999999999996 110.431 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -92.55 -179.88 1.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 123.292 2.661 . . . . 0.97999999999999998 112.399 178.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.4 t70 -131.7 139.65 49.09 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.222 -0.659 . . . . 2.7200000000000002 109.222 170.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -90.23 -26.1 20.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.87 -0.605 . . . . 4.8099999999999996 111.833 -172.314 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 86.4 mm-40 -120.32 36.83 4.43 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.788 0.292 . . . . 4.4199999999999999 111.788 -171.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 19.4 t80 -82.41 87.01 6.64 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.37 0.605 . . . . 2.3599999999999999 110.737 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2101 ' ' VAL . . . . . 0.449 ' HA ' ' HB3' ' A' 2129 ' ' LYS . 46.2 t -92.14 109.84 21.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.793 -0.64 . . . . 2.6800000000000002 109.745 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2102 ' ' GLY . . . . . 0.425 ' C ' ' HD3' ' A' 2104 ' ' PRO . . . 170.75 -113.29 0.49 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.492 -0.643 . . . . 3.8399999999999999 111.492 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -120.01 76.87 22.95 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 121.115 0.483 . . . . 6.7800000000000002 111.533 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2104 ' ' PRO . . . . . 0.425 ' HD3' ' C ' ' A' 2102 ' ' GLY . 8.1 Cg_exo -74.68 157.68 43.93 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.198 2.599 . . . . 2.4300000000000002 111.684 178.184 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.0 t70 -120.09 117.48 32.06 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.477 -0.328 . . . . 2.3300000000000001 110.435 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.532 ' HA ' ' O ' ' A' 2123 ' ' TYR . 52.6 Cg_exo -54.94 128.41 30.42 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.864 2.376 . . . . 1.03 111.828 177.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.1 p -157.51 161.29 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.312 -0.404 . . . . 0.59999999999999998 110.257 -176.125 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.43 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.5 m -140.15 119.05 12.54 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.149 0.5 . . . . 0.37 110.269 176.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.6 t -91.35 138.06 20.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 108.131 -1.063 . . . . 0.76000000000000001 108.131 176.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.495 ' HA ' HG22 ' A' 2120 ' ' THR . 2.2 tmmm? -145.14 108.32 4.57 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.275 0.559 . . . . 1.6299999999999999 111.476 -172.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.492 ' NH1' ' HB3' ' A' 2067 ' ' PRO . 1.4 ptm180 -139.72 142.95 36.82 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 109.207 -0.664 . . . . 3.4700000000000002 109.207 174.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' 2117 ' ' THR . 24.0 m -99.6 161.06 3.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.426 -0.51 . . . . 0.40000000000000002 111.49 -175.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.507 ' OD2' ' HB ' ' A' 2117 ' ' THR . 3.9 p30 -110.01 -169.13 1.41 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.571 -0.74 . . . . 1.46 111.004 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 65.2 mttm -63.49 -25.12 68.12 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 111.938 0.347 . . . . 1.72 111.938 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -85.67 -9.98 56.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.949 0.404 . . . . 1.8400000000000001 110.251 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 86.27 15.99 63.41 Favored Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.333 -0.707 . . . . 0.44 111.333 -176.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.507 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 0.2 OUTLIER -84.99 131.23 49.45 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 109.954 -0.388 . . . . 0.56999999999999995 109.954 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 12.3 Cg_endo -87.78 103.9 0.52 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 122.208 1.938 . . . . 0.60999999999999999 112.428 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 14.8 m -75.42 109.29 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 108.692 -0.855 . . . . 0.59999999999999998 108.692 171.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.495 HG22 ' HA ' ' A' 2110 ' ' LYS . 35.5 p -124.55 169.27 12.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.094 -0.957 . . . . 0.67000000000000004 111.55 -170.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -135.49 127.73 30.08 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.52 -0.764 . . . . 0.72999999999999998 109.6 173.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 13.4 p -94.71 99.67 11.73 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.254 -0.43 . . . . 2.1899999999999999 109.892 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.532 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -103.77 123.93 47.97 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.34 0.59 . . . . 2.8100000000000001 111.788 -174.859 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 25.2 m -154.19 153.07 27.75 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.141 -0.936 . . . . 2.0600000000000001 108.484 175.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -43.45 -38.91 8.98 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 122.837 2.358 . . . . 2.1600000000000001 113.891 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -64.66 -11.79 39.29 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 112.76 0.652 . . . . 4.3300000000000001 112.76 -177.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.54 -5.36 46.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.715 0.293 . . . . 3.8300000000000001 111.416 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 33.0 p -123.25 -39.98 2.42 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.149 0.499 . . . . 5.1100000000000003 110.938 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A 2129 ' ' LYS . . . . . 0.457 ' HG3' HG23 ' A' 2130 ' ' VAL . 51.6 pttt -126.64 -165.27 1.43 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.764 -0.653 . . . . 5.2199999999999998 110.23 177.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A 2130 ' ' VAL . . . . . 0.457 HG23 ' HG3' ' A' 2129 ' ' LYS . 42.6 t . . . . . 0 C--O 1.248 1.026 0 CA-C-O 117.929 -1.034 . . . . 5.8799999999999999 110.185 -178.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 22.0 mp0 . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.821 0.343 . . . . 6.8499999999999996 110.519 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 97.58 79.46 1.46 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.734 -0.746 . . . . 3.4100000000000001 112.188 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 144.58 122.6 1.59 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.712 -0.756 . . . . 1.77 112.016 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 7.1 t70 -79.92 129.36 70.79 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-O 120.678 0.275 . . . . 2.4199999999999999 110.359 -176.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.7 -21.78 33.28 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.387 2.058 . . . . 1.72 112.55 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.9 mm? -93.2 -26.83 17.21 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.887 0.375 . . . . 2.3399999999999999 110.043 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.433 HG11 HD22 ' A' 2115 ' ' ASN . 1.8 t -126.88 90.7 48.9 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.239 -0.437 . . . . 0.87 110.429 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -57.32 121.57 10.28 Favored 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 122.188 1.925 . . . . 1.04 111.586 176.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 48.9 mm -53.04 132.31 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.572 -0.74 . . . . 0.77000000000000002 110.828 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.568 ' O ' HG22 ' A' 2065 ' ' VAL . 24.4 t70 -66.78 135.39 53.89 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 1.4199999999999999 110.493 -177.482 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -92.91 -2.58 55.7 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.195 -0.457 . . . . 1.55 111.889 -171.29 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 31.0 p -106.7 2.21 25.61 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.763 -0.375 . . . . 0.68999999999999995 111.832 178.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' 2062 ' ' ASP . 35.4 m -92.68 -174.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 110.326 -0.249 . . . . 0.81999999999999995 110.326 176.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -91.25 114.13 60.65 Favored Pre-proline 0 C--O 1.24 0.597 0 CA-C-O 121.02 0.438 . . . . 0.78000000000000003 111.389 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' 2065 ' ' VAL . 53.8 Cg_endo -101.06 108.06 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 123.362 2.708 . . . . 0.45000000000000001 111.296 166.46 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 23.2 p -149.25 -177.2 5.7 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.93 0.395 . . . . 0.69999999999999996 110.665 -177.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.632 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 9.3 m-30 -101.56 142.85 32.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.832 -1.173 . . . . 1.1599999999999999 107.832 166.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -64.18 -15.78 60.57 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.421 0.451 . . . . 2.0899999999999999 111.248 -172.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -84.4 2.02 42.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.039 -0.528 . . . . 2.1499999999999999 110.902 176.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 85.58 23.47 46.73 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.111 -0.566 . . . . 0.63 112.706 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.7 p -110.64 164.38 12.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.974 0.416 . . . . 0.89000000000000001 111.37 -177.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2074 ' ' LYS . . . . . 0.602 ' O ' HG22 ' A' 2086 ' ' ILE . 47.9 mmtm -113.32 -44.78 3.2 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.684 -0.689 . . . . 1.1299999999999999 110.696 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.763 ' HG3' HG22 ' A' 2085 ' ' THR . 4.6 mp0 -119.97 138.11 53.67 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.772 -0.455 . . . . 2.0800000000000001 109.772 173.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.5 OUTLIER -127.71 99.25 5.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.15 -0.477 . . . . 1.48 109.736 178.258 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 48.7 m -110.69 121.77 46.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.11 0.481 . . . . 0.63 110.476 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 88.0 mt -126.84 126.17 24.39 Favored Pre-proline 0 C--N 1.315 -0.91 0 N-CA-C 108.521 -0.918 . . . . 1.6200000000000001 108.521 174.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -47.14 109.67 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.295 2.664 . . . . 0.97999999999999998 113.257 -175.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2080 ' ' GLY . . . . . 0.488 ' O ' ' HD2' ' A' 2100 ' ' PHE . . . 93.9 -12.95 68.44 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.706 -0.679 . . . . 0.93999999999999995 113.009 177.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.516 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 0.0 OUTLIER -94.7 -32.47 13.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 117.122 0.461 . . . . 2.02 110.661 -175.96 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.7 -155.24 16.28 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.811 -0.709 . . . . 0.5 111.9 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.555 ' HA ' ' O ' ' A' 2076 ' ' LYS . 55.8 m -155.28 138.92 16.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.698 0.761 . . . . 0.48999999999999999 111.011 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.632 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.2 m-85 -109.01 121.69 45.68 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.774 -1.565 . . . . 1.4399999999999999 106.774 170.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.763 HG22 ' HG3' ' A' 2075 ' ' GLU . 16.8 p -118.84 133.56 55.75 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.721 0.296 . . . . 0.63 111.584 -175.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.602 HG22 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -113.02 136.9 47.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.278 -0.419 . . . . 1.1799999999999999 110.186 176.16 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 18.6 m -122.71 144.82 43.55 Favored Pre-proline 0 C--N 1.319 -0.732 0 N-CA-C 109.975 -0.38 . . . . 0.80000000000000004 109.975 173.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -62.18 0.01 1.52 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.542 2.828 . . . . 0.96999999999999997 114.014 -172.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 37.2 t70 -68.04 -21.29 65.02 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.411 -0.589 . . . . 2.29 109.411 173.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.33 5.18 28.5 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.374 -0.83 . . . . 0.82999999999999996 111.715 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2091 ' ' THR . . . . . 0.505 ' HA ' ' NH2' ' A' 2111 ' ' ARG . 4.9 t -114.23 143.34 45.0 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.185 0.517 . . . . 1.51 110.945 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.407 HG22 ' CG1' ' A' 2086 ' ' ILE . 27.6 t -139.32 137.52 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.529 -0.759 . . . . 1.1799999999999999 109.309 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 7.2 t -107.1 121.23 44.08 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.206 0.527 . . . . 1.46 110.166 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -87.53 97.86 11.08 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.087 -1.079 . . . . 1.27 108.087 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2095 ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' 2083 ' ' THR . 43.9 m -117.63 99.09 52.27 Favored Pre-proline 0 N--CA 1.453 -0.31 0 N-CA-C 112.501 0.556 . . . . 0.57999999999999996 112.501 -174.063 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -86.17 143.17 7.75 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.567 2.178 . . . . 0.97999999999999998 110.231 166.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 17.1 t70 -61.34 135.01 57.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.955 0.407 . . . . 2.7200000000000002 110.499 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 58.9 mttp -72.24 -14.22 61.72 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.618 -0.719 . . . . 4.8099999999999996 111.913 -172.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -120.16 23.41 10.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.998 -0.371 . . . . 4.4199999999999999 109.998 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2100 ' ' PHE . . . . . 0.488 ' HD2' ' O ' ' A' 2080 ' ' GLY . 64.1 t80 -72.64 124.88 26.18 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-O 121.152 0.501 . . . . 2.3599999999999999 110.311 179.499 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2101 ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' 2129 ' ' LYS . 2.3 p -74.89 99.91 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.226 -0.897 . . . . 2.6800000000000002 110.478 177.414 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 102.56 -147.96 17.29 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.803 -0.635 . . . . 3.8399999999999999 112.039 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 48.7 mttp -111.02 134.4 21.03 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 120.613 0.245 . . . . 6.7800000000000002 110.876 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -43.72 149.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 124.409 3.406 . . . . 2.4300000000000002 114.035 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.444 ' H ' ' HG3' ' A' 2081 ' ' GLN . 1.4 m-20 -56.68 153.94 19.74 Favored Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 114.962 -1.017 . . . . 2.3300000000000001 111.898 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -53.22 113.16 1.15 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 124.235 3.29 . . . . 1.03 114.598 -174.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2107 ' ' VAL . . . . . 0.497 HG21 ' HG3' ' A' 2076 ' ' LYS . 4.2 p -160.66 119.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.092 -0.958 . . . . 0.59999999999999998 109.776 172.05 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.486 ' HA ' ' O ' ' A' 2121 ' ' ALA . 62.3 m -95.87 118.29 32.24 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.453 0.644 . . . . 0.37 110.17 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' 2120 ' ' THR . 6.1 t -91.65 136.36 24.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.259 -0.882 . . . . 0.76000000000000001 108.989 -178.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.583 ' HD2' ' C ' ' A' 2110 ' ' LYS . 0.0 OUTLIER -139.97 108.86 5.99 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.156 0.503 . . . . 1.6299999999999999 112.188 -173.089 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.505 ' NH2' ' HA ' ' A' 2091 ' ' THR . 4.2 ptm180 -142.4 132.76 24.95 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.719 -0.845 . . . . 3.4700000000000002 108.719 170.347 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.521 ' O ' HG21 ' A' 2065 ' ' VAL . 33.0 m -99.12 152.82 4.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.587 -0.445 . . . . 0.40000000000000002 111.695 -174.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -92.48 -170.68 2.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.969 -0.56 . . . . 1.46 110.15 178.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -64.72 -34.05 77.4 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.585 0.231 . . . . 1.72 111.255 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2115 ' ' ASN . . . . . 0.433 HD22 HG11 ' A' 2059 ' ' VAL . 37.0 m-80 -69.66 -30.13 67.74 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 1.8400000000000001 110.568 175.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 109.97 7.43 27.14 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.964 -0.636 . . . . 0.44 111.978 -178.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.434 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 87.9 m -81.97 118.73 73.15 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 110.142 -0.318 . . . . 0.56999999999999995 110.142 178.678 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' 2112 ' ' VAL . 3.3 Cg_exo -78.88 116.63 3.77 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 122.21 1.94 . . . . 0.60999999999999999 112.307 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 6.8 m -74.85 108.88 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.423 0 N-CA-C 107.89 -1.152 . . . . 0.59999999999999998 107.89 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' 2109 ' ' VAL . 68.5 p -123.3 168.48 12.43 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.662 -1.154 . . . . 0.67000000000000004 111.006 -170.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.04 126.36 39.31 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.083 -1.08 . . . . 0.72999999999999998 108.083 168.328 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 37.6 m -94.66 98.71 10.99 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.147 -0.686 . . . . 2.1899999999999999 109.147 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -120.57 123.95 44.11 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.574 0.702 . . . . 2.8100000000000001 111.796 -176.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2124 ' ' SER . . . . . 0.598 ' OG ' ' HD2' ' A' 2125 ' ' PRO . 6.6 t -132.87 162.16 59.18 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 114.459 -1.246 . . . . 2.0600000000000001 108.391 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.598 ' HD2' ' OG ' ' A' 2124 ' ' SER . 49.2 Cg_endo -69.17 52.11 0.77 Allowed 'Trans proline' 0 C--N 1.353 0.776 0 C-N-CA 122.584 2.189 . . . . 2.1600000000000001 112.838 176.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -133.08 151.09 52.05 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.965 -1.124 . . . . 4.3300000000000001 107.965 175.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 61.1 m-85 63.87 47.19 3.6 Favored 'General case' 0 C--N 1.331 -0.237 0 O-C-N 123.533 0.52 . . . . 3.8300000000000001 109.969 -173.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 8.4 p -75.57 -168.57 0.86 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.765 -0.652 . . . . 5.1100000000000003 111.241 -178.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A 2129 ' ' LYS . . . . . 0.453 ' HA ' ' O ' ' A' 2101 ' ' VAL . 0.0 OUTLIER -63.97 170.9 3.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.241 0.543 . . . . 5.2199999999999998 111.155 179.575 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 10.1 p . . . . . 0 C--O 1.248 1.006 0 N-CA-C 108.432 -0.951 . . . . 5.8799999999999999 108.432 171.902 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A 2053 ' ' GLN . . . . . 0.452 ' HG2' ' H ' ' A' 2054 ' ' GLY . 21.9 tt0 . . . . . 0 N--CA 1.481 1.077 0 N-CA-C 109.37 -0.604 . . . . 6.8499999999999996 109.37 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2054 ' ' GLY . . . . . 0.452 ' H ' ' HG2' ' A' 2053 ' ' GLN . . . -156.3 167.78 33.49 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.682 -0.77 . . . . 3.4100000000000001 112.17 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 84.39 45.38 6.19 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.016 -0.611 . . . . 1.77 112.097 178.245 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.21 120.88 58.74 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.816 0.341 . . . . 2.4199999999999999 111.343 -179.377 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -76.88 -21.44 12.45 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.341 2.028 . . . . 1.72 111.915 176.03 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.6 mp -85.14 -22.4 28.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.874 -0.603 . . . . 2.3399999999999999 110.048 177.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.8 t -126.17 83.32 63.82 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 108.711 -0.848 . . . . 0.87 108.711 178.162 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2060 ' ' PRO . . . . . 0.495 ' O ' ' HG3' ' A' 2114 ' ' LYS . 33.3 Cg_exo -58.53 141.59 97.46 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.625 2.217 . . . . 1.04 112.196 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.1 mm -63.12 135.79 26.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.693 -0.685 . . . . 0.77000000000000002 110.112 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.421 ' HB3' HG22 ' A' 2065 ' ' VAL . 11.7 t70 -70.51 128.69 37.02 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.28 -0.418 . . . . 1.4199999999999999 110.064 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -89.38 0.19 57.01 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.112 -0.494 . . . . 1.55 112.005 -171.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -105.11 -12.76 15.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.955 0.407 . . . . 0.68999999999999995 110.972 178.329 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' A' 2067 ' ' PRO . 33.3 m -91.72 -174.59 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.744 -0.465 . . . . 0.81999999999999995 109.744 175.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -92.8 113.53 59.94 Favored Pre-proline 0 C--O 1.245 0.829 0 CA-C-O 121.268 0.556 . . . . 0.78000000000000003 111.354 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.548 ' HA ' ' CB ' ' A' 2111 ' ' ARG . 51.0 Cg_endo -100.71 106.93 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.658 0 C-N-CA 123.096 2.531 . . . . 0.45000000000000001 111.45 167.13 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 16.7 p -138.88 178.88 6.83 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.072 0.463 . . . . 0.69999999999999996 111.176 -178.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 97.2 m-85 -103.0 159.45 15.5 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.71 -0.848 . . . . 1.1599999999999999 108.71 168.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2070 ' ' GLU . . . . . 0.414 ' HB2' ' O ' ' A' 2108 ' ' THR . 1.8 tm-20 -51.13 -44.13 61.32 Favored 'General case' 0 N--CA 1.468 0.474 0 O-C-N 123.755 0.66 . . . . 2.0899999999999999 112.203 -168.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 36.9 t70 -81.19 6.04 15.15 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.393 0.616 . . . . 2.1499999999999999 111.109 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 89.87 11.76 63.12 Favored Glycine 0 N--CA 1.45 -0.381 0 N-CA-C 111.675 -0.57 . . . . 0.63 111.675 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2073 ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 4.2 m -74.57 161.58 29.59 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.797 0.332 . . . . 0.89000000000000001 110.875 -173.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -120.37 -21.2 6.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 1.1299999999999999 110.883 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.0 tt0 -156.43 129.91 8.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.983 0.42 . . . . 2.0800000000000001 110.108 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.44 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.1 OUTLIER -126.78 100.59 6.25 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.972 -0.558 . . . . 1.48 110.816 178.029 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 32.2 m -96.34 123.7 40.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.077 -0.511 . . . . 0.63 110.287 174.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.564 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 2.7 mp -126.36 122.55 23.97 Favored Pre-proline 0 C--N 1.314 -0.936 0 N-CA-C 109.206 -0.664 . . . . 1.6200000000000001 109.206 177.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2079 ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' 2078 ' ' ILE . 68.9 Cg_exo -51.36 109.99 0.37 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.329 2.686 . . . . 0.97999999999999998 113.274 -175.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 94.46 -6.65 71.35 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.93999999999999995 112.757 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.564 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.6 tt0 -109.1 -33.39 6.9 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.123 0.487 . . . . 2.02 110.584 -175.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.77 -155.18 16.29 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.628 -0.796 . . . . 0.5 112.552 176.248 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.454 HG22 HG23 ' A' 2085 ' ' THR . 32.1 m -150.72 137.4 18.92 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.32 0.581 . . . . 0.48999999999999999 110.533 178.136 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.3 OUTLIER -111.51 121.88 46.36 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.481 -1.303 . . . . 1.4399999999999999 107.481 170.784 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.454 HG23 HG22 ' A' 2083 ' ' THR . 2.6 p -118.88 158.15 26.23 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 112.828 0.677 . . . . 0.63 112.828 -171.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.558 ' HB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -159.33 124.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 115.009 -0.996 . . . . 1.1799999999999999 109.57 172.223 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A 2087 ' ' VAL . . . . . 0.599 HG22 ' OG1' ' A' 2091 ' ' THR . 9.9 m -107.58 157.52 35.59 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.871 -0.788 . . . . 0.80000000000000004 108.871 173.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.99 0.52 1.2 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 123.392 2.728 . . . . 0.96999999999999997 114.299 -171.258 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2089 ' ' ASP . . . . . 0.44 ' H ' HG23 ' A' 2087 ' ' VAL . 12.9 m-20 -82.45 -12.81 57.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 2.29 110.099 174.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 97.08 32.57 6.38 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.948 -0.644 . . . . 0.82999999999999996 112.338 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2091 ' ' THR . . . . . 0.599 ' OG1' HG22 ' A' 2087 ' ' VAL . 63.7 p -87.86 136.06 33.12 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.261 -0.274 . . . . 1.51 110.261 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.481 HG13 HH11 ' A' 2111 ' ' ARG . 48.9 t -136.78 126.38 38.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 120.891 0.376 . . . . 1.1799999999999999 111.55 -177.536 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.7 t -146.92 109.72 4.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.529 0.681 . . . . 1.46 110.382 171.287 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2094 ' ' PHE . . . . . 0.67 ' CE2' HG11 ' A' 2109 ' ' VAL . 13.6 m-30 -84.91 101.99 12.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.373 -0.973 . . . . 1.27 108.373 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 2.1 m -110.13 88.62 7.28 Favored Pre-proline 0 N--CA 1.452 -0.356 0 CA-C-O 120.9 0.381 . . . . 0.57999999999999996 110.812 -177.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2096 ' ' PRO . . . . . 0.562 ' HD3' ' O ' ' A' 2094 ' ' PHE . 93.3 Cg_endo -92.27 166.97 2.95 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 123.436 2.758 . . . . 0.97999999999999998 112.547 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 13.0 t70 -131.8 110.17 10.65 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.401 -0.592 . . . . 2.7200000000000002 109.401 171.093 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2098 ' ' LYS . . . . . 0.48 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.2 OUTLIER -88.59 18.77 4.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.816 0.341 . . . . 4.8099999999999996 111.381 -176.403 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -119.86 7.13 10.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.076 0.465 . . . . 4.4199999999999999 110.158 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 53.3 t80 -83.57 113.14 20.61 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.635 -0.711 . . . . 2.3599999999999999 111.047 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.5 t -113.46 98.78 7.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.947 -0.57 . . . . 2.6800000000000002 109.664 175.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 172.17 43.3 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.711 -0.677 . . . . 3.8399999999999999 111.512 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 37.1 ttpt 60.45 83.49 0.21 Allowed Pre-proline 0 CA--C 1.531 0.226 0 C-N-CA 123.425 0.69 . . . . 6.7800000000000002 111.441 -178.327 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2104 ' ' PRO . . . . . 0.432 ' HG2' ' O ' ' A' 2124 ' ' SER . 14.1 Cg_endo -58.9 134.24 58.86 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.186 1.924 . . . . 2.4300000000000002 111.042 173.695 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.4 t70 -60.85 124.99 82.19 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.092 -0.504 . . . . 2.3300000000000001 110.889 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.462 ' HA ' ' O ' ' A' 2123 ' ' TYR . 27.2 Cg_endo -64.1 95.85 0.21 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.728 2.286 . . . . 1.03 112.048 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.9 p -128.58 160.83 38.51 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.386 -0.824 . . . . 0.59999999999999998 109.499 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' 2070 ' ' GLU . 93.8 m -140.75 131.19 25.27 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.356 -0.609 . . . . 0.37 109.356 174.32 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.67 HG11 ' CE2' ' A' 2094 ' ' PHE . 6.0 t -92.04 137.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.773 -0.825 . . . . 0.76000000000000001 108.773 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -144.92 108.22 4.59 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.974 -0.38 . . . . 1.6299999999999999 109.974 -178.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.558 HH12 ' HB ' ' A' 2086 ' ' ILE . 15.0 ptp180 -159.6 156.55 28.17 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.162 -0.472 . . . . 3.4700000000000002 109.751 175.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.455 HG23 HG21 ' A' 2065 ' ' VAL . 34.7 m -109.41 140.65 27.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 C-N-CA 120.202 -0.599 . . . . 0.40000000000000002 111.577 -176.007 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.601 ' OD2' ' HB ' ' A' 2117 ' ' THR . 2.5 p30 -90.04 -169.04 2.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.62 -0.718 . . . . 1.46 111.121 178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2114 ' ' LYS . . . . . 0.495 ' HG3' ' O ' ' A' 2060 ' ' PRO . 99.4 mttt -59.47 -29.78 68.06 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.184 0.439 . . . . 1.72 112.184 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -86.05 -11.32 53.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 1.8400000000000001 110.738 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.14 13.03 59.39 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.048 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.601 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 73.5 m -78.81 128.3 77.29 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-O 120.569 0.223 . . . . 0.56999999999999995 110.549 178.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 2.7 Cg_exo -75.61 99.0 1.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.322 2.014 . . . . 0.60999999999999999 111.814 177.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2119 ' ' VAL . . . . . 0.427 ' HB ' ' CA ' ' A' 2054 ' ' GLY . 17.2 m -75.39 109.41 8.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.535 0.683 . . . . 0.59999999999999998 109.466 175.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' 2109 ' ' VAL . 80.3 p -120.33 167.26 12.49 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 115.319 -0.855 . . . . 0.67000000000000004 110.898 -175.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.461 ' HB3' HG23 ' A' 2109 ' ' VAL . . . -140.56 128.58 22.07 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.875 -0.787 . . . . 0.72999999999999998 108.875 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 10.9 p -92.1 98.87 11.81 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.236 0.541 . . . . 2.1899999999999999 110.664 -177.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.0 OUTLIER -115.5 123.41 48.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.784 -0.644 . . . . 2.8100000000000001 110.959 -178.43 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A 2124 ' ' SER . . . . . 0.432 ' O ' ' HG2' ' A' 2104 ' ' PRO . 68.8 m -157.35 163.73 23.93 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.515 -0.766 . . . . 2.0600000000000001 109.04 178.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 93.0 Cg_exo -44.94 -49.23 9.98 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.659 2.239 . . . . 2.1600000000000001 112.523 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -81.99 59.16 4.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.56 0.695 . . . . 4.3300000000000001 110.707 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 90.3 t80 -126.84 124.7 40.24 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.412 -0.813 . . . . 3.8300000000000001 109.207 174.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 71.9 p 50.29 -149.82 0.25 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 123.401 0.68 . . . . 5.1100000000000003 111.724 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 21.2 mtmm 74.13 -172.94 0.13 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.647 0.779 . . . . 5.2199999999999998 111.514 178.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 C--O 1.247 0.972 0 CA-C-N 115.162 -0.926 . . . . 5.8799999999999999 110.257 177.232 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 62.0 tt0 . . . . . 0 N--CA 1.481 1.12 0 CA-C-O 120.702 0.287 . . . . 6.8499999999999996 110.628 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 83.99 -65.51 4.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.682 -0.771 . . . . 3.4100000000000001 112.65 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 163.9 -68.3 0.22 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.97 -0.852 . . . . 1.77 110.97 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -120.42 102.21 45.66 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 110.184 -0.302 . . . . 2.4199999999999999 110.184 173.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -68.43 -9.41 25.91 Favored 'Trans proline' 0 CA--C 1.528 0.218 0 C-N-CA 122.192 1.928 . . . . 1.72 111.862 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.5 mp -84.78 -18.85 33.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.923 -0.58 . . . . 2.3399999999999999 110.11 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.471 HG11 HD22 ' A' 2115 ' ' ASN . 4.6 t -138.84 89.86 12.74 Favored Pre-proline 0 CA--C 1.514 -0.41 0 N-CA-C 109.322 -0.621 . . . . 0.87 109.322 -177.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -53.25 120.68 8.13 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.315 2.01 . . . . 1.04 111.619 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.4 mm -49.77 134.82 8.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.152 -0.931 . . . . 0.77000000000000002 111.679 -176.15 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.552 ' O ' HG22 ' A' 2065 ' ' VAL . 14.6 t70 -76.65 130.26 37.54 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.437 -0.802 . . . . 1.4199999999999999 110.691 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -87.43 -8.29 56.69 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.238 0.458 . . . . 1.55 112.238 -174.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 29.7 p -101.75 0.79 36.47 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 120.5 -0.48 . . . . 0.68999999999999995 111.883 -178.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.595 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.6 m -92.87 -174.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.663 -0.244 . . . . 0.81999999999999995 110.507 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -97.35 107.89 41.36 Favored Pre-proline 0 C--O 1.24 0.598 0 CA-C-O 121.364 0.602 . . . . 0.78000000000000003 111.468 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.595 ' HD3' ' O ' ' A' 2065 ' ' VAL . 5.8 Cg_endo -93.71 108.75 0.17 Allowed 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.518 2.812 . . . . 0.45000000000000001 110.88 167.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.512 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.3 p -148.84 146.1 27.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.912 0.387 . . . . 0.69999999999999996 110.64 -177.187 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.486 ' CD2' ' N ' ' A' 2069 ' ' PHE . 2.4 m-30 -71.64 148.32 46.66 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.44 -1.319 . . . . 1.1599999999999999 107.44 176.071 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -61.08 -19.53 61.55 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.406 0.521 . . . . 2.0899999999999999 112.406 -165.193 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -92.03 1.33 57.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.621 0.248 . . . . 2.1499999999999999 111.131 178.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 87.59 25.21 33.5 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.86 -0.686 . . . . 0.63 112.018 -176.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 19.5 m -95.22 152.33 18.46 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.89000000000000001 110.511 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -111.62 -22.47 11.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.084 -0.507 . . . . 1.1299999999999999 110.58 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' 2084 ' ' TYR . 3.0 tt0 -144.35 144.43 31.44 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.113 0.482 . . . . 2.0800000000000001 110.243 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.425 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.4 OUTLIER -139.59 108.14 5.88 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.401 -0.818 . . . . 1.48 109.505 179.854 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 19.2 m -118.64 133.23 56.01 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.189 0.518 . . . . 0.63 111.493 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.549 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 4.2 mp -136.39 123.03 14.01 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 108.106 -1.072 . . . . 1.6200000000000001 108.106 172.276 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -52.29 109.48 0.34 Allowed 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.669 2.246 . . . . 0.97999999999999998 112.458 -178.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.65 -22.23 28.73 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.736 -0.665 . . . . 0.93999999999999995 112.383 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.549 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 52.7 tt0 -96.06 -31.52 12.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.085 0.469 . . . . 2.02 110.463 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.49 -153.64 17.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.837 -0.697 . . . . 0.5 112.141 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.49 HG22 HG23 ' A' 2085 ' ' THR . 43.0 m -150.0 144.96 26.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.65 0.738 . . . . 0.48999999999999999 110.824 178.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.528 ' O ' ' HA ' ' A' 2075 ' ' GLU . 7.6 m-85 -120.15 125.01 47.17 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 107.236 -1.394 . . . . 1.4399999999999999 107.236 172.625 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.49 HG23 HG22 ' A' 2083 ' ' THR . 17.3 p -129.07 134.75 48.23 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.544 0.572 . . . . 0.63 112.544 -174.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.563 HD13 HG22 ' A' 2092 ' ' VAL . 0.7 OUTLIER -130.82 123.94 55.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.562 -0.744 . . . . 1.1799999999999999 110.142 170.155 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 19.2 m -112.15 151.58 43.75 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.003 -0.74 . . . . 0.80000000000000004 109.003 172.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.76 -6.27 1.06 Allowed 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.057 3.171 . . . . 0.96999999999999997 114.922 -168.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 27.1 t70 -66.85 -24.07 66.1 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.126 0.489 . . . . 2.29 110.179 175.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 104.11 20.07 10.94 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.738 -0.665 . . . . 0.82999999999999996 112.223 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.8 t -110.42 126.38 54.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.962 0.41 . . . . 1.51 110.64 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.563 HG22 HD13 ' A' 2086 ' ' ILE . 7.6 t -133.08 137.42 53.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.016 -0.538 . . . . 1.1799999999999999 110.384 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.3 t -119.36 118.29 30.79 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.042 0.448 . . . . 1.46 110.19 173.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 9.4 m-30 -85.24 97.21 9.8 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.663 -0.866 . . . . 1.27 108.663 173.442 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 13.3 m -116.49 87.05 19.44 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.994 0.426 . . . . 0.57999999999999996 110.76 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -92.44 169.69 2.64 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.327 2.685 . . . . 0.97999999999999998 112.42 176.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.9 t70 -118.35 106.51 12.83 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.872 -0.788 . . . . 2.7200000000000002 108.872 171.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 93.2 mttt -69.77 -10.1 57.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.961 -0.563 . . . . 4.8099999999999996 112.194 -171.523 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -110.46 8.88 23.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.703 0.287 . . . . 4.4199999999999999 111.111 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 44.9 t80 -89.63 76.98 7.25 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.2 0.524 . . . . 2.3599999999999999 110.904 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2101 ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' 2129 ' ' LYS . 4.2 p -103.96 124.98 58.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.216 0.531 . . . . 2.6800000000000002 110.083 174.169 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 164.63 -81.9 0.11 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.047 -0.821 . . . . 3.8399999999999999 111.047 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 22.7 tptm -140.42 76.72 24.99 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 120.935 0.398 . . . . 6.7800000000000002 110.707 175.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -80.53 169.57 16.85 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.16 2.573 . . . . 2.4300000000000002 111.445 173.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.3 t70 -103.06 125.3 35.64 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 116.544 -0.298 . . . . 2.3300000000000001 110.198 178.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' 2123 ' ' TYR . 24.7 Cg_endo -62.96 103.5 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.734 2.29 . . . . 1.03 111.928 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2107 ' ' VAL . . . . . 0.425 HG11 ' HG2' ' A' 2076 ' ' LYS . 7.7 p -141.37 133.78 29.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.137 -0.483 . . . . 0.59999999999999998 111.049 -177.107 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.3 m -102.5 108.71 20.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.652 -0.704 . . . . 0.37 109.906 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' 2120 ' ' THR . 8.5 t -91.09 123.09 43.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.772 -0.825 . . . . 0.76000000000000001 108.772 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.512 ' HB3' ' O ' ' A' 2068 ' ' THR . 1.7 tmmt? -129.59 149.6 51.28 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.402 0.62 . . . . 1.6299999999999999 112.203 -169.432 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.51 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.3 ptt180 -166.91 138.2 3.28 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.97 -1.014 . . . . 3.4700000000000002 108.292 165.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.526 ' O ' HG21 ' A' 2065 ' ' VAL . 27.1 m -98.61 148.88 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 C-N-CA 120.357 -0.537 . . . . 0.40000000000000002 110.871 -175.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.433 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.7 p-10 -94.12 -168.7 1.91 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.933 -0.576 . . . . 1.46 110.448 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.5 mttm -62.88 -32.34 73.57 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.702 0.287 . . . . 1.72 111.393 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2115 ' ' ASN . . . . . 0.471 HD22 HG11 ' A' 2059 ' ' VAL . 41.1 m-80 -77.54 -14.96 59.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.955 0.407 . . . . 1.8400000000000001 110.599 176.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.87 12.47 59.13 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.333 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 27.8 m -85.83 121.26 73.15 Favored Pre-proline 0 C--N 1.324 -0.533 0 N-CA-C 110.106 -0.331 . . . . 0.56999999999999995 110.106 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 3.1 Cg_exo -74.74 107.86 2.57 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.261 1.974 . . . . 0.60999999999999999 112.653 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2119 ' ' VAL . . . . . 0.424 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 15.6 m -74.78 112.03 11.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 107.737 -1.208 . . . . 0.59999999999999998 107.737 169.141 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.616 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.7 p -127.41 159.32 34.83 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.636 -0.711 . . . . 0.67000000000000004 112.192 -169.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.46 127.63 42.86 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.8 -1.185 . . . . 0.72999999999999998 107.8 169.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 12.5 p -115.67 99.53 7.39 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.23 0.538 . . . . 2.1899999999999999 111.171 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.508 ' O ' ' HA ' ' A' 2106 ' ' PRO . 4.4 m-85 -90.08 151.98 21.36 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.677 -0.692 . . . . 2.8100000000000001 111.099 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2124 ' ' SER . . . . . 0.435 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 33.3 p -148.2 168.01 12.04 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 115.957 -0.565 . . . . 2.0600000000000001 110.551 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' 2124 ' ' SER . 71.3 Cg_exo -51.23 -40.68 60.5 Favored 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.574 2.183 . . . . 2.1600000000000001 112.975 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 19.6 mm-40 -91.35 -54.77 3.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.874 0.369 . . . . 4.3300000000000001 110.528 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 63.7 t80 63.51 -94.62 0.04 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.332 -0.849 . . . . 3.8300000000000001 111.821 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A 2128 ' ' THR . . . . . 0.413 ' O ' ' HB ' ' A' 2101 ' ' VAL . 13.1 m -162.42 158.19 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.231 -0.655 . . . . 5.1100000000000003 109.231 -176.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2129 ' ' LYS . . . . . 0.471 ' HB3' HG21 ' A' 2101 ' ' VAL . 17.8 ptpt -125.82 179.15 5.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.806 0.336 . . . . 5.2199999999999998 110.292 175.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.728 -0.653 . . . . 5.8799999999999999 110.382 -176.099 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A 2053 ' ' GLN . . . . . 0.941 ' N ' HE21 ' A' 2053 ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.131 0 CA-C-O 121.081 0.467 . . . . 6.8499999999999996 110.604 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -170.08 -86.18 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.885 -0.674 . . . . 3.4100000000000001 111.96 -179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2055 ' ' GLY . . . . . 0.496 ' O ' ' HD3' ' A' 2057 ' ' PRO . . . 137.3 -9.41 3.8 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.452 -0.88 . . . . 1.77 112.903 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2056 ' ' ASP . . . . . 0.526 ' HB2' ' O ' ' A' 2059 ' ' VAL . 4.1 p-10 -92.82 95.99 1.24 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-O 121.262 0.553 . . . . 2.4199999999999999 110.812 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2057 ' ' PRO . . . . . 0.496 ' HD3' ' O ' ' A' 2055 ' ' GLY . 57.6 Cg_endo -69.0 -53.11 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.375 2.05 . . . . 1.72 112.618 -170.126 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2058 ' ' LEU . . . . . 0.408 HD22 ' HB2' ' A' 2057 ' ' PRO . 3.8 mm? -121.32 19.4 11.4 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.999 -0.371 . . . . 2.3399999999999999 109.999 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.526 ' O ' ' HB2' ' A' 2056 ' ' ASP . 0.0 OUTLIER -131.85 77.52 72.01 Favored Pre-proline 0 N--CA 1.449 -0.523 0 C-N-CA 120.332 -0.547 . . . . 0.87 110.026 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.82 120.99 8.77 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.511 2.141 . . . . 1.04 111.95 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2061 ' ' ILE . . . . . 0.633 HG13 ' NE ' ' A' 2111 ' ' ARG . 47.1 mm -49.94 128.55 6.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.354 -0.839 . . . . 0.77000000000000002 111.846 -178.176 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.489 ' O ' HG22 ' A' 2065 ' ' VAL . 11.1 t70 -66.81 136.8 55.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.746 -0.661 . . . . 1.4199999999999999 110.171 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -88.71 1.19 55.57 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 112.567 0.58 . . . . 1.55 112.567 -171.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 70.1 p -120.29 -0.39 10.44 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.885 0.328 . . . . 0.68999999999999995 111.885 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.676 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.8 m -86.35 -173.13 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.162 -0.31 . . . . 0.81999999999999995 110.162 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -95.65 105.47 20.97 Favored Pre-proline 0 C--O 1.238 0.474 0 CA-C-O 120.966 0.412 . . . . 0.78000000000000003 111.513 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' 2065 ' ' VAL . 33.4 Cg_endo -100.31 106.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 122.898 2.399 . . . . 0.45000000000000001 110.872 167.031 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.51 ' O ' ' HB3' ' A' 2110 ' ' LYS . 18.7 p -141.1 148.27 39.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.223 0.535 . . . . 0.69999999999999996 110.585 -176.118 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.53 ' N ' ' HD1' ' A' 2069 ' ' PHE . 1.3 m-30 -74.58 149.36 40.16 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.416 -0.957 . . . . 1.1599999999999999 108.416 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2070 ' ' GLU . . . . . 0.475 ' CB ' ' HB ' ' A' 2108 ' ' THR . 5.2 tm-20 -50.78 -42.12 57.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.955 0.407 . . . . 2.0899999999999999 110.459 -173.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -71.89 0.79 8.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 115.638 -0.71 . . . . 2.1499999999999999 112.563 -178.152 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 82.92 29.94 33.21 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.572 -0.823 . . . . 0.63 112.001 -176.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 15.7 m -106.75 159.15 16.44 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.849 0.357 . . . . 0.89000000000000001 111.043 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -109.84 -18.8 13.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 1.1299999999999999 110.638 176.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.477 ' HB2' HG22 ' A' 2085 ' ' THR . 6.0 tt0 -148.68 136.69 20.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.146 0.498 . . . . 2.0800000000000001 109.853 173.045 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.408 ' HE2' HD11 ' A' 2078 ' ' ILE . 32.9 tptt -128.29 113.65 15.9 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.541 -0.754 . . . . 1.48 109.183 175.206 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 46.3 m -117.91 124.9 49.4 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 121.482 0.658 . . . . 0.63 110.895 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.595 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 12.3 mt -120.2 120.74 29.89 Favored Pre-proline 0 C--N 1.313 -1.013 0 N-CA-C 107.774 -1.195 . . . . 1.6200000000000001 107.774 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -41.91 108.66 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 123.551 2.834 . . . . 0.97999999999999998 113.806 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.19 -30.48 6.71 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.486 -0.779 . . . . 0.93999999999999995 113.037 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.595 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -74.83 -30.29 61.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.246 0.546 . . . . 2.02 110.172 -174.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 125.82 -171.34 17.67 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.471 -0.871 . . . . 0.5 112.571 175.098 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 38.3 m -140.25 132.29 27.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.534 0.683 . . . . 0.48999999999999999 110.695 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.498 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.6 OUTLIER -106.49 129.82 54.38 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.882 -1.525 . . . . 1.4399999999999999 106.882 169.521 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.477 HG22 ' HB2' ' A' 2075 ' ' GLU . 0.8 OUTLIER -133.06 140.59 47.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.258 0.551 . . . . 0.63 112.438 -175.939 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.538 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -130.27 131.64 65.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.152 -0.931 . . . . 1.1799999999999999 109.672 173.289 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A 2087 ' ' VAL . . . . . 0.401 ' HA ' ' HD3' ' A' 2088 ' ' PRO . 27.7 m -115.33 149.42 42.75 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.727 -0.472 . . . . 0.80000000000000004 109.727 174.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2088 ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' 2087 ' ' VAL . 32.2 Cg_exo -59.04 -6.42 3.62 Favored 'Trans proline' 0 C--N 1.349 0.595 0 C-N-CA 123.808 3.005 . . . . 0.96999999999999997 114.147 -170.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -70.23 -13.89 62.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.002 0.43 . . . . 2.29 110.206 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 96.9 17.71 31.81 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.929 -0.653 . . . . 0.82999999999999996 112.182 178.521 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 4.8 t -115.52 133.46 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.049 0.452 . . . . 1.51 109.824 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.538 HG13 ' HB ' ' A' 2086 ' ' ILE . 11.6 t -135.12 149.79 29.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.581 . . . . 1.1799999999999999 110.237 -173.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.0 t -136.23 123.74 22.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.287 0.565 . . . . 1.46 110.871 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.6 m-30 -99.13 98.72 9.7 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.193 -0.669 . . . . 1.27 109.193 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 12.0 m -113.96 96.79 42.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.873 0.368 . . . . 0.57999999999999996 111.026 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -89.17 176.35 3.17 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 123.246 2.631 . . . . 0.97999999999999998 112.787 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2097 ' ' ASP . . . . . 0.465 ' HB3' ' HA ' ' A' 2081 ' ' GLN . 6.4 p-10 -71.7 102.02 2.7 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.319 -0.855 . . . . 2.7200000000000002 112.139 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2098 ' ' LYS . . . . . 0.66 ' HD2' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -92.05 -9.76 41.6 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.087 -0.506 . . . . 4.8099999999999996 110.263 173.694 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A 2099 ' ' GLN . . . . . 0.402 ' HG3' ' HG2' ' A' 2098 ' ' LYS . 94.3 mt-30 -120.64 -52.55 2.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.073 -0.512 . . . . 4.4199999999999999 110.299 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.13 145.31 42.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.426 -0.806 . . . . 2.3599999999999999 111.454 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2101 ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' 2128 ' ' THR . 8.9 p -160.32 143.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 115.655 -0.702 . . . . 2.6800000000000002 109.382 175.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 152.57 -94.07 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.578 -0.82 . . . . 3.8399999999999999 112.453 -178.207 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 63.7 tttp -120.73 89.17 44.75 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-O 120.857 0.36 . . . . 6.7800000000000002 110.507 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.74 139.44 25.03 Favored 'Trans proline' 0 N--CA 1.459 -0.531 0 C-N-CA 122.712 2.275 . . . . 2.4300000000000002 111.097 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.51 ' HB3' HD13 ' A' 2078 ' ' ILE . 32.0 t70 -85.17 130.69 50.97 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 109.555 -0.535 . . . . 2.3300000000000001 109.555 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' 2123 ' ' TYR . 18.0 Cg_endo -60.41 119.55 6.8 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.117 2.544 . . . . 1.03 112.93 -177.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.5 p -159.36 133.64 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.746 -0.661 . . . . 0.59999999999999998 110.372 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' 2121 ' ' ALA . 34.1 m -105.51 119.31 38.79 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.188 0.518 . . . . 0.37 109.718 173.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -95.29 139.04 19.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.863 -0.792 . . . . 0.76000000000000001 108.863 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.51 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.9 tmmm? -140.68 147.65 39.59 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 118.366 0.53 . . . . 1.6299999999999999 111.438 -171.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.633 ' NE ' HG13 ' A' 2061 ' ' ILE . 29.1 ptt180 -168.98 135.28 1.73 Allowed 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.838 -0.801 . . . . 3.4700000000000002 108.838 171.481 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 23.2 m -99.8 149.99 5.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.207 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.436 ' HB3' HD13 ' A' 2061 ' ' ILE . 4.7 p-10 -93.93 -168.92 1.97 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.923 -0.581 . . . . 1.46 110.736 178.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.31 -41.78 85.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.19 -0.459 . . . . 1.72 111.929 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -18.74 46.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.869 0.366 . . . . 1.8400000000000001 110.45 -177.335 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 106.14 16.76 14.11 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.543 -0.837 . . . . 0.44 113.641 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.419 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.8 m -83.83 119.26 73.28 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 117.187 0.494 . . . . 0.56999999999999995 110.376 175.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -77.92 102.15 1.55 Allowed 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.369 2.046 . . . . 0.60999999999999999 111.988 177.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.7 m -74.88 117.59 19.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 108.545 -0.909 . . . . 0.59999999999999998 108.545 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' 2109 ' ' VAL . 61.2 p -126.25 161.14 28.43 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.524 -0.762 . . . . 0.67000000000000004 111.78 -170.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.537 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.09 127.44 41.48 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 107.981 -1.118 . . . . 0.72999999999999998 107.981 169.04 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 21.9 m -116.15 103.93 11.03 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 120.974 0.416 . . . . 2.1899999999999999 110.54 -174.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.572 ' O ' ' HA ' ' A' 2106 ' ' PRO . 2.3 m-85 -100.72 131.01 46.83 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 112.048 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 16.1 m -131.77 146.81 63.42 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.135 -0.939 . . . . 2.0600000000000001 109.391 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.13 21.13 0.45 Allowed 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.815 2.343 . . . . 2.1600000000000001 112.957 -178.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -81.73 -31.19 32.17 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.029 0.442 . . . . 4.3300000000000001 110.75 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 36.2 t80 -86.12 124.86 33.01 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.681 -0.489 . . . . 3.8300000000000001 109.681 178.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2128 ' ' THR . . . . . 0.478 ' O ' HG22 ' A' 2101 ' ' VAL . 6.0 m -103.59 -81.08 0.52 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.362 -0.381 . . . . 5.1100000000000003 110.592 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 18.8 ptpt 178.16 -176.4 0.2 Allowed 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.303 -0.629 . . . . 5.2199999999999998 109.303 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.441 -0.79 . . . . 5.8799999999999999 110.112 178.218 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 80.6 mt-30 . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.569 0.223 . . . . 6.8499999999999996 110.87 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 59.8 38.22 93.64 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-N 116.0 -0.546 . . . . 3.4100000000000001 113.339 176.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -136.7 -131.85 3.02 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.483 -0.865 . . . . 1.77 111.904 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.31 124.44 29.04 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-O 121.114 0.483 . . . . 2.4199999999999999 110.269 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -69.32 -52.82 0.33 Allowed 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.87 2.38 . . . . 1.72 111.862 177.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2058 ' ' LEU . . . . . 0.828 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -68.33 -9.38 47.45 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.423 -0.808 . . . . 2.3399999999999999 112.854 176.677 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.828 HG23 HD13 ' A' 2058 ' ' LEU . 5.7 t -137.72 86.69 18.16 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 109.666 -0.494 . . . . 0.87 109.666 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.41 131.05 43.91 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.378 2.052 . . . . 1.04 111.847 -177.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 43.1 mm -62.86 122.66 14.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.904 -0.589 . . . . 0.77000000000000002 109.935 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' 2065 ' ' VAL . 21.1 t70 -70.46 134.52 47.84 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.236 0.541 . . . . 1.4199999999999999 110.496 -176.431 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -89.3 -2.09 58.32 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.844 -0.616 . . . . 1.55 111.914 -171.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -113.99 -2.67 13.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.829 -0.348 . . . . 0.68999999999999995 111.848 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.59 ' O ' ' HD3' ' A' 2067 ' ' PRO . 26.8 m -81.59 -174.59 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.973 -0.291 . . . . 0.81999999999999995 110.284 177.391 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.11 109.27 51.11 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.211 0.529 . . . . 0.78000000000000003 111.202 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.59 ' HD3' ' O ' ' A' 2065 ' ' VAL . 50.5 Cg_endo -99.57 111.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.518 0 C-N-CA 123.305 2.67 . . . . 0.45000000000000001 110.875 165.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 8.4 p -145.13 -178.98 6.33 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.211 0.529 . . . . 0.69999999999999996 110.758 -176.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 39.0 m-85 -102.73 148.25 25.84 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.735 -0.839 . . . . 1.1599999999999999 108.735 168.304 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -59.98 -24.23 64.27 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.962 0.789 . . . . 2.0899999999999999 111.593 -172.165 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -86.05 -3.45 58.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.309 -0.405 . . . . 2.1499999999999999 110.858 178.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.57 29.88 12.97 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.147 -0.549 . . . . 0.63 113.066 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 26.3 p -110.61 179.15 4.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.032 0.416 . . . . 0.89000000000000001 111.276 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2074 ' ' LYS . . . . . 0.411 ' O ' HG22 ' A' 2086 ' ' ILE . 34.6 mmtp -124.78 -4.8 7.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-O 120.957 0.408 . . . . 1.1299999999999999 111.159 -178.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -159.56 132.32 6.76 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.457 -0.571 . . . . 2.0800000000000001 109.457 169.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.457 ' HA ' ' HD2' ' A' 2076 ' ' LYS . 3.7 mmmm -120.01 100.89 7.48 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.968 -0.56 . . . . 1.48 110.306 174.072 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 89.5 m -97.51 111.57 23.78 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.876 -0.602 . . . . 0.63 110.242 173.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.469 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 96.6 mt -110.8 117.26 50.83 Favored Pre-proline 0 C--N 1.31 -1.113 0 N-CA-C 108.74 -0.837 . . . . 1.6200000000000001 108.74 175.483 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -46.37 112.52 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.501 2.801 . . . . 0.97999999999999998 113.574 -174.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 87.74 -11.09 67.55 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.783 -0.644 . . . . 0.93999999999999995 112.795 177.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.469 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -101.19 -31.88 10.8 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.22 0.533 . . . . 2.02 110.296 -174.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 131.63 -170.42 21.58 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.45 -0.881 . . . . 0.5 113.095 173.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.536 ' O ' ' HB ' ' A' 2095 ' ' THR . 86.6 m -144.38 136.58 26.37 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.476 -0.564 . . . . 0.48999999999999999 109.476 177.586 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -117.77 126.86 53.23 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.493 -1.299 . . . . 1.4399999999999999 107.493 174.189 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 11.9 p -120.38 127.43 52.28 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.822 -0.351 . . . . 0.63 111.709 -175.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.481 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -108.08 135.44 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.955 -0.566 . . . . 1.1799999999999999 109.864 175.58 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 26.7 m -122.22 150.69 57.48 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 109.41 -0.589 . . . . 0.80000000000000004 109.41 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 34.6 Cg_exo -60.0 -1.28 1.17 Allowed 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.737 2.958 . . . . 0.96999999999999997 113.792 -174.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2089 ' ' ASP . . . . . 0.423 ' HB3' HG22 ' A' 2091 ' ' THR . 16.8 t70 -66.4 -20.17 65.99 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.267 0.556 . . . . 2.29 109.865 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 99.49 14.79 34.1 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.245 -0.742 . . . . 0.82999999999999996 111.245 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2091 ' ' THR . . . . . 0.423 HG22 ' HB3' ' A' 2089 ' ' ASP . 8.8 t -120.31 146.61 45.95 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.312 -0.444 . . . . 1.51 110.376 -177.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 21.5 t -132.82 138.56 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.353 -0.61 . . . . 1.1799999999999999 109.353 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 51.6 m -97.76 109.98 22.63 Favored 'General case' 0 N--CA 1.439 -0.98 0 CA-C-O 120.789 0.328 . . . . 1.46 110.251 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 7.8 m-30 -86.81 98.41 11.17 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.64 -0.504 . . . . 1.27 109.64 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2095 ' ' THR . . . . . 0.536 ' HB ' ' O ' ' A' 2083 ' ' THR . 58.4 m -109.4 99.11 35.37 Favored Pre-proline 0 C--O 1.234 0.241 0 CA-C-O 120.942 0.401 . . . . 0.57999999999999996 110.524 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -88.27 162.15 6.96 Favored 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 123.346 2.697 . . . . 0.97999999999999998 113.966 -174.2 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2097 ' ' ASP . . . . . 0.462 ' HB2' ' CB ' ' A' 2100 ' ' PHE . 10.4 p-10 -72.46 48.31 0.19 Allowed 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.091 -0.959 . . . . 2.7200000000000002 111.776 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -70.63 -10.01 58.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.079 0.466 . . . . 4.8099999999999996 111.167 -175.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -116.65 24.44 11.29 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.117 -0.492 . . . . 4.4199999999999999 110.753 178.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2100 ' ' PHE . . . . . 0.462 ' CB ' ' HB2' ' A' 2097 ' ' ASP . 63.7 t80 -113.8 142.2 46.36 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.156 0.503 . . . . 2.3599999999999999 111.762 -173.4 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2101 ' ' VAL . . . . . 0.49 HG13 ' HB3' ' A' 2129 ' ' LYS . 74.3 t -132.26 105.01 8.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.633 -0.712 . . . . 2.6800000000000002 110.19 176.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.29 -99.46 0.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 N-CA-C 111.279 -0.729 . . . . 3.8399999999999999 111.279 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.18 120.51 0.89 Allowed Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 109.715 -0.476 . . . . 6.7800000000000002 109.715 170.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.52 147.66 22.63 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.73 2.287 . . . . 2.4300000000000002 112.162 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 18.8 m-20 -80.46 147.02 62.78 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.029 -0.532 . . . . 2.3300000000000001 109.94 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.467 ' HA ' ' O ' ' A' 2123 ' ' TYR . 45.9 Cg_endo -68.04 128.95 18.51 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.147 2.565 . . . . 1.03 113.908 -171.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 5.5 p -158.08 160.0 2.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.38 -0.827 . . . . 0.59999999999999998 109.169 177.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 26.5 m -141.25 122.35 14.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.115 0.483 . . . . 0.37 110.415 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 5.2 t -92.22 133.47 33.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 108.922 -0.77 . . . . 0.76000000000000001 108.922 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -125.84 109.63 12.74 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 120.683 0.278 . . . . 1.6299999999999999 111.387 -169.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' 2119 ' ' VAL . 30.8 ptt180 -147.3 135.4 21.46 Favored 'General case' 0 C--N 1.317 -0.818 0 O-C-N 121.797 -0.565 . . . . 3.4700000000000002 110.133 168.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.498 ' O ' HG21 ' A' 2065 ' ' VAL . 34.2 m -99.09 154.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 120.998 0.428 . . . . 0.40000000000000002 110.758 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.546 ' OD2' ' HB ' ' A' 2117 ' ' THR . 10.1 p30 -94.38 -169.59 2.08 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.81 -0.632 . . . . 1.46 110.778 178.139 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.7 mttm -65.06 -22.85 67.03 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.15 0.426 . . . . 1.72 112.15 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -90.5 -19.01 24.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.054 0.455 . . . . 1.8400000000000001 110.235 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 102.94 15.13 24.93 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.662 -0.699 . . . . 0.44 111.962 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.546 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 24.1 m -91.62 119.63 68.44 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 120.805 0.336 . . . . 0.56999999999999995 110.221 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' 2117 ' ' THR . 8.2 Cg_exo -72.68 107.34 2.3 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.46 2.106 . . . . 0.60999999999999999 113.241 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2119 ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.95 109.25 9.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 108.088 -1.078 . . . . 0.59999999999999998 108.088 165.008 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A 2120 ' ' THR . . . . . . . . . . . . . 75.0 p -125.14 179.5 5.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.105 -0.952 . . . . 0.67000000000000004 110.553 -171.034 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.61 127.2 41.8 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.606 -0.887 . . . . 0.72999999999999998 108.606 170.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 30.9 p -93.39 101.67 13.9 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.877 -0.601 . . . . 2.1899999999999999 109.898 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' 2106 ' ' PRO . 5.4 m-85 -120.25 122.96 42.04 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.633 0.73 . . . . 2.8100000000000001 112.17 -175.26 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 46.9 p -152.42 158.18 33.5 Favored Pre-proline 0 C--N 1.321 -0.642 0 CA-C-N 114.478 -1.237 . . . . 2.0600000000000001 108.859 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -72.57 10.75 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.474 2.116 . . . . 2.1600000000000001 112.794 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -79.06 -26.29 43.08 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.201 0.524 . . . . 4.3300000000000001 109.679 176.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -77.22 154.43 33.06 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.606 -0.725 . . . . 3.8300000000000001 109.266 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 14.6 p -135.22 -73.71 0.46 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.152 0.501 . . . . 5.1100000000000003 110.832 -177.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A 2129 ' ' LYS . . . . . 0.49 ' HB3' HG13 ' A' 2101 ' ' VAL . 0.1 OUTLIER -120.48 166.38 13.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.72 -0.673 . . . . 5.2199999999999998 110.066 179.897 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 38.2 t . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.419 -0.801 . . . . 5.8799999999999999 110.007 179.931 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 25.1 tp60 . . . . . 0 N--CA 1.479 1.005 0 N-CA-C 110.204 -0.295 . . . . 6.8499999999999996 110.204 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 73.66 43.32 36.53 Favored Glycine 0 N--CA 1.453 -0.175 0 C-N-CA 120.692 -0.766 . . . . 3.4100000000000001 111.842 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -172.46 -100.12 0.13 Allowed Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 111.031 -0.827 . . . . 1.77 111.031 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 6.9 t70 -125.74 123.43 24.76 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 110.106 -0.331 . . . . 2.4199999999999999 110.106 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.34 -20.31 42.68 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.585 2.19 . . . . 1.72 112.596 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.8 mp -100.29 -26.78 13.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.795 0.331 . . . . 2.3399999999999999 110.301 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 4.6 t -116.52 82.43 12.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.186 -0.461 . . . . 0.87 109.818 178.425 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.44 120.1 7.25 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.374 2.049 . . . . 1.04 111.559 179.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.7 mm -49.9 131.21 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.522 -0.763 . . . . 0.77000000000000002 110.908 179.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' 2065 ' ' VAL . 10.6 t70 -69.25 135.1 50.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.458 -0.792 . . . . 1.4199999999999999 110.588 -176.017 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -97.49 2.96 50.83 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.987 0.366 . . . . 1.55 111.987 -173.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.2 p -109.74 3.32 20.75 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.08 0.943 . . . . 0.68999999999999995 108.97 173.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.709 ' O ' ' HD3' ' A' 2067 ' ' PRO . 1.0 OUTLIER -91.29 165.22 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 CA-C-N 114.041 -1.436 . . . . 0.81999999999999995 110.108 -178.807 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.37 108.98 9.85 Favored Pre-proline 0 C--O 1.24 0.553 0 CA-C-O 120.697 0.284 . . . . 0.78000000000000003 111.368 177.265 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' 2065 ' ' VAL . 60.7 Cg_endo -102.34 108.6 0.04 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.57 0 C-N-CA 123.454 2.769 . . . . 0.45000000000000001 111.328 166.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 21.3 p -134.5 174.45 10.53 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.529 0.68 . . . . 0.69999999999999996 111.335 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.528 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.7 OUTLIER -101.13 151.4 21.87 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.64 -1.245 . . . . 1.1599999999999999 107.64 170.214 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -45.71 -41.72 10.91 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 123.719 0.637 . . . . 2.0899999999999999 112.391 -171.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -90.17 16.58 8.27 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 111.944 0.35 . . . . 2.1499999999999999 111.944 -175.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 30.0 58.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.663 -0.78 . . . . 0.63 112.668 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.3 p -102.92 167.96 9.52 Favored 'General case' 0 C--N 1.323 -0.564 0 O-C-N 122.859 -0.201 . . . . 0.89000000000000001 110.496 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2074 ' ' LYS . . . . . 0.425 ' O ' HG22 ' A' 2086 ' ' ILE . 42.1 mmtm -123.39 -10.45 7.97 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.246 0.462 . . . . 1.1299999999999999 112.246 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -158.77 128.1 5.59 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.928 0.394 . . . . 2.0800000000000001 110.156 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.35 100.47 6.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.185 -0.672 . . . . 1.48 109.185 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 62.8 m -109.78 127.21 54.49 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.282 -0.417 . . . . 0.63 111.112 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.614 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 35.4 mm -131.32 132.01 23.37 Favored Pre-proline 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.917 . . . . 1.6200000000000001 108.523 171.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.76 108.9 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.478 2.119 . . . . 0.97999999999999998 112.197 178.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2080 ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' 2101 ' ' VAL . . . 99.83 -4.09 57.6 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.018 -0.61 . . . . 0.93999999999999995 112.319 -179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.614 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.1 tt0 -107.33 -29.79 9.08 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.125 0.488 . . . . 2.02 110.222 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 103.89 -162.35 15.49 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.565 -0.743 . . . . 0.5 111.641 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.518 ' O ' ' HB ' ' A' 2095 ' ' THR . 47.1 m -139.76 135.43 33.08 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.568 0.699 . . . . 0.48999999999999999 110.729 178.036 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.508 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.6 m-85 -104.58 110.74 23.15 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.069 -1.456 . . . . 1.4399999999999999 107.069 171.368 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.491 HG23 HG22 ' A' 2083 ' ' THR . 13.3 p -108.24 123.67 49.12 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.323 0.49 . . . . 0.63 112.323 -171.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.5 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.93 130.8 72.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.112 -0.494 . . . . 1.1799999999999999 109.84 170.349 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.5 m -122.33 150.59 57.59 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.01 -0.541 . . . . 0.80000000000000004 109.748 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.94 -3.9 1.78 Allowed 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 123.949 3.099 . . . . 0.96999999999999997 114.276 -172.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2089 ' ' ASP . . . . . 0.401 ' HB2' HG22 ' A' 2091 ' ' THR . 5.3 m-20 -69.3 -13.95 62.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.223 0.535 . . . . 2.29 110.057 176.15 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.57 8.16 54.92 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.531 -0.759 . . . . 0.82999999999999996 111.552 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2091 ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' 2089 ' ' ASP . 6.8 t -111.44 129.01 56.16 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.381 0.61 . . . . 1.51 110.501 -177.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.6 HG13 ' NH1' ' A' 2111 ' ' ARG . 1.1 p -150.08 139.29 15.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.529 -0.76 . . . . 1.1799999999999999 110.538 -176.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -127.57 130.92 49.93 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.098 0.475 . . . . 1.46 110.747 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2094 ' ' PHE . . . . . 0.466 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.5 m-30 -84.36 99.02 10.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.463 -0.94 . . . . 1.27 108.463 175.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2095 ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' 2083 ' ' THR . 19.6 m -116.54 89.35 27.25 Favored Pre-proline 0 N--CA 1.454 -0.259 0 CA-C-O 121.215 0.531 . . . . 0.57999999999999996 111.815 -175.281 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2096 ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' 2094 ' ' PHE . 5.3 Cg_endo -87.41 142.2 6.02 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 123.207 2.605 . . . . 0.97999999999999998 110.877 172.339 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.49 137.23 58.19 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.184 -0.462 . . . . 2.7200000000000002 110.712 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.15 -20.21 63.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.378 -0.828 . . . . 4.8099999999999996 112.184 -175.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -103.49 -44.73 5.05 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.711 -0.477 . . . . 4.4199999999999999 109.711 177.105 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2100 ' ' PHE . . . . . 0.465 ' CE1' ' HB3' ' A' 2104 ' ' PRO . 43.1 t80 65.1 72.2 0.44 Allowed 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.654 0.74 . . . . 2.3599999999999999 110.804 177.253 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2101 ' ' VAL . . . . . 0.424 ' O ' ' HA3' ' A' 2080 ' ' GLY . 77.1 t -145.03 117.81 2.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.125 -0.943 . . . . 2.6800000000000002 109.832 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 154.58 48.7 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.038 -1.077 . . . . 3.8399999999999999 113.13 178.096 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.4 ttpp 55.87 72.56 0.99 Allowed Pre-proline 0 CA--C 1.535 0.367 0 C-N-CA 122.616 0.366 . . . . 6.7800000000000002 111.213 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2104 ' ' PRO . . . . . 0.465 ' HB3' ' CE1' ' A' 2100 ' ' PHE . 19.2 Cg_endo -58.87 135.6 68.0 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.906 2.404 . . . . 2.4300000000000002 113.299 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.0 t70 -92.88 130.92 34.83 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.616 -0.72 . . . . 2.3300000000000001 109.723 178.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' 2123 ' ' TYR . 30.8 Cg_endo -64.71 106.61 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.634 2.223 . . . . 1.03 112.235 -176.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.1 p -142.94 135.54 25.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.264 0.554 . . . . 0.59999999999999998 111.34 -178.088 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.607 ' HA ' ' O ' ' A' 2121 ' ' ALA . 88.5 m -111.21 122.85 48.93 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.564 -0.744 . . . . 0.37 109.412 171.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.3 t -95.54 136.73 25.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.929 -0.767 . . . . 0.76000000000000001 108.929 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -141.95 113.58 7.82 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.09 0.774 . . . . 1.6299999999999999 113.09 -171.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.6 ' NH1' HG13 ' A' 2092 ' ' VAL . 23.9 ptt180 -140.69 143.44 35.07 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.26 -0.644 . . . . 3.4700000000000002 109.26 171.375 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.569 ' O ' HG11 ' A' 2065 ' ' VAL . 34.8 m -98.41 149.95 5.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.238 -0.585 . . . . 0.40000000000000002 111.179 -176.138 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 25.1 p30 -88.01 -168.93 2.38 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.708 -0.678 . . . . 1.46 110.783 179.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.3 mttt -65.69 -23.59 66.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.716 0.293 . . . . 1.72 111.553 -178.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -82.57 -27.26 31.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.104 0.478 . . . . 1.8400000000000001 110.56 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 108.29 11.53 23.58 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.358 -0.697 . . . . 0.44 111.358 -177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.438 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 61.6 m -90.59 118.96 69.08 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 120.595 0.236 . . . . 0.56999999999999995 110.481 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' 2117 ' ' THR . 10.5 Cg_exo -71.38 119.72 6.46 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.719 2.279 . . . . 0.60999999999999999 113.014 -179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.6 m -84.79 109.39 17.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.326 -0.991 . . . . 0.59999999999999998 108.326 169.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.573 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.6 p -119.58 149.87 41.22 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.125 -0.943 . . . . 0.67000000000000004 111.747 -170.026 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.607 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.57 126.15 39.71 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.125 -1.065 . . . . 0.72999999999999998 108.125 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 46.5 m -113.57 101.7 9.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.644 -0.502 . . . . 2.1899999999999999 109.644 -177.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.496 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.8 m-85 -97.68 124.95 42.19 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.967 -0.561 . . . . 2.8100000000000001 112.045 -174.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 26.0 m -91.02 150.55 41.98 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 115.105 -0.952 . . . . 2.0600000000000001 110.98 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.46 ' HB3' ' HD3' ' A' 2106 ' ' PRO . 73.5 Cg_endo -78.9 157.91 27.4 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.769 2.313 . . . . 2.1600000000000001 111.863 177.453 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 39.6 tt0 58.7 87.53 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 O-C-N 123.697 0.623 . . . . 4.3300000000000001 111.516 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 28.1 t80 -129.97 111.85 12.93 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.469 -0.937 . . . . 3.8300000000000001 108.469 175.173 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 4.7 t -60.4 160.64 8.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.965 0.888 . . . . 5.1100000000000003 112.266 -174.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A 2129 ' ' LYS . . . . . 0.437 ' O ' ' HD3' ' A' 2129 ' ' LYS . 0.0 OUTLIER -84.67 47.55 1.39 Allowed 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.356 -1.293 . . . . 5.2199999999999998 111.635 -176.717 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 67.6 t . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.119 -0.943 . . . . 5.8799999999999999 110.559 -177.853 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 1.2 mp0 . . . . . 0 N--CA 1.484 1.225 0 CA-C-O 120.758 0.313 . . . . 6.8499999999999996 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -74.79 -25.22 70.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.045 -0.597 . . . . 3.4100000000000001 112.274 179.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 164.31 -112.33 0.5 Allowed Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.522 -0.631 . . . . 1.77 111.522 177.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 16.5 t70 -138.46 121.14 10.8 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.532 -0.544 . . . . 2.4199999999999999 109.532 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.0 -18.57 46.25 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.895 2.397 . . . . 1.72 112.706 -176.15 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.4 mp -87.48 -33.3 19.06 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.377 -0.374 . . . . 2.3399999999999999 110.403 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 2.6 t -135.41 87.38 27.49 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.418 -0.355 . . . . 0.87 110.048 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -38.66 119.71 0.43 Allowed 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 123.411 2.741 . . . . 1.04 112.661 173.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2061 ' ' ILE . . . . . 0.428 HD11 HG21 ' A' 2119 ' ' VAL . 42.4 mm -56.18 123.66 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.828 -0.623 . . . . 0.77000000000000002 111.477 -176.048 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.518 ' O ' HG22 ' A' 2065 ' ' VAL . 30.8 t70 -68.01 135.98 53.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.788 -0.642 . . . . 1.4199999999999999 110.502 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -86.62 -6.62 58.81 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.082 -0.508 . . . . 1.55 111.782 -172.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.5 p -111.18 4.01 18.92 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.166 0.432 . . . . 0.68999999999999995 112.166 -177.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.688 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.7 m -86.99 -174.07 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.904 -0.406 . . . . 0.81999999999999995 109.904 174.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -93.57 105.77 17.79 Favored Pre-proline 0 C--O 1.238 0.494 0 CA-C-O 120.974 0.416 . . . . 0.78000000000000003 111.293 176.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.688 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.4 Cg_endo -100.74 108.64 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.548 0 C-N-CA 123.308 2.672 . . . . 0.45000000000000001 110.62 166.344 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.601 HG22 ' HE2' ' A' 2074 ' ' LYS . 18.5 p -138.75 177.07 8.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.646 0.736 . . . . 0.69999999999999996 111.101 -175.01 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.472 ' CE1' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-85 -101.55 142.18 33.3 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 107.147 -1.427 . . . . 1.1599999999999999 107.147 165.632 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -58.78 -19.08 37.59 Favored 'General case' 0 C--N 1.328 -0.329 0 O-C-N 123.849 0.718 . . . . 2.0899999999999999 111.975 -168.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -98.58 8.04 45.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.82 0.343 . . . . 2.1499999999999999 111.038 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.07 17.72 52.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.089 -0.577 . . . . 0.63 113.195 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 32.3 m -93.89 167.55 11.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.916 0.358 . . . . 0.89000000000000001 110.999 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2074 ' ' LYS . . . . . 0.601 ' HE2' HG22 ' A' 2068 ' ' THR . 34.5 mmtp -127.67 -16.86 4.67 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 116.161 -0.472 . . . . 1.1299999999999999 111.12 178.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.813 ' HG2' HG22 ' A' 2085 ' ' THR . 0.9 OUTLIER -149.72 98.51 2.75 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.761 -0.459 . . . . 2.0800000000000001 109.761 174.239 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 26.1 tptt -92.19 108.35 19.88 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.281 -0.418 . . . . 1.48 110.073 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 86.9 m -107.84 118.13 35.93 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-O 121.408 0.623 . . . . 0.63 110.478 174.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.579 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 72.1 mt -114.02 115.07 45.94 Favored Pre-proline 0 N--CA 1.438 -1.034 0 CA-C-N 114.911 -1.04 . . . . 1.6200000000000001 108.471 175.099 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -47.84 109.52 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 123.332 2.688 . . . . 0.97999999999999998 113.567 -174.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 90.68 -8.64 79.5 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.923 -0.58 . . . . 0.93999999999999995 112.694 176.258 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.579 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.6 tm0? -100.82 -31.11 11.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.096 0.474 . . . . 2.02 109.829 -176.19 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 129.13 -167.57 21.13 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.818 -0.706 . . . . 0.5 112.492 177.142 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 55.0 m -149.57 129.89 13.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.507 0.67 . . . . 0.48999999999999999 110.341 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.472 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 2.7 m-85 -101.85 130.42 48.31 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 106.789 -1.559 . . . . 1.4399999999999999 106.789 171.478 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.813 HG22 ' HG2' ' A' 2075 ' ' GLU . 77.5 p -125.67 137.63 53.87 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.176 -0.61 . . . . 0.63 111.932 -172.639 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.507 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -130.9 133.36 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-N 115.573 -0.739 . . . . 1.1799999999999999 109.878 173.962 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 24.5 m -116.61 149.17 43.38 Favored Pre-proline 0 C--N 1.32 -0.684 0 N-CA-C 109.143 -0.688 . . . . 0.80000000000000004 109.143 172.175 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -61.99 -0.75 1.81 Allowed 'Trans proline' 0 N--CA 1.477 0.533 0 C-N-CA 123.633 2.889 . . . . 0.96999999999999997 113.95 -170.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.08 -14.71 62.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.08 0.467 . . . . 2.29 110.064 177.27 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.14 21.11 18.72 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.868 -0.605 . . . . 0.82999999999999996 112.082 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -120.63 135.97 54.96 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.916 0.389 . . . . 1.51 110.349 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.63 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 5.2 t -136.35 149.44 27.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.922 -0.581 . . . . 1.1799999999999999 110.002 -176.639 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.9 t -134.96 130.03 35.15 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.273 0.558 . . . . 1.46 110.409 172.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.4 m-30 -93.82 98.78 11.31 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.032 -0.729 . . . . 1.27 109.032 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 21.3 m -117.56 88.7 30.13 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-O 120.919 0.39 . . . . 0.57999999999999996 111.891 -177.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -91.78 161.26 3.42 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 123.213 2.609 . . . . 0.97999999999999998 111.822 171.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2097 ' ' ASP . . . . . 0.481 ' HB3' ' HB2' ' A' 2100 ' ' PHE . 11.6 t70 -75.41 114.17 13.65 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.613 -0.514 . . . . 2.7200000000000002 109.613 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 2.7 tpmt? -43.56 -53.31 5.7 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 124.059 0.849 . . . . 4.8099999999999996 113.262 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -121.27 37.4 4.34 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 111.88 0.326 . . . . 4.4199999999999999 111.88 -171.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2100 ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' A' 2097 ' ' ASP . 56.5 t80 -78.59 84.59 4.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.486 0.66 . . . . 2.3599999999999999 110.287 177.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.2 t -93.9 113.22 28.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.627 -0.715 . . . . 2.6800000000000002 110.16 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 179.52 -110.13 0.28 Allowed Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.521 -0.632 . . . . 3.8399999999999999 111.521 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.9 ptpt -135.03 72.97 66.75 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-O 121.207 0.527 . . . . 6.7800000000000002 110.987 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2104 ' ' PRO . . . . . 0.427 ' HB3' ' HG3' ' A' 2081 ' ' GLN . 23.5 Cg_exo -64.94 144.86 84.25 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.889 2.392 . . . . 2.4300000000000002 111.592 177.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 3.7 m-20 -76.6 142.95 71.16 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.424 -0.353 . . . . 2.3300000000000001 110.481 177.341 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.632 ' HA ' ' O ' ' A' 2123 ' ' TYR . 71.7 Cg_endo -80.32 132.58 9.25 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 123.086 2.524 . . . . 1.03 113.441 -176.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 9.0 p -161.5 144.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.734 -0.666 . . . . 0.59999999999999998 110.059 177.295 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' 2121 ' ' ALA . 80.9 m -115.03 126.75 55.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.334 0.588 . . . . 0.37 110.523 175.165 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 1.9 t -98.55 137.7 25.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.535 -0.757 . . . . 0.76000000000000001 109.118 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.588 ' HA ' HG22 ' A' 2120 ' ' THR . 0.6 OUTLIER -133.0 109.57 9.64 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 112.301 0.482 . . . . 1.6299999999999999 112.301 -168.004 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.63 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -143.96 137.27 27.64 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 121.874 -0.517 . . . . 3.4700000000000002 110.473 172.585 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.422 ' O ' HG21 ' A' 2065 ' ' VAL . 34.1 m -102.03 157.72 4.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.439 -0.346 . . . . 0.40000000000000002 110.884 179.309 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.686 ' OD2' ' HB ' ' A' 2117 ' ' THR . 40.1 p30 -97.89 -167.97 1.6 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.028 -0.533 . . . . 1.46 110.541 177.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.4 mttt -55.08 -41.5 71.65 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.319 0.489 . . . . 1.72 112.319 -177.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -86.73 -25.42 24.74 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.766 -0.373 . . . . 1.8400000000000001 110.684 -176.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 119.49 15.31 5.48 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.657 -0.783 . . . . 0.44 112.368 178.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.686 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 47.1 m -77.39 115.64 51.06 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-O 120.763 0.316 . . . . 0.56999999999999995 110.237 174.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' 2111 ' ' ARG . 3.0 Cg_endo -82.36 103.93 1.31 Allowed 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.434 2.09 . . . . 0.60999999999999999 112.624 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2119 ' ' VAL . . . . . 0.558 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.33 108.32 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 N-CA-C 107.839 -1.171 . . . . 0.59999999999999998 107.839 167.856 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.588 HG22 ' HA ' ' A' 2110 ' ' LYS . 69.1 p -126.47 156.53 40.53 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.142 -0.935 . . . . 0.67000000000000004 110.492 -171.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.94 127.1 41.06 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.732 -0.84 . . . . 0.72999999999999998 108.732 172.155 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 57.7 m -115.89 99.75 7.5 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.278 -0.638 . . . . 2.1899999999999999 109.278 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.632 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.7 m-85 -98.67 145.67 26.64 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.422 -0.808 . . . . 2.8100000000000001 111.268 -175.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2124 ' ' SER . . . . . 0.512 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 26.5 m -152.97 169.53 9.55 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.67 -0.696 . . . . 2.0600000000000001 109.447 -177.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.512 ' HD2' ' HB3' ' A' 2124 ' ' SER . 82.7 Cg_exo -46.84 -51.64 8.86 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.706 2.271 . . . . 2.1600000000000001 112.912 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -105.74 113.98 27.87 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.153 0.502 . . . . 4.3300000000000001 110.604 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 14.6 p90 -129.81 11.28 5.63 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.623 -0.717 . . . . 3.8300000000000001 109.907 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 1.5 m 70.55 144.46 0.06 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.297 -0.865 . . . . 5.1100000000000003 110.577 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 55.7 pttt -105.74 128.45 53.7 Favored 'General case' 0 C--N 1.323 -0.572 0 O-C-N 122.187 -0.32 . . . . 5.2199999999999998 111.317 -176.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A 2130 ' ' VAL . . . . . 0.426 ' OXT' HG13 ' A' 2130 ' ' VAL . 9.3 p . . . . . 0 C--O 1.249 1.052 0 CA-C-O 117.609 -1.186 . . . . 5.8799999999999999 112.52 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 11.2 pt20 . . . . . 0 N--CA 1.483 1.208 0 CA-C-O 120.583 0.23 . . . . 6.8499999999999996 111.288 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 85.25 27.59 32.98 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.766 -0.73 . . . . 3.4100000000000001 111.909 -176.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -112.96 -139.16 7.36 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.712 -0.756 . . . . 1.77 112.306 -176.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -149.01 94.05 4.08 Favored Pre-proline 0 C--N 1.32 -0.679 0 CA-C-O 121.17 0.51 . . . . 2.4199999999999999 112.191 -172.292 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2057 ' ' PRO . . . . . 0.431 ' HG2' ' HG ' ' A' 2058 ' ' LEU . 36.8 Cg_endo -71.95 -44.43 0.93 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 121.958 1.772 . . . . 1.72 111.471 176.097 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2058 ' ' LEU . . . . . 0.681 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -83.91 -12.95 54.68 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 114.289 1.218 . . . . 2.3399999999999999 114.289 -176.081 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.681 HG23 HD13 ' A' 2058 ' ' LEU . 0.3 OUTLIER -140.21 82.76 16.44 Favored Pre-proline 0 CA--C 1.508 -0.645 0 C-N-CA 119.739 -0.785 . . . . 0.87 110.929 -176.784 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -52.96 119.09 5.51 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.87 1.713 . . . . 1.04 111.547 179.426 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2061 ' ' ILE . . . . . 0.555 HG13 ' NE ' ' A' 2111 ' ' ARG . 39.3 mm -45.51 135.92 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.236 -0.893 . . . . 0.77000000000000002 112.241 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.557 ' O ' HG22 ' A' 2065 ' ' VAL . 13.0 t70 -71.91 141.51 49.49 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.442 -0.799 . . . . 1.4199999999999999 109.953 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -87.01 -7.79 57.79 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.131 0.419 . . . . 1.55 112.131 -172.32 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 67.2 p -106.81 6.37 29.42 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.702 -0.399 . . . . 0.68999999999999995 111.792 -178.155 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.644 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.4 m -97.84 -174.42 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.81999999999999995 109.997 177.458 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -97.08 105.07 21.73 Favored Pre-proline 0 C--O 1.239 0.504 0 CA-C-O 120.808 0.337 . . . . 0.78000000000000003 110.998 178.545 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.644 ' HD3' ' O ' ' A' 2065 ' ' VAL . 56.5 Cg_endo -100.34 109.59 0.06 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 123.175 2.584 . . . . 0.45000000000000001 111.154 167.631 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.428 HG22 ' HE2' ' A' 2074 ' ' LYS . 12.1 p -137.39 178.08 7.37 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.321 0.581 . . . . 0.69999999999999996 111.086 -175.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.503 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -100.81 149.41 23.86 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.02 -1.104 . . . . 1.1599999999999999 108.02 169.157 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -48.31 -44.52 34.0 Favored 'General case' 0 C--N 1.329 -0.283 0 O-C-N 123.509 0.505 . . . . 2.0899999999999999 111.618 -172.403 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -84.16 13.76 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 2.1499999999999999 111.796 -175.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 81.6 26.15 51.55 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 121.017 -0.611 . . . . 0.63 112.706 177.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.32 166.93 11.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.541 0.21 . . . . 0.89000000000000001 110.978 -179.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2074 ' ' LYS . . . . . 0.428 ' HE2' HG22 ' A' 2068 ' ' THR . 35.4 mmtp -123.21 -26.48 4.31 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.812 0.339 . . . . 1.1299999999999999 111.461 -178.012 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -147.54 135.2 20.98 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 2.0800000000000001 109.497 172.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.1 OUTLIER -127.97 99.6 5.57 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.475 -0.565 . . . . 1.48 109.475 177.349 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.0 m -110.23 114.17 27.44 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 121.139 0.495 . . . . 0.63 110.753 177.066 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2078 ' ' ILE . . . . . . . . . . . . . 75.2 mt -121.76 120.07 28.78 Favored Pre-proline 0 C--N 1.315 -0.908 0 N-CA-C 108.343 -0.984 . . . . 1.6200000000000001 108.343 173.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.53 111.47 0.37 Allowed 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 123.251 2.634 . . . . 0.97999999999999998 112.9 -176.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.78 -15.88 37.23 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.616 -0.72 . . . . 0.93999999999999995 112.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.565 ' CD ' ' HA ' ' A' 2104 ' ' PRO . 24.0 mt-30 -97.8 -37.24 9.93 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.981 0.419 . . . . 2.02 110.837 -178.589 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 118.69 -166.73 12.98 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 111.083 -0.807 . . . . 0.5 111.083 -177.087 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 62.1 m -129.03 119.31 24.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.856 0.836 . . . . 0.48999999999999999 110.738 174.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.43 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 1.9 m-85 -94.82 122.88 37.9 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 105.854 -1.906 . . . . 1.4399999999999999 105.854 168.004 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.33 143.06 41.86 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.801 0.667 . . . . 0.63 112.801 -168.518 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -138.88 132.59 40.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.404 -0.816 . . . . 1.1799999999999999 109.559 170.732 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 30.4 m -119.94 150.42 50.79 Favored Pre-proline 0 C--N 1.325 -0.499 0 N-CA-C 109.657 -0.497 . . . . 0.80000000000000004 109.657 173.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -62.38 0.69 1.25 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 123.686 2.924 . . . . 0.96999999999999997 114.215 -170.377 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -68.33 -18.9 64.61 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.007 0.432 . . . . 2.29 109.876 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 101.92 11.81 36.28 Favored Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.506 -0.77 . . . . 0.82999999999999996 111.767 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.6 t -109.5 136.14 49.38 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.131 0.491 . . . . 1.51 110.419 -178.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' 2086 ' ' ILE . 3.6 t -133.41 149.23 31.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.753 -0.658 . . . . 1.1799999999999999 109.796 -176.554 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -137.76 119.75 15.43 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.147 0.498 . . . . 1.46 111.098 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 16.3 m-30 -94.04 97.27 10.21 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.319 -0.993 . . . . 1.27 108.319 174.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 18.8 m -120.27 87.99 41.01 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 120.772 -0.371 . . . . 0.57999999999999996 111.654 -176.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -91.77 157.51 3.45 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.27 2.646 . . . . 0.97999999999999998 112.582 174.689 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.1 136.56 56.86 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.066 -0.515 . . . . 2.7200000000000002 110.271 169.744 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 23.1 tptm -91.86 -30.89 15.93 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.937 -0.574 . . . . 4.8099999999999996 111.875 -177.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -107.8 -47.1 3.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.852 1.056 . . . . 4.4199999999999999 113.852 -165.164 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.5 122.98 13.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.732 0.777 . . . . 2.3599999999999999 112.279 -169.017 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.1 t -80.98 143.47 12.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.287 -0.869 . . . . 2.6800000000000002 110.362 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 117.63 -52.49 0.69 Allowed Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 108.823 -1.711 . . . . 3.8399999999999999 108.823 -169.178 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2103 ' ' LYS . . . . . 0.467 ' HB2' ' HA ' ' A' 2125 ' ' PRO . 70.1 mmtt 68.69 159.33 0.15 Allowed Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 113.89 1.07 . . . . 6.7800000000000002 113.89 167.425 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2104 ' ' PRO . . . . . 0.565 ' HA ' ' CD ' ' A' 2081 ' ' GLN . 62.4 Cg_exo -44.86 144.25 3.74 Favored 'Trans proline' 0 C--N 1.348 0.548 0 C-N-CA 124.371 3.381 . . . . 2.4300000000000002 116.156 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 25.9 t70 -65.77 132.06 94.78 Favored Pre-proline 0 N--CA 1.451 -0.42 0 CA-C-N 114.312 -1.313 . . . . 2.3300000000000001 107.999 164.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.619 ' HA ' ' O ' ' A' 2123 ' ' TYR . 6.5 Cg_endo -47.12 112.86 0.57 Allowed 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 124.196 3.264 . . . . 1.03 114.595 -170.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 6.0 p -150.15 123.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.34 -0.845 . . . . 0.59999999999999998 110.087 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.6 m -100.62 133.99 44.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.131 -0.486 . . . . 0.37 110.609 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.9 t -110.14 147.77 14.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.465 -0.568 . . . . 0.76000000000000001 109.465 177.407 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' 2110 ' ' LYS . 18.5 ttpt -143.78 109.48 5.2 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.135 0.421 . . . . 1.6299999999999999 112.135 -174.01 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.555 ' NE ' HG13 ' A' 2061 ' ' ILE . 18.2 ptt180 -131.52 136.3 47.76 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.119 -0.697 . . . . 3.4700000000000002 109.119 174.028 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' 2065 ' ' VAL . 34.4 m -98.94 145.13 10.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.431 -0.508 . . . . 0.40000000000000002 111.014 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -91.94 -168.86 2.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.073 -0.512 . . . . 1.46 110.723 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 68.4 mttm -65.77 -28.81 69.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 1.72 111.557 -178.583 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2115 ' ' ASN . . . . . 0.443 HD22 HG11 ' A' 2059 ' ' VAL . 42.4 m-80 -74.26 -20.75 60.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.176 0.512 . . . . 1.8400000000000001 110.081 174.103 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 94.43 9.8 58.7 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.682 -0.69 . . . . 0.44 111.851 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2117 ' ' THR . . . . . . . . . . . . . 30.5 m -82.04 120.06 76.52 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 110.012 -0.366 . . . . 0.56999999999999995 110.012 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -72.93 106.29 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.441 2.094 . . . . 0.60999999999999999 112.528 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 35.3 m -77.48 108.73 11.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.008 -1.108 . . . . 0.59999999999999998 108.008 171.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.4 p -119.98 145.01 47.19 Favored 'General case' 0 N--CA 1.438 -1.031 0 CA-C-N 114.537 -1.21 . . . . 0.67000000000000004 110.573 -172.318 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.48 126.41 40.42 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.581 -0.736 . . . . 0.72999999999999998 109.265 175.493 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 35.0 p -100.33 97.76 8.48 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.874 -0.788 . . . . 2.1899999999999999 108.874 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.619 ' O ' ' HA ' ' A' 2106 ' ' PRO . 24.3 m-85 -89.69 99.75 12.69 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-O 121.493 0.663 . . . . 2.8100000000000001 111.666 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 7.9 p -148.86 170.12 8.13 Favored Pre-proline 0 N--CA 1.435 -1.192 0 CA-C-N 114.456 -1.247 . . . . 2.0600000000000001 109.441 178.624 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.467 ' HA ' ' HB2' ' A' 2103 ' ' LYS . 51.0 Cg_exo -55.86 97.93 0.06 OUTLIER 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.447 2.098 . . . . 2.1600000000000001 111.811 175.296 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -161.59 -56.03 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.613 -0.721 . . . . 4.3300000000000001 109.981 -177.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -68.7 137.53 54.19 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.427 -0.806 . . . . 3.8300000000000001 111.8 -175.196 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 38.4 m 74.53 -56.74 0.63 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.5 0.72 . . . . 5.1100000000000003 112.914 172.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 8.0 ptmm? -73.7 149.58 41.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.866 0.365 . . . . 5.2199999999999998 111.124 -176.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 20.5 t . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.481 -0.771 . . . . 5.8799999999999999 109.718 176.46 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A 2053 ' ' GLN . . . . . 0.447 ' HG3' ' O ' ' A' 2120 ' ' THR . 4.1 pt20 . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.379 0.133 . . . . 6.8499999999999996 111.115 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -101.16 -6.11 51.94 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.736 -0.745 . . . . 3.4100000000000001 113.353 -173.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -166.88 115.99 0.66 Allowed Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.695 -0.765 . . . . 1.77 111.708 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -101.38 113.97 65.76 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 120.94 0.4 . . . . 2.4199999999999999 110.647 178.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -47.19 11.55 Favored 'Trans proline' 0 N--CA 1.473 0.304 0 C-N-CA 123.317 2.678 . . . . 1.72 112.559 -179.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2058 ' ' LEU . . . . . 0.608 HD13 HG23 ' A' 2059 ' ' VAL . 0.1 OUTLIER -61.41 -20.33 62.93 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 115.358 -0.837 . . . . 2.3399999999999999 113.24 177.281 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.608 HG23 HD13 ' A' 2058 ' ' LEU . 6.1 t -130.11 86.72 53.44 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.124 -0.324 . . . . 0.87 110.124 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.01 126.37 20.87 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.396 2.064 . . . . 1.04 111.955 -177.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 37.9 mm -59.54 132.97 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.819 -0.628 . . . . 0.77000000000000002 110.374 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.581 ' O ' HG22 ' A' 2065 ' ' VAL . 13.8 t70 -78.17 138.15 38.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.145 -0.48 . . . . 1.4199999999999999 110.635 -176.098 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2063 ' ' GLU . . . . . 0.405 ' O ' ' HA3' ' A' 2090 ' ' GLY . 41.8 mt-10 -93.66 -0.43 56.09 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.184 -0.462 . . . . 1.55 111.877 -172.284 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.5 p -108.29 -1.83 19.76 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.78 -0.368 . . . . 0.68999999999999995 111.164 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' 2062 ' ' ASP . 32.8 m -89.87 -176.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.441 -0.345 . . . . 0.81999999999999995 110.172 178.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -93.47 111.65 53.16 Favored Pre-proline 0 C--O 1.238 0.485 0 CA-C-O 121.08 0.467 . . . . 0.78000000000000003 111.451 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.556 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -100.88 107.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.523 0 C-N-CA 123.025 2.483 . . . . 0.45000000000000001 111.327 167.44 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.503 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.2 p -145.68 146.51 31.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.853 0.358 . . . . 0.69999999999999996 110.522 -177.703 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.52 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.9 OUTLIER -71.61 148.23 46.78 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.942 -1.133 . . . . 1.1599999999999999 107.942 177.908 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -52.93 -37.42 60.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 118.412 0.551 . . . . 2.0899999999999999 111.297 -171.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 29.1 t70 -67.73 -11.66 58.86 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.679 -0.691 . . . . 2.1499999999999999 111.928 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 91.06 29.85 12.04 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.848 -0.691 . . . . 0.63 112.012 -176.179 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.6 p -110.08 161.68 15.3 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.887 0.375 . . . . 0.89000000000000001 111.22 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2074 ' ' LYS . . . . . 0.4 ' O ' HG22 ' A' 2086 ' ' ILE . 35.4 mmtp -110.94 -21.07 12.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.898 -0.592 . . . . 1.1299999999999999 110.985 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.709 ' HG2' HG22 ' A' 2085 ' ' THR . 3.9 mt-10 -147.57 142.21 26.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.268 -0.424 . . . . 2.0800000000000001 110.141 176.201 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD3' ' C ' ' A' 2076 ' ' LYS . 1.7 tmtp? -141.24 119.72 12.34 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.09 -0.707 . . . . 1.48 109.09 177.385 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2077 ' ' THR . . . . . 0.402 ' N ' ' HD3' ' A' 2076 ' ' LYS . 34.5 m -123.45 125.09 44.31 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.425 0.631 . . . . 0.63 111.356 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.494 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 93.8 mt -125.46 120.98 24.8 Favored Pre-proline 0 C--N 1.316 -0.863 0 N-CA-C 108.536 -0.913 . . . . 1.6200000000000001 108.536 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -47.51 110.65 0.32 Allowed 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 123.203 2.602 . . . . 0.97999999999999998 112.956 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 101.25 -21.45 43.06 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.74 -0.664 . . . . 0.93999999999999995 112.63 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.494 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.2 tt0 -93.3 -31.74 14.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.105 0.478 . . . . 2.02 110.678 -175.322 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.98 -178.42 16.88 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.797 -0.716 . . . . 0.5 112.24 177.669 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.409 HG22 HG23 ' A' 2085 ' ' THR . 45.7 m -128.07 141.95 51.35 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.483 0.659 . . . . 0.48999999999999999 110.103 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.481 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.9 m-85 -113.87 122.56 47.39 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.343 -1.354 . . . . 1.4399999999999999 107.343 173.25 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.709 HG22 ' HG2' ' A' 2075 ' ' GLU . 30.5 p -122.93 129.79 52.03 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.19 0.441 . . . . 0.63 112.19 -173.501 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.514 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.5 129.71 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.817 -0.629 . . . . 1.1799999999999999 109.923 170.74 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.7 m -110.1 148.73 38.91 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 115.644 -0.707 . . . . 0.80000000000000004 109.501 175.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -61.67 0.17 1.24 Allowed 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.679 2.919 . . . . 0.96999999999999997 113.755 -173.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2089 ' ' ASP . . . . . 0.43 ' HB2' HG22 ' A' 2091 ' ' THR . 5.1 m-20 -70.25 -13.64 62.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.124 0.488 . . . . 2.29 109.859 174.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2090 ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' 2063 ' ' GLU . . . 95.5 14.06 48.9 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.71 -0.677 . . . . 0.82999999999999996 111.744 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2091 ' ' THR . . . . . 0.43 HG22 ' HB2' ' A' 2089 ' ' ASP . 10.2 t -119.83 139.24 52.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.06 0.457 . . . . 1.51 110.279 -177.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.514 HG22 ' CG1' ' A' 2086 ' ' ILE . 9.6 t -134.83 153.44 34.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.899 -0.592 . . . . 1.1799999999999999 109.968 -175.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.9 t -131.92 122.31 25.43 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.261 0.553 . . . . 1.46 110.044 171.139 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2094 ' ' PHE . . . . . 0.434 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.1 m-30 -90.15 98.45 11.78 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.343 -0.984 . . . . 1.27 108.343 175.307 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 28.5 m -113.93 89.64 17.05 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.123 0.487 . . . . 0.57999999999999996 111.467 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2096 ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' 2094 ' ' PHE . 85.2 Cg_endo -90.56 149.04 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.008 2.472 . . . . 0.97999999999999998 111.55 174.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.61 126.02 30.17 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.922 0.391 . . . . 2.7200000000000002 110.012 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2098 ' ' LYS . . . . . 0.473 ' O ' ' HB ' ' A' 2130 ' ' VAL . 67.9 mttm -84.01 -10.63 57.74 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.153 -0.476 . . . . 4.8099999999999996 112.067 -174.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 76.4 mt-30 -115.27 13.21 16.63 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.572 -0.451 . . . . 4.4199999999999999 111.247 -175.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 42.5 t80 -77.65 110.89 12.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.004 0.431 . . . . 2.3599999999999999 111.039 -178.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 47.0 t -111.99 98.59 7.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.327 -0.62 . . . . 2.6800000000000002 109.327 174.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -178.2 -142.32 4.64 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.972 -0.632 . . . . 3.8399999999999999 111.65 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2103 ' ' LYS . . . . . 0.41 ' HG3' ' O ' ' A' 2103 ' ' LYS . 24.2 pttm -113.91 101.94 54.36 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-O 121.203 0.525 . . . . 6.7800000000000002 111.287 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 10.5 Cg_exo -71.86 147.18 49.44 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.62 2.213 . . . . 2.4300000000000002 111.159 174.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.447 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.9 t70 -95.77 132.29 27.55 Favored Pre-proline 0 C--N 1.322 -0.61 0 N-CA-C 109.802 -0.444 . . . . 2.3300000000000001 109.802 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.571 ' HA ' ' O ' ' A' 2123 ' ' TYR . 15.7 Cg_endo -57.17 113.31 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 123.515 2.81 . . . . 1.03 114.128 -173.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.7 p -147.19 141.81 20.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.362 -0.836 . . . . 0.59999999999999998 109.525 174.59 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 18.0 m -115.92 113.71 23.67 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.139 0.495 . . . . 0.37 110.276 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.2 t -92.24 132.23 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.058 -0.719 . . . . 0.76000000000000001 109.058 -179.438 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.503 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.0 tmmm? -133.45 145.88 50.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.227 0.537 . . . . 1.6299999999999999 111.664 -170.607 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.475 ' N ' ' HD2' ' A' 2110 ' ' LYS . 32.2 ptt180 -164.57 137.86 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.543 -0.91 . . . . 3.4700000000000002 108.543 169.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.428 ' O ' HG21 ' A' 2065 ' ' VAL . 33.8 m -98.82 148.98 5.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.213 -0.595 . . . . 0.40000000000000002 111.52 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.603 ' OD1' ' HB ' ' A' 2117 ' ' THR . 8.5 p30 -88.91 -168.53 2.21 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.403 -0.817 . . . . 1.46 111.341 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.0 mttm -64.88 -34.25 77.95 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.561 0.578 . . . . 1.72 112.561 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.6 p30 -84.55 -22.92 29.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 119.685 -0.806 . . . . 1.8400000000000001 110.515 177.369 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 116.67 12.09 8.92 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.809 -0.71 . . . . 0.44 112.958 173.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.603 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 86.5 m -83.27 125.64 73.89 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 117.221 0.511 . . . . 0.56999999999999995 110.005 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' 2117 ' ' THR . 1.8 Cg_endo -81.36 111.46 2.37 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.451 2.101 . . . . 0.60999999999999999 112.987 -178.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 11.6 m -75.94 127.0 37.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.357 -0.979 . . . . 0.59999999999999998 108.357 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' 2109 ' ' VAL . 39.9 p -130.89 166.42 20.95 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 115.699 -0.682 . . . . 0.67000000000000004 111.332 -170.711 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -127.56 126.75 42.7 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 107.677 -1.231 . . . . 0.72999999999999998 107.677 169.257 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 3.5 m -110.08 99.42 8.51 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.324 -0.398 . . . . 2.1899999999999999 110.582 -172.293 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.571 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.2 m-85 -104.74 151.69 23.44 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 121.252 0.549 . . . . 2.8100000000000001 111.577 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 6.6 p -168.62 170.97 3.86 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 114.778 -1.101 . . . . 2.0600000000000001 108.33 -173.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -70.6 53.16 1.35 Allowed 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.712 2.275 . . . . 2.1600000000000001 112.185 177.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -124.63 -145.92 0.34 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.309 -0.859 . . . . 4.3300000000000001 108.778 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 93.6 m-85 59.52 83.36 0.13 Allowed 'General case' 0 C--O 1.235 0.302 0 O-C-N 123.601 0.563 . . . . 3.8300000000000001 111.444 174.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 16.1 p -56.52 -53.89 52.18 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.005 -0.543 . . . . 5.1100000000000003 110.128 177.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -170.74 152.62 3.78 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.289 -0.869 . . . . 5.2199999999999998 109.214 174.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A 2130 ' ' VAL . . . . . 0.473 ' HB ' ' O ' ' A' 2098 ' ' LYS . 45.5 t . . . . . 0 C--O 1.246 0.892 0 CA-C-O 118.499 -0.762 . . . . 5.8799999999999999 110.191 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2053 ' ' GLN . . . . . 0.43 ' OE1' ' HB3' ' A' 2057 ' ' PRO . 23.5 mt-30 . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.352 -0.24 . . . . 6.8499999999999996 110.352 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -137.36 48.42 0.9 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.072 -0.585 . . . . 3.4100000000000001 112.076 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2055 ' ' GLY . . . . . 0.472 ' HA3' HD11 ' A' 2061 ' ' ILE . . . 161.86 -102.1 0.2 Allowed Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 121.039 -0.601 . . . . 1.77 112.013 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -136.31 131.66 18.66 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-O 120.831 0.348 . . . . 2.4199999999999999 110.733 -179.349 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2057 ' ' PRO . . . . . 0.43 ' HB3' ' OE1' ' A' 2053 ' ' GLN . 31.1 Cg_endo -64.95 -56.01 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.887 2.391 . . . . 1.72 112.064 177.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2058 ' ' LEU . . . . . 0.697 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -63.81 -12.46 35.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.43 -0.804 . . . . 2.3399999999999999 113.167 177.498 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.697 HG23 HD13 ' A' 2058 ' ' LEU . 21.5 t -136.77 86.06 22.72 Favored Pre-proline 0 C--N 1.322 -0.615 0 N-CA-C 109.814 -0.439 . . . . 0.87 109.814 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.63 137.82 83.1 Favored 'Trans proline' 0 C--O 1.235 0.363 0 C-N-CA 122.629 2.219 . . . . 1.04 112.3 -176.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2061 ' ' ILE . . . . . 0.472 HD11 ' HA3' ' A' 2055 ' ' GLY . 45.9 mm -65.27 136.46 26.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.672 -0.694 . . . . 0.77000000000000002 110.313 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 35.5 t70 -82.77 134.42 35.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.301 0.572 . . . . 1.4199999999999999 111.038 -175.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -87.32 -8.47 56.66 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.661 -0.7 . . . . 1.55 111.588 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 76.5 p -104.49 7.88 35.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.971 0.415 . . . . 0.68999999999999995 111.557 -178.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.554 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.1 m -110.23 -177.83 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.447 -0.575 . . . . 0.81999999999999995 109.447 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -94.88 110.9 52.3 Favored Pre-proline 0 C--O 1.243 0.729 0 CA-C-O 121.092 0.472 . . . . 0.78000000000000003 110.984 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' 2065 ' ' VAL . 43.4 Cg_endo -100.98 106.8 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.62 0 C-N-CA 123.077 2.518 . . . . 0.45000000000000001 111.688 169.04 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.0 p -142.87 -177.93 5.57 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.177 0.513 . . . . 0.69999999999999996 110.907 -176.783 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.562 ' CE2' ' HB2' ' A' 2084 ' ' TYR . 93.9 m-85 -101.51 164.97 11.49 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 108.731 -0.84 . . . . 1.1599999999999999 108.731 170.054 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -53.76 -33.23 55.13 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-N 118.004 0.365 . . . . 2.0899999999999999 111.687 -172.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -86.61 12.65 10.09 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 111.872 0.323 . . . . 2.1499999999999999 111.872 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 17.91 79.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 121.053 -0.594 . . . . 0.63 111.944 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.2 m -78.6 164.23 24.84 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.743 0.306 . . . . 0.89000000000000001 111.097 -173.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -115.5 -18.34 10.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.219 0.533 . . . . 1.1299999999999999 110.425 178.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -147.32 140.64 25.34 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.316 -0.624 . . . . 2.0800000000000001 109.316 173.057 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' 2083 ' ' THR . 27.1 tptt -127.97 116.17 19.65 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.939 -0.393 . . . . 1.48 109.939 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 59.3 m -113.6 132.99 55.54 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.294 0.569 . . . . 0.63 110.957 176.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.573 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 36.0 mt -134.63 121.2 14.91 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.102 -0.954 . . . . 1.6200000000000001 108.859 178.078 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -51.04 108.97 0.26 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.231 2.621 . . . . 0.97999999999999998 113.186 -175.744 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 95.2 -11.15 69.42 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.908 -0.663 . . . . 0.93999999999999995 112.75 176.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.573 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.5 tt0 -103.57 -26.51 12.79 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.262 0.554 . . . . 2.02 109.957 -176.246 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.29 -156.08 15.89 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.405 -0.816 . . . . 0.5 112.538 175.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.469 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -144.69 137.3 26.48 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.714 0.769 . . . . 0.48999999999999999 110.729 177.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 5.7 m-85 -108.38 126.27 52.68 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.114 -1.439 . . . . 1.4399999999999999 107.114 171.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2085 ' ' THR . . . . . 0.467 HG23 HG22 ' A' 2083 ' ' THR . 0.9 OUTLIER -128.15 147.12 50.54 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 112.826 0.676 . . . . 0.63 112.826 -172.221 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.541 ' CB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -141.8 127.1 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 115.248 -0.887 . . . . 1.1799999999999999 109.807 172.7 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -102.62 148.28 35.27 Favored Pre-proline 0 C--N 1.321 -0.643 0 N-CA-C 109.144 -0.687 . . . . 0.80000000000000004 109.144 173.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -61.18 0.24 1.02 Allowed 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.712 2.942 . . . . 0.96999999999999997 114.32 -171.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -71.74 -20.42 61.9 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.758 -0.46 . . . . 2.29 109.758 175.141 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 105.34 17.44 13.76 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.997 -0.62 . . . . 0.82999999999999996 112.289 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.2 t -112.71 135.76 53.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.13 0.49 . . . . 1.51 110.481 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 6.7 t -129.46 152.35 37.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.958 -0.565 . . . . 1.1799999999999999 111.033 -172.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 8.9 t -141.76 123.55 15.23 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.416 0.627 . . . . 1.46 110.267 172.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2094 ' ' PHE . . . . . 0.559 ' CE2' HG11 ' A' 2109 ' ' VAL . 19.3 m-30 -98.55 98.91 10.03 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.522 -0.918 . . . . 1.27 108.522 177.1 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 10.1 m -116.43 87.99 22.29 Favored Pre-proline 0 N--CA 1.454 -0.264 0 C-N-CA 120.238 -0.585 . . . . 0.57999999999999996 111.341 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2096 ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' 2094 ' ' PHE . 18.2 Cg_endo -92.55 143.55 2.44 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.516 2.811 . . . . 0.97999999999999998 112.166 173.453 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 52.7 t0 -88.63 92.52 9.23 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.264 -0.643 . . . . 2.7200000000000002 109.264 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -75.59 -1.48 24.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.031 -0.531 . . . . 4.8099999999999996 111.247 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -81.95 -16.38 50.64 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.125 -0.694 . . . . 4.4199999999999999 109.125 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 78.2 t80 -99.99 110.51 22.84 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.072 -0.967 . . . . 2.3599999999999999 109.673 177.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.6 p -144.24 100.75 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.944 0.878 . . . . 2.6800000000000002 111.452 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -151.73 -77.64 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 110.437 -1.065 . . . . 3.8399999999999999 110.437 175.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 57.8 pttt -129.31 71.73 82.02 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-O 120.982 0.42 . . . . 6.7800000000000002 110.896 173.201 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.88 148.84 91.14 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.407 2.071 . . . . 2.4300000000000002 111.027 175.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.538 ' HB3' HD13 ' A' 2078 ' ' ILE . 16.4 t70 -75.65 132.99 74.11 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 109.582 -0.525 . . . . 2.3300000000000001 109.582 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.603 ' HA ' ' O ' ' A' 2123 ' ' TYR . 33.5 Cg_endo -65.24 106.06 0.78 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.024 2.482 . . . . 1.03 112.645 -176.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2107 ' ' VAL . . . . . 0.44 HG21 ' HG2' ' A' 2076 ' ' LYS . 9.5 p -147.42 134.31 13.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.645 -0.707 . . . . 0.59999999999999998 110.501 177.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.4 m -109.75 128.23 55.15 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 115.88 -0.6 . . . . 0.37 110.065 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' 2120 ' ' THR . 13.0 t -91.42 117.99 35.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 108.697 -0.853 . . . . 0.76000000000000001 108.697 176.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.418 ' HA ' HG22 ' A' 2120 ' ' THR . 0.2 OUTLIER -125.47 108.49 11.69 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.633 -0.427 . . . . 1.6299999999999999 110.918 -172.532 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.541 HH12 ' CB ' ' A' 2086 ' ' ILE . 12.7 ptp180 -155.18 157.46 37.41 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.776 -0.453 . . . . 3.4700000000000002 109.776 175.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.3 m -112.04 149.39 14.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.377 -0.529 . . . . 0.40000000000000002 111.69 -177.133 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.615 ' OD2' ' HB ' ' A' 2117 ' ' THR . 5.0 p30 -91.73 -169.33 2.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.632 -0.713 . . . . 1.46 110.756 177.04 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.8 mttm -62.99 -31.95 73.19 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.014 0.376 . . . . 1.72 112.014 -178.187 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -78.43 -18.62 54.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.083 0.468 . . . . 1.8400000000000001 110.122 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 99.61 10.57 46.82 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.563 -0.744 . . . . 0.44 111.304 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.615 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 62.2 m -81.9 125.89 76.53 Favored Pre-proline 0 N--CA 1.448 -0.542 0 CA-C-O 120.515 0.197 . . . . 0.56999999999999995 110.487 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' 2111 ' ' ARG . 11.9 Cg_exo -70.35 101.43 0.99 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.468 2.112 . . . . 0.60999999999999999 112.589 177.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2119 ' ' VAL . . . . . 0.449 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 23.7 m -75.37 108.63 7.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.374 -0.973 . . . . 0.59999999999999998 108.374 169.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.635 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.6 p -126.63 154.4 44.04 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.189 -0.914 . . . . 0.67000000000000004 111.196 -171.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.59 127.77 42.92 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.282 -1.007 . . . . 0.72999999999999998 108.282 170.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 29.6 p -105.12 99.63 9.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.095 0.474 . . . . 2.1899999999999999 110.172 -177.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.603 ' O ' ' HA ' ' A' 2106 ' ' PRO . 10.6 m-85 -113.38 134.42 54.65 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.966 -0.561 . . . . 2.8100000000000001 111.225 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2124 ' ' SER . . . . . 0.43 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 26.3 p -160.08 161.19 26.38 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 115.602 -0.726 . . . . 2.0600000000000001 109.935 -175.113 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' 2124 ' ' SER . 57.3 Cg_endo -71.18 3.32 3.55 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 122.956 2.438 . . . . 2.1600000000000001 113.011 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -105.0 6.98 33.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.062 0.458 . . . . 4.3300000000000001 109.933 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 29.3 t80 -60.47 122.86 15.67 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.419 -0.81 . . . . 3.8300000000000001 110.28 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 17.7 p -89.73 153.03 21.02 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.216 -0.447 . . . . 5.1100000000000003 111.474 -177.13 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -97.18 145.64 25.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 5.2199999999999998 110.609 -178.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 6.3 p . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.191 -0.909 . . . . 5.8799999999999999 110.454 179.875 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 . . . . . 0 N--CA 1.478 0.956 0 N-CA-C 110.303 -0.258 . . . . 6.8499999999999996 110.303 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -62.21 -41.0 99.71 Favored Glycine 0 C--N 1.33 0.223 0 C-N-CA 121.04 -0.6 . . . . 3.4100000000000001 112.945 -177.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 162.75 -96.76 0.14 Allowed Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 111.212 -0.755 . . . . 1.77 111.212 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2056 ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 1.8 t70 -124.38 134.12 25.26 Favored Pre-proline 0 C--N 1.32 -0.676 0 N-CA-C 109.211 -0.663 . . . . 2.4199999999999999 109.211 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -44.25 -55.08 3.4 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 123.296 2.664 . . . . 1.72 113.231 -175.075 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2058 ' ' LEU . . . . . 0.641 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -101.16 2.07 39.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.014 0.435 . . . . 2.3399999999999999 112.085 -177.909 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A 2059 ' ' VAL . . . . . 0.641 HG23 HD13 ' A' 2058 ' ' LEU . 2.1 t -131.65 78.42 70.88 Favored Pre-proline 0 C--N 1.327 -0.386 0 N-CA-C 110.091 -0.337 . . . . 0.87 110.091 178.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.42 140.03 92.35 Favored 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.182 1.921 . . . . 1.04 111.349 176.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.3 mm -61.06 130.97 25.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.856 -0.611 . . . . 0.77000000000000002 111.404 -178.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.603 ' O ' HG22 ' A' 2065 ' ' VAL . 12.5 t70 -73.67 140.36 46.03 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.393 -0.821 . . . . 1.4199999999999999 109.867 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -86.83 -10.47 53.39 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 111.914 0.338 . . . . 1.55 111.914 -171.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 39.7 p -109.24 10.12 25.8 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.755 0.312 . . . . 0.68999999999999995 111.817 -177.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.617 ' O ' ' HD3' ' A' 2067 ' ' PRO . 35.8 m -91.66 -174.94 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 110.059 -0.348 . . . . 0.81999999999999995 110.059 175.215 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -97.0 105.05 21.24 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.551 -0.295 . . . . 0.78000000000000003 110.775 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -99.91 106.48 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.603 0 C-N-CA 122.562 2.175 . . . . 0.45000000000000001 110.92 168.411 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.517 ' O ' ' HB3' ' A' 2110 ' ' LYS . 40.7 p -145.35 147.66 32.54 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.104 -0.498 . . . . 0.69999999999999996 110.09 -176.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.538 ' HD2' ' N ' ' A' 2069 ' ' PHE . 1.2 m-30 -72.62 153.75 41.09 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.5 -0.926 . . . . 1.1599999999999999 108.5 178.235 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -50.55 -43.51 56.22 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.958 0.409 . . . . 2.0899999999999999 111.139 -173.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 38.1 t70 -77.43 2.58 15.64 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 115.671 -0.695 . . . . 2.1499999999999999 111.587 -177.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 86.28 29.98 23.57 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.162 -0.542 . . . . 0.63 112.558 179.367 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 12.5 m -101.24 162.47 12.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.788 0.328 . . . . 0.89000000000000001 110.941 -176.565 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -115.83 -19.62 10.37 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.092 -0.504 . . . . 1.1299999999999999 110.87 178.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2075 ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' 2084 ' ' TYR . 7.2 tt0 -156.0 125.88 6.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.999 -0.546 . . . . 2.0800000000000001 109.737 172.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' 2083 ' ' THR . 32.1 tptt -117.33 118.89 33.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.655 -0.702 . . . . 1.48 109.411 178.353 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.4 m -111.85 113.73 26.24 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.482 0.658 . . . . 0.63 110.882 176.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 67.0 mt -110.18 113.9 56.23 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.302 -0.999 . . . . 1.6200000000000001 108.302 174.364 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -47.41 109.4 0.22 Allowed 'Trans proline' 0 N--CA 1.474 0.324 0 C-N-CA 123.49 2.793 . . . . 0.97999999999999998 113.879 -171.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 89.42 -11.56 69.49 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.814 -0.63 . . . . 0.93999999999999995 112.73 176.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.54 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.5 tm0? -98.22 -28.45 13.7 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.059 0.456 . . . . 2.02 110.008 -175.098 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 130.37 -173.8 19.88 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.712 -0.756 . . . . 0.5 112.765 173.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -147.79 138.96 23.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.71 0.767 . . . . 0.48999999999999999 110.436 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.536 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.2 OUTLIER -114.14 131.4 56.44 Favored 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 107.261 -1.385 . . . . 1.4399999999999999 107.261 175.382 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 23.7 p -127.84 128.72 45.72 Favored 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 120.527 -0.469 . . . . 0.63 112.173 -174.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.539 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -116.96 129.66 73.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.579 -0.737 . . . . 1.1799999999999999 109.753 170.727 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A 2087 ' ' VAL . . . . . 0.426 ' CG2' HG23 ' A' 2091 ' ' THR . 27.5 m -118.45 145.37 37.18 Favored Pre-proline 0 C--N 1.319 -0.734 0 CA-C-N 115.968 -0.56 . . . . 0.80000000000000004 109.534 173.785 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -59.76 -5.33 3.43 Favored 'Trans proline' 0 N--CA 1.477 0.548 0 C-N-CA 123.85 3.033 . . . . 0.96999999999999997 114.682 -168.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 28.5 t70 -68.82 -21.35 64.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.276 0.56 . . . . 2.29 109.81 176.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.24 7.86 26.08 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.899 -0.667 . . . . 0.82999999999999996 112.077 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2091 ' ' THR . . . . . 0.426 HG23 ' CG2' ' A' 2087 ' ' VAL . 1.6 t -107.21 124.44 49.74 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.34 0.591 . . . . 1.51 110.559 -179.139 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.634 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 10.1 t -129.49 138.48 54.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.351 -0.841 . . . . 1.1799999999999999 109.716 -178.727 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.8 t -123.05 115.29 21.6 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.456 0.646 . . . . 1.46 110.571 175.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2094 ' ' PHE . . . . . 0.485 ' O ' ' HD3' ' A' 2096 ' ' PRO . 14.2 m-30 -85.8 98.47 10.76 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.648 -0.871 . . . . 1.27 108.648 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 7.5 m -113.28 88.08 12.14 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.968 0.414 . . . . 0.57999999999999996 111.302 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2096 ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' 2094 ' ' PHE . 96.8 Cg_endo -92.63 145.44 2.59 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.294 2.663 . . . . 0.97999999999999998 112.683 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.46 102.69 11.28 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.19 -0.67 . . . . 2.7200000000000002 109.19 170.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2098 ' ' LYS . . . . . 0.682 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -87.08 10.89 15.19 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.763 -0.653 . . . . 4.8099999999999996 111.371 -175.036 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -106.44 8.85 31.74 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.193 0.521 . . . . 4.4199999999999999 109.83 177.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 64.9 t80 -79.58 80.59 5.95 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.52 -0.764 . . . . 2.3599999999999999 109.666 174.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 16.6 t -85.13 98.24 6.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.079 -0.51 . . . . 2.6800000000000002 109.78 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.3 48.98 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.639 -0.71 . . . . 3.8399999999999999 111.436 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 1.2 mptm? 59.27 73.76 0.65 Allowed Pre-proline 0 CA--C 1.532 0.26 0 C-N-CA 122.895 0.478 . . . . 6.7800000000000002 111.418 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2104 ' ' PRO . . . . . 0.514 ' HD2' ' HA ' ' A' 2126 ' ' GLU . 31.4 Cg_exo -60.04 131.89 41.69 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.456 2.104 . . . . 2.4300000000000002 111.115 175.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.482 ' HB3' HD13 ' A' 2078 ' ' ILE . 35.6 t70 -68.99 131.23 90.96 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-N 116.098 -0.501 . . . . 2.3300000000000001 110.373 -178.053 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.54 131.98 18.27 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 123.083 2.522 . . . . 1.03 113.616 -177.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 14.7 p -161.26 144.03 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.372 -0.831 . . . . 0.59999999999999998 109.644 174.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2108 ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' 2121 ' ' ALA . 42.9 m -109.79 125.5 52.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.433 0.635 . . . . 0.37 110.744 177.206 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -102.56 138.91 25.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.46 -0.791 . . . . 0.76000000000000001 108.946 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2110 ' ' LYS . . . . . 0.536 ' HG2' ' N ' ' A' 2111 ' ' ARG . 23.5 ttpt -139.68 153.43 47.27 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.296 0.498 . . . . 1.6299999999999999 112.297 -172.768 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.634 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 31.7 ptt180 -175.38 142.76 0.61 Allowed 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 108.447 -0.945 . . . . 3.4700000000000002 108.447 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2112 ' ' VAL . . . . . 0.485 ' O ' HG21 ' A' 2065 ' ' VAL . 33.7 m -99.22 150.21 5.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.297 -178.088 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.677 ' OD1' ' HB ' ' A' 2117 ' ' THR . 7.1 p30 -91.32 -169.31 2.29 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.72 -0.673 . . . . 1.46 111.22 179.535 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 97.5 mttt -58.93 -38.04 78.08 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.354 -0.385 . . . . 1.72 111.64 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -78.72 -30.27 45.82 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.256 0.551 . . . . 1.8400000000000001 109.79 -177.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 115.74 17.85 6.29 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.268 -0.878 . . . . 0.44 112.055 178.271 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.677 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.3 m -88.15 119.21 70.28 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 110.167 -0.309 . . . . 0.56999999999999995 110.167 178.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' 2111 ' ' ARG . 8.7 Cg_exo -71.89 104.12 1.58 Allowed 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.365 2.044 . . . . 0.60999999999999999 112.173 177.453 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 15.4 m -75.08 113.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 108.254 -1.017 . . . . 0.59999999999999998 108.254 170.345 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' 2109 ' ' VAL . 60.6 p -120.93 161.23 21.94 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.467 -0.788 . . . . 0.67000000000000004 111.391 -172.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2121 ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.36 127.04 41.89 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 107.601 -1.259 . . . . 0.72999999999999998 107.601 168.334 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.5 m -115.78 100.65 8.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.285 0.564 . . . . 2.1899999999999999 110.696 -172.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -89.83 131.7 35.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.827 -0.624 . . . . 2.8100000000000001 110.306 176.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 13.4 m -124.01 166.26 20.04 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.716 -0.675 . . . . 2.0600000000000001 109.486 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 70.1 Cg_exo -53.48 115.93 2.64 Favored 'Trans proline' 0 C--O 1.236 0.414 0 C-N-CA 122.466 2.111 . . . . 2.1600000000000001 112.251 177.109 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2126 ' ' GLU . . . . . 0.514 ' HA ' ' HD2' ' A' 2104 ' ' PRO . 43.7 mt-10 64.65 30.66 12.51 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.814 -0.63 . . . . 4.3300000000000001 111.82 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 68.7 t80 -87.72 134.28 33.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.584 -0.28 . . . . 3.8300000000000001 110.331 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 25.2 p 55.53 105.24 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.336 0 O-C-N 124.387 1.054 . . . . 5.1100000000000003 113.104 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 16.0 ptmt -135.4 101.8 4.94 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.481 -1.236 . . . . 5.2199999999999998 109.797 -178.366 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A 2130 ' ' VAL . . . . . 0.432 ' OXT' HG13 ' A' 2130 ' ' VAL . 12.2 p . . . . . 0 C--O 1.252 1.235 0 CA-C-O 117.491 -1.242 . . . . 5.8799999999999999 112.19 -177.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2053 ' ' GLN . . . . . 0.487 ' HB3' ' O ' ' A' 2120 ' ' THR . 72.6 mm-40 . . . . . 0 N--CA 1.48 1.067 0 N-CA-C 109.667 -0.494 . . . . 6.8499999999999996 109.667 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2054 ' ' GLY . . . . . 0.543 ' HA2' ' CD1' ' A' 2094 ' ' PHE . . . 100.64 -84.73 0.57 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.595 -0.812 . . . . 3.4100000000000001 112.3 -178.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -171.33 112.74 0.46 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 121.023 -0.608 . . . . 1.77 111.779 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.55 117.7 46.86 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-O 120.636 0.255 . . . . 2.4199999999999999 111.087 179.032 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -73.56 -14.83 24.8 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.176 1.918 . . . . 1.72 111.313 176.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.47 -41.13 61.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.629 -0.714 . . . . 2.3399999999999999 110.04 177.314 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 1.8 t -126.4 98.77 31.6 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.711 -0.477 . . . . 0.87 109.711 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.69 131.62 41.05 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.171 1.914 . . . . 1.04 111.842 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 49.8 mm -55.67 129.68 17.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 CA-C-N 115.68 -0.691 . . . . 0.77000000000000002 110.622 -178.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2062 ' ' ASP . . . . . 0.602 ' O ' HG22 ' A' 2065 ' ' VAL . 11.3 t70 -75.62 139.62 42.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.983 0.42 . . . . 1.4199999999999999 110.232 -177.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -89.71 -4.75 57.57 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.149 0.425 . . . . 1.55 112.149 -171.492 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 81.8 p -99.33 -13.61 19.55 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.527 -0.469 . . . . 0.68999999999999995 111.238 178.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2065 ' ' VAL . . . . . 0.643 ' O ' ' HD3' ' A' 2067 ' ' PRO . 31.4 m -79.92 -174.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.891 -0.411 . . . . 0.81999999999999995 109.891 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -95.33 109.55 45.73 Favored Pre-proline 0 C--O 1.238 0.447 0 CA-C-O 121.078 0.466 . . . . 0.78000000000000003 111.63 -179.605 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2067 ' ' PRO . . . . . 0.643 ' HD3' ' O ' ' A' 2065 ' ' VAL . 65.4 Cg_endo -100.77 123.23 0.11 Allowed 'Trans proline' 0 N--CA 1.441 -1.605 0 C-N-CA 123.46 2.774 . . . . 0.45000000000000001 110.851 165.384 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2068 ' ' THR . . . . . 0.492 HG22 ' HE3' ' A' 2074 ' ' LYS . 3.6 p -153.28 -179.23 7.54 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.69999999999999996 110.601 -178.479 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2069 ' ' PHE . . . . . 0.625 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 8.5 m-30 -102.43 154.63 18.9 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 107.405 -1.332 . . . . 1.1599999999999999 107.405 163.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -54.45 -35.84 63.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 118.65 0.659 . . . . 2.0899999999999999 111.748 -171.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -78.35 4.9 11.73 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.235 0.457 . . . . 2.1499999999999999 112.235 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 80.48 24.95 57.91 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.127 -0.558 . . . . 0.63 111.903 -177.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 14.7 m -94.07 156.46 16.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.629 0.252 . . . . 0.89000000000000001 110.797 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2074 ' ' LYS . . . . . 0.492 ' HE3' HG22 ' A' 2068 ' ' THR . 0.1 OUTLIER -120.79 5.18 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.25 0.548 . . . . 1.1299999999999999 110.913 179.768 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.58 140.75 4.98 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.123 -0.695 . . . . 2.0800000000000001 109.123 170.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2076 ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' 2083 ' ' THR . 16.5 tptt -138.88 104.0 4.95 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.273 -0.421 . . . . 1.48 110.065 174.329 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 49.0 m -101.51 118.03 36.13 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.123 0.487 . . . . 0.63 110.273 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2078 ' ' ILE . . . . . 0.563 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 75.5 mt -117.16 119.89 34.29 Favored Pre-proline 0 C--N 1.315 -0.925 0 N-CA-C 108.407 -0.96 . . . . 1.6200000000000001 108.407 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -47.11 109.87 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.486 2.791 . . . . 0.97999999999999998 113.496 -174.102 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.42 -12.76 68.95 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.81 -0.632 . . . . 0.93999999999999995 112.677 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2081 ' ' GLN . . . . . 0.563 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.9 tt0 -101.13 -26.28 13.73 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.164 0.507 . . . . 2.02 110.183 -177.354 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 112.85 -163.95 12.1 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.539 -0.838 . . . . 0.5 112.782 173.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2083 ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' 2076 ' ' LYS . 28.1 m -137.14 145.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 121.808 0.814 . . . . 0.48999999999999999 110.553 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2084 ' ' TYR . . . . . 0.625 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 12.8 m-85 -107.13 112.48 25.41 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 106.892 -1.522 . . . . 1.4399999999999999 106.892 166.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 25.3 p -104.99 134.76 47.55 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.745 -0.382 . . . . 0.63 111.563 -173.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2086 ' ' ILE . . . . . 0.599 ' HA ' ' O ' ' A' 2091 ' ' THR . 1.6 tt -151.19 130.55 3.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.799 -0.637 . . . . 1.1799999999999999 111.422 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2087 ' ' VAL . . . . . 0.59 HG22 ' OG1' ' A' 2091 ' ' THR . 18.6 m -115.1 157.75 42.74 Favored Pre-proline 0 C--N 1.328 -0.343 0 N-CA-C 109.565 -0.531 . . . . 0.80000000000000004 109.565 175.43 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.17 -0.54 2.28 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 123.69 2.926 . . . . 0.96999999999999997 114.137 -172.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 19.1 t70 -78.03 -23.18 48.29 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.293 0.568 . . . . 2.29 109.927 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 112.74 17.17 8.13 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.581 -0.736 . . . . 0.82999999999999996 112.133 -178.26 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2091 ' ' THR . . . . . 0.599 ' O ' ' HA ' ' A' 2086 ' ' ILE . 3.2 p -90.51 116.2 28.24 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.355 -0.609 . . . . 1.51 109.355 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2092 ' ' VAL . . . . . 0.473 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 3.8 t -136.2 132.38 49.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.781 -0.368 . . . . 1.1799999999999999 110.285 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.2 t -137.33 122.8 19.58 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.401 0.62 . . . . 1.46 110.239 176.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2094 ' ' PHE . . . . . 0.543 ' CD1' ' HA2' ' A' 2054 ' ' GLY . 3.2 m-30 -86.33 98.41 10.96 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.976 -0.75 . . . . 1.27 108.976 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 16.4 m -121.38 84.59 41.61 Favored Pre-proline 0 N--CA 1.453 -0.284 0 C-N-CA 119.676 -0.81 . . . . 0.57999999999999996 111.585 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -93.47 147.71 2.29 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 123.248 2.632 . . . . 0.97999999999999998 111.884 170.341 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.27 86.35 5.04 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.225 -0.658 . . . . 2.7200000000000002 109.225 171.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 43.8 mtmt -63.26 -24.03 67.69 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.488 -0.778 . . . . 4.8099999999999996 110.92 -175.282 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 83.1 mm-40 -96.44 12.98 29.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.789 -0.641 . . . . 4.4199999999999999 111.052 -176.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.72 104.09 13.55 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.732 -0.667 . . . . 2.3599999999999999 110.414 176.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 86.3 t -90.7 98.7 8.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.399 0.619 . . . . 2.6800000000000002 109.529 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -162.78 -152.86 6.95 Favored Glycine 0 N--CA 1.445 -0.756 0 N-CA-C 110.704 -0.958 . . . . 3.8399999999999999 110.704 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2103 ' ' LYS . . . . . 0.479 ' HB3' ' NZ ' ' A' 2103 ' ' LYS . 0.0 OUTLIER -109.76 94.86 18.05 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 121.3 0.571 . . . . 6.7800000000000002 110.235 177.123 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -76.81 161.43 33.44 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.868 2.379 . . . . 2.4300000000000002 112.391 -177.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2105 ' ' ASP . . . . . 0.47 ' HB2' HD13 ' A' 2078 ' ' ILE . 0.6 OUTLIER -102.01 141.04 21.74 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.027 -0.533 . . . . 2.3300000000000001 110.508 179.63 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A 2106 ' ' PRO . . . . . 0.587 ' HA ' ' O ' ' A' 2123 ' ' TYR . 55.5 Cg_endo -68.99 121.25 8.1 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 123.181 2.587 . . . . 1.03 113.467 -176.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.6 p -157.51 143.85 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.414 -0.812 . . . . 0.59999999999999998 109.707 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 15.6 m -121.48 130.68 53.71 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.37 110.574 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2109 ' ' VAL . . . . . 0.435 HG13 ' CD2' ' A' 2069 ' ' PHE . 2.7 t -92.99 144.68 8.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.101 -0.703 . . . . 0.76000000000000001 109.101 177.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -143.36 108.35 4.95 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 118.157 0.435 . . . . 1.6299999999999999 111.635 -173.084 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2111 ' ' ARG . . . . . 0.473 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -147.25 139.09 24.24 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 121.722 -0.611 . . . . 3.4700000000000002 109.88 171.324 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.5 m -103.5 154.69 5.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 120.926 0.393 . . . . 0.40000000000000002 110.907 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2113 ' ' ASP . . . . . 0.421 ' OD1' ' HB ' ' A' 2117 ' ' THR . 2.3 p-10 -96.29 -167.74 1.63 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.029 -0.532 . . . . 1.46 110.102 178.232 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.4 mttt -53.64 -44.47 69.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.954 -0.566 . . . . 1.72 112.175 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.28 -14.92 45.11 Favored 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 120.487 -0.485 . . . . 1.8400000000000001 111.157 -176.165 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 104.29 15.23 22.04 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.272 -0.966 . . . . 0.44 112.937 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2117 ' ' THR . . . . . 0.45 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 98.1 m -75.85 114.65 38.94 Favored Pre-proline 0 C--N 1.324 -0.538 0 N-CA-C 109.887 -0.412 . . . . 0.56999999999999995 109.887 174.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2118 ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.2 Cg_exo -77.49 100.79 1.42 Allowed 'Trans proline' 0 N--CA 1.454 -0.817 0 C-N-CA 122.407 2.072 . . . . 0.60999999999999999 112.318 179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 7.0 m -74.94 109.36 7.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.433 -0.951 . . . . 0.59999999999999998 108.433 169.524 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2120 ' ' THR . . . . . 0.487 ' O ' ' HB3' ' A' 2053 ' ' GLN . 69.3 p -118.86 -174.31 2.67 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.88 -1.054 . . . . 0.67000000000000004 109.977 -174.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -149.88 127.21 11.41 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.743 -0.836 . . . . 0.72999999999999998 108.743 170.153 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 34.5 p -100.44 97.87 8.55 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.568 -0.53 . . . . 2.1899999999999999 109.568 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2123 ' ' TYR . . . . . 0.587 ' O ' ' HA ' ' A' 2106 ' ' PRO . 12.1 m-85 -118.44 124.35 47.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 111.568 -177.231 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2124 ' ' SER . . . . . 0.5 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 49.5 m -157.77 171.82 6.94 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.689 -1.141 . . . . 2.0600000000000001 108.75 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2125 ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' 2124 ' ' SER . 90.4 Cg_exo -47.54 140.82 15.81 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.318 2.012 . . . . 2.1600000000000001 112.45 173.568 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A 2126 ' ' GLU . . . . . 0.45 ' HA ' ' CD ' ' A' 2129 ' ' LYS . 0.9 OUTLIER 66.39 23.0 10.69 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.75 -0.659 . . . . 4.3300000000000001 112.673 179.332 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 62.1 t80 -107.99 -49.6 3.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.549 -0.461 . . . . 3.8300000000000001 110.56 173.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 2.9 m -63.14 -36.33 83.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.029 -0.532 . . . . 5.1100000000000003 112.393 -174.445 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A 2129 ' ' LYS . . . . . 0.45 ' CD ' ' HA ' ' A' 2126 ' ' GLU . 0.0 OUTLIER -92.64 173.87 7.55 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.367 -0.533 . . . . 5.2199999999999998 110.214 179.154 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.249 1.043 0 CA-C-N 115.812 -0.631 . . . . 5.8799999999999999 111.206 -176.972 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.153 0.502 . . . . 2.4199999999999999 111.384 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.23 -40.18 4.86 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.002 2.468 . . . . 1.72 112.46 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . 0.596 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -81.97 -2.08 50.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 2.3399999999999999 111.607 -177.591 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.596 HG23 HD13 ' A' 2058 ' ' LEU . 13.5 t -136.92 84.42 25.75 Favored Pre-proline 0 C--N 1.326 -0.426 0 N-CA-C 109.159 -0.682 . . . . 0.87 109.159 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . 0.508 ' O ' ' HG3' ' A' 2114 ' ' LYS . 41.6 Cg_exo -55.73 130.64 41.48 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.532 2.155 . . . . 1.04 111.804 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' 2113 ' ' ASP . 41.6 mm -64.49 141.74 17.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.561 . . . . 0.77000000000000002 109.709 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.512 ' O ' HG22 ' A' 2065 ' ' VAL . 10.3 t70 -80.05 128.11 33.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.361 -0.381 . . . . 1.4199999999999999 110.289 -175.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -91.34 1.96 56.74 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.404 -0.362 . . . . 1.55 111.958 -172.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 74.4 p -110.73 -5.04 15.06 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.009 0.433 . . . . 0.68999999999999995 111.171 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.637 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.9 m -91.67 -174.01 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.453 . . . . 0.81999999999999995 109.857 178.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -89.64 111.26 44.94 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.154 0.502 . . . . 0.78000000000000003 111.162 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.637 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.2 Cg_endo -100.71 109.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 123.608 2.872 . . . . 0.45000000000000001 110.792 166.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 9.0 p -148.31 -176.52 5.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.146 0.498 . . . . 0.69999999999999996 110.963 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.606 ' CD2' HG13 ' A' 2109 ' ' VAL . 3.5 m-30 -101.6 156.39 17.51 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 107.165 -1.42 . . . . 1.1599999999999999 107.165 166.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -53.8 -34.95 60.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 118.261 0.482 . . . . 2.0899999999999999 111.951 -169.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -74.81 -4.92 40.62 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.886 0.374 . . . . 2.1499999999999999 111.312 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.91 14.49 57.82 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 121.246 -0.502 . . . . 0.63 111.854 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . 0.473 ' OG ' ' HB2' ' A' 2069 ' ' PHE . 0.3 OUTLIER -85.78 161.78 18.99 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.666 0.27 . . . . 0.89000000000000001 111.277 -174.769 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -115.52 -23.82 8.61 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.431 -0.35 . . . . 1.1299999999999999 111.912 -174.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' 2084 ' ' TYR . 1.6 tm-20 -151.87 137.31 17.67 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.254 0.55 . . . . 2.0800000000000001 110.167 173.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.0 OUTLIER -131.64 99.7 4.88 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.472 -0.786 . . . . 1.48 109.99 175.44 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 7.7 m -103.06 111.78 24.3 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.945 -0.57 . . . . 0.63 110.598 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.548 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 44.4 mm -114.39 123.05 33.05 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 108.004 -1.11 . . . . 1.6200000000000001 108.004 173.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.27 108.69 0.17 Allowed 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.043 2.495 . . . . 0.97999999999999998 113.039 -176.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 100.99 -18.55 54.57 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.644 -0.707 . . . . 0.93999999999999995 112.886 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.548 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -90.59 -30.19 17.35 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.257 0.551 . . . . 2.02 110.827 -173.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.56 -174.58 15.31 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.587 -0.733 . . . . 0.5 111.58 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.45 HG22 HG23 ' A' 2085 ' ' THR . 15.5 m -133.88 134.41 42.67 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.583 0.706 . . . . 0.48999999999999999 110.523 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' 2075 ' ' GLU . 1.5 m-85 -109.47 120.18 41.7 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.986 -1.487 . . . . 1.4399999999999999 106.986 172.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.45 HG23 HG22 ' A' 2083 ' ' THR . 0.7 OUTLIER -127.89 121.59 30.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 112.447 0.536 . . . . 0.63 112.447 -171.789 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.458 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -115.54 134.91 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.089 -0.505 . . . . 1.1799999999999999 110.198 173.703 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 33.6 m -118.2 150.37 47.47 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 109.413 -0.588 . . . . 0.80000000000000004 109.413 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.99 -4.08 0.85 Allowed 'Trans proline' 0 N--CA 1.481 0.768 0 C-N-CA 123.959 3.106 . . . . 0.96999999999999997 114.637 -172.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.73 -7.8 52.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.902 0.382 . . . . 2.29 110.506 176.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 91.18 16.98 52.54 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.91 -0.662 . . . . 0.82999999999999996 112.063 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.2 t -118.61 138.54 52.51 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.854 0.359 . . . . 1.51 110.433 -179.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.461 ' CG2' ' HB2' ' A' 2067 ' ' PRO . 7.4 t -131.21 140.58 48.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.126 -0.488 . . . . 1.1799999999999999 110.512 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -101.99 108.92 20.52 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 116.299 -0.41 . . . . 1.46 110.49 174.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -86.69 96.32 10.1 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.162 -1.051 . . . . 1.27 108.162 173.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 25.1 m -119.04 88.25 36.21 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 121.121 0.486 . . . . 0.57999999999999996 110.554 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.29 2.66 . . . . 0.97999999999999998 111.877 176.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.2 t70 -132.14 99.43 4.71 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.883 0.373 . . . . 2.7200000000000002 110.083 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.23 13.9 2.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.275 -0.42 . . . . 4.8099999999999996 111.101 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 -109.52 5.57 23.32 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.256 0.551 . . . . 4.4199999999999999 109.716 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 52.5 t80 -89.3 92.55 9.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 2.3599999999999999 110.992 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 92.0 t -83.76 107.78 15.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.586 -0.524 . . . . 2.6800000000000002 109.586 174.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.14 -133.55 2.85 Favored Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.673 -0.694 . . . . 3.8399999999999999 111.456 -178.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 61.6 tttm -127.67 99.07 27.06 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.769 0.284 . . . . 6.7800000000000002 110.94 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.92 155.03 48.37 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.318 2.012 . . . . 2.4300000000000002 111.73 174.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.3 t70 -83.42 127.02 70.09 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.066 -0.515 . . . . 2.3300000000000001 109.968 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.654 ' HA ' ' O ' ' A' 2123 ' ' TYR . 43.1 Cg_exo -56.34 102.68 0.1 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.026 2.484 . . . . 1.03 112.881 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.2 p -147.42 138.93 18.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.095 -0.502 . . . . 0.59999999999999998 110.38 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 56.6 m -112.96 124.16 51.99 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.001 -0.545 . . . . 0.37 110.149 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.606 HG13 ' CD2' ' A' 2069 ' ' PHE . 4.7 t -91.63 131.17 39.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.835 -0.802 . . . . 0.76000000000000001 108.835 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -143.6 108.94 5.04 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 112.989 0.737 . . . . 1.6299999999999999 112.989 -173.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.42 ' HD2' HG21 ' A' 2061 ' ' ILE . 28.1 ptt180 -129.65 140.62 51.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.741 -0.837 . . . . 3.4700000000000002 108.741 171.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.457 HG23 HG21 ' A' 2065 ' ' VAL . 35.9 m -99.58 142.01 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 120.358 -0.537 . . . . 0.40000000000000002 110.997 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.669 ' OD1' ' HB ' ' A' 2117 ' ' THR . 4.3 p30 -85.24 -170.72 3.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.949 -0.569 . . . . 1.46 111.615 -178.034 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . 0.508 ' HG3' ' O ' ' A' 2060 ' ' PRO . 91.5 mttt -57.55 -37.17 72.67 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.851 0.315 . . . . 1.72 111.851 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -80.09 -29.7 39.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.313 0.578 . . . . 1.8400000000000001 109.901 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 112.6 21.62 6.04 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.321 -0.854 . . . . 0.44 112.418 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.669 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 92.4 m -86.91 120.97 71.88 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 110.214 -0.291 . . . . 0.56999999999999995 110.214 177.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' 2117 ' ' THR . 7.5 Cg_exo -73.16 101.88 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.453 2.102 . . . . 0.60999999999999999 112.433 178.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.7 m -75.07 113.0 13.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.527 -0.916 . . . . 0.59999999999999998 108.527 171.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' 2109 ' ' VAL . 37.8 p -119.66 154.82 33.46 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 115.483 -0.781 . . . . 0.67000000000000004 112.617 -169.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -130.29 127.54 39.71 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.892 -1.151 . . . . 0.72999999999999998 107.892 167.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.2 m -115.87 103.87 11.06 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.072 0.463 . . . . 2.1899999999999999 110.527 -174.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.654 ' O ' ' HA ' ' A' 2106 ' ' PRO . 3.1 m-85 -98.33 132.29 43.92 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-O 121.198 0.523 . . . . 2.8100000000000001 111.19 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 44.3 m -157.14 165.37 18.95 Favored Pre-proline 0 C--N 1.321 -0.635 0 N-CA-C 108.433 -0.951 . . . . 2.0600000000000001 108.433 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo . . . . . 0 C--N 1.353 0.783 0 C-N-CA 123.199 2.599 . . . . 2.1600000000000001 114.064 -176.686 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 CA--C 1.519 -0.233 0 CA-C-O 120.582 0.23 . . . . 2.4199999999999999 110.621 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.87 -21.91 18.1 Favored 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.404 2.07 . . . . 1.72 111.933 -178.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.74 -18.48 59.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.673 -0.694 . . . . 2.3399999999999999 110.465 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.478 HG11 HD22 ' A' 2115 ' ' ASN . 5.0 t -133.63 98.38 14.99 Favored Pre-proline 0 N--CA 1.452 -0.341 0 CA-C-N 116.062 -0.517 . . . . 0.87 109.811 177.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' 2059 ' ' VAL . 11.3 Cg_endo -55.76 118.86 5.69 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.039 1.826 . . . . 1.04 111.827 178.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.8 mm -53.6 136.84 14.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.251 -0.886 . . . . 0.77000000000000002 111.346 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.517 ' O ' HG22 ' A' 2065 ' ' VAL . 14.8 t70 -71.57 131.56 43.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 1.4199999999999999 110.144 178.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -86.76 -5.2 59.19 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.238 -0.437 . . . . 1.55 112.131 -172.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.7 p -111.37 3.82 18.53 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.091 0.404 . . . . 0.68999999999999995 112.091 -177.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' 2062 ' ' ASP . 27.1 m -90.19 -177.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.728 -0.471 . . . . 0.81999999999999995 109.728 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -94.06 116.73 66.79 Favored Pre-proline 0 C--O 1.241 0.625 0 CA-C-O 121.382 0.61 . . . . 0.78000000000000003 111.6 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.515 ' HB2' HG13 ' A' 2086 ' ' ILE . 28.4 Cg_endo -100.39 108.55 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 123.59 2.86 . . . . 0.45000000000000001 111.416 167.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.459 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.4 p -143.37 145.25 32.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.887 0.375 . . . . 0.69999999999999996 110.549 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.692 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-30 -70.78 156.13 39.91 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 107.936 -1.135 . . . . 1.1599999999999999 107.936 177.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -51.73 -39.13 57.92 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 123.404 0.44 . . . . 2.0899999999999999 111.819 -170.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -91.12 19.18 6.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 2.1499999999999999 111.358 -177.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 75.44 29.44 59.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.047 -0.597 . . . . 0.63 112.66 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . 0.436 ' HB2' ' CD1' ' A' 2069 ' ' PHE . 7.4 m -95.34 162.32 13.72 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 122.743 -0.269 . . . . 0.89000000000000001 110.904 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.7 mmtp -121.57 -24.9 5.23 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.268 -0.424 . . . . 1.1299999999999999 111.673 -177.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.628 ' HA ' ' O ' ' A' 2084 ' ' TYR . 2.0 tt0 -158.62 124.64 4.54 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.368 0.604 . . . . 2.0800000000000001 110.583 175.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -123.55 102.19 7.73 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.375 -0.829 . . . . 1.48 109.931 175.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.7 m -95.92 113.22 24.82 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.204 0.526 . . . . 0.63 110.576 175.157 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 27.3 mm -116.07 108.86 45.48 Favored Pre-proline 0 C--N 1.31 -1.133 0 N-CA-C 107.627 -1.249 . . . . 1.6200000000000001 107.627 170.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.08 115.43 1.7 Allowed 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 123.183 2.589 . . . . 0.97999999999999998 113.41 -173.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' 2100 ' ' PHE . . . 89.58 -8.41 79.88 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.775 -0.648 . . . . 0.93999999999999995 112.513 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.529 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.0 OUTLIER -107.49 -31.05 8.3 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.219 0.533 . . . . 2.02 109.903 -176.679 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 136.45 172.0 12.45 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.519 -0.848 . . . . 0.5 112.94 173.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.4 ' O ' ' HB ' ' A' 2095 ' ' THR . 77.7 m -138.23 127.93 25.12 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.304 0.573 . . . . 0.48999999999999999 109.696 172.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.692 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.1 OUTLIER -108.16 125.99 52.26 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 107.698 -1.223 . . . . 1.4399999999999999 107.698 175.52 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 1.3 p -127.86 129.31 46.71 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 112.074 0.398 . . . . 0.63 112.074 -174.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.515 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.47 132.09 71.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.854 -0.612 . . . . 1.1799999999999999 110.52 174.601 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -125.79 142.56 42.52 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.788 -0.642 . . . . 0.80000000000000004 109.3 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.57 -0.05 1.71 Allowed 'Trans proline' 0 N--CA 1.476 0.491 0 C-N-CA 123.827 3.018 . . . . 0.96999999999999997 114.177 -170.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 36.8 t70 -72.77 -11.8 60.75 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.41 0.624 . . . . 2.29 109.836 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 106.26 6.24 36.6 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.629 -0.714 . . . . 0.82999999999999996 112.381 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 2.2 t -110.8 128.06 55.62 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.257 0.551 . . . . 1.51 110.274 -179.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.471 HG13 ' HB ' ' A' 2086 ' ' ILE . 18.8 t -137.17 137.25 46.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.527 -0.76 . . . . 1.1799999999999999 109.624 -175.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 24.0 m -119.8 109.77 15.99 Favored 'General case' 0 N--CA 1.439 -0.997 0 CA-C-O 120.816 0.341 . . . . 1.46 111.3 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . 0.414 ' O ' ' HD3' ' A' 2096 ' ' PRO . 5.8 m-30 -89.65 98.88 12.02 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.26 -0.645 . . . . 1.27 109.26 174.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' 2083 ' ' THR . 23.0 m -114.01 89.42 16.72 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 120.683 0.278 . . . . 0.57999999999999996 111.662 -178.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' 2094 ' ' PHE . 73.0 Cg_endo -92.52 119.34 0.44 Allowed 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.971 2.447 . . . . 0.97999999999999998 112.702 175.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -89.87 84.68 6.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.34 0.59 . . . . 2.7200000000000002 109.563 173.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.69 -1.91 27.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.566 -0.743 . . . . 4.8099999999999996 112.374 -171.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -84.9 -2.02 57.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.168 0.509 . . . . 4.4199999999999999 110.523 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' 2080 ' ' GLY . 69.0 t80 -83.49 85.47 7.24 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 2.3599999999999999 110.377 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.8 t -92.35 99.63 10.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.147 -0.478 . . . . 2.6800000000000002 110.196 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -169.53 -101.93 0.15 Allowed Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.415 -0.674 . . . . 3.8399999999999999 111.415 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 53.3 mtmt -131.6 73.25 79.59 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-O 120.611 0.244 . . . . 6.7800000000000002 110.615 174.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . 0.426 ' HD2' ' O ' ' A' 2125 ' ' PRO . 18.9 Cg_exo -66.06 127.93 18.63 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.383 2.055 . . . . 2.4300000000000002 111.312 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.3 t70 -60.79 122.88 71.85 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.001 -0.545 . . . . 2.3300000000000001 110.665 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' 2123 ' ' TYR . 31.8 Cg_exo -58.93 120.37 8.19 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 123.101 2.534 . . . . 1.03 112.174 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.7 p -156.72 161.51 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.93 -0.577 . . . . 0.59999999999999998 109.731 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' 2121 ' ' ALA . 67.0 m -140.88 119.74 12.62 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.933 0.397 . . . . 0.37 110.08 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.4 t -92.5 145.18 7.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.029 -0.73 . . . . 0.76000000000000001 109.029 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.459 ' HB3' ' O ' ' A' 2068 ' ' THR . 0.0 OUTLIER -147.47 143.21 27.72 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.224 0.465 . . . . 1.6299999999999999 111.341 -174.787 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.425 ' N ' ' HD2' ' A' 2110 ' ' LYS . 27.2 ptt180 -166.95 146.07 5.28 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.676 -0.861 . . . . 3.4700000000000002 108.676 166.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.444 ' O ' HG21 ' A' 2065 ' ' VAL . 30.5 m -99.01 149.19 5.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 C-N-CA 120.44 -0.504 . . . . 0.40000000000000002 111.289 -175.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.456 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.8 p-10 -90.51 -169.39 2.38 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.951 -0.568 . . . . 1.46 109.976 178.433 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . 0.402 ' HG2' ' HB2' ' A' 2062 ' ' ASP . 96.9 mttt -59.97 -38.56 82.88 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.542 0.21 . . . . 1.72 111.008 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . 0.478 HD22 HG11 ' A' 2059 ' ' VAL . 40.2 m-80 -71.66 -30.28 65.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.844 0.354 . . . . 1.8400000000000001 110.857 177.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 110.55 12.93 15.65 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.851 -0.69 . . . . 0.44 112.214 179.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 5.7 m -79.72 121.58 82.57 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 110.128 -0.323 . . . . 0.56999999999999995 110.128 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.6 Cg_exo -73.95 103.92 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 122.301 2.001 . . . . 0.60999999999999999 112.234 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.5 m -75.32 117.62 19.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.381 -0.97 . . . . 0.59999999999999998 108.381 171.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.545 ' HA ' ' O ' ' A' 2109 ' ' VAL . 47.2 p -129.75 163.35 26.38 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.539 -0.755 . . . . 0.67000000000000004 111.751 -170.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -130.98 126.84 37.07 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.528 -0.915 . . . . 0.72999999999999998 108.528 169.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 20.3 m -100.12 100.45 11.3 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.041 0.448 . . . . 2.1899999999999999 110.335 -176.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.494 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -96.99 114.39 26.0 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.143 -0.48 . . . . 2.8100000000000001 110.899 -177.407 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 17.8 m -127.39 158.57 69.15 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.537 -0.756 . . . . 2.0600000000000001 109.651 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.426 ' O ' ' HD2' ' A' 2104 ' ' PRO . 95.2 Cg_exo . . . . . 0 C--N 1.346 0.402 0 C-N-CA 123.069 2.513 . . . . 2.1600000000000001 113.828 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 2.3 t70 . . . . . 0 CA--C 1.522 -0.129 0 CA-C-O 120.698 0.285 . . . . 2.4199999999999999 111.744 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -76.45 -22.47 12.34 Favored 'Trans proline' 0 N--CA 1.46 -0.471 0 C-N-CA 122.414 2.076 . . . . 1.72 112.477 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.52 -9.57 20.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.821 0.343 . . . . 2.3399999999999999 110.656 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' 2056 ' ' ASP . 21.4 t -127.48 84.48 63.27 Favored Pre-proline 0 CA--C 1.511 -0.534 0 N-CA-C 108.034 -1.099 . . . . 0.87 108.034 175.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -40.48 117.77 0.52 Allowed 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.922 2.415 . . . . 1.04 112.228 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 33.3 mm -54.46 114.96 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.263 -0.88 . . . . 0.77000000000000002 110.911 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 15.7 t70 -72.86 125.71 28.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.47 -0.787 . . . . 1.4199999999999999 111.308 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . 0.423 ' HB3' ' O ' ' A' 2089 ' ' ASP . 44.0 mt-10 -86.89 -2.88 58.94 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.127 -0.488 . . . . 1.55 111.805 -173.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 43.9 p -106.06 -5.53 19.39 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.741 -0.384 . . . . 0.68999999999999995 111.863 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.2 m -96.26 163.66 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.863 -0.421 . . . . 0.81999999999999995 109.863 176.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -73.15 114.09 27.93 Favored Pre-proline 0 C--O 1.24 0.591 0 CA-C-O 121.271 0.557 . . . . 0.78000000000000003 112.22 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.492 ' HB3' ' NH1' ' A' 2111 ' ' ARG . 68.0 Cg_endo -102.29 108.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.423 0 C-N-CA 123.682 2.921 . . . . 0.45000000000000001 112.097 169.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 20.9 p -138.61 -178.64 5.4 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.403 0.62 . . . . 0.69999999999999996 111.273 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.489 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.7 OUTLIER -102.01 152.23 21.2 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.862 -1.162 . . . . 1.1599999999999999 107.862 168.72 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -52.39 -39.21 60.56 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.066 0.394 . . . . 2.0899999999999999 111.741 -170.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.36 -2.94 43.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.91 -0.586 . . . . 2.1499999999999999 111.335 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.78 29.36 13.47 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.849 -0.691 . . . . 0.63 112.159 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 9.1 m -98.06 169.15 9.82 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.894 -0.18 . . . . 0.89000000000000001 110.697 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -128.06 -16.64 4.52 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.964 0.412 . . . . 1.1299999999999999 111.343 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.402 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.8 tt0 -156.24 121.09 4.64 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.719 -0.475 . . . . 2.0800000000000001 109.719 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD2' ' HA ' ' A' 2076 ' ' LYS . 4.5 mmmm -115.45 121.86 44.02 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.967 -0.561 . . . . 1.48 109.534 171.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 55.2 m -129.53 121.48 27.28 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.729 -0.669 . . . . 0.63 110.85 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.436 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 48.4 mm -119.69 124.49 27.96 Favored Pre-proline 0 C--N 1.314 -0.965 0 N-CA-C 107.584 -1.265 . . . . 1.6200000000000001 107.584 171.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.73 107.86 0.21 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.332 2.021 . . . . 0.97999999999999998 112.304 -176.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.19 -23.37 27.31 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.811 -0.631 . . . . 0.93999999999999995 112.534 -178.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.436 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 15.7 tt0 -90.73 -31.14 16.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.003 0.43 . . . . 2.02 110.261 -176.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.62 -173.32 14.72 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.714 -0.755 . . . . 0.5 112.86 176.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 46.4 m -129.99 132.65 46.35 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.556 0.693 . . . . 0.48999999999999999 110.127 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.478 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 0.5 OUTLIER -111.31 112.47 24.26 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 106.735 -1.58 . . . . 1.4399999999999999 106.735 172.397 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.89 131.69 55.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.429 0.529 . . . . 0.63 112.429 -170.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.504 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.93 137.7 54.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.392 -0.822 . . . . 1.1799999999999999 109.561 174.54 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 31.7 m -118.67 153.3 52.19 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 109.889 -0.411 . . . . 0.80000000000000004 109.889 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -60.3 -4.81 3.43 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.773 2.982 . . . . 0.96999999999999997 114.264 -170.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' 2063 ' ' GLU . 27.7 m-20 -72.93 -13.08 61.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.907 0.384 . . . . 2.29 110.215 177.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.72 16.06 32.37 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.967 -0.635 . . . . 0.82999999999999996 112.263 177.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.7 t -115.61 141.25 48.32 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.806 0.336 . . . . 1.51 110.44 -178.111 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.504 HG22 ' CG1' ' A' 2086 ' ' ILE . 12.5 t -133.32 150.78 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.977 -0.556 . . . . 1.1799999999999999 109.96 -178.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -125.86 122.0 34.82 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.46 110.05 173.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -90.47 98.82 12.0 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.265 -0.642 . . . . 1.27 109.265 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 8.9 m -113.25 87.49 11.12 Favored Pre-proline 0 N--CA 1.454 -0.242 0 CA-C-O 120.964 0.411 . . . . 0.57999999999999996 110.431 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -92.55 -179.88 1.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 123.292 2.661 . . . . 0.97999999999999998 112.399 178.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.4 t70 -131.7 139.65 49.09 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.222 -0.659 . . . . 2.7200000000000002 109.222 170.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -90.23 -26.1 20.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.87 -0.605 . . . . 4.8099999999999996 111.833 -172.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -120.32 36.83 4.43 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.788 0.292 . . . . 4.4199999999999999 111.788 -171.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 19.4 t80 -82.41 87.01 6.64 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.37 0.605 . . . . 2.3599999999999999 110.737 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.2 t -92.14 109.84 21.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.793 -0.64 . . . . 2.6800000000000002 109.745 176.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . 0.425 ' C ' ' HD3' ' A' 2104 ' ' PRO . . . 170.75 -113.29 0.49 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.492 -0.643 . . . . 3.8399999999999999 111.492 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -120.01 76.87 22.95 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 121.115 0.483 . . . . 6.7800000000000002 111.533 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . 0.425 ' HD3' ' C ' ' A' 2102 ' ' GLY . 8.1 Cg_exo -74.68 157.68 43.93 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.198 2.599 . . . . 2.4300000000000002 111.684 178.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.0 t70 -120.09 117.48 32.06 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.477 -0.328 . . . . 2.3300000000000001 110.435 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.532 ' HA ' ' O ' ' A' 2123 ' ' TYR . 52.6 Cg_exo -54.94 128.41 30.42 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.864 2.376 . . . . 1.03 111.828 177.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.1 p -157.51 161.29 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.312 -0.404 . . . . 0.59999999999999998 110.257 -176.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.43 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.5 m -140.15 119.05 12.54 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.149 0.5 . . . . 0.37 110.269 176.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.6 t -91.35 138.06 20.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 108.131 -1.063 . . . . 0.76000000000000001 108.131 176.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.495 ' HA ' HG22 ' A' 2120 ' ' THR . 2.2 tmmm? -145.14 108.32 4.57 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.275 0.559 . . . . 1.6299999999999999 111.476 -172.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.492 ' NH1' ' HB3' ' A' 2067 ' ' PRO . 1.4 ptm180 -139.72 142.95 36.82 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 109.207 -0.664 . . . . 3.4700000000000002 109.207 174.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' 2117 ' ' THR . 24.0 m -99.6 161.06 3.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.426 -0.51 . . . . 0.40000000000000002 111.49 -175.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.507 ' OD2' ' HB ' ' A' 2117 ' ' THR . 3.9 p30 -110.01 -169.13 1.41 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.571 -0.74 . . . . 1.46 111.004 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 65.2 mttm -63.49 -25.12 68.12 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 111.938 0.347 . . . . 1.72 111.938 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.67 -9.98 56.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.949 0.404 . . . . 1.8400000000000001 110.251 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 86.27 15.99 63.41 Favored Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.333 -0.707 . . . . 0.44 111.333 -176.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.507 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 0.2 OUTLIER -84.99 131.23 49.45 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 109.954 -0.388 . . . . 0.56999999999999995 109.954 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 12.3 Cg_endo -87.78 103.9 0.52 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 122.208 1.938 . . . . 0.60999999999999999 112.428 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 14.8 m -75.42 109.29 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 108.692 -0.855 . . . . 0.59999999999999998 108.692 171.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.495 HG22 ' HA ' ' A' 2110 ' ' LYS . 35.5 p -124.55 169.27 12.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.094 -0.957 . . . . 0.67000000000000004 111.55 -170.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -135.49 127.73 30.08 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.52 -0.764 . . . . 0.72999999999999998 109.6 173.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 13.4 p -94.71 99.67 11.73 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.254 -0.43 . . . . 2.1899999999999999 109.892 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.532 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -103.77 123.93 47.97 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.34 0.59 . . . . 2.8100000000000001 111.788 -174.859 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 25.2 m -154.19 153.07 27.75 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.141 -0.936 . . . . 2.0600000000000001 108.484 175.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.535 0.55 0 C-N-CA 122.837 2.358 . . . . 2.1600000000000001 113.891 -178.733 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 7.1 t70 . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.678 0.275 . . . . 2.4199999999999999 110.359 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.7 -21.78 33.28 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.387 2.058 . . . . 1.72 112.55 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.9 mm? -93.2 -26.83 17.21 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.887 0.375 . . . . 2.3399999999999999 110.043 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.433 HG11 HD22 ' A' 2115 ' ' ASN . 1.8 t -126.88 90.7 48.9 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.239 -0.437 . . . . 0.87 110.429 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -57.32 121.57 10.28 Favored 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 122.188 1.925 . . . . 1.04 111.586 176.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 48.9 mm -53.04 132.31 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.572 -0.74 . . . . 0.77000000000000002 110.828 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.568 ' O ' HG22 ' A' 2065 ' ' VAL . 24.4 t70 -66.78 135.39 53.89 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 1.4199999999999999 110.493 -177.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -92.91 -2.58 55.7 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.195 -0.457 . . . . 1.55 111.889 -171.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 31.0 p -106.7 2.21 25.61 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.763 -0.375 . . . . 0.68999999999999995 111.832 178.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' 2062 ' ' ASP . 35.4 m -92.68 -174.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 110.326 -0.249 . . . . 0.81999999999999995 110.326 176.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -91.25 114.13 60.65 Favored Pre-proline 0 C--O 1.24 0.597 0 CA-C-O 121.02 0.438 . . . . 0.78000000000000003 111.389 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' 2065 ' ' VAL . 53.8 Cg_endo -101.06 108.06 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 123.362 2.708 . . . . 0.45000000000000001 111.296 166.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 23.2 p -149.25 -177.2 5.7 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.93 0.395 . . . . 0.69999999999999996 110.665 -177.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.632 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 9.3 m-30 -101.56 142.85 32.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.832 -1.173 . . . . 1.1599999999999999 107.832 166.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -64.18 -15.78 60.57 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.421 0.451 . . . . 2.0899999999999999 111.248 -172.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -84.4 2.02 42.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.039 -0.528 . . . . 2.1499999999999999 110.902 176.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 85.58 23.47 46.73 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.111 -0.566 . . . . 0.63 112.706 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.7 p -110.64 164.38 12.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.974 0.416 . . . . 0.89000000000000001 111.37 -177.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . 0.602 ' O ' HG22 ' A' 2086 ' ' ILE . 47.9 mmtm -113.32 -44.78 3.2 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.684 -0.689 . . . . 1.1299999999999999 110.696 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.763 ' HG3' HG22 ' A' 2085 ' ' THR . 4.6 mp0 -119.97 138.11 53.67 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.772 -0.455 . . . . 2.0800000000000001 109.772 173.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.5 OUTLIER -127.71 99.25 5.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.15 -0.477 . . . . 1.48 109.736 178.258 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 48.7 m -110.69 121.77 46.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.11 0.481 . . . . 0.63 110.476 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 88.0 mt -126.84 126.17 24.39 Favored Pre-proline 0 C--N 1.315 -0.91 0 N-CA-C 108.521 -0.918 . . . . 1.6200000000000001 108.521 174.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -47.14 109.67 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.295 2.664 . . . . 0.97999999999999998 113.257 -175.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . 0.488 ' O ' ' HD2' ' A' 2100 ' ' PHE . . . 93.9 -12.95 68.44 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.706 -0.679 . . . . 0.93999999999999995 113.009 177.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.516 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -94.7 -32.47 13.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 117.122 0.461 . . . . 2.02 110.661 -175.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.7 -155.24 16.28 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.811 -0.709 . . . . 0.5 111.9 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.555 ' HA ' ' O ' ' A' 2076 ' ' LYS . 55.8 m -155.28 138.92 16.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.698 0.761 . . . . 0.48999999999999999 111.011 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.632 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.2 m-85 -109.01 121.69 45.68 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.774 -1.565 . . . . 1.4399999999999999 106.774 170.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.763 HG22 ' HG3' ' A' 2075 ' ' GLU . 16.8 p -118.84 133.56 55.75 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.721 0.296 . . . . 0.63 111.584 -175.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.602 HG22 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -113.02 136.9 47.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.278 -0.419 . . . . 1.1799999999999999 110.186 176.16 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 18.6 m -122.71 144.82 43.55 Favored Pre-proline 0 C--N 1.319 -0.732 0 N-CA-C 109.975 -0.38 . . . . 0.80000000000000004 109.975 173.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -62.18 0.01 1.52 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.542 2.828 . . . . 0.96999999999999997 114.014 -172.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 37.2 t70 -68.04 -21.29 65.02 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.411 -0.589 . . . . 2.29 109.411 173.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.33 5.18 28.5 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.374 -0.83 . . . . 0.82999999999999996 111.715 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . 0.505 ' HA ' ' NH2' ' A' 2111 ' ' ARG . 4.9 t -114.23 143.34 45.0 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.185 0.517 . . . . 1.51 110.945 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.407 HG22 ' CG1' ' A' 2086 ' ' ILE . 27.6 t -139.32 137.52 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.529 -0.759 . . . . 1.1799999999999999 109.309 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 7.2 t -107.1 121.23 44.08 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.206 0.527 . . . . 1.46 110.166 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -87.53 97.86 11.08 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.087 -1.079 . . . . 1.27 108.087 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' 2083 ' ' THR . 43.9 m -117.63 99.09 52.27 Favored Pre-proline 0 N--CA 1.453 -0.31 0 N-CA-C 112.501 0.556 . . . . 0.57999999999999996 112.501 -174.063 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -86.17 143.17 7.75 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.567 2.178 . . . . 0.97999999999999998 110.231 166.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 17.1 t70 -61.34 135.01 57.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.955 0.407 . . . . 2.7200000000000002 110.499 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 58.9 mttp -72.24 -14.22 61.72 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.618 -0.719 . . . . 4.8099999999999996 111.913 -172.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -120.16 23.41 10.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.998 -0.371 . . . . 4.4199999999999999 109.998 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . 0.488 ' HD2' ' O ' ' A' 2080 ' ' GLY . 64.1 t80 -72.64 124.88 26.18 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-O 121.152 0.501 . . . . 2.3599999999999999 110.311 179.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.3 p -74.89 99.91 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.226 -0.897 . . . . 2.6800000000000002 110.478 177.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 102.56 -147.96 17.29 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.803 -0.635 . . . . 3.8399999999999999 112.039 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 48.7 mttp -111.02 134.4 21.03 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 120.613 0.245 . . . . 6.7800000000000002 110.876 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -43.72 149.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 124.409 3.406 . . . . 2.4300000000000002 114.035 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.444 ' H ' ' HG3' ' A' 2081 ' ' GLN . 1.4 m-20 -56.68 153.94 19.74 Favored Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 114.962 -1.017 . . . . 2.3300000000000001 111.898 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -53.22 113.16 1.15 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 124.235 3.29 . . . . 1.03 114.598 -174.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . 0.497 HG21 ' HG3' ' A' 2076 ' ' LYS . 4.2 p -160.66 119.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.092 -0.958 . . . . 0.59999999999999998 109.776 172.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.486 ' HA ' ' O ' ' A' 2121 ' ' ALA . 62.3 m -95.87 118.29 32.24 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.453 0.644 . . . . 0.37 110.17 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' 2120 ' ' THR . 6.1 t -91.65 136.36 24.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.259 -0.882 . . . . 0.76000000000000001 108.989 -178.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.583 ' HD2' ' C ' ' A' 2110 ' ' LYS . 0.0 OUTLIER -139.97 108.86 5.99 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.156 0.503 . . . . 1.6299999999999999 112.188 -173.089 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.505 ' NH2' ' HA ' ' A' 2091 ' ' THR . 4.2 ptm180 -142.4 132.76 24.95 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.719 -0.845 . . . . 3.4700000000000002 108.719 170.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.521 ' O ' HG21 ' A' 2065 ' ' VAL . 33.0 m -99.12 152.82 4.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.587 -0.445 . . . . 0.40000000000000002 111.695 -174.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -92.48 -170.68 2.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.969 -0.56 . . . . 1.46 110.15 178.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -64.72 -34.05 77.4 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.585 0.231 . . . . 1.72 111.255 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . 0.433 HD22 HG11 ' A' 2059 ' ' VAL . 37.0 m-80 -69.66 -30.13 67.74 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 1.8400000000000001 110.568 175.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 109.97 7.43 27.14 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.964 -0.636 . . . . 0.44 111.978 -178.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.434 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 87.9 m -81.97 118.73 73.15 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 110.142 -0.318 . . . . 0.56999999999999995 110.142 178.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' 2112 ' ' VAL . 3.3 Cg_exo -78.88 116.63 3.77 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 122.21 1.94 . . . . 0.60999999999999999 112.307 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 6.8 m -74.85 108.88 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.423 0 N-CA-C 107.89 -1.152 . . . . 0.59999999999999998 107.89 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' 2109 ' ' VAL . 68.5 p -123.3 168.48 12.43 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.662 -1.154 . . . . 0.67000000000000004 111.006 -170.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.04 126.36 39.31 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.083 -1.08 . . . . 0.72999999999999998 108.083 168.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 37.6 m -94.66 98.71 10.99 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.147 -0.686 . . . . 2.1899999999999999 109.147 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -120.57 123.95 44.11 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.574 0.702 . . . . 2.8100000000000001 111.796 -176.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . 0.598 ' OG ' ' HD2' ' A' 2125 ' ' PRO . 6.6 t -132.87 162.16 59.18 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 114.459 -1.246 . . . . 2.0600000000000001 108.391 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.598 ' HD2' ' OG ' ' A' 2124 ' ' SER . 49.2 Cg_endo . . . . . 0 C--N 1.353 0.776 0 C-N-CA 122.584 2.189 . . . . 2.1600000000000001 112.838 176.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.458 -0.042 0 CA-C-O 120.816 0.341 . . . . 2.4199999999999999 111.343 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -76.88 -21.44 12.45 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.341 2.028 . . . . 1.72 111.915 176.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.6 mp -85.14 -22.4 28.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.874 -0.603 . . . . 2.3399999999999999 110.048 177.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.8 t -126.17 83.32 63.82 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 108.711 -0.848 . . . . 0.87 108.711 178.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . 0.495 ' O ' ' HG3' ' A' 2114 ' ' LYS . 33.3 Cg_exo -58.53 141.59 97.46 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.625 2.217 . . . . 1.04 112.196 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.1 mm -63.12 135.79 26.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.693 -0.685 . . . . 0.77000000000000002 110.112 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.421 ' HB3' HG22 ' A' 2065 ' ' VAL . 11.7 t70 -70.51 128.69 37.02 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.28 -0.418 . . . . 1.4199999999999999 110.064 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -89.38 0.19 57.01 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.112 -0.494 . . . . 1.55 112.005 -171.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -105.11 -12.76 15.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.955 0.407 . . . . 0.68999999999999995 110.972 178.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' A' 2067 ' ' PRO . 33.3 m -91.72 -174.59 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.744 -0.465 . . . . 0.81999999999999995 109.744 175.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -92.8 113.53 59.94 Favored Pre-proline 0 C--O 1.245 0.829 0 CA-C-O 121.268 0.556 . . . . 0.78000000000000003 111.354 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.548 ' HA ' ' CB ' ' A' 2111 ' ' ARG . 51.0 Cg_endo -100.71 106.93 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.658 0 C-N-CA 123.096 2.531 . . . . 0.45000000000000001 111.45 167.13 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 16.7 p -138.88 178.88 6.83 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.072 0.463 . . . . 0.69999999999999996 111.176 -178.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 97.2 m-85 -103.0 159.45 15.5 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.71 -0.848 . . . . 1.1599999999999999 108.71 168.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . 0.414 ' HB2' ' O ' ' A' 2108 ' ' THR . 1.8 tm-20 -51.13 -44.13 61.32 Favored 'General case' 0 N--CA 1.468 0.474 0 O-C-N 123.755 0.66 . . . . 2.0899999999999999 112.203 -168.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 36.9 t70 -81.19 6.04 15.15 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.393 0.616 . . . . 2.1499999999999999 111.109 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 89.87 11.76 63.12 Favored Glycine 0 N--CA 1.45 -0.381 0 N-CA-C 111.675 -0.57 . . . . 0.63 111.675 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 4.2 m -74.57 161.58 29.59 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.797 0.332 . . . . 0.89000000000000001 110.875 -173.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -120.37 -21.2 6.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 1.1299999999999999 110.883 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.0 tt0 -156.43 129.91 8.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.983 0.42 . . . . 2.0800000000000001 110.108 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.44 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.1 OUTLIER -126.78 100.59 6.25 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.972 -0.558 . . . . 1.48 110.816 178.029 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 32.2 m -96.34 123.7 40.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.077 -0.511 . . . . 0.63 110.287 174.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.564 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 2.7 mp -126.36 122.55 23.97 Favored Pre-proline 0 C--N 1.314 -0.936 0 N-CA-C 109.206 -0.664 . . . . 1.6200000000000001 109.206 177.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' 2078 ' ' ILE . 68.9 Cg_exo -51.36 109.99 0.37 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.329 2.686 . . . . 0.97999999999999998 113.274 -175.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 94.46 -6.65 71.35 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.93999999999999995 112.757 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.564 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.6 tt0 -109.1 -33.39 6.9 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.123 0.487 . . . . 2.02 110.584 -175.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.77 -155.18 16.29 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.628 -0.796 . . . . 0.5 112.552 176.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.454 HG22 HG23 ' A' 2085 ' ' THR . 32.1 m -150.72 137.4 18.92 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.32 0.581 . . . . 0.48999999999999999 110.533 178.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.3 OUTLIER -111.51 121.88 46.36 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.481 -1.303 . . . . 1.4399999999999999 107.481 170.784 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.454 HG23 HG22 ' A' 2083 ' ' THR . 2.6 p -118.88 158.15 26.23 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 112.828 0.677 . . . . 0.63 112.828 -171.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.558 ' HB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -159.33 124.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 115.009 -0.996 . . . . 1.1799999999999999 109.57 172.223 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . 0.599 HG22 ' OG1' ' A' 2091 ' ' THR . 9.9 m -107.58 157.52 35.59 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.871 -0.788 . . . . 0.80000000000000004 108.871 173.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.99 0.52 1.2 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 123.392 2.728 . . . . 0.96999999999999997 114.299 -171.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . 0.44 ' H ' HG23 ' A' 2087 ' ' VAL . 12.9 m-20 -82.45 -12.81 57.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 2.29 110.099 174.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 97.08 32.57 6.38 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.948 -0.644 . . . . 0.82999999999999996 112.338 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . 0.599 ' OG1' HG22 ' A' 2087 ' ' VAL . 63.7 p -87.86 136.06 33.12 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.261 -0.274 . . . . 1.51 110.261 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.481 HG13 HH11 ' A' 2111 ' ' ARG . 48.9 t -136.78 126.38 38.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 120.891 0.376 . . . . 1.1799999999999999 111.55 -177.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.7 t -146.92 109.72 4.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.529 0.681 . . . . 1.46 110.382 171.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . 0.67 ' CE2' HG11 ' A' 2109 ' ' VAL . 13.6 m-30 -84.91 101.99 12.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.373 -0.973 . . . . 1.27 108.373 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 2.1 m -110.13 88.62 7.28 Favored Pre-proline 0 N--CA 1.452 -0.356 0 CA-C-O 120.9 0.381 . . . . 0.57999999999999996 110.812 -177.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . 0.562 ' HD3' ' O ' ' A' 2094 ' ' PHE . 93.3 Cg_endo -92.27 166.97 2.95 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 123.436 2.758 . . . . 0.97999999999999998 112.547 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 13.0 t70 -131.8 110.17 10.65 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.401 -0.592 . . . . 2.7200000000000002 109.401 171.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . 0.48 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.2 OUTLIER -88.59 18.77 4.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.816 0.341 . . . . 4.8099999999999996 111.381 -176.403 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -119.86 7.13 10.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.076 0.465 . . . . 4.4199999999999999 110.158 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 53.3 t80 -83.57 113.14 20.61 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.635 -0.711 . . . . 2.3599999999999999 111.047 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.5 t -113.46 98.78 7.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.947 -0.57 . . . . 2.6800000000000002 109.664 175.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 172.17 43.3 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.711 -0.677 . . . . 3.8399999999999999 111.512 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 37.1 ttpt 60.45 83.49 0.21 Allowed Pre-proline 0 CA--C 1.531 0.226 0 C-N-CA 123.425 0.69 . . . . 6.7800000000000002 111.441 -178.327 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . 0.432 ' HG2' ' O ' ' A' 2124 ' ' SER . 14.1 Cg_endo -58.9 134.24 58.86 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.186 1.924 . . . . 2.4300000000000002 111.042 173.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.4 t70 -60.85 124.99 82.19 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.092 -0.504 . . . . 2.3300000000000001 110.889 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.462 ' HA ' ' O ' ' A' 2123 ' ' TYR . 27.2 Cg_endo -64.1 95.85 0.21 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.728 2.286 . . . . 1.03 112.048 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.9 p -128.58 160.83 38.51 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.386 -0.824 . . . . 0.59999999999999998 109.499 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' 2070 ' ' GLU . 93.8 m -140.75 131.19 25.27 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.356 -0.609 . . . . 0.37 109.356 174.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.67 HG11 ' CE2' ' A' 2094 ' ' PHE . 6.0 t -92.04 137.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.773 -0.825 . . . . 0.76000000000000001 108.773 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -144.92 108.22 4.59 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.974 -0.38 . . . . 1.6299999999999999 109.974 -178.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.558 HH12 ' HB ' ' A' 2086 ' ' ILE . 15.0 ptp180 -159.6 156.55 28.17 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.162 -0.472 . . . . 3.4700000000000002 109.751 175.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.455 HG23 HG21 ' A' 2065 ' ' VAL . 34.7 m -109.41 140.65 27.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 C-N-CA 120.202 -0.599 . . . . 0.40000000000000002 111.577 -176.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.601 ' OD2' ' HB ' ' A' 2117 ' ' THR . 2.5 p30 -90.04 -169.04 2.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.62 -0.718 . . . . 1.46 111.121 178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . 0.495 ' HG3' ' O ' ' A' 2060 ' ' PRO . 99.4 mttt -59.47 -29.78 68.06 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.184 0.439 . . . . 1.72 112.184 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -86.05 -11.32 53.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 1.8400000000000001 110.738 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.14 13.03 59.39 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.048 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.601 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 73.5 m -78.81 128.3 77.29 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-O 120.569 0.223 . . . . 0.56999999999999995 110.549 178.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 2.7 Cg_exo -75.61 99.0 1.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.322 2.014 . . . . 0.60999999999999999 111.814 177.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 17.2 m -75.39 109.41 8.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.535 0.683 . . . . 0.59999999999999998 109.466 175.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' 2109 ' ' VAL . 80.3 p -120.33 167.26 12.49 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 115.319 -0.855 . . . . 0.67000000000000004 110.898 -175.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.461 ' HB3' HG23 ' A' 2109 ' ' VAL . . . -140.56 128.58 22.07 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.875 -0.787 . . . . 0.72999999999999998 108.875 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 10.9 p -92.1 98.87 11.81 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.236 0.541 . . . . 2.1899999999999999 110.664 -177.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.0 OUTLIER -115.5 123.41 48.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.784 -0.644 . . . . 2.8100000000000001 110.959 -178.43 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . 0.432 ' O ' ' HG2' ' A' 2104 ' ' PRO . 68.8 m -157.35 163.73 23.93 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.515 -0.766 . . . . 2.0600000000000001 109.04 178.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 93.0 Cg_exo . . . . . 0 C--N 1.346 0.427 0 C-N-CA 122.659 2.239 . . . . 2.1600000000000001 112.523 177.965 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 CA--C 1.519 -0.247 0 N-CA-C 110.184 -0.302 . . . . 2.4199999999999999 110.184 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -68.43 -9.41 25.91 Favored 'Trans proline' 0 CA--C 1.528 0.218 0 C-N-CA 122.192 1.928 . . . . 1.72 111.862 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.5 mp -84.78 -18.85 33.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.923 -0.58 . . . . 2.3399999999999999 110.11 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.471 HG11 HD22 ' A' 2115 ' ' ASN . 4.6 t -138.84 89.86 12.74 Favored Pre-proline 0 CA--C 1.514 -0.41 0 N-CA-C 109.322 -0.621 . . . . 0.87 109.322 -177.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -53.25 120.68 8.13 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.315 2.01 . . . . 1.04 111.619 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.4 mm -49.77 134.82 8.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.152 -0.931 . . . . 0.77000000000000002 111.679 -176.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.552 ' O ' HG22 ' A' 2065 ' ' VAL . 14.6 t70 -76.65 130.26 37.54 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.437 -0.802 . . . . 1.4199999999999999 110.691 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -87.43 -8.29 56.69 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.238 0.458 . . . . 1.55 112.238 -174.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 29.7 p -101.75 0.79 36.47 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 120.5 -0.48 . . . . 0.68999999999999995 111.883 -178.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.595 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.6 m -92.87 -174.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.663 -0.244 . . . . 0.81999999999999995 110.507 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -97.35 107.89 41.36 Favored Pre-proline 0 C--O 1.24 0.598 0 CA-C-O 121.364 0.602 . . . . 0.78000000000000003 111.468 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.595 ' HD3' ' O ' ' A' 2065 ' ' VAL . 5.8 Cg_endo -93.71 108.75 0.17 Allowed 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.518 2.812 . . . . 0.45000000000000001 110.88 167.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.512 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.3 p -148.84 146.1 27.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.912 0.387 . . . . 0.69999999999999996 110.64 -177.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.486 ' CD2' ' N ' ' A' 2069 ' ' PHE . 2.4 m-30 -71.64 148.32 46.66 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.44 -1.319 . . . . 1.1599999999999999 107.44 176.071 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -61.08 -19.53 61.55 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.406 0.521 . . . . 2.0899999999999999 112.406 -165.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -92.03 1.33 57.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.621 0.248 . . . . 2.1499999999999999 111.131 178.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 87.59 25.21 33.5 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.86 -0.686 . . . . 0.63 112.018 -176.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 19.5 m -95.22 152.33 18.46 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.89000000000000001 110.511 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -111.62 -22.47 11.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.084 -0.507 . . . . 1.1299999999999999 110.58 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' 2084 ' ' TYR . 3.0 tt0 -144.35 144.43 31.44 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.113 0.482 . . . . 2.0800000000000001 110.243 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.425 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.4 OUTLIER -139.59 108.14 5.88 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.401 -0.818 . . . . 1.48 109.505 179.854 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 19.2 m -118.64 133.23 56.01 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.189 0.518 . . . . 0.63 111.493 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.549 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 4.2 mp -136.39 123.03 14.01 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 108.106 -1.072 . . . . 1.6200000000000001 108.106 172.276 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -52.29 109.48 0.34 Allowed 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.669 2.246 . . . . 0.97999999999999998 112.458 -178.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.65 -22.23 28.73 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.736 -0.665 . . . . 0.93999999999999995 112.383 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.549 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 52.7 tt0 -96.06 -31.52 12.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.085 0.469 . . . . 2.02 110.463 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.49 -153.64 17.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.837 -0.697 . . . . 0.5 112.141 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.49 HG22 HG23 ' A' 2085 ' ' THR . 43.0 m -150.0 144.96 26.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.65 0.738 . . . . 0.48999999999999999 110.824 178.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.528 ' O ' ' HA ' ' A' 2075 ' ' GLU . 7.6 m-85 -120.15 125.01 47.17 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 107.236 -1.394 . . . . 1.4399999999999999 107.236 172.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.49 HG23 HG22 ' A' 2083 ' ' THR . 17.3 p -129.07 134.75 48.23 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.544 0.572 . . . . 0.63 112.544 -174.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.563 HD13 HG22 ' A' 2092 ' ' VAL . 0.7 OUTLIER -130.82 123.94 55.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.562 -0.744 . . . . 1.1799999999999999 110.142 170.155 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 19.2 m -112.15 151.58 43.75 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.003 -0.74 . . . . 0.80000000000000004 109.003 172.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.76 -6.27 1.06 Allowed 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.057 3.171 . . . . 0.96999999999999997 114.922 -168.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 27.1 t70 -66.85 -24.07 66.1 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.126 0.489 . . . . 2.29 110.179 175.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 104.11 20.07 10.94 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.738 -0.665 . . . . 0.82999999999999996 112.223 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.8 t -110.42 126.38 54.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.962 0.41 . . . . 1.51 110.64 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.563 HG22 HD13 ' A' 2086 ' ' ILE . 7.6 t -133.08 137.42 53.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.016 -0.538 . . . . 1.1799999999999999 110.384 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.3 t -119.36 118.29 30.79 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.042 0.448 . . . . 1.46 110.19 173.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 9.4 m-30 -85.24 97.21 9.8 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.663 -0.866 . . . . 1.27 108.663 173.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 13.3 m -116.49 87.05 19.44 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.994 0.426 . . . . 0.57999999999999996 110.76 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -92.44 169.69 2.64 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.327 2.685 . . . . 0.97999999999999998 112.42 176.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.9 t70 -118.35 106.51 12.83 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.872 -0.788 . . . . 2.7200000000000002 108.872 171.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 93.2 mttt -69.77 -10.1 57.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.961 -0.563 . . . . 4.8099999999999996 112.194 -171.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -110.46 8.88 23.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.703 0.287 . . . . 4.4199999999999999 111.111 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 44.9 t80 -89.63 76.98 7.25 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.2 0.524 . . . . 2.3599999999999999 110.904 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 4.2 p -103.96 124.98 58.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.216 0.531 . . . . 2.6800000000000002 110.083 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 164.63 -81.9 0.11 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.047 -0.821 . . . . 3.8399999999999999 111.047 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 22.7 tptm -140.42 76.72 24.99 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 120.935 0.398 . . . . 6.7800000000000002 110.707 175.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -80.53 169.57 16.85 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.16 2.573 . . . . 2.4300000000000002 111.445 173.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.3 t70 -103.06 125.3 35.64 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 116.544 -0.298 . . . . 2.3300000000000001 110.198 178.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' 2123 ' ' TYR . 24.7 Cg_endo -62.96 103.5 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.734 2.29 . . . . 1.03 111.928 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . 0.425 HG11 ' HG2' ' A' 2076 ' ' LYS . 7.7 p -141.37 133.78 29.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.137 -0.483 . . . . 0.59999999999999998 111.049 -177.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.3 m -102.5 108.71 20.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.652 -0.704 . . . . 0.37 109.906 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' 2120 ' ' THR . 8.5 t -91.09 123.09 43.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.772 -0.825 . . . . 0.76000000000000001 108.772 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.512 ' HB3' ' O ' ' A' 2068 ' ' THR . 1.7 tmmt? -129.59 149.6 51.28 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.402 0.62 . . . . 1.6299999999999999 112.203 -169.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.51 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.3 ptt180 -166.91 138.2 3.28 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.97 -1.014 . . . . 3.4700000000000002 108.292 165.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.526 ' O ' HG21 ' A' 2065 ' ' VAL . 27.1 m -98.61 148.88 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 C-N-CA 120.357 -0.537 . . . . 0.40000000000000002 110.871 -175.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.433 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.7 p-10 -94.12 -168.7 1.91 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.933 -0.576 . . . . 1.46 110.448 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.5 mttm -62.88 -32.34 73.57 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.702 0.287 . . . . 1.72 111.393 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . 0.471 HD22 HG11 ' A' 2059 ' ' VAL . 41.1 m-80 -77.54 -14.96 59.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.955 0.407 . . . . 1.8400000000000001 110.599 176.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.87 12.47 59.13 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.333 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 27.8 m -85.83 121.26 73.15 Favored Pre-proline 0 C--N 1.324 -0.533 0 N-CA-C 110.106 -0.331 . . . . 0.56999999999999995 110.106 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 3.1 Cg_exo -74.74 107.86 2.57 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.261 1.974 . . . . 0.60999999999999999 112.653 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . 0.424 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 15.6 m -74.78 112.03 11.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 107.737 -1.208 . . . . 0.59999999999999998 107.737 169.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.616 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.7 p -127.41 159.32 34.83 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.636 -0.711 . . . . 0.67000000000000004 112.192 -169.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.46 127.63 42.86 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.8 -1.185 . . . . 0.72999999999999998 107.8 169.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 12.5 p -115.67 99.53 7.39 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.23 0.538 . . . . 2.1899999999999999 111.171 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.508 ' O ' ' HA ' ' A' 2106 ' ' PRO . 4.4 m-85 -90.08 151.98 21.36 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.677 -0.692 . . . . 2.8100000000000001 111.099 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . 0.435 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 33.3 p -148.2 168.01 12.04 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 115.957 -0.565 . . . . 2.0600000000000001 110.551 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' 2124 ' ' SER . 71.3 Cg_exo . . . . . 0 C--N 1.351 0.669 0 C-N-CA 122.574 2.183 . . . . 2.1600000000000001 112.975 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . 0.526 ' HB2' ' O ' ' A' 2059 ' ' VAL . 4.1 p-10 . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 121.262 0.553 . . . . 2.4199999999999999 110.812 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . 0.408 ' HB2' HD22 ' A' 2058 ' ' LEU . 57.6 Cg_endo -69.0 -53.11 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.375 2.05 . . . . 1.72 112.618 -170.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . 0.408 HD22 ' HB2' ' A' 2057 ' ' PRO . 3.8 mm? -121.32 19.4 11.4 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.999 -0.371 . . . . 2.3399999999999999 109.999 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.526 ' O ' ' HB2' ' A' 2056 ' ' ASP . 0.0 OUTLIER -131.85 77.52 72.01 Favored Pre-proline 0 N--CA 1.449 -0.523 0 C-N-CA 120.332 -0.547 . . . . 0.87 110.026 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.82 120.99 8.77 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.511 2.141 . . . . 1.04 111.95 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . 0.633 HG13 ' NE ' ' A' 2111 ' ' ARG . 47.1 mm -49.94 128.55 6.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.354 -0.839 . . . . 0.77000000000000002 111.846 -178.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.489 ' O ' HG22 ' A' 2065 ' ' VAL . 11.1 t70 -66.81 136.8 55.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.746 -0.661 . . . . 1.4199999999999999 110.171 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -88.71 1.19 55.57 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 112.567 0.58 . . . . 1.55 112.567 -171.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 70.1 p -120.29 -0.39 10.44 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.885 0.328 . . . . 0.68999999999999995 111.885 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.676 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.8 m -86.35 -173.13 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.162 -0.31 . . . . 0.81999999999999995 110.162 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -95.65 105.47 20.97 Favored Pre-proline 0 C--O 1.238 0.474 0 CA-C-O 120.966 0.412 . . . . 0.78000000000000003 111.513 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' 2065 ' ' VAL . 33.4 Cg_endo -100.31 106.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 122.898 2.399 . . . . 0.45000000000000001 110.872 167.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.51 ' O ' ' HB3' ' A' 2110 ' ' LYS . 18.7 p -141.1 148.27 39.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.223 0.535 . . . . 0.69999999999999996 110.585 -176.118 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.53 ' N ' ' HD1' ' A' 2069 ' ' PHE . 1.3 m-30 -74.58 149.36 40.16 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.416 -0.957 . . . . 1.1599999999999999 108.416 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . 0.475 ' CB ' ' HB ' ' A' 2108 ' ' THR . 5.2 tm-20 -50.78 -42.12 57.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.955 0.407 . . . . 2.0899999999999999 110.459 -173.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -71.89 0.79 8.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 115.638 -0.71 . . . . 2.1499999999999999 112.563 -178.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 82.92 29.94 33.21 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.572 -0.823 . . . . 0.63 112.001 -176.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 15.7 m -106.75 159.15 16.44 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.849 0.357 . . . . 0.89000000000000001 111.043 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -109.84 -18.8 13.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 1.1299999999999999 110.638 176.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.477 ' HB2' HG22 ' A' 2085 ' ' THR . 6.0 tt0 -148.68 136.69 20.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.146 0.498 . . . . 2.0800000000000001 109.853 173.045 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.408 ' HE2' HD11 ' A' 2078 ' ' ILE . 32.9 tptt -128.29 113.65 15.9 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.541 -0.754 . . . . 1.48 109.183 175.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 46.3 m -117.91 124.9 49.4 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 121.482 0.658 . . . . 0.63 110.895 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.595 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 12.3 mt -120.2 120.74 29.89 Favored Pre-proline 0 C--N 1.313 -1.013 0 N-CA-C 107.774 -1.195 . . . . 1.6200000000000001 107.774 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -41.91 108.66 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 123.551 2.834 . . . . 0.97999999999999998 113.806 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.19 -30.48 6.71 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.486 -0.779 . . . . 0.93999999999999995 113.037 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.595 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -74.83 -30.29 61.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.246 0.546 . . . . 2.02 110.172 -174.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 125.82 -171.34 17.67 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.471 -0.871 . . . . 0.5 112.571 175.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 38.3 m -140.25 132.29 27.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.534 0.683 . . . . 0.48999999999999999 110.695 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.498 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.6 OUTLIER -106.49 129.82 54.38 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.882 -1.525 . . . . 1.4399999999999999 106.882 169.521 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.477 HG22 ' HB2' ' A' 2075 ' ' GLU . 0.8 OUTLIER -133.06 140.59 47.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.258 0.551 . . . . 0.63 112.438 -175.939 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.538 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -130.27 131.64 65.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.152 -0.931 . . . . 1.1799999999999999 109.672 173.289 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . 0.401 ' HA ' ' HD3' ' A' 2088 ' ' PRO . 27.7 m -115.33 149.42 42.75 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.727 -0.472 . . . . 0.80000000000000004 109.727 174.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' 2087 ' ' VAL . 32.2 Cg_exo -59.04 -6.42 3.62 Favored 'Trans proline' 0 C--N 1.349 0.595 0 C-N-CA 123.808 3.005 . . . . 0.96999999999999997 114.147 -170.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -70.23 -13.89 62.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.002 0.43 . . . . 2.29 110.206 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 96.9 17.71 31.81 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.929 -0.653 . . . . 0.82999999999999996 112.182 178.521 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 4.8 t -115.52 133.46 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.049 0.452 . . . . 1.51 109.824 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.538 HG13 ' HB ' ' A' 2086 ' ' ILE . 11.6 t -135.12 149.79 29.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.581 . . . . 1.1799999999999999 110.237 -173.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.0 t -136.23 123.74 22.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.287 0.565 . . . . 1.46 110.871 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.6 m-30 -99.13 98.72 9.7 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.193 -0.669 . . . . 1.27 109.193 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 12.0 m -113.96 96.79 42.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.873 0.368 . . . . 0.57999999999999996 111.026 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -89.17 176.35 3.17 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 123.246 2.631 . . . . 0.97999999999999998 112.787 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . 0.465 ' HB3' ' HA ' ' A' 2081 ' ' GLN . 6.4 p-10 -71.7 102.02 2.7 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.319 -0.855 . . . . 2.7200000000000002 112.139 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . 0.66 ' HD2' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -92.05 -9.76 41.6 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.087 -0.506 . . . . 4.8099999999999996 110.263 173.694 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . 0.402 ' HG3' ' HG2' ' A' 2098 ' ' LYS . 94.3 mt-30 -120.64 -52.55 2.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.073 -0.512 . . . . 4.4199999999999999 110.299 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.13 145.31 42.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.426 -0.806 . . . . 2.3599999999999999 111.454 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 8.9 p -160.32 143.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 115.655 -0.702 . . . . 2.6800000000000002 109.382 175.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 152.57 -94.07 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.578 -0.82 . . . . 3.8399999999999999 112.453 -178.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 63.7 tttp -120.73 89.17 44.75 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-O 120.857 0.36 . . . . 6.7800000000000002 110.507 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.74 139.44 25.03 Favored 'Trans proline' 0 N--CA 1.459 -0.531 0 C-N-CA 122.712 2.275 . . . . 2.4300000000000002 111.097 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.51 ' HB3' HD13 ' A' 2078 ' ' ILE . 32.0 t70 -85.17 130.69 50.97 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 109.555 -0.535 . . . . 2.3300000000000001 109.555 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' 2123 ' ' TYR . 18.0 Cg_endo -60.41 119.55 6.8 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.117 2.544 . . . . 1.03 112.93 -177.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.5 p -159.36 133.64 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.746 -0.661 . . . . 0.59999999999999998 110.372 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' 2121 ' ' ALA . 34.1 m -105.51 119.31 38.79 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.188 0.518 . . . . 0.37 109.718 173.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -95.29 139.04 19.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.863 -0.792 . . . . 0.76000000000000001 108.863 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.51 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.9 tmmm? -140.68 147.65 39.59 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 118.366 0.53 . . . . 1.6299999999999999 111.438 -171.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.633 ' NE ' HG13 ' A' 2061 ' ' ILE . 29.1 ptt180 -168.98 135.28 1.73 Allowed 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.838 -0.801 . . . . 3.4700000000000002 108.838 171.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 23.2 m -99.8 149.99 5.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.207 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.436 ' HB3' HD13 ' A' 2061 ' ' ILE . 4.7 p-10 -93.93 -168.92 1.97 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.923 -0.581 . . . . 1.46 110.736 178.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.31 -41.78 85.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.19 -0.459 . . . . 1.72 111.929 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -18.74 46.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.869 0.366 . . . . 1.8400000000000001 110.45 -177.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 106.14 16.76 14.11 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.543 -0.837 . . . . 0.44 113.641 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.419 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.8 m -83.83 119.26 73.28 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 117.187 0.494 . . . . 0.56999999999999995 110.376 175.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -77.92 102.15 1.55 Allowed 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.369 2.046 . . . . 0.60999999999999999 111.988 177.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.7 m -74.88 117.59 19.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 108.545 -0.909 . . . . 0.59999999999999998 108.545 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' 2109 ' ' VAL . 61.2 p -126.25 161.14 28.43 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.524 -0.762 . . . . 0.67000000000000004 111.78 -170.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.537 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.09 127.44 41.48 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 107.981 -1.118 . . . . 0.72999999999999998 107.981 169.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 21.9 m -116.15 103.93 11.03 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 120.974 0.416 . . . . 2.1899999999999999 110.54 -174.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.572 ' O ' ' HA ' ' A' 2106 ' ' PRO . 2.3 m-85 -100.72 131.01 46.83 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 112.048 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 16.1 m -131.77 146.81 63.42 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.135 -0.939 . . . . 2.0600000000000001 109.391 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 CA--C 1.53 0.305 0 C-N-CA 122.815 2.343 . . . . 2.1600000000000001 112.957 -178.278 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 121.114 0.483 . . . . 2.4199999999999999 110.269 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -69.32 -52.82 0.33 Allowed 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.87 2.38 . . . . 1.72 111.862 177.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . 0.828 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -68.33 -9.38 47.45 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.423 -0.808 . . . . 2.3399999999999999 112.854 176.677 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.828 HG23 HD13 ' A' 2058 ' ' LEU . 5.7 t -137.72 86.69 18.16 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 109.666 -0.494 . . . . 0.87 109.666 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.41 131.05 43.91 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.378 2.052 . . . . 1.04 111.847 -177.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 43.1 mm -62.86 122.66 14.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.904 -0.589 . . . . 0.77000000000000002 109.935 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' 2065 ' ' VAL . 21.1 t70 -70.46 134.52 47.84 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.236 0.541 . . . . 1.4199999999999999 110.496 -176.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -89.3 -2.09 58.32 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.844 -0.616 . . . . 1.55 111.914 -171.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -113.99 -2.67 13.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.829 -0.348 . . . . 0.68999999999999995 111.848 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.59 ' O ' ' HD3' ' A' 2067 ' ' PRO . 26.8 m -81.59 -174.59 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.973 -0.291 . . . . 0.81999999999999995 110.284 177.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.11 109.27 51.11 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.211 0.529 . . . . 0.78000000000000003 111.202 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.59 ' HD3' ' O ' ' A' 2065 ' ' VAL . 50.5 Cg_endo -99.57 111.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.518 0 C-N-CA 123.305 2.67 . . . . 0.45000000000000001 110.875 165.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 8.4 p -145.13 -178.98 6.33 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.211 0.529 . . . . 0.69999999999999996 110.758 -176.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 39.0 m-85 -102.73 148.25 25.84 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.735 -0.839 . . . . 1.1599999999999999 108.735 168.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -59.98 -24.23 64.27 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.962 0.789 . . . . 2.0899999999999999 111.593 -172.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -86.05 -3.45 58.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.309 -0.405 . . . . 2.1499999999999999 110.858 178.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.57 29.88 12.97 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.147 -0.549 . . . . 0.63 113.066 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 26.3 p -110.61 179.15 4.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.032 0.416 . . . . 0.89000000000000001 111.276 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . 0.411 ' O ' HG22 ' A' 2086 ' ' ILE . 34.6 mmtp -124.78 -4.8 7.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-O 120.957 0.408 . . . . 1.1299999999999999 111.159 -178.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -159.56 132.32 6.76 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.457 -0.571 . . . . 2.0800000000000001 109.457 169.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.457 ' HA ' ' HD2' ' A' 2076 ' ' LYS . 3.7 mmmm -120.01 100.89 7.48 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.968 -0.56 . . . . 1.48 110.306 174.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 89.5 m -97.51 111.57 23.78 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.876 -0.602 . . . . 0.63 110.242 173.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.469 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 96.6 mt -110.8 117.26 50.83 Favored Pre-proline 0 C--N 1.31 -1.113 0 N-CA-C 108.74 -0.837 . . . . 1.6200000000000001 108.74 175.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -46.37 112.52 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.501 2.801 . . . . 0.97999999999999998 113.574 -174.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 87.74 -11.09 67.55 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.783 -0.644 . . . . 0.93999999999999995 112.795 177.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.469 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -101.19 -31.88 10.8 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.22 0.533 . . . . 2.02 110.296 -174.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 131.63 -170.42 21.58 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.45 -0.881 . . . . 0.5 113.095 173.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.536 ' O ' ' HB ' ' A' 2095 ' ' THR . 86.6 m -144.38 136.58 26.37 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.476 -0.564 . . . . 0.48999999999999999 109.476 177.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -117.77 126.86 53.23 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.493 -1.299 . . . . 1.4399999999999999 107.493 174.189 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 11.9 p -120.38 127.43 52.28 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.822 -0.351 . . . . 0.63 111.709 -175.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.481 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -108.08 135.44 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.955 -0.566 . . . . 1.1799999999999999 109.864 175.58 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 26.7 m -122.22 150.69 57.48 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 109.41 -0.589 . . . . 0.80000000000000004 109.41 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 34.6 Cg_exo -60.0 -1.28 1.17 Allowed 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.737 2.958 . . . . 0.96999999999999997 113.792 -174.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . 0.423 ' HB3' HG22 ' A' 2091 ' ' THR . 16.8 t70 -66.4 -20.17 65.99 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.267 0.556 . . . . 2.29 109.865 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 99.49 14.79 34.1 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.245 -0.742 . . . . 0.82999999999999996 111.245 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . 0.423 HG22 ' HB3' ' A' 2089 ' ' ASP . 8.8 t -120.31 146.61 45.95 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.312 -0.444 . . . . 1.51 110.376 -177.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 21.5 t -132.82 138.56 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.353 -0.61 . . . . 1.1799999999999999 109.353 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 51.6 m -97.76 109.98 22.63 Favored 'General case' 0 N--CA 1.439 -0.98 0 CA-C-O 120.789 0.328 . . . . 1.46 110.251 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 7.8 m-30 -86.81 98.41 11.17 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.64 -0.504 . . . . 1.27 109.64 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . 0.536 ' HB ' ' O ' ' A' 2083 ' ' THR . 58.4 m -109.4 99.11 35.37 Favored Pre-proline 0 C--O 1.234 0.241 0 CA-C-O 120.942 0.401 . . . . 0.57999999999999996 110.524 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -88.27 162.15 6.96 Favored 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 123.346 2.697 . . . . 0.97999999999999998 113.966 -174.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . 0.462 ' HB2' ' CB ' ' A' 2100 ' ' PHE . 10.4 p-10 -72.46 48.31 0.19 Allowed 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.091 -0.959 . . . . 2.7200000000000002 111.776 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -70.63 -10.01 58.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.079 0.466 . . . . 4.8099999999999996 111.167 -175.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -116.65 24.44 11.29 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.117 -0.492 . . . . 4.4199999999999999 110.753 178.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . 0.462 ' CB ' ' HB2' ' A' 2097 ' ' ASP . 63.7 t80 -113.8 142.2 46.36 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.156 0.503 . . . . 2.3599999999999999 111.762 -173.4 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 74.3 t -132.26 105.01 8.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.633 -0.712 . . . . 2.6800000000000002 110.19 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.29 -99.46 0.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 N-CA-C 111.279 -0.729 . . . . 3.8399999999999999 111.279 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.18 120.51 0.89 Allowed Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 109.715 -0.476 . . . . 6.7800000000000002 109.715 170.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.52 147.66 22.63 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.73 2.287 . . . . 2.4300000000000002 112.162 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 18.8 m-20 -80.46 147.02 62.78 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.029 -0.532 . . . . 2.3300000000000001 109.94 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.467 ' HA ' ' O ' ' A' 2123 ' ' TYR . 45.9 Cg_endo -68.04 128.95 18.51 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.147 2.565 . . . . 1.03 113.908 -171.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 5.5 p -158.08 160.0 2.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.38 -0.827 . . . . 0.59999999999999998 109.169 177.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 26.5 m -141.25 122.35 14.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.115 0.483 . . . . 0.37 110.415 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 5.2 t -92.22 133.47 33.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 108.922 -0.77 . . . . 0.76000000000000001 108.922 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -125.84 109.63 12.74 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 120.683 0.278 . . . . 1.6299999999999999 111.387 -169.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' 2119 ' ' VAL . 30.8 ptt180 -147.3 135.4 21.46 Favored 'General case' 0 C--N 1.317 -0.818 0 O-C-N 121.797 -0.565 . . . . 3.4700000000000002 110.133 168.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.498 ' O ' HG21 ' A' 2065 ' ' VAL . 34.2 m -99.09 154.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 120.998 0.428 . . . . 0.40000000000000002 110.758 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.546 ' OD2' ' HB ' ' A' 2117 ' ' THR . 10.1 p30 -94.38 -169.59 2.08 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.81 -0.632 . . . . 1.46 110.778 178.139 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.7 mttm -65.06 -22.85 67.03 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.15 0.426 . . . . 1.72 112.15 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -90.5 -19.01 24.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.054 0.455 . . . . 1.8400000000000001 110.235 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 102.94 15.13 24.93 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.662 -0.699 . . . . 0.44 111.962 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.546 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 24.1 m -91.62 119.63 68.44 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 120.805 0.336 . . . . 0.56999999999999995 110.221 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' 2117 ' ' THR . 8.2 Cg_exo -72.68 107.34 2.3 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.46 2.106 . . . . 0.60999999999999999 113.241 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.95 109.25 9.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 108.088 -1.078 . . . . 0.59999999999999998 108.088 165.008 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . . . . . . . . . 75.0 p -125.14 179.5 5.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.105 -0.952 . . . . 0.67000000000000004 110.553 -171.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.61 127.2 41.8 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.606 -0.887 . . . . 0.72999999999999998 108.606 170.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 30.9 p -93.39 101.67 13.9 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.877 -0.601 . . . . 2.1899999999999999 109.898 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' 2106 ' ' PRO . 5.4 m-85 -120.25 122.96 42.04 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.633 0.73 . . . . 2.8100000000000001 112.17 -175.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 46.9 p -152.42 158.18 33.5 Favored Pre-proline 0 C--N 1.321 -0.642 0 CA-C-N 114.478 -1.237 . . . . 2.0600000000000001 108.859 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo . . . . . 0 C--N 1.346 0.41 0 C-N-CA 122.474 2.116 . . . . 2.1600000000000001 112.794 -179.428 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 6.9 t70 . . . . . 0 N--CA 1.452 -0.364 0 N-CA-C 110.106 -0.331 . . . . 2.4199999999999999 110.106 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.34 -20.31 42.68 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.585 2.19 . . . . 1.72 112.596 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.8 mp -100.29 -26.78 13.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.795 0.331 . . . . 2.3399999999999999 110.301 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 4.6 t -116.52 82.43 12.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.186 -0.461 . . . . 0.87 109.818 178.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.44 120.1 7.25 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.374 2.049 . . . . 1.04 111.559 179.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.7 mm -49.9 131.21 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.522 -0.763 . . . . 0.77000000000000002 110.908 179.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' 2065 ' ' VAL . 10.6 t70 -69.25 135.1 50.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.458 -0.792 . . . . 1.4199999999999999 110.588 -176.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -97.49 2.96 50.83 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.987 0.366 . . . . 1.55 111.987 -173.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.2 p -109.74 3.32 20.75 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.08 0.943 . . . . 0.68999999999999995 108.97 173.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.709 ' O ' ' HD3' ' A' 2067 ' ' PRO . 1.0 OUTLIER -91.29 165.22 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 CA-C-N 114.041 -1.436 . . . . 0.81999999999999995 110.108 -178.807 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.37 108.98 9.85 Favored Pre-proline 0 C--O 1.24 0.553 0 CA-C-O 120.697 0.284 . . . . 0.78000000000000003 111.368 177.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' 2065 ' ' VAL . 60.7 Cg_endo -102.34 108.6 0.04 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.57 0 C-N-CA 123.454 2.769 . . . . 0.45000000000000001 111.328 166.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 21.3 p -134.5 174.45 10.53 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.529 0.68 . . . . 0.69999999999999996 111.335 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.528 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.7 OUTLIER -101.13 151.4 21.87 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.64 -1.245 . . . . 1.1599999999999999 107.64 170.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -45.71 -41.72 10.91 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 123.719 0.637 . . . . 2.0899999999999999 112.391 -171.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -90.17 16.58 8.27 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 111.944 0.35 . . . . 2.1499999999999999 111.944 -175.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 30.0 58.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.663 -0.78 . . . . 0.63 112.668 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.3 p -102.92 167.96 9.52 Favored 'General case' 0 C--N 1.323 -0.564 0 O-C-N 122.859 -0.201 . . . . 0.89000000000000001 110.496 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . 0.425 ' O ' HG22 ' A' 2086 ' ' ILE . 42.1 mmtm -123.39 -10.45 7.97 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.246 0.462 . . . . 1.1299999999999999 112.246 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -158.77 128.1 5.59 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.928 0.394 . . . . 2.0800000000000001 110.156 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.35 100.47 6.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.185 -0.672 . . . . 1.48 109.185 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 62.8 m -109.78 127.21 54.49 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.282 -0.417 . . . . 0.63 111.112 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.614 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 35.4 mm -131.32 132.01 23.37 Favored Pre-proline 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.917 . . . . 1.6200000000000001 108.523 171.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.76 108.9 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.478 2.119 . . . . 0.97999999999999998 112.197 178.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' 2101 ' ' VAL . . . 99.83 -4.09 57.6 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.018 -0.61 . . . . 0.93999999999999995 112.319 -179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.614 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.1 tt0 -107.33 -29.79 9.08 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.125 0.488 . . . . 2.02 110.222 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 103.89 -162.35 15.49 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.565 -0.743 . . . . 0.5 111.641 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.518 ' O ' ' HB ' ' A' 2095 ' ' THR . 47.1 m -139.76 135.43 33.08 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.568 0.699 . . . . 0.48999999999999999 110.729 178.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.508 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.6 m-85 -104.58 110.74 23.15 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.069 -1.456 . . . . 1.4399999999999999 107.069 171.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.491 HG23 HG22 ' A' 2083 ' ' THR . 13.3 p -108.24 123.67 49.12 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.323 0.49 . . . . 0.63 112.323 -171.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.5 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.93 130.8 72.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.112 -0.494 . . . . 1.1799999999999999 109.84 170.349 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.5 m -122.33 150.59 57.59 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.01 -0.541 . . . . 0.80000000000000004 109.748 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.94 -3.9 1.78 Allowed 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 123.949 3.099 . . . . 0.96999999999999997 114.276 -172.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . 0.401 ' HB2' HG22 ' A' 2091 ' ' THR . 5.3 m-20 -69.3 -13.95 62.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.223 0.535 . . . . 2.29 110.057 176.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.57 8.16 54.92 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.531 -0.759 . . . . 0.82999999999999996 111.552 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' 2089 ' ' ASP . 6.8 t -111.44 129.01 56.16 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.381 0.61 . . . . 1.51 110.501 -177.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.6 HG13 ' NH1' ' A' 2111 ' ' ARG . 1.1 p -150.08 139.29 15.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.529 -0.76 . . . . 1.1799999999999999 110.538 -176.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -127.57 130.92 49.93 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.098 0.475 . . . . 1.46 110.747 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . 0.466 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.5 m-30 -84.36 99.02 10.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.463 -0.94 . . . . 1.27 108.463 175.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' 2083 ' ' THR . 19.6 m -116.54 89.35 27.25 Favored Pre-proline 0 N--CA 1.454 -0.259 0 CA-C-O 121.215 0.531 . . . . 0.57999999999999996 111.815 -175.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' 2094 ' ' PHE . 5.3 Cg_endo -87.41 142.2 6.02 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 123.207 2.605 . . . . 0.97999999999999998 110.877 172.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.49 137.23 58.19 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.184 -0.462 . . . . 2.7200000000000002 110.712 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.15 -20.21 63.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.378 -0.828 . . . . 4.8099999999999996 112.184 -175.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -103.49 -44.73 5.05 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.711 -0.477 . . . . 4.4199999999999999 109.711 177.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . 0.465 ' CE1' ' HB3' ' A' 2104 ' ' PRO . 43.1 t80 65.1 72.2 0.44 Allowed 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.654 0.74 . . . . 2.3599999999999999 110.804 177.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . 0.424 ' O ' ' HA3' ' A' 2080 ' ' GLY . 77.1 t -145.03 117.81 2.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.125 -0.943 . . . . 2.6800000000000002 109.832 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 154.58 48.7 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.038 -1.077 . . . . 3.8399999999999999 113.13 178.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.4 ttpp 55.87 72.56 0.99 Allowed Pre-proline 0 CA--C 1.535 0.367 0 C-N-CA 122.616 0.366 . . . . 6.7800000000000002 111.213 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . 0.465 ' HB3' ' CE1' ' A' 2100 ' ' PHE . 19.2 Cg_endo -58.87 135.6 68.0 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.906 2.404 . . . . 2.4300000000000002 113.299 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.0 t70 -92.88 130.92 34.83 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.616 -0.72 . . . . 2.3300000000000001 109.723 178.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' 2123 ' ' TYR . 30.8 Cg_endo -64.71 106.61 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.634 2.223 . . . . 1.03 112.235 -176.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.1 p -142.94 135.54 25.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.264 0.554 . . . . 0.59999999999999998 111.34 -178.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.607 ' HA ' ' O ' ' A' 2121 ' ' ALA . 88.5 m -111.21 122.85 48.93 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.564 -0.744 . . . . 0.37 109.412 171.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.3 t -95.54 136.73 25.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.929 -0.767 . . . . 0.76000000000000001 108.929 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -141.95 113.58 7.82 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.09 0.774 . . . . 1.6299999999999999 113.09 -171.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.6 ' NH1' HG13 ' A' 2092 ' ' VAL . 23.9 ptt180 -140.69 143.44 35.07 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.26 -0.644 . . . . 3.4700000000000002 109.26 171.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.569 ' O ' HG11 ' A' 2065 ' ' VAL . 34.8 m -98.41 149.95 5.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.238 -0.585 . . . . 0.40000000000000002 111.179 -176.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 25.1 p30 -88.01 -168.93 2.38 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.708 -0.678 . . . . 1.46 110.783 179.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.3 mttt -65.69 -23.59 66.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.716 0.293 . . . . 1.72 111.553 -178.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -82.57 -27.26 31.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.104 0.478 . . . . 1.8400000000000001 110.56 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 108.29 11.53 23.58 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.358 -0.697 . . . . 0.44 111.358 -177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.438 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 61.6 m -90.59 118.96 69.08 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 120.595 0.236 . . . . 0.56999999999999995 110.481 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' 2117 ' ' THR . 10.5 Cg_exo -71.38 119.72 6.46 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.719 2.279 . . . . 0.60999999999999999 113.014 -179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.6 m -84.79 109.39 17.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.326 -0.991 . . . . 0.59999999999999998 108.326 169.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.573 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.6 p -119.58 149.87 41.22 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.125 -0.943 . . . . 0.67000000000000004 111.747 -170.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.607 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.57 126.15 39.71 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.125 -1.065 . . . . 0.72999999999999998 108.125 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 46.5 m -113.57 101.7 9.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.644 -0.502 . . . . 2.1899999999999999 109.644 -177.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.496 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.8 m-85 -97.68 124.95 42.19 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.967 -0.561 . . . . 2.8100000000000001 112.045 -174.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 26.0 m -91.02 150.55 41.98 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 115.105 -0.952 . . . . 2.0600000000000001 110.98 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.46 ' HB3' ' HD3' ' A' 2106 ' ' PRO . 73.5 Cg_endo . . . . . 0 N--CA 1.46 -0.468 0 C-N-CA 122.769 2.313 . . . . 2.1600000000000001 111.863 177.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 16.5 t70 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.532 -0.544 . . . . 2.4199999999999999 109.532 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.0 -18.57 46.25 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.895 2.397 . . . . 1.72 112.706 -176.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.4 mp -87.48 -33.3 19.06 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.377 -0.374 . . . . 2.3399999999999999 110.403 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 2.6 t -135.41 87.38 27.49 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.418 -0.355 . . . . 0.87 110.048 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -38.66 119.71 0.43 Allowed 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 123.411 2.741 . . . . 1.04 112.661 173.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . 0.428 HD11 HG21 ' A' 2119 ' ' VAL . 42.4 mm -56.18 123.66 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.828 -0.623 . . . . 0.77000000000000002 111.477 -176.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.518 ' O ' HG22 ' A' 2065 ' ' VAL . 30.8 t70 -68.01 135.98 53.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.788 -0.642 . . . . 1.4199999999999999 110.502 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -86.62 -6.62 58.81 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.082 -0.508 . . . . 1.55 111.782 -172.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.5 p -111.18 4.01 18.92 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.166 0.432 . . . . 0.68999999999999995 112.166 -177.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.688 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.7 m -86.99 -174.07 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.904 -0.406 . . . . 0.81999999999999995 109.904 174.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -93.57 105.77 17.79 Favored Pre-proline 0 C--O 1.238 0.494 0 CA-C-O 120.974 0.416 . . . . 0.78000000000000003 111.293 176.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.688 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.4 Cg_endo -100.74 108.64 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.548 0 C-N-CA 123.308 2.672 . . . . 0.45000000000000001 110.62 166.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.601 HG22 ' HE2' ' A' 2074 ' ' LYS . 18.5 p -138.75 177.07 8.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.646 0.736 . . . . 0.69999999999999996 111.101 -175.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.472 ' CE1' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-85 -101.55 142.18 33.3 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 107.147 -1.427 . . . . 1.1599999999999999 107.147 165.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -58.78 -19.08 37.59 Favored 'General case' 0 C--N 1.328 -0.329 0 O-C-N 123.849 0.718 . . . . 2.0899999999999999 111.975 -168.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -98.58 8.04 45.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.82 0.343 . . . . 2.1499999999999999 111.038 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.07 17.72 52.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.089 -0.577 . . . . 0.63 113.195 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 32.3 m -93.89 167.55 11.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.916 0.358 . . . . 0.89000000000000001 110.999 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . 0.601 ' HE2' HG22 ' A' 2068 ' ' THR . 34.5 mmtp -127.67 -16.86 4.67 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 116.161 -0.472 . . . . 1.1299999999999999 111.12 178.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.813 ' HG2' HG22 ' A' 2085 ' ' THR . 0.9 OUTLIER -149.72 98.51 2.75 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.761 -0.459 . . . . 2.0800000000000001 109.761 174.239 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 26.1 tptt -92.19 108.35 19.88 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.281 -0.418 . . . . 1.48 110.073 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 86.9 m -107.84 118.13 35.93 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-O 121.408 0.623 . . . . 0.63 110.478 174.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.579 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 72.1 mt -114.02 115.07 45.94 Favored Pre-proline 0 N--CA 1.438 -1.034 0 CA-C-N 114.911 -1.04 . . . . 1.6200000000000001 108.471 175.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -47.84 109.52 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 123.332 2.688 . . . . 0.97999999999999998 113.567 -174.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 90.68 -8.64 79.5 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.923 -0.58 . . . . 0.93999999999999995 112.694 176.258 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.579 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.6 tm0? -100.82 -31.11 11.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.096 0.474 . . . . 2.02 109.829 -176.19 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 129.13 -167.57 21.13 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.818 -0.706 . . . . 0.5 112.492 177.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 55.0 m -149.57 129.89 13.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.507 0.67 . . . . 0.48999999999999999 110.341 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.472 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 2.7 m-85 -101.85 130.42 48.31 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 106.789 -1.559 . . . . 1.4399999999999999 106.789 171.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.813 HG22 ' HG2' ' A' 2075 ' ' GLU . 77.5 p -125.67 137.63 53.87 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.176 -0.61 . . . . 0.63 111.932 -172.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.507 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -130.9 133.36 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-N 115.573 -0.739 . . . . 1.1799999999999999 109.878 173.962 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 24.5 m -116.61 149.17 43.38 Favored Pre-proline 0 C--N 1.32 -0.684 0 N-CA-C 109.143 -0.688 . . . . 0.80000000000000004 109.143 172.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -61.99 -0.75 1.81 Allowed 'Trans proline' 0 N--CA 1.477 0.533 0 C-N-CA 123.633 2.889 . . . . 0.96999999999999997 113.95 -170.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.08 -14.71 62.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.08 0.467 . . . . 2.29 110.064 177.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.14 21.11 18.72 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.868 -0.605 . . . . 0.82999999999999996 112.082 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -120.63 135.97 54.96 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.916 0.389 . . . . 1.51 110.349 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.63 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 5.2 t -136.35 149.44 27.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.922 -0.581 . . . . 1.1799999999999999 110.002 -176.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.9 t -134.96 130.03 35.15 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.273 0.558 . . . . 1.46 110.409 172.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.4 m-30 -93.82 98.78 11.31 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.032 -0.729 . . . . 1.27 109.032 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 21.3 m -117.56 88.7 30.13 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-O 120.919 0.39 . . . . 0.57999999999999996 111.891 -177.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -91.78 161.26 3.42 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 123.213 2.609 . . . . 0.97999999999999998 111.822 171.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . 0.481 ' HB3' ' HB2' ' A' 2100 ' ' PHE . 11.6 t70 -75.41 114.17 13.65 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.613 -0.514 . . . . 2.7200000000000002 109.613 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 2.7 tpmt? -43.56 -53.31 5.7 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 124.059 0.849 . . . . 4.8099999999999996 113.262 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -121.27 37.4 4.34 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 111.88 0.326 . . . . 4.4199999999999999 111.88 -171.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' A' 2097 ' ' ASP . 56.5 t80 -78.59 84.59 4.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.486 0.66 . . . . 2.3599999999999999 110.287 177.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.2 t -93.9 113.22 28.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.627 -0.715 . . . . 2.6800000000000002 110.16 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 179.52 -110.13 0.28 Allowed Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.521 -0.632 . . . . 3.8399999999999999 111.521 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.9 ptpt -135.03 72.97 66.75 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-O 121.207 0.527 . . . . 6.7800000000000002 110.987 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . 0.427 ' HB3' ' HG3' ' A' 2081 ' ' GLN . 23.5 Cg_exo -64.94 144.86 84.25 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.889 2.392 . . . . 2.4300000000000002 111.592 177.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 3.7 m-20 -76.6 142.95 71.16 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.424 -0.353 . . . . 2.3300000000000001 110.481 177.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.632 ' HA ' ' O ' ' A' 2123 ' ' TYR . 71.7 Cg_endo -80.32 132.58 9.25 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 123.086 2.524 . . . . 1.03 113.441 -176.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 9.0 p -161.5 144.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.734 -0.666 . . . . 0.59999999999999998 110.059 177.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' 2121 ' ' ALA . 80.9 m -115.03 126.75 55.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.334 0.588 . . . . 0.37 110.523 175.165 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 1.9 t -98.55 137.7 25.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.535 -0.757 . . . . 0.76000000000000001 109.118 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.588 ' HA ' HG22 ' A' 2120 ' ' THR . 0.6 OUTLIER -133.0 109.57 9.64 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 112.301 0.482 . . . . 1.6299999999999999 112.301 -168.004 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.63 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -143.96 137.27 27.64 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 121.874 -0.517 . . . . 3.4700000000000002 110.473 172.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.422 ' O ' HG21 ' A' 2065 ' ' VAL . 34.1 m -102.03 157.72 4.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.439 -0.346 . . . . 0.40000000000000002 110.884 179.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.686 ' OD2' ' HB ' ' A' 2117 ' ' THR . 40.1 p30 -97.89 -167.97 1.6 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.028 -0.533 . . . . 1.46 110.541 177.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.4 mttt -55.08 -41.5 71.65 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.319 0.489 . . . . 1.72 112.319 -177.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.3 p30 -86.73 -25.42 24.74 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.766 -0.373 . . . . 1.8400000000000001 110.684 -176.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 119.49 15.31 5.48 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.657 -0.783 . . . . 0.44 112.368 178.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.686 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 47.1 m -77.39 115.64 51.06 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-O 120.763 0.316 . . . . 0.56999999999999995 110.237 174.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' 2111 ' ' ARG . 3.0 Cg_endo -82.36 103.93 1.31 Allowed 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.434 2.09 . . . . 0.60999999999999999 112.624 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . 0.558 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.33 108.32 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 N-CA-C 107.839 -1.171 . . . . 0.59999999999999998 107.839 167.856 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.588 HG22 ' HA ' ' A' 2110 ' ' LYS . 69.1 p -126.47 156.53 40.53 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.142 -0.935 . . . . 0.67000000000000004 110.492 -171.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.94 127.1 41.06 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.732 -0.84 . . . . 0.72999999999999998 108.732 172.155 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 57.7 m -115.89 99.75 7.5 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.278 -0.638 . . . . 2.1899999999999999 109.278 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.632 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.7 m-85 -98.67 145.67 26.64 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.422 -0.808 . . . . 2.8100000000000001 111.268 -175.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . 0.512 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 26.5 m -152.97 169.53 9.55 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.67 -0.696 . . . . 2.0600000000000001 109.447 -177.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.512 ' HD2' ' HB3' ' A' 2124 ' ' SER . 82.7 Cg_exo . . . . . 0 C--N 1.354 0.857 0 C-N-CA 122.706 2.271 . . . . 2.1600000000000001 112.912 177.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.455 -0.221 0 CA-C-O 121.17 0.51 . . . . 2.4199999999999999 112.191 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . 0.431 ' HG2' ' HG ' ' A' 2058 ' ' LEU . 36.8 Cg_endo -71.95 -44.43 0.93 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 121.958 1.772 . . . . 1.72 111.471 176.097 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . 0.681 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -83.91 -12.95 54.68 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 114.289 1.218 . . . . 2.3399999999999999 114.289 -176.081 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.681 HG23 HD13 ' A' 2058 ' ' LEU . 0.3 OUTLIER -140.21 82.76 16.44 Favored Pre-proline 0 CA--C 1.508 -0.645 0 C-N-CA 119.739 -0.785 . . . . 0.87 110.929 -176.784 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -52.96 119.09 5.51 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.87 1.713 . . . . 1.04 111.547 179.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . 0.555 HG13 ' NE ' ' A' 2111 ' ' ARG . 39.3 mm -45.51 135.92 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.236 -0.893 . . . . 0.77000000000000002 112.241 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.557 ' O ' HG22 ' A' 2065 ' ' VAL . 13.0 t70 -71.91 141.51 49.49 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.442 -0.799 . . . . 1.4199999999999999 109.953 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -87.01 -7.79 57.79 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.131 0.419 . . . . 1.55 112.131 -172.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 67.2 p -106.81 6.37 29.42 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.702 -0.399 . . . . 0.68999999999999995 111.792 -178.155 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.644 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.4 m -97.84 -174.42 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.81999999999999995 109.997 177.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -97.08 105.07 21.73 Favored Pre-proline 0 C--O 1.239 0.504 0 CA-C-O 120.808 0.337 . . . . 0.78000000000000003 110.998 178.545 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.644 ' HD3' ' O ' ' A' 2065 ' ' VAL . 56.5 Cg_endo -100.34 109.59 0.06 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 123.175 2.584 . . . . 0.45000000000000001 111.154 167.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.428 HG22 ' HE2' ' A' 2074 ' ' LYS . 12.1 p -137.39 178.08 7.37 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.321 0.581 . . . . 0.69999999999999996 111.086 -175.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.503 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -100.81 149.41 23.86 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.02 -1.104 . . . . 1.1599999999999999 108.02 169.157 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -48.31 -44.52 34.0 Favored 'General case' 0 C--N 1.329 -0.283 0 O-C-N 123.509 0.505 . . . . 2.0899999999999999 111.618 -172.403 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -84.16 13.76 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 2.1499999999999999 111.796 -175.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 81.6 26.15 51.55 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 121.017 -0.611 . . . . 0.63 112.706 177.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.32 166.93 11.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.541 0.21 . . . . 0.89000000000000001 110.978 -179.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . 0.428 ' HE2' HG22 ' A' 2068 ' ' THR . 35.4 mmtp -123.21 -26.48 4.31 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.812 0.339 . . . . 1.1299999999999999 111.461 -178.012 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -147.54 135.2 20.98 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 2.0800000000000001 109.497 172.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.1 OUTLIER -127.97 99.6 5.57 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.475 -0.565 . . . . 1.48 109.475 177.349 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.0 m -110.23 114.17 27.44 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 121.139 0.495 . . . . 0.63 110.753 177.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . . . . . . . . . 75.2 mt -121.76 120.07 28.78 Favored Pre-proline 0 C--N 1.315 -0.908 0 N-CA-C 108.343 -0.984 . . . . 1.6200000000000001 108.343 173.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.53 111.47 0.37 Allowed 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 123.251 2.634 . . . . 0.97999999999999998 112.9 -176.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.78 -15.88 37.23 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.616 -0.72 . . . . 0.93999999999999995 112.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.565 ' CD ' ' HA ' ' A' 2104 ' ' PRO . 24.0 mt-30 -97.8 -37.24 9.93 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.981 0.419 . . . . 2.02 110.837 -178.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 118.69 -166.73 12.98 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 111.083 -0.807 . . . . 0.5 111.083 -177.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . . . . . . . . . 62.1 m -129.03 119.31 24.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.856 0.836 . . . . 0.48999999999999999 110.738 174.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.43 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 1.9 m-85 -94.82 122.88 37.9 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 105.854 -1.906 . . . . 1.4399999999999999 105.854 168.004 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.33 143.06 41.86 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.801 0.667 . . . . 0.63 112.801 -168.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -138.88 132.59 40.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.404 -0.816 . . . . 1.1799999999999999 109.559 170.732 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 30.4 m -119.94 150.42 50.79 Favored Pre-proline 0 C--N 1.325 -0.499 0 N-CA-C 109.657 -0.497 . . . . 0.80000000000000004 109.657 173.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -62.38 0.69 1.25 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 123.686 2.924 . . . . 0.96999999999999997 114.215 -170.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -68.33 -18.9 64.61 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.007 0.432 . . . . 2.29 109.876 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 101.92 11.81 36.28 Favored Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.506 -0.77 . . . . 0.82999999999999996 111.767 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.6 t -109.5 136.14 49.38 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.131 0.491 . . . . 1.51 110.419 -178.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' 2086 ' ' ILE . 3.6 t -133.41 149.23 31.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.753 -0.658 . . . . 1.1799999999999999 109.796 -176.554 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -137.76 119.75 15.43 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.147 0.498 . . . . 1.46 111.098 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 16.3 m-30 -94.04 97.27 10.21 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.319 -0.993 . . . . 1.27 108.319 174.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 18.8 m -120.27 87.99 41.01 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 120.772 -0.371 . . . . 0.57999999999999996 111.654 -176.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -91.77 157.51 3.45 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.27 2.646 . . . . 0.97999999999999998 112.582 174.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.1 136.56 56.86 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.066 -0.515 . . . . 2.7200000000000002 110.271 169.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 23.1 tptm -91.86 -30.89 15.93 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.937 -0.574 . . . . 4.8099999999999996 111.875 -177.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -107.8 -47.1 3.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.852 1.056 . . . . 4.4199999999999999 113.852 -165.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.5 122.98 13.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.732 0.777 . . . . 2.3599999999999999 112.279 -169.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.1 t -80.98 143.47 12.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.287 -0.869 . . . . 2.6800000000000002 110.362 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 117.63 -52.49 0.69 Allowed Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 108.823 -1.711 . . . . 3.8399999999999999 108.823 -169.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . 0.467 ' HB2' ' HA ' ' A' 2125 ' ' PRO . 70.1 mmtt 68.69 159.33 0.15 Allowed Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 113.89 1.07 . . . . 6.7800000000000002 113.89 167.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . 0.565 ' HA ' ' CD ' ' A' 2081 ' ' GLN . 62.4 Cg_exo -44.86 144.25 3.74 Favored 'Trans proline' 0 C--N 1.348 0.548 0 C-N-CA 124.371 3.381 . . . . 2.4300000000000002 116.156 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 25.9 t70 -65.77 132.06 94.78 Favored Pre-proline 0 N--CA 1.451 -0.42 0 CA-C-N 114.312 -1.313 . . . . 2.3300000000000001 107.999 164.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.619 ' HA ' ' O ' ' A' 2123 ' ' TYR . 6.5 Cg_endo -47.12 112.86 0.57 Allowed 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 124.196 3.264 . . . . 1.03 114.595 -170.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 6.0 p -150.15 123.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.34 -0.845 . . . . 0.59999999999999998 110.087 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.6 m -100.62 133.99 44.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.131 -0.486 . . . . 0.37 110.609 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.9 t -110.14 147.77 14.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.465 -0.568 . . . . 0.76000000000000001 109.465 177.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' 2110 ' ' LYS . 18.5 ttpt -143.78 109.48 5.2 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.135 0.421 . . . . 1.6299999999999999 112.135 -174.01 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.555 ' NE ' HG13 ' A' 2061 ' ' ILE . 18.2 ptt180 -131.52 136.3 47.76 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.119 -0.697 . . . . 3.4700000000000002 109.119 174.028 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' 2065 ' ' VAL . 34.4 m -98.94 145.13 10.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.431 -0.508 . . . . 0.40000000000000002 111.014 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -91.94 -168.86 2.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.073 -0.512 . . . . 1.46 110.723 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 68.4 mttm -65.77 -28.81 69.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 1.72 111.557 -178.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . 0.443 HD22 HG11 ' A' 2059 ' ' VAL . 42.4 m-80 -74.26 -20.75 60.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.176 0.512 . . . . 1.8400000000000001 110.081 174.103 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 94.43 9.8 58.7 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.682 -0.69 . . . . 0.44 111.851 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . . . . . . . . . 30.5 m -82.04 120.06 76.52 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 110.012 -0.366 . . . . 0.56999999999999995 110.012 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -72.93 106.29 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.441 2.094 . . . . 0.60999999999999999 112.528 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 35.3 m -77.48 108.73 11.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.008 -1.108 . . . . 0.59999999999999998 108.008 171.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.4 p -119.98 145.01 47.19 Favored 'General case' 0 N--CA 1.438 -1.031 0 CA-C-N 114.537 -1.21 . . . . 0.67000000000000004 110.573 -172.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.48 126.41 40.42 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.581 -0.736 . . . . 0.72999999999999998 109.265 175.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 35.0 p -100.33 97.76 8.48 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.874 -0.788 . . . . 2.1899999999999999 108.874 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.619 ' O ' ' HA ' ' A' 2106 ' ' PRO . 24.3 m-85 -89.69 99.75 12.69 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-O 121.493 0.663 . . . . 2.8100000000000001 111.666 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 7.9 p -148.86 170.12 8.13 Favored Pre-proline 0 N--CA 1.435 -1.192 0 CA-C-N 114.456 -1.247 . . . . 2.0600000000000001 109.441 178.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.467 ' HA ' ' HB2' ' A' 2103 ' ' LYS . 51.0 Cg_exo . . . . . 0 C--N 1.349 0.565 0 C-N-CA 122.447 2.098 . . . . 2.1600000000000001 111.811 175.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 120.94 0.4 . . . . 2.4199999999999999 110.647 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -47.19 11.55 Favored 'Trans proline' 0 N--CA 1.473 0.304 0 C-N-CA 123.317 2.678 . . . . 1.72 112.559 -179.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . 0.608 HD13 HG23 ' A' 2059 ' ' VAL . 0.1 OUTLIER -61.41 -20.33 62.93 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 115.358 -0.837 . . . . 2.3399999999999999 113.24 177.281 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.608 HG23 HD13 ' A' 2058 ' ' LEU . 6.1 t -130.11 86.72 53.44 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.124 -0.324 . . . . 0.87 110.124 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.01 126.37 20.87 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.396 2.064 . . . . 1.04 111.955 -177.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 37.9 mm -59.54 132.97 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.819 -0.628 . . . . 0.77000000000000002 110.374 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.581 ' O ' HG22 ' A' 2065 ' ' VAL . 13.8 t70 -78.17 138.15 38.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.145 -0.48 . . . . 1.4199999999999999 110.635 -176.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . 0.405 ' O ' ' HA3' ' A' 2090 ' ' GLY . 41.8 mt-10 -93.66 -0.43 56.09 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.184 -0.462 . . . . 1.55 111.877 -172.284 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.5 p -108.29 -1.83 19.76 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.78 -0.368 . . . . 0.68999999999999995 111.164 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' 2062 ' ' ASP . 32.8 m -89.87 -176.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.441 -0.345 . . . . 0.81999999999999995 110.172 178.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -93.47 111.65 53.16 Favored Pre-proline 0 C--O 1.238 0.485 0 CA-C-O 121.08 0.467 . . . . 0.78000000000000003 111.451 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.556 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -100.88 107.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.523 0 C-N-CA 123.025 2.483 . . . . 0.45000000000000001 111.327 167.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.503 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.2 p -145.68 146.51 31.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.853 0.358 . . . . 0.69999999999999996 110.522 -177.703 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.52 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.9 OUTLIER -71.61 148.23 46.78 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.942 -1.133 . . . . 1.1599999999999999 107.942 177.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -52.93 -37.42 60.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 118.412 0.551 . . . . 2.0899999999999999 111.297 -171.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 29.1 t70 -67.73 -11.66 58.86 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.679 -0.691 . . . . 2.1499999999999999 111.928 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 91.06 29.85 12.04 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.848 -0.691 . . . . 0.63 112.012 -176.179 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.6 p -110.08 161.68 15.3 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.887 0.375 . . . . 0.89000000000000001 111.22 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . 0.4 ' O ' HG22 ' A' 2086 ' ' ILE . 35.4 mmtp -110.94 -21.07 12.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.898 -0.592 . . . . 1.1299999999999999 110.985 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.709 ' HG2' HG22 ' A' 2085 ' ' THR . 3.9 mt-10 -147.57 142.21 26.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.268 -0.424 . . . . 2.0800000000000001 110.141 176.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD3' ' C ' ' A' 2076 ' ' LYS . 1.7 tmtp? -141.24 119.72 12.34 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.09 -0.707 . . . . 1.48 109.09 177.385 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . 0.402 ' N ' ' HD3' ' A' 2076 ' ' LYS . 34.5 m -123.45 125.09 44.31 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.425 0.631 . . . . 0.63 111.356 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.494 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 93.8 mt -125.46 120.98 24.8 Favored Pre-proline 0 C--N 1.316 -0.863 0 N-CA-C 108.536 -0.913 . . . . 1.6200000000000001 108.536 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -47.51 110.65 0.32 Allowed 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 123.203 2.602 . . . . 0.97999999999999998 112.956 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 101.25 -21.45 43.06 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.74 -0.664 . . . . 0.93999999999999995 112.63 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.494 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.2 tt0 -93.3 -31.74 14.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.105 0.478 . . . . 2.02 110.678 -175.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.98 -178.42 16.88 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.797 -0.716 . . . . 0.5 112.24 177.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.409 HG22 HG23 ' A' 2085 ' ' THR . 45.7 m -128.07 141.95 51.35 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.483 0.659 . . . . 0.48999999999999999 110.103 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.481 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.9 m-85 -113.87 122.56 47.39 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.343 -1.354 . . . . 1.4399999999999999 107.343 173.25 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.709 HG22 ' HG2' ' A' 2075 ' ' GLU . 30.5 p -122.93 129.79 52.03 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.19 0.441 . . . . 0.63 112.19 -173.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.514 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.5 129.71 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.817 -0.629 . . . . 1.1799999999999999 109.923 170.74 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.7 m -110.1 148.73 38.91 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 115.644 -0.707 . . . . 0.80000000000000004 109.501 175.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -61.67 0.17 1.24 Allowed 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.679 2.919 . . . . 0.96999999999999997 113.755 -173.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . 0.43 ' HB2' HG22 ' A' 2091 ' ' THR . 5.1 m-20 -70.25 -13.64 62.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.124 0.488 . . . . 2.29 109.859 174.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' 2063 ' ' GLU . . . 95.5 14.06 48.9 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.71 -0.677 . . . . 0.82999999999999996 111.744 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . 0.43 HG22 ' HB2' ' A' 2089 ' ' ASP . 10.2 t -119.83 139.24 52.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.06 0.457 . . . . 1.51 110.279 -177.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.514 HG22 ' CG1' ' A' 2086 ' ' ILE . 9.6 t -134.83 153.44 34.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.899 -0.592 . . . . 1.1799999999999999 109.968 -175.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.9 t -131.92 122.31 25.43 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.261 0.553 . . . . 1.46 110.044 171.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . 0.434 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.1 m-30 -90.15 98.45 11.78 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.343 -0.984 . . . . 1.27 108.343 175.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 28.5 m -113.93 89.64 17.05 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.123 0.487 . . . . 0.57999999999999996 111.467 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' 2094 ' ' PHE . 85.2 Cg_endo -90.56 149.04 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.008 2.472 . . . . 0.97999999999999998 111.55 174.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.61 126.02 30.17 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.922 0.391 . . . . 2.7200000000000002 110.012 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -84.01 -10.63 57.74 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.153 -0.476 . . . . 4.8099999999999996 112.067 -174.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -115.27 13.21 16.63 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.572 -0.451 . . . . 4.4199999999999999 111.247 -175.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 42.5 t80 -77.65 110.89 12.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.004 0.431 . . . . 2.3599999999999999 111.039 -178.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 47.0 t -111.99 98.59 7.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.327 -0.62 . . . . 2.6800000000000002 109.327 174.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -178.2 -142.32 4.64 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.972 -0.632 . . . . 3.8399999999999999 111.65 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . 0.41 ' HG3' ' O ' ' A' 2103 ' ' LYS . 24.2 pttm -113.91 101.94 54.36 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-O 121.203 0.525 . . . . 6.7800000000000002 111.287 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 10.5 Cg_exo -71.86 147.18 49.44 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.62 2.213 . . . . 2.4300000000000002 111.159 174.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.447 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.9 t70 -95.77 132.29 27.55 Favored Pre-proline 0 C--N 1.322 -0.61 0 N-CA-C 109.802 -0.444 . . . . 2.3300000000000001 109.802 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.571 ' HA ' ' O ' ' A' 2123 ' ' TYR . 15.7 Cg_endo -57.17 113.31 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 123.515 2.81 . . . . 1.03 114.128 -173.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.7 p -147.19 141.81 20.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.362 -0.836 . . . . 0.59999999999999998 109.525 174.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 18.0 m -115.92 113.71 23.67 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.139 0.495 . . . . 0.37 110.276 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.2 t -92.24 132.23 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.058 -0.719 . . . . 0.76000000000000001 109.058 -179.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.503 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.0 tmmm? -133.45 145.88 50.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.227 0.537 . . . . 1.6299999999999999 111.664 -170.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.475 ' N ' ' HD2' ' A' 2110 ' ' LYS . 32.2 ptt180 -164.57 137.86 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.543 -0.91 . . . . 3.4700000000000002 108.543 169.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.428 ' O ' HG21 ' A' 2065 ' ' VAL . 33.8 m -98.82 148.98 5.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.213 -0.595 . . . . 0.40000000000000002 111.52 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.603 ' OD1' ' HB ' ' A' 2117 ' ' THR . 8.5 p30 -88.91 -168.53 2.21 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.403 -0.817 . . . . 1.46 111.341 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.0 mttm -64.88 -34.25 77.95 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.561 0.578 . . . . 1.72 112.561 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.6 p30 -84.55 -22.92 29.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 119.685 -0.806 . . . . 1.8400000000000001 110.515 177.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 116.67 12.09 8.92 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.809 -0.71 . . . . 0.44 112.958 173.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.603 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 86.5 m -83.27 125.64 73.89 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 117.221 0.511 . . . . 0.56999999999999995 110.005 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' 2117 ' ' THR . 1.8 Cg_endo -81.36 111.46 2.37 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.451 2.101 . . . . 0.60999999999999999 112.987 -178.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 11.6 m -75.94 127.0 37.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.357 -0.979 . . . . 0.59999999999999998 108.357 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' 2109 ' ' VAL . 39.9 p -130.89 166.42 20.95 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 115.699 -0.682 . . . . 0.67000000000000004 111.332 -170.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -127.56 126.75 42.7 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 107.677 -1.231 . . . . 0.72999999999999998 107.677 169.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 3.5 m -110.08 99.42 8.51 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.324 -0.398 . . . . 2.1899999999999999 110.582 -172.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.571 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.2 m-85 -104.74 151.69 23.44 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 121.252 0.549 . . . . 2.8100000000000001 111.577 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 6.6 p -168.62 170.97 3.86 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 114.778 -1.101 . . . . 2.0600000000000001 108.33 -173.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo . . . . . 0 C--N 1.351 0.68 0 C-N-CA 122.712 2.275 . . . . 2.1600000000000001 112.185 177.098 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 C--O 1.226 -0.167 0 CA-C-O 120.831 0.348 . . . . 2.4199999999999999 110.733 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -64.95 -56.01 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.887 2.391 . . . . 1.72 112.064 177.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . 0.697 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -63.81 -12.46 35.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.43 -0.804 . . . . 2.3399999999999999 113.167 177.498 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.697 HG23 HD13 ' A' 2058 ' ' LEU . 21.5 t -136.77 86.06 22.72 Favored Pre-proline 0 C--N 1.322 -0.615 0 N-CA-C 109.814 -0.439 . . . . 0.87 109.814 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.63 137.82 83.1 Favored 'Trans proline' 0 C--O 1.235 0.363 0 C-N-CA 122.629 2.219 . . . . 1.04 112.3 -176.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.9 mm -65.27 136.46 26.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.672 -0.694 . . . . 0.77000000000000002 110.313 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 35.5 t70 -82.77 134.42 35.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.301 0.572 . . . . 1.4199999999999999 111.038 -175.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -87.32 -8.47 56.66 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.661 -0.7 . . . . 1.55 111.588 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 76.5 p -104.49 7.88 35.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.971 0.415 . . . . 0.68999999999999995 111.557 -178.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.554 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.1 m -110.23 -177.83 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.447 -0.575 . . . . 0.81999999999999995 109.447 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -94.88 110.9 52.3 Favored Pre-proline 0 C--O 1.243 0.729 0 CA-C-O 121.092 0.472 . . . . 0.78000000000000003 110.984 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' 2065 ' ' VAL . 43.4 Cg_endo -100.98 106.8 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.62 0 C-N-CA 123.077 2.518 . . . . 0.45000000000000001 111.688 169.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.0 p -142.87 -177.93 5.57 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.177 0.513 . . . . 0.69999999999999996 110.907 -176.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.562 ' CE2' ' HB2' ' A' 2084 ' ' TYR . 93.9 m-85 -101.51 164.97 11.49 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 108.731 -0.84 . . . . 1.1599999999999999 108.731 170.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -53.76 -33.23 55.13 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-N 118.004 0.365 . . . . 2.0899999999999999 111.687 -172.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -86.61 12.65 10.09 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 111.872 0.323 . . . . 2.1499999999999999 111.872 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 17.91 79.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 121.053 -0.594 . . . . 0.63 111.944 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.2 m -78.6 164.23 24.84 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.743 0.306 . . . . 0.89000000000000001 111.097 -173.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -115.5 -18.34 10.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.219 0.533 . . . . 1.1299999999999999 110.425 178.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -147.32 140.64 25.34 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.316 -0.624 . . . . 2.0800000000000001 109.316 173.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' 2083 ' ' THR . 27.1 tptt -127.97 116.17 19.65 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.939 -0.393 . . . . 1.48 109.939 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 59.3 m -113.6 132.99 55.54 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.294 0.569 . . . . 0.63 110.957 176.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.573 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 36.0 mt -134.63 121.2 14.91 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.102 -0.954 . . . . 1.6200000000000001 108.859 178.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -51.04 108.97 0.26 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.231 2.621 . . . . 0.97999999999999998 113.186 -175.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 95.2 -11.15 69.42 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.908 -0.663 . . . . 0.93999999999999995 112.75 176.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.573 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.5 tt0 -103.57 -26.51 12.79 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.262 0.554 . . . . 2.02 109.957 -176.246 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.29 -156.08 15.89 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.405 -0.816 . . . . 0.5 112.538 175.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.469 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -144.69 137.3 26.48 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.714 0.769 . . . . 0.48999999999999999 110.729 177.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 5.7 m-85 -108.38 126.27 52.68 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.114 -1.439 . . . . 1.4399999999999999 107.114 171.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . 0.467 HG23 HG22 ' A' 2083 ' ' THR . 0.9 OUTLIER -128.15 147.12 50.54 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 112.826 0.676 . . . . 0.63 112.826 -172.221 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.541 ' CB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -141.8 127.1 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 115.248 -0.887 . . . . 1.1799999999999999 109.807 172.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -102.62 148.28 35.27 Favored Pre-proline 0 C--N 1.321 -0.643 0 N-CA-C 109.144 -0.687 . . . . 0.80000000000000004 109.144 173.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -61.18 0.24 1.02 Allowed 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.712 2.942 . . . . 0.96999999999999997 114.32 -171.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -71.74 -20.42 61.9 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.758 -0.46 . . . . 2.29 109.758 175.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 105.34 17.44 13.76 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.997 -0.62 . . . . 0.82999999999999996 112.289 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.2 t -112.71 135.76 53.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.13 0.49 . . . . 1.51 110.481 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 6.7 t -129.46 152.35 37.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.958 -0.565 . . . . 1.1799999999999999 111.033 -172.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 8.9 t -141.76 123.55 15.23 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.416 0.627 . . . . 1.46 110.267 172.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . 0.559 ' CE2' HG11 ' A' 2109 ' ' VAL . 19.3 m-30 -98.55 98.91 10.03 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.522 -0.918 . . . . 1.27 108.522 177.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 10.1 m -116.43 87.99 22.29 Favored Pre-proline 0 N--CA 1.454 -0.264 0 C-N-CA 120.238 -0.585 . . . . 0.57999999999999996 111.341 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' 2094 ' ' PHE . 18.2 Cg_endo -92.55 143.55 2.44 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.516 2.811 . . . . 0.97999999999999998 112.166 173.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 52.7 t0 -88.63 92.52 9.23 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.264 -0.643 . . . . 2.7200000000000002 109.264 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -75.59 -1.48 24.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.031 -0.531 . . . . 4.8099999999999996 111.247 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.3 mt-30 -81.95 -16.38 50.64 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.125 -0.694 . . . . 4.4199999999999999 109.125 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 78.2 t80 -99.99 110.51 22.84 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.072 -0.967 . . . . 2.3599999999999999 109.673 177.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.6 p -144.24 100.75 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.944 0.878 . . . . 2.6800000000000002 111.452 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -151.73 -77.64 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 110.437 -1.065 . . . . 3.8399999999999999 110.437 175.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 57.8 pttt -129.31 71.73 82.02 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-O 120.982 0.42 . . . . 6.7800000000000002 110.896 173.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.88 148.84 91.14 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.407 2.071 . . . . 2.4300000000000002 111.027 175.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.538 ' HB3' HD13 ' A' 2078 ' ' ILE . 16.4 t70 -75.65 132.99 74.11 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 109.582 -0.525 . . . . 2.3300000000000001 109.582 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.603 ' HA ' ' O ' ' A' 2123 ' ' TYR . 33.5 Cg_endo -65.24 106.06 0.78 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.024 2.482 . . . . 1.03 112.645 -176.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . 0.44 HG21 ' HG2' ' A' 2076 ' ' LYS . 9.5 p -147.42 134.31 13.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.645 -0.707 . . . . 0.59999999999999998 110.501 177.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.4 m -109.75 128.23 55.15 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 115.88 -0.6 . . . . 0.37 110.065 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' 2120 ' ' THR . 13.0 t -91.42 117.99 35.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 108.697 -0.853 . . . . 0.76000000000000001 108.697 176.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.418 ' HA ' HG22 ' A' 2120 ' ' THR . 0.2 OUTLIER -125.47 108.49 11.69 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.633 -0.427 . . . . 1.6299999999999999 110.918 -172.532 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.541 HH12 ' CB ' ' A' 2086 ' ' ILE . 12.7 ptp180 -155.18 157.46 37.41 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.776 -0.453 . . . . 3.4700000000000002 109.776 175.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.3 m -112.04 149.39 14.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.377 -0.529 . . . . 0.40000000000000002 111.69 -177.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.615 ' OD2' ' HB ' ' A' 2117 ' ' THR . 5.0 p30 -91.73 -169.33 2.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.632 -0.713 . . . . 1.46 110.756 177.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.8 mttm -62.99 -31.95 73.19 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.014 0.376 . . . . 1.72 112.014 -178.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -78.43 -18.62 54.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.083 0.468 . . . . 1.8400000000000001 110.122 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 99.61 10.57 46.82 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.563 -0.744 . . . . 0.44 111.304 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.615 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 62.2 m -81.9 125.89 76.53 Favored Pre-proline 0 N--CA 1.448 -0.542 0 CA-C-O 120.515 0.197 . . . . 0.56999999999999995 110.487 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' 2111 ' ' ARG . 11.9 Cg_exo -70.35 101.43 0.99 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.468 2.112 . . . . 0.60999999999999999 112.589 177.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . 0.449 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 23.7 m -75.37 108.63 7.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.374 -0.973 . . . . 0.59999999999999998 108.374 169.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.635 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.6 p -126.63 154.4 44.04 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.189 -0.914 . . . . 0.67000000000000004 111.196 -171.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.59 127.77 42.92 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.282 -1.007 . . . . 0.72999999999999998 108.282 170.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 29.6 p -105.12 99.63 9.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.095 0.474 . . . . 2.1899999999999999 110.172 -177.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.603 ' O ' ' HA ' ' A' 2106 ' ' PRO . 10.6 m-85 -113.38 134.42 54.65 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.966 -0.561 . . . . 2.8100000000000001 111.225 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . 0.43 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 26.3 p -160.08 161.19 26.38 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 115.602 -0.726 . . . . 2.0600000000000001 109.935 -175.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' 2124 ' ' SER . 57.3 Cg_endo . . . . . 0 C--N 1.351 0.661 0 C-N-CA 122.956 2.438 . . . . 2.1600000000000001 113.011 -177.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 1.8 t70 . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.211 -0.663 . . . . 2.4199999999999999 109.211 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -44.25 -55.08 3.4 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 123.296 2.664 . . . . 1.72 113.231 -175.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . 0.641 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -101.16 2.07 39.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.014 0.435 . . . . 2.3399999999999999 112.085 -177.909 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . 0.641 HG23 HD13 ' A' 2058 ' ' LEU . 2.1 t -131.65 78.42 70.88 Favored Pre-proline 0 C--N 1.327 -0.386 0 N-CA-C 110.091 -0.337 . . . . 0.87 110.091 178.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.42 140.03 92.35 Favored 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.182 1.921 . . . . 1.04 111.349 176.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.3 mm -61.06 130.97 25.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.856 -0.611 . . . . 0.77000000000000002 111.404 -178.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.603 ' O ' HG22 ' A' 2065 ' ' VAL . 12.5 t70 -73.67 140.36 46.03 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.393 -0.821 . . . . 1.4199999999999999 109.867 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -86.83 -10.47 53.39 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 111.914 0.338 . . . . 1.55 111.914 -171.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 39.7 p -109.24 10.12 25.8 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.755 0.312 . . . . 0.68999999999999995 111.817 -177.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.617 ' O ' ' HD3' ' A' 2067 ' ' PRO . 35.8 m -91.66 -174.94 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 110.059 -0.348 . . . . 0.81999999999999995 110.059 175.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -97.0 105.05 21.24 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.551 -0.295 . . . . 0.78000000000000003 110.775 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -99.91 106.48 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.603 0 C-N-CA 122.562 2.175 . . . . 0.45000000000000001 110.92 168.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.517 ' O ' ' HB3' ' A' 2110 ' ' LYS . 40.7 p -145.35 147.66 32.54 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.104 -0.498 . . . . 0.69999999999999996 110.09 -176.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.538 ' HD2' ' N ' ' A' 2069 ' ' PHE . 1.2 m-30 -72.62 153.75 41.09 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.5 -0.926 . . . . 1.1599999999999999 108.5 178.235 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -50.55 -43.51 56.22 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.958 0.409 . . . . 2.0899999999999999 111.139 -173.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 38.1 t70 -77.43 2.58 15.64 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 115.671 -0.695 . . . . 2.1499999999999999 111.587 -177.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 86.28 29.98 23.57 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.162 -0.542 . . . . 0.63 112.558 179.367 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 12.5 m -101.24 162.47 12.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.788 0.328 . . . . 0.89000000000000001 110.941 -176.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -115.83 -19.62 10.37 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.092 -0.504 . . . . 1.1299999999999999 110.87 178.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' 2084 ' ' TYR . 7.2 tt0 -156.0 125.88 6.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.999 -0.546 . . . . 2.0800000000000001 109.737 172.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' 2083 ' ' THR . 32.1 tptt -117.33 118.89 33.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.655 -0.702 . . . . 1.48 109.411 178.353 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.4 m -111.85 113.73 26.24 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.482 0.658 . . . . 0.63 110.882 176.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 67.0 mt -110.18 113.9 56.23 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.302 -0.999 . . . . 1.6200000000000001 108.302 174.364 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -47.41 109.4 0.22 Allowed 'Trans proline' 0 N--CA 1.474 0.324 0 C-N-CA 123.49 2.793 . . . . 0.97999999999999998 113.879 -171.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 89.42 -11.56 69.49 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.814 -0.63 . . . . 0.93999999999999995 112.73 176.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.54 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.5 tm0? -98.22 -28.45 13.7 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.059 0.456 . . . . 2.02 110.008 -175.098 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 130.37 -173.8 19.88 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.712 -0.756 . . . . 0.5 112.765 173.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -147.79 138.96 23.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.71 0.767 . . . . 0.48999999999999999 110.436 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.536 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.2 OUTLIER -114.14 131.4 56.44 Favored 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 107.261 -1.385 . . . . 1.4399999999999999 107.261 175.382 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 23.7 p -127.84 128.72 45.72 Favored 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 120.527 -0.469 . . . . 0.63 112.173 -174.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.539 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -116.96 129.66 73.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.579 -0.737 . . . . 1.1799999999999999 109.753 170.727 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . 0.426 ' CG2' HG23 ' A' 2091 ' ' THR . 27.5 m -118.45 145.37 37.18 Favored Pre-proline 0 C--N 1.319 -0.734 0 CA-C-N 115.968 -0.56 . . . . 0.80000000000000004 109.534 173.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -59.76 -5.33 3.43 Favored 'Trans proline' 0 N--CA 1.477 0.548 0 C-N-CA 123.85 3.033 . . . . 0.96999999999999997 114.682 -168.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 28.5 t70 -68.82 -21.35 64.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.276 0.56 . . . . 2.29 109.81 176.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.24 7.86 26.08 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.899 -0.667 . . . . 0.82999999999999996 112.077 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . 0.426 HG23 ' CG2' ' A' 2087 ' ' VAL . 1.6 t -107.21 124.44 49.74 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.34 0.591 . . . . 1.51 110.559 -179.139 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.634 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 10.1 t -129.49 138.48 54.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.351 -0.841 . . . . 1.1799999999999999 109.716 -178.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.8 t -123.05 115.29 21.6 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.456 0.646 . . . . 1.46 110.571 175.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . 0.485 ' O ' ' HD3' ' A' 2096 ' ' PRO . 14.2 m-30 -85.8 98.47 10.76 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.648 -0.871 . . . . 1.27 108.648 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 7.5 m -113.28 88.08 12.14 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.968 0.414 . . . . 0.57999999999999996 111.302 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' 2094 ' ' PHE . 96.8 Cg_endo -92.63 145.44 2.59 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.294 2.663 . . . . 0.97999999999999998 112.683 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.46 102.69 11.28 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.19 -0.67 . . . . 2.7200000000000002 109.19 170.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . 0.682 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -87.08 10.89 15.19 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.763 -0.653 . . . . 4.8099999999999996 111.371 -175.036 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 -106.44 8.85 31.74 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.193 0.521 . . . . 4.4199999999999999 109.83 177.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 64.9 t80 -79.58 80.59 5.95 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.52 -0.764 . . . . 2.3599999999999999 109.666 174.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 16.6 t -85.13 98.24 6.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.079 -0.51 . . . . 2.6800000000000002 109.78 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.3 48.98 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.639 -0.71 . . . . 3.8399999999999999 111.436 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 1.2 mptm? 59.27 73.76 0.65 Allowed Pre-proline 0 CA--C 1.532 0.26 0 C-N-CA 122.895 0.478 . . . . 6.7800000000000002 111.418 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.04 131.89 41.69 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.456 2.104 . . . . 2.4300000000000002 111.115 175.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.482 ' HB3' HD13 ' A' 2078 ' ' ILE . 35.6 t70 -68.99 131.23 90.96 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-N 116.098 -0.501 . . . . 2.3300000000000001 110.373 -178.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.54 131.98 18.27 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 123.083 2.522 . . . . 1.03 113.616 -177.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 14.7 p -161.26 144.03 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.372 -0.831 . . . . 0.59999999999999998 109.644 174.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' 2121 ' ' ALA . 42.9 m -109.79 125.5 52.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.433 0.635 . . . . 0.37 110.744 177.206 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -102.56 138.91 25.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.46 -0.791 . . . . 0.76000000000000001 108.946 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . 0.536 ' HG2' ' N ' ' A' 2111 ' ' ARG . 23.5 ttpt -139.68 153.43 47.27 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.296 0.498 . . . . 1.6299999999999999 112.297 -172.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.634 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 31.7 ptt180 -175.38 142.76 0.61 Allowed 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 108.447 -0.945 . . . . 3.4700000000000002 108.447 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . 0.485 ' O ' HG21 ' A' 2065 ' ' VAL . 33.7 m -99.22 150.21 5.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.297 -178.088 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.677 ' OD1' ' HB ' ' A' 2117 ' ' THR . 7.1 p30 -91.32 -169.31 2.29 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.72 -0.673 . . . . 1.46 111.22 179.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 97.5 mttt -58.93 -38.04 78.08 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.354 -0.385 . . . . 1.72 111.64 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -78.72 -30.27 45.82 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.256 0.551 . . . . 1.8400000000000001 109.79 -177.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 115.74 17.85 6.29 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.268 -0.878 . . . . 0.44 112.055 178.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.677 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.3 m -88.15 119.21 70.28 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 110.167 -0.309 . . . . 0.56999999999999995 110.167 178.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' 2111 ' ' ARG . 8.7 Cg_exo -71.89 104.12 1.58 Allowed 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.365 2.044 . . . . 0.60999999999999999 112.173 177.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 15.4 m -75.08 113.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 108.254 -1.017 . . . . 0.59999999999999998 108.254 170.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' 2109 ' ' VAL . 60.6 p -120.93 161.23 21.94 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.467 -0.788 . . . . 0.67000000000000004 111.391 -172.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.36 127.04 41.89 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 107.601 -1.259 . . . . 0.72999999999999998 107.601 168.334 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.5 m -115.78 100.65 8.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.285 0.564 . . . . 2.1899999999999999 110.696 -172.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -89.83 131.7 35.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.827 -0.624 . . . . 2.8100000000000001 110.306 176.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . . . . . . . . . 13.4 m -124.01 166.26 20.04 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.716 -0.675 . . . . 2.0600000000000001 109.486 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 70.1 Cg_exo . . . . . 0 C--O 1.236 0.414 0 C-N-CA 122.466 2.111 . . . . 2.1600000000000001 112.251 177.109 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.519 -0.221 0 CA-C-O 120.636 0.255 . . . . 2.4199999999999999 111.087 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -73.56 -14.83 24.8 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.176 1.918 . . . . 1.72 111.313 176.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.47 -41.13 61.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.629 -0.714 . . . . 2.3399999999999999 110.04 177.314 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 1.8 t -126.4 98.77 31.6 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.711 -0.477 . . . . 0.87 109.711 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.69 131.62 41.05 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.171 1.914 . . . . 1.04 111.842 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 49.8 mm -55.67 129.68 17.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 CA-C-N 115.68 -0.691 . . . . 0.77000000000000002 110.622 -178.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2062 ' ' ASP . . . . . 0.602 ' O ' HG22 ' A' 2065 ' ' VAL . 11.3 t70 -75.62 139.62 42.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.983 0.42 . . . . 1.4199999999999999 110.232 -177.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -89.71 -4.75 57.57 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.149 0.425 . . . . 1.55 112.149 -171.492 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2064 ' ' THR . . . . . . . . . . . . . 81.8 p -99.33 -13.61 19.55 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.527 -0.469 . . . . 0.68999999999999995 111.238 178.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2065 ' ' VAL . . . . . 0.643 ' O ' ' HD3' ' A' 2067 ' ' PRO . 31.4 m -79.92 -174.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.891 -0.411 . . . . 0.81999999999999995 109.891 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -95.33 109.55 45.73 Favored Pre-proline 0 C--O 1.238 0.447 0 CA-C-O 121.078 0.466 . . . . 0.78000000000000003 111.63 -179.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2067 ' ' PRO . . . . . 0.643 ' HD3' ' O ' ' A' 2065 ' ' VAL . 65.4 Cg_endo -100.77 123.23 0.11 Allowed 'Trans proline' 0 N--CA 1.441 -1.605 0 C-N-CA 123.46 2.774 . . . . 0.45000000000000001 110.851 165.384 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2068 ' ' THR . . . . . 0.492 HG22 ' HE3' ' A' 2074 ' ' LYS . 3.6 p -153.28 -179.23 7.54 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.69999999999999996 110.601 -178.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2069 ' ' PHE . . . . . 0.625 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 8.5 m-30 -102.43 154.63 18.9 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 107.405 -1.332 . . . . 1.1599999999999999 107.405 163.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -54.45 -35.84 63.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 118.65 0.659 . . . . 2.0899999999999999 111.748 -171.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -78.35 4.9 11.73 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.235 0.457 . . . . 2.1499999999999999 112.235 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 80.48 24.95 57.91 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.127 -0.558 . . . . 0.63 111.903 -177.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2073 ' ' SER . . . . . . . . . . . . . 14.7 m -94.07 156.46 16.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.629 0.252 . . . . 0.89000000000000001 110.797 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2074 ' ' LYS . . . . . 0.492 ' HE3' HG22 ' A' 2068 ' ' THR . 0.1 OUTLIER -120.79 5.18 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.25 0.548 . . . . 1.1299999999999999 110.913 179.768 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.58 140.75 4.98 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.123 -0.695 . . . . 2.0800000000000001 109.123 170.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2076 ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' 2083 ' ' THR . 16.5 tptt -138.88 104.0 4.95 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.273 -0.421 . . . . 1.48 110.065 174.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2077 ' ' THR . . . . . . . . . . . . . 49.0 m -101.51 118.03 36.13 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.123 0.487 . . . . 0.63 110.273 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2078 ' ' ILE . . . . . 0.563 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 75.5 mt -117.16 119.89 34.29 Favored Pre-proline 0 C--N 1.315 -0.925 0 N-CA-C 108.407 -0.96 . . . . 1.6200000000000001 108.407 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -47.11 109.87 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.486 2.791 . . . . 0.97999999999999998 113.496 -174.102 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.42 -12.76 68.95 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.81 -0.632 . . . . 0.93999999999999995 112.677 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2081 ' ' GLN . . . . . 0.563 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.9 tt0 -101.13 -26.28 13.73 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.164 0.507 . . . . 2.02 110.183 -177.354 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 112.85 -163.95 12.1 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.539 -0.838 . . . . 0.5 112.782 173.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2083 ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' 2076 ' ' LYS . 28.1 m -137.14 145.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 121.808 0.814 . . . . 0.48999999999999999 110.553 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2084 ' ' TYR . . . . . 0.625 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 12.8 m-85 -107.13 112.48 25.41 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 106.892 -1.522 . . . . 1.4399999999999999 106.892 166.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2085 ' ' THR . . . . . . . . . . . . . 25.3 p -104.99 134.76 47.55 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.745 -0.382 . . . . 0.63 111.563 -173.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2086 ' ' ILE . . . . . 0.599 ' HA ' ' O ' ' A' 2091 ' ' THR . 1.6 tt -151.19 130.55 3.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.799 -0.637 . . . . 1.1799999999999999 111.422 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2087 ' ' VAL . . . . . 0.59 HG22 ' OG1' ' A' 2091 ' ' THR . 18.6 m -115.1 157.75 42.74 Favored Pre-proline 0 C--N 1.328 -0.343 0 N-CA-C 109.565 -0.531 . . . . 0.80000000000000004 109.565 175.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.17 -0.54 2.28 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 123.69 2.926 . . . . 0.96999999999999997 114.137 -172.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 19.1 t70 -78.03 -23.18 48.29 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.293 0.568 . . . . 2.29 109.927 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 112.74 17.17 8.13 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.581 -0.736 . . . . 0.82999999999999996 112.133 -178.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2091 ' ' THR . . . . . 0.599 ' O ' ' HA ' ' A' 2086 ' ' ILE . 3.2 p -90.51 116.2 28.24 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.355 -0.609 . . . . 1.51 109.355 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2092 ' ' VAL . . . . . 0.473 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 3.8 t -136.2 132.38 49.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.781 -0.368 . . . . 1.1799999999999999 110.285 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.2 t -137.33 122.8 19.58 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.401 0.62 . . . . 1.46 110.239 176.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 3.2 m-30 -86.33 98.41 10.96 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.976 -0.75 . . . . 1.27 108.976 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2095 ' ' THR . . . . . . . . . . . . . 16.4 m -121.38 84.59 41.61 Favored Pre-proline 0 N--CA 1.453 -0.284 0 C-N-CA 119.676 -0.81 . . . . 0.57999999999999996 111.585 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -93.47 147.71 2.29 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 123.248 2.632 . . . . 0.97999999999999998 111.884 170.341 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.27 86.35 5.04 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.225 -0.658 . . . . 2.7200000000000002 109.225 171.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 43.8 mtmt -63.26 -24.03 67.69 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.488 -0.778 . . . . 4.8099999999999996 110.92 -175.282 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -96.44 12.98 29.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.789 -0.641 . . . . 4.4199999999999999 111.052 -176.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.72 104.09 13.55 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.732 -0.667 . . . . 2.3599999999999999 110.414 176.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 86.3 t -90.7 98.7 8.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.399 0.619 . . . . 2.6800000000000002 109.529 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -162.78 -152.86 6.95 Favored Glycine 0 N--CA 1.445 -0.756 0 N-CA-C 110.704 -0.958 . . . . 3.8399999999999999 110.704 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2103 ' ' LYS . . . . . 0.479 ' HB3' ' NZ ' ' A' 2103 ' ' LYS . 0.0 OUTLIER -109.76 94.86 18.05 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 121.3 0.571 . . . . 6.7800000000000002 110.235 177.123 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -76.81 161.43 33.44 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.868 2.379 . . . . 2.4300000000000002 112.391 -177.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2105 ' ' ASP . . . . . 0.47 ' HB2' HD13 ' A' 2078 ' ' ILE . 0.6 OUTLIER -102.01 141.04 21.74 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.027 -0.533 . . . . 2.3300000000000001 110.508 179.63 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A 2106 ' ' PRO . . . . . 0.587 ' HA ' ' O ' ' A' 2123 ' ' TYR . 55.5 Cg_endo -68.99 121.25 8.1 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 123.181 2.587 . . . . 1.03 113.467 -176.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.6 p -157.51 143.85 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.414 -0.812 . . . . 0.59999999999999998 109.707 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2108 ' ' THR . . . . . . . . . . . . . 15.6 m -121.48 130.68 53.71 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.37 110.574 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2109 ' ' VAL . . . . . 0.435 HG13 ' CD2' ' A' 2069 ' ' PHE . 2.7 t -92.99 144.68 8.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.101 -0.703 . . . . 0.76000000000000001 109.101 177.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -143.36 108.35 4.95 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 118.157 0.435 . . . . 1.6299999999999999 111.635 -173.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2111 ' ' ARG . . . . . 0.473 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -147.25 139.09 24.24 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 121.722 -0.611 . . . . 3.4700000000000002 109.88 171.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.5 m -103.5 154.69 5.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 120.926 0.393 . . . . 0.40000000000000002 110.907 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2113 ' ' ASP . . . . . 0.421 ' OD1' ' HB ' ' A' 2117 ' ' THR . 2.3 p-10 -96.29 -167.74 1.63 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.029 -0.532 . . . . 1.46 110.102 178.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.4 mttt -53.64 -44.47 69.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.954 -0.566 . . . . 1.72 112.175 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 5.9 p30 -85.28 -14.92 45.11 Favored 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 120.487 -0.485 . . . . 1.8400000000000001 111.157 -176.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 104.29 15.23 22.04 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.272 -0.966 . . . . 0.44 112.937 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2117 ' ' THR . . . . . 0.45 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 98.1 m -75.85 114.65 38.94 Favored Pre-proline 0 C--N 1.324 -0.538 0 N-CA-C 109.887 -0.412 . . . . 0.56999999999999995 109.887 174.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2118 ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.2 Cg_exo -77.49 100.79 1.42 Allowed 'Trans proline' 0 N--CA 1.454 -0.817 0 C-N-CA 122.407 2.072 . . . . 0.60999999999999999 112.318 179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 7.0 m -74.94 109.36 7.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.433 -0.951 . . . . 0.59999999999999998 108.433 169.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2120 ' ' THR . . . . . . . . . . . . . 69.3 p -118.86 -174.31 2.67 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.88 -1.054 . . . . 0.67000000000000004 109.977 -174.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -149.88 127.21 11.41 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.743 -0.836 . . . . 0.72999999999999998 108.743 170.153 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2122 ' ' THR . . . . . . . . . . . . . 34.5 p -100.44 97.87 8.55 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.568 -0.53 . . . . 2.1899999999999999 109.568 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A 2123 ' ' TYR . . . . . 0.587 ' O ' ' HA ' ' A' 2106 ' ' PRO . 12.1 m-85 -118.44 124.35 47.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 111.568 -177.231 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2124 ' ' SER . . . . . 0.5 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 49.5 m -157.77 171.82 6.94 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.689 -1.141 . . . . 2.0600000000000001 108.75 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A 2125 ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' 2124 ' ' SER . 90.4 Cg_exo . . . . . 0 C--N 1.348 0.516 0 C-N-CA 122.318 2.012 . . . . 2.1600000000000001 112.45 173.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 3.3 pt20 . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 110.113 -0.328 . . . . 6.8499999999999996 110.113 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 72.39 -77.06 0.75 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.094 -0.574 . . . . 3.4100000000000001 112.47 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -158.61 84.0 0.13 Allowed Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 111.192 -0.763 . . . . 1.77 111.192 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -63.68 121.44 70.64 Favored Pre-proline 0 C--N 1.327 -0.413 0 CA-C-O 121.153 0.502 . . . . 2.4199999999999999 111.384 -177.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.23 -40.18 4.86 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.002 2.468 . . . . 1.72 112.46 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . 0.596 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -81.97 -2.08 50.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 2.3399999999999999 111.607 -177.591 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.596 HG23 HD13 ' A' 2058 ' ' LEU . 13.5 t -136.92 84.42 25.75 Favored Pre-proline 0 C--N 1.326 -0.426 0 N-CA-C 109.159 -0.682 . . . . 0.87 109.159 178.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . 0.508 ' O ' ' HG3' ' A' 2114 ' ' LYS . 41.6 Cg_exo -55.73 130.64 41.48 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.532 2.155 . . . . 1.04 111.804 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' 2113 ' ' ASP . 41.6 mm -64.49 141.74 17.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.561 . . . . 0.77000000000000002 109.709 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.512 ' O ' HG22 ' A' 2065 ' ' VAL . 10.3 t70 -80.05 128.11 33.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.361 -0.381 . . . . 1.4199999999999999 110.289 -175.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -91.34 1.96 56.74 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.404 -0.362 . . . . 1.55 111.958 -172.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 74.4 p -110.73 -5.04 15.06 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.009 0.433 . . . . 0.68999999999999995 111.171 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.637 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.9 m -91.67 -174.01 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.453 . . . . 0.81999999999999995 109.857 178.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -89.64 111.26 44.94 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.154 0.502 . . . . 0.78000000000000003 111.162 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.637 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.2 Cg_endo -100.71 109.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 123.608 2.872 . . . . 0.45000000000000001 110.792 166.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 9.0 p -148.31 -176.52 5.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.146 0.498 . . . . 0.69999999999999996 110.963 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.606 ' CD2' HG13 ' A' 2109 ' ' VAL . 3.5 m-30 -101.6 156.39 17.51 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 107.165 -1.42 . . . . 1.1599999999999999 107.165 166.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -53.8 -34.95 60.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 118.261 0.482 . . . . 2.0899999999999999 111.951 -169.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -74.81 -4.92 40.62 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 120.886 0.374 . . . . 2.1499999999999999 111.312 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.91 14.49 57.82 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 121.246 -0.502 . . . . 0.63 111.854 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . 0.473 ' OG ' ' HB2' ' A' 2069 ' ' PHE . 0.3 OUTLIER -85.78 161.78 18.99 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.666 0.27 . . . . 0.89000000000000001 111.277 -174.769 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -115.52 -23.82 8.61 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.431 -0.35 . . . . 1.1299999999999999 111.912 -174.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' 2084 ' ' TYR . 1.6 tm-20 -151.87 137.31 17.67 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.254 0.55 . . . . 2.0800000000000001 110.167 173.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.0 OUTLIER -131.64 99.7 4.88 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.472 -0.786 . . . . 1.48 109.99 175.44 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 7.7 m -103.06 111.78 24.3 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.945 -0.57 . . . . 0.63 110.598 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.548 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 44.4 mm -114.39 123.05 33.05 Favored Pre-proline 0 C--N 1.315 -0.902 0 N-CA-C 108.004 -1.11 . . . . 1.6200000000000001 108.004 173.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.27 108.69 0.17 Allowed 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.043 2.495 . . . . 0.97999999999999998 113.039 -176.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 100.99 -18.55 54.57 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.644 -0.707 . . . . 0.93999999999999995 112.886 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.548 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -90.59 -30.19 17.35 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.257 0.551 . . . . 2.02 110.827 -173.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.56 -174.58 15.31 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.587 -0.733 . . . . 0.5 111.58 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.45 HG22 HG23 ' A' 2085 ' ' THR . 15.5 m -133.88 134.41 42.67 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.583 0.706 . . . . 0.48999999999999999 110.523 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' 2075 ' ' GLU . 1.5 m-85 -109.47 120.18 41.7 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.986 -1.487 . . . . 1.4399999999999999 106.986 172.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.45 HG23 HG22 ' A' 2083 ' ' THR . 0.7 OUTLIER -127.89 121.59 30.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 112.447 0.536 . . . . 0.63 112.447 -171.789 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.458 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -115.54 134.91 57.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 116.089 -0.505 . . . . 1.1799999999999999 110.198 173.703 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 33.6 m -118.2 150.37 47.47 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 109.413 -0.588 . . . . 0.80000000000000004 109.413 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.99 -4.08 0.85 Allowed 'Trans proline' 0 N--CA 1.481 0.768 0 C-N-CA 123.959 3.106 . . . . 0.96999999999999997 114.637 -172.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.73 -7.8 52.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.902 0.382 . . . . 2.29 110.506 176.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 91.18 16.98 52.54 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.91 -0.662 . . . . 0.82999999999999996 112.063 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 8.2 t -118.61 138.54 52.51 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.854 0.359 . . . . 1.51 110.433 -179.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.461 ' CG2' ' HB2' ' A' 2067 ' ' PRO . 7.4 t -131.21 140.58 48.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.126 -0.488 . . . . 1.1799999999999999 110.512 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -101.99 108.92 20.52 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 116.299 -0.41 . . . . 1.46 110.49 174.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -86.69 96.32 10.1 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.162 -1.051 . . . . 1.27 108.162 173.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 25.1 m -119.04 88.25 36.21 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 121.121 0.486 . . . . 0.57999999999999996 110.554 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.29 2.66 . . . . 0.97999999999999998 111.877 176.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.2 t70 -132.14 99.43 4.71 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.883 0.373 . . . . 2.7200000000000002 110.083 178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.23 13.9 2.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.275 -0.42 . . . . 4.8099999999999996 111.101 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 -109.52 5.57 23.32 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.256 0.551 . . . . 4.4199999999999999 109.716 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 52.5 t80 -89.3 92.55 9.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 2.3599999999999999 110.992 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 92.0 t -83.76 107.78 15.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.586 -0.524 . . . . 2.6800000000000002 109.586 174.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.14 -133.55 2.85 Favored Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.673 -0.694 . . . . 3.8399999999999999 111.456 -178.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 61.6 tttm -127.67 99.07 27.06 Favored Pre-proline 0 C--N 1.319 -0.72 0 CA-C-N 116.769 0.284 . . . . 6.7800000000000002 110.94 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.92 155.03 48.37 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.318 2.012 . . . . 2.4300000000000002 111.73 174.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.3 t70 -83.42 127.02 70.09 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 116.066 -0.515 . . . . 2.3300000000000001 109.968 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.654 ' HA ' ' O ' ' A' 2123 ' ' TYR . 43.1 Cg_exo -56.34 102.68 0.1 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.026 2.484 . . . . 1.03 112.881 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.2 p -147.42 138.93 18.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.095 -0.502 . . . . 0.59999999999999998 110.38 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 56.6 m -112.96 124.16 51.99 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.001 -0.545 . . . . 0.37 110.149 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.606 HG13 ' CD2' ' A' 2069 ' ' PHE . 4.7 t -91.63 131.17 39.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.835 -0.802 . . . . 0.76000000000000001 108.835 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -143.6 108.94 5.04 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 112.989 0.737 . . . . 1.6299999999999999 112.989 -173.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.42 ' HD2' HG21 ' A' 2061 ' ' ILE . 28.1 ptt180 -129.65 140.62 51.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.741 -0.837 . . . . 3.4700000000000002 108.741 171.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.457 HG23 HG21 ' A' 2065 ' ' VAL . 35.9 m -99.58 142.01 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 120.358 -0.537 . . . . 0.40000000000000002 110.997 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.669 ' OD1' ' HB ' ' A' 2117 ' ' THR . 4.3 p30 -85.24 -170.72 3.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.949 -0.569 . . . . 1.46 111.615 -178.034 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . 0.508 ' HG3' ' O ' ' A' 2060 ' ' PRO . 91.5 mttt -57.55 -37.17 72.67 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.851 0.315 . . . . 1.72 111.851 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -80.09 -29.7 39.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.313 0.578 . . . . 1.8400000000000001 109.901 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 112.6 21.62 6.04 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.321 -0.854 . . . . 0.44 112.418 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.669 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 92.4 m -86.91 120.97 71.88 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 110.214 -0.291 . . . . 0.56999999999999995 110.214 177.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' 2117 ' ' THR . 7.5 Cg_exo -73.16 101.88 1.39 Allowed 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.453 2.102 . . . . 0.60999999999999999 112.433 178.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.7 m -75.07 113.0 13.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.527 -0.916 . . . . 0.59999999999999998 108.527 171.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' 2109 ' ' VAL . 37.8 p -119.66 154.82 33.46 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 115.483 -0.781 . . . . 0.67000000000000004 112.617 -169.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -130.29 127.54 39.71 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.892 -1.151 . . . . 0.72999999999999998 107.892 167.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.2 m -115.87 103.87 11.06 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.072 0.463 . . . . 2.1899999999999999 110.527 -174.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.654 ' O ' ' HA ' ' A' 2106 ' ' PRO . 3.1 m-85 -98.33 132.29 43.92 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-O 121.198 0.523 . . . . 2.8100000000000001 111.19 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 44.3 m -157.14 165.37 18.95 Favored Pre-proline 0 C--N 1.321 -0.635 0 N-CA-C 108.433 -0.951 . . . . 2.0600000000000001 108.433 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -58.5 -6.09 2.89 Favored 'Trans proline' 0 C--N 1.353 0.783 0 C-N-CA 123.199 2.599 . . . . 2.1600000000000001 114.064 -176.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -81.45 -36.23 29.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.357 0.598 . . . . 4.3300000000000001 109.468 175.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -86.12 68.55 10.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.544 -0.753 . . . . 3.8300000000000001 110.703 -175.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -117.82 -81.11 0.62 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.038 -0.528 . . . . 5.1100000000000003 111.05 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 17.3 ptpt -87.99 52.04 2.36 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.654 0.74 . . . . 5.2199999999999998 110.578 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 29.4 t . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.197 -0.91 . . . . 5.8799999999999999 110.223 -177.214 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 26.4 mp0 . . . . . 0 N--CA 1.483 1.193 0 CA-C-O 120.785 0.326 . . . . 6.8499999999999996 110.337 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 63.67 39.04 97.11 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.762 -0.732 . . . . 3.4100000000000001 111.376 -175.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 127.5 123.38 2.61 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.171 -0.772 . . . . 1.77 111.171 -175.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -88.42 117.02 67.91 Favored Pre-proline 0 C--N 1.322 -0.588 0 CA-C-O 120.582 0.23 . . . . 2.4199999999999999 110.621 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.87 -21.91 18.1 Favored 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.404 2.07 . . . . 1.72 111.933 -178.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 48.9 mt -75.74 -18.48 59.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.673 -0.694 . . . . 2.3399999999999999 110.465 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.478 HG11 HD22 ' A' 2115 ' ' ASN . 5.0 t -133.63 98.38 14.99 Favored Pre-proline 0 N--CA 1.452 -0.341 0 CA-C-N 116.062 -0.517 . . . . 0.87 109.811 177.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' 2059 ' ' VAL . 11.3 Cg_endo -55.76 118.86 5.69 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.039 1.826 . . . . 1.04 111.827 178.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.8 mm -53.6 136.84 14.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.251 -0.886 . . . . 0.77000000000000002 111.346 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.517 ' O ' HG22 ' A' 2065 ' ' VAL . 14.8 t70 -71.57 131.56 43.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 1.4199999999999999 110.144 178.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -86.76 -5.2 59.19 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.238 -0.437 . . . . 1.55 112.131 -172.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.7 p -111.37 3.82 18.53 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.091 0.404 . . . . 0.68999999999999995 112.091 -177.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' 2062 ' ' ASP . 27.1 m -90.19 -177.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.728 -0.471 . . . . 0.81999999999999995 109.728 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -94.06 116.73 66.79 Favored Pre-proline 0 C--O 1.241 0.625 0 CA-C-O 121.382 0.61 . . . . 0.78000000000000003 111.6 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.515 ' HB2' HG13 ' A' 2086 ' ' ILE . 28.4 Cg_endo -100.39 108.55 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.614 0 C-N-CA 123.59 2.86 . . . . 0.45000000000000001 111.416 167.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.459 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.4 p -143.37 145.25 32.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.887 0.375 . . . . 0.69999999999999996 110.549 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.692 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-30 -70.78 156.13 39.91 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 107.936 -1.135 . . . . 1.1599999999999999 107.936 177.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -51.73 -39.13 57.92 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 123.404 0.44 . . . . 2.0899999999999999 111.819 -170.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -91.12 19.18 6.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 2.1499999999999999 111.358 -177.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 75.44 29.44 59.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.047 -0.597 . . . . 0.63 112.66 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . 0.436 ' HB2' ' CD1' ' A' 2069 ' ' PHE . 7.4 m -95.34 162.32 13.72 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 122.743 -0.269 . . . . 0.89000000000000001 110.904 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 35.7 mmtp -121.57 -24.9 5.23 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 116.268 -0.424 . . . . 1.1299999999999999 111.673 -177.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.628 ' HA ' ' O ' ' A' 2084 ' ' TYR . 2.0 tt0 -158.62 124.64 4.54 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.368 0.604 . . . . 2.0800000000000001 110.583 175.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -123.55 102.19 7.73 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.375 -0.829 . . . . 1.48 109.931 175.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.7 m -95.92 113.22 24.82 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.204 0.526 . . . . 0.63 110.576 175.157 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 27.3 mm -116.07 108.86 45.48 Favored Pre-proline 0 C--N 1.31 -1.133 0 N-CA-C 107.627 -1.249 . . . . 1.6200000000000001 107.627 170.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -49.08 115.43 1.7 Allowed 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 123.183 2.589 . . . . 0.97999999999999998 113.41 -173.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' 2100 ' ' PHE . . . 89.58 -8.41 79.88 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.775 -0.648 . . . . 0.93999999999999995 112.513 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.529 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.0 OUTLIER -107.49 -31.05 8.3 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.219 0.533 . . . . 2.02 109.903 -176.679 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 136.45 172.0 12.45 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.519 -0.848 . . . . 0.5 112.94 173.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.4 ' O ' ' HB ' ' A' 2095 ' ' THR . 77.7 m -138.23 127.93 25.12 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.304 0.573 . . . . 0.48999999999999999 109.696 172.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.692 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.1 OUTLIER -108.16 125.99 52.26 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 107.698 -1.223 . . . . 1.4399999999999999 107.698 175.52 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 1.3 p -127.86 129.31 46.71 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 112.074 0.398 . . . . 0.63 112.074 -174.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.515 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.47 132.09 71.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.854 -0.612 . . . . 1.1799999999999999 110.52 174.601 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -125.79 142.56 42.52 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 115.788 -0.642 . . . . 0.80000000000000004 109.3 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.57 -0.05 1.71 Allowed 'Trans proline' 0 N--CA 1.476 0.491 0 C-N-CA 123.827 3.018 . . . . 0.96999999999999997 114.177 -170.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 36.8 t70 -72.77 -11.8 60.75 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.41 0.624 . . . . 2.29 109.836 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 106.26 6.24 36.6 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.629 -0.714 . . . . 0.82999999999999996 112.381 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 2.2 t -110.8 128.06 55.62 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.257 0.551 . . . . 1.51 110.274 -179.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.471 HG13 ' HB ' ' A' 2086 ' ' ILE . 18.8 t -137.17 137.25 46.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 115.527 -0.76 . . . . 1.1799999999999999 109.624 -175.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 24.0 m -119.8 109.77 15.99 Favored 'General case' 0 N--CA 1.439 -0.997 0 CA-C-O 120.816 0.341 . . . . 1.46 111.3 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . 0.414 ' O ' ' HD3' ' A' 2096 ' ' PRO . 5.8 m-30 -89.65 98.88 12.02 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.26 -0.645 . . . . 1.27 109.26 174.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' 2083 ' ' THR . 23.0 m -114.01 89.42 16.72 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-O 120.683 0.278 . . . . 0.57999999999999996 111.662 -178.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' 2094 ' ' PHE . 73.0 Cg_endo -92.52 119.34 0.44 Allowed 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.971 2.447 . . . . 0.97999999999999998 112.702 175.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -89.87 84.68 6.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.34 0.59 . . . . 2.7200000000000002 109.563 173.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . 0.511 ' HA ' ' CG2' ' A' 2128 ' ' THR . 0.0 OUTLIER -75.69 -1.91 27.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.566 -0.743 . . . . 4.8099999999999996 112.374 -171.596 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -84.9 -2.02 57.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.168 0.509 . . . . 4.4199999999999999 110.523 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' 2080 ' ' GLY . 69.0 t80 -83.49 85.47 7.24 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 2.3599999999999999 110.377 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.8 t -92.35 99.63 10.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.147 -0.478 . . . . 2.6800000000000002 110.196 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -169.53 -101.93 0.15 Allowed Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.415 -0.674 . . . . 3.8399999999999999 111.415 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 53.3 mtmt -131.6 73.25 79.59 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-O 120.611 0.244 . . . . 6.7800000000000002 110.615 174.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . 0.426 ' HD2' ' O ' ' A' 2125 ' ' PRO . 18.9 Cg_exo -66.06 127.93 18.63 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.383 2.055 . . . . 2.4300000000000002 111.312 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.3 t70 -60.79 122.88 71.85 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.001 -0.545 . . . . 2.3300000000000001 110.665 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' 2123 ' ' TYR . 31.8 Cg_exo -58.93 120.37 8.19 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 123.101 2.534 . . . . 1.03 112.174 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.7 p -156.72 161.51 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.93 -0.577 . . . . 0.59999999999999998 109.731 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' 2121 ' ' ALA . 67.0 m -140.88 119.74 12.62 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.933 0.397 . . . . 0.37 110.08 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.4 t -92.5 145.18 7.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.029 -0.73 . . . . 0.76000000000000001 109.029 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.459 ' HB3' ' O ' ' A' 2068 ' ' THR . 0.0 OUTLIER -147.47 143.21 27.72 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.224 0.465 . . . . 1.6299999999999999 111.341 -174.787 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.425 ' N ' ' HD2' ' A' 2110 ' ' LYS . 27.2 ptt180 -166.95 146.07 5.28 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.676 -0.861 . . . . 3.4700000000000002 108.676 166.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.444 ' O ' HG21 ' A' 2065 ' ' VAL . 30.5 m -99.01 149.19 5.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 C-N-CA 120.44 -0.504 . . . . 0.40000000000000002 111.289 -175.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.456 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.8 p-10 -90.51 -169.39 2.38 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.951 -0.568 . . . . 1.46 109.976 178.433 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . 0.402 ' HG2' ' HB2' ' A' 2062 ' ' ASP . 96.9 mttt -59.97 -38.56 82.88 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.542 0.21 . . . . 1.72 111.008 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . 0.478 HD22 HG11 ' A' 2059 ' ' VAL . 40.2 m-80 -71.66 -30.28 65.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.844 0.354 . . . . 1.8400000000000001 110.857 177.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 110.55 12.93 15.65 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.851 -0.69 . . . . 0.44 112.214 179.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 5.7 m -79.72 121.58 82.57 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 110.128 -0.323 . . . . 0.56999999999999995 110.128 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.6 Cg_exo -73.95 103.92 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 122.301 2.001 . . . . 0.60999999999999999 112.234 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.5 m -75.32 117.62 19.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.381 -0.97 . . . . 0.59999999999999998 108.381 171.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.545 ' HA ' ' O ' ' A' 2109 ' ' VAL . 47.2 p -129.75 163.35 26.38 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.539 -0.755 . . . . 0.67000000000000004 111.751 -170.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -130.98 126.84 37.07 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.528 -0.915 . . . . 0.72999999999999998 108.528 169.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 20.3 m -100.12 100.45 11.3 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.041 0.448 . . . . 2.1899999999999999 110.335 -176.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.494 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -96.99 114.39 26.0 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.143 -0.48 . . . . 2.8100000000000001 110.899 -177.407 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 17.8 m -127.39 158.57 69.15 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.537 -0.756 . . . . 2.0600000000000001 109.651 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.426 ' O ' ' HD2' ' A' 2104 ' ' PRO . 95.2 Cg_exo -45.31 -45.32 15.35 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.069 2.513 . . . . 2.1600000000000001 113.828 -177.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -108.29 28.15 8.61 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 122.213 -0.304 . . . . 4.3300000000000001 111.516 -176.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 79.9 t80 -79.38 -47.09 16.37 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.086 0.47 . . . . 3.8300000000000001 110.8 -179.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . 0.511 ' CG2' ' HA ' ' A' 2098 ' ' LYS . 22.2 p -88.77 109.13 19.91 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.951 -0.568 . . . . 5.1100000000000003 111.934 -173.307 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 9.7 ptmm? -178.24 40.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.85 -1.068 . . . . 5.2199999999999998 109.864 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.248 1.004 0 CA-C-N 115.073 -0.967 . . . . 5.8799999999999999 111.264 -176.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 35.5 tt0 . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.833 0.349 . . . . 6.8499999999999996 110.535 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 101.45 -14.13 58.06 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.611 -0.804 . . . . 3.4100000000000001 112.434 178.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 159.67 -107.93 0.34 Allowed Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.402 -0.904 . . . . 1.77 113.12 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . 0.413 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 2.3 t70 -83.88 127.2 68.27 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 120.698 0.285 . . . . 2.4199999999999999 111.744 -171.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -76.45 -22.47 12.34 Favored 'Trans proline' 0 N--CA 1.46 -0.471 0 C-N-CA 122.414 2.076 . . . . 1.72 112.477 177.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.52 -9.57 20.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.821 0.343 . . . . 2.3399999999999999 110.656 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' 2056 ' ' ASP . 21.4 t -127.48 84.48 63.27 Favored Pre-proline 0 CA--C 1.511 -0.534 0 N-CA-C 108.034 -1.099 . . . . 0.87 108.034 175.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -40.48 117.77 0.52 Allowed 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.922 2.415 . . . . 1.04 112.228 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 33.3 mm -54.46 114.96 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.263 -0.88 . . . . 0.77000000000000002 110.911 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 15.7 t70 -72.86 125.71 28.2 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.47 -0.787 . . . . 1.4199999999999999 111.308 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . 0.423 ' HB3' ' O ' ' A' 2089 ' ' ASP . 44.0 mt-10 -86.89 -2.88 58.94 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.127 -0.488 . . . . 1.55 111.805 -173.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 43.9 p -106.06 -5.53 19.39 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.741 -0.384 . . . . 0.68999999999999995 111.863 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.2 m -96.26 163.66 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.863 -0.421 . . . . 0.81999999999999995 109.863 176.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -73.15 114.09 27.93 Favored Pre-proline 0 C--O 1.24 0.591 0 CA-C-O 121.271 0.557 . . . . 0.78000000000000003 112.22 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.492 ' HB3' ' NH1' ' A' 2111 ' ' ARG . 68.0 Cg_endo -102.29 108.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.423 0 C-N-CA 123.682 2.921 . . . . 0.45000000000000001 112.097 169.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 20.9 p -138.61 -178.64 5.4 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.403 0.62 . . . . 0.69999999999999996 111.273 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.489 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.7 OUTLIER -102.01 152.23 21.2 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.862 -1.162 . . . . 1.1599999999999999 107.862 168.72 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -52.39 -39.21 60.56 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.066 0.394 . . . . 2.0899999999999999 111.741 -170.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.36 -2.94 43.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.91 -0.586 . . . . 2.1499999999999999 111.335 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.78 29.36 13.47 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.849 -0.691 . . . . 0.63 112.159 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 9.1 m -98.06 169.15 9.82 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.894 -0.18 . . . . 0.89000000000000001 110.697 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -128.06 -16.64 4.52 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-O 120.964 0.412 . . . . 1.1299999999999999 111.343 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.402 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.8 tt0 -156.24 121.09 4.64 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.719 -0.475 . . . . 2.0800000000000001 109.719 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD2' ' HA ' ' A' 2076 ' ' LYS . 4.5 mmmm -115.45 121.86 44.02 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.967 -0.561 . . . . 1.48 109.534 171.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 55.2 m -129.53 121.48 27.28 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.729 -0.669 . . . . 0.63 110.85 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.436 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 48.4 mm -119.69 124.49 27.96 Favored Pre-proline 0 C--N 1.314 -0.965 0 N-CA-C 107.584 -1.265 . . . . 1.6200000000000001 107.584 171.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.73 107.86 0.21 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.332 2.021 . . . . 0.97999999999999998 112.304 -176.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.19 -23.37 27.31 Favored Glycine 0 N--CA 1.446 -0.659 0 CA-C-N 115.811 -0.631 . . . . 0.93999999999999995 112.534 -178.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.436 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 15.7 tt0 -90.73 -31.14 16.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.003 0.43 . . . . 2.02 110.261 -176.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.62 -173.32 14.72 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.714 -0.755 . . . . 0.5 112.86 176.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 46.4 m -129.99 132.65 46.35 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.556 0.693 . . . . 0.48999999999999999 110.127 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.478 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 0.5 OUTLIER -111.31 112.47 24.26 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 106.735 -1.58 . . . . 1.4399999999999999 106.735 172.397 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.89 131.69 55.32 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.429 0.529 . . . . 0.63 112.429 -170.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.504 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.93 137.7 54.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.392 -0.822 . . . . 1.1799999999999999 109.561 174.54 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 31.7 m -118.67 153.3 52.19 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 109.889 -0.411 . . . . 0.80000000000000004 109.889 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -60.3 -4.81 3.43 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.773 2.982 . . . . 0.96999999999999997 114.264 -170.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' 2063 ' ' GLU . 27.7 m-20 -72.93 -13.08 61.18 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.907 0.384 . . . . 2.29 110.215 177.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.72 16.06 32.37 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.967 -0.635 . . . . 0.82999999999999996 112.263 177.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.7 t -115.61 141.25 48.32 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.806 0.336 . . . . 1.51 110.44 -178.111 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.504 HG22 ' CG1' ' A' 2086 ' ' ILE . 12.5 t -133.32 150.78 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.977 -0.556 . . . . 1.1799999999999999 109.96 -178.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -125.86 122.0 34.82 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.46 110.05 173.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 20.4 m-30 -90.47 98.82 12.0 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.265 -0.642 . . . . 1.27 109.265 177.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 8.9 m -113.25 87.49 11.12 Favored Pre-proline 0 N--CA 1.454 -0.242 0 CA-C-O 120.964 0.411 . . . . 0.57999999999999996 110.431 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -92.55 -179.88 1.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 123.292 2.661 . . . . 0.97999999999999998 112.399 178.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.4 t70 -131.7 139.65 49.09 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.222 -0.659 . . . . 2.7200000000000002 109.222 170.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -90.23 -26.1 20.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.87 -0.605 . . . . 4.8099999999999996 111.833 -172.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -120.32 36.83 4.43 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.788 0.292 . . . . 4.4199999999999999 111.788 -171.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 19.4 t80 -82.41 87.01 6.64 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.37 0.605 . . . . 2.3599999999999999 110.737 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . 0.449 ' HA ' ' HB3' ' A' 2129 ' ' LYS . 46.2 t -92.14 109.84 21.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.793 -0.64 . . . . 2.6800000000000002 109.745 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . 0.425 ' C ' ' HD3' ' A' 2104 ' ' PRO . . . 170.75 -113.29 0.49 Allowed Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.492 -0.643 . . . . 3.8399999999999999 111.492 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -120.01 76.87 22.95 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 121.115 0.483 . . . . 6.7800000000000002 111.533 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . 0.425 ' HD3' ' C ' ' A' 2102 ' ' GLY . 8.1 Cg_exo -74.68 157.68 43.93 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.198 2.599 . . . . 2.4300000000000002 111.684 178.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.0 t70 -120.09 117.48 32.06 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.477 -0.328 . . . . 2.3300000000000001 110.435 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.532 ' HA ' ' O ' ' A' 2123 ' ' TYR . 52.6 Cg_exo -54.94 128.41 30.42 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.864 2.376 . . . . 1.03 111.828 177.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.1 p -157.51 161.29 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.312 -0.404 . . . . 0.59999999999999998 110.257 -176.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.43 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.5 m -140.15 119.05 12.54 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.149 0.5 . . . . 0.37 110.269 176.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.6 t -91.35 138.06 20.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 108.131 -1.063 . . . . 0.76000000000000001 108.131 176.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.495 ' HA ' HG22 ' A' 2120 ' ' THR . 2.2 tmmm? -145.14 108.32 4.57 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.275 0.559 . . . . 1.6299999999999999 111.476 -172.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.492 ' NH1' ' HB3' ' A' 2067 ' ' PRO . 1.4 ptm180 -139.72 142.95 36.82 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 109.207 -0.664 . . . . 3.4700000000000002 109.207 174.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' 2117 ' ' THR . 24.0 m -99.6 161.06 3.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.426 -0.51 . . . . 0.40000000000000002 111.49 -175.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.507 ' OD2' ' HB ' ' A' 2117 ' ' THR . 3.9 p30 -110.01 -169.13 1.41 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.571 -0.74 . . . . 1.46 111.004 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 65.2 mttm -63.49 -25.12 68.12 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 111.938 0.347 . . . . 1.72 111.938 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.67 -9.98 56.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.949 0.404 . . . . 1.8400000000000001 110.251 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 86.27 15.99 63.41 Favored Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.333 -0.707 . . . . 0.44 111.333 -176.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.507 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 0.2 OUTLIER -84.99 131.23 49.45 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 109.954 -0.388 . . . . 0.56999999999999995 109.954 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 12.3 Cg_endo -87.78 103.9 0.52 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 122.208 1.938 . . . . 0.60999999999999999 112.428 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 14.8 m -75.42 109.29 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 108.692 -0.855 . . . . 0.59999999999999998 108.692 171.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.495 HG22 ' HA ' ' A' 2110 ' ' LYS . 35.5 p -124.55 169.27 12.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.094 -0.957 . . . . 0.67000000000000004 111.55 -170.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -135.49 127.73 30.08 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.52 -0.764 . . . . 0.72999999999999998 109.6 173.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 13.4 p -94.71 99.67 11.73 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.254 -0.43 . . . . 2.1899999999999999 109.892 177.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.532 ' O ' ' HA ' ' A' 2106 ' ' PRO . 0.2 OUTLIER -103.77 123.93 47.97 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.34 0.59 . . . . 2.8100000000000001 111.788 -174.859 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 25.2 m -154.19 153.07 27.75 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.141 -0.936 . . . . 2.0600000000000001 108.484 175.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -43.45 -38.91 8.98 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 122.837 2.358 . . . . 2.1600000000000001 113.891 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -64.66 -11.79 39.29 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 112.76 0.652 . . . . 4.3300000000000001 112.76 -177.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -94.54 -5.36 46.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.715 0.293 . . . . 3.8300000000000001 111.416 -179.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 33.0 p -123.25 -39.98 2.42 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.149 0.499 . . . . 5.1100000000000003 110.938 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . 0.457 ' HG3' HG23 ' A' 2130 ' ' VAL . 51.6 pttt -126.64 -165.27 1.43 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.764 -0.653 . . . . 5.2199999999999998 110.23 177.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . 0.457 HG23 ' HG3' ' A' 2129 ' ' LYS . 42.6 t . . . . . 0 C--O 1.248 1.026 0 CA-C-O 117.929 -1.034 . . . . 5.8799999999999999 110.185 -178.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 22.0 mp0 . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.821 0.343 . . . . 6.8499999999999996 110.519 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 97.58 79.46 1.46 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.734 -0.746 . . . . 3.4100000000000001 112.188 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 144.58 122.6 1.59 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.712 -0.756 . . . . 1.77 112.016 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 7.1 t70 -79.92 129.36 70.79 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-O 120.678 0.275 . . . . 2.4199999999999999 110.359 -176.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.7 -21.78 33.28 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.387 2.058 . . . . 1.72 112.55 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 3.9 mm? -93.2 -26.83 17.21 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.887 0.375 . . . . 2.3399999999999999 110.043 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.433 HG11 HD22 ' A' 2115 ' ' ASN . 1.8 t -126.88 90.7 48.9 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.239 -0.437 . . . . 0.87 110.429 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -57.32 121.57 10.28 Favored 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 122.188 1.925 . . . . 1.04 111.586 176.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 48.9 mm -53.04 132.31 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.572 -0.74 . . . . 0.77000000000000002 110.828 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.568 ' O ' HG22 ' A' 2065 ' ' VAL . 24.4 t70 -66.78 135.39 53.89 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 1.4199999999999999 110.493 -177.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -92.91 -2.58 55.7 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.195 -0.457 . . . . 1.55 111.889 -171.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 31.0 p -106.7 2.21 25.61 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.763 -0.375 . . . . 0.68999999999999995 111.832 178.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' 2062 ' ' ASP . 35.4 m -92.68 -174.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 110.326 -0.249 . . . . 0.81999999999999995 110.326 176.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -91.25 114.13 60.65 Favored Pre-proline 0 C--O 1.24 0.597 0 CA-C-O 121.02 0.438 . . . . 0.78000000000000003 111.389 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' 2065 ' ' VAL . 53.8 Cg_endo -101.06 108.06 0.05 OUTLIER 'Trans proline' 0 N--CA 1.444 -1.416 0 C-N-CA 123.362 2.708 . . . . 0.45000000000000001 111.296 166.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 23.2 p -149.25 -177.2 5.7 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.93 0.395 . . . . 0.69999999999999996 110.665 -177.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.632 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 9.3 m-30 -101.56 142.85 32.31 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.832 -1.173 . . . . 1.1599999999999999 107.832 166.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -64.18 -15.78 60.57 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.421 0.451 . . . . 2.0899999999999999 111.248 -172.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -84.4 2.02 42.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.039 -0.528 . . . . 2.1499999999999999 110.902 176.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 85.58 23.47 46.73 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 121.111 -0.566 . . . . 0.63 112.706 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.7 p -110.64 164.38 12.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.974 0.416 . . . . 0.89000000000000001 111.37 -177.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . 0.602 ' O ' HG22 ' A' 2086 ' ' ILE . 47.9 mmtm -113.32 -44.78 3.2 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.684 -0.689 . . . . 1.1299999999999999 110.696 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.763 ' HG3' HG22 ' A' 2085 ' ' THR . 4.6 mp0 -119.97 138.11 53.67 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.772 -0.455 . . . . 2.0800000000000001 109.772 173.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.5 OUTLIER -127.71 99.25 5.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.15 -0.477 . . . . 1.48 109.736 178.258 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 48.7 m -110.69 121.77 46.14 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.11 0.481 . . . . 0.63 110.476 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 88.0 mt -126.84 126.17 24.39 Favored Pre-proline 0 C--N 1.315 -0.91 0 N-CA-C 108.521 -0.918 . . . . 1.6200000000000001 108.521 174.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -47.14 109.67 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 123.295 2.664 . . . . 0.97999999999999998 113.257 -175.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . 0.488 ' O ' ' HD2' ' A' 2100 ' ' PHE . . . 93.9 -12.95 68.44 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.706 -0.679 . . . . 0.93999999999999995 113.009 177.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.516 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -94.7 -32.47 13.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 117.122 0.461 . . . . 2.02 110.661 -175.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.7 -155.24 16.28 Favored Glycine 0 N--CA 1.448 -0.567 0 C-N-CA 120.811 -0.709 . . . . 0.5 111.9 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.555 ' HA ' ' O ' ' A' 2076 ' ' LYS . 55.8 m -155.28 138.92 16.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.698 0.761 . . . . 0.48999999999999999 111.011 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.632 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.2 m-85 -109.01 121.69 45.68 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.774 -1.565 . . . . 1.4399999999999999 106.774 170.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.763 HG22 ' HG3' ' A' 2075 ' ' GLU . 16.8 p -118.84 133.56 55.75 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 120.721 0.296 . . . . 0.63 111.584 -175.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.602 HG22 ' O ' ' A' 2074 ' ' LYS . 0.0 OUTLIER -113.02 136.9 47.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.278 -0.419 . . . . 1.1799999999999999 110.186 176.16 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 18.6 m -122.71 144.82 43.55 Favored Pre-proline 0 C--N 1.319 -0.732 0 N-CA-C 109.975 -0.38 . . . . 0.80000000000000004 109.975 173.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -62.18 0.01 1.52 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.542 2.828 . . . . 0.96999999999999997 114.014 -172.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 37.2 t70 -68.04 -21.29 65.02 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.411 -0.589 . . . . 2.29 109.411 173.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.33 5.18 28.5 Favored Glycine 0 N--CA 1.447 -0.611 0 CA-C-N 115.374 -0.83 . . . . 0.82999999999999996 111.715 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . 0.505 ' HA ' ' NH2' ' A' 2111 ' ' ARG . 4.9 t -114.23 143.34 45.0 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.185 0.517 . . . . 1.51 110.945 -174.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.407 HG22 ' CG1' ' A' 2086 ' ' ILE . 27.6 t -139.32 137.52 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.529 -0.759 . . . . 1.1799999999999999 109.309 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 7.2 t -107.1 121.23 44.08 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.206 0.527 . . . . 1.46 110.166 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 4.3 m-30 -87.53 97.86 11.08 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.087 -1.079 . . . . 1.27 108.087 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . 0.463 ' HB ' ' O ' ' A' 2083 ' ' THR . 43.9 m -117.63 99.09 52.27 Favored Pre-proline 0 N--CA 1.453 -0.31 0 N-CA-C 112.501 0.556 . . . . 0.57999999999999996 112.501 -174.063 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -86.17 143.17 7.75 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.567 2.178 . . . . 0.97999999999999998 110.231 166.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 17.1 t70 -61.34 135.01 57.56 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.955 0.407 . . . . 2.7200000000000002 110.499 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 58.9 mttp -72.24 -14.22 61.72 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.618 -0.719 . . . . 4.8099999999999996 111.913 -172.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -120.16 23.41 10.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.998 -0.371 . . . . 4.4199999999999999 109.998 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . 0.488 ' HD2' ' O ' ' A' 2080 ' ' GLY . 64.1 t80 -72.64 124.88 26.18 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-O 121.152 0.501 . . . . 2.3599999999999999 110.311 179.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' 2129 ' ' LYS . 2.3 p -74.89 99.91 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.226 -0.897 . . . . 2.6800000000000002 110.478 177.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 102.56 -147.96 17.29 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.803 -0.635 . . . . 3.8399999999999999 112.039 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 48.7 mttp -111.02 134.4 21.03 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 120.613 0.245 . . . . 6.7800000000000002 110.876 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -43.72 149.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 124.409 3.406 . . . . 2.4300000000000002 114.035 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.444 ' H ' ' HG3' ' A' 2081 ' ' GLN . 1.4 m-20 -56.68 153.94 19.74 Favored Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 114.962 -1.017 . . . . 2.3300000000000001 111.898 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -53.22 113.16 1.15 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 124.235 3.29 . . . . 1.03 114.598 -174.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . 0.497 HG21 ' HG3' ' A' 2076 ' ' LYS . 4.2 p -160.66 119.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.092 -0.958 . . . . 0.59999999999999998 109.776 172.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.486 ' HA ' ' O ' ' A' 2121 ' ' ALA . 62.3 m -95.87 118.29 32.24 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.453 0.644 . . . . 0.37 110.17 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' 2120 ' ' THR . 6.1 t -91.65 136.36 24.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.259 -0.882 . . . . 0.76000000000000001 108.989 -178.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.583 ' HD2' ' C ' ' A' 2110 ' ' LYS . 0.0 OUTLIER -139.97 108.86 5.99 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.156 0.503 . . . . 1.6299999999999999 112.188 -173.089 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.505 ' NH2' ' HA ' ' A' 2091 ' ' THR . 4.2 ptm180 -142.4 132.76 24.95 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.719 -0.845 . . . . 3.4700000000000002 108.719 170.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.521 ' O ' HG21 ' A' 2065 ' ' VAL . 33.0 m -99.12 152.82 4.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.587 -0.445 . . . . 0.40000000000000002 111.695 -174.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -92.48 -170.68 2.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.969 -0.56 . . . . 1.46 110.15 178.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.9 mttm -64.72 -34.05 77.4 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.585 0.231 . . . . 1.72 111.255 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . 0.433 HD22 HG11 ' A' 2059 ' ' VAL . 37.0 m-80 -69.66 -30.13 67.74 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 1.8400000000000001 110.568 175.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 109.97 7.43 27.14 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.964 -0.636 . . . . 0.44 111.978 -178.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.434 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 87.9 m -81.97 118.73 73.15 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 110.142 -0.318 . . . . 0.56999999999999995 110.142 178.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' 2112 ' ' VAL . 3.3 Cg_exo -78.88 116.63 3.77 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 122.21 1.94 . . . . 0.60999999999999999 112.307 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 6.8 m -74.85 108.88 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.423 0 N-CA-C 107.89 -1.152 . . . . 0.59999999999999998 107.89 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' 2109 ' ' VAL . 68.5 p -123.3 168.48 12.43 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.662 -1.154 . . . . 0.67000000000000004 111.006 -170.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.04 126.36 39.31 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.083 -1.08 . . . . 0.72999999999999998 108.083 168.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 37.6 m -94.66 98.71 10.99 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.147 -0.686 . . . . 2.1899999999999999 109.147 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -120.57 123.95 44.11 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.574 0.702 . . . . 2.8100000000000001 111.796 -176.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . 0.598 ' OG ' ' HD2' ' A' 2125 ' ' PRO . 6.6 t -132.87 162.16 59.18 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 114.459 -1.246 . . . . 2.0600000000000001 108.391 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.598 ' HD2' ' OG ' ' A' 2124 ' ' SER . 49.2 Cg_endo -69.17 52.11 0.77 Allowed 'Trans proline' 0 C--N 1.353 0.776 0 C-N-CA 122.584 2.189 . . . . 2.1600000000000001 112.838 176.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -133.08 151.09 52.05 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.965 -1.124 . . . . 4.3300000000000001 107.965 175.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 61.1 m-85 63.87 47.19 3.6 Favored 'General case' 0 C--N 1.331 -0.237 0 O-C-N 123.533 0.52 . . . . 3.8300000000000001 109.969 -173.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 8.4 p -75.57 -168.57 0.86 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.765 -0.652 . . . . 5.1100000000000003 111.241 -178.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . 0.453 ' HA ' ' O ' ' A' 2101 ' ' VAL . 0.0 OUTLIER -63.97 170.9 3.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.241 0.543 . . . . 5.2199999999999998 111.155 179.575 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 10.1 p . . . . . 0 C--O 1.248 1.006 0 N-CA-C 108.432 -0.951 . . . . 5.8799999999999999 108.432 171.902 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . 0.452 ' HG2' ' H ' ' A' 2054 ' ' GLY . 21.9 tt0 . . . . . 0 N--CA 1.481 1.077 0 N-CA-C 109.37 -0.604 . . . . 6.8499999999999996 109.37 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . 0.452 ' H ' ' HG2' ' A' 2053 ' ' GLN . . . -156.3 167.78 33.49 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.682 -0.77 . . . . 3.4100000000000001 112.17 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 84.39 45.38 6.19 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 121.016 -0.611 . . . . 1.77 112.097 178.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.21 120.88 58.74 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 120.816 0.341 . . . . 2.4199999999999999 111.343 -179.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -76.88 -21.44 12.45 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.341 2.028 . . . . 1.72 111.915 176.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.6 mp -85.14 -22.4 28.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.874 -0.603 . . . . 2.3399999999999999 110.048 177.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 13.8 t -126.17 83.32 63.82 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 108.711 -0.848 . . . . 0.87 108.711 178.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . 0.495 ' O ' ' HG3' ' A' 2114 ' ' LYS . 33.3 Cg_exo -58.53 141.59 97.46 Favored 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 122.625 2.217 . . . . 1.04 112.196 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.1 mm -63.12 135.79 26.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.693 -0.685 . . . . 0.77000000000000002 110.112 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.421 ' HB3' HG22 ' A' 2065 ' ' VAL . 11.7 t70 -70.51 128.69 37.02 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.28 -0.418 . . . . 1.4199999999999999 110.064 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -89.38 0.19 57.01 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.112 -0.494 . . . . 1.55 112.005 -171.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -105.11 -12.76 15.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.955 0.407 . . . . 0.68999999999999995 110.972 178.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' A' 2067 ' ' PRO . 33.3 m -91.72 -174.59 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 109.744 -0.465 . . . . 0.81999999999999995 109.744 175.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -92.8 113.53 59.94 Favored Pre-proline 0 C--O 1.245 0.829 0 CA-C-O 121.268 0.556 . . . . 0.78000000000000003 111.354 179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.548 ' HA ' ' CB ' ' A' 2111 ' ' ARG . 51.0 Cg_endo -100.71 106.93 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.658 0 C-N-CA 123.096 2.531 . . . . 0.45000000000000001 111.45 167.13 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 16.7 p -138.88 178.88 6.83 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.072 0.463 . . . . 0.69999999999999996 111.176 -178.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 97.2 m-85 -103.0 159.45 15.5 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.71 -0.848 . . . . 1.1599999999999999 108.71 168.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . 0.414 ' HB2' ' O ' ' A' 2108 ' ' THR . 1.8 tm-20 -51.13 -44.13 61.32 Favored 'General case' 0 N--CA 1.468 0.474 0 O-C-N 123.755 0.66 . . . . 2.0899999999999999 112.203 -168.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 36.9 t70 -81.19 6.04 15.15 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 121.393 0.616 . . . . 2.1499999999999999 111.109 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 89.87 11.76 63.12 Favored Glycine 0 N--CA 1.45 -0.381 0 N-CA-C 111.675 -0.57 . . . . 0.63 111.675 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' 2069 ' ' PHE . 4.2 m -74.57 161.58 29.59 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.797 0.332 . . . . 0.89000000000000001 110.875 -173.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -120.37 -21.2 6.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 1.1299999999999999 110.883 179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' 2084 ' ' TYR . 8.0 tt0 -156.43 129.91 8.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.983 0.42 . . . . 2.0800000000000001 110.108 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.44 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.1 OUTLIER -126.78 100.59 6.25 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.972 -0.558 . . . . 1.48 110.816 178.029 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 32.2 m -96.34 123.7 40.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.077 -0.511 . . . . 0.63 110.287 174.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.564 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 2.7 mp -126.36 122.55 23.97 Favored Pre-proline 0 C--N 1.314 -0.936 0 N-CA-C 109.206 -0.664 . . . . 1.6200000000000001 109.206 177.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' 2078 ' ' ILE . 68.9 Cg_exo -51.36 109.99 0.37 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.329 2.686 . . . . 0.97999999999999998 113.274 -175.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 94.46 -6.65 71.35 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.93999999999999995 112.757 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.564 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.6 tt0 -109.1 -33.39 6.9 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.123 0.487 . . . . 2.02 110.584 -175.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 120.77 -155.18 16.29 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.628 -0.796 . . . . 0.5 112.552 176.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.454 HG22 HG23 ' A' 2085 ' ' THR . 32.1 m -150.72 137.4 18.92 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.32 0.581 . . . . 0.48999999999999999 110.533 178.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.3 OUTLIER -111.51 121.88 46.36 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.481 -1.303 . . . . 1.4399999999999999 107.481 170.784 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.454 HG23 HG22 ' A' 2083 ' ' THR . 2.6 p -118.88 158.15 26.23 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 112.828 0.677 . . . . 0.63 112.828 -171.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.558 ' HB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -159.33 124.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 115.009 -0.996 . . . . 1.1799999999999999 109.57 172.223 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . 0.599 HG22 ' OG1' ' A' 2091 ' ' THR . 9.9 m -107.58 157.52 35.59 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 108.871 -0.788 . . . . 0.80000000000000004 108.871 173.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.99 0.52 1.2 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 123.392 2.728 . . . . 0.96999999999999997 114.299 -171.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . 0.44 ' H ' HG23 ' A' 2087 ' ' VAL . 12.9 m-20 -82.45 -12.81 57.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 2.29 110.099 174.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 97.08 32.57 6.38 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.948 -0.644 . . . . 0.82999999999999996 112.338 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . 0.599 ' OG1' HG22 ' A' 2087 ' ' VAL . 63.7 p -87.86 136.06 33.12 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.261 -0.274 . . . . 1.51 110.261 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.481 HG13 HH11 ' A' 2111 ' ' ARG . 48.9 t -136.78 126.38 38.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 120.891 0.376 . . . . 1.1799999999999999 111.55 -177.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.7 t -146.92 109.72 4.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.529 0.681 . . . . 1.46 110.382 171.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . 0.67 ' CE2' HG11 ' A' 2109 ' ' VAL . 13.6 m-30 -84.91 101.99 12.77 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.373 -0.973 . . . . 1.27 108.373 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 2.1 m -110.13 88.62 7.28 Favored Pre-proline 0 N--CA 1.452 -0.356 0 CA-C-O 120.9 0.381 . . . . 0.57999999999999996 110.812 -177.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . 0.562 ' HD3' ' O ' ' A' 2094 ' ' PHE . 93.3 Cg_endo -92.27 166.97 2.95 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 123.436 2.758 . . . . 0.97999999999999998 112.547 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 13.0 t70 -131.8 110.17 10.65 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.401 -0.592 . . . . 2.7200000000000002 109.401 171.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . 0.48 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.2 OUTLIER -88.59 18.77 4.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.816 0.341 . . . . 4.8099999999999996 111.381 -176.403 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -119.86 7.13 10.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.076 0.465 . . . . 4.4199999999999999 110.158 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 53.3 t80 -83.57 113.14 20.61 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.635 -0.711 . . . . 2.3599999999999999 111.047 -178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 46.5 t -113.46 98.78 7.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.947 -0.57 . . . . 2.6800000000000002 109.664 175.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 172.17 43.3 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.711 -0.677 . . . . 3.8399999999999999 111.512 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 37.1 ttpt 60.45 83.49 0.21 Allowed Pre-proline 0 CA--C 1.531 0.226 0 C-N-CA 123.425 0.69 . . . . 6.7800000000000002 111.441 -178.327 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . 0.432 ' HG2' ' O ' ' A' 2124 ' ' SER . 14.1 Cg_endo -58.9 134.24 58.86 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.186 1.924 . . . . 2.4300000000000002 111.042 173.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 23.4 t70 -60.85 124.99 82.19 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.092 -0.504 . . . . 2.3300000000000001 110.889 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.462 ' HA ' ' O ' ' A' 2123 ' ' TYR . 27.2 Cg_endo -64.1 95.85 0.21 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.728 2.286 . . . . 1.03 112.048 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 4.9 p -128.58 160.83 38.51 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.386 -0.824 . . . . 0.59999999999999998 109.499 179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' 2070 ' ' GLU . 93.8 m -140.75 131.19 25.27 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.356 -0.609 . . . . 0.37 109.356 174.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.67 HG11 ' CE2' ' A' 2094 ' ' PHE . 6.0 t -92.04 137.51 21.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.773 -0.825 . . . . 0.76000000000000001 108.773 177.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -144.92 108.22 4.59 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.974 -0.38 . . . . 1.6299999999999999 109.974 -178.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.558 HH12 ' HB ' ' A' 2086 ' ' ILE . 15.0 ptp180 -159.6 156.55 28.17 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.162 -0.472 . . . . 3.4700000000000002 109.751 175.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.455 HG23 HG21 ' A' 2065 ' ' VAL . 34.7 m -109.41 140.65 27.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 C-N-CA 120.202 -0.599 . . . . 0.40000000000000002 111.577 -176.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.601 ' OD2' ' HB ' ' A' 2117 ' ' THR . 2.5 p30 -90.04 -169.04 2.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.62 -0.718 . . . . 1.46 111.121 178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . 0.495 ' HG3' ' O ' ' A' 2060 ' ' PRO . 99.4 mttt -59.47 -29.78 68.06 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.184 0.439 . . . . 1.72 112.184 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -86.05 -11.32 53.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 1.8400000000000001 110.738 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.14 13.03 59.39 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.048 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.601 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 73.5 m -78.81 128.3 77.29 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-O 120.569 0.223 . . . . 0.56999999999999995 110.549 178.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' 2117 ' ' THR . 2.7 Cg_exo -75.61 99.0 1.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.322 2.014 . . . . 0.60999999999999999 111.814 177.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . 0.427 ' HB ' ' CA ' ' A' 2054 ' ' GLY . 17.2 m -75.39 109.41 8.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.535 0.683 . . . . 0.59999999999999998 109.466 175.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' 2109 ' ' VAL . 80.3 p -120.33 167.26 12.49 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 115.319 -0.855 . . . . 0.67000000000000004 110.898 -175.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.461 ' HB3' HG23 ' A' 2109 ' ' VAL . . . -140.56 128.58 22.07 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.875 -0.787 . . . . 0.72999999999999998 108.875 173.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 10.9 p -92.1 98.87 11.81 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.236 0.541 . . . . 2.1899999999999999 110.664 -177.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.0 OUTLIER -115.5 123.41 48.47 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.784 -0.644 . . . . 2.8100000000000001 110.959 -178.43 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . 0.432 ' O ' ' HG2' ' A' 2104 ' ' PRO . 68.8 m -157.35 163.73 23.93 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.515 -0.766 . . . . 2.0600000000000001 109.04 178.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 93.0 Cg_exo -44.94 -49.23 9.98 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.659 2.239 . . . . 2.1600000000000001 112.523 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -81.99 59.16 4.22 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.56 0.695 . . . . 4.3300000000000001 110.707 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 90.3 t80 -126.84 124.7 40.24 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.412 -0.813 . . . . 3.8300000000000001 109.207 174.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 71.9 p 50.29 -149.82 0.25 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 123.401 0.68 . . . . 5.1100000000000003 111.724 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 21.2 mtmm 74.13 -172.94 0.13 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.647 0.779 . . . . 5.2199999999999998 111.514 178.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 C--O 1.247 0.972 0 CA-C-N 115.162 -0.926 . . . . 5.8799999999999999 110.257 177.232 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 62.0 tt0 . . . . . 0 N--CA 1.481 1.12 0 CA-C-O 120.702 0.287 . . . . 6.8499999999999996 110.628 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 83.99 -65.51 4.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.682 -0.771 . . . . 3.4100000000000001 112.65 176.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 163.9 -68.3 0.22 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.97 -0.852 . . . . 1.77 110.97 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -120.42 102.21 45.66 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 110.184 -0.302 . . . . 2.4199999999999999 110.184 173.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -68.43 -9.41 25.91 Favored 'Trans proline' 0 CA--C 1.528 0.218 0 C-N-CA 122.192 1.928 . . . . 1.72 111.862 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.5 mp -84.78 -18.85 33.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.923 -0.58 . . . . 2.3399999999999999 110.11 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.471 HG11 HD22 ' A' 2115 ' ' ASN . 4.6 t -138.84 89.86 12.74 Favored Pre-proline 0 CA--C 1.514 -0.41 0 N-CA-C 109.322 -0.621 . . . . 0.87 109.322 -177.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -53.25 120.68 8.13 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.315 2.01 . . . . 1.04 111.619 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 45.4 mm -49.77 134.82 8.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.152 -0.931 . . . . 0.77000000000000002 111.679 -176.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.552 ' O ' HG22 ' A' 2065 ' ' VAL . 14.6 t70 -76.65 130.26 37.54 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.437 -0.802 . . . . 1.4199999999999999 110.691 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -87.43 -8.29 56.69 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.238 0.458 . . . . 1.55 112.238 -174.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 29.7 p -101.75 0.79 36.47 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 120.5 -0.48 . . . . 0.68999999999999995 111.883 -178.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.595 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.6 m -92.87 -174.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.663 -0.244 . . . . 0.81999999999999995 110.507 176.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -97.35 107.89 41.36 Favored Pre-proline 0 C--O 1.24 0.598 0 CA-C-O 121.364 0.602 . . . . 0.78000000000000003 111.468 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.595 ' HD3' ' O ' ' A' 2065 ' ' VAL . 5.8 Cg_endo -93.71 108.75 0.17 Allowed 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.518 2.812 . . . . 0.45000000000000001 110.88 167.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.512 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.3 p -148.84 146.1 27.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.912 0.387 . . . . 0.69999999999999996 110.64 -177.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.486 ' CD2' ' N ' ' A' 2069 ' ' PHE . 2.4 m-30 -71.64 148.32 46.66 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.44 -1.319 . . . . 1.1599999999999999 107.44 176.071 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -61.08 -19.53 61.55 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.406 0.521 . . . . 2.0899999999999999 112.406 -165.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -92.03 1.33 57.26 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.621 0.248 . . . . 2.1499999999999999 111.131 178.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 87.59 25.21 33.5 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.86 -0.686 . . . . 0.63 112.018 -176.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 19.5 m -95.22 152.33 18.46 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.831 0.348 . . . . 0.89000000000000001 110.511 -179.211 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -111.62 -22.47 11.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.084 -0.507 . . . . 1.1299999999999999 110.58 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' 2084 ' ' TYR . 3.0 tt0 -144.35 144.43 31.44 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.113 0.482 . . . . 2.0800000000000001 110.243 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.425 ' O ' ' HA ' ' A' 2083 ' ' THR . 0.4 OUTLIER -139.59 108.14 5.88 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.401 -0.818 . . . . 1.48 109.505 179.854 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 19.2 m -118.64 133.23 56.01 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.189 0.518 . . . . 0.63 111.493 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.549 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 4.2 mp -136.39 123.03 14.01 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 108.106 -1.072 . . . . 1.6200000000000001 108.106 172.276 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -52.29 109.48 0.34 Allowed 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.669 2.246 . . . . 0.97999999999999998 112.458 -178.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.65 -22.23 28.73 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.736 -0.665 . . . . 0.93999999999999995 112.383 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.549 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 52.7 tt0 -96.06 -31.52 12.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.085 0.469 . . . . 2.02 110.463 -175.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.49 -153.64 17.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.837 -0.697 . . . . 0.5 112.141 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.49 HG22 HG23 ' A' 2085 ' ' THR . 43.0 m -150.0 144.96 26.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.65 0.738 . . . . 0.48999999999999999 110.824 178.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.528 ' O ' ' HA ' ' A' 2075 ' ' GLU . 7.6 m-85 -120.15 125.01 47.17 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 107.236 -1.394 . . . . 1.4399999999999999 107.236 172.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.49 HG23 HG22 ' A' 2083 ' ' THR . 17.3 p -129.07 134.75 48.23 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.544 0.572 . . . . 0.63 112.544 -174.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.563 HD13 HG22 ' A' 2092 ' ' VAL . 0.7 OUTLIER -130.82 123.94 55.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.562 -0.744 . . . . 1.1799999999999999 110.142 170.155 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 19.2 m -112.15 151.58 43.75 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.003 -0.74 . . . . 0.80000000000000004 109.003 172.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.76 -6.27 1.06 Allowed 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.057 3.171 . . . . 0.96999999999999997 114.922 -168.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 27.1 t70 -66.85 -24.07 66.1 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.126 0.489 . . . . 2.29 110.179 175.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 104.11 20.07 10.94 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.738 -0.665 . . . . 0.82999999999999996 112.223 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 1.8 t -110.42 126.38 54.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.962 0.41 . . . . 1.51 110.64 -177.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.563 HG22 HD13 ' A' 2086 ' ' ILE . 7.6 t -133.08 137.42 53.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.016 -0.538 . . . . 1.1799999999999999 110.384 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.3 t -119.36 118.29 30.79 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.042 0.448 . . . . 1.46 110.19 173.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 9.4 m-30 -85.24 97.21 9.8 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.663 -0.866 . . . . 1.27 108.663 173.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 13.3 m -116.49 87.05 19.44 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.994 0.426 . . . . 0.57999999999999996 110.76 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -92.44 169.69 2.64 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.327 2.685 . . . . 0.97999999999999998 112.42 176.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 10.9 t70 -118.35 106.51 12.83 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.872 -0.788 . . . . 2.7200000000000002 108.872 171.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 93.2 mttt -69.77 -10.1 57.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.961 -0.563 . . . . 4.8099999999999996 112.194 -171.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -110.46 8.88 23.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.703 0.287 . . . . 4.4199999999999999 111.111 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 44.9 t80 -89.63 76.98 7.25 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.2 0.524 . . . . 2.3599999999999999 110.904 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' 2129 ' ' LYS . 4.2 p -103.96 124.98 58.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.216 0.531 . . . . 2.6800000000000002 110.083 174.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 164.63 -81.9 0.11 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.047 -0.821 . . . . 3.8399999999999999 111.047 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 22.7 tptm -140.42 76.72 24.99 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 120.935 0.398 . . . . 6.7800000000000002 110.707 175.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -80.53 169.57 16.85 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.16 2.573 . . . . 2.4300000000000002 111.445 173.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 35.3 t70 -103.06 125.3 35.64 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 116.544 -0.298 . . . . 2.3300000000000001 110.198 178.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' 2123 ' ' TYR . 24.7 Cg_endo -62.96 103.5 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.734 2.29 . . . . 1.03 111.928 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . 0.425 HG11 ' HG2' ' A' 2076 ' ' LYS . 7.7 p -141.37 133.78 29.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.137 -0.483 . . . . 0.59999999999999998 111.049 -177.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.3 m -102.5 108.71 20.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.652 -0.704 . . . . 0.37 109.906 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' 2120 ' ' THR . 8.5 t -91.09 123.09 43.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.772 -0.825 . . . . 0.76000000000000001 108.772 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.512 ' HB3' ' O ' ' A' 2068 ' ' THR . 1.7 tmmt? -129.59 149.6 51.28 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.402 0.62 . . . . 1.6299999999999999 112.203 -169.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.51 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.3 ptt180 -166.91 138.2 3.28 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.97 -1.014 . . . . 3.4700000000000002 108.292 165.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.526 ' O ' HG21 ' A' 2065 ' ' VAL . 27.1 m -98.61 148.88 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 C-N-CA 120.357 -0.537 . . . . 0.40000000000000002 110.871 -175.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.433 ' OD2' HG11 ' A' 2059 ' ' VAL . 2.7 p-10 -94.12 -168.7 1.91 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.933 -0.576 . . . . 1.46 110.448 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.5 mttm -62.88 -32.34 73.57 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.702 0.287 . . . . 1.72 111.393 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . 0.471 HD22 HG11 ' A' 2059 ' ' VAL . 41.1 m-80 -77.54 -14.96 59.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.955 0.407 . . . . 1.8400000000000001 110.599 176.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 91.87 12.47 59.13 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.906 -0.664 . . . . 0.44 112.333 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 27.8 m -85.83 121.26 73.15 Favored Pre-proline 0 C--N 1.324 -0.533 0 N-CA-C 110.106 -0.331 . . . . 0.56999999999999995 110.106 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' 2117 ' ' THR . 3.1 Cg_exo -74.74 107.86 2.57 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 122.261 1.974 . . . . 0.60999999999999999 112.653 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . 0.424 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 15.6 m -74.78 112.03 11.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 107.737 -1.208 . . . . 0.59999999999999998 107.737 169.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.616 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.7 p -127.41 159.32 34.83 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.636 -0.711 . . . . 0.67000000000000004 112.192 -169.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.46 127.63 42.86 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.8 -1.185 . . . . 0.72999999999999998 107.8 169.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 12.5 p -115.67 99.53 7.39 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.23 0.538 . . . . 2.1899999999999999 111.171 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.508 ' O ' ' HA ' ' A' 2106 ' ' PRO . 4.4 m-85 -90.08 151.98 21.36 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.677 -0.692 . . . . 2.8100000000000001 111.099 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . 0.435 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 33.3 p -148.2 168.01 12.04 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 115.957 -0.565 . . . . 2.0600000000000001 110.551 -177.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' 2124 ' ' SER . 71.3 Cg_exo -51.23 -40.68 60.5 Favored 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.574 2.183 . . . . 2.1600000000000001 112.975 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 19.6 mm-40 -91.35 -54.77 3.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.874 0.369 . . . . 4.3300000000000001 110.528 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 63.7 t80 63.51 -94.62 0.04 OUTLIER 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.332 -0.849 . . . . 3.8300000000000001 111.821 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . 0.413 ' O ' ' HB ' ' A' 2101 ' ' VAL . 13.1 m -162.42 158.19 23.52 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.231 -0.655 . . . . 5.1100000000000003 109.231 -176.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . 0.471 ' HB3' HG21 ' A' 2101 ' ' VAL . 17.8 ptpt -125.82 179.15 5.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.806 0.336 . . . . 5.2199999999999998 110.292 175.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.728 -0.653 . . . . 5.8799999999999999 110.382 -176.099 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 8.2 mp0 . . . . . 0 N--CA 1.482 1.131 0 CA-C-O 121.081 0.467 . . . . 6.8499999999999996 110.604 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -170.08 -86.18 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.885 -0.674 . . . . 3.4100000000000001 111.96 -179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . 0.496 ' O ' ' HD3' ' A' 2057 ' ' PRO . . . 137.3 -9.41 3.8 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.452 -0.88 . . . . 1.77 112.903 179.101 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . 0.526 ' HB2' ' O ' ' A' 2059 ' ' VAL . 4.1 p-10 -92.82 95.99 1.24 Allowed Pre-proline 0 C--N 1.327 -0.404 0 CA-C-O 121.262 0.553 . . . . 2.4199999999999999 110.812 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . 0.496 ' HD3' ' O ' ' A' 2055 ' ' GLY . 57.6 Cg_endo -69.0 -53.11 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.375 2.05 . . . . 1.72 112.618 -170.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . 0.408 HD22 ' HB2' ' A' 2057 ' ' PRO . 3.8 mm? -121.32 19.4 11.4 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.999 -0.371 . . . . 2.3399999999999999 109.999 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.526 ' O ' ' HB2' ' A' 2056 ' ' ASP . 0.0 OUTLIER -131.85 77.52 72.01 Favored Pre-proline 0 N--CA 1.449 -0.523 0 C-N-CA 120.332 -0.547 . . . . 0.87 110.026 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.82 120.99 8.77 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.511 2.141 . . . . 1.04 111.95 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . 0.633 HG13 ' NE ' ' A' 2111 ' ' ARG . 47.1 mm -49.94 128.55 6.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.354 -0.839 . . . . 0.77000000000000002 111.846 -178.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.489 ' O ' HG22 ' A' 2065 ' ' VAL . 11.1 t70 -66.81 136.8 55.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.746 -0.661 . . . . 1.4199999999999999 110.171 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -88.71 1.19 55.57 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 112.567 0.58 . . . . 1.55 112.567 -171.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 70.1 p -120.29 -0.39 10.44 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.885 0.328 . . . . 0.68999999999999995 111.885 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.676 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.8 m -86.35 -173.13 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.162 -0.31 . . . . 0.81999999999999995 110.162 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -95.65 105.47 20.97 Favored Pre-proline 0 C--O 1.238 0.474 0 CA-C-O 120.966 0.412 . . . . 0.78000000000000003 111.513 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' 2065 ' ' VAL . 33.4 Cg_endo -100.31 106.96 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 122.898 2.399 . . . . 0.45000000000000001 110.872 167.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.51 ' O ' ' HB3' ' A' 2110 ' ' LYS . 18.7 p -141.1 148.27 39.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.223 0.535 . . . . 0.69999999999999996 110.585 -176.118 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.53 ' N ' ' HD1' ' A' 2069 ' ' PHE . 1.3 m-30 -74.58 149.36 40.16 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.416 -0.957 . . . . 1.1599999999999999 108.416 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . 0.475 ' CB ' ' HB ' ' A' 2108 ' ' THR . 5.2 tm-20 -50.78 -42.12 57.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.955 0.407 . . . . 2.0899999999999999 110.459 -173.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -71.89 0.79 8.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 115.638 -0.71 . . . . 2.1499999999999999 112.563 -178.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 82.92 29.94 33.21 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.572 -0.823 . . . . 0.63 112.001 -176.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 15.7 m -106.75 159.15 16.44 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.849 0.357 . . . . 0.89000000000000001 111.043 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -109.84 -18.8 13.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 1.1299999999999999 110.638 176.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.477 ' HB2' HG22 ' A' 2085 ' ' THR . 6.0 tt0 -148.68 136.69 20.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.146 0.498 . . . . 2.0800000000000001 109.853 173.045 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.408 ' HE2' HD11 ' A' 2078 ' ' ILE . 32.9 tptt -128.29 113.65 15.9 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.541 -0.754 . . . . 1.48 109.183 175.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 46.3 m -117.91 124.9 49.4 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-O 121.482 0.658 . . . . 0.63 110.895 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.595 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 12.3 mt -120.2 120.74 29.89 Favored Pre-proline 0 C--N 1.313 -1.013 0 N-CA-C 107.774 -1.195 . . . . 1.6200000000000001 107.774 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -41.91 108.66 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 123.551 2.834 . . . . 0.97999999999999998 113.806 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.19 -30.48 6.71 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.486 -0.779 . . . . 0.93999999999999995 113.037 177.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.595 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.4 tt0 -74.83 -30.29 61.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.246 0.546 . . . . 2.02 110.172 -174.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 125.82 -171.34 17.67 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.471 -0.871 . . . . 0.5 112.571 175.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 38.3 m -140.25 132.29 27.86 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.534 0.683 . . . . 0.48999999999999999 110.695 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.498 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.6 OUTLIER -106.49 129.82 54.38 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.882 -1.525 . . . . 1.4399999999999999 106.882 169.521 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.477 HG22 ' HB2' ' A' 2075 ' ' GLU . 0.8 OUTLIER -133.06 140.59 47.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.258 0.551 . . . . 0.63 112.438 -175.939 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.538 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -130.27 131.64 65.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.152 -0.931 . . . . 1.1799999999999999 109.672 173.289 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . 0.401 ' HA ' ' HD3' ' A' 2088 ' ' PRO . 27.7 m -115.33 149.42 42.75 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.727 -0.472 . . . . 0.80000000000000004 109.727 174.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' 2087 ' ' VAL . 32.2 Cg_exo -59.04 -6.42 3.62 Favored 'Trans proline' 0 C--N 1.349 0.595 0 C-N-CA 123.808 3.005 . . . . 0.96999999999999997 114.147 -170.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -70.23 -13.89 62.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.002 0.43 . . . . 2.29 110.206 177.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 96.9 17.71 31.81 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.929 -0.653 . . . . 0.82999999999999996 112.182 178.521 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 4.8 t -115.52 133.46 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.049 0.452 . . . . 1.51 109.824 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.538 HG13 ' HB ' ' A' 2086 ' ' ILE . 11.6 t -135.12 149.79 29.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.581 . . . . 1.1799999999999999 110.237 -173.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.0 t -136.23 123.74 22.18 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.287 0.565 . . . . 1.46 110.871 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.6 m-30 -99.13 98.72 9.7 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.193 -0.669 . . . . 1.27 109.193 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 12.0 m -113.96 96.79 42.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.873 0.368 . . . . 0.57999999999999996 111.026 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -89.17 176.35 3.17 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 123.246 2.631 . . . . 0.97999999999999998 112.787 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . 0.465 ' HB3' ' HA ' ' A' 2081 ' ' GLN . 6.4 p-10 -71.7 102.02 2.7 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.319 -0.855 . . . . 2.7200000000000002 112.139 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . 0.66 ' HD2' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -92.05 -9.76 41.6 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.087 -0.506 . . . . 4.8099999999999996 110.263 173.694 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . 0.402 ' HG3' ' HG2' ' A' 2098 ' ' LYS . 94.3 mt-30 -120.64 -52.55 2.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.073 -0.512 . . . . 4.4199999999999999 110.299 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 85.9 t80 -59.13 145.31 42.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.426 -0.806 . . . . 2.3599999999999999 111.454 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' 2128 ' ' THR . 8.9 p -160.32 143.41 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 115.655 -0.702 . . . . 2.6800000000000002 109.382 175.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 152.57 -94.07 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.578 -0.82 . . . . 3.8399999999999999 112.453 -178.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 63.7 tttp -120.73 89.17 44.75 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-O 120.857 0.36 . . . . 6.7800000000000002 110.507 177.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.74 139.44 25.03 Favored 'Trans proline' 0 N--CA 1.459 -0.531 0 C-N-CA 122.712 2.275 . . . . 2.4300000000000002 111.097 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.51 ' HB3' HD13 ' A' 2078 ' ' ILE . 32.0 t70 -85.17 130.69 50.97 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 109.555 -0.535 . . . . 2.3300000000000001 109.555 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' 2123 ' ' TYR . 18.0 Cg_endo -60.41 119.55 6.8 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.117 2.544 . . . . 1.03 112.93 -177.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.5 p -159.36 133.64 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.746 -0.661 . . . . 0.59999999999999998 110.372 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' 2121 ' ' ALA . 34.1 m -105.51 119.31 38.79 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.188 0.518 . . . . 0.37 109.718 173.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -95.29 139.04 19.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.863 -0.792 . . . . 0.76000000000000001 108.863 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.51 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.9 tmmm? -140.68 147.65 39.59 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 118.366 0.53 . . . . 1.6299999999999999 111.438 -171.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.633 ' NE ' HG13 ' A' 2061 ' ' ILE . 29.1 ptt180 -168.98 135.28 1.73 Allowed 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.838 -0.801 . . . . 3.4700000000000002 108.838 171.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 23.2 m -99.8 149.99 5.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.207 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.436 ' HB3' HD13 ' A' 2061 ' ' ILE . 4.7 p-10 -93.93 -168.92 1.97 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.923 -0.581 . . . . 1.46 110.736 178.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 98.7 mttt -58.31 -41.78 85.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.19 -0.459 . . . . 1.72 111.929 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -18.74 46.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.869 0.366 . . . . 1.8400000000000001 110.45 -177.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 106.14 16.76 14.11 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.543 -0.837 . . . . 0.44 113.641 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.419 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.8 m -83.83 119.26 73.28 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 117.187 0.494 . . . . 0.56999999999999995 110.376 175.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -77.92 102.15 1.55 Allowed 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.369 2.046 . . . . 0.60999999999999999 111.988 177.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 27.7 m -74.88 117.59 19.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 108.545 -0.909 . . . . 0.59999999999999998 108.545 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' 2109 ' ' VAL . 61.2 p -126.25 161.14 28.43 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.524 -0.762 . . . . 0.67000000000000004 111.78 -170.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.537 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -129.09 127.44 41.48 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 107.981 -1.118 . . . . 0.72999999999999998 107.981 169.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 21.9 m -116.15 103.93 11.03 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 120.974 0.416 . . . . 2.1899999999999999 110.54 -174.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.572 ' O ' ' HA ' ' A' 2106 ' ' PRO . 2.3 m-85 -100.72 131.01 46.83 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 112.048 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 16.1 m -131.77 146.81 63.42 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.135 -0.939 . . . . 2.0600000000000001 109.391 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.13 21.13 0.45 Allowed 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.815 2.343 . . . . 2.1600000000000001 112.957 -178.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -81.73 -31.19 32.17 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.029 0.442 . . . . 4.3300000000000001 110.75 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 36.2 t80 -86.12 124.86 33.01 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.681 -0.489 . . . . 3.8300000000000001 109.681 178.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . 0.478 ' O ' HG22 ' A' 2101 ' ' VAL . 6.0 m -103.59 -81.08 0.52 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.362 -0.381 . . . . 5.1100000000000003 110.592 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 18.8 ptpt 178.16 -176.4 0.2 Allowed 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.303 -0.629 . . . . 5.2199999999999998 109.303 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.441 -0.79 . . . . 5.8799999999999999 110.112 178.218 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 80.6 mt-30 . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.569 0.223 . . . . 6.8499999999999996 110.87 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 59.8 38.22 93.64 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-N 116.0 -0.546 . . . . 3.4100000000000001 113.339 176.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -136.7 -131.85 3.02 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.483 -0.865 . . . . 1.77 111.904 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.31 124.44 29.04 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-O 121.114 0.483 . . . . 2.4199999999999999 110.269 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -69.32 -52.82 0.33 Allowed 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.87 2.38 . . . . 1.72 111.862 177.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . 0.828 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -68.33 -9.38 47.45 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.423 -0.808 . . . . 2.3399999999999999 112.854 176.677 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.828 HG23 HD13 ' A' 2058 ' ' LEU . 5.7 t -137.72 86.69 18.16 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 109.666 -0.494 . . . . 0.87 109.666 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -55.41 131.05 43.91 Favored 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.378 2.052 . . . . 1.04 111.847 -177.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 43.1 mm -62.86 122.66 14.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.904 -0.589 . . . . 0.77000000000000002 109.935 -179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' 2065 ' ' VAL . 21.1 t70 -70.46 134.52 47.84 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.236 0.541 . . . . 1.4199999999999999 110.496 -176.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -89.3 -2.09 58.32 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.844 -0.616 . . . . 1.55 111.914 -171.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 73.6 p -113.99 -2.67 13.48 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.829 -0.348 . . . . 0.68999999999999995 111.848 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.59 ' O ' ' HD3' ' A' 2067 ' ' PRO . 26.8 m -81.59 -174.59 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.973 -0.291 . . . . 0.81999999999999995 110.284 177.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.11 109.27 51.11 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.211 0.529 . . . . 0.78000000000000003 111.202 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.59 ' HD3' ' O ' ' A' 2065 ' ' VAL . 50.5 Cg_endo -99.57 111.19 0.07 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.518 0 C-N-CA 123.305 2.67 . . . . 0.45000000000000001 110.875 165.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 8.4 p -145.13 -178.98 6.33 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.211 0.529 . . . . 0.69999999999999996 110.758 -176.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.562 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 39.0 m-85 -102.73 148.25 25.84 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.735 -0.839 . . . . 1.1599999999999999 108.735 168.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -59.98 -24.23 64.27 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.962 0.789 . . . . 2.0899999999999999 111.593 -172.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -86.05 -3.45 58.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.309 -0.405 . . . . 2.1499999999999999 110.858 178.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.57 29.88 12.97 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.147 -0.549 . . . . 0.63 113.066 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 26.3 p -110.61 179.15 4.15 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.032 0.416 . . . . 0.89000000000000001 111.276 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . 0.411 ' O ' HG22 ' A' 2086 ' ' ILE . 34.6 mmtp -124.78 -4.8 7.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-O 120.957 0.408 . . . . 1.1299999999999999 111.159 -178.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -159.56 132.32 6.76 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.457 -0.571 . . . . 2.0800000000000001 109.457 169.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.457 ' HA ' ' HD2' ' A' 2076 ' ' LYS . 3.7 mmmm -120.01 100.89 7.48 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.968 -0.56 . . . . 1.48 110.306 174.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 89.5 m -97.51 111.57 23.78 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.876 -0.602 . . . . 0.63 110.242 173.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.469 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 96.6 mt -110.8 117.26 50.83 Favored Pre-proline 0 C--N 1.31 -1.113 0 N-CA-C 108.74 -0.837 . . . . 1.6200000000000001 108.74 175.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -46.37 112.52 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.501 2.801 . . . . 0.97999999999999998 113.574 -174.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 87.74 -11.09 67.55 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.783 -0.644 . . . . 0.93999999999999995 112.795 177.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.469 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.2 tm0? -101.19 -31.88 10.8 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.22 0.533 . . . . 2.02 110.296 -174.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 131.63 -170.42 21.58 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.45 -0.881 . . . . 0.5 113.095 173.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.536 ' O ' ' HB ' ' A' 2095 ' ' THR . 86.6 m -144.38 136.58 26.37 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.476 -0.564 . . . . 0.48999999999999999 109.476 177.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -117.77 126.86 53.23 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.493 -1.299 . . . . 1.4399999999999999 107.493 174.189 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 11.9 p -120.38 127.43 52.28 Favored 'General case' 0 C--N 1.316 -0.862 0 C-N-CA 120.822 -0.351 . . . . 0.63 111.709 -175.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.481 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -108.08 135.44 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.955 -0.566 . . . . 1.1799999999999999 109.864 175.58 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 26.7 m -122.22 150.69 57.48 Favored Pre-proline 0 C--N 1.318 -0.787 0 N-CA-C 109.41 -0.589 . . . . 0.80000000000000004 109.41 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 34.6 Cg_exo -60.0 -1.28 1.17 Allowed 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 123.737 2.958 . . . . 0.96999999999999997 113.792 -174.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . 0.423 ' HB3' HG22 ' A' 2091 ' ' THR . 16.8 t70 -66.4 -20.17 65.99 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.267 0.556 . . . . 2.29 109.865 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 99.49 14.79 34.1 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.245 -0.742 . . . . 0.82999999999999996 111.245 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . 0.423 HG22 ' HB3' ' A' 2089 ' ' ASP . 8.8 t -120.31 146.61 45.95 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.312 -0.444 . . . . 1.51 110.376 -177.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 21.5 t -132.82 138.56 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.353 -0.61 . . . . 1.1799999999999999 109.353 179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 51.6 m -97.76 109.98 22.63 Favored 'General case' 0 N--CA 1.439 -0.98 0 CA-C-O 120.789 0.328 . . . . 1.46 110.251 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 7.8 m-30 -86.81 98.41 11.17 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.64 -0.504 . . . . 1.27 109.64 179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . 0.536 ' HB ' ' O ' ' A' 2083 ' ' THR . 58.4 m -109.4 99.11 35.37 Favored Pre-proline 0 C--O 1.234 0.241 0 CA-C-O 120.942 0.401 . . . . 0.57999999999999996 110.524 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -88.27 162.15 6.96 Favored 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 123.346 2.697 . . . . 0.97999999999999998 113.966 -174.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . 0.462 ' HB2' ' CB ' ' A' 2100 ' ' PHE . 10.4 p-10 -72.46 48.31 0.19 Allowed 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.091 -0.959 . . . . 2.7200000000000002 111.776 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -70.63 -10.01 58.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.079 0.466 . . . . 4.8099999999999996 111.167 -175.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -116.65 24.44 11.29 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.117 -0.492 . . . . 4.4199999999999999 110.753 178.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . 0.462 ' CB ' ' HB2' ' A' 2097 ' ' ASP . 63.7 t80 -113.8 142.2 46.36 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.156 0.503 . . . . 2.3599999999999999 111.762 -173.4 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . 0.49 HG13 ' HB3' ' A' 2129 ' ' LYS . 74.3 t -132.26 105.01 8.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.633 -0.712 . . . . 2.6800000000000002 110.19 176.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.29 -99.46 0.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 N-CA-C 111.279 -0.729 . . . . 3.8399999999999999 111.279 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.18 120.51 0.89 Allowed Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 109.715 -0.476 . . . . 6.7800000000000002 109.715 170.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.52 147.66 22.63 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.73 2.287 . . . . 2.4300000000000002 112.162 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 18.8 m-20 -80.46 147.02 62.78 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.029 -0.532 . . . . 2.3300000000000001 109.94 179.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.467 ' HA ' ' O ' ' A' 2123 ' ' TYR . 45.9 Cg_endo -68.04 128.95 18.51 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.147 2.565 . . . . 1.03 113.908 -171.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 5.5 p -158.08 160.0 2.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.38 -0.827 . . . . 0.59999999999999998 109.169 177.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 26.5 m -141.25 122.35 14.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.115 0.483 . . . . 0.37 110.415 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 5.2 t -92.22 133.47 33.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 108.922 -0.77 . . . . 0.76000000000000001 108.922 178.144 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -125.84 109.63 12.74 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 120.683 0.278 . . . . 1.6299999999999999 111.387 -169.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' 2119 ' ' VAL . 30.8 ptt180 -147.3 135.4 21.46 Favored 'General case' 0 C--N 1.317 -0.818 0 O-C-N 121.797 -0.565 . . . . 3.4700000000000002 110.133 168.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.498 ' O ' HG21 ' A' 2065 ' ' VAL . 34.2 m -99.09 154.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 120.998 0.428 . . . . 0.40000000000000002 110.758 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.546 ' OD2' ' HB ' ' A' 2117 ' ' THR . 10.1 p30 -94.38 -169.59 2.08 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.81 -0.632 . . . . 1.46 110.778 178.139 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 67.7 mttm -65.06 -22.85 67.03 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.15 0.426 . . . . 1.72 112.15 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -90.5 -19.01 24.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.054 0.455 . . . . 1.8400000000000001 110.235 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 102.94 15.13 24.93 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.662 -0.699 . . . . 0.44 111.962 179.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.546 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 24.1 m -91.62 119.63 68.44 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-O 120.805 0.336 . . . . 0.56999999999999995 110.221 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' 2117 ' ' THR . 8.2 Cg_exo -72.68 107.34 2.3 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.46 2.106 . . . . 0.60999999999999999 113.241 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.95 109.25 9.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 108.088 -1.078 . . . . 0.59999999999999998 108.088 165.008 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . . . . . . . . . 75.0 p -125.14 179.5 5.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.105 -0.952 . . . . 0.67000000000000004 110.553 -171.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.61 127.2 41.8 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.606 -0.887 . . . . 0.72999999999999998 108.606 170.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 30.9 p -93.39 101.67 13.9 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.877 -0.601 . . . . 2.1899999999999999 109.898 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' 2106 ' ' PRO . 5.4 m-85 -120.25 122.96 42.04 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.633 0.73 . . . . 2.8100000000000001 112.17 -175.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 46.9 p -152.42 158.18 33.5 Favored Pre-proline 0 C--N 1.321 -0.642 0 CA-C-N 114.478 -1.237 . . . . 2.0600000000000001 108.859 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -72.57 10.75 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.474 2.116 . . . . 2.1600000000000001 112.794 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -79.06 -26.29 43.08 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.201 0.524 . . . . 4.3300000000000001 109.679 176.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -77.22 154.43 33.06 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.606 -0.725 . . . . 3.8300000000000001 109.266 176.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 14.6 p -135.22 -73.71 0.46 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.152 0.501 . . . . 5.1100000000000003 110.832 -177.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . 0.49 ' HB3' HG13 ' A' 2101 ' ' VAL . 0.1 OUTLIER -120.48 166.38 13.67 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.72 -0.673 . . . . 5.2199999999999998 110.066 179.897 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 38.2 t . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.419 -0.801 . . . . 5.8799999999999999 110.007 179.931 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 . . . . . 0 N--CA 1.479 1.005 0 N-CA-C 110.204 -0.295 . . . . 6.8499999999999996 110.204 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 73.66 43.32 36.53 Favored Glycine 0 N--CA 1.453 -0.175 0 C-N-CA 120.692 -0.766 . . . . 3.4100000000000001 111.842 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -172.46 -100.12 0.13 Allowed Glycine 0 N--CA 1.444 -0.831 0 N-CA-C 111.031 -0.827 . . . . 1.77 111.031 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 6.9 t70 -125.74 123.43 24.76 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 110.106 -0.331 . . . . 2.4199999999999999 110.106 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.34 -20.31 42.68 Favored 'Trans proline' 0 C--O 1.233 0.265 0 C-N-CA 122.585 2.19 . . . . 1.72 112.596 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.8 mp -100.29 -26.78 13.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.795 0.331 . . . . 2.3399999999999999 110.301 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 4.6 t -116.52 82.43 12.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.186 -0.461 . . . . 0.87 109.818 178.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.44 120.1 7.25 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.374 2.049 . . . . 1.04 111.559 179.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 44.7 mm -49.9 131.21 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.522 -0.763 . . . . 0.77000000000000002 110.908 179.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' 2065 ' ' VAL . 10.6 t70 -69.25 135.1 50.03 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.458 -0.792 . . . . 1.4199999999999999 110.588 -176.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -97.49 2.96 50.83 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.987 0.366 . . . . 1.55 111.987 -173.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.2 p -109.74 3.32 20.75 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.08 0.943 . . . . 0.68999999999999995 108.97 173.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.709 ' O ' ' HD3' ' A' 2067 ' ' PRO . 1.0 OUTLIER -91.29 165.22 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 CA-C-N 114.041 -1.436 . . . . 0.81999999999999995 110.108 -178.807 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.37 108.98 9.85 Favored Pre-proline 0 C--O 1.24 0.553 0 CA-C-O 120.697 0.284 . . . . 0.78000000000000003 111.368 177.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' 2065 ' ' VAL . 60.7 Cg_endo -102.34 108.6 0.04 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.57 0 C-N-CA 123.454 2.769 . . . . 0.45000000000000001 111.328 166.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 21.3 p -134.5 174.45 10.53 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.529 0.68 . . . . 0.69999999999999996 111.335 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.528 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.7 OUTLIER -101.13 151.4 21.87 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.64 -1.245 . . . . 1.1599999999999999 107.64 170.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -45.71 -41.72 10.91 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 123.719 0.637 . . . . 2.0899999999999999 112.391 -171.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -90.17 16.58 8.27 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 111.944 0.35 . . . . 2.1499999999999999 111.944 -175.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 30.0 58.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.663 -0.78 . . . . 0.63 112.668 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 1.3 p -102.92 167.96 9.52 Favored 'General case' 0 C--N 1.323 -0.564 0 O-C-N 122.859 -0.201 . . . . 0.89000000000000001 110.496 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . 0.425 ' O ' HG22 ' A' 2086 ' ' ILE . 42.1 mmtm -123.39 -10.45 7.97 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.246 0.462 . . . . 1.1299999999999999 112.246 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -158.77 128.1 5.59 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.928 0.394 . . . . 2.0800000000000001 110.156 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.35 100.47 6.96 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.185 -0.672 . . . . 1.48 109.185 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 62.8 m -109.78 127.21 54.49 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.282 -0.417 . . . . 0.63 111.112 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.614 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 35.4 mm -131.32 132.01 23.37 Favored Pre-proline 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.917 . . . . 1.6200000000000001 108.523 171.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.76 108.9 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.478 2.119 . . . . 0.97999999999999998 112.197 178.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' 2101 ' ' VAL . . . 99.83 -4.09 57.6 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.018 -0.61 . . . . 0.93999999999999995 112.319 -179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.614 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.1 tt0 -107.33 -29.79 9.08 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.125 0.488 . . . . 2.02 110.222 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 103.89 -162.35 15.49 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.565 -0.743 . . . . 0.5 111.641 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.518 ' O ' ' HB ' ' A' 2095 ' ' THR . 47.1 m -139.76 135.43 33.08 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.568 0.699 . . . . 0.48999999999999999 110.729 178.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.508 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.6 m-85 -104.58 110.74 23.15 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 107.069 -1.456 . . . . 1.4399999999999999 107.069 171.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.491 HG23 HG22 ' A' 2083 ' ' THR . 13.3 p -108.24 123.67 49.12 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.323 0.49 . . . . 0.63 112.323 -171.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.5 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -125.93 130.8 72.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.112 -0.494 . . . . 1.1799999999999999 109.84 170.349 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.5 m -122.33 150.59 57.59 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.01 -0.541 . . . . 0.80000000000000004 109.748 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.94 -3.9 1.78 Allowed 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 123.949 3.099 . . . . 0.96999999999999997 114.276 -172.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . 0.401 ' HB2' HG22 ' A' 2091 ' ' THR . 5.3 m-20 -69.3 -13.95 62.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.223 0.535 . . . . 2.29 110.057 176.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.57 8.16 54.92 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.531 -0.759 . . . . 0.82999999999999996 111.552 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' 2089 ' ' ASP . 6.8 t -111.44 129.01 56.16 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.381 0.61 . . . . 1.51 110.501 -177.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.6 HG13 ' NH1' ' A' 2111 ' ' ARG . 1.1 p -150.08 139.29 15.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.529 -0.76 . . . . 1.1799999999999999 110.538 -176.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -127.57 130.92 49.93 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.098 0.475 . . . . 1.46 110.747 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . 0.466 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.5 m-30 -84.36 99.02 10.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.463 -0.94 . . . . 1.27 108.463 175.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' 2083 ' ' THR . 19.6 m -116.54 89.35 27.25 Favored Pre-proline 0 N--CA 1.454 -0.259 0 CA-C-O 121.215 0.531 . . . . 0.57999999999999996 111.815 -175.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' 2094 ' ' PHE . 5.3 Cg_endo -87.41 142.2 6.02 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 123.207 2.605 . . . . 0.97999999999999998 110.877 172.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.49 137.23 58.19 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.184 -0.462 . . . . 2.7200000000000002 110.712 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.15 -20.21 63.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.378 -0.828 . . . . 4.8099999999999996 112.184 -175.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -103.49 -44.73 5.05 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.711 -0.477 . . . . 4.4199999999999999 109.711 177.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . 0.465 ' CE1' ' HB3' ' A' 2104 ' ' PRO . 43.1 t80 65.1 72.2 0.44 Allowed 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.654 0.74 . . . . 2.3599999999999999 110.804 177.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . 0.424 ' O ' ' HA3' ' A' 2080 ' ' GLY . 77.1 t -145.03 117.81 2.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.125 -0.943 . . . . 2.6800000000000002 109.832 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 154.58 48.7 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.038 -1.077 . . . . 3.8399999999999999 113.13 178.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.4 ttpp 55.87 72.56 0.99 Allowed Pre-proline 0 CA--C 1.535 0.367 0 C-N-CA 122.616 0.366 . . . . 6.7800000000000002 111.213 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . 0.465 ' HB3' ' CE1' ' A' 2100 ' ' PHE . 19.2 Cg_endo -58.87 135.6 68.0 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.906 2.404 . . . . 2.4300000000000002 113.299 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 36.0 t70 -92.88 130.92 34.83 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.616 -0.72 . . . . 2.3300000000000001 109.723 178.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' 2123 ' ' TYR . 30.8 Cg_endo -64.71 106.61 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.634 2.223 . . . . 1.03 112.235 -176.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.1 p -142.94 135.54 25.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.264 0.554 . . . . 0.59999999999999998 111.34 -178.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.607 ' HA ' ' O ' ' A' 2121 ' ' ALA . 88.5 m -111.21 122.85 48.93 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.564 -0.744 . . . . 0.37 109.412 171.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.3 t -95.54 136.73 25.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.929 -0.767 . . . . 0.76000000000000001 108.929 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -141.95 113.58 7.82 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.09 0.774 . . . . 1.6299999999999999 113.09 -171.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.6 ' NH1' HG13 ' A' 2092 ' ' VAL . 23.9 ptt180 -140.69 143.44 35.07 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.26 -0.644 . . . . 3.4700000000000002 109.26 171.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.569 ' O ' HG11 ' A' 2065 ' ' VAL . 34.8 m -98.41 149.95 5.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.238 -0.585 . . . . 0.40000000000000002 111.179 -176.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 25.1 p30 -88.01 -168.93 2.38 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.708 -0.678 . . . . 1.46 110.783 179.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.3 mttt -65.69 -23.59 66.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.716 0.293 . . . . 1.72 111.553 -178.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -82.57 -27.26 31.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.104 0.478 . . . . 1.8400000000000001 110.56 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 108.29 11.53 23.58 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.358 -0.697 . . . . 0.44 111.358 -177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.438 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 61.6 m -90.59 118.96 69.08 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 120.595 0.236 . . . . 0.56999999999999995 110.481 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' 2117 ' ' THR . 10.5 Cg_exo -71.38 119.72 6.46 Favored 'Trans proline' 0 N--CA 1.462 -0.339 0 C-N-CA 122.719 2.279 . . . . 0.60999999999999999 113.014 -179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 13.6 m -84.79 109.39 17.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.326 -0.991 . . . . 0.59999999999999998 108.326 169.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.573 ' HA ' ' O ' ' A' 2109 ' ' VAL . 34.6 p -119.58 149.87 41.22 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.125 -0.943 . . . . 0.67000000000000004 111.747 -170.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.607 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.57 126.15 39.71 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.125 -1.065 . . . . 0.72999999999999998 108.125 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 46.5 m -113.57 101.7 9.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.644 -0.502 . . . . 2.1899999999999999 109.644 -177.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.496 ' O ' ' HA ' ' A' 2106 ' ' PRO . 1.8 m-85 -97.68 124.95 42.19 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.967 -0.561 . . . . 2.8100000000000001 112.045 -174.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 26.0 m -91.02 150.55 41.98 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 115.105 -0.952 . . . . 2.0600000000000001 110.98 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.46 ' HB3' ' HD3' ' A' 2106 ' ' PRO . 73.5 Cg_endo -78.9 157.91 27.4 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.769 2.313 . . . . 2.1600000000000001 111.863 177.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 39.6 tt0 58.7 87.53 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 O-C-N 123.697 0.623 . . . . 4.3300000000000001 111.516 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 28.1 t80 -129.97 111.85 12.93 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.469 -0.937 . . . . 3.8300000000000001 108.469 175.173 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 4.7 t -60.4 160.64 8.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.965 0.888 . . . . 5.1100000000000003 112.266 -174.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . 0.437 ' O ' ' HD3' ' A' 2129 ' ' LYS . 0.0 OUTLIER -84.67 47.55 1.39 Allowed 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.356 -1.293 . . . . 5.2199999999999998 111.635 -176.717 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 67.6 t . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.119 -0.943 . . . . 5.8799999999999999 110.559 -177.853 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 1.2 mp0 . . . . . 0 N--CA 1.484 1.225 0 CA-C-O 120.758 0.313 . . . . 6.8499999999999996 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -74.79 -25.22 70.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.045 -0.597 . . . . 3.4100000000000001 112.274 179.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 164.31 -112.33 0.5 Allowed Glycine 0 N--CA 1.446 -0.642 0 N-CA-C 111.522 -0.631 . . . . 1.77 111.522 177.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 16.5 t70 -138.46 121.14 10.8 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.532 -0.544 . . . . 2.4199999999999999 109.532 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.0 -18.57 46.25 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.895 2.397 . . . . 1.72 112.706 -176.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 8.4 mp -87.48 -33.3 19.06 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.377 -0.374 . . . . 2.3399999999999999 110.403 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 2.6 t -135.41 87.38 27.49 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.418 -0.355 . . . . 0.87 110.048 -178.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -38.66 119.71 0.43 Allowed 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 123.411 2.741 . . . . 1.04 112.661 173.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . 0.428 HD11 HG21 ' A' 2119 ' ' VAL . 42.4 mm -56.18 123.66 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.828 -0.623 . . . . 0.77000000000000002 111.477 -176.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.518 ' O ' HG22 ' A' 2065 ' ' VAL . 30.8 t70 -68.01 135.98 53.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.788 -0.642 . . . . 1.4199999999999999 110.502 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -86.62 -6.62 58.81 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.082 -0.508 . . . . 1.55 111.782 -172.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 45.5 p -111.18 4.01 18.92 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.166 0.432 . . . . 0.68999999999999995 112.166 -177.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.688 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.7 m -86.99 -174.07 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 109.904 -0.406 . . . . 0.81999999999999995 109.904 174.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -93.57 105.77 17.79 Favored Pre-proline 0 C--O 1.238 0.494 0 CA-C-O 120.974 0.416 . . . . 0.78000000000000003 111.293 176.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.688 ' HD3' ' O ' ' A' 2065 ' ' VAL . 55.4 Cg_endo -100.74 108.64 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.548 0 C-N-CA 123.308 2.672 . . . . 0.45000000000000001 110.62 166.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.601 HG22 ' HE2' ' A' 2074 ' ' LYS . 18.5 p -138.75 177.07 8.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.646 0.736 . . . . 0.69999999999999996 111.101 -175.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.472 ' CE1' ' HB2' ' A' 2084 ' ' TYR . 1.4 m-85 -101.55 142.18 33.3 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 107.147 -1.427 . . . . 1.1599999999999999 107.147 165.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -58.78 -19.08 37.59 Favored 'General case' 0 C--N 1.328 -0.329 0 O-C-N 123.849 0.718 . . . . 2.0899999999999999 111.975 -168.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -98.58 8.04 45.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.82 0.343 . . . . 2.1499999999999999 111.038 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 90.07 17.72 52.66 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 121.089 -0.577 . . . . 0.63 113.195 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 32.3 m -93.89 167.55 11.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.916 0.358 . . . . 0.89000000000000001 110.999 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . 0.601 ' HE2' HG22 ' A' 2068 ' ' THR . 34.5 mmtp -127.67 -16.86 4.67 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 116.161 -0.472 . . . . 1.1299999999999999 111.12 178.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.813 ' HG2' HG22 ' A' 2085 ' ' THR . 0.9 OUTLIER -149.72 98.51 2.75 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 109.761 -0.459 . . . . 2.0800000000000001 109.761 174.239 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . . . . . . . . . 26.1 tptt -92.19 108.35 19.88 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.281 -0.418 . . . . 1.48 110.073 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 86.9 m -107.84 118.13 35.93 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-O 121.408 0.623 . . . . 0.63 110.478 174.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.579 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 72.1 mt -114.02 115.07 45.94 Favored Pre-proline 0 N--CA 1.438 -1.034 0 CA-C-N 114.911 -1.04 . . . . 1.6200000000000001 108.471 175.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -47.84 109.52 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 123.332 2.688 . . . . 0.97999999999999998 113.567 -174.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 90.68 -8.64 79.5 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.923 -0.58 . . . . 0.93999999999999995 112.694 176.258 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.579 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.6 tm0? -100.82 -31.11 11.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.096 0.474 . . . . 2.02 109.829 -176.19 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 129.13 -167.57 21.13 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.818 -0.706 . . . . 0.5 112.492 177.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 55.0 m -149.57 129.89 13.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.507 0.67 . . . . 0.48999999999999999 110.341 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.472 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 2.7 m-85 -101.85 130.42 48.31 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 106.789 -1.559 . . . . 1.4399999999999999 106.789 171.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.813 HG22 ' HG2' ' A' 2075 ' ' GLU . 77.5 p -125.67 137.63 53.87 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.176 -0.61 . . . . 0.63 111.932 -172.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.507 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -130.9 133.36 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-N 115.573 -0.739 . . . . 1.1799999999999999 109.878 173.962 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 24.5 m -116.61 149.17 43.38 Favored Pre-proline 0 C--N 1.32 -0.684 0 N-CA-C 109.143 -0.688 . . . . 0.80000000000000004 109.143 172.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -61.99 -0.75 1.81 Allowed 'Trans proline' 0 N--CA 1.477 0.533 0 C-N-CA 123.633 2.889 . . . . 0.96999999999999997 113.95 -170.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.08 -14.71 62.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.08 0.467 . . . . 2.29 110.064 177.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 98.14 21.11 18.72 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.868 -0.605 . . . . 0.82999999999999996 112.082 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.8 t -120.63 135.97 54.96 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.916 0.389 . . . . 1.51 110.349 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.63 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 5.2 t -136.35 149.44 27.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.922 -0.581 . . . . 1.1799999999999999 110.002 -176.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.9 t -134.96 130.03 35.15 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.273 0.558 . . . . 1.46 110.409 172.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 15.4 m-30 -93.82 98.78 11.31 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.032 -0.729 . . . . 1.27 109.032 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 21.3 m -117.56 88.7 30.13 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-O 120.919 0.39 . . . . 0.57999999999999996 111.891 -177.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -91.78 161.26 3.42 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 123.213 2.609 . . . . 0.97999999999999998 111.822 171.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . 0.481 ' HB3' ' HB2' ' A' 2100 ' ' PHE . 11.6 t70 -75.41 114.17 13.65 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.613 -0.514 . . . . 2.7200000000000002 109.613 176.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 2.7 tpmt? -43.56 -53.31 5.7 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 124.059 0.849 . . . . 4.8099999999999996 113.262 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -121.27 37.4 4.34 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 111.88 0.326 . . . . 4.4199999999999999 111.88 -171.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' A' 2097 ' ' ASP . 56.5 t80 -78.59 84.59 4.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.486 0.66 . . . . 2.3599999999999999 110.287 177.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.2 t -93.9 113.22 28.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.627 -0.715 . . . . 2.6800000000000002 110.16 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 179.52 -110.13 0.28 Allowed Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.521 -0.632 . . . . 3.8399999999999999 111.521 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 16.9 ptpt -135.03 72.97 66.75 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-O 121.207 0.527 . . . . 6.7800000000000002 110.987 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . 0.427 ' HB3' ' HG3' ' A' 2081 ' ' GLN . 23.5 Cg_exo -64.94 144.86 84.25 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.889 2.392 . . . . 2.4300000000000002 111.592 177.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.448 ' HB2' HD13 ' A' 2078 ' ' ILE . 3.7 m-20 -76.6 142.95 71.16 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.424 -0.353 . . . . 2.3300000000000001 110.481 177.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.632 ' HA ' ' O ' ' A' 2123 ' ' TYR . 71.7 Cg_endo -80.32 132.58 9.25 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 123.086 2.524 . . . . 1.03 113.441 -176.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 9.0 p -161.5 144.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.734 -0.666 . . . . 0.59999999999999998 110.059 177.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' 2121 ' ' ALA . 80.9 m -115.03 126.75 55.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.334 0.588 . . . . 0.37 110.523 175.165 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . . . . . . . . . 1.9 t -98.55 137.7 25.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.535 -0.757 . . . . 0.76000000000000001 109.118 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.588 ' HA ' HG22 ' A' 2120 ' ' THR . 0.6 OUTLIER -133.0 109.57 9.64 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 112.301 0.482 . . . . 1.6299999999999999 112.301 -168.004 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.63 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -143.96 137.27 27.64 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 121.874 -0.517 . . . . 3.4700000000000002 110.473 172.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.422 ' O ' HG21 ' A' 2065 ' ' VAL . 34.1 m -102.03 157.72 4.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.439 -0.346 . . . . 0.40000000000000002 110.884 179.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.686 ' OD2' ' HB ' ' A' 2117 ' ' THR . 40.1 p30 -97.89 -167.97 1.6 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.028 -0.533 . . . . 1.46 110.541 177.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 96.4 mttt -55.08 -41.5 71.65 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.319 0.489 . . . . 1.72 112.319 -177.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.3 p30 -86.73 -25.42 24.74 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.766 -0.373 . . . . 1.8400000000000001 110.684 -176.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 119.49 15.31 5.48 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.657 -0.783 . . . . 0.44 112.368 178.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.686 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 47.1 m -77.39 115.64 51.06 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-O 120.763 0.316 . . . . 0.56999999999999995 110.237 174.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' 2111 ' ' ARG . 3.0 Cg_endo -82.36 103.93 1.31 Allowed 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 122.434 2.09 . . . . 0.60999999999999999 112.624 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . 0.558 HG23 ' HG3' ' A' 2111 ' ' ARG . 0.0 OUTLIER -75.33 108.32 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.532 0 N-CA-C 107.839 -1.171 . . . . 0.59999999999999998 107.839 167.856 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.588 HG22 ' HA ' ' A' 2110 ' ' LYS . 69.1 p -126.47 156.53 40.53 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.142 -0.935 . . . . 0.67000000000000004 110.492 -171.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.94 127.1 41.06 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.732 -0.84 . . . . 0.72999999999999998 108.732 172.155 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 57.7 m -115.89 99.75 7.5 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.278 -0.638 . . . . 2.1899999999999999 109.278 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.632 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.7 m-85 -98.67 145.67 26.64 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.422 -0.808 . . . . 2.8100000000000001 111.268 -175.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . 0.512 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 26.5 m -152.97 169.53 9.55 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.67 -0.696 . . . . 2.0600000000000001 109.447 -177.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.512 ' HD2' ' HB3' ' A' 2124 ' ' SER . 82.7 Cg_exo -46.84 -51.64 8.86 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.706 2.271 . . . . 2.1600000000000001 112.912 177.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -105.74 113.98 27.87 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.153 0.502 . . . . 4.3300000000000001 110.604 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 14.6 p90 -129.81 11.28 5.63 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.623 -0.717 . . . . 3.8300000000000001 109.907 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 1.5 m 70.55 144.46 0.06 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.297 -0.865 . . . . 5.1100000000000003 110.577 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 55.7 pttt -105.74 128.45 53.7 Favored 'General case' 0 C--N 1.323 -0.572 0 O-C-N 122.187 -0.32 . . . . 5.2199999999999998 111.317 -176.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . 0.426 ' OXT' HG13 ' A' 2130 ' ' VAL . 9.3 p . . . . . 0 C--O 1.249 1.052 0 CA-C-O 117.609 -1.186 . . . . 5.8799999999999999 112.52 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 11.2 pt20 . . . . . 0 N--CA 1.483 1.208 0 CA-C-O 120.583 0.23 . . . . 6.8499999999999996 111.288 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . 85.25 27.59 32.98 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.766 -0.73 . . . . 3.4100000000000001 111.909 -176.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -112.96 -139.16 7.36 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.712 -0.756 . . . . 1.77 112.306 -176.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -149.01 94.05 4.08 Favored Pre-proline 0 C--N 1.32 -0.679 0 CA-C-O 121.17 0.51 . . . . 2.4199999999999999 112.191 -172.292 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . 0.431 ' HG2' ' HG ' ' A' 2058 ' ' LEU . 36.8 Cg_endo -71.95 -44.43 0.93 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 121.958 1.772 . . . . 1.72 111.471 176.097 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . 0.681 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -83.91 -12.95 54.68 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 114.289 1.218 . . . . 2.3399999999999999 114.289 -176.081 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.681 HG23 HD13 ' A' 2058 ' ' LEU . 0.3 OUTLIER -140.21 82.76 16.44 Favored Pre-proline 0 CA--C 1.508 -0.645 0 C-N-CA 119.739 -0.785 . . . . 0.87 110.929 -176.784 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -52.96 119.09 5.51 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.87 1.713 . . . . 1.04 111.547 179.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . 0.555 HG13 ' NE ' ' A' 2111 ' ' ARG . 39.3 mm -45.51 135.92 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.236 -0.893 . . . . 0.77000000000000002 112.241 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.557 ' O ' HG22 ' A' 2065 ' ' VAL . 13.0 t70 -71.91 141.51 49.49 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.442 -0.799 . . . . 1.4199999999999999 109.953 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -87.01 -7.79 57.79 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.131 0.419 . . . . 1.55 112.131 -172.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 67.2 p -106.81 6.37 29.42 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.702 -0.399 . . . . 0.68999999999999995 111.792 -178.155 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.644 ' O ' ' HD3' ' A' 2067 ' ' PRO . 34.4 m -97.84 -174.42 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.81999999999999995 109.997 177.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -97.08 105.07 21.73 Favored Pre-proline 0 C--O 1.239 0.504 0 CA-C-O 120.808 0.337 . . . . 0.78000000000000003 110.998 178.545 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.644 ' HD3' ' O ' ' A' 2065 ' ' VAL . 56.5 Cg_endo -100.34 109.59 0.06 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 123.175 2.584 . . . . 0.45000000000000001 111.154 167.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.428 HG22 ' HE2' ' A' 2074 ' ' LYS . 12.1 p -137.39 178.08 7.37 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.321 0.581 . . . . 0.69999999999999996 111.086 -175.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.503 ' HD2' ' N ' ' A' 2069 ' ' PHE . 0.9 OUTLIER -100.81 149.41 23.86 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.02 -1.104 . . . . 1.1599999999999999 108.02 169.157 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -48.31 -44.52 34.0 Favored 'General case' 0 C--N 1.329 -0.283 0 O-C-N 123.509 0.505 . . . . 2.0899999999999999 111.618 -172.403 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -84.16 13.76 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 2.1499999999999999 111.796 -175.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 81.6 26.15 51.55 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 121.017 -0.611 . . . . 0.63 112.706 177.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.32 166.93 11.15 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.541 0.21 . . . . 0.89000000000000001 110.978 -179.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . 0.428 ' HE2' HG22 ' A' 2068 ' ' THR . 35.4 mmtp -123.21 -26.48 4.31 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.812 0.339 . . . . 1.1299999999999999 111.461 -178.012 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -147.54 135.2 20.98 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 2.0800000000000001 109.497 172.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' 2076 ' ' LYS . 0.1 OUTLIER -127.97 99.6 5.57 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.475 -0.565 . . . . 1.48 109.475 177.349 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 34.0 m -110.23 114.17 27.44 Favored 'General case' 0 N--CA 1.443 -0.818 0 CA-C-O 121.139 0.495 . . . . 0.63 110.753 177.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . . . . . . . . . 75.2 mt -121.76 120.07 28.78 Favored Pre-proline 0 C--N 1.315 -0.908 0 N-CA-C 108.343 -0.984 . . . . 1.6200000000000001 108.343 173.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 83.2 Cg_exo -46.53 111.47 0.37 Allowed 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 123.251 2.634 . . . . 0.97999999999999998 112.9 -176.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 107.78 -15.88 37.23 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.616 -0.72 . . . . 0.93999999999999995 112.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.565 ' CD ' ' HA ' ' A' 2104 ' ' PRO . 24.0 mt-30 -97.8 -37.24 9.93 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.981 0.419 . . . . 2.02 110.837 -178.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 118.69 -166.73 12.98 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 111.083 -0.807 . . . . 0.5 111.083 -177.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . . . . . . . . . 62.1 m -129.03 119.31 24.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.856 0.836 . . . . 0.48999999999999999 110.738 174.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.43 ' HB2' ' CE1' ' A' 2069 ' ' PHE . 1.9 m-85 -94.82 122.88 37.9 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 105.854 -1.906 . . . . 1.4399999999999999 105.854 168.004 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.33 143.06 41.86 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.801 0.667 . . . . 0.63 112.801 -168.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' 2092 ' ' VAL . 0.0 OUTLIER -138.88 132.59 40.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.404 -0.816 . . . . 1.1799999999999999 109.559 170.732 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 30.4 m -119.94 150.42 50.79 Favored Pre-proline 0 C--N 1.325 -0.499 0 N-CA-C 109.657 -0.497 . . . . 0.80000000000000004 109.657 173.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -62.38 0.69 1.25 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 123.686 2.924 . . . . 0.96999999999999997 114.215 -170.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -68.33 -18.9 64.61 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.007 0.432 . . . . 2.29 109.876 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 101.92 11.81 36.28 Favored Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.506 -0.77 . . . . 0.82999999999999996 111.767 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.6 t -109.5 136.14 49.38 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.131 0.491 . . . . 1.51 110.419 -178.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' 2086 ' ' ILE . 3.6 t -133.41 149.23 31.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.753 -0.658 . . . . 1.1799999999999999 109.796 -176.554 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 4.2 t -137.76 119.75 15.43 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.147 0.498 . . . . 1.46 111.098 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . . . . . . . . . 16.3 m-30 -94.04 97.27 10.21 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.319 -0.993 . . . . 1.27 108.319 174.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 18.8 m -120.27 87.99 41.01 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 120.772 -0.371 . . . . 0.57999999999999996 111.654 -176.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -91.77 157.51 3.45 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.27 2.646 . . . . 0.97999999999999998 112.582 174.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -65.1 136.56 56.86 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.066 -0.515 . . . . 2.7200000000000002 110.271 169.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 23.1 tptm -91.86 -30.89 15.93 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.937 -0.574 . . . . 4.8099999999999996 111.875 -177.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -107.8 -47.1 3.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.852 1.056 . . . . 4.4199999999999999 113.852 -165.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.5 122.98 13.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.732 0.777 . . . . 2.3599999999999999 112.279 -169.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 25.1 t -80.98 143.47 12.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.287 -0.869 . . . . 2.6800000000000002 110.362 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 117.63 -52.49 0.69 Allowed Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 108.823 -1.711 . . . . 3.8399999999999999 108.823 -169.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . 0.467 ' HB2' ' HA ' ' A' 2125 ' ' PRO . 70.1 mmtt 68.69 159.33 0.15 Allowed Pre-proline 0 C--N 1.329 -0.299 0 N-CA-C 113.89 1.07 . . . . 6.7800000000000002 113.89 167.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . 0.565 ' HA ' ' CD ' ' A' 2081 ' ' GLN . 62.4 Cg_exo -44.86 144.25 3.74 Favored 'Trans proline' 0 C--N 1.348 0.548 0 C-N-CA 124.371 3.381 . . . . 2.4300000000000002 116.156 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . . . . . . . . . 25.9 t70 -65.77 132.06 94.78 Favored Pre-proline 0 N--CA 1.451 -0.42 0 CA-C-N 114.312 -1.313 . . . . 2.3300000000000001 107.999 164.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.619 ' HA ' ' O ' ' A' 2123 ' ' TYR . 6.5 Cg_endo -47.12 112.86 0.57 Allowed 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 124.196 3.264 . . . . 1.03 114.595 -170.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 6.0 p -150.15 123.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.34 -0.845 . . . . 0.59999999999999998 110.087 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' 2121 ' ' ALA . 56.6 m -100.62 133.99 44.25 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.131 -0.486 . . . . 0.37 110.609 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' 2120 ' ' THR . 4.9 t -110.14 147.77 14.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.465 -0.568 . . . . 0.76000000000000001 109.465 177.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' 2110 ' ' LYS . 18.5 ttpt -143.78 109.48 5.2 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.135 0.421 . . . . 1.6299999999999999 112.135 -174.01 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.555 ' NE ' HG13 ' A' 2061 ' ' ILE . 18.2 ptt180 -131.52 136.3 47.76 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.119 -0.697 . . . . 3.4700000000000002 109.119 174.028 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.462 ' O ' HG21 ' A' 2065 ' ' VAL . 34.4 m -98.94 145.13 10.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.431 -0.508 . . . . 0.40000000000000002 111.014 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -91.94 -168.86 2.11 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.073 -0.512 . . . . 1.46 110.723 -178.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 68.4 mttm -65.77 -28.81 69.3 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.648 0.261 . . . . 1.72 111.557 -178.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . 0.443 HD22 HG11 ' A' 2059 ' ' VAL . 42.4 m-80 -74.26 -20.75 60.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.176 0.512 . . . . 1.8400000000000001 110.081 174.103 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 94.43 9.8 58.7 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.682 -0.69 . . . . 0.44 111.851 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . . . . . . . . . 30.5 m -82.04 120.06 76.52 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 110.012 -0.366 . . . . 0.56999999999999995 110.012 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -72.93 106.29 2.11 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.441 2.094 . . . . 0.60999999999999999 112.528 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 35.3 m -77.48 108.73 11.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.008 -1.108 . . . . 0.59999999999999998 108.008 171.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.4 p -119.98 145.01 47.19 Favored 'General case' 0 N--CA 1.438 -1.031 0 CA-C-N 114.537 -1.21 . . . . 0.67000000000000004 110.573 -172.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.48 126.41 40.42 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.581 -0.736 . . . . 0.72999999999999998 109.265 175.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 35.0 p -100.33 97.76 8.48 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.874 -0.788 . . . . 2.1899999999999999 108.874 177.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.619 ' O ' ' HA ' ' A' 2106 ' ' PRO . 24.3 m-85 -89.69 99.75 12.69 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-O 121.493 0.663 . . . . 2.8100000000000001 111.666 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 7.9 p -148.86 170.12 8.13 Favored Pre-proline 0 N--CA 1.435 -1.192 0 CA-C-N 114.456 -1.247 . . . . 2.0600000000000001 109.441 178.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.467 ' HA ' ' HB2' ' A' 2103 ' ' LYS . 51.0 Cg_exo -55.86 97.93 0.06 OUTLIER 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.447 2.098 . . . . 2.1600000000000001 111.811 175.296 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -161.59 -56.03 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.613 -0.721 . . . . 4.3300000000000001 109.981 -177.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -68.7 137.53 54.19 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.427 -0.806 . . . . 3.8300000000000001 111.8 -175.196 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 38.4 m 74.53 -56.74 0.63 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.5 0.72 . . . . 5.1100000000000003 112.914 172.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 8.0 ptmm? -73.7 149.58 41.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.866 0.365 . . . . 5.2199999999999998 111.124 -176.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 20.5 t . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.481 -0.771 . . . . 5.8799999999999999 109.718 176.46 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . 0.447 ' HG3' ' O ' ' A' 2120 ' ' THR . 4.1 pt20 . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.379 0.133 . . . . 6.8499999999999996 111.115 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -101.16 -6.11 51.94 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.736 -0.745 . . . . 3.4100000000000001 113.353 -173.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -166.88 115.99 0.66 Allowed Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.695 -0.765 . . . . 1.77 111.708 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -101.38 113.97 65.76 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 120.94 0.4 . . . . 2.4199999999999999 110.647 178.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -47.19 11.55 Favored 'Trans proline' 0 N--CA 1.473 0.304 0 C-N-CA 123.317 2.678 . . . . 1.72 112.559 -179.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . 0.608 HD13 HG23 ' A' 2059 ' ' VAL . 0.1 OUTLIER -61.41 -20.33 62.93 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 115.358 -0.837 . . . . 2.3399999999999999 113.24 177.281 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.608 HG23 HD13 ' A' 2058 ' ' LEU . 6.1 t -130.11 86.72 53.44 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.124 -0.324 . . . . 0.87 110.124 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.01 126.37 20.87 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.396 2.064 . . . . 1.04 111.955 -177.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 37.9 mm -59.54 132.97 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.819 -0.628 . . . . 0.77000000000000002 110.374 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.581 ' O ' HG22 ' A' 2065 ' ' VAL . 13.8 t70 -78.17 138.15 38.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.145 -0.48 . . . . 1.4199999999999999 110.635 -176.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . 0.405 ' O ' ' HA3' ' A' 2090 ' ' GLY . 41.8 mt-10 -93.66 -0.43 56.09 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.184 -0.462 . . . . 1.55 111.877 -172.284 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 65.5 p -108.29 -1.83 19.76 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.78 -0.368 . . . . 0.68999999999999995 111.164 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' 2062 ' ' ASP . 32.8 m -89.87 -176.0 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.441 -0.345 . . . . 0.81999999999999995 110.172 178.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -93.47 111.65 53.16 Favored Pre-proline 0 C--O 1.238 0.485 0 CA-C-O 121.08 0.467 . . . . 0.78000000000000003 111.451 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.556 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -100.88 107.26 0.05 OUTLIER 'Trans proline' 0 N--CA 1.442 -1.523 0 C-N-CA 123.025 2.483 . . . . 0.45000000000000001 111.327 167.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.503 ' O ' ' HB3' ' A' 2110 ' ' LYS . 19.2 p -145.68 146.51 31.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.853 0.358 . . . . 0.69999999999999996 110.522 -177.703 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.52 ' N ' ' HD1' ' A' 2069 ' ' PHE . 0.9 OUTLIER -71.61 148.23 46.78 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.942 -1.133 . . . . 1.1599999999999999 107.942 177.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -52.93 -37.42 60.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 118.412 0.551 . . . . 2.0899999999999999 111.297 -171.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 29.1 t70 -67.73 -11.66 58.86 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.679 -0.691 . . . . 2.1499999999999999 111.928 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 91.06 29.85 12.04 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.848 -0.691 . . . . 0.63 112.012 -176.179 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.6 p -110.08 161.68 15.3 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.887 0.375 . . . . 0.89000000000000001 111.22 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . 0.4 ' O ' HG22 ' A' 2086 ' ' ILE . 35.4 mmtp -110.94 -21.07 12.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.898 -0.592 . . . . 1.1299999999999999 110.985 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.709 ' HG2' HG22 ' A' 2085 ' ' THR . 3.9 mt-10 -147.57 142.21 26.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.268 -0.424 . . . . 2.0800000000000001 110.141 176.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.435 ' HD3' ' C ' ' A' 2076 ' ' LYS . 1.7 tmtp? -141.24 119.72 12.34 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.09 -0.707 . . . . 1.48 109.09 177.385 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . 0.402 ' N ' ' HD3' ' A' 2076 ' ' LYS . 34.5 m -123.45 125.09 44.31 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.425 0.631 . . . . 0.63 111.356 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.494 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 93.8 mt -125.46 120.98 24.8 Favored Pre-proline 0 C--N 1.316 -0.863 0 N-CA-C 108.536 -0.913 . . . . 1.6200000000000001 108.536 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -47.51 110.65 0.32 Allowed 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 123.203 2.602 . . . . 0.97999999999999998 112.956 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 101.25 -21.45 43.06 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.74 -0.664 . . . . 0.93999999999999995 112.63 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.494 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 51.2 tt0 -93.3 -31.74 14.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.105 0.478 . . . . 2.02 110.678 -175.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 117.98 -178.42 16.88 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.797 -0.716 . . . . 0.5 112.24 177.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.409 HG22 HG23 ' A' 2085 ' ' THR . 45.7 m -128.07 141.95 51.35 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.483 0.659 . . . . 0.48999999999999999 110.103 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.481 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 1.9 m-85 -113.87 122.56 47.39 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.343 -1.354 . . . . 1.4399999999999999 107.343 173.25 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.709 HG22 ' HG2' ' A' 2075 ' ' GLU . 30.5 p -122.93 129.79 52.03 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.19 0.441 . . . . 0.63 112.19 -173.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.514 ' CG1' HG22 ' A' 2092 ' ' VAL . 0.0 OUTLIER -121.5 129.71 75.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.817 -0.629 . . . . 1.1799999999999999 109.923 170.74 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 15.7 m -110.1 148.73 38.91 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 115.644 -0.707 . . . . 0.80000000000000004 109.501 175.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -61.67 0.17 1.24 Allowed 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.679 2.919 . . . . 0.96999999999999997 113.755 -173.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . 0.43 ' HB2' HG22 ' A' 2091 ' ' THR . 5.1 m-20 -70.25 -13.64 62.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.124 0.488 . . . . 2.29 109.859 174.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' 2063 ' ' GLU . . . 95.5 14.06 48.9 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.71 -0.677 . . . . 0.82999999999999996 111.744 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . 0.43 HG22 ' HB2' ' A' 2089 ' ' ASP . 10.2 t -119.83 139.24 52.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.06 0.457 . . . . 1.51 110.279 -177.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.514 HG22 ' CG1' ' A' 2086 ' ' ILE . 9.6 t -134.83 153.44 34.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.899 -0.592 . . . . 1.1799999999999999 109.968 -175.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.9 t -131.92 122.31 25.43 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.261 0.553 . . . . 1.46 110.044 171.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . 0.434 ' O ' ' HD3' ' A' 2096 ' ' PRO . 15.1 m-30 -90.15 98.45 11.78 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.343 -0.984 . . . . 1.27 108.343 175.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 28.5 m -113.93 89.64 17.05 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.123 0.487 . . . . 0.57999999999999996 111.467 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' 2094 ' ' PHE . 85.2 Cg_endo -90.56 149.04 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.008 2.472 . . . . 0.97999999999999998 111.55 174.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.4 t70 -78.61 126.02 30.17 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.922 0.391 . . . . 2.7200000000000002 110.012 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . 0.473 ' O ' ' HB ' ' A' 2130 ' ' VAL . 67.9 mttm -84.01 -10.63 57.74 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.153 -0.476 . . . . 4.8099999999999996 112.067 -174.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -115.27 13.21 16.63 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.572 -0.451 . . . . 4.4199999999999999 111.247 -175.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 42.5 t80 -77.65 110.89 12.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.004 0.431 . . . . 2.3599999999999999 111.039 -178.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 47.0 t -111.99 98.59 7.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.327 -0.62 . . . . 2.6800000000000002 109.327 174.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -178.2 -142.32 4.64 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.972 -0.632 . . . . 3.8399999999999999 111.65 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . 0.41 ' HG3' ' O ' ' A' 2103 ' ' LYS . 24.2 pttm -113.91 101.94 54.36 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-O 121.203 0.525 . . . . 6.7800000000000002 111.287 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 10.5 Cg_exo -71.86 147.18 49.44 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.62 2.213 . . . . 2.4300000000000002 111.159 174.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.447 ' HB3' ' CD1' ' A' 2078 ' ' ILE . 16.9 t70 -95.77 132.29 27.55 Favored Pre-proline 0 C--N 1.322 -0.61 0 N-CA-C 109.802 -0.444 . . . . 2.3300000000000001 109.802 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.571 ' HA ' ' O ' ' A' 2123 ' ' TYR . 15.7 Cg_endo -57.17 113.31 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 123.515 2.81 . . . . 1.03 114.128 -173.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.7 p -147.19 141.81 20.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.362 -0.836 . . . . 0.59999999999999998 109.525 174.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 18.0 m -115.92 113.71 23.67 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.139 0.495 . . . . 0.37 110.276 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' 2120 ' ' THR . 3.2 t -92.24 132.23 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.058 -0.719 . . . . 0.76000000000000001 109.058 -179.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.503 ' HB3' ' O ' ' A' 2068 ' ' THR . 5.0 tmmm? -133.45 145.88 50.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.227 0.537 . . . . 1.6299999999999999 111.664 -170.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.475 ' N ' ' HD2' ' A' 2110 ' ' LYS . 32.2 ptt180 -164.57 137.86 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.543 -0.91 . . . . 3.4700000000000002 108.543 169.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.428 ' O ' HG21 ' A' 2065 ' ' VAL . 33.8 m -98.82 148.98 5.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.213 -0.595 . . . . 0.40000000000000002 111.52 -176.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.603 ' OD1' ' HB ' ' A' 2117 ' ' THR . 8.5 p30 -88.91 -168.53 2.21 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.403 -0.817 . . . . 1.46 111.341 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.0 mttm -64.88 -34.25 77.95 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.561 0.578 . . . . 1.72 112.561 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 10.6 p30 -84.55 -22.92 29.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 119.685 -0.806 . . . . 1.8400000000000001 110.515 177.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 116.67 12.09 8.92 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.809 -0.71 . . . . 0.44 112.958 173.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.603 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 86.5 m -83.27 125.64 73.89 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 117.221 0.511 . . . . 0.56999999999999995 110.005 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' 2117 ' ' THR . 1.8 Cg_endo -81.36 111.46 2.37 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.451 2.101 . . . . 0.60999999999999999 112.987 -178.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 11.6 m -75.94 127.0 37.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.357 -0.979 . . . . 0.59999999999999998 108.357 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' 2109 ' ' VAL . 39.9 p -130.89 166.42 20.95 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 115.699 -0.682 . . . . 0.67000000000000004 111.332 -170.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -127.56 126.75 42.7 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 107.677 -1.231 . . . . 0.72999999999999998 107.677 169.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 3.5 m -110.08 99.42 8.51 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.324 -0.398 . . . . 2.1899999999999999 110.582 -172.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.571 ' O ' ' HA ' ' A' 2106 ' ' PRO . 6.2 m-85 -104.74 151.69 23.44 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 121.252 0.549 . . . . 2.8100000000000001 111.577 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 6.6 p -168.62 170.97 3.86 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 114.778 -1.101 . . . . 2.0600000000000001 108.33 -173.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -70.6 53.16 1.35 Allowed 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.712 2.275 . . . . 2.1600000000000001 112.185 177.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -124.63 -145.92 0.34 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.309 -0.859 . . . . 4.3300000000000001 108.778 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 93.6 m-85 59.52 83.36 0.13 Allowed 'General case' 0 C--O 1.235 0.302 0 O-C-N 123.601 0.563 . . . . 3.8300000000000001 111.444 174.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 16.1 p -56.52 -53.89 52.18 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.005 -0.543 . . . . 5.1100000000000003 110.128 177.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -170.74 152.62 3.78 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.289 -0.869 . . . . 5.2199999999999998 109.214 174.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . 0.473 ' HB ' ' O ' ' A' 2098 ' ' LYS . 45.5 t . . . . . 0 C--O 1.246 0.892 0 CA-C-O 118.499 -0.762 . . . . 5.8799999999999999 110.191 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . 0.43 ' OE1' ' HB3' ' A' 2057 ' ' PRO . 23.5 mt-30 . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 110.352 -0.24 . . . . 6.8499999999999996 110.352 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -137.36 48.42 0.9 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 121.072 -0.585 . . . . 3.4100000000000001 112.076 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . 0.472 ' HA3' HD11 ' A' 2061 ' ' ILE . . . 161.86 -102.1 0.2 Allowed Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 121.039 -0.601 . . . . 1.77 112.013 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -136.31 131.66 18.66 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-O 120.831 0.348 . . . . 2.4199999999999999 110.733 -179.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . 0.43 ' HB3' ' OE1' ' A' 2053 ' ' GLN . 31.1 Cg_endo -64.95 -56.01 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.887 2.391 . . . . 1.72 112.064 177.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . 0.697 HD13 HG23 ' A' 2059 ' ' VAL . 0.2 OUTLIER -63.81 -12.46 35.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.43 -0.804 . . . . 2.3399999999999999 113.167 177.498 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.697 HG23 HD13 ' A' 2058 ' ' LEU . 21.5 t -136.77 86.06 22.72 Favored Pre-proline 0 C--N 1.322 -0.615 0 N-CA-C 109.814 -0.439 . . . . 0.87 109.814 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.63 137.82 83.1 Favored 'Trans proline' 0 C--O 1.235 0.363 0 C-N-CA 122.629 2.219 . . . . 1.04 112.3 -176.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . 0.472 HD11 ' HA3' ' A' 2055 ' ' GLY . 45.9 mm -65.27 136.46 26.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.672 -0.694 . . . . 0.77000000000000002 110.313 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.411 ' HB3' HG22 ' A' 2065 ' ' VAL . 35.5 t70 -82.77 134.42 35.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.301 0.572 . . . . 1.4199999999999999 111.038 -175.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -87.32 -8.47 56.66 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.661 -0.7 . . . . 1.55 111.588 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 76.5 p -104.49 7.88 35.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.971 0.415 . . . . 0.68999999999999995 111.557 -178.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.554 ' O ' ' HD3' ' A' 2067 ' ' PRO . 27.1 m -110.23 -177.83 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.447 -0.575 . . . . 0.81999999999999995 109.447 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -94.88 110.9 52.3 Favored Pre-proline 0 C--O 1.243 0.729 0 CA-C-O 121.092 0.472 . . . . 0.78000000000000003 110.984 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' 2065 ' ' VAL . 43.4 Cg_endo -100.98 106.8 0.05 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.62 0 C-N-CA 123.077 2.518 . . . . 0.45000000000000001 111.688 169.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . . . . . . . . . 12.0 p -142.87 -177.93 5.57 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.177 0.513 . . . . 0.69999999999999996 110.907 -176.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.562 ' CE2' ' HB2' ' A' 2084 ' ' TYR . 93.9 m-85 -101.51 164.97 11.49 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 108.731 -0.84 . . . . 1.1599999999999999 108.731 170.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -53.76 -33.23 55.13 Favored 'General case' 0 CA--C 1.54 0.567 0 CA-C-N 118.004 0.365 . . . . 2.0899999999999999 111.687 -172.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -86.61 12.65 10.09 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 111.872 0.323 . . . . 2.1499999999999999 111.872 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 76.02 17.91 79.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 121.053 -0.594 . . . . 0.63 111.944 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 2.2 m -78.6 164.23 24.84 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.743 0.306 . . . . 0.89000000000000001 111.097 -173.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 45.8 mmtm -115.5 -18.34 10.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.219 0.533 . . . . 1.1299999999999999 110.425 178.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -147.32 140.64 25.34 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.316 -0.624 . . . . 2.0800000000000001 109.316 173.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' 2083 ' ' THR . 27.1 tptt -127.97 116.17 19.65 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.939 -0.393 . . . . 1.48 109.939 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 59.3 m -113.6 132.99 55.54 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.294 0.569 . . . . 0.63 110.957 176.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.573 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 36.0 mt -134.63 121.2 14.91 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.102 -0.954 . . . . 1.6200000000000001 108.859 178.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -51.04 108.97 0.26 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.231 2.621 . . . . 0.97999999999999998 113.186 -175.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 95.2 -11.15 69.42 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.908 -0.663 . . . . 0.93999999999999995 112.75 176.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.573 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.5 tt0 -103.57 -26.51 12.79 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.262 0.554 . . . . 2.02 109.957 -176.246 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 114.29 -156.08 15.89 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.405 -0.816 . . . . 0.5 112.538 175.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.469 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -144.69 137.3 26.48 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.714 0.769 . . . . 0.48999999999999999 110.729 177.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.562 ' HB2' ' CE2' ' A' 2069 ' ' PHE . 5.7 m-85 -108.38 126.27 52.68 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.114 -1.439 . . . . 1.4399999999999999 107.114 171.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . 0.467 HG23 HG22 ' A' 2083 ' ' THR . 0.9 OUTLIER -128.15 147.12 50.54 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 112.826 0.676 . . . . 0.63 112.826 -172.221 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.541 ' CB ' HH12 ' A' 2111 ' ' ARG . 0.0 OUTLIER -141.8 127.1 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 115.248 -0.887 . . . . 1.1799999999999999 109.807 172.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . . . . . . . . . 17.1 m -102.62 148.28 35.27 Favored Pre-proline 0 C--N 1.321 -0.643 0 N-CA-C 109.144 -0.687 . . . . 0.80000000000000004 109.144 173.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -61.18 0.24 1.02 Allowed 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.712 2.942 . . . . 0.96999999999999997 114.32 -171.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -71.74 -20.42 61.9 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.758 -0.46 . . . . 2.29 109.758 175.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 105.34 17.44 13.76 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.997 -0.62 . . . . 0.82999999999999996 112.289 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . . . . . . . . . 6.2 t -112.71 135.76 53.07 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.13 0.49 . . . . 1.51 110.481 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . . . . . . . . . 6.7 t -129.46 152.35 37.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.958 -0.565 . . . . 1.1799999999999999 111.033 -172.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 8.9 t -141.76 123.55 15.23 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.416 0.627 . . . . 1.46 110.267 172.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . 0.559 ' CE2' HG11 ' A' 2109 ' ' VAL . 19.3 m-30 -98.55 98.91 10.03 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 108.522 -0.918 . . . . 1.27 108.522 177.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 10.1 m -116.43 87.99 22.29 Favored Pre-proline 0 N--CA 1.454 -0.264 0 C-N-CA 120.238 -0.585 . . . . 0.57999999999999996 111.341 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' 2094 ' ' PHE . 18.2 Cg_endo -92.55 143.55 2.44 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.516 2.811 . . . . 0.97999999999999998 112.166 173.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 52.7 t0 -88.63 92.52 9.23 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.264 -0.643 . . . . 2.7200000000000002 109.264 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -75.59 -1.48 24.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.031 -0.531 . . . . 4.8099999999999996 111.247 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 22.3 mt-30 -81.95 -16.38 50.64 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.125 -0.694 . . . . 4.4199999999999999 109.125 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 78.2 t80 -99.99 110.51 22.84 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.072 -0.967 . . . . 2.3599999999999999 109.673 177.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 2.6 p -144.24 100.75 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.944 0.878 . . . . 2.6800000000000002 111.452 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -151.73 -77.64 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 110.437 -1.065 . . . . 3.8399999999999999 110.437 175.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 57.8 pttt -129.31 71.73 82.02 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-O 120.982 0.42 . . . . 6.7800000000000002 110.896 173.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.88 148.84 91.14 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.407 2.071 . . . . 2.4300000000000002 111.027 175.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.538 ' HB3' HD13 ' A' 2078 ' ' ILE . 16.4 t70 -75.65 132.99 74.11 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 109.582 -0.525 . . . . 2.3300000000000001 109.582 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.603 ' HA ' ' O ' ' A' 2123 ' ' TYR . 33.5 Cg_endo -65.24 106.06 0.78 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.024 2.482 . . . . 1.03 112.645 -176.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . 0.44 HG21 ' HG2' ' A' 2076 ' ' LYS . 9.5 p -147.42 134.31 13.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.645 -0.707 . . . . 0.59999999999999998 110.501 177.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 61.4 m -109.75 128.23 55.15 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 115.88 -0.6 . . . . 0.37 110.065 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' 2120 ' ' THR . 13.0 t -91.42 117.99 35.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 108.697 -0.853 . . . . 0.76000000000000001 108.697 176.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.418 ' HA ' HG22 ' A' 2120 ' ' THR . 0.2 OUTLIER -125.47 108.49 11.69 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.633 -0.427 . . . . 1.6299999999999999 110.918 -172.532 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.541 HH12 ' CB ' ' A' 2086 ' ' ILE . 12.7 ptp180 -155.18 157.46 37.41 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.776 -0.453 . . . . 3.4700000000000002 109.776 175.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.3 m -112.04 149.39 14.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 120.377 -0.529 . . . . 0.40000000000000002 111.69 -177.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.615 ' OD2' ' HB ' ' A' 2117 ' ' THR . 5.0 p30 -91.73 -169.33 2.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.632 -0.713 . . . . 1.46 110.756 177.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 66.8 mttm -62.99 -31.95 73.19 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.014 0.376 . . . . 1.72 112.014 -178.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -78.43 -18.62 54.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.083 0.468 . . . . 1.8400000000000001 110.122 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 99.61 10.57 46.82 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.563 -0.744 . . . . 0.44 111.304 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.615 ' HB ' ' OD2' ' A' 2113 ' ' ASP . 62.2 m -81.9 125.89 76.53 Favored Pre-proline 0 N--CA 1.448 -0.542 0 CA-C-O 120.515 0.197 . . . . 0.56999999999999995 110.487 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' 2111 ' ' ARG . 11.9 Cg_exo -70.35 101.43 0.99 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.468 2.112 . . . . 0.60999999999999999 112.589 177.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . 0.449 ' CG2' ' HG3' ' A' 2111 ' ' ARG . 23.7 m -75.37 108.63 7.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.374 -0.973 . . . . 0.59999999999999998 108.374 169.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.635 ' HA ' ' O ' ' A' 2109 ' ' VAL . 43.6 p -126.63 154.4 44.04 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.189 -0.914 . . . . 0.67000000000000004 111.196 -171.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -128.59 127.77 42.92 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.282 -1.007 . . . . 0.72999999999999998 108.282 170.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 29.6 p -105.12 99.63 9.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.095 0.474 . . . . 2.1899999999999999 110.172 -177.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.603 ' O ' ' HA ' ' A' 2106 ' ' PRO . 10.6 m-85 -113.38 134.42 54.65 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.966 -0.561 . . . . 2.8100000000000001 111.225 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . 0.43 ' HB2' ' HD2' ' A' 2125 ' ' PRO . 26.3 p -160.08 161.19 26.38 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 115.602 -0.726 . . . . 2.0600000000000001 109.935 -175.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' 2124 ' ' SER . 57.3 Cg_endo -71.18 3.32 3.55 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 122.956 2.438 . . . . 2.1600000000000001 113.011 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -105.0 6.98 33.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.062 0.458 . . . . 4.3300000000000001 109.933 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 29.3 t80 -60.47 122.86 15.67 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.419 -0.81 . . . . 3.8300000000000001 110.28 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 17.7 p -89.73 153.03 21.02 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.216 -0.447 . . . . 5.1100000000000003 111.474 -177.13 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -97.18 145.64 25.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 5.2199999999999998 110.609 -178.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 6.3 p . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.191 -0.909 . . . . 5.8799999999999999 110.454 179.875 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . . . . . . . . . 66.3 mt-30 . . . . . 0 N--CA 1.478 0.956 0 N-CA-C 110.303 -0.258 . . . . 6.8499999999999996 110.303 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . . . . . . . . . . . -62.21 -41.0 99.71 Favored Glycine 0 C--N 1.33 0.223 0 C-N-CA 121.04 -0.6 . . . . 3.4100000000000001 112.945 -177.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . 162.75 -96.76 0.14 Allowed Glycine 0 CA--C 1.507 -0.431 0 N-CA-C 111.212 -0.755 . . . . 1.77 111.212 179.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' 2059 ' ' VAL . 1.8 t70 -124.38 134.12 25.26 Favored Pre-proline 0 C--N 1.32 -0.676 0 N-CA-C 109.211 -0.663 . . . . 2.4199999999999999 109.211 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -44.25 -55.08 3.4 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 123.296 2.664 . . . . 1.72 113.231 -175.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . 0.641 HD13 HG23 ' A' 2059 ' ' VAL . 0.0 OUTLIER -101.16 2.07 39.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.014 0.435 . . . . 2.3399999999999999 112.085 -177.909 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . 0.641 HG23 HD13 ' A' 2058 ' ' LEU . 2.1 t -131.65 78.42 70.88 Favored Pre-proline 0 C--N 1.327 -0.386 0 N-CA-C 110.091 -0.337 . . . . 0.87 110.091 178.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.42 140.03 92.35 Favored 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.182 1.921 . . . . 1.04 111.349 176.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 47.3 mm -61.06 130.97 25.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.856 -0.611 . . . . 0.77000000000000002 111.404 -178.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.603 ' O ' HG22 ' A' 2065 ' ' VAL . 12.5 t70 -73.67 140.36 46.03 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.393 -0.821 . . . . 1.4199999999999999 109.867 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -86.83 -10.47 53.39 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 111.914 0.338 . . . . 1.55 111.914 -171.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 39.7 p -109.24 10.12 25.8 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.755 0.312 . . . . 0.68999999999999995 111.817 -177.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.617 ' O ' ' HD3' ' A' 2067 ' ' PRO . 35.8 m -91.66 -174.94 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 110.059 -0.348 . . . . 0.81999999999999995 110.059 175.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -97.0 105.05 21.24 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.551 -0.295 . . . . 0.78000000000000003 110.775 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' 2065 ' ' VAL . 47.7 Cg_endo -99.91 106.48 0.05 OUTLIER 'Trans proline' 0 N--CA 1.441 -1.603 0 C-N-CA 122.562 2.175 . . . . 0.45000000000000001 110.92 168.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.517 ' O ' ' HB3' ' A' 2110 ' ' LYS . 40.7 p -145.35 147.66 32.54 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.104 -0.498 . . . . 0.69999999999999996 110.09 -176.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.538 ' HD2' ' N ' ' A' 2069 ' ' PHE . 1.2 m-30 -72.62 153.75 41.09 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.5 -0.926 . . . . 1.1599999999999999 108.5 178.235 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -50.55 -43.51 56.22 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.958 0.409 . . . . 2.0899999999999999 111.139 -173.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 38.1 t70 -77.43 2.58 15.64 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 115.671 -0.695 . . . . 2.1499999999999999 111.587 -177.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 86.28 29.98 23.57 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.162 -0.542 . . . . 0.63 112.558 179.367 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 12.5 m -101.24 162.47 12.87 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.788 0.328 . . . . 0.89000000000000001 110.941 -176.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -115.83 -19.62 10.37 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 116.092 -0.504 . . . . 1.1299999999999999 110.87 178.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' 2084 ' ' TYR . 7.2 tt0 -156.0 125.88 6.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.999 -0.546 . . . . 2.0800000000000001 109.737 172.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' 2083 ' ' THR . 32.1 tptt -117.33 118.89 33.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.655 -0.702 . . . . 1.48 109.411 178.353 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 94.4 m -111.85 113.73 26.24 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.482 0.658 . . . . 0.63 110.882 176.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 67.0 mt -110.18 113.9 56.23 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.302 -0.999 . . . . 1.6200000000000001 108.302 174.364 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -47.41 109.4 0.22 Allowed 'Trans proline' 0 N--CA 1.474 0.324 0 C-N-CA 123.49 2.793 . . . . 0.97999999999999998 113.879 -171.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 89.42 -11.56 69.49 Favored Glycine 0 N--CA 1.451 -0.358 0 CA-C-N 115.814 -0.63 . . . . 0.93999999999999995 112.73 176.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.54 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 1.5 tm0? -98.22 -28.45 13.7 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.059 0.456 . . . . 2.02 110.008 -175.098 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 130.37 -173.8 19.88 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.712 -0.756 . . . . 0.5 112.765 173.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' 2076 ' ' LYS . 89.5 m -147.79 138.96 23.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.71 0.767 . . . . 0.48999999999999999 110.436 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.536 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 0.2 OUTLIER -114.14 131.4 56.44 Favored 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 107.261 -1.385 . . . . 1.4399999999999999 107.261 175.382 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 23.7 p -127.84 128.72 45.72 Favored 'General case' 0 C--N 1.319 -0.753 0 C-N-CA 120.527 -0.469 . . . . 0.63 112.173 -174.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.539 HG13 ' HB2' ' A' 2067 ' ' PRO . 0.0 OUTLIER -116.96 129.66 73.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.579 -0.737 . . . . 1.1799999999999999 109.753 170.727 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . 0.426 ' CG2' HG23 ' A' 2091 ' ' THR . 27.5 m -118.45 145.37 37.18 Favored Pre-proline 0 C--N 1.319 -0.734 0 CA-C-N 115.968 -0.56 . . . . 0.80000000000000004 109.534 173.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -59.76 -5.33 3.43 Favored 'Trans proline' 0 N--CA 1.477 0.548 0 C-N-CA 123.85 3.033 . . . . 0.96999999999999997 114.682 -168.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 28.5 t70 -68.82 -21.35 64.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.276 0.56 . . . . 2.29 109.81 176.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 110.24 7.86 26.08 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.899 -0.667 . . . . 0.82999999999999996 112.077 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . 0.426 HG23 ' CG2' ' A' 2087 ' ' VAL . 1.6 t -107.21 124.44 49.74 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.34 0.591 . . . . 1.51 110.559 -179.139 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.634 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 10.1 t -129.49 138.48 54.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.351 -0.841 . . . . 1.1799999999999999 109.716 -178.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 5.8 t -123.05 115.29 21.6 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.456 0.646 . . . . 1.46 110.571 175.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . 0.485 ' O ' ' HD3' ' A' 2096 ' ' PRO . 14.2 m-30 -85.8 98.47 10.76 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.648 -0.871 . . . . 1.27 108.648 174.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 7.5 m -113.28 88.08 12.14 Favored Pre-proline 0 N--CA 1.453 -0.32 0 CA-C-O 120.968 0.414 . . . . 0.57999999999999996 111.302 -176.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' 2094 ' ' PHE . 96.8 Cg_endo -92.63 145.44 2.59 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.294 2.663 . . . . 0.97999999999999998 112.683 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.46 102.69 11.28 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.19 -0.67 . . . . 2.7200000000000002 109.19 170.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . 0.682 ' HD3' ' H ' ' A' 2098 ' ' LYS . 0.0 OUTLIER -87.08 10.89 15.19 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.763 -0.653 . . . . 4.8099999999999996 111.371 -175.036 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 -106.44 8.85 31.74 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.193 0.521 . . . . 4.4199999999999999 109.83 177.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 64.9 t80 -79.58 80.59 5.95 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.52 -0.764 . . . . 2.3599999999999999 109.666 174.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 16.6 t -85.13 98.24 6.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.079 -0.51 . . . . 2.6800000000000002 109.78 -179.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . 170.3 48.98 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.639 -0.71 . . . . 3.8399999999999999 111.436 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . . . . . . . . . 1.2 mptm? 59.27 73.76 0.65 Allowed Pre-proline 0 CA--C 1.532 0.26 0 C-N-CA 122.895 0.478 . . . . 6.7800000000000002 111.418 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . 0.514 ' HD2' ' HA ' ' A' 2126 ' ' GLU . 31.4 Cg_exo -60.04 131.89 41.69 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.456 2.104 . . . . 2.4300000000000002 111.115 175.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.482 ' HB3' HD13 ' A' 2078 ' ' ILE . 35.6 t70 -68.99 131.23 90.96 Favored Pre-proline 0 C--N 1.325 -0.478 0 CA-C-N 116.098 -0.501 . . . . 2.3300000000000001 110.373 -178.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.54 131.98 18.27 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 123.083 2.522 . . . . 1.03 113.616 -177.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 14.7 p -161.26 144.03 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.372 -0.831 . . . . 0.59999999999999998 109.644 174.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' 2121 ' ' ALA . 42.9 m -109.79 125.5 52.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.433 0.635 . . . . 0.37 110.744 177.206 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' 2120 ' ' THR . 2.1 t -102.56 138.91 25.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.46 -0.791 . . . . 0.76000000000000001 108.946 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . 0.536 ' HG2' ' N ' ' A' 2111 ' ' ARG . 23.5 ttpt -139.68 153.43 47.27 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 118.296 0.498 . . . . 1.6299999999999999 112.297 -172.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.634 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 31.7 ptt180 -175.38 142.76 0.61 Allowed 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 108.447 -0.945 . . . . 3.4700000000000002 108.447 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . 0.485 ' O ' HG21 ' A' 2065 ' ' VAL . 33.7 m -99.22 150.21 5.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.393 -0.523 . . . . 0.40000000000000002 111.297 -178.088 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.677 ' OD1' ' HB ' ' A' 2117 ' ' THR . 7.1 p30 -91.32 -169.31 2.29 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.72 -0.673 . . . . 1.46 111.22 179.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 97.5 mttt -58.93 -38.04 78.08 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.354 -0.385 . . . . 1.72 111.64 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -78.72 -30.27 45.82 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.256 0.551 . . . . 1.8400000000000001 109.79 -177.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 115.74 17.85 6.29 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.268 -0.878 . . . . 0.44 112.055 178.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.677 ' HB ' ' OD1' ' A' 2113 ' ' ASP . 88.3 m -88.15 119.21 70.28 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 110.167 -0.309 . . . . 0.56999999999999995 110.167 178.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' 2111 ' ' ARG . 8.7 Cg_exo -71.89 104.12 1.58 Allowed 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.365 2.044 . . . . 0.60999999999999999 112.173 177.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 15.4 m -75.08 113.03 13.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 108.254 -1.017 . . . . 0.59999999999999998 108.254 170.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' 2109 ' ' VAL . 60.6 p -120.93 161.23 21.94 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.467 -0.788 . . . . 0.67000000000000004 111.391 -172.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' 2108 ' ' THR . . . -128.36 127.04 41.89 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 107.601 -1.259 . . . . 0.72999999999999998 107.601 168.334 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 24.5 m -115.78 100.65 8.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.285 0.564 . . . . 2.1899999999999999 110.696 -172.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -89.83 131.7 35.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.827 -0.624 . . . . 2.8100000000000001 110.306 176.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . . . . . . . . . 13.4 m -124.01 166.26 20.04 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.716 -0.675 . . . . 2.0600000000000001 109.486 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . . . . . . . . . 70.1 Cg_exo -53.48 115.93 2.64 Favored 'Trans proline' 0 C--O 1.236 0.414 0 C-N-CA 122.466 2.111 . . . . 2.1600000000000001 112.251 177.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . 0.514 ' HA ' ' HD2' ' A' 2104 ' ' PRO . 43.7 mt-10 64.65 30.66 12.51 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.814 -0.63 . . . . 4.3300000000000001 111.82 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 68.7 t80 -87.72 134.28 33.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.584 -0.28 . . . . 3.8300000000000001 110.331 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 25.2 p 55.53 105.24 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.336 0 O-C-N 124.387 1.054 . . . . 5.1100000000000003 113.104 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . . . . . . . . . 16.0 ptmt -135.4 101.8 4.94 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.481 -1.236 . . . . 5.2199999999999998 109.797 -178.366 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . 0.432 ' OXT' HG13 ' A' 2130 ' ' VAL . 12.2 p . . . . . 0 C--O 1.252 1.235 0 CA-C-O 117.491 -1.242 . . . . 5.8799999999999999 112.19 -177.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2053 ' ' GLN . . . . . 0.487 ' HB3' ' O ' ' A' 2120 ' ' THR . 72.6 mm-40 . . . . . 0 N--CA 1.48 1.067 0 N-CA-C 109.667 -0.494 . . . . 6.8499999999999996 109.667 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2054 ' ' GLY . . . . . 0.543 ' HA2' ' CD1' ' A' 2094 ' ' PHE . . . 100.64 -84.73 0.57 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.595 -0.812 . . . . 3.4100000000000001 112.3 -178.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2055 ' ' GLY . . . . . . . . . . . . . . . -171.33 112.74 0.46 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 121.023 -0.608 . . . . 1.77 111.779 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2056 ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.55 117.7 46.86 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-O 120.636 0.255 . . . . 2.4199999999999999 111.087 179.032 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2057 ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -73.56 -14.83 24.8 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.176 1.918 . . . . 1.72 111.313 176.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2058 ' ' LEU . . . . . . . . . . . . . 6.6 mp -74.47 -41.13 61.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.629 -0.714 . . . . 2.3399999999999999 110.04 177.314 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2059 ' ' VAL . . . . . . . . . . . . . 1.8 t -126.4 98.77 31.6 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 109.711 -0.477 . . . . 0.87 109.711 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2060 ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.69 131.62 41.05 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.171 1.914 . . . . 1.04 111.842 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2061 ' ' ILE . . . . . . . . . . . . . 49.8 mm -55.67 129.68 17.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 CA-C-N 115.68 -0.691 . . . . 0.77000000000000002 110.622 -178.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2062 ' ' ASP . . . . . 0.602 ' O ' HG22 ' A' 2065 ' ' VAL . 11.3 t70 -75.62 139.62 42.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.983 0.42 . . . . 1.4199999999999999 110.232 -177.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2063 ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -89.71 -4.75 57.57 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.149 0.425 . . . . 1.55 112.149 -171.492 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2064 ' ' THR . . . . . . . . . . . . . 81.8 p -99.33 -13.61 19.55 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.527 -0.469 . . . . 0.68999999999999995 111.238 178.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2065 ' ' VAL . . . . . 0.643 ' O ' ' HD3' ' A' 2067 ' ' PRO . 31.4 m -79.92 -174.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.891 -0.411 . . . . 0.81999999999999995 109.891 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2066 ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -95.33 109.55 45.73 Favored Pre-proline 0 C--O 1.238 0.447 0 CA-C-O 121.078 0.466 . . . . 0.78000000000000003 111.63 -179.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2067 ' ' PRO . . . . . 0.643 ' HD3' ' O ' ' A' 2065 ' ' VAL . 65.4 Cg_endo -100.77 123.23 0.11 Allowed 'Trans proline' 0 N--CA 1.441 -1.605 0 C-N-CA 123.46 2.774 . . . . 0.45000000000000001 110.851 165.384 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2068 ' ' THR . . . . . 0.492 HG22 ' HE3' ' A' 2074 ' ' LYS . 3.6 p -153.28 -179.23 7.54 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.69999999999999996 110.601 -178.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2069 ' ' PHE . . . . . 0.625 ' CZ ' ' HB2' ' A' 2084 ' ' TYR . 8.5 m-30 -102.43 154.63 18.9 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 107.405 -1.332 . . . . 1.1599999999999999 107.405 163.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2070 ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -54.45 -35.84 63.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 118.65 0.659 . . . . 2.0899999999999999 111.748 -171.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2071 ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -78.35 4.9 11.73 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.235 0.457 . . . . 2.1499999999999999 112.235 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2072 ' ' GLY . . . . . . . . . . . . . . . 80.48 24.95 57.91 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.127 -0.558 . . . . 0.63 111.903 -177.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2073 ' ' SER . . . . . . . . . . . . . 14.7 m -94.07 156.46 16.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.629 0.252 . . . . 0.89000000000000001 110.797 -176.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2074 ' ' LYS . . . . . 0.492 ' HE3' HG22 ' A' 2068 ' ' THR . 0.1 OUTLIER -120.79 5.18 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.25 0.548 . . . . 1.1299999999999999 110.913 179.768 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A 2075 ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -165.58 140.75 4.98 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.123 -0.695 . . . . 2.0800000000000001 109.123 170.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2076 ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' 2083 ' ' THR . 16.5 tptt -138.88 104.0 4.95 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.273 -0.421 . . . . 1.48 110.065 174.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2077 ' ' THR . . . . . . . . . . . . . 49.0 m -101.51 118.03 36.13 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.123 0.487 . . . . 0.63 110.273 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2078 ' ' ILE . . . . . 0.563 ' HB ' ' HB3' ' A' 2081 ' ' GLN . 75.5 mt -117.16 119.89 34.29 Favored Pre-proline 0 C--N 1.315 -0.925 0 N-CA-C 108.407 -0.96 . . . . 1.6200000000000001 108.407 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2079 ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -47.11 109.87 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.486 2.791 . . . . 0.97999999999999998 113.496 -174.102 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2080 ' ' GLY . . . . . . . . . . . . . . . 92.42 -12.76 68.95 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.81 -0.632 . . . . 0.93999999999999995 112.677 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2081 ' ' GLN . . . . . 0.563 ' HB3' ' HB ' ' A' 2078 ' ' ILE . 53.9 tt0 -101.13 -26.28 13.73 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.164 0.507 . . . . 2.02 110.183 -177.354 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2082 ' ' GLY . . . . . . . . . . . . . . . 112.85 -163.95 12.1 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.539 -0.838 . . . . 0.5 112.782 173.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2083 ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' 2076 ' ' LYS . 28.1 m -137.14 145.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 121.808 0.814 . . . . 0.48999999999999999 110.553 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2084 ' ' TYR . . . . . 0.625 ' HB2' ' CZ ' ' A' 2069 ' ' PHE . 12.8 m-85 -107.13 112.48 25.41 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 106.892 -1.522 . . . . 1.4399999999999999 106.892 166.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2085 ' ' THR . . . . . . . . . . . . . 25.3 p -104.99 134.76 47.55 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.745 -0.382 . . . . 0.63 111.563 -173.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2086 ' ' ILE . . . . . 0.599 ' HA ' ' O ' ' A' 2091 ' ' THR . 1.6 tt -151.19 130.55 3.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.799 -0.637 . . . . 1.1799999999999999 111.422 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2087 ' ' VAL . . . . . 0.59 HG22 ' OG1' ' A' 2091 ' ' THR . 18.6 m -115.1 157.75 42.74 Favored Pre-proline 0 C--N 1.328 -0.343 0 N-CA-C 109.565 -0.531 . . . . 0.80000000000000004 109.565 175.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2088 ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.17 -0.54 2.28 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 123.69 2.926 . . . . 0.96999999999999997 114.137 -172.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2089 ' ' ASP . . . . . . . . . . . . . 19.1 t70 -78.03 -23.18 48.29 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.293 0.568 . . . . 2.29 109.927 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2090 ' ' GLY . . . . . . . . . . . . . . . 112.74 17.17 8.13 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.581 -0.736 . . . . 0.82999999999999996 112.133 -178.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2091 ' ' THR . . . . . 0.599 ' O ' ' HA ' ' A' 2086 ' ' ILE . 3.2 p -90.51 116.2 28.24 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.355 -0.609 . . . . 1.51 109.355 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2092 ' ' VAL . . . . . 0.473 ' HB ' ' NH1' ' A' 2111 ' ' ARG . 3.8 t -136.2 132.38 49.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.781 -0.368 . . . . 1.1799999999999999 110.285 179.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2093 ' ' THR . . . . . . . . . . . . . 9.2 t -137.33 122.8 19.58 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.401 0.62 . . . . 1.46 110.239 176.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2094 ' ' PHE . . . . . 0.543 ' CD1' ' HA2' ' A' 2054 ' ' GLY . 3.2 m-30 -86.33 98.41 10.96 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.976 -0.75 . . . . 1.27 108.976 179.356 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2095 ' ' THR . . . . . . . . . . . . . 16.4 m -121.38 84.59 41.61 Favored Pre-proline 0 N--CA 1.453 -0.284 0 C-N-CA 119.676 -0.81 . . . . 0.57999999999999996 111.585 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2096 ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -93.47 147.71 2.29 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 123.248 2.632 . . . . 0.97999999999999998 111.884 170.341 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2097 ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -79.27 86.35 5.04 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.225 -0.658 . . . . 2.7200000000000002 109.225 171.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2098 ' ' LYS . . . . . . . . . . . . . 43.8 mtmt -63.26 -24.03 67.69 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.488 -0.778 . . . . 4.8099999999999996 110.92 -175.282 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2099 ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -96.44 12.98 29.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.789 -0.641 . . . . 4.4199999999999999 111.052 -176.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2100 ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.72 104.09 13.55 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.732 -0.667 . . . . 2.3599999999999999 110.414 176.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2101 ' ' VAL . . . . . . . . . . . . . 86.3 t -90.7 98.7 8.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.399 0.619 . . . . 2.6800000000000002 109.529 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2102 ' ' GLY . . . . . . . . . . . . . . . -162.78 -152.86 6.95 Favored Glycine 0 N--CA 1.445 -0.756 0 N-CA-C 110.704 -0.958 . . . . 3.8399999999999999 110.704 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2103 ' ' LYS . . . . . 0.479 ' HB3' ' NZ ' ' A' 2103 ' ' LYS . 0.0 OUTLIER -109.76 94.86 18.05 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 121.3 0.571 . . . . 6.7800000000000002 110.235 177.123 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A 2104 ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -76.81 161.43 33.44 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.868 2.379 . . . . 2.4300000000000002 112.391 -177.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2105 ' ' ASP . . . . . 0.47 ' HB2' HD13 ' A' 2078 ' ' ILE . 0.6 OUTLIER -102.01 141.04 21.74 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.027 -0.533 . . . . 2.3300000000000001 110.508 179.63 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A 2106 ' ' PRO . . . . . 0.587 ' HA ' ' O ' ' A' 2123 ' ' TYR . 55.5 Cg_endo -68.99 121.25 8.1 Favored 'Trans proline' 0 C--O 1.235 0.343 0 C-N-CA 123.181 2.587 . . . . 1.03 113.467 -176.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2107 ' ' VAL . . . . . . . . . . . . . 7.6 p -157.51 143.85 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.414 -0.812 . . . . 0.59999999999999998 109.707 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2108 ' ' THR . . . . . . . . . . . . . 15.6 m -121.48 130.68 53.71 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.37 110.574 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2109 ' ' VAL . . . . . 0.435 HG13 ' CD2' ' A' 2069 ' ' PHE . 2.7 t -92.99 144.68 8.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.101 -0.703 . . . . 0.76000000000000001 109.101 177.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2110 ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -143.36 108.35 4.95 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 118.157 0.435 . . . . 1.6299999999999999 111.635 -173.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2111 ' ' ARG . . . . . 0.473 ' NH1' ' HB ' ' A' 2092 ' ' VAL . 32.1 ptt180 -147.25 139.09 24.24 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 121.722 -0.611 . . . . 3.4700000000000002 109.88 171.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2112 ' ' VAL . . . . . . . . . . . . . 35.5 m -103.5 154.69 5.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 120.926 0.393 . . . . 0.40000000000000002 110.907 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2113 ' ' ASP . . . . . 0.421 ' OD1' ' HB ' ' A' 2117 ' ' THR . 2.3 p-10 -96.29 -167.74 1.63 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.029 -0.532 . . . . 1.46 110.102 178.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2114 ' ' LYS . . . . . . . . . . . . . 93.4 mttt -53.64 -44.47 69.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.954 -0.566 . . . . 1.72 112.175 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2115 ' ' ASN . . . . . . . . . . . . . 5.9 p30 -85.28 -14.92 45.11 Favored 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 120.487 -0.485 . . . . 1.8400000000000001 111.157 -176.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2116 ' ' GLY . . . . . . . . . . . . . . . 104.29 15.23 22.04 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.272 -0.966 . . . . 0.44 112.937 176.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2117 ' ' THR . . . . . 0.45 ' HA ' ' HD3' ' A' 2118 ' ' PRO . 98.1 m -75.85 114.65 38.94 Favored Pre-proline 0 C--N 1.324 -0.538 0 N-CA-C 109.887 -0.412 . . . . 0.56999999999999995 109.887 174.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2118 ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' 2117 ' ' THR . 5.2 Cg_exo -77.49 100.79 1.42 Allowed 'Trans proline' 0 N--CA 1.454 -0.817 0 C-N-CA 122.407 2.072 . . . . 0.60999999999999999 112.318 179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2119 ' ' VAL . . . . . . . . . . . . . 7.0 m -74.94 109.36 7.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.433 -0.951 . . . . 0.59999999999999998 108.433 169.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2120 ' ' THR . . . . . 0.487 ' O ' ' HB3' ' A' 2053 ' ' GLN . 69.3 p -118.86 -174.31 2.67 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.88 -1.054 . . . . 0.67000000000000004 109.977 -174.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2121 ' ' ALA . . . . . . . . . . . . . . . -149.88 127.21 11.41 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.743 -0.836 . . . . 0.72999999999999998 108.743 170.153 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2122 ' ' THR . . . . . . . . . . . . . 34.5 p -100.44 97.87 8.55 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.568 -0.53 . . . . 2.1899999999999999 109.568 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2123 ' ' TYR . . . . . 0.587 ' O ' ' HA ' ' A' 2106 ' ' PRO . 12.1 m-85 -118.44 124.35 47.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.244 0.545 . . . . 2.8100000000000001 111.568 -177.231 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2124 ' ' SER . . . . . 0.5 ' HB3' ' HD2' ' A' 2125 ' ' PRO . 49.5 m -157.77 171.82 6.94 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.689 -1.141 . . . . 2.0600000000000001 108.75 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2125 ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' 2124 ' ' SER . 90.4 Cg_exo -47.54 140.82 15.81 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.318 2.012 . . . . 2.1600000000000001 112.45 173.568 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A 2126 ' ' GLU . . . . . 0.45 ' HA ' ' CD ' ' A' 2129 ' ' LYS . 0.9 OUTLIER 66.39 23.0 10.69 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.75 -0.659 . . . . 4.3300000000000001 112.673 179.332 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A 2127 ' ' PHE . . . . . . . . . . . . . 62.1 t80 -107.99 -49.6 3.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.549 -0.461 . . . . 3.8300000000000001 110.56 173.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2128 ' ' THR . . . . . . . . . . . . . 2.9 m -63.14 -36.33 83.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.029 -0.532 . . . . 5.1100000000000003 112.393 -174.445 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A 2129 ' ' LYS . . . . . 0.45 ' CD ' ' HA ' ' A' 2126 ' ' GLU . 0.0 OUTLIER -92.64 173.87 7.55 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.367 -0.533 . . . . 5.2199999999999998 110.214 179.154 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A 2130 ' ' VAL . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.249 1.043 0 CA-C-N 115.812 -0.631 . . . . 5.8799999999999999 111.206 -176.972 . . . . . . . . 0 0 . 1 stop_ save_